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Carbohydrates are the most diverse and abundant class of biomolecules on earth, and 
play important roles in all facets of life, amongst others in cell-cell recognition and 
activation of the immune system.1,2 Extracting carbohydrates from natural sources, if 
available at all, is a tedious and expensive process owing to the complex mixture of similar 
compounds present. Synthetic chemistry is one of the most important suppliers of well-
defined carbohydrates and glycoconjugates, in sufficient quantities and free from 
contaminants that may interfere with or are detrimental to the activity. However, the 
assembly of complex oligosaccharides remains a complex task and gaining full control 
over the stereoselectivity in the crucial glycosylation reaction still is a major challenge in 
synthetic carbohydrate chemistry. This Thesis investigates the mechanisms of the 
glycosylation reaction by establishing structure-reactivity-selectivity relationships. 
In a glycosylation reaction, a carbohydrate donor is activated to provide an 
electrophilic species to react with a nucleophilic acceptor molecule (see Scheme 1), which 
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can be as simple and small as water, or as structurally complex and large as a protein.3–8 
In a chemical glycosylation, the glycosyl donor has protecting groups to temporarily 
inactivate the reactive carbohydrate alcohol groups and avoid side reactions, and a 
leaving group at the anomeric (C-1) position.9,10 This leaving group can be activated by a 
promotor to make it sufficiently reactive to be substituted by the nucleophilic acceptor, 
which also bears protecting groups to mask positions where reactions must be avoided. 
The additional synthetic steps to construct protected building blocks and exchange or 
remove them can in itself be a monumental undertaking, but one that is often 
unavoidable due to inherent similarities between the carbohydrate alcohols.11–15  
Scheme 1. Depiction of a glycosylation reaction: synthesis of lactose through enzymatic and chemical 
methods.a  
aUDP = uridine diphosphate. Numbers indicate the conventional labelling of glycosides. The biosynthetic 
pathway,16 and conditions for enzymatic biosynthesis17 and chemical synthesis18 are reported in cited references. 
The glycosylation reaction mechanism 
There is no single general reaction mechanism to describe every chemical glycosylation 
reaction. For over a century, and especially the past 50 years,19,20 many new glycosylation 
protocols have been developed and each of these requires different reagents and reaction 
conditions. The current mechanistic understanding, which was already formulated and 
proposed in the 1960s and 1970s,21–24 centers on the equilibrium between a covalent 
glycosylating species, in which the anomeric leaving group is attached to the glycosyl 
donor, and the related ion pairs, in which the leaving group is dissociated from the donor 
(see Scheme 2). Substitution may take place on any of the intermediate states, with 
partially dissociated bonds, or in a geometry not generally depicted in a reaction 





may be very different. Whether a reaction is feasible is determined by many factors, not 
the least of which are the potential of ionization at the anomeric center, the geometry of 
the donor when it undergoes glycosylation, and the nucleophilicity of the acceptor. 
 
Scheme 2. General glycosylation mechanism.a 
 
aLG = leaving group. E-X = electrophilic activator. Donor and acceptor substituents are left out for clarification. 
The fate of the acceptor proton, donor leaving group and activator is ignored. 
Earlier work on chemical glycosylations evolved around (modified) Koenings-
Knorr reactions featuring glycosyl halides as glycosyl donors.20,26,27 When activated and 
sufficiently reactive, the covalently linked leaving group can be substituted in an SN2 
substitution reaction, or isomerized to the opposite anomer followed by an SN2 
substitution. The intermediacy of the oxocarbenium ion (solvent-separated ion pair, 
SSIP, Scheme 2) in a glycosylation reaction was largely ignored as it was argued that the 
lifetime of an oxonium-type ion in water is too short even for solvent equilibration, and 
for the typical low polarity glycosylation solvents the ion pairs would not separate 
sufficiently to allow the free oxocarbenium ion to play a role as an intermediate.28,29 
Instead, exploded transition states with elongated bonds or tightly packed contact ion 
pairs (CIP) were deemed responsible for the interconversion of anomeric halides and 
some glycosylations.  
 
Donor reactivity: electronic and conformational aspects 
A large variety of anomeric leaving groups exists to date, each with its own reactivity and 
activation scheme.9,19 Using them in tandem enables orthogonal glycosylation 
strategies.30 Chemically similar groups may be distinguished by their reactivity, resulting 
in chemoselective glycosylations. The difference in reactivity is a result of the cumulative 

































The nature of the anomeric leaving group has a large impact on the outcome of a 
glycosylation reaction. In general, a better leaving group, for example a glycosyl bromide 
versus a glycosyl chloride, gives a more reactive donor.20 The higher reactivity can lead to 
a faster SN2 substitution, but also a faster anomerisation reaction to provide the opposite 
anomer. Generally, an equatorially oriented β-anomer, lacking the stabilizing anomeric 
effect, is more reactive than its α-anomer, which is often the most prevalent species 
present. The role of the more reactive β-anomer becomes more important when poor 
acceptors are to be glycosylated.22,32,33 When better leaving groups such as triflates are 
employed,34 the potency to depart is high enough to cause a large degree of SN2 
substitution but also establish a fast equilibrium between various ionic species. 
The reactivity of the donor is largely determined by the different protecting and 
functional groups present, a fact already known for over half a century.35–37 Inductive 
effects from electronegative atoms and electron-withdrawing groups destabilize the 
developing positive charge at the anomeric center upon departure of the leaving group. 
Ether-type protecting groups (benzyl, methyl, etc.) are less electron-withdrawing than 
esters (acetyl, benzoyl, etc.) and these are consequently termed “arming” and 
“disarming”, respectively (Figure 1D).38–40 Removing an oxygen substituent from the 
carbohydrate ring (e.g. in the common deoxysugars rhamnose and fucose) increases the 
reactivity of the donor.41 The configuration of the donor is important as well, with a 
pattern of hydrolysis reactivity following the order: α-galactose > α-mannose > α-
glucose. This trend is in part related to the eclipsing interactions that develop between 
neighboring substituents, upon the formation of an oxocarbenium ion-type 
intermediate.42 More severe torsional strain may be imposed on the system by ring-fusing 
the carbohydrate ring with another five- or six-membered ring, which makes the system 
more rigid. The isopropylidene, benzylidene and butane diacetal (BDA) are examples of 
such torsionally restrained systems (Figure 1A).43,44 Trans-fused six-membered ring 
systems such as the benzylidene in 2 are unable to ring flip from their di-equatorial 
setting to a di-axial constellation: the atoms end up too far apart. Additional eclipsing 
interactions are developed in the secondary ring, which must now deviate from its 
preferred chair conformation to conform to the changing geometry associated with the 
transition to the oxocarbenium ion in the primary ring. These attributes come at the cost 
of an energy penalty and these fused-ring systems are therefore torsionally disarming. 





oxocarbenium ion (Figure 1C), which is of critical importance to the stereoselectivity of 
the reaction (vide infra). 
Besides torsionally disarming the system, cyclic diol protecting groups can also 
impose electronic effects. The 4,6-O-benzylidene system is interesting in this respect, 
since it fixes the C-6–O-6 dipole such that it is directed away from the anomeric center. 
This results in the most disarming orientation of the O-6 group: the tg rotamer (Figure 
1B).45–47 The relative reactivity of different donors has been investigated by the groups of 
Fraser-Reid, Ley, and Bols complemented by an extensive study by the group of Wong, 




Figure 1. (A) Example structures of isopropylidene, benzylidene, and BDA cyclic protecting groups. (B) Top-
view Newman projection of the C-6–C-5 bond, with gg-, tg-, gt-rotamers, the C-6–O-6 dipole is indicated by 
the small arrow, and partial charges are displayed. (C) Both oxocarbenium ion conformations available for a 
donor without torsional strain, only the 4H3 conformation is available for benzylidene and BDA structures 2 
and 3. (D) Armed-disarmed principle with relative reactivity values obtained by the laboratory of Wong, 
relative to tolyl tetraacetyl-1-thio-α-D-mannopyranoside. 
 
Glycosylation stereoselectivity 
There are numerous strategies that enable the stereoselective formation of 
glycosylation linkages, but unfortunately these are often not generally applicable and 
each new glycosylation presents another challenge. Two types of products can be formed 
in a glycosylation reaction: 1,2-trans- and 1,2-cis-linked glycosidic bonds. For the former 
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type, anchimeric assistance of an acyl-type protecting group on C-2 is usually sufficient 
to direct stereoselectivity (Figure 2). This form of neighboring group participation is 
reliable, but its efficiency does depend on the other groups on the carbohydrate ring.60–64 
Double stereodifferentiation (see also next chapter) or severe steric hindrance (as is the 
case with 4,6-silylidene protected galactopyranosides) may thwart effective neighboring 
group participation.65–67  
Figure 2. 1,2-trans and 1,2-cis glycosylation strategies. 
1,2-Cis-glycosidic linkages are much more difficult to construct and can generally 
only be affected using a non-participating group at C-2. Several different approaches 
have been reported to date to install specific 1,2-cis-linkages, which for example make 
use of remote participation,68–70 site selective delivery of the acceptor, 71,72 steric screening 
from one of the ring faces by a bulky group66,67,73, or exploiting the anomeric effect during 
or after the glycosylation,74–80 among others.81–83 From a mechanistic point of view, two 
pathways may be followed: inverting a 1,2-trans-leaving group in an SN2 reaction, or 
exploiting the stereoselective addition on oxocarbenium ion-type intermediates in an SN1 
reaction. 
Several examples have been reported using the SN2 directed inversion of a leaving 
group. For example glycosyl halides can be used. Here, α-halides are generated and an 
equilibrium is set up with the more reactive β-halide.22 Substitution of the latter halide 
then provides the α-product. The same idea applies for other anomeric leaving groups 
and in situ formed anomeric functionalities, such as those formed in the presence of 
participating solvents, such as DMF, acetonitrile or diethyl ether.84–86 Inversion reactions 
also happen when the nucleophile is part of a chimeric activator, as was demonstrated 
for carboxylic acid and phosphate acceptors on the activation and inversion of 
trichloroimidates.87,88  
On the SN1 side of the reaction continuum, oxocarbenium ions and their 
associated ion pairs can provide 1,2-cis-stereoselective glycosylations. Simple 
carbocations or oxocarbenium ions have long been regarded as “flat” and unselective but 
the recent appreciation of the effect of the rich stereochemical environment of (cyclic) 
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carbohydrate oxocarbenium ions has changed that perspective. The generation of an 
oxocarbenium ion is preceded by efficient orbital overlap of the ring oxygen’s lone pair 
electrons and the antibonding σ*-orbital of the leaving group. For an axial leaving group 
the orbitals readily overlap as they have an anti-periplanar orientation leading directly to 
an oxocarbenium ion in a half-chair conformation. The opposite anomer with equatorial 
orientation must change its conformation first to accommodate efficient orbital overlap 
(which may occur with syn-periplanar arrangement), and will provide a skew-boat 
conformation.89–92 These initially formed oxocarbenium ion conformations can be 
attacked immediately, with or without steric screening from its counter ion. In the 
absence of an acceptor, or in reactions with poor nucleophiles, the oxocarbenium ion 
may change to its most stable conformation, which then dictates the stereochemical 
outcome.  
A model system to account for the stereoselectivity of cyclic oxocarbenium ions 
was devised by Woerpel and co-workers, which was termed the two-conformer model.93–
96 This model assumes that the most stable oxocarbenium ions will have a C-1–O-4/5 
double bond and therefore a flat constellation of four atoms (C-2–C-1–O-5–C-5 in six-
membered ring pyranoses and C-2–C-1–O-4–C-4 in five-membered ring furanoses). 
This gives rise to two low energy conformations of a five-membered ring (3E and E3) and 
eight of a six-membered ring (3H4, 4H3, 2,5B, B2,5, 3E, E3, 4E, E4) excluding the completely 
flat geometry. For six-membered rings the 3H4 and 4H3 half-chair conformations are 
generally energetically most favorable as these have less steric (eclipsing and 1,3-diaxial) 
interactions than their relatives in the boat and envelope conformations, resulting in two 
conformations relevant for the stereoselectivity in this model. Central to this model are 
two possible approaches for the nucleophile: from the top or bottom side, arbitrarily 
defined for the D-glycosides in the representations in Figure 3. Since furanoses have only 
a single out-of-plane ring atom, the type of nucleophilic attack is also referred to as inside 
or outside attack, relating to the concave or convex face of C-3 respectively.97 Without 
considering the type of substituents on the furanose ring, two things become readily 
apparent. Firstly, the incoming nucleophile has eclipsing interactions with the axially 
orientated substituent on C-2 when performing an outside attack, and 1,3-






Figure 3. (top) The two-conformer model for furanoses and pyranoses. (bottom) Newman projections along 
the C-1–C-2 bond visualizing the movement of the nucleophile and equatorial substituents at C-1 and C-2, and 
consequently the eclipsing interactions that occur, indicted by crossed arrows.  
Secondly, rehybridisation of the anomeric center will lead to an eclipsed C-1–C-2 
situation upon outside attack, while inside attack will provide a staggered constellation. 
In the pyranose case, attack on the top face of the 4H3 conformer will change the half-
chair conformation to a skew-boat conformation with increasing eclipsing interactions 
between the pseudo-equatorial substituents on C-1 and C-2 in the transition state.98 
Attack from the top face of the alternative 3H4 half chair, or bottom face of the 4H3 
however, will lead to a favorable chair conformation, free of eclipsing interactions, and 
has therefore a lower transition state energy. These arguments dictate the general rules 
for facial selectivity: in furanosides inside attack will be favorable where pyranosyl 
oxocarbenium ions will be preferentially attacked on the face that leads to a chair-like, 
lowest energy transition state. 
Having established the face-selective preferences of oxocarbenium ions in the 
two-conformer model, the next goal was to qualitatively and ultimately quantitatively 
predict which conformation is preferentially formed and attacked. The group of Woerpel 
has made predictions based on experimental evidence and rationalization of relative 





were gauged by glycosylating allyltrimethylsilane with a series of (partially) substituted 
furanosides and pyranosides (“stripped-down carbohydrates”). 93,94,99–102 In summary, the 
substituents prefer to occupy a pseudo-equatorial orientation to minimize steric 
interactions with its neighbors when the substituent is an electropositive/neutral group, 
such as carbon-substituent. When a substituent has an electronegative element bound to 
the cyclic oxocarbenium ion, which is the case for all carbohydrates, the preference for 
the orientation of the substituents at C-3 (for furanosides) and C-3 and C-4 (for 
pyranosides) changes dramatically. By placing them in a pseudo-axial orientation the 
oxygen (or another electronegative element) is brought closer in space to the 
oxocarbenium ion. In effect, this constellation has a more favorable dipole direction of 
the C–O bond and electrostatic stabilization from the lone electron pairs on oxygen 
towards the anomeric center. The preference for a pseudo-equatorial orientation of C-2 
is enhanced by an electronegative substituent. The decisive effect at play here is the 
hyperconjugative stabilisation of the pseudo-axially orientated C–H or C–C bond, 
overlapping its σ-orbital with the p- or π*-orbital of the oxocarbenium ion (a σ-bond of 
a carbon and an electronegative element is generally a very poor hyperconjugative σ-
bond donor). For the C-4 position in furanosides and C-5 in pyranosides, steric and 
electronic effects strongly oppose each other and the rotation around the C-4–C-5 or C-
5–C-6 bond also plays an important role. In general, most stabilization can be effected in 
the geometry that places the lone pairs on O-6 closest to the oxocarbenium ion anomeric 
carbon atom (i.e. the gg-rotamer, see Figure 1B). 
Figure 4. Stereoelectronic effects of individual substituents. The preferred conformation is reflected in each 
case by the isolated product ratios (given below the equilibrium arrows) of glycosylation with 
allyltrimethylsilane, based on the inside-attack model. 
 
With this set of preferences Woerpel and co-workers have formulated qualitative 
selectivity rules, and substantial experimental evidence has corroborated these (Figure 
4). In some cases, an axial-rich half-chair conformation may have interfering 1,3-diaxial 
interactions with the incoming nucleophile, especially with the C-5 position (See Figure 
































model can be called into question when other conformations start to become relevant, 
including skew-boat and twist structures. A quantitative approach based on Density 
Functional Theory, predicts the favorable geometries of an oxocarbenium ion based on 
their relative energies, and their thermodynamic distribution can dictate the 
stereoselectivity behind the reaction.104–106 The contribution of unusual conformations 
and their selectivity are difficult to estimate and quantum mechanical calculations from 
these structures have yet to give a decisive answer. Ultimately, the energy difference of 
the transition states leading to the different products and their pre-equilibria in a Curtin-
Hammett type scenario are the deciding factors in the reaction outcome.22,107  
 
Conclusions 
The glycosylation reaction is not just a simple substitution reaction proceeding with 
either an SN2 or SN1 reaction profile. The buildup of positive charge at the anomeric 
center, a secondary carbon atom, can be sustained by the lone pairs of the ring oxygen 
atom, but is inductively destabilized by the oxygen ring-substituents. Overall, the 
intricate balance of stabilizing and destabilizing stereoelectronic effects in the system 
determines how well the positive charge can be accommodated during a glycosylation 
reaction. Depending on the nucleophilicity of the acceptor, stronger or weaker 
electrophilic species may be required for an effective glycosylation. Currently it is 
impossible to predict, up front, where on the SN2-SN1 reaction continuum a glycosylation 
will take place and deeper insight into the factors that decide this position (reactivity of 
the activated donor, reactivity of the acceptor, role of the solvent) are dearly needed. 
 
Outline of this thesis 
In this thesis several approaches have been undertaken to systematically investigate the 
glycosylation mechanism. The main focus of the content described here is the origin of 
the stereoselectivity observed in glycosylation reactions and the constructions of models 
with a qualitative predictive value. Both reaction partners, the donor and acceptor, are 
systematically studied. Chapter 2 provides an overview of the current ideas and findings 
regarding the reactivity of the acceptor nucleophile. Although many isolated cases have 
been reported on the influence of the acceptor on the outcome of a glycosylation reaction, 
a focused study on how to exploit acceptor reactivity has not before been reported. 
Chapter 3 introduces a set of fluorinated ethanol-based nucleophiles to serve as model 





glycosylation reactions. With the use of this model set it is shown how the selectivity of 
glycosylations of three types of glycosyl donors changes upon changing acceptor 
nucleophilicity, as a consequence of a change in reaction mechanism. Chapter 4 expands 
on Chapter 3 with a focus on how the stereoselectivitiy of glucosazide-based donors 
changes depending on acceptor nucleophilicity. Both the reactivity of the donor and of 
the acceptor have impact on the outcome of the glycosylation reaction selectivity. 
Whereas the donors in Chapter 4 all had a 4,6-tethering group, in Chapter 5 a 
glucosazide with a 3,4-tethering group (a butane diacetal, BDA) is investigated. Although 
the conformational restraint imposed by the 3,4- and 4,6-tethering protecting groups is 
similar, it is shown that the different torsional and electronic effects of the groups have a 
major effect on the glycosylation results. Chapter 6 provides a systematic approach to 
establish a first set of relative reactivities for carbohydrate acceptors. Two donors from 
Chapters 3 and 4 are used as model donors because the stereoselectivity of glycosylations 
of these donors was shown to strongly correlate with the reactivity of the acceptor 
nucleophiles. A broad and systematic set of C-4–OH acceptors, varying in benzyl and 
benzoyl protecting groups, as well as the nature of the C-6 functionality are examined 
and structure-reactivity-stereoselectivity relationships are established. Chapter 7 
describes the syntheses, of the complete set of diastereoisomeric ribo-, arabino-, xylo- and 
lyxofuranoside donors, modified at the C-2 and C-5 position. These are used in Chapter 
8, to establish the effect the substituents (C-2–N3, C-2–F, C-5–CO2Me) have on the 
stereochemical outcome of the glycosylations of these donors. The putative 
oxocarbenium ion intermediates are studied by DFT calculations. Chapter 9 provides a 
concise summary of the results of this thesis, as well as an outlook for extended 
investigations and new paths to take to unravel the details of the glycosylation 
mechanism. 
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The chemical glycosylation reaction involving the union of two species to form a new 
glycosidic bond is dependent on a large set of variables.1–3 The previous chapter 
introduced the basic concepts of reactivity and selectivity in glycosylation reactions, 
primarily from the perspective of the glycosyl donor. As amply illustrated by the vast 
amount of chemical carbohydrate literature, the donor is the reactant to which most of 
the attention has been directed and it is now well appreciated how the reactivity depends 
on the substitution pattern of the glycoside and how donor reactivity affects the outcome 
of a glycosylation reaction. The reactivity of the acceptor, on the other hand, is less well 
studied and detailed knowledge of this reaction partner may provide new mechanistic 
understanding and practical guidelines for glycosylation reactions. Although it was 
stated by Paulsen in 1982 that the nature of the acceptor is mostly a priori determined, 
differences in reactivity can influence the glycosylation outcome both in terms of 
stereoselectivity and isolated yield.4 Not many studies directed at understanding and 
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harnessing acceptor reactivity have been reported and, notwithstanding the systematic 
studies that have been reported and that will be described in this Chapter, the influence 
of the acceptor on the outcome of a glycosylation reaction is often neglected. 
Numerous examples of glycosylation reactions indicate that the reactivity of the 
acceptor, like that of glycosyl donors, can be manipulated by changing protecting 
groups.5–15 Unfortunately, most studies that report on new glycosylation methods, 
strategies or mechanisms, employ a rather variable set of acceptors, often chosen because 
of ease of availability, or used because a target oriented approach is taken. As a result the 
acceptors used in these studies differ greatly in steric and electronic properties, making 
it difficult to establish structure-reactivity relationships.16–21 Unexpected 
stereoselectivities and/or poor yields, as a result of ill understood acceptor reactivity, 
continue to be reported,22–26 clearly indicating the need for more systematic and deeper 
insight into how glycosylations are influenced by the reactivity of the glycosyl acceptor. 
At a time when the mechanism of glycosylation and the reactivity of the donor is 
understood better than ever before, the details of the mechanism and the influence of the 
acceptor therein will be an important pursuit to arrive at a more complete and 
generalized picture of glycosylation reactions.27 This Chapter surveys the systematic 
approaches that have been undertaken to probe the influence of the reactivity of the 
acceptor on the outcome of a glycosylation reaction and describes methods to analyze 
and quantify acceptor reactivity. 
Observations on acceptor reactivity 
In two early examples by Sinaÿ in 197828 and Paulsen in 1981,29 the influence of the 
acceptor on the glycosylation outcome was recognized. The work of Sinaÿ clearly showed 
how the yield of glycosylations of galactosyl bromide 1 (Table 1) varied upon changing 
the protecting groups on the acceptor. N-acetyl-glucosamine acceptors 2-5, with an O- 
benzyl (2) or O-allyl (3, 4) group at C-3 gave good yields, regardless of the nature of 
Table 1. Acceptor protecting groups influencing glycosylation yield. (Sinaÿ, 1978). 
Acceptor Product Yield (%) 
2 6 87 
3 7 77 
4 8 78 
5 9 5 
All glycosylations proceeded with exclusive β-selectivity. 
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the protecting group at C-6 (O-benzyl or O-acetyl). In contrast, the yield dropped to a 
mere 5% when the acceptor bearing an O-acetyl at the C-3 (4) was used. 
Paulsen and Lockhoff examined a set of donors (12-14, Table 2) with two very 
similar rhamnosyl acceptors, differing only in the anomeric protection (O-benzyl in 10 
vs O-trichloroethyl in 11). In this set of experiments both the influence of the reactivity 
of the donor (12>13>14) and acceptor (10>11) was evident. The trichloroethyl protected 
rhamnosyl acceptor 11 provided relatively more of the α-linked products than the benzyl 
protected analogue 10, which could be correlated to the lower reactivity of acceptor 11. 
The more nucleophilic 10 can displace the α-bromide of ‘armed’ donor 12 to provide the 
β-product. Lowering the reactivity of either the donor or the acceptor hampers this direct 
substitution pathway and the less reactive acceptor can only substitute the more reactive 
β-bromide, formed by in situ anomerization with HgBr2, giving the α-galactosyl linkage. 
Table 2. Decrease in acceptor reactivity leads to increase in α-selectivity. (Paulsen and Lockhoff, 1981). 








19 : 81 
(75%) 
18 
81 : 19 
(82%) 
13 16 
34 : 66 
(66%) 
19 
100 : 0 
(54%) 
14 17 
100 : 0 
(81%) 
20 
100 : 0 
(87%) 
Yields of combined isolated anomers. Reagents and conditions: donor (1 eq.), acceptor (1 eq.), powdered 4Å 
M.S., HgBr2 (0.1 eq.), DCM, room temperature (20), 0°C (17), or -20°C (15, 16, 18, 19).
In another example by Paulsen and Lebuhn the silver-silicate promoted 
glycosylation of mannosyl bromide 21 with different glucose and glucosamine acceptors 
was investigated (Table 3). While the conformationally locked glucosamine acceptor 23 
Table 3. Conformationally restricted acceptors provide more β-product. (Paulsen and Lebuhn, 1983). 
Acceptor Product Yield (%) α : β 
22 25 75 α only
23 26 65 1 : 6
24 27 63 1 : 5.5
Yields of the β-anomer. Reagents and conditions: donor (1.1 eq.), acceptor (1 eq.), powdered 4Å M.S., silver-





























and glucose acceptor 24 proved efficient acceptors for the synthesis of 1,2-cis-linked 
disaccharides 26 and 27, likely formed through an SN2-type displacement of the activated 
bromide, the use of N-acetyl glucosamine 22 only gave the undesired α-product.30 
Over the years it has become clear that N-acetylglucosamine C-4–OH acceptors 
are generally very poor nucleophiles.4 In a detailed study by Crich and co-workers, 
several glucosamine acceptors (30-34, Table 4) were used to investigate the underlying 
reasons why N-acetylglucosamine acceptors behave so poorly in glycosylation 
reactions.31 Glucosamine acceptors bearing various N-protecting groups were 
investigated (acetyl 30, phthalimide 31, azide 32, and imides 33 and 34). Glycosylations 
of these acceptors with mannosyl sulfoxide 28 are reported in Table 4 and the results 
showed the azide to be far superior to the imides, which in turn are superior to amide 30 
in terms of isolated yield. Competition experiments of 30, 31, and 32 by glycosylating a 
mixture of an equimolar amount of all three acceptors and analyzing the product mixture 
 







α : β 
30 38 9 β only 
31 39 33 β only 
32 40 70 β only 
33 41 47a β only 
34 42 39a β only 
35 43 8 β only 
36 44 63 β only 
37 45 39 β only 
36 46 87 1 : 1.2 
37 47 18 1 : 2.4 
Reagents and conditions: for 28: donor (0.2 mmol), DTBMP (0.4 mmol), Tf2O (0.22 mmol), DCM (8 mL), then 
acceptor (0.4 mmol, 2 mL DCM), -78°C to 0°C; for 29: donor (0.1 mmol), Ph2SO (0.28 mmol) Tf2O (0.15 mmol), 
toluene/DCM (3/1, 1 mL), -78°C to -40°C then TTBP (0.5 mmol, 0.5 mL DCM), acceptor (0.1 mmol, 1 mL 
DCM), -78°C to room temperature. 




by HPLC, revealed a ratio of 1:3:10 (30:31:32) supporting the results of the individual 
glycosylations. An intermolecular hydrogen-bonding network from the amide (NH and 
C=O) was hypothesized to be at the basis of the poor reactivity of 30 and to support this, 
picolyl protected 35 and 36 were prepared to disrupt this network by favoring 
intramolecular hydrogen-bonding. Glycosylation with C-4–OH acceptor 35 was as 
ineffective as with benzylated acceptor 30. To account for this result the hydrogen-bond 
interaction between C-4–OH and the picolyl-N was forwarded as destructive for the 
acceptor reactivity, instead of making the acceptor more reactive. The C-6–OH 
derivatives 36 and 37 in comparison gave the anticipated result. Intramolecular 
hydrogen-bonding between the picolyl and amide provided a more reactive acceptor, 
leading to a higher yield in the glycosylation reaction with 36, with respect to the 
coupling of C-3–O-benzyl acceptor 37 which is incapable of forming an intramolecular 
hydrogen-bond. The use of glucose donor 29, activated under dehydrative conditions, 
corroborated these findings, and a good yield was obtained in the condensation with 
acceptor 36 while the coupling of 29 and acceptor 37 proceeded with poor yield. Cyclic 
carbamates have also been used as a protecting group to provide appropriate 
glucosamine C-4–OH acceptors. The cyclic nature of the 2-N-3-O-carbamate ties back 
the group at C-3, rendering the C-4–OH more accessible.32–34 
Rúveda and co-workers investigated the relative reactivities of a series of 
dimethylmaleimide (DMM) protected glucosamine acceptors (49, 51, and 52, Table 5) 
by competition experiments.35 The reactivity of these nucleophiles was compared to that 
of N-acetyl glucosamine acceptor 53 and cyclic carbamate 50. From these results it  
 
Table 5. Acceptor competitions revealed the effect of protecting groups on the reaction rates. (Rúveda, 2006). 
 
Acceptors Products Ratio 
50 : 49 54 : 55 1 : 4 
50 : 51 54 : 56 1.5 : 1 
50 : 52 54 : 57 7 : 1 
50 : 53 54 : 58 11 : 1 
 
Reagents and conditions: two acceptors (1 eq. each), donor (1.2 eq.), TMSOTf (1.25 eq.), 4Å M.S., DCM/CH3CN 




becomes clear that benzoyl groups in the acceptor have a retarding effect on the 
glycosylation rate, as 49 proved to be the most reactive acceptor, followed by 51 and 
finally 52. Also in this study the poor reactivity of N-actyl glucosamine 53 is apparent. 
Another set of competition experiments, comparing benzylidene allosamine and 
glucosamine acceptors with the DMM N-protecting group, was conducted by the same 
research group (Table 6).36 Allosamine 60 by far outcompeted its epimeric acceptors 61 
and 62. These results show that axially orientated hydroxyl groups, as in 60 (C-3–OH), 
although sterically more encumbered, are not always less reactive than their equatorial 
counterparts.37 In this particular series, the relative reactivity results were supported by 
NMR and computational studies on the possibility of hydrogen-bond formation between 
the C-3–OH and the maleimide C=O. 
 
Table 6. Acceptor competitions revealed the effect of protecting groups on the reaction rates. (Rúveda, 2011). 
 
Acceptors Products Ratio 
60 : 61 64 : 65 10 : 1 
60 : 62 64 : 66 13 : 1 
61 : 62 65 : 66 2 : 1 
61 : 63 65 : 67 5 : 1 
62 : 63 66 : 67 3 : 1 
 
Reagents and conditions: two acceptors (1 eq. each), donor (1.1 eq.), TMSOTf (0.28 eq.), 4Å M.S., DCM, -25°C. 
 
The influence of the C-6 protecting group on the regioselectivity of DMM 
protected glucosamine acceptors 68-70 when glycosylated with donors 48 and 57 was 
investigated by the group of Rúveda (Table 7).38 The regioselectivity for the C-3-OH over 
the C-4–OH increased in the order of C-6–OBz > C-6–OTBDPS > C-6–OBn. The C-6–
OBz in 68 makes the C-4–OH more electron poor than the C-3–OH, leading to the 
strong preference to glycosylate the latter alcohol (C-3/C-4, 1:0 for 48, and 2:1 for 67). 
The bulky TBDPS sterically hampers the nucleophilic attack of the C-4–OH, leading to 
improved C-3/C-4-regioselectivity with respect to the C-6–OBn (compare 5:1 for 70 and 
3.2:1 for 69, with donor 48). Notably, the β-anomeric acceptors showed different 
regioselectivities (see also Table 16), which was again attributed to the difference in 
hydrogen-bonding capacity of the DMM group with the C-3-OH in the different 




anomers.39,40 The conformational change at the reducing end of an acceptor in a 
monosaccharide, disaccharide or oligosaccharide, has been reported to influence 
reactivity of the nucleophilic hydroxyl on the other side of the acceptor.41–43  
Table 7. Stereoelectronic effects of protecting groups influence the regioselectivity of diols. (Rúveda, 2007). 
 
 
Donor Acceptor Yield (%) (1→3) : (1→4) 
48 68 68 1 : 0 
48 69 71 3.2 : 1 
48 70 73 5 : 1 
59 68 91 2 : 1 
59 69 56 1 : 1 
59 70 50 1.6 : 1 
Reagents and conditions: donor (0.11 mmol, 1.1 eq.), acceptor (0.1 mmol, 1 eq.), 4Å M.S., TMSOTf (0.21 mmol, 
2.1 eq.), DCM/CH3CN (37/1), -25°C. 
The group of Konovov investigated the difference in reaction rates by observing 
differences in the activation temperature of the reaction (Table 8).44 Two donors of 
varying reactivity (71 and 72) were glycosylated with acceptor 73, bearing two electron-
withdrawing benzoyl groups, and with acceptor 74 having the cyclic silylidene protecting 
group. The activation temperature varied from -42°C to -22°C following the order of 
reactivity of both the donor and acceptor. 
 
Table 8. The impact of acceptor reactivity on the temperature of activation. (Kononov, 2014). 
 





α : β 
71 73 75 -22 66 1 : 2 
71 74 76 -30 84 1 : 6.3 
72 73 77 -39 92 1 : 4.5 
72 74 78 -42 80 1 : 3 
Reagents and conditions: donor (0.042 mmol, 1.5 eq.), acceptor (0.028 mmol, 1 eq.), powdered 4Å M.S., NIS 




In the early 90’s Spijker and van Boeckel were the first to introduce the concept 
of double stereodifferentation45 in synthetic carbohydrate chemistry.46 They 
unambiguously showed how the chirality of the coupling partners could impact the 
transition state of the glycosylation reaction. Carbohydrates experience different steric 
effects when coupled to different enantiomers of the same reaction partner. In their 1991 
publication, two situations are highlighted (Scheme 1). Either two enantiomeric donors 
(D-fucosyl bromide D-79 and L-fucosyl bromide L-79) were coupled to the same D-
glucosamine acceptor 80, or the absolute chirality of the acceptor was changed from D-
diacetoneglucose D-82 to its L-enantiomer L-82 while keeping the donor the same (D-
glucosyl bromide 81). Remarkable results were obtained. While neighboring group 
participation to provide 1,2-trans-glycosides is generally a very powerful 
stereocontrolling phenomenon, the glycosylation of donor D-79 and acceptor 80 
provided an anomeric mixture (α:β, 2:1). The use of the enantiomeric donor L-79 
restored the expected trans-selectivtity (α:β, 1:8.4). The difference in α:β product ratio is 
less pronounced in the second case, in which acceptor D-82 provides more α-product 
than its enantiomer L-82. The observed changes in stereoselectivity are clearly the result 
of drastically different steric interactions in the diastereoisomeric transition states. 
 
Scheme 1. Double stereodifferentation in glycosylation reactions. (Spijker and van Boeckel, 1991). 
 
Reagents and conditions: AgOTf, 2,6-di-tert-butylpyridine (0.8 eq.), 4Å M.S., DCM, -50°C. 
Another clear manifestation of the effect of the shape of the acceptor on the 
outcome of a glycosylation reaction can be observed when carbohydrate acceptors are 
locked in ‘inverted’ chair conformations. As was shown above, conformationally locking 
a glucose/glucosamine acceptor in a 1C4 chair places the C-4–OH in a position that is well 
accessible leading to a better nucleophile.30,47 It is well established in the field of heparin 
synthesis that glycosylations of glucosazide donors with L-idose/L-iduronic acid 
acceptors, generally adopting a 1C4 chair conformation, proceed with excellent α-




selectivity (an important manifestation of double stereodifferentiation).48,49 Based on this 
knowledge Seeberger and co-workers decided to lock D-glucuronic acid ester acceptors 
for heparin synthesis in a similar 1C4 chair conformation (Table 9).50, In condensations 
with glucosazide donor 84 D-glucuronic acid acceptor 85 provided an anomeric mixture 
(88; α:β, 3:1) in relatively low yield. By conformationally locking the glucuronate 
acceptor in the inverted 1C4 conformation (as in 86), a high yield and excellent α-
selectivity was obtained in the condensation with 84. The use of L-iduronic acid acceptor 
87 provided an analogous result. 
 





α : β 
85 88 57 3 : 1 
86 89 86 α only 
87 90 91 α only 
Reagents and conditions: donor (1.25 eq.), acceptor (1 eq.), TBSOTf (0.125 eq.), 4Å M.S., DCM, -78°C to room 
temperature, 2.5 h. 
A rigid conformational lock is not always necessary to mold an acceptor in a 
reactive conformation, as was described by Zhang et al. (Table 10).51 They showed that 
the conformational rigidity of disaccharide acceptor 92 hampered the glycosylation with 
donor 91. Changing the reducing end of the disaccharide acceptor from a β-O-
(azidopropyl) mannuronic acid to an α-S-tolyl manuronic acid (93), provided a more  
 
Table 10. Conformational flexibility of acceptor 161 dramatically increased glycosylation yield. (Codée, 2015). 
 
 
Acceptor Product Yield (%) 
92 96 45 
93 97 91 
94 98 71 
95 99 95 
All glycosylations proceeded with exclusive β-selectivity. Reagents and conditions: donor (3 eq.), acceptor (1 


































flexible acceptor, as judged from the broadened resonances observed in NMR- 
spectroscopy. The flexible character of acceptor 93 led to greatly enhanced glycosylation 
productivity. The contribution of the 1C4 structure in the conformational equilibrium of 
93 was verified by the use of model disaccharide acceptors having a conformationally 
locked 1C4 reducing end saccharide (either an α-O-methyl (94) or an α-S-tolyl (95)). 
Systematic studies on acceptor reactivity 
Although it is clear that the nature of the protecting groups has an influence on the 
glycosylation outcome it is often difficult to dissect electronic, steric and conformational 
effects.52 Woerpel and co-workers have reported a systematic study relating the effect of 
the nucleophilicity of the acceptor on the outcome of a glycosylation reaction, using both 
C- and O-model nucleophiles.53–57 Table 11 reports the results of both sets of
nucleophiles, with 2-deoxyglucosyl acetate or ethanethiolate donors 108 and 109. The
trend that becomes apparent from these results is that poorer nucleophiles provide more 
α-product. To account for these results, it was reasoned that the poorest C- and O-
nucleophiles 100 and 104, as assessed by Mayr’s nucleophilicity parameter N,58–63 or the
field inductive parameter F,64 react with the glucosyl oxocarbenium ion that
Table 11. Model C- and O-nucleophilic acceptors in glycosylations correlating nucleophilicity to 
stereoselectivity. (Woerpel, 2008-2010). 




100 1.8 110 80 89 : 11 
101 4.4 111 79 43 : 57 
102 6.2 112 83 61 : 39 
103 8.2 113 83 45 : 55 




104 0.38 114 80 83 : 17 
105 0.29 115 78 67 : 33 
106 0.15 116 69 56 : 44 
107 0.0 117 82 51 : 49 
aMayr’s nucleophilicity parameter. bField inductive parameter.61 Reagents and conditions for acetyl donors: 
donor (1 eq.), acceptor (4 eq.), BF3OEt2 (1.5 eq.), DCM, -42°C to 0°C. Reagents and conditions for thiodonors: 





































preferentially takes up a 4H3 conformation (119), in a stereoselective manner from the α-
face. The selectivity is reduced when the nucleophilicity is increased. This erosion of 
stereoselectivity (from 110 to 113, and from 114 to 117) is caused by alternative reaction 
pathways becoming accessible for the stronger nucleophiles: either a non-selective SN1 
reaction in which both sides of oxocarbenium ion 119 are attacked, or an SN2-type 
substitution. 
In line with the results of Woerpel, a glycosylation study of linkers 121 and 122 
with donor 120 by the group of Seeberger, found the more nucleophilic 121 to give high 
β-selectivity whereas the weaker nucleophile 122 gave mainly the α-product (Scheme 
2).65 These results can be explained by an SN2-type substitution of the reactive primary 
alcohol on the intermediately formed anomeric α-triflate, where attack of the weaker 
difluoro acceptor requires a more reactive electrophile, either an intermediate 
oxocarbenium ion or the corresponding β-triflate. By tweaking the reaction temperature 
and solvent, nearly complete α-stereoselectivity could be obtained. A variety of different 
donors provided a similar reactivity-stereoselectivity trend. 
 
Scheme 2. Linkers of varying nucleophilicity gave opposite glycosylation stereoselectivity. (Seeberger, 2016). 
 
Reagents and conditions: donor (1.5 eq.), acceptor (1 eq.), NIS (1.5 eq.), TfOH (0.2 eq.); a) DCM, -20°C; b) 
CH3CN -40°C; c) toluene/dioxane (3/1), room temperature. 
Le Mai Hoang and Liu introduced donors equipped with a 2-cyanobenzyl group 
at the C-2-OH and they investigated these donors, using a preactivation glycosylation 
scheme, with a panel of acceptors (Table 12).66 Next to the model acceptors n-butanol 
125 and trifluoroethanol 104, this study also included carbohydrate acceptors with 
benzyl and acetyl protection groups. It was observed that the stronger nucleophiles 
stereoselectively provided the β-linked product, while the use of weaker nucleophiles led 
to the generation of the α-linked products in a fully stereoselective manner.67 The 
stronger nucleophiles 24, 125-127 can partake in an SN2-like substitution of the anomeric 
α-triflate, a closely related contact ion pair, or as suggested by the authors by a 
substitution of the intermediate α-nitrilium ion 131, to provide selectively the β-product. 




directed by hydrogen-bonding with the cyano functionality on the C-2–O-protecting 
group to the α-face of the donor (as in 132), as poorer nucleophiles are generally also 
stronger acids, forming hydrogen-bonds more readily. Alternatively, the weaker 
acceptors may also attack the oxocarbenium ion selectively on the α-diastereotopic face 
without coordination by the 2-cyanobenzyl group.  






α : β 
125 133 90 β only 
24 134 86 β only 
126 135 89 β only 
127 136 86 β only 
128a 137 87 α only 
129 138 81 α only 
104a 139 71 α only 
Reagents and conditions: donor (1 eq.), acceptor (1.3 eq.), Ph2SO (1.4 eq.), TTBP (3 eq.), Tf2O (2.8 eq.), toluene 
-60°C. aEt2O was used as solvent. 
A systematic study by Demchenko revealed the effect of acyl vs alkyl protecting 
groups and the position of the free alcohol on the carbohydrate acceptors on the 
stereochemistry of glycosylations with STaz donor 140 (Table 13).68 The acceptors 
studied, varied from tri-O-benzyl protected acceptors 126, 127, 141, and 142 to tri-O-
benzoyl protected acceptors 143-146. While the yields of the silver triflate mediated 
reactions proved independent of acceptor reactivity, the stereoselectivity of the 
glycosylations involving the O-benzyl protected acceptors is generally lower than the 
selectivity for the same acceptors bearing O-benzoyl groups. The latter group 
consistently give higher α-selectivities. It was observed that the O-benzyl protected 
acceptors were converted faster to their respective products than their O-benzoyl 



























strong nucleophiles: weak nucleophiles:
Ph2SO, Tf2O
TTBP




Table 13. Differentially substituted glucose acceptors provide a trend in reaction times and stereoselectivity. 
(Demchenko, 2010). 
 





α : β 
126 147 1.5 81 2.7 : 1 
143 148 2 89 7.4 : 1 
141 149 14 90 6.8 : 1 
144 150 16 89 11.7 : 1 
127 151 8 85 6.5 : 1 
145 152 12 87 12.1 : 1 
142 153 6 87 9.3 : 1 
146 154 12 72 12.0 : 1 
Reagents and conditions: donor (0.11 mmol, 1.1 eq.), acceptor (0.10 mmol, 1 eq.), 3Å M.S., AgOTf (0.22 mmol, 
2 eq.), 1,2-dichloroethane (2 mL), room temperature. 
In an extension of the work of Demchenko, Kalikanda and Li investigated the 
effect of different configurations of the glycosyl acceptors. In one of the few systematic 
studies devoted to acceptor reactivity, they studied twelve tri-O-benzylated acceptors, 
having either a gluco-, galacto-, or manno-configuration in glycosylations with 
galactosazide donor 155 (Table 14).69 Again, it becomes clear that the most reactive 
alcohols react in a β-selective manner, while the least reactive nucleophiles provide α-
linked products. Although the exact mechanism of these glycosylations are not clear, the  
 





α : β 
126 164 98 β only 
141 165 56 1.8 : 1 
127 166 53 1 : 3.4 
142 167 68 α only 
156 168 75 1 : 4 
157 169 63 α only 
158 170 65 3 : 1 
159 171 90 1.3 : 1 
160 172 90 1 : 10 
161 173 81 1.2 : 1 
162 174 82 1 : 4.7 
163 175 93 α only 
















































































result show that in general, the primary alcohols are the most reactive and the secondary, 
axially orientated hydroxyls are the least reactive. Notably, the reactivity order, as 
assessed from the α/β-product ratio, in the glucose series matches those established in 
Demchenko’s study described above.68 However, the relative order of reactivity may 
strongly depend on the donor used and the steric interactions between donor and 
acceptor in the product forming transition state.  
In fact, the relative reactivity of two alcohol nucleophiles can even be reversed 
depending on the donor system used and it has already been suggested by Paulsen that 
for an optimal glycosylaton outcome the reactivity of both reaction partners should be 
“matched”.70–73 This becomes apparent form the following striking examples. Scheme 3 
shows an attempted synthesis by van Boom and co-workers of a mycobacterial 
phospholipid using mannosyl donor 176 and myo-inositol acceptor 177.74 Glycosylation 
of the C-2–OH of this acceptor proved ineffective, but the construction of the desired 
pseudo-trisaccharide 179 in a different order was successful. In the event, pseudo-
disaccharide 178, in which the mannosyl substituent had already been installed at the C-
2–OH, could be effectively glycosylated at the inositol C-6–OH with mannosyl donor 
176 to give product 179 in 84% yield.75 Similar results were later reported by Fraser-Reid, 
who noted a distinct preference of donors 181 and 183 for different alcohols on diol 180. 
 
Scheme 3. Donor-acceptor match and mismatch, led to the formulation of reciprocal donor-acceptor 
selectivity. (van Boom, 1990, 1992; Fraser-Reid, 2000). 
 
Reagents and conditions: van Boom: donor (1.1 eq.), acceptor (1 eq.), NIS (1.2 eq.), TfOH (0.24 eq.), DCE,  
-10°C. Fraser-Reid: donor (1.3 eq.), acceptor (1 eq.), NIS (1.3 eq.), TBSOTf (cat), DCM, room temperature. 




The preference of the equatorial hydroxyl in structures 178, 180, and 184 to be 
glycosylated with a donor bearing a participating group (176 or 181) is evident from the 
results in Scheme 3. However, donor 183, bearing a non-participating benzyl group 
preferentially glycosylates the axial hydroxyl.76,77 From these observations Fraser-Reid 
developed the concept of reciprocal donor acceptor selectivity (RDAS), to classify 
reactions of diols that have different regioselective preferences towards different 
donors.78–81 The RDAS concept still awaits a better mechanistic explanation but the 
counter-intuitive outcome of several more recent reactions have been interpreted with 
this phenomenon.82–86  
Quantification of acceptor reactivity 
Notwithstanding the progress that has been made in computational chemistry, only few 
attempts have been reported to investigate the nucleophilicity of glycosyl alcohol 
acceptors. The Fukui function, and its atom-condensed numerical indices provide a 
measure of change in electron density at the atom of interest when an electron is 
subtracted (or added). The Fukui indices have been reported as a measure for site 
selectivity of electrophilic (f –) or nucleophilic (f +) reactions. For the reaction of the OH-
nucleophile on an electrophilic center, the index f – can be computationally approached. 
Kalikanda and Li have computed Fukui f –-indices for a series of mannosyl diol acceptors 
(Table 15).87 The higher value of the two computed for each diol system will indicate the 
regioselectivity of the reaction. Indeed, the diols 187 and 189 are completely 
 
Table 15. Fukui values determined for mannosyl diol acceptors. (Kalikanda and Li, 2010). 
  
   
Entry Electrophile Ratio O3/O2 Ratio O3/O2 Ratio O3/O2 
1 Ac2O (+pyridine) 6: 1 3 : 2 1 : 0 
2 
 
1 : 0 3 : 1 1 : 0 
Thiophenyl and trichloroimidate donors also gave trisaccharide byproducts, the disaccharides were formed 
with the same selectivity regardless of the donor. Atom-condensed Fukui values fm- were based on Mulliken 
charges and were obtained by DFT (Q-CHEM 3.2, B3LYP/6-31+G*). Reagents and conditions: donor (1 eq.), 




stereoselective in experimental glycosylations with donor 186 and with acetic anhydride. 
When the Fukui values are close to each other a loss in stereoselectivity is observed (as 
for 188), the preference then found can be a result of the different steric requirements 
and hydrogen-bonding capabilities.88 
The group of Rúveda and Stortz also employed Fukui functions, and discussed 
the chemical hardness/softness and atomic charges as indicators for the relative reactivity 
of a series of acceptors (190-192, Figure 1). They reached the conclusion that 
carbohydrate acceptors and donors are neither well described by hard-hard (atomic 
charges) interactions nor by soft-soft (Fukui functions) interactions.35,39 The chemical 
softness (s) in these examples provided the best correlation with experimental results (see 
Table 5), with the lowest sO-4 value in 190 corresponding to the most reactive acceptor 
(49). 
 
Figure 1. Computation evaluation of relative acceptor reactivities. (Rúveda, 2006). 
 
Atomic charge q, atom condensed Fukui value f and local chemical softness s are determined by multiple 
approaches, see the original publication for details. 
 
In a different approach by the same group, the reactivity of the acceptors was 
assessed by calculation of the methylated regioisomeric acceptors (see examples 194 and 
195).89 The charged structures served to mimic the glycosylation transition state and 
allow for the investigation of the influence of intramolecular hydrogen-bonding on the 
stability and geometry on the acceptor part.90,91 Table 16 reports the experimental and 
computational results of a variety of diol acceptors (see also Table 7 above). 
Galactopyranose and -furanose donors 59 and 48 were glycosylated with glucosamine 
acceptors 68, 69, 198, and 199, and allosamine acceptors 196 and 197. Experimentally, 
acceptors 196 and 197 gave exclusive condensation with donor 59 at the axial C-3 
position rather than the equatorial C-4 position. The calculated energy difference 
between the isomeric cationic structures 194 and 195 and their respective α-anomers 
provided evidence in support of the regioselectivities observed. Applying the same 
technique to glucosamine acceptors 68, 69, 198, and 199, the calculated energy 




differences again correlated well with the experimentally observed regioselectivity ratios, 
bar the glycosylation pair 59 and 198. The computational gas-phase approach may be a 
shortcoming in this case, and the steric hindrance in the transition state with a 
carbohydrate donor will be significantly different. In benzylidene allose diols 200 and 
201 the C-3–OH also proved to be the most reactive nucleophile, both experimentally 
and computationally. Questioning whether the computational method would allow the 
comparison of the reactivity of individual acceptors with a single free hydroxyl group, 
the authors compared the energies of formation (from the neutral hydroxyl acceptor and 
methyl cation) of structures 202 and 203. The energy difference ΔΔE of 7.9 kcal∙mol-1 
between the two systems is in agreement with the observed reactivity difference (Table 
6; 61/63, 5:1). It appears that this relatively simple method is a promising way to estimate 
relative acceptor reactivities qualitatively when a higher level of theory, a larger set of 
acceptors, and an experimentally well-understood donor/activator system is used. 
 











196 1 : 0   -8.64 
197 1 : 0   -6.93 
68 2 : 1 1 : 0  -4.60 
69 1 : 1 3.2 : 1  -1.85 
198 1 : 13 1 : 1  -0.03 
199 0 : 1 1 : 2.9  +2.15 
200   2.6 : 1 -4.39 
201   1.2 : 1 -2.25 
 
Energies obtained by DFT (Jaguar 6.0, B3LYP/6-31+G**). Reagents and conditions: donor (1.1 eq.), acceptor (1 










































Figure 2. Anti-periplanar relationship between the ring oxygen and the C-4 substituent in methyl glucoside. 
Bols and Inouye have taken a rather different approach to estimate the reactivity 
of different carbohydrate alcohols. They evaluated model systems in which specific 
hydroxyl groups were changed to amine functions.92,93 The pKas of their ammonium salts 
were determined by titration and the results are displayed in Table 17. The pKa values 
indicate the 6-NH2 group to be the most nucleophilic (towards H3O+). The order of 
reactivity in glucose found with aminoglycosides 204-207a/b, C-6–NH3+ > C-3–NH3+ > 
C-2–NH3+ > C-4–NH3+, roughly corresponds with the nucleophilicity on the parent 
hexoses.94–96 Using the pKa data in Table 17, the authors established correlations between 
the effects of the neighboring substituent and the pKa values of the ammonium group. It 
was pointed out that an anti-periplanar arrangement of the C-4–N and the C-5–O in 
206a/b/d (Figure 2), but also of C-2–N and C-1–O in 204a/b/d led to a less basic NH2 
group.97 
Table 17. pKa values of aminosugars. (Inouye, 1968; Bols, 2011). 
 
Position α-Glc pKa β-Glc pKa α-Gal pKa α-Man pKa 
2-NH3+ 204a 7.5 204b 7.2 204c 7.9 204d 7.2 
3-NH3+ 205a 7.8 205b 7.6 205c 8.0 205d 8.1 
4-NH3+ 206a 6.8 206b 6.7 206c 7.3 206d 7.2 
6-NH3+ 207a 8.9 207b 8.6 207c 8.9 207d 9.0 
 
Conclusions 
The reactivity of a glycosyl acceptor is of fundamental importance to the outcome of a 
glycosylation reaction. The nucleophilicity of a carbohydrate alcohol is influenced by 
electronic aspects, through inductive effects and hydrogen-bonding, and by steric and 
conformational effects. The protecting groups on the acceptor play a pivotal role in 
shaping the acceptor reactivity. In contrast to the reactivity of glycosyl donors, for which 


































compare their reactivity, the relative reactivity of glycosyl acceptors remains relatively 
poorly understood and no numerical scales are available to assess acceptor reactivity. The 
insightful competition experiments performed by Rúveda did provide relative acceptor 
reactivities based on kinetics but to be more generally useful should be significantly 
expanded.38 It would also be of interest to see how relative acceptor values change with 
different donors. A systematic evaluation of different well established donor systems with 
the same set of acceptors may provide an accurate structure-reactivity-stereoselectivity 
map. Another approach would be to establish Kinetic Isotope Effects for donor-acceptor 
combinations or to perform cation-clock kinetics. Both methods have been used by the 
group of Crich, but only on the relatively nucleophilic and minimally intrusive iso-
propanol.100–104 An extention of these methods spanning a wider range of acceptors, such 
as the model acceptors introduced by Woerpel and the set used in Chapter 3 of this Thesis, 
will provide the much needed insight how the reactivity of the acceptors determines the 
position of the operational reaction mechanisms along the SN2-SN1-continuum.  
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Chapter 3 
The influence of acceptor nucleophilicity on 
the glycosylation reaction mechanism 
Introduction 
The connection of two carbohydrate building blocks to construct a glycosidic linkage in 
a glycosylation reaction is one of the most important and one of the most difficult steps 
in the assembly of an oligosaccharide.1–3 The stereoselective formation of 1,2-cis-
glycosidic linkages remains a major synthetic challenge and often requires careful tuning 
of reaction conditions for a profitable outcome.4 The variation in stereochemical 
outcome of a chemical glycosylation reaction originates from the different mechanistic 
pathways that can be followed for the union of an activated donor glycoside and an 
acceptor. Figure 1 depicts the current understanding of the continuum of mechanisms 
operational during a glycosylation reaction. The activation of a donor glycoside leads to 
an array of reactive intermediates, formed from the donor glycoside and the activator 
derived counterion. α- and β-configured covalent reactive intermediates can be formed 
and these are in equilibrium with less stable and more reactive oxocarbenium ion based 
species. These can be either closely associated with the counterion providing close (or 
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contact) ion pairs (CIPs), or further separated from their counterion in solvent separated 
ion pairs (SSIPs). These reactive intermediates can be attacked by an incoming 
nucleophile following a reaction mechanism with both SN1 and SN2 features. The 
covalent species are displaced in a reaction mechanism having an associative SN2-
character, while the oxocarbenium ion-like intermediates are engaged in an SN1-like 
reaction. The exact position(s) on the continuum where a given glycosylation reaction 
Figure 1. The reaction mechanism manifold operational during glycosylation reactions. 
takes place, and hence the stereoselectivity of the process, depends critically on the 
reactivity of both reaction partners: the donor and the acceptor glycoside. The impact of 
the reactivity of the donor glycoside on the stereochemical outcome has been studied 
extensively, and the effect of functional and protecting groups on glycosyl donor 
reactivity is well documented.5–10 In contrast, the influence of the reactivity of the 
nucleophile (the acceptor) on the outcome of a glycosylation reaction remains poorly 
understood.11–18 This chapter presents a systematic study to determine the effect of 
acceptor nucleophilicity on the stereochemical course of a glycosylation reaction. It is 
shown how a simple “toolset” of partially fluorinated alcohols13 can be used to dissect 
reaction mechanisms that are operational during a glycosylation reaction. It is revealed 
that the stereoselectivity of some glycosylation systems varies more with changing 
acceptor nucleophilicity than others, and these differences are related to changes in 
reaction pathways that are followed. A panel of model carbohydrate acceptors is 
scrutinized to place the reactivity of these building blocks in the context of the 
nucleophilicity scale set by the series of fluorinated ethanols.  
Results and discussion 
In this study the effect of acceptor nucleophilicity on the glycosylation selectivity is 
systematically investigated by the hand of a set of model O-nucleophiles, encompassing 
ethanol, monofluoroethanol (MFE), difluoroethanol (DFE), trifluoroethanol (TFE), 




hexafluoro-iso-propanol (HFIP) and cyclohexanol, as well as a C-nucleophile, 
allyltrimethylsilane (allyl-TMS), and a deuterium nucleophile, deuterated triethylsilane 
(TES-d).12,13 Next a series of carbohydrate acceptors is used to put the reactivity of these 
alcohols in the context of the reactivity of the ethanol model acceptors (See Figure 2B 
and C). Three glycosylation systems have been investigated with these acceptors: the 
benzylidene mannose and analogous benzylidene glucose system as well as the 
mannuronic acid system (See Figure 2A). These systems have been selected because they 
have previously been studied in depth to provide insight into the major reaction 
pathways that operate during glycosylation reactions of these donors (vide infra). 
Although these three glycosylation systems all selectively provide 1,2-cis-products, the 
major product-forming pathways significantly differ. 
The benzylidene mannose system, introduced by Crich and co-workers for the 
stereoselective construction of β-mannosidic linkages, represents the best studied 
 
 
Figure 2. (A) The benzylidene mannose, benzylidene glucose and mannuronic acid glycosylation systems 
studied and the major glycosylation pathways of these donors. (B) Set of model nucleophiles used in this study. 
(C) Set of carbohydrate alcohols used. 
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glycosylation system to date.19,20 It has been found that benzylidene mannose donors can 
be transformed into the corresponding α-anomeric triflate 4 upon activation. These 
triflates have been extensively characterized in variable temperature NMR studies.21–24 A 
significant body of evidence has been gathered through a vast amount of glycosylation 
reactions19–23,25–33, the establishment of kinetic isotope effects in combination with 
computational methods34,35, and the application of cation clock methodology36–38, to 
indicate that these triflates can be substituted in an SN2-manner to provide β-
mannosides. However, an alternative hypothesis to account for the β-selectivity of 
benzylidene mannose glycosylations has also been forwarded. This hypothesis is based 
on a B2,5-oxocarbenium ion as product forming intermediate.39–42 
The closely related benzylidene glucose system provides α-selective glycosylation 
reactions.21,22,29,40,43–47 It has been proposed that this selectivity originates from an in situ 
anomerization kinetic scheme, in which the initially formed α-triflate 5α anomerizes 
into its more reactive β-counterpart 5β.21 Substitution of this species provides the α-
glucosyl products. Mechanistic studies, amongst others kinetic isotope effect and cation-
clock experiments, using the reactive nucleophile iso-propanol have provided support 
for this pathway.34,37,38  
Glycosylations of mannuronic acids have been shown to proceed in a highly 
selective manner to provide α-mannuronic acid products. Based on the conformational 
behavior of the donors and the intermediate α-triflates 18α, adopting an 1C4 
conformation48,49, the high reactivity of these donors50,51 and a large variety of 
glycosylation reactions, both in solution50,52–55, and on fluorous56 and solid supports57, it 
has been postulated that the selectivity in these glycosylation reactions can be related to 
the intermediacy of an 4H3 oxocarbenium ion-like intermediate.53,54,58 
The experimental setup that was used in this study is based on preactivation of 
the thioglycoside donors 159, 221 and 3 using a slight excess of diphenyl sulfoxide and 
triflic anhydride (Ph2SO/Tf2O) at low temperature. This transforms all three donors into 
the corresponding anomeric triflates21–24,48,60, prior to addition of the acceptor 
nucleophiles. The preactivation set-up generates a pool of reactive intermediates in the 
absence of the acceptor, thereby eliminating product forming pathways that originate 
from direct displacement reactions on the activated parent donor species. Table 1 
summarizes the results obtained with the three donor systems and the set of model 
acceptors. As a measure for the reactivity of the used acceptors, Mayr’s nucleophilicity 
parameters have been tabularized where available.61–63 The field inductive parameters for 
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the -CH3, -CH2F, -CHF2 and -CF3 groups have also been shown, to indicate the gradual 
increase of electron-withdrawing character of these groups.64 
From the results depicted in Table 1 it becomes immediately apparent that the 
stereoselectivity of the benzylidene mannose and mannuronic acid systems shows 
relatively little variation with changing nucleophilicity, where the stereoselectivity of the 
glycosylations involving the benzylidene glucose donor changes significantly depending 
on the reactivity of the used nucleophile. Reactive nucleophiles such as ethanol, 
Table 1. Model acceptor glycosylations. 
1 2 3









1 : 6 
(96%) 
2A 
1 : 5 
(71 %) 
3A 




1 : 5 
(70 %) 
2B 
1 : 10 
(68 %) 
3B 




1 : 5 
(86 %) 
2C 
1 : 3 
(70 %) 
3C 




1 : 5 
(90 %) 
2D 
5 : 1 
(70 %) 
3D 




1 : 4 
(78 %) 
2E 
> 20 : 1
(64 %)
3E 




3 : 1 
(56 %) 
2F 
> 20 : 1
(65 %) 
3F 




< 1 : 20 
(60 %) 
2G 
> 20 : 1
(79 %)
3G 




< 1 : 20 
(44 %)d 
2H 
> 20 : 1
(42 %)d
3H 
< 1 : 20 
(40%)d 
aMayr’s nucleophilicity parameters. bField inductive parameters. cα/β-Ratios were established by NMR 
spectroscopy of the crude and purified reaction mixtures. dBoth anomers of donor glycoside were also found 





cyclohexanol and MFE predominantly provide β-linked products (2A,65 2B and 2C), 
where the use of less reactive nucleophiles such as DFE, TFE, HFIP, TES-d and allyl-TMS 
leads to the preferential formation of the α-glucosyl products (2D-2H). A clear trend 
becomes apparent between the reactivity of the non-fluorinated and partially fluorinated 
ethanols and the stereoselectivity of the glucosylations involving these acceptors. The 
formation of the β-linked products 2A, 2B and 2C can be explained to originate from an 
SN2-like substitution on the intermediate α-triflate 5α (See Figure 3). The α-products in 
these glucosylations (α-2A, α-2B, α-2C) may be formed from the corresponding β-
glucosyl triflate 5β, as postulated by Crich and co-workers and as supported by kinetic 
isotope effect and cation clock studies.34,35,37,66 It is however less likely that the unreactive 
O-nucleophiles, such as TFE and HFIP, and the weak C- and D-nucleophiles, are capable 
of displacing the anomeric triflate 5 in an SN2-manner. Woerpel and co-workers have
previously shown that TFE requires a glycosylating agent bearing significant
oxocarbenium ion character.13 An explanation for the observed α-selectivity in the
glucosylations of these nucleophiles may be found in the SN1-like substitution on the
benzylidene glucose oxocarbenium ion 15. This ion preferentially adopts a 4H3/4E-
structure, as verified by several computational studies67,68, that is attacked in a
diastereoselective fashion from the bottom face, leading via a chair-like transition state
to the α-linked products. As the reactivity of the nucleophile diminishes, it is likely that
the amount of SN2-character in the substitution of the β-triflate 5β gradually
Figure 3. Mechanistic pathways to account for the selectivity in glycosylations of benzylidene glucose donors. 
decreasing nucleophilicity, increasing SN1 character




decreases and the amount of SN1-character with the intermediacy of the corresponding 
CIP and SSIP (15) increases.13 The least reactive nucleophiles require the most “naked” 
oxocarbenium ions, with the triflate counterions significantly, if not completely, 
dissociated from the carbohydrate ring.  
The stereoselectivity of the benzylidene mannose system seems to be less sensitive 
to variation in nucleophilicity of the acceptor. Donor 1 provides β-selective 
glycosylations with the range of acceptors studied. There is a slight decrease in selectivity 
going from the reactive O-nucleophiles to the weak O-nucleophiles and the condensation 
of benzylidene mannose 1 with HFIP proceeds with moderate α-selectivity. The most 
likely explanation for the β-selectivity observed with the reactive O-nucleophiles is an 
associative SN2-type substitution of the intermediate α-triflate 4 (See Figure 4). As 
discussed above, it is unlikely that unreactive acceptors such as TFE and HFIP react in 
an SN2-type reaction, directly displacing the α-mannosyl triflate 4. Formation of the β-
linked products formed from the unreactive acceptors and donor 1 may be better 
explained with an oxocarbenium ion-like product forming intermediate. Various 
theoretical studies have indicated that the B2,5-oxocarbenium ion 16 is the most stable 
benzylidene mannose oxocarbenium ion conformer.67,68 This oxocarbenium ion is 
preferentially attacked from the convex top face, as attack from the bottom face would 
lead to unfavorable interactions with the pseudo-axial H-2 and to an eclipsed C-1–C-2 
configuration upon rehybridization.36,40,69,70 
 
 
Figure 4. Mechanistic pathways to account for the selectivity in glycosylations of benzylidene mannose donors. 
decreasing nucleophilicity, increasing SN1 character
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The α-products formed in the condensations of donors 1 likely originate from an 
oxocarbenium ion intermediate. Reactive O-nucleophiles may react with an 
oxocarbenium ion in a relatively indiscriminative manner leading to the formation of 
both α- and β-products.11–13 Because unreactive O-nucleophiles are expected to react in 
a more diastereoselective fashion with an oxocarbenium ion, it is unlikely that the α-
products derived from the weak O-nucleophiles, such as TFE and HFIP, originate from 
the B2,5-oxocarbenium ion 16. Instead, α-face attack on the 4H3 half-chair conformer 17 
may be a plausible reaction pathway to account for the α-products of the less reactive O-
nucleophiles. In a later transition state, product development control plays a more 
important role, and the developing anomeric effect and the low energy chair 
conformation that results from the α-face attack on the 4H3 half-chair 17, make this 
trajectory favorable71. For the weak C- and D-nucleophiles, which react in a highly β-
selective manner, this latter pathway does not play a major role, and these nucleophiles 
attack the B2,5-oxocarbenium ion 16 selectively from the top face.40,72 
In line with the benzylidene mannose system, the mannuronic acid donor 
provides β-selective condensations with all acceptors explored, except with the very 
unreactive O-nucleophile HFIP where both anomers were formed in equal amounts. 
Where reactions with nucleophilic O-nucleophiles can be expected to form from the α-
triflate 18α,34–37 the weaker O-nucleophiles and allyl-TMS and TES-d will react 
preferentially with an oxocarbenium ion (Figure 5). It has been postulated that the 3H4 
half-chair mannuronic acid oxocarbenium ion 6 is the most stable oxocarbenium ion 
conformer.51,54,55 To substantiate this hypothesis, the energy associated with a range of 
mannuronic acid oxocarbenium ion conformers have been calculated using DFT-
calculations at the B3LYP/6-311G level.73 From these calculations the 3H4 conformer 6 
appears to be significantly more stable (by > 5 kcal⋅mol-1) than other conformers such as 
the alternative 4H3 half-chair 19 and the B2,5 boat conformers. The relative stability of the 
3H4 half-chair oxocarbenium ion can be explained by favorable interaction of the ring 
substituents with the electron depleted carbocation. Hyperconjugative stabilization of 
the C-2–H bond and through space stabilization of the pseudo-axial C-3, C-4 oxygen 
atoms and the axial C-5 carboxylate each contribute to the stability of the half-chair 
oxocarbenium ion.51,54,74–76 This oxocarbenium ion is preferentially attacked from the top 
face to provide the β-linked products via a chair-like transition state. For the weaker O-
nucleophiles, a later transition state leads to significant steric interactions with the axial 
substituents in the 3H4 half-chair oxocarbenium 6 and a reaction pathway, involving 
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attack of the nucleophiles on the higher energy 4H3 half-chair oxocarbenium ion 19 
becomes relevant. In line with the discussion above, product development control is 
favorable for the formation of α-O-mannuronic acids.  
Next, the set of carbohydrate acceptors depicted in Figure 2C was explored. The 
results of these condensation reactions are summarized in Table 2. Where it can be 
reasoned that the secondary carbohydrate acceptors 1177, 1278, 1377 and 1479 electronically 
resemble DFE and TFE, because of the amount of electron-withdrawing β- and/or γ- and 
δ-substituents, the size of the carbohydrate acceptors obviously differs significantly from 
the small ethanol based acceptors. The picture that emerges from Table 2 follows in broad 
lines the results described in Table 1 and corroborates this analysis. The benzylidene 
glucose donor system 2 shows most variation in stereoselectivity, where both the 
benzylidene mannose and mannuronic acid donors 1 and 3 provide β-selective reactions 
with all carbohydrate acceptors studied. The series of benzylidene glucose condensations 
again reveals that reactive O-nucleophiles can provide β-selective glycosylations, while 
less reactive O-nucleophiles give the α-linked products. The electron-withdrawing effect 
of the C-5 carboxylate in acceptor 12, makes this acceptor less reactive and more α-
selective than its C-5-benzyloxymethylene counterpart 11. In line with the discussion 
above, formation of the β-linked products can be explained with triflate 5α as product 
forming intermediate. Less reactive acceptors require a glycosylating species that is more 
electrophilic and react in a more dissociative substitution reaction, with a substantial 
Figure 5. Mechanistic pathways to account for the selectivity in glycosylations of mannuronic acid donors. 



































































Table 2. Glycosylation of donors 1-3 with carbohydrate acceptors 10-14. 
 
   










1 : 10 
(97 %) 
25 
1 : 3 
(81 %) 
30 




1 : 9 
(75 %) 
26 
1 : 1 
(79 %) 
31 




1 : 10 
(87 %) 
27 
5 : 1 
(90 %) 
32 
1 : 10 
(71 %) 
23 
< 1 : 20 
(70%) 
28 
> 20 : 1 
(83 %) 
33 




< 1 : 20 
(87 %) 
29 
> 20 : 1 
(80 %) 
34 
1 : 7 
(80 %) 
 
amount of oxocarbenium ion character and the glucose ring taking up a 4H3-like 
structure (15).  
The benzylidene mannose and mannuronic acid donors 1 and 3 provide very β-
selective condensation reactions, in line with the vast amount of previously reported 
glycosylations of these two donors. Based on the results presented here and in previous 
work the following picture emerges. Reactive carbohydrate acceptors react in a reaction 
with significant SN2-character, displacing the anomeric α-triflate (4 and 18α). Weaker 
nucleophiles, such as most secondary carbohydrate acceptors, will react with a species 
that bears more carbocation character. For the benzylidene mannose donor, this species 
will resemble B2,5 boat oxocarbenium ion 16, whereas the mannuronic acid reactive 
intermediate will be structurally close to 3H4 oxocarbenium ion 6. The minor α-products 
in these condensations likely arise from a higher energy 4H3 oxocarbenium ion 19, 
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Conclusions 
The influence of structural changes in a glycosyl donor on the outcome of a glycosylation 
reaction, in terms of yield and stereoselectivity, has received considerable attention over 
the years and many ingenious donor systems have been developed for the stereoselective 
construction of glycosidic bonds. The influence of the reactivity of the acceptor in 
glycosylation reactions, on the other hand, is less well understood. Here we have 
investigated in a systematic manner how the outcome of a glycosylation system can 
change depending on the gradually changing reactivity of the nucleophile. We have 
shown that a series of partially fluorinated alcohols of gradually decreasing 
nucleophilicity, can be used to map how the stereoselectivity of a glycosylation system 
varies with changing acceptor reactivity. The simple “toolset” of partially fluorinated 
ethanols represents a rapid and easy means to dissect SN2-type (for ethanol) and SN1-type 
(for trifluoroethanol and hexafluoro-iso-propanol) glycosylation reaction mechanisms.80 
It is expected that application of this set of model nucleophiles to newly developed 
glycosylation methodology or re-investigation of already established methods will bring 
detailed insight into the complex and intriguing glycosylation reaction mechanism. This 
will allow for more directed optimization of glycosylation reactions, taking away the trial 
and error component and ill-understood reaction protocols that have plagued 





General procedure for Tf2O/Ph2SO mediated glycosylations: Donor (0.1 mmol), Ph2SO (26 mg, 0.13 mmol, 1.3 eq.) and 
TTBP (62 mg, 0.25 mmol, 2.5 eq.) were coevaporated twice with dry toluene (4 Å molecular sieves) and dissolved in 
DCM (2 mL, 0.05 M donor). Activated 3Å molecular sieves (rods, size 1/16 in.) were added and the reaction mixture 
stirred for 30 min at room temperature. The solution was cooled to -78°C and Tf2O (22 μl, 0.13 mmol, 1.3 eq.) was 
slowly added. The reaction mixture was allowed to warm to -60°C in approximately 45 min, followed by recooling to -
78°C and addition of the acceptor (0.2 mmol, 2 eq.) in DCM (0.4 mL, 0.5 M). The reaction mixture was allowed to 
warm to -40°C in approximately 60 min and stirred for an additional 0-18 h depending on the acceptor. The reaction 
was quenched with Et3N (0.1 mL, 0.72 mmol, 7.2 eq.) at -40°C and diluted with DCM. The solution was transferred to 
a separatory funnel and water was added, the layers were separated and the water phase extracted once more with 
DCM. The combined organic layers were dried over MgSO4, filtered, and concentrated in vacuo. Purification by silica 
gel flash column chromatography and when needed, sephadexTM LH-20 size exclusion chromatography yielded the 
glycosylation product as a mixture of anomers. 
General computational procedure: Density functional theory (DFT) ab initio calculations were performed with the 
B3LYP model. Conformations were generated from a conformer distribution search option included in the Spartan 04 
program82 in the gas phase at the 6-31G* basis set level. All generated geometries were further optimized with 
Gaussian 0383 at the 6-311G** level, their zero-point energy (ZPE) corrections calculated and further optimized with 
incorporated polarizable continuum model (PCM) to correct for solvation in dichloromethane. 
Preparation of donors 1, 2, and 3. 
 
Phenyl 2,3,4,6-tetra-O-acetyl-1-thio-β-D-mannopyranoside (S1). To a mixture of HBr (33 wt% in 
AcOH, 35 mL, 200 mmol, 1 eq.) and Ac2O (93 mL, 1020 mmol, 5.1 eq.) and 10 drops of 70% aq. 
HClO4 , D-mannose (36.0 g, 200 mmol) was added portion wise at 0 ⁰C. After 20 minutes an additional amount of HBr 
(33 wt% in AcOH, 70 mL, 400 mmol, 2 eq.) was added. After stirring for 16 h at r.t. the reaction mixture was 
concentrated in vacuo at 30 ⁰C. The resulting black oil was co-evaporated with toluene until neutral pH was reached 
and was used in the following step without further purification. To a solution of the crude product in DMF (400 mL), 
thiophenol (21.5 mL, 210 mmol, 1.05 eq.) was added. The reaction mixture was cooled to 0 ⁰C and NaH (60% 
dispersion in mineral oil, 8.4 g, 210 mmol, 1.05 eq.) was added portion wise. After 2 h stirring at r.t. the reaction was 
quenched by the addition of aq. HCl (1 M). To the resulting black suspension, 4 L of water was added and extracted 
10 times with Et2O. The combined organic layers were washed with water, dried with MgSO4 and concentrated in 
vacuo. Flash column chromatography (9/1 to 7/3 pentane/EtOAc) afforded the title compound as an orange oil (57.3 
g, 130 mmol, 65%). Rf: 0.70 (1/1 pentane/EtOAc). Spectroscopic data were in accord with those previously 
reported.84,85 [α]  = -44.4° (c = 0.5, CHCl3); IR (neat): 1047, 1213, 1368, 1742; 1H NMR (400 MHz, CDCl3, HH-COSY, 
HSQC): δ 7.56 – 7.47 (m, 2H, CHarom SPh), 7.34 – 7.30 (m, 3H, CHarom SPh), 5.66 (dd, 1H, J = 3.5, 0.8 Hz, H-2), 5.28 (t, 
1H, J = 10.0 Hz, H-4), 5.07 (dd, 1H, J = 10.1, 3.5 Hz, H-3), 4.94 (d, 1H, J = 1.0 Hz, H-1), 4.29 (dd, 1H, J = 12.2, 6.5 Hz, H-
6), 4.17 (dd, 1H, J = 12.2, 2.4 Hz, H-6), 3.72 (ddd, 1H, J = 10.0, 6.4, 2.5 Hz, H-5), 2.20 (s, 3H, CH3 OAc), 2.09 (s, 3H, CH3 









(C=O Ac), 133.2 (Cq SPh), 131.9, 129.1, 128.1 (CHarom SPh), 85.5 (C-1), 76.4 (C-5), 71.8 (C-3), 70.6 (C-2), 65.8 (C-4), 62.8 
(C-6), 20.7, 20.7, 20.6, 20.6 (CH3 Ac); 13C-GATED NMR (101 MHz, CDCl3): δ 85.5 (JC1,H1 = 153 Hz, C-1 β); HRMS: [M+Na]+ 
calcd for C20H24O9SNa 463.10332, found 463.10305. 
Phenyl 1-thio-β-D-mannopyranoside (S2). To a solution of S1 (24.9 g, 56.5 mmol) in MeOH (280 
mL), NaOMe (0.31 g, 5.7 mmol, 0.1 eq.) was added. The reaction mixture was stirred for 16 h. 
Amberlite IR120 H+ was added until pH 6 was reached and the mixture was filtered and concentrated in vacuo. This 
afforded the title compound (15.3 g, 56.4 mmol, 99%) as a white foam. Rf: 0.20 (9/1 DCM/MeOH). Spectroscopic data 
were in accord with those previously reported.86,87 IR (neat, cm-1): 880, 1085, 1636, 2974, 3312; 1H NMR (400 MHz, 
MeOD, HH-COSY, HSQC): δ 7.53 – 7.46 (m, 2H, CHarom SPh), 7.34 – 7.17 (m, 3H, CHarom SPh), 5.00 (s, 1H, H-1), 4.05 (dd, 
1H, J = 3.4, 1.0 Hz, H-2), 3.88 (dd, 1H, J = 11.9, 2.4 Hz, H-6), 3.73 (dd, 1H, J = 12.1, 5.7 Hz, H-6), 3.63 (t, 1H, J = 9.5 Hz, 
H-4), 3.51 (dd, 1H, J = 9.5, 3.4 Hz, H-3), 3.29 (m, 1H, J = 5.8 Hz, H-5); 13C-APT NMR (101 MHz, MeOD, HSQC): δ 131.0, 
130.0, 127.7 (CHarom SPh), 88.8 (C-1), 82.4 (C-5), 76.2 (C-3), 74.3 (C-2), 68.3 (C-4), 62.9 (C-6); HRMS: [M+Na]+ calcd for 
C12H16O5SNa 295.06107, found 295.06107. 
Phenyl 2,3-di-O-benzyl-4,6-O-benzylidene-1-thio-β-D-mannopyranoside (1). To a solution of S2 
(1.36 g, 5 mmol) in DMF (50 mL), benzaldehyde dimethyl acetal (3.0 mL, 20 mmol, 4 eq.) and 
CSA (0.25 g, 1 mmol, 0.2 eq.) were added. After the solution was stirred for 16 h, benzyl bromide (2.4 mL, 20 mmol, 4 
eq.) and NaH (60% dispersion in mineral oil, 0.48 g, 20 mmol, 4 eq.) were added at 0 ⁰C. The suspension was allowed 
to warm up until r.t. and stirred for an additional 2 h. The reaction mixture was quenched with MeOH, followed by 
the addition of DCM (250 mL) and ice water (500 mL). The water layer was extracted once with DCM and the combined 
organic layers were washed with water and brine. The combined organic layers were dried over MgSO4, filtered and 
concentrated under reduced pressure. Flash column chromatography (1/0 to 9/1 pentane/EtOAc) and subsequent 
recrystallization from EtOAc and pentane afforded the title compound as a white solid (1.38 g, 2.56 mmol, 51% over 
2 steps). Rf: 0.27 (9/1 pentane/EtOAc). Spectroscopic data were in accord with those previously reported.59 IR (neat): 
733, 1026, 1069, 1452, 2864; 1H NMR (400 MHz, CDCl3, HH-COSY, HSQC, HMBC): δ 7.64 – 7.14 (m, 20H, CHarom), 5.64 
(s, 1H, CHPh), 5.12 (d, 1H, J = 11.1 Hz, CHH Bn), 4.89 (d, 1H, J = 12.3 Hz, CHH Bn), 4.86 (d, 1H, J = 11.1 Hz, CHH Bn), 
4.85 (d, 1H, J = 1.3 Hz, H-1), 4.74 (d, 1H, J = 12.3 Hz, CHH Bn), 4.36 – 4.26 (m, 2H, H-4, H-6), 4.18 (dd, 1H, J = 3.1, 1.3 
Hz, H-2), 3.95 (t, 1H, J = 10.3 Hz, H-6), 3.74 (dd, 1H, J = 9.8, 3.1 Hz, H-3), 3.42 (td, 1H, J = 9.7, 4.9 Hz, H-5); 13C-APT NMR 
(101 MHz, CDCl3, HSQC, HMBC): δ 138.1, 137.6, 135.1 (Cq), 131.2, 129.1, 129.1, 128.8, 128.6, 128.4, 127.9, 127.9, 
127.8, 127.6, 126.2 (CHarom), 101.6 (CHPh), 89.2 (C-1), 79.9 (C-3), 79.1 (C-2), 78.8 (C-4), 76.0, 73.3 (CH2 Bn), 71.8 (C-5), 
68.6 (C-6); 13C-GATED NMR (101 MHz, CDCl3) δ 89.2 (JC1,H1 = 152 Hz, C-1 β); HRMS: [M+NH4]+ calcd for C33H36NO5S 
558.23087, found 558.23071. 
Phenyl 2,3,4,6-tetra-O-acetyl-1-thio-β-D-glucopyranoside (S3). To a 140°C solution of NaOAc (8.2 
g, 100 mmol, 0.5 eq) in Ac2O (190 mL, 2 mol, 10 eq.) D-glucose (36 g, 200 mmol, 1 eq.) was 
added portionwise and the reaction mixture was refluxed for an additional 15 min. The solution 
was cooled to r.t. and poured over crushed ice. The product was filtered, taken up in DCM, concentrated in vacuo and 
recrystallized from hot EtOH (750 mL) to give the pentaacetate as a white solid (69.4 g, 178 mmol, 89%). Spectroscopic 
data were in accord with those previously reported.88,89 Data for the β-anomer: 1H NMR (CDCl3, 400 MHz, HH-COSY, 
HSQC): δ 5.72 (d, 1H, J = 8.3 Hz, H-1), 5.26 (t, 1H, J = 9.4 Hz, H-3), 5.19 – 5.08 (m, 2H, H-2, H-4), 4.30 (dd, 1H, J = 12.7, 
3.8 Hz, H-6), 4.15 – 4.08 (m, 1H, H-6), 3.88 – 3.81 (m, 1H, H-5), 2.12 (s, 3H, CH3 OAc), 2.09 (s, 3H, CH3 OAc), 2.04 (s, 
6H, 2xCH3 OAc), 2.02 (s, 3H, CH3 OAc); 13C-APT NMR (CDCl3, 101 MHz, HSQC): δ 170.7, 170.2, 169.5, 169.4, 169.1 (Cq 
OAc), 91.8 (C-1), 72.9, 72.8 (C-3, C-5), 70.3, 67.9 (C-2, C-4), 61.6 (C-6), 21.0, 20.8, 20.7 (CH3 OAc).D-glucose 
pentaacetate (20 g, 51 mmol) was dissolved in DCM (100 mL) and cooled to 0°C. Thiophenol (7.8 mL, 76.5 mmol, 1.5 
eq.) was added followed by addition of boron trifluoride diethyl etherate (10.9 mL, 76.5 mmol, 1.5 eq.) and the mixture 
was refluxed overnight. Sat. aq. NaHCO3 (300 mL) and Et2O (100 mL) were added and the mixture was extracted three 
times with Et2O. The organic layer was washed with brine, dried with MgSO4, filtered and concentrated under reduced 
pressure. The crude product was purified by crystallization from EtOAc/hexane (1/10) to obtain the title compound as 
a white solid. (16.8 g, 38.2 mmol, 75%). Spectroscopic data were in accord with those previously reported.77,90–92 1H 
NMR (CDCl3, 400 MHz, HH-COSY, HSQC): δ 7.50 (dd, 2H, J = 6.6, 3.0 Hz, CHarom), 7.34 – 7.28 (m, 3H, CHarom), 5.24 (t, 
1H, J = 9.3 Hz, H-3), 5.04 (t, 1H, J = 9.8 Hz, H-4), 4.97 (t, 1H, J = 9.6 Hz, H-2), 4.75 (d, 1H, J = 10.0 Hz, H-1), 4.23 (dd, 1H, 
J = 12.3, 5.1 Hz, H-6), 4.17 (dd, 1H, J = 12.3, 2.5 Hz, H-6), 3.76 (ddd, 1H, J = 10.0, 5.1, 2.5 Hz, H-5), 2.07 (s, 3H, CH3 
OAc), 2.06 (s, 3H, CH3 OAc), 2.01 (s, 3H, CH3 OAc), 1.98 (s, 3H, CH3 OAc); 13C-APT NMR (CDCl3, 101 MHz, HSQC): δ 
170.2, 169.8, 169.2, 169.0 (C=O Ac), 132.8 (CHarom), 131.5 (Cq), 128.8, 128.2 (CHarom), 85.3 (C-1), 75.5 (C-5), 73.8 (C-3), 




Phenyl 1-thio-β-D-glucopyranoside (S4). To a solution of S3 (16.3 g, 37.0 mmol) in MeOH (200 mL) 
was added Na(s) (89 mg, 3.7 mmol, 0.1 eq) and the reaction was stirred for 18 h at r.t. The 
reaction mixture was neutralized with Amberlite H+, filtered and Celite® was added to the filtrate 
and the mixture concentrated in vacuo. The residue was purified by flash column chromatography (1% to 12% EtOH 
in EtOAc) to obtain a white solid (8.6 g, 31.6 mmol, 85%). Spectroscopic data were in accord with those previously 
reported.93 1H NMR (MeOD, 400 MHz, HH-COSY, HSQC): δ 7.61 – 7.54 (m, 2H, CHarom), 7.33 – 7.24 (m, 3H, CHarom), 
4.60 (d, 1H, J = 9.8 Hz, H-1), 3.87 (dd, 1H, J = 12.1, 1.8 Hz, H-6), 3.67 (dd, 1H, J = 12.2, 5.2 Hz, H-6), 3.39 (t, 1H, J = 8.5 
Hz, H-3), 3.35 – 3.26 (m, 2H, H-4, H-5), 3.22 (dd, 1H, J = 9.8, 8.6 Hz, H-2); 13C-APT NMR (MeOD, 101 MHz, HSQC): δ 
135.3 (Cq), 132.7, 129.9, 128.3 (CHarom), 89.4 (C-1), 82.0 (C-4), 79.7 (C-3), 73.7 (C-2), 71.3 (C-5), 62.8 (C-6). 
Phenyl 4,6-O-benzylidene-1-thio-β-D-glucopyranoside (S5). To a solution of S4 (12.81 g, 47 
mmol) and p-TsOH⋅H2O (100 mg, 0.5 mmol, 0.01 eq.) in DMF (25 mL) and CH3CN (100 mL) 
was added benzaldehyde dimethyl acetal (9.9 mL, 65.8 mmol, 1.4 eq.). The reaction was 
heated to 50°C at 250 mbar for 5 hours and subsequently quenched with Et3N (2 mL) and diluted with EtOAc (250 mL). 
The solution was washed with H2O (2x 100 mL) and brine (100 mL). The organic layer was dried (MgSO4) and 
concentrated in vacuo. Precipitation from EtOAc/petroleum ether formed a waxy material (12.0 g, 33.3 mmol) and 
the remaining mother liquors were purified by column chromatography (3/1 to 1/3 pentane/EtOAc) to give another 
batch of product (3.86 g, 10.7 mmol). Total yield 15.9 g, 44 mmol, 94%. Rf: 0.50 (1/2 pentane/EtOAc). Spectroscopic 
data were in accord with those previously reported.90–92 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC): δ 7.59 – 7.51 (m, 
2H, CHarom), 7.51 – 7.44 (m, 2H, CHarom), 7.40 – 7.31 (m, 6H, CHarom), 5.54 (s, 1H, CHPh), 4.64 (d, 1H, J = 9.8 Hz, H-1), 
4.39 (dd, 1H, J = 10.5, 4.4 Hz, H-6), 3.91 – 3.74 (m, 2H, H-4, H-6), 3.59 – 3.43 (m, 3H, H-2, H-3, H-5); 13C-APT NMR 
(CDCl3, 101 MHz, HSQC): δ 137.0 (Cq), 133.2 (CHarom), 131.4 (Cq), 129.5, 129.3, 128.7, 128.5, 126.4 (CHarom), 102.1 
(CHPh), 88.8 (C-1), 80.4 (C-3), 74.7 (C-4), 72.7 (C-2), 70.7 (C-5), 68.7 (C-6). 
Phenyl 2,3-di-O-benzyl-4,6-O-benzylidene-1-thio-β-D-glucopyranoside (2). Diol S5 (7.21 g, 20 
mmol) was dissolved in DMF (100 mL) and cooled to 0°C. Benzyl bromide (5.75 mL, 48 mmol, 
2.4 eq.) and NaH (60% dispersion in mineral oil, 2.4 g, 60 mmol, 3 eq.) were added and the 
reaction mixture was allowed to stir overnight. MeOH was added to quench the reaction followed by H2O (500 mL) 
and EtOAc (300 mL). The organic layer was washed with brine and dried with MgSO4. After concentration of the 
organic layer under reduced pressure, the crude product was crystallized from EtOAc (50 mL) and hexane (100 mL) to 
obtain the title compound as a white solid (9.49 g, 17.4 mmol, 86%). Spectroscopic data were in accord with those 
previously reported.21,90–92 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC): δ 7.56 – 7.51 (m, 2H, CHarom), 7.51 – 7.46 (m, 
2H, CHarom), 7.42 – 7.26 (m, 16H, CHarom), 5.59 (s, 1H, CHPh), 4.94 (d, 1H, J = 11.1 Hz, CHH Bn), 4.86 (d, 1H, J = 10.2 Hz, 
CHH Bn), 4.81 (d, 1H, J = 10.3 Hz, CHH Bn), 4.80 – 4.73 (m, 2H, CHH Bn, H-1), 4.39 (dd, 1H, J = 10.5, 5.0 Hz, H-6), 3.84 
(dd, 1H, J = 9.3, 8.3 Hz, H-3), 3.80 (t, 1H, J = 10.3 Hz, H-6), 3.71 (t, 1H, J = 9.3 Hz, H-4), 3.56 – 3.42 (m, 2H, H-2, H-5); 
13C-APT NMR (CDCl3, 101 MHz, HSQC): δ 138.4, 138.1, 137.4, 133.2 (Cq-arom), 132.5, 129.1, 129.1, 128.5, 128.5, 128.4, 
128.3, 128.2, 128.0, 128.0, 127.9, 126.1 (CHarom), 101.3 (CHPh), 88.4 (C-1), 83.1 (C-3), 81.6 (C-4), 80.6 (C-2), 76.0, 75.5 
(CH2 Bn), 70.4 (C-5), 68.8 (C-6); HRMS: [M+H]+ calcd for C33H33O5S 541.20432, found 541.20392. 
Phenyl 2,3-di-O-benzyl-1-thio-β-D-mannopyranoside (S6). To a solution of 1 (1.62 g, 3 mmol) in 
MeOH (30 mL), p-TsOH·H2O (60 mg, 0.3 mmol, 0.1 eq.) was added. The suspension was stirred 
for 1 h at 50 ⁰C and subsequently quenched with Et3N. After concentration in vacuo the resulting product was purified 
by flash column chromatography (9/1 to 1/1 pentane/EtOAc) to yield the title compound as a colourless foam (1.26 g, 
2.78 mmol, 93%). Rf: 0.10 (4/1 pentane/EtOAc). Spectroscopic data were in accord with those previously reported.51 [α]  = -62.4° (c = 0.5, CHCl3); IR (neat): 734, 1026, 1119, 1454, 924, 3391; 1H NMR (400 MHz, CDCl3, HH-COSY, HSQC): 
δ 7.54 – 7.19 (m, 15H, CHarom), 4.97 (d, 1H, J = 11.3 Hz, CHH Bn), 4.85 (s, 1H, H-1), 4.85 (d, 1H, J = 11.3 Hz, CHH Bn), 
4.75 (d, 1H, J = 11.7 Hz, CHH Bn), 4.53 (d, 1H, J = 11.7 Hz, CHH Bn), 4.20 (d, 1H, J = 2.1 Hz, H-2), 4.05 (td, 1H, J = 9.5, 
2.3 Hz, H-4), 3.93 (ddd, 1H, J = 11.0, 7.2, 3.6 Hz, H-6), 3.82 (dt, 1H, J = 12.1, 6.3 Hz, H-6), 3.46 (dd, 1H, J = 9.5, 2.8 Hz, 
H-3), 3.38 (ddd, 1H, J = 9.5, 6.0, 3.6 Hz, H-5), 2.33 (s, 1H, 4-OH), 2.14 (t, 1H, J = 6.4 Hz, 6-OH); 13C-APT NMR (101 MHz, 
CDCl3, HSQC): δ 138.0, 137.6, 135.1 (Cq), 130.7, 129.2, 128.8, 128.5, 128.4, 128.3, 127.9, 127.9, 127.5 (CHarom), 87.9 
(C-1), 83.6 (C-3), 80.1 (C-5), 76.7 (C-2), 75.3, 72.3 (CH2 Bn), 67.5 (C-4), 63.1 (C-6); 13C-GATED NMR (101 MHz, CDCl3): 
δ 87.9 (J = 152 Hz, C-1 β); HRMS: [M+Na]+ calcd for C26H28O5SNa 475.15497, found 475.15430. 
Methyl (phenyl 2,3-di-O-benzyl-1-thio-β-D-mannopyranosyl uronate) (S7). To a two phase system 
of S6 (1.25 g, 2.76 mmol) in DCM (10 mL) and H2O (5 mL), TEMPO (86 mg, 0.55 mmol, 0.2 eq.), 
BAIB (2.22 g, 6.9 mmol, 2.5 eq.) and AcOH (50 μL) were added. The reaction mixture was stirred for 6 h and was 




quenched with sat. aq. Na2S2O3. The resulting suspension was concentrated under reduced pressure and co-
evaporated three times with toluene. The formed solid was dissolved in DMF (15 mL), K2CO3 (1.14 g, 8.28 mmol, 3 eq.) 
and methyl iodide (0.52 mL, 8.28 mmol, 3 eq.) were added. The suspension was stirred for 16 h at r.t. and followed 
by the addition of H2O (150 mL). The aqueous layer was extracted three times with Et2O and subsequently washed 
with sat. aq. NaHCO3 and brine. The combined organic layers were dried over MgSO4, filtered and concentrated under 
reduced pressure. Flash column chromatography (1/0 to 3/1 pentane/EtOAc) followed by recrystallization in EtOAc 
and pentane afforded the title compound as a white solid (0.48 g, 1.75 mmol, 63% over 2 steps). Rf: 0.70 (1/1 
pentane/EtOAc). Spectroscopic data were in accord with those previously reported.51 [α]  = -72,0° (c = 0.5, CHCl3); 
IR (neat): 696, 735, 1026, 1064, 1123, 1429, 1454, 1744, 2855, 2924, 3462; 1H NMR (400 MHz, CDCl3, HH-COSY, HSQC): 
δ 7.51 – 7.25 (m, 20H, CHarom), 5.02 (d, 1H, J = 11.4 Hz, CHH Bn), 4.86 (d, 1H, J = 11.3 Hz, CHH Bn), 4.79 – 4.74 (m, 3H, 
CHH Bn, CHH Bn, H-1), 4.41 (td, 1H,  J = 9.5, 2.1 Hz, H-4), 4.12 (dd, 1H, J = 3.0, 1.0 Hz, H-2), 3.84 – 3.77 (m, 4H, H-5, 
CH3 CO2Me), 3.50 (dd, 1H, J = 9.5, 2.9 Hz, H-3), 3.11 (d, 1H, J = 2.3 Hz, 4-OH); 13C-APT NMR (101 MHz, CDCl3, HSQC): δ 
138.0, 135.1 (Cq), 131.3, 129.1, 128.7, 128.6, 128.3, 128.1, 127.9, 127.9, 127.6 (CHarom), 89.0 (C-1), 82.4 (C-3), 78.3 (C-
5), 77.0 (C-2), 75.4, 73.1 (CH2 Bn), 68.6 (C-4), 52.9 (CH3 CO2Me); 13C- GATED NMR (101 MHz, CDCl3): δ 89.0 (JC1,H1 = 
154 Hz, C-1 β). HRMS: [M+H]+ calcd for C27H29O6S 481,16794, found 481,16812.  
Methyl (phenyl 4-O-acetyl-2,3-di-O-benzyl-thio-β-D-mannopyranosyl uronate) (3). To a 
suspension of S7 (1.20 g, 2.5 mmol) in pyridine (3.0 mL, 37.5 mmol, 15 eq.), Ac2O (0.30 mL, 3.1 
mmol, 1.25 eq.) was added. After stirring for 16 h at r.t., the reaction mixture was quenched with H2O (25 mL). To the 
quenched reaction mixture, EtOAc was added and the layers were separated. The water layer was extracted for an 
additional 2 times with EtOAc. The combined organic layers were washed with sat. aq. NaHCO3 and brine. The resulting 
organic layer was dried over MgSO4, filtered and concentrated under reduced pressure. Flash column chromatography 
(9/1 to 7/3 pentane/EtOAc) afforded the title compound as a white solid (1.2 g, 2.3 mmol, 92%). Rf: 0.42 (7/3 
pentane/EtOAc). [α]  = -84.0° (c = 0.5, CHCl3); IR (neat): 733, 1024, 1053, 1089, 1746, 2870; 1H NMR (400 MHz, CDCl3, 
HH-COSY, HSQC): δ 7.50 – 7.23 (m, 15H, CHarom), 5.61 (t, 1H, J = 9.6 Hz, H-4), 5.03 (d, 1H, J = 11.6 Hz, CHH Bn), 4.85 (d, 
1H, J = 11.6 Hz, CHH Bn), 4.78 (d, 1H, J = 1.1 Hz, H-1), 4.67 (d, 1H, J = 12.2 Hz, CHH Bn), 4.57 (d, 1H, J = 12.2 Hz, CHH 
Bn), 4.15 (dd, 1H, J = 2.8, 1.0 Hz, H-2), 3.88 (d, 1H, J = 9.6 Hz, H-5), 3.74 (s, 3H, CH3 CO2Me), 3.61 (dd, 1H, J = 9.7, 2.9 
Hz, H-3), 2.01 (s, 3H, CH3 OAc); 13C-APT NMR (101 MHz, CDCl3, HSQC): δ 169.7, 167.8 (C=O CO2Me, Ac), 137.9, 137.7, 
135.1 (Cq), 131.3, 129.1, 128.7, 128.6, 128.3, 128.1, 127.9, 127.7, 127.7 (CHarom), 88.7 (C-1), 80.4 (C-3), 77.3 (C-5), 76.4 
(C-2), 75.1, 72.6 (CH2 Bn), 68.9 (C-4), 52.8 (CH3 CO2Me), 21.0 (CH3 Ac); 13C-GATED NMR (101 MHz, CDCl3): δ 88.7  (JC1,H1 
= 152 Hz, C-1 β); HRMS: [M+NH4]+ calcd for C29H34NO7S 540.20505, found 540.20515.  
Preparation of acceptors 10, 11, and 12. 
 
Methyl 2,3,4-tri-O-benzyl-α-D-glucopyranoside (10). To a solution of methyl-α-D-glucopyranoside 
(1.94 g, 10 mmol, 1 eq.) in DMF (50 mL), trityl chloride (3.1 g, 11 mmol, 1.1 eq.), Et3N (2.1 mL, 15 
mmol, 1.5 eq.) and DMAP (0.12 g, 1 mmol, 0.1 eq.) were added. After stirring for 6 h at 60 ⁰C the 
reaction was cooled to 0 ⁰C and followed by the addition of benzyl bromide (4.8 mL, 40 mmol, 4 
eq.), NaH (2 g, 50 mmol, 5 eq.). The suspension was stirred for 16 h at r.t. and subsequently quenched with MeOH. 
The reaction mixture was concentrated under reduced pressure and the remaining oil was transferred to a separation 




with Et2O. The combined organic layers were washed with water, sat. aq. NaHCO3 and brine. The resulting organic 
layer was dried over MgSO4, filtered and concentrated under reduced pressure. The crude product S8 was suspended 
in MeOH (100 mL) followed by the addition of p-TsOH·H2O (0.19 g, 1 mmol, 0.1 eq.). After stirring for 1 h at 50 ⁰C the 
reaction mixture was quenched with sat. aq. NaHCO3 and concentrated in vacuo. Flash column chromatography (1/0 
to 7/3 pentane/EtOAc) afforded the title compound as a waxy solid (3.6 g, 7.7 mmol, 78% over 3 steps). Spectroscopic 
data were in accord with those previously reported.77,94 Rf: 0.57 (7/3 pentane/EtOAc). IR (neat): 880, 1043, 1086, 1381, 
1636, 2893, 2974, 3312; 1H NMR (400 MHz, CDCl3, HH-COSY, HSQC): δ 7.42 – 7.24 (m, 15H, CHarom), 4.99 (d, 1H, J = 
10.8 Hz, CHH Bn), 4.92 – 4.77 (m, 3H, CHH Bn, CHH Bn, CHH Bn), 4.72 – 4.60 (m, 2H, CHH Bn, CHH Bn), 4.56 (d, 1H, J 
= 3.5 Hz, H-1), 4.01 (t, 1H, J = 9.3 Hz, H-4), 3.82 – 3.73 (m, 1H, H-6), 3.73 – 3.61 (m, 2H, H-6, H-5), 3.58 – 3.45 (m, 2H, 
H-6, H-2, H-3), 3.37 (s, 3H, CH3 OMe), 1.61 (dd, 1H, J = 7.3, 5.4 Hz, 6-OH); 13C-APT NMR (101 MHz, CDCl3, HSQC, HMBC): 
δ 138.8, 138.2 (Cq), 128.6, 128.6, 128.6, 128.3, 128.2, 128.1, 128.1, 128.0, 127.8 (CHarom), 98.3 (C-1), 82.1 (C-4), 80.0 
(C-2), 77.4 (C-3), 75.9, 75.2, 73.6 (CH2 Bn), 70.7 (C-5), 62.0 (C-6), 55.3 (CH3 OMe); 13C-GATED NMR (101 MHz, CDCl3): 
δ 98.3 (JC1,H1 = 164 Hz, C-1 α); HRMS: [M+Na]+ calcd for C28H32O6Na 487.20911, found 487.20851.  
Methyl 4,6-O-benzylidene-α-D-glucopyranoside (S9). To a solution of methyl α-D-
glucopyranoside (38.8 g, 200 mmol) in acetonitrile (800 mL) was added PhCH(OMe)2 (36 mL, 
240 mmol, 1.2 eq.) and p-TsOH⋅H2O (3.8 g, 20 mmol, 0.1 eq.). The solution was stirred overnight 
at ambient temperature followed by concentration in vacuo (60°C, 600 mbar, 1.5 h) to a quarter of its original volume. 
The reaction mixture was treated with Et3N (3 mL), diluted with EtOAc (500 mL) and subsequently washed with H2O 
(2x 150 mL), sat. aq. NaHCO3 (50 mL) and brine (2x 100 mL). The organic layer was dried (MgSO4), filtered and 
concentrated in vacuo. The resulting crude residue was crystalized from EtOAc/petroleum ether to give the title 
product in two crops (49.2 g, 174 mmol, 87%, white solid). Spectroscopic data were in accord with those previously 
reported.77,95 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC): δ 7.51 – 7.45 (m, 2H, CHarom), 7.36 (dd, 3H, J = 5.1, 2.0 Hz, 
CHarom), 5.51 (s, 1H, CHPh), 4.75 (d, 1H, J = 3.8 Hz, H-1), 4.28 (dd, 1H, J = 9.6, 4.3 Hz, H-6), 3.91 (t, 1H, J = 9.2 Hz, H-3), 
3.84 – 3.68 (m, 2H, H-5, H-6), 3.60 (dd, 1H, J = 9.2, 3.9 Hz, H-2), 3.47 (t, 1H, J = 9.3 Hz, H-4), 3.43 (s, 3H, CH3 OMe), 
2.87 (bs, 2H, OH); 13C-APT NMR (CDCl3, 101 MHz, HSQC): δ 137.2 (Cq), 129.4, 128.4, 126.4 (CHarom), 102.0 (CHPh), 99.9 
(C-1), 81.1 (C-4), 72.9 (C-2), 71.7 (C-3), 69.0 (C-6), 62.5 (C-5), 55.7 (OMe).  
Methyl 2,3-di-O-benzyl-4,6-O-benzylidene-α-D-glucopyranoside (S10). Benzyl bromide (10.5 mL, 
88 mmol, 2.2 eq.) and sodium hydride (60% dispersion, 4.16 g, 104 mmol, 2.6 eq.) were added 
to a 0°C solution of diol S9 (11.29 g, 40 mmol) in DMF (200 mL) and the solution was stirred 
overnight. The reaction mixture was quenched by slow addition of MeOH, diluted with EtOAc (500 mL) and washed 
with H2O (200 mL) and brine (200 mL). The organic layer was dried with MgSO4, filtered and concentrated in vacuo. 
The solid residue was recrystallization from EtOAc/pentane to yield the title compound as a white solid (16.0 g, 34.6 
mmol, 87%). Rf: 0.57 (4/1 pentane/EtOAc). Spectroscopic data were in accord with those previously reported.21,77 1H 
NMR (CDCl3, 400 MHz, HH-COSY, HSQC): δ 7.52 – 7.46 (m, 2H, CHarom), 7.41 – 7.25 (m, 13H, CHarom), 5.55 (s, 1H, CHPh), 
4.92 (d, 1H, J = 11.3 Hz, CHH Bn), 4.85 (d, 1H, J = 12.1 Hz, CHH Bn), 4.84 (d, 1H, J = 11.3 Hz, CHH Bn), 4.70 (d, 1H, J = 
12.1 Hz, CHH Bn), 4.59 (d, 1H, J = 3.7 Hz, H-1), 4.26 (dd, 1H, J = 10.1, 4.7 Hz H-6), 4.05 (t, 1H, J = 9.3 Hz, H-3), 3.83 (td, 
1H, J = 9.9, 4.7 Hz, H-5), 3.70 (t, 1H, J = 10.2 Hz, H-6), 3.60 (t, 1H, J = 9.4 Hz, H-4), 3.56 (dd, 1H, J = 9.3, 3.7 Hz, H-2), 
3.40 (s, 3H, CH3 OMe); 13C-APT NMR (CDCl3, 101 MHz, HSQC): δ 138.8, 138.3, 137.5 (Cq), 129.0, 128.6, 128.4, 128.3, 
128.2, 128.1, 128.0, 127.7, 126.1 (CHarom), 101.4 (CHPh), 99.3 (C-1), 82.2 (C-4), 79.3 (C-2), 78.7 (C-3), 75.5, 73.9 (CH2 
Bn), 69.2 (C-6), 62.4 (C-5), 55.5 (OMe). 
Methyl 2,3,6-tri-O-benzyl-α-D-glucopyranoside (11). Fully protected compound S10 (3.24 g, 7.0 
mmol) was dissolved in THF (100 mL) and NaCNBH3 (4.0 g, 63 mmol, 9 eq.) was added. To this 
solution 4.0 M HCl in 1,4-dioxane (18 mL, 72 mmol, 10.3 eq.) was slowly added and the reaction 
was stirred for an additional hour. Ice cold H2O (300 mL) was added and the mixture extracted with DCM (2x 120 mL). 
The combined organic layers were washed with sat. aq. NaHCO3 (100 mL) and brine (100 mL), dried with MgSO4 and 
concentrated in vacuo. Flash column chromatography (6/1 to 4/1 pentane/EtOAc,) gave the title compound as a 
colorless oil (2.7 g, 5.85 mmol, 87%). Rf: 0.37 (4/1 pentane/EtOAc). Spectroscopic data were in accord with those 
previously reported.77 IR (neat): 695, 732, 1027, 1047, 1453, 2910, 3477; 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC): 
δ 7.41 – 7.23 (m, 15H, CHarom), 4.99 (d, 1H, J = 11.4 Hz, CHH Bn), 4.75 (d, 1H, J = 12.1 Hz, CHH Bn), 4.73 (d, 1H, J = 11.4 
Hz, CHH Bn), 4.68 – 4.60 (m, 2H, CHH Bn, H-1), 4.57 (d, 1H, J = 12.1 Hz, CHH Bn), 4.52 (d, 1H, J = 12.2 Hz, CHH Bn), 3.78 
(dd, 1H, J = 9.6, 8.8 Hz, H-3), 3.74 – 3.63 (m, 3H, H-5, H-6, H-6), 3.59 (t, 1H, J = 9.2 Hz, H-4), 3.52 (dd, 1H, J = 9.6, 3.5 
Hz, H-2), 3.37 (s, 3H, CH3 OMe), 2.44 (bs, 1H, 4-OH); 13C-APT NMR (CDCl3, 101 MHz, HSQC): δ 138.8, 138.1, 138.0 (Cq), 










(CH2 Bn), 70.7 (C-4), 69.9 (C-5), 69.5 (C-6), 55.2 (OMe); HRMS: [M+NH4]+ calcd for C28H36NO6 482.25371, found 
482.25357. 
Methyl 2,3-di-O-benzyl-α-D-glucopyranoside (S11). Fully protected S10 (9.25 g, 20 mmol) and p-
TsOH·H2O (380 mg, 2 mmol, 0.1 eq.) were added to MeOH (100 mL) and heated at 60°C for 15 min 
after all solids were dissolved and TLC analysis showed full conversion to a lower running spot. The 
reaction mixture was quenched with Et3N (1 mL) and concentrated in vacuo. The crude product was purified by flash 
column chromatography (8/1 to 3/2 pentane/acetone) to give the tile compound as a white solid (7.4 g, 19.8 mmol, 
99%) as a white solid. Rf: 0.33 (2/1 pentane/acetone). Spectroscopic data were in accord with those previously 
reported.77,96 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC): δ 7.37 – 7.26 (m, 10H, CHarom), 5.00 (d, 1H, J = 11.4 Hz, CHH 
Bn), 4.75 (d, 1H, J = 12.2 Hz, CHH Bn), 4.71 (d, 1H, J = 11.5 Hz, CHH Bn), 4.64 (d, 1H, J = 12.1 Hz, CHH Bn), 4.59 (d, 1H, 
J = 3.5 Hz, H-1), 3.78 (dd, 1H, J = 9.6, 8.6 Hz, H-3), 3.78 – 3.69 (m, 2H, H-6), 3.61 – 3.56 (m, 1H, H-5), 3.51 (dd, 1H, J = 
9.8, 8.6 Hz, H-4), 3.48 (dd, 1H, J = 9.5, 3.5 Hz, H-2), 3.36 (s, 3H, CH3 OMe), 2.46 (bs, 2H, OH); 13C-APT NMR (CDCl3, 101 
MHz, HSQC): δ 138.8, 138.1 (Cq-arom), 128.7, 128.6, 128.2, 128.1, 128.0, 127.9 (CHarom), 98.2 (C-1), 81.4 (C-3), 79.9 (C-
2), 75.5, 73.2 (CH2 Bn), 70.8 (C-5), 70.3 (C-4), 62.3 (C-6), 55.3 (OMe). 
Methyl (methyl 2,3-di-O-benzyl-α-D-glucopyranosyl uronate) (12). To a solution of diol S11 (6.95 g, 
18.6 mmol) in DCM (70 mL) and AcOH (0.1 mL) was added BAIB (14.95 g, 46.4 mmol, 2.5 eq.), 
TEMPO (580 mg, 3.7 mmol, 0.2 eq.) and H2O (30 mL). The solution was stirred vigorously for 2.5 
hours at room temperature, quenched by the addition of Na2S2O3 (10% aq.) and this suspension stirred for 15 min. 
The mixture was extracted two times with EtOAc and the combined organic fractions were dried (MgSO4), filtered, 
concentrated in vacuo and coevaporated with toluene once. The crude carboxylic acid was dissolved in DMF (75 mL) 
and cooled to 0°C. K2CO3 (7.7 g, 55.7 mmol, 3 eq.) and MeI (3.5 mL, 55.7 mmol, 3 eq.) were added and the reaction 
mixture stirred overnight. H2O was added and the reaction mixture was extracted twice with EtOAc. The combined 
organic layers where dried (MgSO4), filtered and concentrated in vacuo. Purification by flash column chromatography 
(1/0 to 9/1 toluene/acetone) followed by recrystallization from DCM/EtOAc/petroleum ether (1/1/23) gave the title 
product as white needles (3.84 g, 9.54 mmol, 52%, 2 steps). Spectroscopic data were in accord with those previously 
reported.78 [α]  = +19.0° (c=1.0, CHCl3), lit.: [α]  = +17.9° (c=0.5, CHCl3)78 ; IR: 700, 738, 1040, 1061, 1738, 2918, 
3532; 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC): δ 7.39 – 7.26 (m, 10H, CHarom), 4.92 (d, 1H, J = 11.3 Hz, CHH Bn), 
4.81 (d, 1H, J = 11.4 Hz, CHH Bn), 4.79 (d, 1H, J = 12.1 Hz, CHH Bn), 4.67 – 4.62 (m, 2H, CHH Bn, H-1), 4.15 (d, 1H, J = 
8.9 Hz, H-5), 3.87 – 3.76 (m, 5H, H-3, H-4, CH3 CO2Me), 3.53 (dd, 1H, J = 8.9, 3.4 Hz, H-2), 3.42 (s, 3H, CH3 OMe), 2.89 
(bs, 1H, 4-OH); 13C-APT NMR (CDCl3, 101 MHz, HSQC): δ 170.8 (C=O CO2Me), 138.7, 138.0 (Cq-arom), 128.6, 128.3, 128.1, 
128.0, 127.9 (CHarom), 98.8 (C-1), 80.5 (C-3), 78.6 (C-2), 75.6, 73.7 (CH2 Bn), 71.9 (C-4), 70.6 (C-5), 56.0 (OMe), 52.8 
(CO2Me); HRMS: [M+Na]+ calcd for C22H26O7Na 425.15707, found 425.15649. 
Preparation of acceptors 13 and 14. 
 
Methyl 2,3,4,6-tetra-O-acetyl-β-D-galactopyranoside (S12). Following the procedure of Kartha et 
al.97 D-galactose (4.5 g, 25 mmol) was portionwise added to a mixture of 70% aq. HClO4 (cat., 5 
drops) and Ac2O (14.2 mL, 150 mmol, 6 eq.). After stirring overnight a 33 wt% solution of HBr in 
AcOH (13.1 mL, 75 mmol, 3 eq.) was added and the reaction stirred at r.t. for 5 h. Solvents were evaporated by a water 
aspirator and the crude product was dissolved in EtOAc and washed with cold sat.aq. NaHCO3 and brine. The organic 
phase was dried (Na2SO4) and concentrated in vacuo. The crude bromide was dissolved in MeOH (100 mL) and cooled 
to 0°C. Iodine (3.17 g, 12.5 mmol, 0.5 eq.) was added and the reaction was stirred for 2 h. The reaction mixture was 
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quenched by sat. aq. Na2S2O3 and extracted with Et2O twice. The organic layer was washed with sat. aq. NaHCO3 and 
brine, dried (MgSO4), filtered, and concentrated in vacuo. Flash column chromatography (8/1 to 1/1 pentane/EtOAc) 
gave the methyl galactoside as an anomerically pure yellow oil (4.31 g, 11.9 mmol, 48% over three steps). 
Spectroscopic data were in accord with those previously reported.98,99 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC): δ 
5.40 (dd, 1H, J = 3.4, 1.2 Hz, H-4), 5.20 (dd, 1H, J = 10.5, 7.9 Hz, H-2), 5.03 (dd, 1H, J = 10.5, 3.4 Hz, H-3), 4.42 (d, 1H, J 
= 7.9 Hz, H-1), 4.25 – 4.11 (m, 2H, H-6), 3.93 (td, 1H, J = 6.7, 1.2 Hz, H-5), 3.52 (s, 3H, CH3 OMe), 2.16 (s, 3H, CH3 Ac), 
2.07 (s, 3H, CH3 Ac), 2.06 (s, 3H, CH3 Ac), 1.99 (s, 3H, CH3 Ac); 13C-APT NMR (CDCl3, 101 MHz, HSQC): δ 170.4, 170.2, 
170.1, 169.5 (C=O Ac), 102.0 (C-1), 71.0 (C-3), 70.6 (C-5), 68.8 (C-2), 67.1 (C-4), 61.3 (C-6), 57.0 (OMe), 20.8, 20.7, 20.7, 
20.6 (CH3 Ac). 
Methyl β-D-galactopyranoside (S13). Acetylated S12 (4.31 g, 11.9 mmol) was dissolved in MeOH 
(50 mL) and NaOMe (325 mg, 6.0 mmol, 0.5 eq.) was added. After 30 min Amberlite H+ was added 
until neutral pH was achieved and the resin was subsequently filtered off. The solution was 
concentrated in vacuo to give the crude tetra-ol. Spectroscopic data were in accord with those previously reported.100 
1H NMR (D2O, 400 MHz, HSQC): δ 4.79 (bs, 4H, OH), 4.30 (d, 1H, J = 7.9 Hz, H-1), 3.90 (d, 1H, J = 3.5 Hz, H-4), 3.81 – 
3.73 (m, 2H, H-6), 3.75 – 3.64 (m, 1H, H-5), 3.63 (dd, 1H, J = 9.9, 3.5 Hz, H-3), 3.55 (s, 3H, CH3 OMe), 3.48 (dd, 1H, J = 
9.9, 7.9 Hz, H-2); 13C NMR (D2O, 101 MHz, HSQC): δ 103.8 (C-1), 75.2 (C-5), 72.8 (C-3), 70.8 (C-2), 68.7 (C-4), 61.0 (C-
6), 57.2 (OMe).  
Methyl 2,3-di-O-benzyl-4,6-O-benzylidene-β-D-galactopyranoside (S14). Crude S13 (1.94 g, 10 
mmol), benzaldehyde dimethyl acetal (0.30 mL, 20 mmol, 2 eq.) and p-TsOH⋅H2O (475 mg, 2,5 
mmol, 0.25 eq.) were dissolved in CH3CN (50 mL) and DMF (15 mL) and the poorly soluble 
reaction mixture was stirred at 60°C, 350 mbar for 3 h. Et3N (0.8 mL) was added and the reaction 
mixture was portioned between EtOAc and H2O. The organic layer did not contain observable 
product, therefore the water layer was evaporated to give the crude product. Column chromatography (1:0 to 9/1 
DCM/MeOH) gave the benzylidene protected galactoside as a waxy solid (1.73 g, 6.1 mmol, 61%). Spectroscopic data 
were in accord with those previously reported.77,95,101 1H NMR (CDCl3, 400 MHz): δ 7.55 – 7.46 (m, 2H), 7.40 – 7.34 (m, 
3H), 5.55 (s, 1H), 4.36 (dd, 1H, J = 12.5, 1.5 Hz), 4.24 – 4.20 (m, 2H), 4.12 – 4.07 (m, 1H), 3.79 – 3.67 (m, 2H), 3.59 (d, 
3H, J = 0.7 Hz), 3.49 (t, 1H, J = 1.6 Hz).The crude methyl 4,6-O-benzylidene-β-D-galactopyranoside was coevaporated 
with dry toluene twice before being dissolved in DMF (30 mL). Benzyl bromide (3.2 mL, 18.4 mmol, 3 eq.) and NaH 
(60% dispersion in mineral oil, 736 mg, 18.4 mmol, 3 eq.) were added and the reaction mixture was stirred overnight. 
H2O was added and the mixture was extracted with EtOAc twice. The organic layer was washed with brine twice and 
dried (MgSO4), filtered, and concentrated in vacuo. The crude product was purified by flash column chromatography 
(8/1 to 3/1 pentane/EtOAc) to afford the benzylated product (2.11 g, 4.56 mmol, 75%). Rf: 0.63 (3/2 pentane/EtOAc). 
Spectroscopic data were in accord with those previously reported.77 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC): δ 
7.59 – 7.53 (m, 2H, CHarom), 7.42 – 7.26 (m, 13H, CHarom), 5.50 (s, 1H, CHPh), 4.91 (d, 1H, J = 10.9 Hz, CHH Bn), 4.81 – 
4.71 (m, 3H, CHH Bn, CH2 Bn), 4.36 – 4.27 (m, 2H, H-1, H-6), 4.11 (dd, 1H, J = 3.7, 1.1 Hz, H-4), 4.02 (dd, 1H, J = 12.3, 
1.8 Hz, H-6), 3.84 (dd, 1H, J = 9.7, 7.7 Hz, H-2), 3.60 – 3.53 (m, 4H, H-3, CH3 OMe), 3.32 (d, 1H, J = 1.3 Hz, H-5); 13C-APT 
NMR (CDCl3, 101 MHz, HSQC): δ 139.0, 138.5, 137.9 (Cq), 129.1, 128.5, 128.4, 128.2, 128.2, 127.9, 127.8, 127.6, 126.7 
(CHarom), 104.8 (C-1), 101.5 (CHPh), 79.3 (C-3), 78.6 (C-2), 75.4 (CH2 Bn), 74.1 (C-4), 72.1 (CH2 Bn), 69.4 (C-6), 66.5 (C-
5), 57.2 (OMe).  
Methyl 2,3,6-tri-O-benzyl-β-D-galactopyranoside (13). To a solution of S16 (2.10 g, 4.54 mmol) and 
NaCNBH3 (1.7 g, 27.2 mmol, 6 eq.) in THF (60 mL), 4.0 M HCl in 1,4-dioxane (9 mL, 36 mmol, 7.9 
eq.) was added. The reaction mixture was stirred for 1 h and then H2O was added. The solution 
was extracted twice with DCM and the organic layer was washed with brine, dried with MgSO4 en concentrated in 
vacuo. Flash column chromatography (9/1 to 1/1 pentane/EtOAc) provided the free alcohol as an oil (1.56 g, 3.36 
mmol, 74%). Rf: 0.74 (3/2 pentane/EtOAc). Spectroscopic data were in accord with those previously reported.77,102,103 
1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC): δ 7.41 – 7.21 (m, 15H, CHarom), 4.88 (d, 1H, J = 11.1 Hz, CHH Bn), 4.71 (d, 
1H, J = 11.0 Hz, CHH Bn), 4.67 (s, 2H, CH2 Bn), 4.56 (s, 2H, CH2 Bn), 4.26 (d, 1H, J = 7.7 Hz, H-1), 3.98 (d, 1H, J = 3.4 Hz, 
H-4)), 3.79 (dd, 1H, J = 9.9, 5.9 Hz, H-6), 3.72 (dd, 1H, J = 9.9, 6.0 Hz, H-6), 3.64 (dd, 1H, J = 9.4, 7.7 Hz, H-2), 3.59 – 
3.50 (m, 4H, H-5, CH3 OMe), 3.46 (dd, 1H, J = 9.4, 3.4 Hz, H-3), 2.70 (s, 1H, 4-OH); 13C-APT NMR (CDCl3, 101 MHz,
HSQC): δ 138.6, 137.9, 137.8 (Cq), 128.4, 128.3, 128.0, 127.8, 127.8, 127.7, 127.7, 127.5 (CHarom), 104.7 (C-1), 80.5 (C-
3), 79.0 (C-2), 75.1, 73.6 (CH2 Bn), 73.1 (C-5), 72.3 (CH2 Bn), 69.2 (C-6), 66.8 (C-4), 56.9 (OMe); HRMS: [M+Na]+ calcd 
for C28H33O6Na 487.20911, found 487.20848. 




Methyl 2,3-exo;4,6-di-O-benzylidene-α-D-mannopyranoside (S15). To a solution of methyl α-D-
mannoside (19.4 g, 100 mmol) in CH3CN (120 mL) was added benzylidene dimethyl acetal (36 
mL, 240 mmol, 2.4 eq.) and p-TsOH⋅H2O (475 mg, 2.5 mmol, 0.025 eq.). The reaction mixture 
was stirred at 60°C and 500 mbar for 3 h and the volume was reduced by half. Sat. aq. NaHCO3 
was added to quench the reaction and the precipitate collected and washed with cold H2O. The solids were 
recrystallized from EtOH/EtOAc to obtain two crops of white needles (total yield: 29.6 g, 80 mmol, 80% exo only). 
Spectroscopic data were in accord with those previously reported.104 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC): δ 
7.55 – 7.51 (m, 2H, CHarom), 7.48 – 7.44 (m, 2H, CHarom), 7.41 – 7.34 (m, 6H, CHarom), 6.30 (s, 1H, CHPh2,3 exo), 5.64 (s, 
1H, CHPh4,6), 5.02 (s, 1H, H-1), 4.63 (dd, 1H, J = 7.8, 5.4 Hz, H-3), 4.40 – 4.32 (m, 1H, H-6), 4.14 (d, 1H, J = 5.4 Hz, H-2), 
3.93 – 3.88 (m, 1H, H-4), 3.88 – 3.81 (m, 2H, H-5, H-6), 3.41 (s, 3H, CH3 OMe); 13C-APT NMR (CDCl3, 101 MHz, HSQC): 
δ 138.7, 137.3 (Cq), 129.3, 128.5, 128.4, 126.4, 126.2 (CHarom), 103.1 (CHPh2,3 exo), 102.2 (CHPh4,6), 99.0 (C-1), 77.6 (C-
4), 75.7 (C-3), 75.4 (C-2), 69.1 (C-6), 60.5 (C-5), 55.4 (OMe). 
Methyl 3-O-benzyl-4,6-O-benzylidene-α-D-mannopyranoside (14). Compound S15 (5.56 g, 15 
mmol) was dissolved in 100 mL DCM and 150 mL Et2O. A solution of LiAlH4 (2.4 M in THF, 8 mL, 
19.2 mmol, 1.3 eq.) was added to the reaction mixture at 0°C followed by addition of AlCl3 (2.2 
g, 16.4 mmol, 1.1 eq.). The reaction mixture was allowed to stir for 3 h at r.t. before being quenched by careful addition 
of EtOAc and H2O. The mixture was extracted with EtOAc and the organic phase was washed with brine, dried MgSO4 
and concentrated under reduced pressure. Purification of the crude product by flash column chromatography (6/1 to 
1/1 pentane/EtOAc) gave the title compound as a colorless oil (5.37 g, 14.4 mmol, 96%). Rf: 0.38 (2/1 pentane/EtOAc). 
Spectroscopic data were in accord with those previously reported.32,79,104 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC): 
δ 7.53 – 7.47 (m, 2H, CHarom), 7.41 – 7.27 (m, 8H, CHarom), 5.60 (s, 1H, CHPh), 4.84 (d, 1H, J = 11.9 Hz, CHH Bn), 4.73 (d, 
1H, J = 1.4 Hz, H-1), 4.69 (d, 1H, J = 11.9 Hz, CHH Bn), 4.27 (dd, 1H, J = 9.4, 4.0 Hz, H-6), 4.09 (t, 1H, J = 9.2 Hz, H-4), 
4.01 (dt, 1H, J = 3.3, 1.6 Hz, H-2), 3.93 – 3.75 (m, 3H, H-3, H-5, H-5), 3.35 (s, 3H, CH3 OMe), 2.82 (d, 1H, J = 1.7 Hz, 2-
OH); 13C-APT NMR (CDCl3, 101 MHz, HSQC): δ 138.1, 137.7 (Cq), 129.0, 128.6, 128.3, 128.0, 127.9, 126.2 (CHarom), 
101.7 (CHPh), 101.2 (C-1), 78.9 (C-4), 75.7 (C-3), 73.1 (CH2 Bn), 69.9 (C-2), 69.0 (C-6), 63.3 (C-5), 55.0 (OMe); HRMS: 
[M+Na]+ calcd for C21H24O6Na 395.14651, found 395.14638.  
Cyclohexyl 2,3-di-O-benzyl-4,6-O-benzylidene-α/β-D-mannopyranoside (1A). Donor 1 and 
cyclohexanol were condensed using the general procedure for Tf2O/Ph2SO mediated 
and purified by flash column chromatography (1/0 to 9/1 pentane/EtOAc) to yield 
glycosylation product 1A (50.9 mg, 51 μmol, 96%, α:β = 1:5). Rf: 0.43 (9/1 pentane/EtOAc). Spectroscopic data were 
in accord with those previously reported.105,106 IR (neat): 694, 733, 964, 1026, 1047, 1084, 1361, 1452, 2857, 2857, 
2930; Data for the β-anomer: 1H NMR (400 MHz, CDCl3, HH-COSY, HSQC): δ 7.55 – 7.23 (m, 15H, CHarom), 5.61 (s, 1H, 
CHPh), 5.02 (d, 1H, J = 12.5 Hz, CHH Bn), 4.91 (d, 1H, J = 12.5 Hz, CHH Bn), 4.67 (d, 1H, J = 12.5 Hz, CHH Bn), 4.58 (s, 
1H, H-1), 4.58 (d, 1H, J = 12.5 Hz, CHH Bn), 4.30 (dd, 1H, J = 10.4, 4.9 Hz, H-6), 4.22 (t, 1H, J = 9.6 Hz, H-4), 3.94 (t, 1H, 
J = 10.3 Hz, H-6), 3.87 (d, 1H, J = 3.0 Hz, H-2), 3.70 (dt, 1H, J = 8.6, 4.7 Hz, CH Cy), 3.58 (dd, 1H, J = 9.9, 3.1 Hz, H-3), 
3.31 (td, 1H, J = 9.9, 4.9 Hz, H-5), 2.06 – 0.99 (m, 10H, CH2 Cy); 13C-APT NMR (101 MHz, CDCl3, HSQC): δ 138.68, 138.54, 
137.79 (Cq), 129.05, 128.92, 128.85, 128.49, 128.40, 128.28, 128.22, 128.19, 127.84, 127.68, 127.62, 127.60, 127.58, 
127.53, 126.18, 126.14, 125.21 (CHarom), 101.48 (CHPh), 100.12 (C-1), 78.76 (C-4), 78.25 (C-3), 76.84 (CH Cy), 76.31 
(C-2), 74.71 (CH2 Bn), 72.39 (CH2 Bn), 68.82 (C-6), 67.68 (C-5), 33.48, 31.57, 25.78, 23.87, 23.72 (CH2 Cy); 13C-GATED 
NMR (101 MHz, CDCl3): 100.1 (JC1,H1 = 154 Hz, C-1 β); Diagnostic peaks α-anomer: 1H NMR (400 MHz, CDCl3, HH-COSY, 
HSQC): δ 5.64 (s, 0.20H, CHPh), 4.89 – 4.79 (m, 0.60H, CHH Bn, CHH Bn, C-1), 4.71 (d, 0.20H, J = 12.3 Hz, CHH Bn), 4.00 
(dd, 0.20H, J = 10.0, 3.2 Hz, H-2), 3.78 (dd, 0.20H, J = 3.1, 1.6 Hz, H-3), 3.54 – 3.49 (m, 0.20H, CH Cy); 13C-APT NMR 
(101 MHz, CDCl3, HSQC): δ 97.41 (C-1), 64.36 (C-5), 33.38, 31.31, 25.69, 25.25, 24.11 (CH2 Cy); HRMS: [M+Na]+ calcd 
for C33H38O6Na 553.25606, found 553.25531.  
Ethyl 2,3-di-O-benzyl-4,6-O-benzylidene-α/β-D-mannopyranoside (1B). Donor 1 and ethanol 
were condensed using the general procedure for Tf2O/Ph2SO mediated glycosylations and 
purified by flash column chromatography (1/0 to 9/1 pentane/EtOAc) to yield glycosylation 
product 1B (33.5 mg, 70 μmol, 70%, α:β = 1:5). Rf: 0.43 (9/1 pentane/EtOAc). IR (neat): 696, 734, 893, 912, 968, 1004, 
1049, 1088, 1373, 1452, 2866, 2926; Data for the β-anomer: 1H NMR (400 MHz, CDCl3, HH-COSY, HSQC): δ 7.53 – 7.28 
(m, 15H, CHarom), 5.62 (s, 1H, CHPh), 4.99 (d, 1H, J = 12.4 Hz, CHH Bn), 4.89 (d, 1H, J = 12.4 Hz, CHH Bn), 4.68 (d, 1H, J 
= 12.6 Hz, CHH Bn), 4.58 (d, 1H, J = 12.5 Hz, CHH Bn), 4.46 (s, 1H, H-1), 4.31 (dd, 1H, J = 10.4, 4.9 Hz, H-6), 4.21 (t, 1H, 
J = 9.6 Hz, H-4), 4.02 – 3.89 (m, 3H, CHHCH3 Et, H-2, H-6), 3.58 (dd, 1H, J = 9.9, 3.1 Hz, H-3), 3.56 – 3.47 (m, 1H, CHHCH3 
Et), 3.36 – 3.28 (m, 1H, H-5), 1.27 (t, 3H, J = 7.0 Hz, CH3 Et); 13C-APT NMR (101 MHz, CDCl3, HSQC): δ 138.6, 138.5, 
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137.8 (Cq), 123.0, 128.9, 128.4, 128.3, 128.2, 127.7, 127.7, 127.6, 126.2, (CHarom) 102.2 (C-1), 101.5 (CHPh), 78.8 (C-
4), 78.0 (C-3), 75.9 (C-2), 74.8 (CH2 Bn), 72.5 (CH2 Bn), 68.8 (C-6), 67.7 (C-5), 65.7 (CH2 Et), 15.3 (CH3 Et); 13C-GATED 
NMR (101 MHz, CDCl3): δ 102.2 (JC1,H1 = 153 Hz, C-1 β); Diagnostic peaks α-anomer: 1H NMR (400 MHz, CDCl3): δ 5.65 
(s, 0.20H), 4.86 – 4.81 (m, 0.40H, CHH Bn, CHH Bn), 4.80 (d, 0.20H, J = 1.5 Hz, H-1), 4.74 (d, 0.20H, J = 12.3 Hz, CHH 
Bn), 3.74 – 3.66 (m, 0.20H, CHHCH3), 3.46 – 3.39 (m, 0.20H, CHHCH3 Et); 13C-APT NMR (101 MHz, CDCl3, HSQC): δ 
128.9, 128.5, 128.4, 128.3, 128.2, 127.9, 127.6, 126.2 (Cq), 101.6 (CHPh), 99.3 (C-1), 79.4 (C-3), 76.5 (C-4), 76.4 (C-2), 
73.7 (CH2 Bn), 73.3 (CH2 Bn), 69.3 (C-6), 64.3 (C-5) 63.3 (CH2 Et), 15.1 (CH3 Et); HRMS: [M+Na]+ calcd for C29H32O6Na 
499.20911, found 499.20846. 
2-Fluoroethyl 2,3-di-O-benzyl-4,6-O-benzylidene-α/β-D-mannopyranoside (1C). Donor 1 
and 2-fluoroethanol were condensed using the general procedure for Tf2O/Ph2SO
mediated and purified by flash column chromatography (1/0 to 4/1 pentane/EtOAc) to 
yield glycosylation product 1C (42.7 mg, 86 μmol, 86%, α:β = 1:5). Rf: 0.18 (9/1 pentane/EtOAc). IR (neat): 696, 738, 
802, 887, 1025, 1043, 1066, 1086, 1261, 1371, 1454, 2870; Data for the β-anomer: 1H NMR (400 MHz, CDCl3, HH-COSY, 
HSQC): δ 7.66 – 7.32 (m, 15H, CHarom), 5.62 (s, 1H, CHPh), 4.99 (d, 1H, J = 12.3 Hz, CHH Bn), 4.89 (d, 1H, J = 12.3 Hz, 
CHH Bn), 4.70 – 4.51 (m, 5H, CHH Bn, CHH Bn, H-1, CH2CHHF, CH2CHHF), 4.30 (dd, 1H, J = 10.4, 4.8 Hz, H-6), 4.22 (t, 
1H, J = 9.6 Hz, H-4), 4.08 (ddt, 1H, J = 35.7, 12.2, 3.0 Hz, CHHCH2F), 3.98 (d, 1H, J = 2.9 Hz, H-2), 3.92 (t, 1H, J = 10.3 
Hz, H-6), 3.80 (dtd, 1H, J = 22.6, 11.9, 7.8, 2.4 Hz, CHHCH2F), 3.59 (dd, 1H, J = 9.9, 3.1 Hz, H-3), 3.33 (td, 1H, J = 9.7, 4.9 
Hz, H-5); 13C-APT NMR (101 MHz, CDCl3, HSQC): δ 138.4, 138.4, 137.6 (Cq), 131.2, 129.4, 129.0, 128.8, 128.4, 128.3, 
128.2, 127.7, 127.7, 126.2, 124.9 (CHarom), 102.3 (C-1), 101.5 (CHPh), 82.8 (d, J = 169.74 Hz, CH2F), 78.6 (C-4), 77.8 (C-
3), 75.7 (C-2), 75.0 (CH2 Bn), 72.5 (CH2 Bn), 69.0 (d, J = 19.7 Hz, CH2CH2F), 67.7 (C-6). 13C-GATED NMR (101 MHz, CDCl3): 
δ 102.3 (JC1,H1 = 156 Hz, C-1 β); Diagnostic peaks α-anomer: 1H NMR (400 MHz, CDCl3, HH-COSY, HSQC): δ 5.62 (s, 0.20H, 
CHPh), 4.93 – 4.80 (m, 0.60H, CHH Bn, CHH Bn, H-1); 13C-APT NMR (101 MHz, CDCl3, HSQC): δ 99.7 (C-1), 82.5 (d, J = 
170 Hz, CH2F), 79.2 (C-4), 76.5 (C-3), 76.4 (C-2), 73.8 (CH2 Bn), 73.3 (CH2 Bn), 68.9 (C-6), 66.7 (d, J = 19.9 Hz, CH2CH2F), 
64.4 (C-5); 13C-GATED NMR (101 MHz, CDCl3): δ 99.7 (JC1,H1 = 170 Hz, C-1 α); HRMS: [M+Na]+ calcd for C29H31FO6Na 
517.19969, found 517.19888.  
2,2-Difluoroethyl 2,3-di-O-benzyl-4,6-O-benzylidene-α/β-D-mannopyranoside (1D). 
Donor 1 and 2,2-difluoroethanol were condensed using the general procedure for 
Tf2O/Ph2SO mediated glycosylations and purified by flash column chromatography (1/0 
to 4/1 pentane/EtOAc) to yield glycosylation product 1D (46.1 mg, 90 μmol, 90%, α:β = 
1:5). Rf: 0.50 (9/1 pentane/EtOAc). IR (neat): 694, 744, 795, 1026, 1094, 1261, 1369, 1454, 2868; Data for the β-
anomer: 1H NMR (400 MHz, CDCl3, HH-COSY, HSQC): δ 7.68 – 7.27 (m, 15H, CHarom), 5.90 (dddd, 1H, J = 54.8, 5.1, 2.8, 
1.5 Hz, CHF2) 5.62 (s, 1H, CHPh), 4.94 (d, 1H, J = 12.2 Hz, CHH Bn), 4.86 (d, 1H, J = 12.2 Hz, CHH Bn), 4.70 (d, 1H, J = 
12.5 Hz, CHH Bn), 4.60 (d, 1H, J = 12.4 Hz, CHH Bn), 4.51 (s, 1H. H-1), 4.31 (dd, 1H, J = 10.4, 4.9 Hz, H-6), 4.22 (t, 1H, J 
= 9.6 Hz, H-4), 4.05 (dtd, 1H, J = 20.7, 11.1, 2.9 Hz, CHHCHF2), 3.98 – 3.88 (m, 2H, H-2, H-6), 3.82 – 3.65 (m, 1H, 
CHHCHF2), 3.59 (dd, 1H, J = 9.9, 3.1 Hz, H-3), 3.33 (td, 1H, J = 9.7, 4.8 Hz, H-5); 13C-APT NMR (101 MHz, CDCl3, HSQC): 
δ 138.3, 138.2, 137.5 (Cq), 128.8, 128.5, 128.3, 127.7, 126.2 (Carom), 115.4 (t, J = 241.9, CHF2), 102.3 (C-1), 101.6 (CHPh), 
78.6 (C-4), 77.8 (C-3), 75.5 (C-2), 75.1 (CH2 Bn), 72.6 (CH2 Bn), 68.5 (t, J = 33.0 Hz, CH2CHF2), 68.5 (C-6), 67.8 (C-5); 13C-
GATED NMR (101 MHz, CDCl3): 102.3 (JC1,H1 = 156 Hz, C-1 β); Diagnostic peaks α-anomer: 1H NMR (400 MHz, CDCl3, 
HH-COSY, HSQC): δ 5.98 (dt, 0.03 H, J = 5.7, 4.1 Hz, CHF2), 5.84 (dt, 0.10H, J = 5.9, 4.1 Hz, CHF2), 5.70 (dt, 0.03H, J = 
6.1, 4.1 Hz, CHF2), 4.84 (m, 0.34H, C-1, CHH Bn), 4.72 (d, 0.17H, J = 12.1 Hz, CHH Bn), 4.66 (d, 0.17H, J = 12.2 Hz, CHH 
Bn); 13C-APT NMR (101 MHz, CDCl3, HSQC): δ 115.4 (t, J = 240.10, CHF2), 101.6 (CHPh), 100.1 (C-1), 79.0 (C-4), 76.3 (C-
3), 76.2 (C-2), 73.9 (CH2 Bn), 73.4 (CH2 Bn), 68.5 (C-6), 64.8 (C-5); HRMS: [M+Na]+ calcd for C29H30F2O6Na 535.19027, 
found 535.18950. 
2,2,2-Trifluoroethyl 2,3-di-O-benzyl-4,6-O-benzylidene-α/β-D-mannopyranoside (1E). 
Donor 1 and 2,2,2-trifluoroethanol were condensed using the general procedure for 
Tf2O/Ph2SO mediated glycosylations and purified by flash column chromatography (1/0 
to 9/1 pentane/EtOAc) to yield glycosylation product 1E (41.7 mg, 79 μmol, 79%, α:β = 1:3.4). Rf: 0.60 (9/1 
pentane/EtOAc). IR (neat): 696, 737, 1028, 1057, 1085, 1161, 1277, 1454, 2870; Data for the β-anomer: 1H NMR (400 
MHz, CDCl3, HH-COSY, HSQC): δ 7.50 – 7.28 (m, 15H, CHarom) 5.62 (s, 1H, CHPh), 4.96 (d, 1H, J = 12.2 Hz, CHH Bn), 4.87 
(d, 1H, J = 12.1 Hz, CHH Bn), 4.69 (d, 1H, J = 12.5 Hz, CHH Bn), 4.59 (d, 1H, J = 12.5 Hz, CHH Bn), 4.57 (s, 1H, H-1), 4.31 
(dd, 1H, J = 10.4, 4.9 Hz, C-6), 4.28 – 4.17 (m, 2H, C-4, CHHCF3), 4.01 – 3.86 (m, 3H, H-2, H-6, CHHCF3), 3.59 (dd, 1H, J 
= 9.9, 3.1 Hz, H-3), 3.34 (td, 1H, J = 9.8, 4.9 Hz, H-5); 13C-APT NMR (101 MHz, CDCl3, HSQC): δ 138.2, 138.0, 137.5 (Cq), 
129.1, 128.9, 128.5, 128.3, 127.9, 127.8, 127.7, 126.2 (Carom), 123.7 (q, J = 277.6 Hz, CF3) 101.9 (C-1), 101.6 (CHPh), 
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78.4 (C-4), 77.7 (C-3), 77.5 (C-2), 75.1 (CH2 Bn), 75.0 (CH2 Bn), 72.6 (C-6), 68.4 (C-5), 66.2 (q, J = 34.9 Hz, CH2CF3); 13C-
GATED NMR (101 MHz, CDCl3): 101.9 (JC1,H1 = 157 Hz, C-1 β); Diagnostic peaks α-anomer: 1H NMR (400 MHz, CDCl3, 
HH-COSY, HSQC): δ 5.64 (s, 0.29H, CHPh), 4.88 – 4.82 (m, 0.87H, CHH Bn, CHH Bn, H-1), 4.73 – 4.64 (m, 0.58H, CHH 
Bn, CHH Bn); 13C-APT NMR (101 MHz, CDCl3, HSQC): δ 101.6 (CHPh), 100.1 (C-1), 78.9 (C-4), 76.2 (C-3), 76.0 (C-2), 74.1 
(CH2 Bn), 73.5 (CH2 Bn), 68.7 (C-6), 65.0 (C-5); HRMS: [M+Na]+ calcd for C29H29F3O6Na 553.18084, found 553.18021. 
1,1,1,3,3,3-Hexafluoro-2-propyl 2,3-di-O-benzyl-4,6-O-benzylidene-α/β-D-
mannopyranoside (1F). Donor 1 and 1,1,1,3,3,3-hexafluoro-2-propanol were condensed 
using the general procedure for Tf2O/Ph2SO mediated glycosylations (for an additional 
120 hours at -40°C) and purified by flash column chromatography (1/0 to 9/1 pentane/EtOAc) to yield glycosylation 
product 1F (33.6 mg, 34 μmol, 56%, α:β = 3.3:1). Rf: 0.81 (8/2 pentane/EtOAc). IR (neat): 694, 898, 977, 1058, 1091, 
1195, 1217, 1287, 136, 2924; Data for the α-anomer: 1H NMR (400 MHz, CDCl3, HH-COSY, HSQC): δ 7.54 – 7.27 (m, 
15H, CHarom), 5.64 (s, 1H, CHPh), 4.95 (s, 1H, H-1), 4.86 (d, 1H, J = 5.5 Hz, CHH Bn), 4.82 (d, 1H, J = 8.9 Hz, CHH Bn), 
4.69 (d, 1H, J = 2.8 Hz, CHH Bn), 4.65 (d, 1H, J = 7.7 Hz, CHH Bn), 4.38 – 4.19 (m, 3H, H-3, H-6, CH(CF3)2), 3.92 (d, 1H, J 
= 4.9 Hz, H-4), 3.89 – 3.83 (m, 2H, H-6, H-5); 13C-APT NMR (101 MHz, CDCl3, HSQC): δ 138.5, 137.5, 137.4 (Cq), 129.1, 
128.7, 128.5, 128.4, 128.3, 127.8, 127.7, 126.1 (CHarom), 121.6 (q, J = 282.7 Hz, CF3), 101.8 (C-1), 101.6 (CHPh), 78.4 
(C-3), 76.1 (C-4), 75.5 (C-2), 74.3 (CH2 Bn), 73.8 (CH2 Bn), 72.4 (hept, J = 32.7 Hz, CH(CF3)2), 72.1 (CH2 Bn), 68.3 (C-6), 
65.8 (C-5);13C-GATED NMR (101 MHz, CDCl3): δ 101.8 (JC1,H1 = 175 Hz, C-1 α); Diagnostic peaks β-anomer: 1H NMR (400 
MHz, CDCl3, HH-COSY, HSQC, HMBC): δ 5.61 (s, 0.30H, CHPh), 4.82 (d, 0.60H, J = 11.9 Hz, CHH Bn), 4.79 (s, 0.30H, H-
1,), 4.69 (d, 0.30H, J = 12.9 Hz, CHH Bn), 4.02 (d, 0.30H, J = 2.9 Hz, H-2), 3.61 (dd, 0.30H, J = 9.9, 3.1 Hz, H-3), 3.36 (td, 
0.30H, J = 9.9, 4.9 Hz, H-5); 13C-APT NMR (101 MHz, CDCl3, HSQC, HMBC): δ 101.3 (C-1), 72.6 (C-6), 68.2 (C-5); 13C 
HMBC-GATED NMR (101 MHz, CDCl3): δ 101.3 (JC1,H1 = 159 Hz, C-1 β); HRMS: [M+Na]+ calcd for C30H28F6O6Na 
621.16823, found 621.16790. 
1-[2H]-1,5-anhydro-2,3-di-O-benzyl-4,6-O-benzylidene-α-D-mannitol (1G). Donor 1 and 
triethylsilane-D were condensed using the general procedure for Tf2O/Ph2SO mediated 
glycosylations (for an additional 24 hours at -40°C) and purified by flash column 
chromatography (19/1 to 3/1 pentane/Et2O) to yield glycosylation product 42 (25.8 mg, 60 μmol, 60%, α:β = <1:20). 
Rf: 0.2 (4/1 pentane/Et2O). Spectroscopic data of the non-dueterated mannitol were in accord with those previously 
reported.107 [α]  = -27.2° (c = 0.5, CHCl3); IR (neat): 694, 733, 1092, 1119, 1452, 2349, 2866; Data for the β-anomer:
1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC): δ 7.54 – 7.48 (m, 2H, CHarom), 7.44 – 7.26 (m, 13H, CHarom), 5.65 (s, 1H, 
CHPh), 4.82 (d, 1H, J = 12.6 Hz, CHH Bn), 4.81 (d, 1H, J = 12.5 Hz, CHH Bn), 4.76 (d, 1H, J = 12.5 Hz, CHH Bn), 4.68 (d, 
1H, J = 12.4 Hz, CHH Bn), 4.28 (dd, 1H, J = 11.2, 4.1 Hz, H-6), 4.25 (t, 1H, J = 10.1 Hz, H-4), 3.85 (t, 1H, J = 10.3 Hz, H-
6), 3.79 (d, 1H, J = 3.3 Hz, H-2), 3.68 (dd, 1H, J = 9.8, 3.3 Hz, H-3), 3.42 (s, 1H, H-1), 3.34 (td, 1H, J = 9.7, 4.9 Hz, H-5); 
13C-APT NMR (CDCl3, 101 MHz, HSQC): δ 138.6, 138.3, 137.8 (Cq), 128.9, 128.5, 128.4, 128.3, 128.2, 127.9, 127.7, 
127.7, 126.1 (CHarom), 101.5 (CHPh), 79.4 (C-4), 78.6 (C-3), 74.4 (C-2), 72.7 (CH2 Bn), 72.5 (C-5), 72.4 (CH2 Bn), 68.8 (t, 
J = 22 Hz, C-1), 68.7 (C-6); 2H NMR (CHCl3, 77 MHz): δ 4.08 (D-1); HRMS: [M+H]+ calcd for C27H28DO5 434.20723, found 
434.20691. 
Allyl 2,3-di-O-benzyl-4,6-O-benzylidene-1-deoxy-β-D-mannopyranose (1H). Donor 1 and allyl 
trimethylsilane were condensed using the general procedure for Tf2O/Ph2SO mediated 
glycosylations (for an additional 96 hours at -40°C) and purified by flash column 
chromatography (1/0 to 9/1 pentane/EtOAc) to yield glycosylation product 1H (20.7 mg, 44 μmol, 44%, α:β = <1:20). 
Rf: 0.80 (9/1 pentane/EtOAc). Spectroscopic data were in accord with those previously reported.72 [α]  = -19.6° (c = 
0.5, CHCl3); IR (neat): 696, 1028, 1097, 1454, 2860, 2924; Data for the β-anomer: 1H NMR (400 MHz, CDCl3, HH-COSY, 
HSQC, NOESY): δ 7.52 – 7.26 (m, 15H, CHarom), 5.76 – 5.59 (m, 1H, CHCH2 allyl), 5.64 (s, 1H, CHPh), 5.11 – 4.98 (m, 3H, 
CHH Bn, CHCH2 allyl), 4.92 (d, 1H, J = 12.3 Hz, CHH Bn), 4.76 (d, 1H, J = 12.3 Hz, CHH Bn), 4.69 (d, 1H, J = 11.4 Hz, CHH 
Bn), 4.35 – 4.16 (m, 2H, H-4, H-6), 3.84 (t, 1H, J = 10.3 Hz, H-6), 3.80 (d, 1H, J = 2.2 Hz, H-2), 3.73 (dd, 1H, J = 9.8, 2.9 
Hz, H-3), 3.45 (t, 1H, J = 6.8 Hz, H-1), 3.38 (td, 1H, J = 9.8, 4.9 Hz, H-5), 2.46 (dt, 1H, J = 13.5, 6.7 Hz, CHHCH allylic), 
2.25 (dt, 1H, J = 14.3, 7.2 Hz, CHHCH allylic); 13C-APT NMR (101 MHz, CDCl3, HSQC, HMBC): δ 138.8, 138.6, 137.9 (Cq), 
134.4 (CHCH2 allyl), 128.9, 128.6, 128.5, 128.4, 128.3, 127.8, 127.7, 127.7, 126.2 (CHarom), 117.6 (CHCH2 allyl), 101.5 
(CHPh), 80.9 (C-3), 79.8 (C-1), 79.7 (C-4), 76.6 (C-2), 75.1 (CH2 Bn), 73.3 (CH2 Bn), 72.1 (C-5), 68.8 (C-6), 35.6 (CH2CH 




benzyl-α-D-glucopyranoside (20). Donor 1 and acceptor 10 were condensed using the 
general procedure for Tf2O/Ph2SO mediated glycosylations (for an additional 16 
hours at -40°C) and purified by flash column chromatography (9/1 to 7/3 
pentane/EtOAc) to yield glycosylation product 20 (86.6mg, 97 μmol, 97%, α:β = 1:10). 
Rf: 0.67 (7/3 pentane/EtOAc). Spectroscopic data were in accord with those previously reported.105,108,109 [α]  +5.2° 
(c = 1, CHCl3, 546 nm), [α]  0.0° (c = 1, CHCl3, 589 nm), (lit:108 [α]  = -1.7° (c = 1.8, CHCl3), lit:105 [α]  = -5.8° (c = 
0.94, CHCl3)); IR (neat): 731, 1026, 1049, 1084, 1452, 2872; Data for the β-anomer: 1H NMR (400 MHz, CDCl3, HH-COSY, 
HSQC): δ 7.58 – 7.05 (m, 30H, CHarom), 5.59 (s, 1H, CHPh), 5.03 (d, 1H, J = 10.9 Hz, CHH Bn), 4.92 (d, 1H, J = 12.3 Hz, 
CHH Bn), 4.86 – 4.76 (m, 4H, CHH Bn, CHH Bn, CHH Bn, CHH Bn), 4.72 (d, 1H, J = 12.5 Hz, CHH Bn), 4.67 (d, 1H, J = 12.2 
Hz, CHH Bn), 4.61 (d, 1H, J = 12.6 Hz, CHH Bn), 4.58 (d, 1H, J = 3.5 Hz, H-1), 4.50 (d, 1H, J = 11.6 Hz, CHH Bn), 4.25 (dd, 
1H, J = 10.4, 4.8 Hz, H-6’), 4.18 (t, 1H, J = 9.6 Hz, H-4’), 4.08 (m, 2H, H-1’, H-6), 4.02 (t, 1H, J = 9.3 Hz, H-4), 3.91 (t, 1H, 
J = 10.3 Hz, H-6’), 3.80 – 3.72 (m, 1H, H-2), 3.69 (d, 1H, J = 2.9 Hz, H-2’), 3.47 (m, 4H, H-3, H-3’, H-5, H-6), 3.33 (s, 3H, 
CH3 OMe), 3.22 (td, 1H, J = 9.8, 4.8 Hz, H-5’); 13C-APT NMR (101 MHz, CDCl3): δ 138.9, 138.5, 138.5, 138.5, 138.1, 
137.7 (Cq), 129.0, 128.7, 128.6, 128.5, 128.5, 128.5, 128.3, 128.3, 128.2, 128.1, 128.1, 127.8, 127.8, 127.7, 126.1 
(CHarom), 102.1 (H-1’), 101.5 (CHPh), 97.9 (C-1), 82.3 (C-4), 79.9 (C-3), 78.8 (C-4), 77.9 (C-3’), 76.8 (C-5), 75.8 (CH2 Bn), 
75.7 (C-2’), 74.8 (CH2 Bn), 74.6 (CH2 Bn), 73.5 (CH2 Bn), 72.6 (CH2 Bn), 69.7 (C-2), 68.7 (C-6’), 68.3 (C-6), 67.7 (C-5’), 
55.2 (CH3 OMe); HRMS: [M+Na]+ calcd for C55H58O11Na 917.38713, found 917.38729. 
Methyl 4-O-(2,3-di-O-benzyl-4,6-O-benzylidene-α/β-D-mannopyranosyl)-2,3,6-tri-O-
benzyl-α-D-glucopyranoside (21). Donor 1 and acceptor 11 were condensed using 
the general procedure for Tf2O/Ph2SO mediated glycosylations (for an additional 16 
hours at -40°C) and purified by flash column chromatography (9/1 to 7/3 
pentane/EtOAc) to yield glycosylation product 21 (67.4 mg, 75 μmol, 75%, α:β = 1:9). Rf: 0.67 (7/3 pentane/EtOAc). 
Spectroscopic data were in accord with those previously reported.105,108–110 [α]  −15.8° (c = 1, CHCl3), (lit:110 [α]  = 
–15.5° (c = 0.8, CHCl3)); IR (neat): 735, 1028, 1083, 1452, 2862; Data for the β-anomer: 1H NMR (400 MHz, CDCl3, HH-
COSY, HSQC): δ 7.46 – 7.21 (m, 25H, CHarom), 5.51 (s, 1H, CHPh), 5.05 (d, 1H, J = 10.6 Hz, CHH Bn), 4.84 – 4.70 (m, 5H, 
CHH Bn, CHH Bn, CHH Bn, CHH Bn, CHH Bn), 4.70 – 4.52 (m, 4H, CHH Bn, CHH Bn, CHH Bn, H-1), 4.36 (s, 1H, H-1’), 4.28 
(d, 1H, J = 12.1 Hz, CHH Bn), 4.12 – 4.01 (m, 2H, H-4’, H-6), 3.94 – 3.81 (m, 2H, H-3, H-4), 3.63 (d, 1H, J = 2.9 Hz, H-2’), 
3.62 – 3.47 (m, 4H, H-5, H-2, H-6, H-6’, H-6’), 3.47, 3.40 (s, 3H, CH3 OMe), 3.32 (dd, 1H, J = 9.8, 3.0 Hz, H-3’), 3.05 (td, 
1H, J = 9.7, 4.8 Hz, H-5’); 13C-APT NMR (101 MHz, CDCl3, HSQC): δ 139.5, 138.8, 138.7, 138.4, 137.8, 137.6 (Cq), 128.9,
128.7, 128.6, 128.5, 128.5, 128.4, 128.3, 128.2, 128.1, 127.9, 127.8, 127.6, 127.6, 127.4, 127.3, 126.2 (CHarom), 101.7 
(C-1’), 101.4 (CHPh), 98.5 (C-1), 80.4 (C-4), 79.1 (C-2), 78.8 (C-4’), 78.4 (C-3’), 77.8 (C-3), 77.1 (C-2), 75.4 (CH2 Bn), 75.1
(CH2 Bn), 73.8 (CH2 Bn), 73.7 (CH2 Bn), 72.6 (CH2 Bn), 69.7 (C-5), 68.7 (C-6), 68.4 (C-6’), 67.4 (C-5), 55.5 (CH3 OMe);
13C-GATED NMR (101 MHz, CDCl3): 101.7 (JC1,H1 = 156 Hz, C-1 β); Diagnostic peaks α-anomer: 1H NMR (400 MHz, CDCl3, 
HH-COSY, HSQC): δ 5.60 (s, 0.11H, CHPh), 5.30 (d, 0.11H, J = 1.3 Hz, C-1’); 13C-APT NMR (101 MHz, CDCl3, HSQC): δ 
101.5 (C-1’), 101.4 (CHPh); HRMS: [M+Na]+ calcd for C55H58O11Na 917.38713, found 917.38706.
Methyl (methyl [4-O-(2,3-di-O-benzyl-4,6-O-benzylidene-α/β-D-mannopyranosyl]-
2,3-di-O-benzyl-α-D-glucopyranosyl uronate) (22). Donor 1 and acceptor 12 were 
condensed using the general procedure for Tf2O/Ph2SO mediated glycosylations 
(for an additional 48 hours at -40°C) and purified by flash column chromatography 
(9/1 to 7/3 pentane/EtOAc) to yield glycosylation product 22 (72.8 mg, 87 μmol, 87%, α:β = 1:10). Rf: 0.65 (7/3 
pentane/EtOAc); [α]  = -19.2° (c = 1, CHCl3); IR (neat): 735, 1045, 1084, 1454, 1748, 2866; Data for the β-anomer: 1H 
NMR (400 MHz, CDCl3, HH-COSY, HSQC): δ 7.55 – 7.24 (m, 25H, CHarom), 5.54 (s, 1H, CHPh), 5.06 (d, 1H, J = 10.6 Hz, 
CHH Bn), 4.88 – 4.71 (m, 5H, CHH Bn, CHH Bn, CHH Bn, CHHBn, CHH Bn), 4.67 – 4.53 (m, 4H, CHH Bn, CHH Bn, H-1), 
4.45 (s, 1H, H-1), 4.17 – 4.01 (m, 3H, H-4, H-4’, H-6’), 3.95 – 3.85 (m, 2H, H-3, H-5), 3.82 – 3.75 (m, 1H, H-2’), 3.65 – 
3.55 (m, 4H, H-6’, CH3 CO2Me), 3.55 – 3.47 (m, 2H, H-2, H-3’), 3.44 (s, 3H, CH3 OMe), 3.19 (td, 1H, J = 9.6, 4.8 Hz, H-
5’); 13C-APT NMR (101 MHz, CDCl3, HSQC): δ 170.2 (C=O CO2Me), 139.2, 138.7, 138.5, 138.1, 137.7 (Cq), 128.6, 128.5, 
128.4, 128.3, 128.2, 128.2, 128.1, 127.7, 127.7, 127.6, 127.4, 126.2 (CHarom), 102.5 (H-1’), 101.5 (CHPh), 98.9 (C-1), 
80.2 (C-3/C-5), 79.8 (C-3/C-5), 78.7 (C-4’), 78.5 (H-2, H-3’), 77.9 (C-2’), 77.2 (CH2 Bn), 75.6 (CH2 Bn), 75.2 (CH2 Bn), 74.0 
(CH2 Bn), 72.7 (CH2 Bn), 69.7 (C-6), 68.6 (C-6’), 67.7 (C-5’), 56.0 (CH3 CO2Me) , 52.5 (CH3 OMe); 13C-GATED NMR (101 
MHz, CDCl3): δ 102.5 (JC1,H1 = 157 Hz, C-1 β); Diagnostic peaks α-anomer: 1H NMR (400 MHz, CDCl3, HH-COSY, HSQC): 
δ 5.58 (s, 0.10H, CHPh), 5.27 (s, 0.10H, H-1’), 4.98 (d, 0.10H, J = 11.4 Hz, CHH Bn), 4.31 (d, 0.10H, J = 11.9 Hz, CHH Bn); 
13C-APT NMR (101 MHz, CDCl3): δ 101.54 (CHPh), 100.45 (C-1’), 98.63 (C-1); HRMS: [M+Na]+ calcd for C49H52O12Na 
855.33510, found 855.33507. 





benzyl-β-D-galactopyranoside (23). Donor 1 and acceptor 13 were condensed using 
the general procedure for Tf2O/Ph2SO mediated glycosylations (for an additional 
16 hours at -40°C) and purified by flash column chromatography (9/1 to 7/3 
pentane/EtOAc) to yield glycosylation product 23 (62.7 mg, 70 μmol, 70%, α:β = <1:20). Rf: 0.80 (7/3 pentane/EtOAc); [α]  = -26.8° (c = 1, CHCl3); IR (neat): 737, 1072, 1454, 2866; Data for the β-anomer: 1H NMR (400 MHz, CDCl3, HH-
COSY, HSQC): δ 7.46 – 7.14 (m, 30H, CHarom), 5.59 (s, 1H, CHPh), 4.96 (d, 1H, J = 12.4 Hz, CHH Bn), 4.91 (d, 1H, J = 11.0 
Hz, CHH Bn), 4.86 (d, 1H, J = 12.4 Hz, CHH Bn), 4.79 (s, 1H, H-1’), 4.78 (d, 1H, J = 11.6 Hz, CHH Bn), 4.68 (d, 1H, J = 11.0 
Hz, CHH Bn), 4.62 – 4.47 (m, 5H, CHH Bn, CHH Bn, CHH Bn, CHH Bn, CHH Bn), 4.31 (d, 1H, J = 7.7 Hz, H-1), 4.21 – 4.09 
(m, 3H, H-4’, H-6’), 4.01 (d, 1H, J = 3.0 Hz, H-2’), 3.90 – 3.81 (m, 2H, H-6, H-6’), 3.72 (dd, 1H, J = 9.8, 5.7 Hz, H-6), 3.67 
(dd, 1H, J = 9.6, 7.7 Hz, H-2), 3.63 – 3.55 (m, 4H, H-5, CH3 OMe), 3.52 (dd, 1H, J = 9.6, 3.0 Hz, H-3), 3.40 (dd, 1H, J = 
9.9, 3.1 Hz, H-3’), 3.18 (td, 1H, J = 9.8, 4.9 Hz, H-5); 13C-APT NMR (101 MHz, CDCl3, HSQC): δ 138.9, 138.8, 138.5, 138.4, 
138.2, 137.6 (Cq), 129.0, 128.7, 128.7, 128.5, 128.4, 128.4, 128.3, 128.3, 128.2, 128.0, 127.8, 127.7, 127.6, 127.6, 
127.5, 126.1 (CHarom), 105.1 (C-1), 102.6 (C-1’), 101.4 (CHPh), 81.8 (H-3), 79.5 (H-2), 78.5 (C-3’), 78.5 (C-4’), 75.4 (C-
2’), 75.1 (CH2 Bn), 74.7 (CH2 Bn), 73.7 (CH2 Bn), 73.6 (H-5), 73.6 (CH2 Bn), 73.3 (C-4), 72.2(CH2 Bn), 69.5 (C-6), 68.7 (C-
6’), 67.8 (C-5), 57.2 (CH3 OMe); 13C-GATED NMR (101 MHz, CDCl3): δ 102.6 (JC1,H1 = 159 Hz, C-1 β); HRMS: [M+Na]+ 
calcd for C55H58O11Na 917.38713, found 917.38696. 
Methyl 2-O-(2,3-di-O-benzyl-4,6-O-benzylidene-β-D-mannopyranosyl)-3-O-benzyl-4,6-O-
benzylidene-α-D-mannopyranoside (24). Donor 1 and acceptor 14 were condensed using 
the general procedure for Tf2O/Ph2SO mediated glycosylations (for an additional 16 
hours at -40°C) and purified by flash column chromatography (9/1 to 7/3 pentane/EtOAc) 
to yield glycosylation product 24 (70.2 mg, 87 μmol, 87%, α:β = <1:20). Rf: 0.68 (7/3 
pentane/EtOAc). Spectroscopic data were in accord with those previously reported.108–111 [α]  −44.4° (c = 1, CHCl3); 
(lit:110 [α]  = –44.2° (c = 4.2, CHCl3), lit:111 [α]  = –44.8° (c = 3.9, CHCl3)); IR (neat): 733, 1002, 1028, 1055, 1083, 
1452, 2862; Data for the β-anomer: 1H NMR (400 MHz, CDCl3, HH-COSY, HSQC): δ 7.53 – 7.16 (m, 25H, CHarom), 5.60 
(s, 1H, CHPh), 5.51 (s, 1H, CHPh), 5.06 (d, 1H, J = 12.3 Hz, CHH Bn), 4.97 (d, 1H, J = 12.3 Hz, CHH Bn), 4.81 – 4.56 (m, 
6H, CHH Bn, CHH Bn, CHH Bn, CHH Bn, H-1, H-1’), 4.30 – 4.18 (m, 4H, H-2, H-4´, H-6, H-6’), 4.10 (t, 1H, J = 9.2 Hz, H-4), 
3.98 (d, 1H, J = 2.8 Hz, H-2’), 3.94 (dd, 1H, J = 10.0, 3.2 Hz, H-3) 3.88 (t, 1H, J = 10.3 Hz, H-6’), 3.78 (m, 2H, H-5, H-6), 
3.59 (dd, 1H, J = 9.9, 3.0 Hz, H-3’), 3.46 – 3.21 (m, 4H, H-5’, CH3 OMe); 13C-APT NMR (101 MHz, CDCl3, HSQC): δ δ 
139.0, 138.7, 138.5, 137.7, 137.7 (Cq), 129.0, 128.7, 128.4, 128.3, 128.3, 128.2, 127.7, 127.6, 127.6, 127.4, 126.2, 
126.2 (CHarom), 101.7 (CHPh), 101.5 (CHPh), 101.0 (C-1’), 99.6 (C-1), 78.8 (C-4), 78.6 (H-4’), 77.8 (C-3’), 76.1 (C-2’), 75.3 
(H-2), 74.7 (H-3), 74.2 (CH2 Bn), 72.4 (CH2 Bn), 71.5 (CH2 Bn), 69.1 (C-6), 68.7 (C-6’), 67.9 (C-5’), 64.2 (C-5), 55.1 (CH3 
OMe); 13C-GATED NMR (101 MHz, CDCl3): δ 101.0 (JC1,H1 = 154 Hz, C-1’ β); HRMS: [M+Na]+ calcd for C48H50O11Na 
825.32453, found 825.32425.  
Cyclohexyl 2,3-di-O-benzyl-4,6-O-benzylidene- α/β-D-glucopyranoside (2A). Donor 2 and 
cyclohexanol were condensed using the general procedure for Tf2O/Ph2SO mediated 
glycosylations and purified by flash column chromatography (1/0 to 0/1 
pentane/toluene to 6% EtOAc in toluene) to yield glycosylation product 2A (37.8 mg, 71 µmol, 71%, α:β = 1:5). Rf: 0.22 
(toluene). Spectroscopic data were in accord with those previously reported.65 IR (neat): 696, 735, 746, 997, 1028, 
1049, 1072, 1366, 1452, 1497, 2857, 2930; Data for the β-anomer:1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC): δ 7.51 
– 7.46 (m, 2H, CHarom), 7.41 – 7.24 (m, 13H, CHarom), 5.56 (s, 1H, CHPh), 4.94 (d, 1H, J = 10.8 Hz, CHH Bn), 4.90 (d, 1H, 
J = 11.1 Hz, CHH Bn), 4.79 (d, 1H, J = 11.5 Hz, CHH Bn), 4.76 (d, 1H, J = 10.9 Hz, CHH Bn), 4.62 (d, 1H, J = 7.7 Hz, H-1), 
4.33 (dd, 1H, J = 10.5, 5.0 Hz, H-6), 3.79 (t, 1H, J = 10.3 Hz, H-6), 3.76 – 3.65 (m, 3H, CH Cy, H-3, H-4), 3.46 (t, 1H, J = 
8.1 Hz, H-2), 3.39 (td, 1H, J = 9.5, 5.0 Hz, H-5), 2.00 – 1.91 (m, 2H, CH2 Cy), 1.82 – 1.72 (m, 2H, CH2 Cy), 1.59 – 1.18 (m, 
6H, CH2 Cy); 13C-APT NMR (CDCl3, 101 MHz, HSQC): δ 138.7, 138.6, 137.5 (Cq), 129.0, 128.4, 128.4, 128.3, 128.3, 128.1, 
127.8, 127.7, 126.1 (CHarom), 102.5 (C-1), 101.2 (CHPh), 82.3 (C-2), 81.6, 81.2 (C-3, C-4), 78.3 (CH Cy), 75.5, 75.2 (CH2 
Bn), 69.0 (C-6), 66.1 (C-5), 33.9, 32.1, 25.7, 24.2, 24.1 (CH2 Cy); Diagnostic peaks α-anomer: 1H NMR (CDCl3, 400 MHz, 
HH-COSY, HSQC): δ 4.69 (d, 1H, J = 12.1 Hz, CHH Bn), 4.26 (dd, 1H, J = 10.2, 4.9 Hz, H-6), 4.07 (t, 1H, J = 9.3 Hz, H-3), 
3.96 (td, 1H, J = 10.0, 4.9 Hz, H-5), 3.61 (t, 1H, J = 9.4 Hz, H-4), 3.58 – 3.50 (m, 2H, CH Cy, H-2); 13C-APT NMR (CDCl3, 
101 MHz, HSQC): δ 101.3 (CHPh), 96.1 (C-1), 82.5 (C-4), 79.5 (C-2) 78.8 (C-3), 76.1 (CH Cy), 75.4, 73.4 (CH2 Bn), 69.2 
(C-6), 62.6 (C-5); HRMS: [M+H]+ calcd for C33H39O6 531.27412, found 531.27400. 
Ethyl 2,3-di-O-benzyl-4,6-O-benzylidene-α/β-D-glucopyranoside (2B). Donor 2 and ethanol 




purified by flash column chromatography (1/1 to 0/1 pentane/toluene to 6% EtOAc in toluene) to yield glycosylation 
product 2B (32.2 mg, 68 µmol, 68%, α:β = 1:10). Rf: 0.43 (6% EtOAc in toluene). IR (neat): 692, 743, 1006, 1028, 1183, 
1364, 1453, 2872; Data for the β-anomer: 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC): δ 7.52 – 7.46 (m, 2H, CHarom), 
7.41 – 7.24 (m, 13H, CHarom), 5.56 (s, 1H, CHPh), 4.93 – 4.88 (m, 2H, 2xCHH Bn), 4.83 – 4.74 (m, 2H, 2xCHH Bn), 4.51 
(d, 1H, J = 7.7 Hz, H-1), 4.34 (dd, 1H, J = 10.5, 5.0 Hz, H-6), 3.97 (dq, 1H, J = 9.6, 7.1 Hz, CHH Et), 3.79 (t, 1H, J = 9.5 Hz, 
H-6), 3.76 – 3.63 (m, 3H, H-3, H-4, CHH Et), 3.46 (t, 1H, J = 8.1 Hz, H-2), 3.40 (ddd, 1H, J = 10.0, 9.0, 5.0 Hz, H-5), 1.29 
(t, 3H, J = 7.0 Hz, CH3 Et); 13C-APT NMR (CDCl3, 101 MHz, HSQC): δ 138.7, 138.6, 137.5 (Cq), 129.0, 128.5, 128.4, 128.4, 
128.2, 128.1, 127.8, 127.7, 126.1 (CHarom), 104.1 (C-1), 101.3 (CHPh), 82.3 (C-2), 81.7 (C-4), 81.0 (C-3), 75.5, 75.2 (CH2 
Bn), 69.0 (C-6), 66.2 (CH2 Et), 66.2 (C-5), 15.5 (CH3 Et); Diagnostic peaks α-anomer: 1H NMR (CDCl3, 400 MHz, HH-COSY, 
HSQC): δ 5.55 (s, 1H, CHPh), 4.92 (d, 1H, J = 11.2 Hz, CHH Bn), 4.86 – 4.83 (m, 2H, CHH Bn, CHH Bn), 4.73 (d, 1H, J = 
3.8 Hz, H-1), 4.68 (d, 1H, J = 12.2 Hz, CHH Bn), 4.25 (dd, 1H, J = 10.2, 4.8 Hz, H-6), 4.06 (t, 1H, J = 9.3 Hz, H-3), 3.88 (td, 
1H, J = 10.0, 4.8 Hz, H-5), 3.63 – 3.60 (m, 1H, H-4), 3.59 – 3.52 (m, 2H, H-2, CHH Et); 13C-APT NMR (CDCl3, 101 MHz, 
HSQC): δ 101.3 (CHPh), 97.9 (C-1), 82.4 (C-4), 79.5 (C-2), 78.8 (C-3), 73.7 (CH2 Bn), 69.2 (C-6), 63.8 (CH2 Et), 62.5 (C-5); 
HRMS: [M+H]+ calcd for C29H33O6 477.22717, found 477.22699. 
2-Fluoroethyl 2,3-di-O-benzyl-4,6-O-benzylidene-α/β-D-glucopyranoside (2C). Donor 2 
and 2-fluoroethanol were condensed using the general procedure for Tf2O/Ph2SO 
mediated glycosylations and purified by flash column chromatography (1/1 to 0/1 
pentane/toluene to 6% EtOAc in toluene) to yield glycosylation product 2C (34.7 mg, 70 µmol, 70%, α:β = 1:3). Rf: 0.30 
and 0.34 (4% EtOAc in toluene). IR (neat): 695, 744, 1000, 1028, 1072, 1085, 1177, 1452, 2868. Reported as a 0.33 : 
1.00 mixture of anomers: 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC): δ 7.52 – 7.44 (m, 2.66H, CHarom), 7.42 – 7.24 (m, 
17.29H, CHarom), 5.56 (s, 1H, CHPhβ), 5.55 (s, 0.33H, CHPhα), 4.92 (dd, 2.33H, J = 11.1, 3.4 Hz, 2xCHH Bnβ, CHH Bnα), 
4.87 – 4.73 (m, 2.99H, 2xCHH Bnβ, CHH Bnα, CHH Bnα, H-1α), 4.72 – 4.60 (m, 1.66H, CHH Bnα, CHH-CH2Fα, CHH-CH2Fβ), 
4.59 – 4.49 (m, 2.33H, CHH-CH2Fα, CHH-CH2Fβ, H-1β), 4.34 (dd, 1H, J = 10.5, 5.0 Hz, H-6β), 4.26 (dd, 0.33H, J = 10.2, 4.9 
Hz, H-6α), 4.13 (ddd, 0.50H, J = 12.1, 4.7, 2.6 Hz, CHHFβ), 4.10 – 4.02 (m, 0.83H, CHHFβ, H-3α), 3.94 – 3.66 (m, 5.32H, 
CHHFβ, CH2Fα, H-3β, H-4β, H-5α, H-6α, H-6β), 3.61 (t, 0.33H, J = 9.4 Hz, H-4α), 3.58 (dd, 0.33H, J = 9.3, 3.8 Hz, H-2α), 3.50 
(t, 1H, J = 8.1 Hz, H-2β), 3.41 (ddd, 1H, J = 10.0, 9.0, 5.0 Hz, H-5β); 13C-APT NMR (CDCl3, 101 MHz, HSQC): δ 138.9, 
138.6, 138.4, 138.3, 137.5, 137.4 (Cq), 129.1, 129.0, 128.6, 128.5, 128.4, 128.4, 128.3, 128.2, 128.1, 128.1, 128.0, 
127.7, 126.1 (CHarom), 104.4 (C-1β, 101.4 (CHPhα), 101.3 (CHPhβ), 98.4 (C-1α), 82.7 (d, J = 170.2 Hz, CH2Fα), 82.6 (d, J = 
170.2 Hz, CH2Fβ), 82.2 (C-4α), 82.1 (C-2β), 81.5 (C-4β), 80.9 (C-3β), 79.4 (C-2α), 78.6 (C-3α), 75.5 (CH2 Bnα,β), 75.2 (CH2 
Bnβ), 73.7 (CH2 Bnα), 69.4 (d, J = 20.0 Hz, CH2-CH2Fβ), 69.1 (C-6α), 68.8 (C-6), 67.3 (d, J = 20.2 Hz, CH2-CH2Fα), 66.2 (C-
5β), 62.6 (C-5α); HRMS: [M+H]+ calcd for C29H32FO6 495.21774, found 495.21745. 
2,2-Difluoroethyl 2,3-di-O-benzyl-4,6-O-benzylidene-α/β-D-glucopyranoside (2D). Donor 
2 and 2,2-difluoroethanol were condensed using the general procedure for Tf2O/Ph2SO 
mediated glycosylations and purified by flash column chromatography (1/1 to 0/1 
pentane/toluene to 6% EtOAc in toluene) to yield glycosylation product 2D (36 mg, 70 
µmol, 70%, α:β = 5:1). Rf: 0.32 and 0.36 (4% EtOAc in toluene). IR (neat): 696, 747, 996, 1028, 1071, 1086, 1369, 1453, 
2865. Data for the α-anomer: 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC): δ 7.48 (m, 2H, CHarom), 7.41 – 7.26 (m, 13H, 
CHarom), 5.95 (tt, 1H, J = 55.4, 4.2 Hz, CHF2), 5.55 (s, 1H, CHPh), 4.92 (d, 1H, J = 11.3 Hz, CHH Bn), 4.84 (d, 1H, J = 12.0 
Hz, CHH Bn), 4.83 (d, 1H, J = 11.4 Hz, CHH Bn), 4.75 (d, 1H, J = 3.9 Hz, H-1), 4.66 (d, 1H, J = 12.0 Hz, CHH Bn), 4.25 (dd, 
1H, J = 10.2, 4.8 Hz, H-6), 4.03 (t, 1H, J = 9.3 Hz, H-3), 3.90 – 3.65 (m, 4H, CH2-CHF2, H-5, H-6), 3.62 (t, 1H, J = 9.4 Hz, 
H-4), 3.58 (dd, 1H, J = 9.3, 3.8 Hz, H-2); 13C-APT NMR (CDCl3, 101 MHz, HSQC): δ 138.8, 138.2, 137.4 (Cq), 129.1, 128.6, 
128.4, 128.4, 128.2, 128.1, 128.1, 127.7, 126.1 (CHarom), 114.2 (t, J = 241.5 Hz, CHF2), 101.4 (CHPh), 98.9 (C-1), 82.0 
(C-4), 79.3 (C-2), 78.4 (C-3), 75.5, 74.0 (CH2 Bn), 69.0 (C-6), 67.4 (t, J = 28.8 Hz, CH2-CHF2), 63.0 (C-5); Diagnostic peaks 
β-anomer: 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC): δ 5.90 (tdd, 1H, J = 55.4, 5.0, 3.4 Hz, CHF2), 5.56 (s, 1H, CHPh), 
4.54 (d, 1H, J = 7.6 Hz, H-1), 4.34 (dd, 1H, J = 10.5, 5.0 Hz, H-6), 3.48 (t, 1H, J = 8.1 Hz, H-2), 3.41 (td, 1H, J = 9.6, 5.0 
Hz, H-5); 13C-APT NMR (CDCl3, 101 MHz, HSQC): δ 104.5 (C-1), 101.3 (CHPh), 81.9 (c-2), 81.4, 80.8 (C-3, C-4), 75.6, 75.3 
(CH2 Bn), 68.7 (C-6), 66.3 (C-5); HRMS: [M+H]+ calcd for C29H31F2O6 513.20832, found 513.20808. 
2,2,2-Trifluoroethyl 2,3-di-O-benzyl-4,6-O-benzylidene-α-D-glucopyranoside (2E). Donor 2 
and 2,2,2-trifluoroethanol were condensed using the general procedure for Tf2O/Ph2SO 
mediated glycosylations and purified by flash column chromatography (1/1 to 0/1 
pentane/toluene to 6% EtOAc in toluene) to yield glycosylation product 2E (33.7 mg, 64 µmol, 64%, α:β = >20:1). Rf: 
0.45 (4% EtOAc in toluene). [α]  = +7.0° (c = 0.67, DCM); IR (neat): 697, 747, 1001, 1029, 1077, 1161, 1279, 1373, 
1454, 2864; Data for the α-anomer: 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC): δ 7.51 – 7.46 (m, 2H, CHarom), 7.41 – 




7.26 (m, 13H, CHarom), 5.55 (s, 1H, CHPh), 4.92 (d, 1H, J = 11.2 Hz, CHH Bn), 4.84 (d, 1H, J = 12.0 Hz, CHH Bn), 4.83 (d, 
1H, J = 11.3 Hz, CHH Bn), 4.80 (d, 1H, J = 3.9 Hz, H-1), 4.67 (d, 1H, J = 12.0 Hz, CHH Bn), 4.25 (dd, 1H, J = 10.2, 4.8 Hz, 
H-6), 4.05 (t, 1H, J = 9.3 Hz, H-3), 3.92 (q, 2H, J = 8.7 Hz, CH2-CF3), 3.85 (td, 1H, J = 9.9, 4.8 Hz, H-5), 3.70 (t, 1H, J = 10.3 
Hz, H-6), 3.63 (t, 1H, J = 9.4 Hz, H-4), 3.59 (dd, 1H, J = 9.3, 3.8 Hz, H-2); 13C-APT NMR (CDCl3, 101 MHz, HSQC): δ 138.8, 
138.2, 137.4 (Cq), 129.1, 128.6, 128.4, 128.4, 128.2, 128.1, 128.1, 127.8, 126.2 (CHarom), 123.8 (q, J = 278.6 Hz, CF3), 
101.4 (CHPh), 99.0 (C-1), 81.9 (C-4), 79.2 (C-2), 78.3 (C-3), 75.5, 73.9 (CH2 Bn), 68.9 (C-6), 65.2 (q, J = 35.0 Hz, CH2-CF3), 
63.3 (C-5); Diagnostic peaks β-anomer: 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC): δ 5.56 (s, 1H, CHPh), 4.73 (d, 1H, 
J = 10.7 Hz, CHH Bn), 4.60 (d, 1H, J = 7.7 Hz, H-1), 4.34 (dd, 1H, J = 10.5, 5.0 Hz, H-6), 3.51 (t, 1H, J = 8.0 Hz), 3.41 (td, 
1H, J = 9.6, 5.2 Hz, H-5); HRMS: [M+H]+ calcd for C29H30F3O6 531.19890, found 531.19857. 
1,1,1,3,3,3-Hexafluoro-2-propyl 2,3-di-O-benzyl-4,6-O-benzylidene-α-D-glucopyranoside 
(2F). Donor 2 and 1,1,1,3,3,3-hexafluoroisopropanol were condensed using the general 
procedure for Tf2O/Ph2SO mediated glycosylations (for an additional 144 hours at -40°C) 
and purified by flash column chromatography (1/1 to 0/1 pentane/toluene to 10% EtOAc 
in toluene) to yield glycosylation product 2F (39 mg, 65 µmol, 65%, α:β = >20:1). Rf: 0.31 (4/1 pentane/Et2O). [α]  = 
-40.9° (c = 0.68, CHCl3); IR (neat): 689, 746, 997, 1086, 1196, 1219, 1368, 1454, 2868; 1H NMR (CDCl3, 400 MHz, HH-
COSY, HSQC): δ 7.51 – 7.47 (m, 2H, CHarom), 7.40 – 7.27 (m, 13H, CHarom), 5.55 (s, 1H, CHPh), 5.07 (d, 1H, J = 4.0 Hz, H-
1), 4.93 (d, 1H, J = 11.1 Hz, CHH Bn), 4.83 (d, 1H, J = 11.1 Hz, CHH Bn), 4.79 (d, 1H, J = 11.7 Hz, CHH Bn), 4.73 (d, 1H, J 
= 11.7 Hz, CHH Bn), 4.41 (hept, 1H, J = 5.9 Hz, CH HFIP), 4.24 (dd, 1H, J = 10.2, 5.0 Hz, H-6), 4.06 (t, 1H, J = 9.4 Hz, H-
3), 3.94 (td, 1H, J = 10.0, 4.9 Hz, H-5), 3.70 (t, 1H, J = 10.2 Hz, H-6), 3.75 – 3.60 (m, 2H, H-2, H-4); 13C-APT NMR (CDCl3, 
101 MHz, HSQC): δ 138.6, 137.7, 137.2 (Cq), 129.2, 128.6, 128.5, 128.4, 128.2, 128.1, 127.8, 126.1 (CHarom), 121.7 (q, 
J = 285 Hz, CF3), 121.2 (q, J = 285 Hz, CF3), 101.4 (CHPh), 100.4 (C-1), 81.5 (C-4), 78.3, 78.3 (C-2, C-3), 75.6, 74.1 (CH2 
Bn), 73.4 (hept, J = 32.9 Hz, CH HFIP), 68.5 (C-6), 64.0 (C-5); 13C-HMBC NMR (CDCl3, 101 MHz): 3J(HHFIP-C1) observed; 
HRMS: [2M-2(CF3)2CHO+H2O+NH4]+ calcd for (C27H27O5)2O 896.40044, found 896.40115; LC-MS: Rt = 10.09, no 
conclusive mass. TLC-MS: [M+Na]+ calcd for C30H28F6O6Na 621.17 found 621.2, and [M+H2O-benzaldehyde+Na]+ calcd 
for C23H24F6O6Na 533.14 found 533.0. 
1-[2H]-1,5-anhydro-2,3-di-O-benzyl-4,6-O-benzylidene-α-D-glucitol (2G). Donor 2 and 
triethylsilane-D were condensed using the general procedure for Tf2O/Ph2SO mediated 
glycosylations (for an additional 144 hours at -40°C) and purified by flash column 
chromatography (19/1 to 4/1 Et2O/pentane) to yield glycosylation product 2G (34 mg, 79 µmol, 79%, α:β = >20:1). Rf: 
0.38 (4/1 pentane/Et2O). Spectroscopic data of the non-dueterated glucitol were in accord with those previously 
reported.112 [α]  = +5.4° (c = 0.78, CHCl3); IR (neat): 696, 748, 1009, 1028, 1088, 1368, 1454, 2868; 1H NMR (CDCl3, 
400 MHz, HH-COSY, HSQC): δ 7.51 – 7.48 (m, 2H, CHarom), 7.41 – 7.34 (m, 5H, CHarom), 7.34 – 7.26 (m, 7H, CHarom), 5.55 
(s, 1H, CHPh), 4.96 (d, 1H, J = 11.4 Hz, CHH Bn), 4.83 (d, 1H, J = 11.6 Hz, CHH Bn), 4.80 (d, 1H, J = 11.7 Hz, CHH Bn), 
4.66 (d, 1H, J = 11.6 Hz, CHH Bn), 4.31 (dd, 1H, J = 10.4, 5.0 Hz, H-6), 3.98 (d, 1H, J = 5.6 Hz, H-1), 3.75 (t, 1H, J = 8.8 
Hz, H-3), 3.70 – 3.63 (m, 2H, H-2, H-6), 3.61 (t, 1H, J = 9.2 Hz, H-4), 3.36 (ddd, 1H, J = 10.1, 9.2, 5.0 Hz, H-5); 13C-APT 
NMR (CDCl3, 101 MHz, HSQC): δ 138.8, 138.3, 137.5 (Cq), 129.0, 128.6, 128.4, 128.4, 128.1, 128.0, 128.0, 127.7, 126.1 
(CHarom), 101.3 (CHPh), 82.5 (C-3), 82.2 (C-4), 77.7 (C-2, 75.1, 74.0 (CH2 Bn), 71.4 (C-5), 69.0 (C-6), 68.7 (t, JC1,D1 = 22.3 
Hz); 2H NMR (CHCl3, 61 MHz): 3.34 (s, 1D, D-1); HRMS: [M+H]+ calcd for C27H28DO5S 434.20723, found 434.20714.  
Allyl 2,3-di-O-benzyl-1-deoxy-4,6-O-benzylidene-α-D-glucopyranoside (2H). Donor 2 and allyl 
trimethylsilane were condensed using the general procedure for Tf2O/Ph2SO mediated 
glycosylations (for an additional 16 hours at -40°C) and purified by flash column 
chromatography (19/1 to 9/1 pentane/EtOAc) to yield glycosylation product 2H (20 mg, 42 µmol, 42%, α:β = >1:20). 
Contaminated with a 1-OTMS glycoside by-product. α-Thio glycoside 2α was formed as a by-product. Rf: 0.60 (9/1 
pentane/EtOAc). Spectroscopic data were in accord with those previously reported.40,72 1H NMR (CDCl3, 400 MHz, HH-
COSY, HH-NOESY, HSQC): δ 7.53 – 7.47 (m, 2H, CHarom), 7.42 – 7.27 (m, 13H, CHarom), 5.77 (ddt, 1H, J = 17.1, 10.2, 6.9 
Hz, CH allyl), 5.57 (s, 1H, CHPh), 5.18 – 5.05 (m, 2H, CH2 allyl), 4.93 (d, 1H, J = 11.4 Hz, CHH Bn), 4.81 (d, 1H, J = 11.4 
Hz, CHH Bn), 4.78 (d, 1H, J = 11.7 Hz, CHH Bn), 4.64 (d, 1H, J = 11.7 Hz, CHH Bn), 4.27 – 4.21 (m, 1H, H-6), 4.08 (td, 1H, 
J = 7.7, 5.7 Hz, H-1), 3.92 – 3.85 (m, 1H, H-3), 3.76 (dd, 1H, J = 8.6, 5.7 Hz, H-2), 3.69 – 3.63 (m, 3H, H-4, H-5, H-6), 2.57 
– 2.51 (m, 2H, CH2 allylic); 13C-APT NMR (CDCl3, 101 MHz, HSQC, HMBC): δ 138.7, 138.3, 137.5 (Cq-arom), 134.4 (CH 
allyl), 129.0, 128.6, 128.5, 128.4, 128.1, 128.0, 127.9, 127.8, 126.1 (CHarom), 117.4 (CH2 allyl), 101.3 (CHPh), 82.9 (C-4), 
79.5 (C-2), 78.9 (C-3), 75.0 (C-1), 75.0, 73.7 (CH2 Bn), 69.6 (C-6), 63.5 (C-5), 30.8 (CH2 allylic); HRMS: [M+H]+ calcd for 
C30H33O5 473.23225, found 473.23228.   
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Phenyl 2,3-di-O-benzyl-4,6-O-benzylidene-1-thio-α-D-glucopyranoside (2α). Rf: 0.38 (4/1 
pentane/Et2O). Spectroscopic data were in accord with those previously reported.21 1H NMR 
(CDCl3, 400 MHz, HH-COSY, HSQC): δ 7.53 – 7.44 (m, 4H, CHarom), 7.43 – 7.36 (m, 7H, CHarom), 
7.36 – 7.27 (m, 9H, CHarom), 5.59 (d, 1H, J = 5.5 Hz, H-1), 5.57 (s, 1H, CHPh), 4.92 (d, 1H, J = 11.3 Hz, CHH Bn), 4.86 (d, 
1H, J = 11.3 Hz, CHH Bn), 4.81 (d, 1H, J = 11.8 Hz, CHH Bn), 4.76 (d, 1H, J = 11.8 Hz, CHH Bn), 4.39 (td, 1H, J = 9.9, 4.9 
Hz, H-5), 4.19 (dd, 1H, J = 10.3, 5.0 Hz, H-6), 3.98 (t, 1H, J = 9.2 Hz, H-3), 3.90 (dd, 1H, J = 9.3, 5.5 Hz, H-2), 3.71 (t, J = 
10.3 Hz, H-6), 3.66 (t, J = 9.3 Hz, H-4); HRMS: [M+NH4]+ calcd for C33H36NO5 558.23087, found 558.23075. 
Methyl 6-O-(2,3-di-O-benzyl-4,6-O-benzylidene-α/β-ᴅ-glucopyranosyl)-2,3,4-tri-O-
benzyl-α-ᴅ-glucopyranoside (25). Donor 2 and acceptor 10 were condensed using the 
general procedure for Tf2O/Ph2SO mediated glycosylations (for an additional 16 
hours at -40°C) and purified by flash column chromatography (9/1 to 3/1 
pentane/EtOAc) to yield glycosylation product 25 (72.1 mg, 81 µmol, 81%, α:β = 
1:2.7). Rf: 0.83 (6/4 pentane/EtOAc). Spectroscopic data were in accord with those previously reported.108 1H NMR 
(CDCl3, 400 MHz, HH-COSY, HSQC, HMBC): δ 7.51 – 7.44 (m, 2H, CHarom), 7.41 – 7.12 (m, 28H, CHarom), 5.54 (s, 1H, 
CHPh), 4.97 (d, 1H, J = 10.8 Hz, CHH Bn), 4.93 – 4.88 (m, 2H, 2xCHH Bn), 4.84 – 4.76 (m, 4H, 3xCHH Bn, CHH Bn), 4.73 
– 4.63 (m, 2H, CHH Bn, CHH Bn), 4.61 (d, 1H, J = 3.6 Hz, H-1), 4.49 (d, 1H, J = 11.2 Hz, CHH Bn), 4.44 (d, 1H, J = 7.7 Hz,
H-1’), 4.31 (dd, 1H, J = 10.5, 5.0 Hz, H-6’), 4.11 (dd, 1H, J = 10.7, 2.0 Hz, H-6), 3.99 (t, J = 9.3 Hz, 1H, H-3), 3.82 – 3.65 
(m, 5H, H-3’, H-4’, H-5, H-6, H-6’), 3.56 – 3.48 (m, 3H, H-2, H-2’, H-4), 3.40 – 3.34 (m, 1H, H-5’), 3.33 (s, 3H, CH3 OMe); 
13C-APT NMR (CDCl3, 101 MHz, HSQC, HMBC): δ 138.9, 138.5, 138.4, 138.3, 138.2, 137.4 (Cq), 128.6, 128.5, 128.5,
128.4, 128.4, 128.4, 128.4, 128.3, 128.3, 128.3, 128.2, 128.1, 128.1, 128.1, 128.1, 128.0, 128.0, 128.0, 127.7, 127.7,
127.7, 127.7, 126.1 (CHarom), 104.2 (C-1’), 101.2 (CHPh), 98.2 (C-1), 82.1 (C-3), 81.9 (C-2’), 81.5, 81.2 (C-3’, C-4’), 79.8 
(C-2), 77.9 (C-4), 75.8, 75.5, 75.2, 75.0, 73.5 (CH2 Bn), 69.8 (C-5), 68.8 (C-6, C-6’), 66.2 (C-5’), 55.3 (OMe); Diagnostic 
peaks α-anomer: 1H NMR (CDCl3, 400 MHz): δ 5.53 (s, 0.33H), 4.57 (d, 0.33H, J = 3.6 Hz), 4.20 (dd, 0.33H, J = 10.1, 4.8
Hz), 3.89 (td, 0.33H, J = 10.0, 4.8 Hz), 3.43 (dd, 0.33H, J = 9.6, 3.6 Hz), 3.34 (s, 1H); 13C-APT NMR (CDCl3, 101 MHz): δ 
138.9, 138.8, 138.5, 138.3, 137.6, 129.0-126.2, 101.4, 98.3, 98.1, 82.3, 82.2, 80.2, 79.4, 78.0, 77.8, 75.8, 75.1, 75.1,
73.5, 73.0, 70.5, 69.2, 66.4, 62.6, 55.3; HRMS: [M+Na]+ calcd for C55H58O11Na 917.38713, found 917.38678. 
Methyl 4-O-(2,3-di-O-benzyl-4,6-O-benzylidene-α/β-ᴅ-glucopyranosyl)-2,3,6-tri-O-
benzyl-α-ᴅ-glucopyranoside (26). Donor 2 and acceptor 11 were condensed using 
the general procedure for Tf2O/Ph2SO mediated glycosylations (for an additional 16 
hours at -40°C) and purified by flash column chromatography (19/1 to 4/1 
pentane/EtOAc) to yield glycosylation product 26 (71 mg, 79 µmol, 79%, α:β = 1:1). Rf: 0.54 (4/1 pentane/EtOAc). 
Spectroscopic data were in accord with those previously reported for the α-anomer.108 1H NMR (CDCl3, 400 MHz, HH-
COSY, HSQC, HMBC): δ 7.52 – 7.45 (m, 4H, CHarom), 7.44 – 7.18 (m, 56H, CHarom), 5.75 (d, 1H, J = 3.8 Hz, H-1’α), 5.52 (s, 
1H, CHPhα), 5.49 (s, 1H, CHPhβ), 5.04 (d, 1H, J = 11.7 Hz, CHH Bnα), 4.95 – 4.87 (m, 3H, 3xCHH Bn), 4.84 – 4.51 (m, 17H, 
6xCHH Bn, 9xCHH Bn, H-1, H-1β), 4.36 (d, 1H, J = 7.8 Hz, H-1’β), 4.30 (d, 1H, J = 12.0 Hz, CHH Bnβ), 4.19 (dd, 1H, J = 
10.5, 5.0 Hz, H-6’β), 4.15 – 4.09 (m, 3H, H-3α, H-4α, H-6’α), 3.99 (t, 1H, J = 9.3 Hz, H-3’α), 3.94 (t, 1H, J = 9.4 Hz, H-4β), 
3.90 – 3.78 (m, 5H, H-2β, H-5α, H-5α’, H-6α, H-6β), 3.69 – 3.41 (m, 11H, H-2α, H-2’α, H-3β, H-3’β, H-4’α, H-4’β, H-5β, H-6α, 
H-6β, H-6’α, H-6’β), 3.40 – 3.31 (m, 7H, CH3 OMe, CH3 OMeβ, H-2’β), 3.10 (td, 1H, J = 9.5, 4.9 Hz, H-5’β); 13C-APT NMR 
(CDCl3, 101 MHz, HSQC, HMBC): δ 139.4, 139.0, 138.7, 138.6, 138.5, 138.4, 138.2, 138.0, 137.9, 137.9, 137.6, 137.5
(Cq), 129.0, 128.9, 128.6, 128.5, 128.5, 128.4, 128.3, 128.3, 128.3, 128.2, 128.2, 128.2, 128.1, 128.1, 128.0, 128.0,
127.9, 127.8, 127.7, 127.7, 127.5, 127.5, 127.4, 127.3, 126.8, 126.1, 126.1 (CHarom), 102.9 (C-1’β), 101.2 (CHPh), 98.5, 
97.8 (C-1α, C-1β), 97.2 (C-1’α), 82.7 (C-2’β), 82.4 (C-4’α), 82.2 (C-3α), 81.8 (C-4’β), 81.0 (C-3’β), 80.3 (C-2β), 80.3, 78.9 (C-
2α, C-3’α), 78.8 (C-2’α, C-3β), 76.9 (C-4β), 75.6, 75.5, 75.4, 75.0, 74.4, 73.9, 73.7, 73.4, 73.4 (CH2 Bn), 71.6 (C-4α), 70.0 
(C-5β), 69.4 (C-5α), 69.0, 68.9, 68.8 (C-6α, C-6’α, C-6’β), 67.7 (C-6β), 65.8 (C-5’β), 63.4 (C-5’α), 55.5 (OMeβ), 55.3 (OMeα); 
HRMS: [M+NH4]+ calcd for C55H62O11N 912.43174, found 912.43282. 
Methyl (methyl 4-O-[2,3-di-O-benzyl-4,6-O-benzylidene-α/β-ᴅ-glucopyranosyl]-
2,3,6-tri-O-benzyl-α-ᴅ-glucopyranosyl uronate) (27). Donor 2 and acceptor 12 were 
condensed using the general procedure for Tf2O/Ph2SO mediated glycosylations 
(for an additional 24 hours at -40°C) and purified by flash column chromatography 
(19/1 to 4/1 pentane/EtOAc) to yield glycosylation product 27 (75.2 mg, 90 µmol, 90%, α:β = 5:1). Rf: 0.77 (7/3 
pentane/EtOAc). IR (neat): 694, 732, 912, 988, 1026, 1043, 1074, 1086, 1358, 1454, 1749, 28866, 2932; Data for the 
α-anomer: 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC, HMBC): δ 7.48 – 7.43 (m, 2H, CHarom), 7.40 – 7.16 (m, 23H, 
CHarom), 5.51 (s, 1H, CHPh), 5.44 (d, 1H, J = 3.8 Hz, H-1’), 4.95 – 4.86 (m, 3H, CH2 Bn, CHH Bn), 4.78 (d, 1H, J = 11.2 Hz, 




CHH Bn), 4.71 (d, 1H, J = 12.1 Hz, CHH Bn), 4.67 (d, 1H, J = 12.0 Hz, CHH Bn), 4.59 – 4.53 (m, 3H, 2xCHH Bn, H-1), 4.28 
(dd, 1H, J = 6.5, 3.8 Hz, H-6’), 4.25 (d, 1H, J = 9.5 Hz, H-5), 4.11 (t, 1H, J = 9.1 Hz, H-4), 4.05 (t, 1H, J = 8.9 Hz, H-3), 3.98 
(t, 1H, J = 9.1 Hz, H-3’), 3.76 (s, 3H, CH3 CO2Me), 3.64 (t, 1H, J = 10.0 Hz, H-6’), 3.61 – 3.54 (m, 3H, H-2, H-4’, H-5’), 3.48 
(dd, 1H, J = 5.6, 3.9 Hz, H-2’), 3.40 (s, 3H, CH3 OMe); 13C-APT NMR (CDCl3, 101 MHz, HSQC, HMBC): δ 170.1 (C=O 
CO2Me), 139.0, 138.6, 138.0, 137.8, 137.6 (Cq), 129.0, 128.6, 128.4, 128.4, 128.3, 128.3, 128.3, 128.2, 128.1, 128.1, 
127.8, 127.7, 127.7, 127.3, 127.0, 126.1 (CHarom), 101.3 (CHPh), 98.6 (C-1), 98.4 (C-1’), 82.0 (C-4’), 80.8 (C-3), 79.2 (C-
2), 78.7 (C-2’), 78.4 (C-3’), 76.1 (C-4), 75.3, 75.0, 73.7, 73.7 (CH2 Bn), 70.3 (C-5), 68.6 (C-6’), 63.1 (C-5’), 55.8 (CH3 OMe), 
52.9 (CH3 CO2Me); 13C-HMBC NMR (CDCl3, 101 MHz): δ 98.4 (JC1’,H1’ = 174 Hz, C-1’ α); Diagnostic peaks β-anomer: 1H 
NMR (CDCl3, 400 MHz): δ 5.47 (s, 0.18H, CHPh), 4.62 (d, 0.18H, J = 12.1 Hz), 3.87 (dd, 0.18H, J = 9.6, 8.4 Hz), 3.50 (s, 
0.54H, CH3 CO2Me), 3.44 (s, 0.54H, CH3 OMe), 3.38 – 3.28 (m, 0.36H, H-2’, H-5’); 13C-APT NMR (CDCl3, 101 MHz): δ 
170.1, 139.2, 138.6, 138.2, 137.4, 129.0, 128.5, 128.3, 128.1, 127.7, 127.5, 126.1, 102.9 (C-1’), 101.2 (CHPh), 99.0 (C-
1), 82.3, 81.8, 81.3, 79.6, 78.5, 78.2, 75.6, 75.5, 75.2, 73.9, 70.0, 68.8, 65.9, 55.9, 52.7; 13C-HMBC NMR (CDCl3, 101 
MHz): δ 102.9 (JC1’,H1’ = 164 Hz, C-1’ β); HRMS: [M+Na]+ calcd for C49H52O12Na 855.33510, found 855.33496. 
Methyl 4-O-(2,3-di-O-benzyl-4,6-O-benzylidene-α-ᴅ-glucopyranosyl)-2,3,6-tri-O-
benzyl-β-ᴅ-galactopyranoside (28). Donor 2 and acceptor 13 were condensed using 
the general procedure for Tf2O/Ph2SO mediated glycosylations (for an additional 16 
hours at -40°C) and purified by flash column chromatography (19/1 to 4/1 
pentane/EtOAc) to yield glycosylation product 28 (74 mg, 83 µmol, 83%, α:β = >20:1). 
Rf: 0.50 (4/1 pentane/EtOAc). [α]  = +38.4° (c = 1.0, CHCl3); IR (neat): 696, 735, 997, 1028, 1072, 1366, 1452, 1497, 
2859, 2922; 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC, HMBC): δ 7.49 (dd, 2H, J = 7.9, 1.8 Hz, CHarom), 7.42 – 7.16 (m, 
28H, CHarom), 5.50 (s, 1H, CHPh), 4.98 (d, J = 3.7 Hz, H-1’), 4.97 (d, J = 11.0 Hz, CHH Bn), 4.93 – 4.87 (m, 2H, 2xCHH Bn), 
4.85 – 4.74 (m, 3H, 2xCHH Bn, CHH Bn), 4.72 – 4.63 (m, 2H, 2xCHH Bn), 4.31 – 4.22 (m, 4H, CH2 Bn, H-1, H-5’), 4.18 (t, 
1H, J = 9.4 Hz, H-3’), 4.06 – 3.97 (m, 2H, H-4, H-6), 3.84 (dd, 1H, J = 10.1, 4.9 Hz, H-6’), 3.72 (dd, 1H, J = 10.0, 7.6 Hz, 
H-2), 3.63 – 3.45 (m, 8H, CH3 OMe, H-2’, H-4’, H-5, H-6, H-6’), 3.42 (dd, 1H, J = 10.0, 2.9 Hz, H-3); 13C-APT NMR (CDCl3, 
101 MHz, HSQC, HMBC): δ 138.9, 138.7, 138.6, 138.4, 138.2, 137.8 (Cq), 128.9, 128.5, 128.4, 128.4, 128.3, 128.3, 
128.1, 128.0, 127.8, 127.7, 127.6, 126.2 (CHarom), 105.1 (C-1), 101.2 (CHPh), 100.7 (C-1’), 83.0 (C-4’), 80.6 (C-3), 79.7 
(C-2’), 78.9 (C-2, C-3’), 75.9 (C-4), 75.3, 75.2, 74.0 (CH2 Bn), 73.5 (C-5), 73.2, 72.8 (CH2 Bn), 69.1 (C-6’), 68.0 (C-6), 63.0 
(C-5’), 57.2 (OMe); 13C-HMBC NMR (CDCl3, 101 MHz): δ 105.1 (JC1’,H1’ = 159 Hz, C-1 β), 100.7 (JC1’,H1’ = 170 Hz, C-1’ α); 
HRMS: [M+NH4]+ calcd for C55H62O11N 912.43174, found 912.43266.  
Methyl 2-O-(2,3-di-O-benzyl-4,6-O-benzylidene-α/β-ᴅ-glucopyranosyl)-3-O-benzyl-4,6-O-
benzylidene-α-ᴅ-mannopyranoside (29). Donor 2 and acceptor 14 were condensed using the 
general procedure for Tf2O/Ph2SO mediated glycosylations (for an additional 16 hours at -
40°C) and purified by flash column chromatography (19/1 to 4/1 pentane/EtOAc) to yield 
glycosylation product 29 (64.3 mg, 80 µmol, 80%, α:β = >20:1). Rf: 0.27 (8/1 pentane/EtOAc). 
Spectroscopic data were in accord with those previously reported.108 IR (neat): 696, 748, 999, 1028, 1074, 1088, 1369, 
1454, 1498, 2864, 2911; 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC, HMBC): δ 7.49 (ddd, 4H, J = 8.9, 5.8, 1.9 Hz, 
CHarom), 7.44 – 7.35 (m, 8H, CHarom), 7.35 – 7.24 (m, 10H, CHarom), 7.17 (dp, 3H, J = 4.4, 1.6 Hz, CHarom), 5.60 (d, 1H, J = 
3.9 Hz, H-1’), 5.57 (s, 1H, CHPh’), 5.43 (s, 1H, CHPh), 4.95 – 4.85 (m, 3H, CHH Bn, CH2 Bn), 4.78 (d, 1H, J = 11.2 Hz, CHH 
Bn), 4.72 (d, 1H, J = 11.7 Hz, CHH Bn), 4.71 (d, 1H, J = 1.7 Hz, H-1), 4.47 (d, 1H, J = 11.1 Hz, CHH Bn), 4.33 – 4.26 (m, 
2H, H-4, H-6’), 4.24 – 4.18 (m, 2H, H-2, H-6), 4.08 (t, 1H, J = 9.3 Hz, H-3’), 4.02 (dd, 1H, J = 9.9, 2.9 Hz, H-3), 3.93 – 3.70 
(m, 4H, H-5, H-5’, H-6, H-6’), 3.63 (t, 1H, J = 9.4 Hz, H-4’), 3.56 (dd, 1H, J = 9.3, 3.9 Hz, H-2’), 3.36 (s, 3H, CH3 OMe); 
13C-APT NMR (CDCl3, 101 MHz, HSQC, HMBC): δ 139.1, 138.6, 138.5, 137.9, 137.5 (Cq), 129.1, 129.0, 128.5, 128.4, 
128.3, 128.3, 128.3, 128.0, 127.9, 127.9, 127.8, 127.6, 127.6, 126.1, 126.1 (CHarom), 101.3, 101.3, 101.2 (CHPh, C-1’), 
98.0 (C-1), 82.1 (C-4’), 79.4 (C-2’), 79.3 (C-4), 77.9 (C-3’), 76.9 (C-3), 75.3 (CH2 Bn), 74.4 (C-2), 74.0, 71.9 (CH2 Bn), 69.1 
(C-6’), 68.8 (C-6), 64.4 (C-5), 63.0 (C-5’), 54.9 (OMe); 13C-HMBC NMR (CDCl3, 101 MHz): δ 101.3 (JC1’,H1’ = 168 Hz, C-1’ 
α), 98.0 (JC1’,H1’ = 170 Hz, C-1’ α); HRMS: [M+NH4]+ calcd for C48H54NO11 820.36914, found 820.36958.  
Methyl (cyclohexyl 4-O-acetyl-2,3-di-O-benzyl-α/β-D-mannopyranosyl uronate) (3A). Donor 3 
and cyclohexanol were condensed using the general procedure for Tf2O/Ph2SO mediated 
glycosylations (for an additional 16 hours at -40°C) and purified by flash column 
chromatography (9/1 to 4/1 pentane/EtOAc) to yield glycosylation product 3A (42.5 mg, 83 μmol, 83%, α:β = 1:8.3). 
Rf: 0.46 (7/3 pentane/EtOAc). IR (neat): 1026, 1047, 1105, 1238, 1368, 1452, 1740, 1751, 2855, 2930; Data for the β-
anomer: 1H NMR (400 MHz, CDCl3, HH-COSY, HSQC): δ 7.48 – 7.18 (m, 10H, CHarom), 5.50 (t, 1H, J = 9.7 Hz, H-4), 5.00 






















(d, 1H, J = 12.4 Hz, CHH Bn), 3.84 (d, 1H, J = 2.8 Hz, H-2), 3.82 (d, 1H, J = 9.7 Hz, H-5), 3.73 (s, 3H, CH3 CO2Me), 3.73 – 
3.65 (m, 1H, CH Cy), 3.46 (dd, 1H, J = 9.8, 2.9 Hz, H-2), 2.02 (s, 3H, CH3 OAc), 1.99 – 1.21 (m, 15H, CH2 Cy); 13C-APT 
NMR (101 MHz, CDCl3, HSQC): δ 169.7, 168.3 (C=O CO2Me, Ac), 138.6, 138.0 (Cq), 128.7, 128.5, 128.2, 127.8, 127.5, 
127.5 (CHarom), 99.5 (C-1), 78.7 (C-3), 77.0 (CH Cy), 74.0 (C-5), 73.9 (CH2 Bn), 73.4 (C-2), 71.4 (CH2 Bn), 69.1 (C-4), 52.7 
(CH3 CO2Me), 33.4, 31.4, 25.8, 23.9 (CH2 Cy), 21.0 (CH3 Ac); Diagnostic peaks α-anomer: 1H NMR (400 MHz, CDCl3, HH-
COSY, HSQC): δ 5.50 (t, 0.12H, J = 9.7 Hz, H-4), 5.24 (d, 0.12H, J = 3.3 Hz, H-1), 4.78 (d, 0.12H, J = 12.0 Hz, CHH Bn), 
4.68 (d, 0.12H, J = 12.4 Hz, CHH Bn); 13C-APT NMR (101 MHz, CDCl3, HSQC): δ 69.7 (C-1); HRMS: [M+NH4]+ calcd for 
C29H40NO8 530.27484, found 530.27495.  
Methyl (ethyl 4-O-acetyl-2,3-di-O-benzyl-α/β-D-mannopyranosyl uronate) (3B). Donor 3 and 
ethanol were condensed using the general procedure for Tf2O/Ph2SO mediated glycosylations 
(for an additional 16 hours at -40°C) and purified by flash column chromatography (9/1 to 4/1 
pentane/EtOAc) to yield glycosylation product 3B (43.4 mg, 95 μmol, 95%, α:β = 1:8.3). Rf: 0.36 (7/3 pentane/EtOAc). 
IR (neat): 735, 1026, 1047, 1103, 1229, 1369, 1454, 1744, 2924; Data for the β-anomer: 1H NMR (400 MHz, CDCl3, HH-
COSY, HSQC): δ 7.68 – 7.15 (m, 10H, CHarom), 5.51 (t, 1H, J = 9.5 Hz, H-4), 4.96 (d, 1H, J = 12.6 Hz, CHHBn), 4.84 (d, 1H, 
J = 12.6 Hz, CHH Bn), 4.48 (d, 1H, J = 12.4 Hz, CHH Bn), 4.43 (s, 1H, H-1), 4.33 (d, 1H, J = 12.4 Hz, CHH Bn), 4.02 (dq, 
1H, J = 9.2, 7.1 Hz, CHHCH3 Et), 3.88 (d, 1H, J = 2.8 Hz, H-2), 3.84 (d, 1H, J = 9.5 Hz, H-5), 3.73 (s, 3H, CH3 CO2Me), 3.54 
– 3.44 (m, 2H, H-3, CHHCH3 Et, H-3), 2.02 (s, 3H, CH3 OAc), 1.27 (t, 3H, J = 7.0 Hz, CH3 Et); 13C-APT NMR (101 MHz, 
CDCl3, HSQC): δ 169.7, 168.2 (C=O CO2Me, Ac), 138.5, 137.9 (Cq), 129.4, 128.6, 1285, 128.2, 124.9 (CHarom), 101.5 (C-
1), 78.2 (C-3), 73.9 (CH2 Bn), 73.9 (C-5), 73.1 (C-2), 71.4 (CH2 Bn), 69.1 (C-4), 65.9 (CH2 Et), 52.7 (CH3 CO2Me), 21.0 
(CH3 Ac), 15.2 (CH3 Et); 13C-GATED NMR (101 MHz, CDCl3): δ 101.5 (JC1,H1 = 160 Hz, C-1 β); Diagnostic peaks α-anomer: 
1H NMR (400 MHz, CDCl3, HH-COSY, HSQC): δ 5.51 (t, 0.12H, H-4), 5.13 (d, 0.12H, J = 4.3 Hz, H-1), 4.78 (d, 0.12H, J = 
12.4 Hz, CHH Bn), 4.68 (d, 0.12H, J = 12.3 Hz, CHH Bn), 3.67 (s, 0.36H, CH3 CO2Me). 13C-APT NMR (101 MHz, CDCl3) δ 
98.4 (C-1), 77.4 (C-3), 74.6 (C-5), 73.2 (CH2 Bn), 72.5 (CH2 Bn), 69.5 (CH2 Et), 52.6 (CH3 CO2Me); HRMS: [M+Na]+ calcd 
for C25H30O8Na 481.18329, found 481.18250.  
Methyl (2-fluoroethyl 4-O-acetyl-2,3-di-O-benzyl-α/β-D-mannopyranosyl uronate) (3C). 
Donor 3 and 2-fluoroethanol were condensed using the general procedure for Tf2O/Ph2SO 
mediated glycosylations (for an additional 16 hours at -40°C) and purified by flash column 
chromatography (9/1 to 7/3 pentane/EtOAc) to yield glycosylation product 3C (33.2 mg, 70 μmol, 70%, α:β = 1:5). Rf: 
0.18 (7/3 pentane/EtOAc). IR (neat): 1045, 1103, 1231, 1369, 1454, 1746, 2895, 2924; Data for the β-anomer: 1H NMR 
(400 MHz, CDCl3, HH-COSY, HSQC): δ 7.69 – 7.18 (m, 10H, CHarom), 5.52 (t, 1H, J = 9.3 Hz, H-4), 4.95 (d, 1H, J = 12.5 Hz, 
CHH Bn), 4.83 (d, 1H, J = 12.5 Hz, CHH Bn), 4.76 – 4.94 (m, 2H, CH2F), 4.54 (s, 1H, H-1), 4.49 (d, 1H, J = 12.4 Hz, CHH 
Bn), 4.34 (d, 1H, J = 12.4 Hz, CHH Bn) 4.13 (dddd, 1H, J = 37.0, 12.2, 3.3, 2.2 Hz, CHHCH2F), 3.95 (d, 1H, J = 2.6 Hz, H-
2), 3.86 (d, 1H, J = 9.2 Hz, H-5), 3.84 – 3.74 (m, 1H, CHHCH2F), 3.72 (s, 3H, CH3 CO2Me), 3.49 (dd, 1H, J = 9.4, 2.9 Hz, 
H-3), 2.10 – 1.94 (s, 3H, CH3 OAc); 13C-APT NMR (101 MHz, CDCl3, HSQC): δ 169.7, 168.1 (C=O CO2Me, Ac), 138.3, 
137.81 (Cq), 131.2, 129.46, 128.6, 128.5, 128.4, 128.3, 128.0, 127.9, 127.7, 127.7, 127.6, 124.9 (CHarom), 101.6 (C-1), 
82.96 (d, J = 169.5 Hz, CH2F), 77.9 (C-3), 74.5 (CH2 Bn), 74.1 (C-5), 73.8 (C-2), 72.9 (CH2 Bn), 69.01 (d, J = 19.5 Hz, 
CH2CH2F), 68.9 (C-4), 52.8 (CH3 CO2Me), 21.0 (CH3 Ac). 13C-GATED NMR (101 MHz, CDCl3) δ 101.6 (JC1,H1 = 156 Hz, C-
1); Diagnostic peaks α-anomer: 1H NMR (400 MHz, CDCl3, HH-COSY, HSQC): δ 5.52 (t, 0.20H, J = 9.3 Hz, H-4), 5.19 (d, 
0.20H, J = 4.7 Hz, H-1), 3.66 (s, 0.60H, CH3 CO2Me), 2.04 (s, 0.6H, CH3 OAc); 13C-APT NMR (101 MHz, CDCl3): δ 98.9 (C-
1); HRMS: [M+Na]+ calcd for C25H29FO8Na 499.17387, found 499.17297.  
Methyl (2,2-difluoroethyl 4-O-acetyl-2,3-di-O-benzyl-α/β-D-mannopyranosyl uronate) (3D). 
Donor 3 and 2,2-difluoroethanol were condensed using the general procedure for 
Tf2O/Ph2SO mediated glycosylations (for an additional 16 hours at -40°C) and purified by 
flash column chromatography (9/1 to 7/3 pentane/EtOAc) to yield glycosylation product 3D 
(43.1 mg, 87 μmol, 87%, α:β = 1:4.2). Rf: 0.51 (7/3 pentane/EtOAc). IR (neat): 737, 1026, 1051, 1078, 1232, 1439, 1454, 
1741, 2870, 2924; Data for the β-anomer: 1H NMR (400 MHz, CDCl3, HH-COSY, HSQC): δ 7.57 – 7.12 (m, 10H, CHarom), 
5.94 (dddd, 1H, J = 56.7, 54.4, 5.7, 2.5 Hz, CH2CHF2), 5.54 (t, 1H, J = 8.9 Hz, H-4), 4.89 (d, 1H, J = 12.4 Hz, CHH Bn), 4.78 
(d, 1H, J = 12.4 Hz, CHH Bn), 4.56 (s, 1H, H-1), 4.53 (d, 1H, J = 12.3 Hz, CHH Bn), 4.38 (d, 1H, J = 12.4 Hz, CHH Bn), 4.19 
– 4.04 (m, 1H, CHHCHF2), 3.92 (d, 1H, J = 2.1 Hz, H-2), 3.89 (d, 1H, J = 8.7 Hz, H-5), 3.80 – 3.67 (m, 1H, CHHCHF2), 3.70 
(s, 3H, CH3 CO2Me), 3.52 (dd, 1H, J = 9.0, 2.9 Hz, H-3), 2.03 (s, 3H, CH3 OAc); 13C-APT NMR (101 MHz, CDCl3, HSQC):δ 
169.7, 167.9 (C=O CO2Me, Ac), 138.1, 137.8 (Cq), 131.2, 129.5, 128.5, 128.3, 127.9, 127.8, 127.6, 124.9 (CHarom), 114.3 
(dd, J = 242.2, 239.7 Hz, CHF2), 101.3 (C-1), 77.4 (C-3), 74.0 (CH2 Bn), 73.6 (C-5), 72.8 (C-2), 71.7 (CH2 Bn), 69.0 (C-4) 
68.5 (dd, J = 31.2, 25.6 Hz, CH2CHF2), 52.8 (CH3 CO2Me), 21.0 (CH3 Ac); 13C-GATED NMR (101 MHz, CDCl3): δ 101.3 




(JC1,H1 = 160 Hz, C-1 β); Diagnostic peaks α-anomer: 1H NMR (400 MHz, CDCl3, HH-COSY, HSQC): δ 5.52 (t, 0.24H, J = 
11.2 Hz, H-4), 5.23 (d, 0.24H, J = 5.6 Hz, H-1), 3.64 (s, 0.72H, CH3 CO2Me); 13C-APT NMR (101 MHz, CDCl3, HSQC):δ 
99.31 (C-1), 75.45 (C-3), 74.47 (C-2), 73.41 (CH2 Bn), 69.46 (C-4), 52.61 (CH3 CO2Me); HRMS: [M+NH4]+ calcd for 
C25H32F2NO8 512.20905, found 512.20889.  
Methyl (2,2,2-trifluoroethyl 4-O-acetyl-2,3-di-O-benzyl-α/β-D-mannopyranosyl uronate) (3E). 
Donor 3 and 2,2,2-trifluoroethanol were condensed using the general procedure for 
Tf2O/Ph2SO mediated glycosylations (for an additional 24 hours at -40°C) and purified by 
flash column chromatography (9/1 to 7/3 pentane/EtOAc) to yield glycosylation product 3E (43.7 mg, 85 μmol, 85%, 
α:β = 1:2.6). Rf: 0.60 (9/1 pentane/EtOAc). IR (neat): 741, 1058, 1161, 1234, 1280, 1371, 1443, 1748, 2854, 2924; Data 
for the β-anomer: 1H NMR (400 MHz, CDCl3, HH-COSY, HSQC): δ 7.83 – 6.86 (m, 10H, CHarom), 5.55 (t, 1H, J = 8.6 Hz, H-
4), 4.90 (d, 1H, J = 12.3 Hz, CHH Bn), 4.78 (d, 1H, J = 12.4 Hz, CHH Bn), 4.65 (s, 1H, H-1), 4.54 (d, 1H, J = 12.3 Hz, CHH 
Bn), 4.37 (d, 1H, J = 12.3 Hz, CHH Bn), 4.35 – 4.23 (m, 1H, CHHCF3), 3.98 – 3.94 (m, 2H, CHHCF3, H-2), 3.92 (d, 1H, J = 
8.3 Hz, H-5), 3.69 (s, 3H, CH3 CO2Me), 3.54 (dd, 1H, J = 8.8, 2.8 Hz, H-3), 2.03 (s, 3H, CH3 OAc); 13C-APT NMR (101 MHz, 
CDCl3, HSQC): δ 169.7, 167.8 (C=O CO2Me, Ac), 137.9, 137.8 (Cq), 131.2, 129.5, 129.5, 128.5, 128.5, 128.3, 128.0, 
127.9, 127.8, 127.5 (CHarom), 123.8 (q, J = 278.7 Hz, CF3), 100.8 (C-1), 77.1 (C-3), 73.8 (CH2 Bn), 73.6 (C-5), 72.4 (C-2), 
71.7 (CH2 Bn), 69.0 (C-4), 66.1 (q, J = 34.8 Hz, CH2CF3), 52.8 (CH3 CO2Me), 21.0 (CH3 Ac); 13C-GATED NMR (101 MHz, 
CDCl3): δ 100.8 (JC1,H1 = 160 Hz, C-1 β); Diagnostic peaks α-anomer: 1H NMR (400 MHz, CDCl3, HH-COSY, HSQC): δ 5.51 
(t, 0.38H, J = 5.5 Hz, H-4), 5.27 (d, 0.38H, J = 5.6 Hz, H-1), 4.23 – 4.12 (m, 0.38H, CHHCHF2), 3.86 (dd, 0.38H, J = 6.2, 
3.0 Hz, H-3); 13C-APT NMR (101 MHz, CDCl3, HSQC): δ 99.1 (C-1), 75.4 (C-3), 74.3 (C-2), 73.5 (CH2 Bn), 72.9 (CH2 Bn), 
69.4 (C-4), 52.6 (CH3 CO2Me), 21.0 (CH3 Ac); 13C-GATED NMR (101 MHz, CDCl3) δ 99.1 (JC1,H1 = 172 Hz, C-1 α); HRMS: 
[M+Na]+ calcd for C25H27F3O8Na 535.15502, found 535.15415.  
Methyl (1,1,1,3,3,3-hexafluoro-2-propyl 4-O-acetyl-2,3-di-O-benzyl-α/β-D-mannopyranosyl 
uronate) (3F). Donor 3 and 1,1,1,3,3,3-hexafluoro-2-propanol were condensed using the 
general procedure for Tf2O/Ph2SO mediated glycosylations (for an additional 240 hours at -
40°C) and purified by flash column chromatography (9/1 to 4/1 pentane/EtOAc) to yield glycosylation product 3F (30.1 
mg, 52 μmol, 52%, α:β = 1:1). Rf: 0.85 (α), 0.75 (β) (7/3 pentane/EtOAc). IR (neat): 1105, 1371, 1454, 1751, 2872, 
2924; Data for the β-anomer: 1H NMR (400 MHz, CDCl3, HH-COSY, HSQC): δ 7.72 – 7.13 (m, 10H, CHarom), 5.55 (t, 1H, J 
= 9.5 Hz, H-4), 4.92 (d, 1H, J = 12.3 Hz, CHH Bn), 4.78 (d, 1H, J = 12.1 Hz, CHH Bn), 4.74 (s, 1H, H-1), 4.51 (d, 1H, J = 
12.3 Hz, CHH Bn), 4.72 – 4.56 (m, 1H, CH(CF3)2) 4.36 (d, 1H, J = 12.7 Hz, CHH Bn), 3.99 (d, 1H, J = 2.5 Hz, H-2), 3.87 (d, 
1H, J = 9.4 Hz, H-5), 3.73 (s, 3H, CH3 CO2Me), 3.50 (dd, 1H, J = 9.6, 2.8 Hz, H-3), 2.02 (s, 3H, CH3 OAc); 13C-APT NMR 
(101 MHz, CDCl3, HSQC): δ 169.6, 167.3 (C=O CO2Me, Ac), 137.8, 137.5 (Cq), 128.6, 128.5, 128.4, 128.0, 128.0, 127.8, 
127.6, (CHarom), 120.8 (q, J = 281.0 Hz, CF3), 100.3 (C-1), 78.0 (C-3), 74.3 (CH2 Bn), 73.9 (C-5), 72.8 (C-2), 72.4 (CH2 Bn), 
71.8 (hept, J = 33.0 Hz, CH(CF3)2), 68.5 (C-4), 53.0 (CH3 CO2Me), 20.9 (CH3 Ac); 13C-GATED NMR (101 MHz, CDCl3): δ 
100.3 (JC1,H1 = 165 Hz, C-1 β); Diagnostic peaks α-anomer: 1H NMR (400 MHz, CDCl3, HH-COSY, HSQC): δ 5.49 (t, 0.90H, 
J = 5.6 Hz, H-4), 5.39 (d, 0.90H, J = 5.5 Hz, H-1), 4.72 – 4.56 (m, 4.5H, CHH Bn, CHH Bn, CHH Bn, CHH Bn, CH(CF3)2), 
4.37 – 4.35 (m, 0.90H, H-5), 3.84 (dd, 0.90H, J = 6.0, 2.9 Hz, H-3), 3.68 (dd, 0.90H, J = 5.5, 2.8 Hz, H-2). 13C-APT NMR 
(101 MHz, CDCl3, HSQC):δ 169.9, 168.3 (C=O CO2Me, Ac), 137.8, 137.65 (Cq), 128.6, 128.5, 128.4, 128.0, 128.0, 127.9, 
127.8, 127.6 (CHarom), 100.0 (C-1), 75.4 (C-3), 74.3 (CH2 Bn), 74.3 (C-2), 73.7 (C-2), 73.17 (d, J = 32.8 Hz, CH(CF3)2), 72.7 
(C-5), 69.3 (C-4), 52.7 (CH3 CO2Me), 21.0 (CH3 Ac); 13C-GATED NMR (101 MHz, CDCl3): δ 100.0 (JC1,H1 = 175 Hz, C-1 α); 
HRMS: [M+NH4]+ calcd for C26H30F6NO8 598.18707, found 598.18711.  
Methyl (4-O-acetyl-2,3-di-O-benzyl-1-deoxy-β-deuterio-D-mannopyranosyl uronate) (3G). Donor 3 
and triethylsilane-D were condensed using the general procedure for Tf2O/Ph2SO mediated 
glycosylations (for an additional 240 hours at -40°C) and purified by flash column chromatography 
(9/1 to 7/3 pentane/EtOAc) to yield glycosylation product 3G (39.6 mg, 95 μmol, 95%, α:β = <1:20). 
Rf: 0.45 (7/3 pentane/EtOAc). [α]  = -34.4° (c = 0.5, CHCl3); IR (neat): 698, 736, 1051, 1136, 1228, 1371, 1454, 1745, 
2872, 2924; Data for the β-anomer: 1H NMR (400 MHz, CDCl3, HH-COSY, HSQC, NOESY) δ 7.39 – 7.17 (m, 10H, CHarom), 
5.60 (dd, 1H, J = 4.9, 3.5 Hz, H-4), 4.63 (s, 2H, CH2 Bn), 4.53 (s, 2H, CH2 Bn), 4.19 (d, 1H, J = 3.2 Hz, H-5), 3.81 (m, 2H, 
H-2, H-3), 3.68 (d, 1H, J = 3.9 Hz, H-1), 3.61 (s, 3H, CH3 CO2Me), 2.06 (s, 3H, CH3 OAc); 2H NMR (61 MHz, CHCl3) δ 4.73 
(D-1); 13C-APT NMR (101 MHz, CDCl3, HSQC, HMBC): δ 169.9, 168.9 (C=O CO2Me, Ac), 138.1, 137.8 (Cq), 131.2, 129.4, 
128.6, 128.5, 128.4, 127.9, 127.8, 127.8, 127.8, 124.9 (CHarom), 73.8 (C-5), 73.4 (C-3), 72.3 (CH2 Bn), 71.4 (C-2), 71.3 
(CH2 Bn), 70.0 (C-4), 62.4 (C-1), 52.4 (CH3 CO2Me), 21.1 (CH3 Ac). HRMS: [M+Na]+ calcd for C23H25DO7Na 438.16335, 




Methyl (allyl 4-O-acetyl-2,3-di-O-benzyl-1-deoxy-β-D-mannopyranosyl uronate) (3H). Donor 3 
and allyl trimethylsilane were condensed using the general procedure for Tf2O/Ph2SO 
mediated glycosylations (for an additional 96 hours at -40°C) and purified by flash column 
chromatography (9/1 to 7/3 pentane/EtOAc) to yield glycosylation product 3H (18.3 mg, 40 μmol, 40%, α:β = <1:20). 
Rf: 0.25 (8/2 pentane/EtOAc). [α]  = -38.8° (c = 1, CHCl3); IR (neat): 696, 735, 1026, 1055, 1114, 1228, 1368, 1746, 
2855, 2924; Data for the β-anomer: 1H NMR (400 MHz, CDCl3, HH-COSY, HSQC, NOESY): δ 7.36 – 7.20 (m, 10H, CHarom), 
5.71 – 5.58 (m, 1H, CHCH2 allyl), 5.53 (t, 1H, J = 9.8 Hz, H-4), 5.07 – 4.95 (m, 1H, CHCH2 allyl), 5.01 (d, 1H, J = 11.5 Hz, 
CHH Bn), 4.72 (d, 1H, J = 12.2 Hz, CHH Bn), 4.66 (d, 1H, J = 11.6 Hz, CHH Bn), 4.61 (d, 1H, J = 12.2 Hz, CHH Bn), 3.83 (d, 
1H, J = 9.9 Hz, H-5), 3.79 (d, 1H, J = 2.3 Hz, H-2), 3.71 (s, 3H, CH3 CO2Me), 3.60 (dd, 1H, J = 9.9, 2.7 Hz, H-3), 3.36 (t, 1H, 
J = 7.1 Hz, H-1), 2.56 – 2.48 (m, 1H, CHHCH allylic), 2.40 – 2.26 (m, 1H, CHHCH), 2.01 (s, 3H, CH3 OAc); 13C-APT NMR 
(101 MHz, CDCl3, HSQC, HMBC): δ 169.9, 168.5 (C=O CO2Me, Ac), 138.3, 138.0 (Cq), 134.0 (CHCH2 allyl), 131.3, 131.2, 
129.4, 129.1, 128.6, 128.6, 128.6, 128.5, 128.4, 128.3, 128.1, 128.1, 128.0, 127.9, 127.8, 127.7, 127.6, 127.6, 124.9 
(CHarom), 117.9 (CHCH2 allyl), 88.6 (H-3), 79.1 (H-1), 77.6 (C-5), 74.5 (CH2 Bn), 73.7 (C-2), 72.6 (CH2 Bn), 69.5 (C-4), 52.7 
(CH3 CO2Me), 35.4 (CH2CH allyl), 21.0 (CH3 Ac); HRMS: [M+NH4]+ calcd for C26H34NO7 472.23298, found 472.23294.  
Methyl 6-O-(methyl [4-O-acetyl-2,3-di-O-benzyl-β-D-mannopyranosyl uronate])-2,3,4-
tri-O-benzyl-α-D-glucopyranoside (30). Donor 3 and acceptor 10 were condensed using 
the general procedure for Tf2O/Ph2SO mediated glycosylations (for an additional 16 
hours at -40°C) and purified by flash column chromatography (9/1 to 7/3 
pentane/EtOAc) to yield glycosylation product 30 (57.5 mg, 66 μmol, 66%, α:β = <1:20). Rf: 0.54 (7/3 pentane/EtOAc). 
Spectroscopic data were in accord with those previously reported.113 [α]  = -11,6° (c = 1, CHCl3), (lit:113 [α]  = -11.0° 
(c = 0.6, CHCl3)). IR (neat): 733, 906, 1028, 1055, 1101, 1242, 1361, 1452, 1748, 2908; Data for the β-anomer: 1H NMR 
(400 MHz, CDCl3, HH-COSY, HSQC, HMBC): δ 7.40 – 7.19 (m, 25H, CHarom), 5.48 (t, 1H, J = 9.6 Hz, H-4’), 5.02 (d, 1H, J = 
10.9 Hz, CHH Bn), 4.91 (d, 1H, J = 12.6 Hz, CHH Bn), 4.83 (d, 1H, J = 10.9 Hz, CHH Bn), 4.82 (d, 1H, J = 11.7 Hz, CHH Bn), 
4.80 – 4.71 (m, 3H, CHH Bn, CHH Bn, CHH Bn), 4.67 (d, 1H, J = 12.2 Hz, CHH Bn), 4.57 (d, 1H, J = 3.5 Hz, H-1), 4.50 (d, 
1H, J = 4.4 Hz, CHH Bn), 4.47 (d, 1H, J = 5.3 Hz, CHH Bn), 4.36 (d, 1H, J = 12.4 Hz, CHH Bn), 4.16 – 4.09 (m, 2H, H-6, H-
1’), 4.01 (t, 1H, J = 9.2 Hz, H-3), 3.79 (dq, 1H, J = 7.3, 2.8, 1.7 Hz, H-5), 3.74 (d, 1H, J = 9.5 Hz, H-5’), 3.72 – 3.66 (m, 4H, 
CH3 CO2Me, H-2’), 3.50 (dd, 1H, J = 9.7, 3.5 Hz, H-2), 3.45 – 3.34 (m, 3H, H-4, H-6, H-3’), 3.31 (s, 3H, CH3 OMe), 2.02 
(s, 3H, CH3 OAc); 13C-APT NMR (101 MHz, CDCl3, HSQC, HMBC): δ 169.7, 168.1 (C=O CO2Me, Ac), 138.9, 138.4, 138.1, 
137.8 (Cq), 128.6, 128.5, 128.5, 128.5, 128.3, 128.3, 128.2, 128.1, 128.1, 127.9, 127.8, 127.8, 127.6, 127.6 (CHarom), 
101.7 (C-1’), 97.9 (C-1), 82.2 (H-3), 79.9 (H-2), 78.3 (H-3’), 77.7 (H-4), 75.9 (CH2 Bn), 74.9 (CH2 Bn), 73.8 (C-5’), 73.7 
(CH2 Bn), 73.5 (CH2 Bn), 72.9 (C-2’), 71.6 (CH2 Bn), 69.8 (C-5), 69.0 (C-4’), 68.8 (C-6), 55.2 (CH3 OMe), 52.7 (CH3 CO2Me), 
21.0 (CH3 Ac); 13C-GATED NMR (101 MHz, CDCl3) δ 101.7 (JC1,H1 = 155 Hz, C-1’ β); HRMS: [M+Na]+ calcd for C51H56O13Na 
899.36131, found 899.36111.  
Methyl 4-O-(methyl [4-O-acetyl-2,3-di-O-benzyl-β-D-mannopyranosyl uronate])-2,3,6-
tri-O-benzyl-α-D-glucopyranoside (31). Donor 3 and acceptor 11 were condensed 
using the general procedure for Tf2O/Ph2SO mediated glycosylations (for an 
additional 16 hours at -40°C) and purified by flash column chromatography (9/1 to 
7/3 pentane/EtOAc) to yield glycosylation product 31 (53.1 mg, 61 μmol, 61%, α:β = <1:20). Rf: 0.65 (7/3 
pentane/EtOAc); [α]  = -30.2° (c = 1, CHCl3). IR (neat): 733, 1026, 1096, 1366, 1454, 1746, 2920; Data for the β-
anomer: 1H NMR (400 MHz, CDCl3, HH-COSY, HSQC, HMBC): δ 7.39 – 7.19 (m, 25H, CHarom), 5.41 (t, 1H, J = 9.7 Hz, H-
4’), 5.17 (d, 1H, J = 11.3 Hz, CHH Bn), 4.78 – 4.72 (m, 4H, CHH Bn, CHH Bn, CHH Bn, CHH Bn), 4.64 – 4.56 (m, 3H, CHH 
Bn, CHH Bn, H-1), 4.44 (d, 1H, J = 12.3 Hz, CHH Bn), 4.40 (s, 1H, H-1’), 4.36 (d, 1H, J = 12.3 Hz, CHH Bn), 4.28 (d, 1H, J 
= 12.1 Hz, CHH Bn), 3.89 (m, 2H, H-3, H-5), 3.68 – 3.63 (m, 1H, ), 3.62 (d, 1H, J = 2.7 Hz, H-2’), 3.57 (d, 1H, J = 9.7 Hz, 
H-5’), 3.55 – 3.45 (m, 5H, H-2, CH3 CO2Me, C-6), 3.38 (s, 3H, CH3 OMe), 3.18 (dd, 1H, J = 9.7, 2.8 Hz, H-3’), 2.01 (s, 3H, 
CH3 OAc); 13C-APT NMR (101 MHz, CDCl3, HSQC, HMBC): δ 169.7, 167.9 (C=O CO2Me, Ac), 139.6, 138.5, 138.3, 138.1, 
137.9 (Cq), 128.7, 128.5, 128.5, 128.2, 128.2, 128.2, 128.2, 128.1, 128.0, 127.9, 127.9, 127.8, 127.5, 127.4, 127.1 
(CHarom), 101.1 (C-1’), 98.4 (C-1), 80.4 (C-3), 79.3 (H-2), 78.8 (C-3’), 78.2 (C-5), 75.4 (CH2 Bn), 74.6 (C-2’), 74.2 (C-5’), 
73.7 (CH2 Bn), 73.7 (CH2 Bn), 73.6 (CH2 Bn), 71.8 (CH2 Bn), 69.5 (H-4), 69.0 (C-4’), 68.7 (C-6), 55.4 (CH3 OMe), 52.5 (CH3 
CO2Me), 20.9 (CH3 Ac); 13C-GATED NMR (101 MHz, CDCl3): δ 101.1 (JC1,H1 = 158 Hz, C-1’ β); HRMS: [M+Na]+ calcd for 
C51H56O13Na 899.36131, found 899.36094.   




Methyl (methyl 4-O-[methyl (4-O-acetyl-2,3-di-O-benzyl-α/β-D-mannopyranosyl 
uronate)]-2,3-di-O-benzyl-α-D-glucopyranosyl uronate) (32). Donor 3 and acceptor 12 
were condensed using the general procedure for Tf2O/Ph2SO mediated glycosylations 
(for an additional 48 hours at -40°C) and purified by flash column chromatography (9/1 
to 7/3 pentane/EtOAc) to yield glycosylation product 32 (58.0 mg, 71 μmol, 71%, α:β = 1:10). Rf: 0.38 (7/3 
pentane/EtOAc); [α]  = -31.2° (c = 1, CHCl3). IR (neat): 733, 1026, 1043, 1229, 1454, 1744, 2855, 2926; Data for the 
β-anomer: 1H NMR (400 MHz, CDCl3, HH-COSY, HSQC, HMBC): δ 7.42 – 7.23 (m, 20H, CHarom), 5.44 (t, 1H, J = 9.8 Hz, H-
4’), 5.19 (d, 1H, J = 11.3 Hz, CHH Bn), 4.88 – 4.69 (m, 4H, CHH Bn, CHH Bn, CHH Bn, CHH Bn), 4.62 – 4.38 (m, 5H, CHH 
Bn, CHH Bn, CHH Bn, H-1’, H-1), 4.08 (d, 1H, J = 9.3 Hz, H-5), 3.96 – 3.85 (m, 2H, H-3, H-4), 3.76 (d, 1H, J = 2.7 Hz, H-
2’), 3.70 (d, 1H, J = 9.7 Hz, H-5’), 3.59 (s, 3H, CH3 CO2Me), 3.53 – 3.46 (m, 4H, CH3 CO2Me, H-2), 3.46 – 3.37 (m, 4H, 
CH3 OMe, H-3’), 2.00 (s, 3H, CH3 OAc); 13C-APT NMR (101 MHz, CDCl3, HSQC, HMBC): δ 170.2, 169.8, 167.8 (C=O 
CO2Me, Ac), 139.4, 138.6, 138.1, 137.9 (Cq), 128.6, 128.5, 128.5, 128.5, 128.4, 128.3, 128.3, 128.2, 128.2, 128.1, 127.9, 
127.8, 127.7, 127.6, 127.5, 127.2 (CHarom), 102.3 (C-1’), 98.9 (C-1), 80.7 (C-4), 80.0 (C-3), 78.6 (C-2), 78.4 (C-3’), 75.7 
(CH2 Bn), 74.7 (C-2’), 74.5 (CH2 Bn), 73.9 (CH2 Bn, C-5’), 71.8 (CH2 Bn), 69.6 (C-5), 69.0 (C-4’), 56.0 (CH3 OMe), 52.6 
(CH3 CO2Me), 52.5 (CH3 CO2Me), 20.9 (CH3 Ac); 13C-GATED NMR (101 MHz, CDCl3): δ 102.3 (JC1,H1 = 154 Hz, C-1’ β); 
Diagnostic peaks α-anomer: 1H NMR (400 MHz, CDCl3, HH-COSY, HSQC): 5.44 (m, 0.20H, H-1’, H-4’), 2.00 (s, 0.30H, CH3 
OAc); HRMS: [M+Na]+ calcd for C45H50O14Na 837.30928, found 837.30903.  
Methyl 4-O-(methyl [4-O-acetyl-2,3-di-O-benzyl-β-D-mannopyranosyl uronate])-2,3,6-
tri-O-benzyl-β-D-galactopyranoside (33). Donor 3 and acceptor 13 were condensed 
using the general procedure for Tf2O/Ph2SO mediated glycosylations (for an additional 
16 hours at -40°C) and purified by flash column chromatography (9/1 to 7/3 
pentane/EtOAc) to yield glycosylation product 33 (66.8 mg, 76 μmol, 76%, α:β = <1:20). Rf: 0.39 (7/3 pentane/EtOAc); [α]  = -31.6° (c = 1, CHCl3). IR (neat): 735, 1026, 1051 1231, 1748, 2870; Data for the β-anomer: 1H NMR (400 MHz, 
CDCl3, HH-COSY, HSQC, HMBC): δ 7.35 – 7.22 (m, 25H, CHarom), 5.45 (t, 1H, J = 9.8 Hz, H-4’), 4.95 (d, 1H, J = 12.7 Hz, 
CHH Bn), , 4.93 (d, 1H, J = 10.9 Hz, CHH Bn), 4.85 (d, 1H, J = 12.7 Hz, CHH Bn), 4.78 (d, 1H, J = 11.7 Hz, CHH Bn), 4.75 
(s, 1H, H-1’), 4.67 (d, 1H, J = 11.0 Hz, CHH Bn), 4.60 (d, 1H, J = 11.7 Hz, CHH Bn), 4.58 (d, 1H, J = 11.7 Hz, CHH Bn), 4.51 
(d, 1H, J = 11.7 Hz, CHH Bn), 4.43 (d, 1H, J = 12.3 Hz, CHH Bn), 4.30 (d, 1H, J = 7.6 Hz, H-1), 4.22 (d, 1H, J = 12.3 Hz, 
CHH Bn), 4.15 (d, 1H, J = 2.5 Hz, H-2), 3.95 (d, 1H, J = 2.8 Hz, H-2’), 3.90 (dd, 1H, J = 9.7, 6.3 Hz, H-6), 3.74 (dd, 1H, J = 
9.6, 5.7 Hz, H-6), 3.70 – 3.63 (m, 2H, H-5, H-5’), 3.63 – 3.56 (m, 7H, H-4, CH3 OMe, CH3 CO2Me), 3.56 – 3.50 (m, 1H, H-
3), 3.24 (dd, 1H, J = 9.8, 2.9 Hz, H-3’), 1.99 (s, 3H, CH3 OAc); 13C-APT NMR (101 MHz, CDCl3, HSQC, HMBC): δ 169.8, 
168.1 (C=O CO2Me, Ac), 138.8, 138.7, 138.3, 138.0 (Cq), 128.7, 128.6, 128.5, 128.3, 128.2, 128.0, 127.9, 127.8, 127.8, 
127.7, 127.5, 127.5 (CHarom), 105.1 (C-1), 101.9 (C-1’), 81.8 (C-3), 79.6 (C-5), 79.0 (C-3’), 75.1 (CH2 Bn), 73.9 (C-5), 73.8 
(CH2 Bn), 73.6 (CH2 Bn), 73.6 (C-4), 73.2 (C-2), 72.5 (C-2’), 71.3 (CH2 Bn), 69.4 (C-6), 68.9 (C-4’ ),57.2 (CH3 CO2Me), 52.6 
(CH3 OMe), 20.9 (CH3 Ac); HRMS: [M+Na]+ calcd for C51H56O13Na 899.36131, found 899.36109.  
Methyl 2-O-(methyl [4-O-acetyl-2,3-di-O-benzyl-α/β-D-mannopyranosyl uronate])-3-O-benzyl-
4,6-bezylidene-α-D-mannopyranoside (34). Donor 3 and acceptor 14 were condensed using 
the general procedure for Tf2O/Ph2SO mediated glycosylations (for an additional 16 hours at 
-40°C) and purified by flash column chromatography (9/1 to 7/3 pentane/EtOAc) to yield 
glycosylation product 34 (60.4 mg, 77 μmol, 77%, α:β = 1:7.1). Rf: .34 (7/3 pentane/EtOAc); [α]  = -48.6° (c = 1, CHCl3). IR (neat): 735, 1026, 1053, 1230, 1369, 1454, 1748, 2868, 2924; Data for the β-anomer: 
1H NMR (400 MHz, CDCl3, HH-COSY, HSQC, HMBC): δ 7.51 – 7.22 (m, 15H, CHarom), 5.60 – 5.53 (m, 2H, H-4’, CHPh), 
5.02 (d, 1H, J = 12.5 Hz, CHH Bn), 4.93 (d, 1H, J = 12.5 Hz, CHH Bn), 4.83 (d, 1H, J = 12.1 Hz, CHH Bn), 4.72 (d, 1H, J = 
1.1 Hz, H-1), 4.64 (d, 1H, J = 12.1 Hz, CHH Bn), 4.62 (s, 1H, H-1’), 4.50 (d, 1H, J = 12.4 Hz, CHH Bn), 4.36 – 4.31 (m, 2H, 
CHH Bn, H-2), 4.29 – 4.24 (m, 1H, H-6), 4.15 – 4.07 (m, 1H, H-4), 4.01 – 3.91 (m, 2H, H-2’, H-3), 3.85 (d, 1H, J = 9.7 Hz, 
H-5’), 3.82 – 3.75 (m, 2H, H-5, H-6), 3.63 (s, 3H, CH3 CO2Me), 3.48 (dd, 1H, J = 9.7, 2.9 Hz, H-3’), 3.35 (s, 3H, CH3 OMe), 
2.03 (s, 3H, CH3 OAc); 13C-APT NMR (101 MHz, CDCl3, HSQC, HMBC): δ 169.7, 167.9 (C=O CO2Me, Ac), 138.8, 138.5, 
137.8, 137.7 (Cq), 129.0, 128.7, 128.5, 128.4, 128.4, 128.4, 128.3, 128.3, 127.9, 127.9, 127.8, 127.8, 127.7, 127.6, 
127.5, 127.4, 126.3, 126.2 (Carom), 101.8 (CHPh), 99.8 (C-1’), 99.2 (C-1), 78.5 (C-4), 78.2 (C-3), 74.0 (C-5’), 73.9 (H-2), 
73.9 (H-3), 73.9 (CH2 Bn), 73.0 (H-2’), 71.3 (CH2 Bn), 71.0 (CH2 Bn), 69.0 (C-6), 68.8 (C-4’), 64.1 (H-5), 55.1 (CH3 OMe), 
52.7 (CH3 CO2Me), 21.0 (CH3 Ac); 13C-GATED NMR (101 MHz, CDCl3): δ 99.8 (JC1,H1 = 154 Hz, C-1’ β); Diagnostic peaks 
α-anomer: 1H NMR (400 MHz, CDCl3, HH-COSY, HSQC, HMBC): 5.59 (s, 0.14H, CHPh), 5.50 (t, 0.14H, J = 7.5 Hz, H-4’), 
5.45 (d, 0.14H, J = 4.0 Hz, H-1’), 3.66 (s, 0.42H, CH3 CO2Me), 3.35 (s, 0.42H, CH3 OMe), 2.03 (s, 0.42H, CH3 OAc); 13C-
APT NMR (101 MHz, CDCl3, HSQC, HMBC): δ 100.3 (C-1’), 69.5 (C-4’); HRMS: [M+NH4]+ calcd for C44H52NO13 802.34332, 




Footnotes and references 
(1)  Boltje, T. J.; Buskas, T.; Boons, G.-J. Nat. Chem. 2009, 1 (8), 611–622. 
(2)  Sinnott, M. Carbohydrate Chemistry and Biochemistry: Structure and Mechanism; The Royal Society of 
Chemistry, 2007. 
(3)  Demchenko, A. V. Handbook of Chemical Glycosylation: Advances in Stereoselectivity and Therapeutic 
Relevance; Wiley-VCH Verlag GmbH & Co. KGaA, 2008. 
(4)  Bennett, C. S. Selective Glycosylations: Synthetic Methods and Catalysts; Wiley VCH Verlag GmbH, 2017. 
(5)  Cheung, M.-K.; Douglas, N.; Hinzen, B.; Ley, S.; Pannecoucke, X. Synlett 1997, 1997 (3), 257–260. 
(6)  Douglas, N. L.; Ley, S. V.; Lücking, U.; Warriner, S. L. J. Chem. Soc. [Perkin 1] 1998, No. 1, 51–66. 
(7)  Baeschlin, D. K.; Green, L. G.; Hahn, M. G.; Hinzen, B.; Ince, S. J.; Ley, S. V. Tetrahedron Asymmetry 2000, 
11 (1), 173–197. 
(8)  Zhang, Z.; Ollmann, I. R.; Ye, X.-S.; Wischnat, R.; Baasov, T.; Wong, C.-H. J. Am. Chem. Soc. 1999, 121 (4), 
734–753. 
(9)  Lee, J.-C.; Greenberg, W. A.; Wong, C.-H. Nat. Protoc. 2007, 1 (6), 3143–3152. 
(10)  Ritter, T. K.; Mong, K.-K. T.; Liu, H.; Nakatani, T.; Wong, C.-H. Angew. Chem. Int. Ed. 2003, 42 (38), 4657–
4660. 
(11)  Krumper, J. R.; Salamant, W. A.; Woerpel, K. A. Org. Lett. 2008, 10 (21), 4907–4910. 
(12)  Krumper, J. R.; Salamant, W. A.; Woerpel, K. A. J. Org. Chem. 2009, 74 (21), 8039–8050. 
(13)  Beaver, M. G.; Woerpel, K. A. J. Org. Chem. 2010, 75 (4), 1107–1118. 
(14)  Kalikanda, J.; Li, Z. Carbohydr. Res. 2011, 346 (15), 2380–2383. 
(15)  Heuckendorff, M.; Jensen, H. H. Eur. J. Org. Chem. 2016, 2016 (30), 5136–5145. 
(16)  Bohn, M. L.; Colombo, M. I.; Stortz, C. A.; Rúveda, E. A. Carbohydr. Res. 2006, 341 (9), 1096–1104. 
(17)  Colombo, M. I.; Stortz, C. A.; Rúveda, E. A. Carbohydr. Res. 2011, 346 (5), 569–576. 
(18)  Schumann, B.; Parameswarappa, S. G.; Lisboa, M. P.; Kottari, N.; Guidetti, F.; Pereira, C. L.; Seeberger, P. H. 
Angew. Chem. Int. Ed. 2016, 55 (46), 14431–14434. 
(19)  Crich, D.; Sun, S. J. Org. Chem. 1996, 61 (14), 4506–4507. 
(20)  Crich, D.; Sun, S. J. Org. Chem. 1997, 62 (5), 1198–1199. 
(21)  Crich, D.; Cai, W. J. Org. Chem. 1999, 64 (13), 4926–4930. 
(22)  Crich, D.; Smith, M. Org. Lett. 2000, 2 (25), 4067–4069. 
(23)  Crich, D.; Smith, M. J. Am. Chem. Soc. 2001, 123 (37), 9015–9020. 
(24)  Frihed, T. G.; Bols, M.; Pedersen, C. M. Chem. Rev. 2015, 115 (11), 4963–5013. 
(25)  Crich, D.; Sun, S. J. Am. Chem. Soc. 1998, 120 (2), 435–436. 
(26)  Crich, D.; Dudkin, V. J. Am. Chem. Soc. 2001, 123 (28), 6819–6825. 
(27)  Crich, D.; Smith, M. J. Am. Chem. Soc. 2002, 124 (30), 8867–8869. 
(28)  Ohara, K.; Lin, C.-C.; Yang, P.-J.; Hung, W.-T.; Yang, W.-B.; Cheng, T.-J. R.; Fang, J.-M.; Wong, C.-H. J. 
Org. Chem. 2013, 78 (13), 6390–6411. 
(29)  Crich, D.; Vinod, A. U. Org. Lett. 2003, 5 (8), 1297–1300. 
(30)  Crich, D.; Li, W.; Li, H. J. Am. Chem. Soc. 2004, 126 (46), 15081–15086. 
(31)  Mukherjee, C.; Ranta, K.; Savolainen, J.; Leino, R. Eur. J. Org. Chem. 2012, 2012 (15), 2957–2968. 
(32)  Poláková, M.; Roslund, M. U.; Ekholm, F. S.; Saloranta, T.; Leino, R. Eur. J. Org. Chem. 2009, 2009 (6), 870–
888. 
(33)  Crich, D.; Sun, S. J. Am. Chem. Soc. 1997, 119 (46), 11217–11223. 
(34)  Huang, M.; Garrett, G. E.; Birlirakis, N.; Bohé, L.; Pratt, D. A.; Crich, D. Nat. Chem. 2012, 4 (8), 663–667. 
(35)  Crich, D.; Chandrasekera, N. S. Angew. Chem. Int. Ed. 2004, 43 (40), 5386–5389. 
(36)  Huang, M.; Retailleau, P.; Bohé, L.; Crich, D. J. Am. Chem. Soc. 2012, 134 (36), 14746–14749. 
(37)  Adero, P. O.; Furukawa, T.; Huang, M.; Mukherjee, D.; Retailleau, P.; Bohé, L.; Crich, D. J. Am. Chem. Soc. 
2015, 137 (32), 10336–10345. 
(38)  Huang, M.; Furukawa, T.; Retailleau, P.; Crich, D.; Bohé, L. Carbohydr. Res. 2016, 427, 21–28. 
(39)  Bohé, L.; Crich, D. Carbohydr. Res. 2015, 403, 48–59. 
(40)  Moumé-Pymbock, M.; Crich, D. J. Org. Chem. 2012, 77 (20), 8905–8912. 
(41)  Heuckendorff, M.; Bols, P. S.; Barry, C. B.; Frihed, T. G.; Pedersen, C. M.; Bols, M. Chem. Commun. 2015, 
51 (68), 13283–13285. 
(42)  Heuckendorff, M.; Bendix, J.; Pedersen, C. M.; Bols, M. Org. Lett. 2014, 16 (4), 1116–1119. 




(43)  Crich, D.; de la Mora, M.; Vinod, A. U. J. Org. Chem. 2003, 68 (21), 8142–8148. 
(44)  Hogendorf, W. F. J.; Bos, L. J. V. den; Overkleeft, H. S.; Codée, J. D. C.; Marel, G. A. V. der. Bioorg. Med. 
Chem. 2010, 18 (11), 3668–3678. 
(45)  Lourenço, E. C.; Maycock, C. D.; Rita Ventura, M. Carbohydr. Res. 2009, 344 (15), 2073–2078. 
(46)  Crich, D.; Sharma, I. J. Org. Chem. 2010, 75 (24), 8383–8391. 
(47)  Bousquet, E.; Khitri, M.; Lay, L.; Nicotra, F.; Panza, L.; Russo, G. Carbohydr. Res. 1998, 311 (4), 171–181. 
(48)  Walvoort, M. T. C.; Lodder, G.; Mazurek, J.; Overkleeft, H. S.; Codée, J. D. C.; van der Marel, G. A. J. Am. 
Chem. Soc. 2009, 131 (34), 12080–12081. 
(49)  Rönnols, J.; Walvoort, M. T. C.; Marel, G. A. van der; Codée, J. D. C.; Widmalm, G. Org. Biomol. Chem. 
2013, 11 (46), 8127–8134. 
(50)  Walvoort, M. T. C.; de Witte, W.; van Dijk, J.; Dinkelaar, J.; Lodder, G.; Overkleeft, H. S.; Codée, J. D. C.; 
van der Marel, G. A. Org. Lett. 2011, 13 (16), 4360–4363. 
(51)  Codée, J. D. C.; van den Bos, L. J.; de Jong, A.-R.; Dinkelaar, J.; Lodder, G.; Overkleeft, H. S.; van der Marel, 
G. A. J. Org. Chem. 2009, 74 (1), 38–47. 
(52)  van den Bos, L. J.; Dinkelaar, J.; Overkleeft, H. S.; van der Marel, G. A. J. Am. Chem. Soc. 2006, 128 (40), 
13066–13067. 
(53)  van den Bos, L. J.; Codée, J. D. C.; Litjens, R. E. J. N.; Dinkelaar, J.; Overkleeft, H. S.; van der Marel, G. A. 
Eur. J. Org. Chem. 2007, 2007 (24), 3963–3976. 
(54)  Codée, J. D. C.; Walvoort, M. T. C.; Jong, A.-R. de; Lodder, G.; Overkleeft, H. S.; Marel, G. A. van der. J. 
Carbohydr. Chem. 2011, 30 (7–9), 438–457. 
(55)  Dinkelaar, J.; de Jong, A. R.; van Meer, R.; Somers, M.; Lodder, G.; Overkleeft, H. S.; Codée, J. D. C.; van der 
Marel, G. A. J. Org. Chem. 2009, 74 (14), 4982–4991. 
(56)  Tang, S.-L.; Pohl, N. L. B. Org. Lett. 2015, 17 (11), 2642–2645. 
(57)  Walvoort, M. T. C.; van den Elst, H.; Plante, O. J.; Kröck, L.; Seeberger, P. H.; Overkleeft, H. S.; van der 
Marel, G. A.; Codée, J. D. C. Angew. Chem. Int. Ed. 2012, 51 (18), 4393–4396. 
(58)  Walvoort, M. T. C.; Dinkelaar, J.; van den Bos, L. J.; Lodder, G.; Overkleeft, H. S.; Codée, J. D. C.; van der 
Marel, G. A. Carbohydr. Res. 2010, 345 (10), 1252–1263. 
(59)  Lee, Y. J.; Baek, J. Y.; Lee, B.-Y.; Kang, S. S.; Park, H.-S.; Jeon, H. B.; Kim, K. S. Carbohydr. Res. 2006, 341 
(10), 1708–1716. 
(60)  Frihed, T. G.; Walvoort, M. T. C.; Codée, J. D. C.; van der Marel, G. A.; Bols, M.; Pedersen, C. M. J. Org. 
Chem. 2013, 78 (6), 2191–2205. 
(61)  Minegishi, S.; Kobayashi, S.; Mayr, H. J. Am. Chem. Soc. 2004, 126 (16), 5174–5181. 
(62)  Ammer, J.; Nolte, C.; Mayr, H. J. Am. Chem. Soc. 2012, 134 (33), 13902–13911. 
(63)  Ammer, J.; Mayr, H. J. Phys. Org. Chem. 2013, 26 (1), 59–63. 
(64)  Hansch, C.; Leo, A.; Taft, R. W. Chem. Rev. 1991, 91 (2), 165–195. 
(65)  Worm‐Leonhard, K.; Larsen, K.; Jensen, K. J. J. Carbohydr. Chem. 2007, 26 (7), 349–368. 
(66)  Acid catalyzed anomerization reactions do not play a major role in the studied glycosylation reactions as 
the released acid is scavenged by tri-tert-butyl methyl pyrimidine (TTBP) and executed at low temperature. 
See ref.42. 
(67)  Whitfield, D. M. Carbohydr. Res. 2007, 342 (12–13), 1726–1740. 
(68)  Hosoya, T.; Kosma, P.; Rosenau, T. Carbohydr. Res. 2015, 411, 64–69. 
(69)  Wang, H.; Houk, K. N. Chem. Sci. 2013, 5 (2), 462–470. 
(70)  Crich, D. Acc. Chem. Res. 2010, 43 (8), 1144–1153. 
(71)  Seeman, J. I. Chem. Rev. 1983, 83 (2), 83–134. 
(72)  Crich, D.; Sharma, I. Org. Lett. 2008, 10 (21), 4731–4734. 
(73)  Calculated energies (kcal⋅mol-1) of the methyl 2,3,4-tri-O-methyl mannuronate oxocarbenium ion 
(B3LYP/6-311G, with a PCM model to correct for solvation in dichloromethane): 3H4 = 0.0, 4H3 = +5.0, B2,5 
= +6.1. 
(74)  Romero, J. A. C.; Tabacco, S. A.; Woerpel, K. A. J. Am. Chem. Soc. 2000, 122 (1), 168–169. 
(75)  Ayala, L.; Lucero, C. G.; Romero, J. A. C.; Tabacco, S. A.; Woerpel, K. A. J. Am. Chem. Soc. 2003, 125 (50), 
15521–15528. 
(76)  Lucero, C. G.; Woerpel, K. A. J. Org. Chem. 2006, 71 (7), 2641–2647. 
(77)  Balmond, E. I.; Coe, D. M.; Galan, M. C.; McGarrigle, E. M. Angew. Chem. Int. Ed. 2012, 51 (36), 9152–9155. 
(78)  Ingle, A. B.; Chao, C.-S.; Hung, W.-C.; Mong, K.-K. T. Org. Lett. 2013, 15 (20), 5290–5293. 
Chapter 3 
78 
(79) Giordano, M.; Iadonisi, A. J. Org. Chem. 2014, 79 (1), 213–222. 
(80) The concentration dependence of SN2-type reactions indicates that this parameter should be carefully
considered in optimizing these glycosylations. See for example ref. 36 and Fang, T.; Gu, Y.; Huang, W.;
Boons, G.-J.; J. Am. Chem. Soc. 2016, 138, 3002–3011. 
(81) Crich, D.; Smith, M.; Yao, Q.; Picione, J. Synthesis 2001, 2001 (02), 0323–0326. 
(82) Spartan ’04; Kong, J. et al. 2004, Wavefunction Inc.
(83) Gaussian 03 (Revision E.01); Frisch, M. J. et al. 2004, Gaussian, Inc. 
(84) Pedretti, V.; Veyrières, A.; Sinaÿ, P. Tetrahedron 1990, 46 (1), 77–88. 
(85) Kametani, T.; Kawamura, K.; Honda, T. J. Am. Chem. Soc. 1987, 109 (10), 3010–3017. 
(86) Kohata, K.; Meguro, H. Agric. Biol. Chem. 1982, 46 (4), 919–925. 
(87) Emmadi, M.; Kulkarni, S. S. J. Org. Chem. 2011, 76 (11), 4703–4709. 
(88) Smid, P.; Noort, D.; Broxterman, H. J. G.; van Straten, N. C. R.; van der Marel, G. A.; van Boom, J. H. Recl. 
Trav. Chim. Pays-Bas 1992, 111 (12), 524–528. 
(89) Michihata, N.; Kaneko, Y.; Kasai, Y.; Tanigawa, K.; Hirokane, T.; Higasa, S.; Yamada, H. J. Org. Chem. 2013, 
78 (9), 4319–4328. 
(90) Blom, P.; Ruttens, B.; Van Hoof, S.; Hubrecht, I.; Van der Eycken, J.; Sas, B.; Van hemel, J.; Vandenkerckhove, 
J. J. Org. Chem. 2005, 70 (24), 10109–10112. 
(91) Raju, R.; Castillo, B. F.; Richardson, S. K.; Thakur, M.; Severins, R.; Kronenberg, M.; Howell, A. R. Bioorg. 
Med. Chem. Lett. 2009, 19 (15), 4122–4125. 
(92) Janczuk, A. J.; Zhang, W.; Andreana, P. R.; Warrick, J.; Wang, P. G. Carbohydr. Res. 2002, 337 (14), 1247–
1259. 
(93) Gantt, R. W.; Goff, R. D.; Williams, G. J.; Thorson, J. S. Angew. Chem. Int. Ed. 2008, 47 (46), 8889–8892. 
(94) Boonyarattanakalin, S.; Liu, X.; Michieletti, M.; Lepenies, B.; Seeberger, P. H. J. Am. Chem. Soc. 2008, 130 
(49), 16791–16799. 
(95) Yoza, K.; Amanokura, N.; Ono, Y.; Akao, T.; Shinmori, H.; Takeuchi, M.; Shinkai, S.; Reinhoudt, D. N. Chem. 
– Eur. J. 1999, 5 (9), 2722–2729. 
(96) Michigami, K.; Hayashi, M. Tetrahedron 2013, 69 (21), 4221–4225. 
(97) Kartha, K. P. R.; Aloui, M.; Field, R. A. Tetrahedron Lett. 1996, 37 (48), 8807–8810. 
(98) Ren, B.; Dong, H.; Ramström, O. Chem. – Asian J. 2014, 9 (5), 1298–1304. 
(99) Goux, W. J. Carbohydr. Res. 1988, 184, 47–65. 
(100) Bock, K.; Refn, S.; Pedersen, C.; Taft, R. W.; Fischer, G. W. Acta Chem. Scand. 1987, 41b, 469–472. 
(101) Wong, C.-H.; Moris-Varas, F.; Hung, S.-C.; Marron, T. G.; Lin, C.-C.; Gong, K. W.; Weitz-Schmidt, G. J.
Am. Chem. Soc. 1997, 119 (35), 8152–8158. 
(102) Attolino, E.; Catelani, G.; D’Andrea, F. Eur. J. Org. Chem. 2006, 2006 (23), 5279–5292. 
(103) J. Garegg, P.; Hultberg, H.; Wallin, S. Carbohydr. Res. 1982, 108 (1), 97–101. 
(104) Ennis, S. C.; Cumpstey, I.; Fairbanks, A. J.; Butters, T. D.; Mackeen, M.; Wormald, M. R. Tetrahedron 2002, 
58 (46), 9403–9411. 
(105) Nagai, H.; Sasaki, K.; Matsumura, S.; Toshima, K. Carbohydr. Res. 2005, 340 (3), 337–353. 
(106) Sun, P.; Wang, P.; Zhang, Y.; Zhang, X.; Wang, C.; Liu, S.; Lu, J.; Li, M. J. Org. Chem. 2015, 80 (8), 4164–
4175. 
(107) Ella-Menye, J.-R.; Nie, X.; Wang, G. Carbohydr. Res. 2008, 343 (10–11), 1743–1753. 
(108) Kim, K. S.; Fulse, D. B.; Baek, J. Y.; Lee, B.-Y.; Jeon, H. B. J. Am. Chem. Soc. 2008, 130 (26), 8537–8547. 
(109) Baek, J. Y.; Choi, T. J.; Jeon, H. B.; Kim, K. S. Angew. Chem. Int. Ed. 2006, 45 (44), 7436–7440. 
(110) Kim, K. S.; Kim, J. H.; Lee, Y. J.; Lee, Y. J.; Park, J. J. Am. Chem. Soc. 2001, 123 (35), 8477–8481. 
(111) Crich, D.; Sun, S. Tetrahedron 1998, 54 (29), 8321–8348. 
(112) Nie, X.; Wang, G. J. Org. Chem. 2005, 70 (22), 8687–8692. 
(113) van den Bos, L. J.; Dinkelaar, J.; Overkleeft, H. S.; van der Marel, G. A. J. Am. Chem. Soc. 2006, 128 (40),
13066–13067.
 








Stereoselectivity of conformationally 





Glucosamine is a key constituent in numerous important oligosaccharides and 
glycoconjugates, where it can be either α- or β-linked.1–5 Whereas the former type of 
linkage can be reliably installed through the use of neighboring-group participation of 
an C-2-amide- or carbamate based protecting group, the latter type continues to present 
a synthetic challenge.6–8 A thorough understanding of the glycosylation mechanism and 
the influence of both reaction partners and reaction conditions on glycosylation 
stereoselectivity is needed to enable reliable and predictable glycosylation reactions. The 
in-depth research conducted on conformationally restricted benzylidene mannose and 
glucose donors has provided important insight into the glycosylation mechanisms of this 
type of 1,2-cis-selective donor.9–17 To construct 1,2-cis-linkages of glucosamine donors, 
the C-2-amino group is most commonly masked as the nonparticipating azide.18,19 
Notably, benzylidene glucosazides have not been systematically investigated with respect 




of the stereoselectivity of benzylidene glucose donors to their glucosazide counterparts 
suggests that benzylidene or analogously protected glucosazides might represent an 
attractive class of 1,2-cis-selective glucosamine donor synthons.20,21  
In Chapter 3 a comprehensive set of partially fluorinated ethanols, of gradually 
decreasing nucleophilicity, that can be used to map how the stereoselectivity of a given 
glycosylation system is dependent on the nucleophilicity of the acceptor, was 
introduced.22 The stereoselectivity of the benzylidene glucose donor system proved to be 
greatly affected by the reactivity of the nucleophile.23–27 In light of the demand for 1,2-cis-
selective glucosaminylations but also with the aim in mind of furthering the 
understanding of the stereoelectronic effects exerted by the azido group, this chapter sets 
out to systematically evaluate a series of glucosazide donors in a set of glycosylation 
reactions involving the toolset of partially fluorinated ethanols and a selection of 
carbohydrate acceptors. As is described here, changes in the structure and reactivity of 
the donor can be effectively mapped using the panel of model acceptors, and a clear 
reactivity-selectivity relationship for the stereoselectivity of the glycosylations, emerges 
for all donors studied. Differences among the donors and the stereochemical variation in 
the glycosylation outcome can be explained on the basis of competition experiments and 
the characterization of the reactive intermediates involved. 
Results and discussion 
The set of (partially) fluorinated ethanol acceptors that was employed in Chapter 3, to 
relate the glycosylation stereoselectivity to the acceptor nucleophilicity is depicted in 
Figure 1 (compounds 6-11). Glycosylating these acceptors with benzylidene mannose, 
benzylidene glucose, and mannuronic acid donors, as well as fucosazide donors bearing 
various protecting groups, established the dependence of the stereoselectivity of the 
 
 
Figure 1. Glucose-configured donors 1-5 and model acceptors 6-11 used in this study. 
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glycosylations with these donors on the nucleophilicity of the acceptor.22,28 For 
benzylidene protected glucose donor 1, the gradual decrease in acceptor nucleophilicity 
going from ethanol, monofluoroethanol (MFE), difluoroethanol (DFE), trifluoroethanol 
(TFE), and hexafluoro-iso-propanol (HFIP) led to a gradual shift of the stereoselecivity 
from high β-selectivity to exclusive α-selectivity (See Table 3 below). Here, the results 
from investigating the set of conformationally restricted glucosamine donors depicted in 
Figure 1 (1-5) is presented. Variation in the structure of these donors is found in the 
cyclic protecting groups (benzylidene vs silylidene), in the functionality at the C-3–OH 
(benzyl vs benzoyl), and in the nature of the C-2–N-protecting group (azide vs the 
dinitropyridone [DNPY] group). The DNPY is introduced here as a nonparticipating N-
protecting group.29,30 The reactivity and selectivity of the set of glucosamine donors are 
related to the corresponding properties of well-studied benzylidene glucose donor 1.9,22  
Synthesis 
Benzylidene-protected glucosazide donors 331 and 432 with an O-benzyl and an O-
benzoyl, respectively, at C-3, as well as silylidene-protected donor 2, were prepared from 
common building block 1233 as depicted in Scheme 1. Hydrolysis of all acetyl esters and 
the trichloroacetamide was followed by a diazotransfer to install the desired C-2-azide.34  
 
Scheme 1. Preparation of donors 2-5. 
 
Reagents and conditions: (a) i. K2CO3, EtOH, H2O; ii. CuSO4∙5H2O, imidazole-1-sulfonyl azide hydrochloride34; 
(b) di-tert-butylsilyl bis(trifluoromethanesulfonate), pyridine, 14: 71% (three steps); (c) PhCH(OMe)2, p-
TsOH∙H2O, 13: 78% (three steps); (d) BnBr, NaH, DMF, 2: 80%, 3: 89%; (e) BzCl, DMAP, pyridine, DCM, 90%; 





Subsequent introduction of the di-tert-butylsilylidene (DTBS) and the benzylidene acetal 
gave intermediates 1331 and 14, respectively. Benzylation of 14 and 13 and benzoylation 
of 13 gave the target donor compounds 2, 3, and 4, respectively. Donor 5 was prepared 
in two steps from thioglucoside 1535 by exchange of the phthaloyl group for the DNPY 
functionality. To this end, compound 15 was treated with ethylenediamine to give amine 
16, wich was treated with DNPY reagent 1830,36 to furnish the target donor. 
Observation of anomeric triflates 
With these five donors in hand, the formation of potential covalent reactive 
intermediates was investigated by low-temperature NMR studies.37 The donors were 
treated with the diphenyl sulfoxide/triflic anhydride (Ph2SO/Tf2O)38 combination of 
reagents in deuterated dichloromethane. Figure 3 shows the results of these studies and 
Table 1 summarizes the anomeric chemical shifts of the observed triflates and the 
temperatures at which decomposition starts (Tdecomp). Activation of reference donor 1 led  
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Figure 3. 1H-NMR spectra at -40°C of activated donors 1-5 showing their respective anomeric triflates 19-23. 
to the formation of two species: In addition to the anomeric triflate 19,9 the oxosulfonium 
triflate 19α* (6.68 ppm, 3.6 Hz) was also formed, as was confirmed by the activation of a 
sample containing additional Ph2SO. Donors 2 and 3 were cleanly converted to their 
anomeric α-triflates 20 and 21 respectively, by treatment at -80°C with the activation 
couple. Activation of donor 4 proceeded more slowly, and an increase of the temperature 
from -80°C to -35°C was required for complete activation. Donor 5 proved difficult to 
study by low-temperature NMR spectroscopy because of significant line broadening in 
the resonance sets for both the donor and the products formed upon activation. 
Complete activation of the thioglycoside could only be achieved at -40°C, but at this 
temperature, decomposition of the reactive intermediates also set in. Two anomeric 
signals can be discriminated in the spectrum of the activated DNPY donor 5 (Figure 3), 
and these were tentatively assigned as the intermediate triflate (6.06 ppm) and 
oxosulfonium triflate (6.54 ppm). Unfortunately, complete characterization was 
hampered by the severe line broadening.39 The reactive intermediates formed all 
decomposed to give the glucal product 24 (Figure 2). The formation of the glucal double 
bond is relatively fast, as the proton at C-2 is readily eliminated to provide the enol ether 
double bond that is conjugated to the DNPY aromatic ring.  
 
 









Competitive glycosylations and relative reactivities. 
To investigate the reactivities of donors 1-5, a series of competitive glycosylations were 
performed between the different thioglycosides.40–44 In these competition experiments, 
an in situ activation protocol was used, employing N-iodosuccinimide (NIS)/ 
trifluoromethanesulfonic acid (TfOH) as activator and 2,3,4-tri-O-benzyl-α-O-methyl 
glucose (25) as the acceptor, as is commonly done to determine the reactivities of 
thioglycoside donors.45,46 It should be noted, however, that the reactivity of the 
thiophenyl donor does not directly compare with the reactivity of an intermediate triflate 
in the glycosylation, although it does provide an indication of the relative disarming or 
arming nature of the protecting groups present on the different donors. It is apparent 
from Table 2 that the azide has a profound effect on the reactivity of donor 3, as it is 
completely outcompeted by the C-2-O-benzyl donor 1.46 Silylidene donor 2 is more 
reactive than donor 3, and the disaccharide products derived from donor 2 and 3 are  
 
 
Table 2. Competitive donor activations. 
 
Entry Donor I Donor II Productsa Ratios Yieldb (%) 
1 1 2 1C/2C 14 : 1 65 
2 1 3 1C/3C 1 : 0 80 
3 2 3 2C/3C 6 : 1 37 
4 3 4 3C/4C 1.6 : 1 39 
5c 4 5 4C/5C 1 : 0 64 
aDetermined by 1H-NMR of the isolated disaccharide. bThe disaccharide fraction was quantified after isolation 
by size-exclusion chromatography and related to the limiting amount of NIS (see experimental section). cThe 
combined donor concentration for entry 5 was 0.1 M, triflic acid was added at -20°C and the reaction mixture 
was heated to +15°C overnight, and then the reaction was quenched (Et3N). 
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formed in a 6:1 ratio. C-3-O-Benzyl donor 3 in turn outcompetes benzoylated donor 4 
slightly, as a result of the electron-withdrawing nature of the benzoate, giving a 1.6:1 ratio 
of the addition products 3C and 4C.47–49 DNPY-protected donor 5 is the least reactive of 
the set of donors, as it did not provide any disaccharide product in the competition 
experiment with donor 4. 
Glycosylations 
With the reactivities of these five donors established, the series of glycosylations with 
model acceptors 6-11 and carbohydrate acceptors 25-2950–52 was undertaken using the 
Ph2SO/Tf2O preactivation procedure. Table 3 list all glycosylations ordered by acceptor 
and donor reactivity. A clear relation between acceptor nucleophilicity and 
stereochemical outcome of the glycosylation reactions of all studied glucosamine donors 
was observed, in line with the results previously obtained with donor 1. Upon 
comparison of the outcomes of the coupling reactions of glucosazide 3 with the results 
obtained with C-2-O-benzyl donor 1, it becomes apparent that the latter donor reacts 
with higher α-selectivity. Donor 2, bearing the DTBS group, overall provides slightly 
more of the α-linked products than its benzylidene counterpart 3. The stereoselectivity 
of the condensations of donor 4, bearing an additional electron-withdrawing protecting 
group (i.e., the C-3-O-benzoyl), is very similar to the stereoselectivity observed with C-
3-O-benzyl donor 3. Finally, donor 5, carrying the strongly electron-withdrawing DNPY 
group, is the most β-selective of the series of donors listed in Table 3.53 
The selectivities of glycosylations with carbohydrate acceptors were also found to 
vary in a nucleophilicity-dependent fashion. The primary perbenzylated acceptor 25 
reacts similarly to ethanol 7 to give primarily the β-linked products for all glucosamine 
donors studied. Secondary carbohydrate acceptors that were less nucleophilic showed 
variations in selectivity with the proportion of α-product increasing with decreasing 
acceptor reactivity. In line with the results from Chapter 3, the nucleophilicities of the 
secondary equatorial carbohydrate alcohols fall somewhere between the reactivities of 
MFE and DFE, with the reactivities of the axial hydroxyls approaching the reactivity of 
TFE. The differences in the reactivities of the donors are reflected in the stereoselectivities 
of both the glycosylations that involve the model acceptors and the glycosylations with 
the carbohydrate acceptors. A recurring trend is apparent for all acceptors, with the most 
reactive donor 1 providing most α-linked product and the least reactive donor 5 giving 






























1 : 10 
(68 %) 
2A 
< 1 : 20 
(65 %) 
3A 
< 1 : 20 
(83 %) 
4A 
< 1 : 20 
(86 %) 
5A 





1 : 5.1 
(71 %) 
2B 
< 1 : 20 
(77 %) 
3B 
< 1 : 20 
(93 %) 
4B 
< 1 : 20 
(91 %) 
5B 





1 : 2.7 
(81 %) 
2C 
1 : 14 
(92 %) 
3C 
< 1 : 20 
(89 %) 
4C 
1 : 14 
(79 %) 
5C 





1 : 2.8 
(70 %) 
2D 
1 : 5 
(79 %) 
3D 
1 : 6.7 
(90 %) 
4D 
1 : 6.5 
(83 %) 
5D 





1 : 1 
(79 %) 
2E 
1 : 3 
(81 %) 
3E 
1 : 7 
(88 %) 
4E 
1 : 6 
(71 %) 
5E 





5 : 1 
(90 %) 
2F 
3.3 : 1 
(84 %) 
3F 
1.1 : 1 
(93 %) 
4F 
1 : 1.4 
(59 %) 
5F 





5 : 1 
(70 %) 
2G 
2.7 : 1 
(76 %) 
3G 
2.9 : 1 
(64 %) 
4G 
2.7 : 1 
(84 %) 
5G 





> 20 : 1 
(83 %) 
2H 
7 : 1 
(52 %) 
3H 
9 : 1 
(75 %) 
4H 
4 : 1 
(51 %) 
5H 





> 20 : 1 
(80 %) 
2I 
> 20 : 1 
(85 %) 
3I 
9 : 1 
(74 %) 
4I 
5 : 1 
(73 %) 
5I 





> 20 : 1 
(64 %) 
2J 
> 20 : 1 
(82 %) 
3J 
> 20 : 1 
(94 %) 
4J 
> 20 : 1 
(86 %) 
5J 





> 20 : 1 
(65 %) 
2K 
> 20 : 1 
(34 %) 
3K 
> 20 : 1 
(53 %) 
-c 32% 24 
aGlycosylation results of donor 1, are also reported in Chapter 2 of this thesis. bRatio and yield of isolated 


















Two major trends become apparent from the table of glycosylations. First, with 
decreasing acceptor nucleophilicity the α/β ratio increases. Second, decreasing donor 
reactivity corresponds to a decrease in the α/β ratio. These trends also emerged in 
Chapter 3 and the work on fucosazide donors.22,28 The reactive intermediates that can 
play a role in the glycosylations of the conformationally restricted glucosamine donors 
and the reaction trajectories of the incoming nucleophiles are presented in Figure 4. 
Previous studies by the group of Crich have indicated that substitutions on the 
benzylidene glucosyl triflate 19 proceed in an SN2-like manner. In these mechanistic 
studies, which involved the determination of kinetic isotope effects and cation-clock 
methodology, isopropanol was used as an acceptor.12,14 In the kinetic scenario that was 
proposed the relatively stable α-triflate (observed by low-temperature NMR 
spectroscopy) is in equilibrium with its more reactive β-counterpart. In both species, the 
triflate can be displaced by alcohols if they are nucleophilic enough. The higher β-
selectivity that is seen for the glucosazide and DNPY-glucosamine donors in comparison 
to donor 1 can be explained by the stronger electron-withdrawing effect of the azide with 
respect to the benzyl ether. This leads to a more stable covalent α-triflate and favors an 
associative displacement mechanism. A similar effect has been observed by the group of 
Crich in glycosylations of the analogous 2-deoxy-2-fluoro benzylidene glucosides.54 The 
DNPY group is even more electron withdrawing, leading to a further increase in β-
selectivity through associative displacement. However, an SN2-like reaction pathway is 
 




less likely for the weaker nucleophiles, such as TFE and HFIP. The high α-selectivity for 
these acceptors can be explained perhaps more precisely by considering the involvement 
of more electrophilic intermediates such as the glycosyl oxocarbenium ion. The 
benzylidene and silylidene protecting groups restrict the conformational space that the 
donor pyranosides can adopt and the intermediate oxocarbenium ion likely adopt 
a4E/4H3–like conformation.55,56 Nucleophiles attack this envelope/half-chair conformer 
preferentially from the bottom face to lead to the α-linked products through a chair-like 
transition state.57 The more reactive donors more readily dissociate to form an 
oxocarbenium ion, and this accounts for the increased α-selectivity for these donors. 
Donor 2, bearing the silylidene group is the most reactive of the studied glucosamine 
donors. It also is slightly more flexible than the benzylidene restricted donors, and these 
two factors allow the activated donor to more readily form a flattened oxocarbenium ion-
like intermediate. Consequently, it is the most α-selective of the studied glucosamine 
donors. Finally, it is notable that the C-3-O-benzoyl protected glucosazide 4 reacts in a 
slightly more β-selective fashion than its C-3-O-benzyl counterpart 3. In light of the 
discussion above, this makes sense, as the electron-withdrawing benzoyl stabilizes the 
anomeric α-triflate. It contrasts, however, with the behavior of acyl groups at the C-3 
position of benzylidene mannosyl donors. The 1,2-cis-selectivity generally observed for 
these donors can be completely changed to selectively give the α-linked products by 
installing a C-3-acyl group in the donor.58,59 The difference between the benzylidene 
mannose and benzylidene glucose series can be found in the different geometries that the 
oxocarbenium ions adopts. For the benzylidene mannose system, a B2,5-like structure is 
one of the lower-energy oxocarbenium ion conformers.12,55,56 In this constellation, the C-
3-benzoate can fold over to the electron-depleted anomeric center to provide 
stabilization, without a major skeletal rearrangement. For the benzylidene glucose, on 
the other hand, a B2,5-like structure such as 32 is significantly less favorable because this 
puts the C-2-azide in a flagpole position. Given the selectivities observed for this donor, 
influences arising from this boat conformation do not play a significant role here.  
Conclusions 
A set of model acceptors of gradually changing nucleophilicity has been used to 
investigate how the stereochemistry of glycosylations involving 4,6-tethered glucosamine 
donors relates to the nucleophilicity of the acceptor. The set of acceptors was 
complemented by a suite of carbohydrate alcohols to translate the results obtained with 
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the model acceptors to a more relevant glycosylation setting. Four glucosamine donors 
were probed that differed in the type of tether spanning the C-4 and C-6-alcohols, the 
nature of the protecting group at the C-3-OH, and the amino functionality at C-2. 
Similarly to the previously described benzylidene glucose donor 1, the stereoselectivity 
of the studied glucosamine donors show a strong correlation to the nucleophilicity of the 
acceptor, with strong nucleophiles providing completely β-selective condensations and 
weak nucleophiles selectively leading to the formation of the α-linked products. 
Benzylidene glucosazide donors are less α-selective than their C-2-O-benzyl congeners, 
because of the increased electron-withdrawing power of the azide, which retards the 
formation of an oxocarbenium ion species and favors a more associative mechanistic 
pathway. This chapter also introduced a novel protecting group for the C-2-amino 
group: the dinitropyridone functionality.29,30,36 Although this group is easily installed and 
removed from the C-2-amine, its strongly electron-withdrawing character limits its use. 
In the 4,6-benzylidene glucosamine donor studied here it disarms the donor glycoside to 
the extent that it turns into a suboptimal glycosyl donor. A major incentive for the 
reported study was the good to excellent α-selectivity that has previously been reported 
for benzylidene glucose donor 1. Unfortunately, installation of a 4,6-benzylidene on the 
analogous glucosazide donors does not provide a reliable donor to affect 1,2-cis-selective 
glycosylations. Only with relatively poor nucleophiles are useful stereoselectivities 
obtained. Changing the benzylidene for a silylidene group, however, turns the donor into 
a more reactive glycosylating agent showing improved α-selectivity. This donor, 
attractive because of its fully orthogonal protecting group scheme, might find application 
in the future assembly of oligosaccharides featuring α-glucosamines. Finally, it is prudent 
to note that this study provides another illustration of the application of the toolset of 
partially fluorinated ethanols to efficiently map the reactivity-selectivity relationship of a 
class of donor glycosides. Implementation of this methodology to investigate novel 
donor systems will broaden the insight into the different mechanistic pathways at play 
during glycosylations and eventually generate a complete picture how to tune both 









General procedure for Tf2O/Ph2SO mediated glycosylations: Donor (0.1 mmol), Ph2SO (26 mg, 0.13 mmol, 1.3 eq.) and 
TTBP60 (62 mg, 0.25 mmol, 2.5 eq.) were coevaporated twice with dry toluene and dissolved in dry DCM (2 mL, 0.05 
M donor). Activated 3Å molecular sieves (rods, size 1/16 in.) were added, and the reaction mixture stirred for 1 h at 
room temperature under a nitrogen atmosphere. The solution was cooled to -78°C and Tf2O (22 μl, 0.13 mmol, 1.3 
eq.) was added. The reaction mixture was allowed to warm to -60°C (donor 1, 2, 3), -45°C (donor 5), -35°C (donor 4), 
followed by recooling to -78°C and addition of the acceptor (0.2 mmol, 2 eq.) in DCM (0.4 mL, 0.5 M). The reaction 
mixture was allowed to warm to -40°C in approximately 90 min and stirred for an additional 0-18 h depending on the 
acceptor. The reaction was quenched with Et3N (0.1 mL, 0.72 mmol, 5.5 eq.) at -40 ⁰C and diluted with DCM. The 
solution was transferred to a separatory funnel and water was added, the layers were separated and the water phase 
extracted once more with DCM. The combined organic layers were dried over MgSO4, filtered, and concentrated in 
vacuo. Purification by silica gel flash column chromatography and when needed, sephadexTM LH-20 size exclusion 
chromatography yielded the glycosylation product as a mixture of anomers. 
General procedure for the NIS/TfOH mediated competition experiments: Donor I (0.1 mmol, 1 eq.), donor II (0.1 mmol, 
1 eq.) and acceptor 25 (0.2 mmol, 2 eq.) were together coevaporated with dry toluene (2x). Dry DCM (4 mL, donor 
concentration 0.05 M), a Teflon stirring bar and 3Å activated molecular sieves (rods, size 1/16 in.) were added and the 
mixture was stirred under a nitrogen atmosphere for 1 h at room temperature. The mixture was cooled to -40°C and 
NIS (0.1 mmol, 1 eq.) was added. TfOH (50 µL of a freshly prepared 0.2 M stock solution in dry DCM, 0.1 eq.) was 
added and the mixture was allowed to warm to 0°C in 3 hours. Et3N (0.1 mL) was added and the mixture was diluted 
with EtOAc, washed with sat. aq. NaS2O3 and brine, dried over Na2SO4 and concentrated in vacuo. Size exclusion 
chromatography (Sephadex LH-20, 1/1 DCM/MeOH) enabled isolation of the disaccharide products and the 
monosaccharide rests, which were both analysed with NMR spectroscopy. The yield of the disaccharide fraction was 
determined. For the competition between donors 4 and 5, a 0.1 M concentration, and a starting temperature of -20°C 
was used, which was allowed to warm to +15°C in 18h. 
General procedure for the low temperature NMR experiments: A mixture of donor (30 µmol) and Ph2SO (39 µmol) was 
coevaporated with dry toluene twice (for the activation of donor 1 also TTBP (75 µmol) was added). Under a nitrogen 
atmosphere, CD2Cl2 (0.6 mL) was added and the mixture transferred to a nitrogen flushed NMR tube and closed with 
a NMR tube septum. The NMR magnet was cooled to -80°C, locked and shimmed and the sample was measure prior 
to activation. In a long narrow cold bath (EtOH, -85°C) the sample was treated with Tf2O (39 µmol), shaken thrice and 
cooled again after every shake. The cold sample was wiped dry and quickly inserted back in the cold magnet. The first 
1H NMR spectrum was immediately recorded. The sample was then reshimmed and spectra were recorded in 10°C 
intervals with at least 5 min equilibration time for every temperature.  
Phenyl 2-azido-4,6-O-benzylidene-2-deoxy-1-thio-β-D-glucopyranoside (13). To a suspension 
of thioglycoside 1233 (27.14 g, 50 mmol, 1 eq.) in EtOH (200 mL) was added K2CO3 (41.5 g, 
300 mmol, 6 eq), and 20 mL H2O and the mixture was refluxed overnight. The flask was cooled 
to r.t. and to the crude free amine61 was added the diazo transfer reagent imidazole-1-sulfonyl azide hydrochloride34 
(13.10 g, 62.5 mmol, 1.25 eq.) in 3 equal portions followed by a catalytic amount of CuSO4∙5 H2O (125 mg, 0.5 mmol, 
0.01 eq.). After stirring for 5 hours, the solution was filtered and reduced to 1/4 of its volume in vacuo. H2O (150 mL) 
and 1 M aq. HCl (150 mL) were added to obtain an acidic (pH ≈ 3) solution which was extracted with EtOAc (3x 120 
mL). The combined organic layers were washed with sat. aq. NaHCO3 (150 mL) and brine (150 mL), dried with MgSO4 
and concentrated in vacuo to obtain crude azide; phenyl 2-azido-2-deoxy-1-thio-β-D-glucopyranoside.62 The crude 
azide (≤50 mmol) was coevaporated with toluene twice and subsequently dissolved in DMF (50 mL) and MeCN (200 
mL) to which benzaldehyde dimethyl acetal (15 mL, 100 mmol, 2 eq.) and p-TsOH∙H2O (950 mg, 5 mmol, 0.1 eq.) were 
added. The reaction mixture was heated at 60°C overnight, followed by an additional 5 hours of heating at 60°C under 
reduced pressure (300 mbar) to reduce the volume to 1/3. The reaction was quench by the addition of triethylamine 
(1 mL), and diluted with EtOAc (350 mL), washed with H2O (2x 100 mL), sat. aq. NaHCO3 (1x 100 mL), and brine (1x 
100 mL). The organic layer was dried (MgSO4) and concentrated in vacuo. The crude mixture was purified by 
percipitation from hot EtOAc (100 mL) / heptane (300 mL) by adding petroleum ether (500 mL) while stirring and 
slowly cooling to 0°C to obtain the title compound as a white powder (11.38 g, 29.5 mmol, 59%). The mother liquors 
were purified by flash column chromatography (8/1 to 4/1 pentane/EtOAc) to obtain an additional batch of white solid 
product (3.8 g, 9.6 mmol, total yield = 39.1 mmol, 78%, 3 steps). A purified sample could be recrystallized from either 
hot MeOH or EtOAc/petroleum ether to obtain white cotton like needles. Rf: 0.50 (6/1 pentane/EtOAc). Spectroscopic 
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data were in accord with those previously reported.31 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC): δ 7.64 – 7.52 (m, 
2H, CHarom), 7.50 – 7.43 (m, 2H, CHarom), 7.42 – 7.32 (m, 6H, CHarom), 5.53 (s, 1H, CHPh), 4.54 (d, 1H, J = 10.1 Hz, H-1), 
4.38 (dd, 1H, J = 10.5, 4.6 Hz, H-6), 3.85 – 3.70 (m, 2H, H-3, H-6), 3.52 – 3.40 (m, 2H, H-4, H-5), 3.35 (dd, 1H, J = 10.2, 
9.0 Hz, H-6), 2.75 (bs, 1H, 3-OH); 13C-APT NMR (CDCl3, 101 MHz, HSQC): δ 136.8 (Cq CHPh), 133.8 (CHarom), 130.9 (Cq 
SPh), 129.6, 129.3, 128.8, 128.5, 126.4 (CHarom), 102.1 (CHPh), 86.9 (C-1), 80.3 (C-4), 74.2 (C-3), 70.4 (C-5), 68.5 (C-6), 
65.2 (C-2); HRMS: [M+H]+ calcd for C19H20N3O4S 386.11690, found 386.11708. 
Phenyl 2-azido-2-deoxy-4,6-O-di-tert-butylsilylidene-1-thio-β-D-glucopyranoside (14). Crude 
triol phenyl 2-azido-2-deoxy-1-thio-β-D-glucopyranoside (synthesized as described for 
compound 13) (≤10 mmol) was dissolved in pyridine (15 mL) and cooled to 0°C. Di-tert-
butylsilyl bis(trifluoromethanesulfonate) (3.6 mL, 11 mmol, 1.1 eq.) was slowly added and 
the reaction was stirred for 1 h before being quenched with MeOH. The reaction mixture 
was diluted with 200 mL Et2O and washed with 1M aq. HCl (3x 60 mL), sat. aq. NaHCO3 (60 mL), and brine (60 mL). 
The organic layer was dried with Na2SO4, filtered and concentrated in vacuo. Purification by flash column 
chromatography (1-10% Et2O/pentane) afforded the silylidene protected title compound as a colorless oil (3.10 g, 7.1 
mmol, 71% over three steps). Rf: 0.18 (19/1 pentane/Et2O). [α]  = -42.6° (c = 1.0, CHCl3); IR (neat): 652, 733, 824, 
1072, 1092, 1155, 1277, 1474, 2112, 2859, 2884, 2934, 2963, 3449; 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC) δ 7.57 
– 7.51 (m, 2H, CHarom), 7.36 – 7.31 (m, 3H, CHarom), 4.49 (d, 1H, J = 10.2 Hz, H-1), 4.21 (dd, 1H, J = 10.2, 5.1 Hz, H-
6), 3.89 (t, 1H, J = 10.2 Hz, H-6), 3.64 (t, 1H, J = 9.1 Hz, H-4), 3.56 (td, 1H, J = 9.0, 1.2 Hz, H-3), 3.40 (ddd, 1H, J = 10.1, 
9.3, 5.1 Hz, H-5), 3.31 (dd, 1H, J = 10.2, 9.1 Hz, H-2), 2.92 (d, 1H, J = 1.6 Hz, 3-OH), 1.04 (s, 9H, CH3 tBu), 0.97 (s, 9H, 
CH3 tBu); 13C-APT NMR (CDCl3, 101 MHz, HSQC): δ 133.7 (CHarom), 131.2 (Cq), 129.2, 128.7 (CHarom), 86.8 (C-1), 77.4 (C-
3), 76.6 (C-4), 74.4 (C-5), 66.0 (C-6), 64.4 (C-2), 27.5, 27.0 (CH3 tBu), 22.8, 20.0 (Cq tBu); HRMS: [M-N2+H]+ calcd for 
C20H32NO4SSi 410.18213, found 410.18220. 
Phenyl 2-azido-3-O-benzyl-2-deoxy-4,6-O-di-tert-butylsilylidene-1-thio-β-D-glucopyranoside 
(2). Compound 14 (1.4 g, 3.2 mmol) was dissolved in DMF (15 mL) and cooled to 0°C. Benzyl 
bromide (421 µL, 3.52 mmol, 1.1 eq.) and NaH (60% dispersion in mineral oil, 166 mg, 4.16 
mmol, 1.3 eq.) were added and the reaction was stirred for 2 h at 0°C and 1 h at r.t. The 
reaction mixture was quenched with MeOH and H2O (100 mL) was added. The water phase 
was extracted three times with 30 mL Et2O and the combined organic layers were washed with brine (2x), dried with 
Na2SO4 and concentrated under reduced pressure. Purification by flash column chromatography (1%-8% 
Et2O/pentane) yielded compound 2 as a colorless oil (1.35 g, 2.56 mmol, 80%). Additional impurities as observed by 
1H NMR originating from the previous crude steps could be removed by size exclusion chromatography (SephadexTM 
LH-20, 1/1 DCM/MeOH). Rf: 0.51 (19/1 pentane/Et2O). [α]  = -85.0° (c = 1.0, CHCl3); IR (neat): 654, 694, 746, 766, 
826, 1059, 1078, 1099, 1159, 1474, 2110, 2859, 2884, 2934, 2963; 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC): δ 7.55 
– 7.48 (m, 2H, CHarom), 7.43 – 7.37 (m, 2H, CHarom), 7.36 – 7.27 (m, 6H, CHarom), 4.99 (d, 1H, J = 10.7 Hz, CHH Bn), 
4.81 (d, 1H, J = 10.7 Hz, CHH Bn), 4.41 (d, 1H, J = 10.2 Hz, H-1), 4.21 (dd, 1H, J = 10.3, 5.1 Hz, H-6), 3.90 (t, 1H, J = 10.2 
Hz, H-6), 3.87 (dd, 1H, J = 9.5, 8.7 Hz, H-4), 3.48 – 3.38 (m, 2H, H-3, H-5), 3.28 (dd, 1H, J = 10.2, 9.2 Hz, H-2), 1.07 (s, 
9H, CH3 tBu), 1.01 (s, 9H, CH3 tBu); 13C-APT NMR (CDCl3, 101 MHz, HSQC): δ 137.9 (Cq Bn), 133.9 (CHarom), 130.9 (Cq 
SPh), 129.1, 128.7, 128.5, 128.5, 128.1 (CHarom), 86.4 (C-1), 84.2 (C-3), 77.8 (C-4), 75.7 (CH2 Bn), 74.7 (C-5), 66.2 (C-6), 
64.2 (C-2), 27.5, 27.1 (CH3 tBu), 22.7, 20.0 (CH3 tBu); HRMS: [M+H]+ calcd for C27H38N3O4SSi 528.23468, found 
528.23451. and [M-N2+H]+ calcd for C27H38NO4SSi 500.22853, found 500.22839. 
Phenyl 2-azido-3-O-benzyl-4,6-O-benzylidene-2-deoxy-1-thio-β-D-glucopyranoside (3). 
Compound 13 (4.36 g, 11.3 mmol) was coevaporated once with dry toluene and then 
dissolved in DMF (50 mL) and cooled to 0°C. Benzyl bromide (1.9 mL, 15.8 mmol, 1.4 eq.) and 
NaH (60% dispersion in mineral oil, 900 mg, 22.6 mmol, 2 eq.) were added in succession and the reaction mixture was 
stirred at r.t. for 4.5 h. MeOH (5 mL) was slowly added and the reaction mixture was diluted with EtOAc (150 mL) and 
washed with H2O (2x 60 mL) and brine (50 mL). The organic layer was dried (MgSO4), filtered, and concentrated in 
vacuo. The crude product was purified by crystallization (10 mL hot EtOAc, addition of 100 mL petroleum ether) to 
yield the title compound as a white cotton like solid (4.79 g, 10.1 mmol, 89%). Rf: 0.71 (8/1 pentane/EtOAc). 
Spectroscopic data were in accord with those previously reported.31 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC): δ 
7.56 (ddt, 2H, J = 5.0, 3.4, 1.5 Hz, CHarom), 7.47 (dd, 2H, J = 7.5, 2.3 Hz, CHarom), 7.42 – 7.26 (m, 11H, CHarom), 5.57 (s, 
1H, CHPh), 4.91 (d, 1H, J = 10.9 Hz, CHH Bn), 4.78 (d, 1H, J = 10.9 Hz, CHH Bn), 4.49 (d, 1H, J = 10.2 Hz, H-1), 4.39 (dd, 
1H, J = 10.6, 5.0 Hz, H-6), 3.79 (t, 1H, J = 10.3 Hz, H-6), 3.71 – 3.59 (m, 2H, H-3, H-4), 3.52 – 3.42 (m, 1H, H-5), 3.41 – 




129.2, 128.8, 128.5, 128.4, 128.4, 128.1, 126.0 (CHarom), 101.3 (CHPh), 86.5 (C-1), 81.3, 81.0 (C-3, C-4), 75.3 (CH2 Bn), 
70.5 (C-5), 68.5 (C-6), 64.6 (C-2); HRMS: [M+H]+ calcd for C26H26N3O4S 476.16385, found 476.16375. 
Phenyl 2-azido-3-O-benzoyl-4,6-O-benzylidene-2-deoxy-1-thio-β-D-glucopyranoside (4). To a 
0°C solution of compound 13 (1.34 g, 3.48 mmol) in DCM (17 mL) and pyridine (1.4 mL, 34.8 
mmol, 5 eq.) was added benzoyl chloride (0.61 mL, 5.22 mmol, 1.5 eq.) and DMAP (42 mg, 
0.35 mmol, 0.1 eq.). The reaction mixture was allowed to stir overnight after which H2O and DCM were added. The 
organic layer was separated and washed with sat. aq. NaHCO3 and brine. The organic layer was dried with MgSO4 and 
concentrated in vacuo. Flash column chromatography (19/1 to 8/1 pentane/EtOAc) afforded the title compound as a 
white solid (1.54 g, 3.15 mmol, 90%). The product could be recrystallized from EtOAc and petroleum ether to obtain 
a fluffy white solid. Rf: 0.53 (8/1 pentane/EtOAc). Spectroscopic data were in accord with those previously reported.63 
1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC): δ 8.05 (d, 2H, J = 7.3 Hz, CHarom), 7.59 (dd, 2H, J = 6.5, 3.1 Hz, CHarom), 7.53 
(t, 1H, J = 7.4 Hz, CHarom), 7.44 – 7.33 (m, 7H, CHarom), 7.29 – 7.23 (m, 3H, CHarom), 5.52 (t, 1H, J = 9.6 Hz, H-3), 5.46 (s, 
1H, CHPh), 4.69 (d, 1H, J = 10.1 Hz, H-1), 4.38 (dd, 1H, J = 10.5, 4.9 Hz, H-6), 3.79 (t, 1H, J = 10.2 Hz, H-6), 3.71 (t, 1H, J 
= 9.5 Hz, H-4), 3.62 – 3.53 (m, 2H, H-2, H-5); 13C-APT NMR (CDCl3, 101 MHz, HSQC): δ 165.3 (C=O Bz), 136.7 (Cq), 133.7, 
133.4 (CHarom), 130.8 (Cq), 129.9, 129.3 (CHarom), 129.2 (Cq), 129.1, 128.8, 128.5, 128.2, 126.1 (CHarom), 101.3 (CHPh), 
87.1 (C-1), 78.4 (C-4), 73.5 (C-3), 70.7 (C-5), 68.3 (C-6), 63.9 (C-2); HRMS: [M+H]+ calcd for C26H24N3O5S 490.14312, 
found 490.14305. 
Phenyl 2-amino-3-O-benzyl-4,6-O-benzylidene-2-deoxy-1-thio-β-D-glucopyranoside (16). Fully 
protected glycoside 1535 (9.11 g, 15.7 mmol) was dissolved in 160 ml EtOH and heated to 
reflux upon which ethylene diamine (52 mL, 785 mmol, 50 eq.) was added in three portions 
and reflux was maintained overnight. The reaction mixture was concentrated under reduced pressure and mixed with 
toluene (100 mL) and 45 g of silica gel, and the mixture evaporated to dryness. Column chromatography (8/2 to 2/1 
pentane/EtOAc) gave the free amine as a white solid (6.19 g, 13.76 mmol, 88%) which could be recrystallized in 
EtOAc/petroleum ether. Rf: 0.40 (2/1 pentane/EtOAc). m.p. 136.1-137.5 °C. [α]  = -33.5° (c = 0.57, CHCl3); IR (thin 
film): 698, 748, 1026, 1069, 1123, 1371, 1452, 1583, 2870, 3030, 3059; 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC): δ 
7.56 – 7.44 (m, 4H, CHarom), 7.42 – 7.24 (m, 11H, CHarom), 5.59 (s, 1H, CHPh), 4.99 (d, 1H, J = 11.3 Hz, CHH Bn), 4.68 (d, 
1H, J = 11.2 Hz, CHH Bn), 4.58 (d, 1H, J = 9.9 Hz, H-1), 4.38 (dd, 1H, J = 10.5, 5.0 Hz, H-6), 3.81 (t, 1H, J = 10.3 Hz, H-6), 
3.72 (t, 1H, J = 9.2 Hz, H-4), 3.59 (t, 1H, J = 9.0 Hz, H-3), 3.52 (td, 1H, J = 9.7, 4.9 Hz, H-5), 2.91 (t, 1H, J = 9.4 Hz, H-2), 
1.75 (bs, 2H, NH2); 13C-APT NMR (CDCl3, 101 MHz, HSQC): δ 138.2, 137.4 (Cq), 133.0 (CHarom), 131.8 (Cq SPh), 129.1, 
128.6, 128.4, 128.3, 128.3, 128.0, 126.0 (CHarom), 101.3 (CHPh), 89.6 (C-1), 82.2, 82.2 (C-3, C-4), 75.1 (CH2 Bn), 70.7 
(C-5), 68.8 (C-6), 55.5 (C-2); HRMS: [M+H]+ calcd for C26H28NO4S 450.17336, found 450.17238. 
1-(4-nitrophenyl)-4-pyridone (17). Following the procedure of You and Twieg64 4-
hydroxypyridine (14.3 g, 150 mmol), 4-chloronitrobenzene (22.9 g, 145 mmol) and K2CO3 
(20.7 g, 150 mmol) were suspended in N-methyl-2-pyrrolidone (110 mL) and heated at 150°C for 2 h. The hot solution 
was then poured directly onto ice and allowed to precipitate until all the ice had melted. The suspension was then 
filtered and washed four times with cold H2O. The resulting solid was dried under vacuum at 100°C until dry. Yield: 
26.6 g, 123 mmol, 85%. IR (neat): 606, 692, 741, 752, 843, 1015, 1111, 1198, 1285, 1339, 1495, 1514, 1582, 1638, 
3071; 1H NMR (DMSO, 400 MHz, HH-COSY, HSQC): δ 8.38 (d, 2H, J = 9.1 Hz), 8.14 (d, 2H, J = 7.8 Hz), 7.86 (d, 2H, J = 
9.1 Hz), 6.29 (d, 2H, J = 7.8 Hz); 13C-APT NMR (DMSO, 101 MHz, HSQC): δ 177.6, 147.1, 145.9, 139.2, 125.3, 123.2, 
118.3; HRMS: [M+H]+ calcd for C11H9N2O3 217.06077, found 217.06074. 
3,5-dinitro-1-(4-nitrophenyl)-4-pyridone (18). Modification of the procedure from 
Matsumura et al.30, an ice cooled three-neck flask equipped with a condenser was charged 
with 120 mL H2SO4 (30% SO3) followed by the slow addition of 120 mL fuming 99% HNO3. 
To the cold mixture pyridone 17 (21.6 g, 100 mmol) was added in small portions. When 
addition was complete the mixture was slowly brought to 130°C and stirred for 40 h. The cooled down mixture was 
then poured over ice, stirred for 3 h, filtered, and washed three times with cold water. Yield: 18.4 g, 60 mmol, 60%. 
Purity (NMR): 90%. Tetra-nitro (3,5-dinitro-1-(2,4-dinitrophenyl)-4-pyridone 1H NMR (DMSO, 400 MHz): δ 9.42 (s, 2H), 
9.05 (d, 1H, J = 2.6 Hz), 8.87 (dd, 1H, J = 8.8, 2.6 Hz), 8.32 (d, 1H, J = 8.7 Hz)) and di-nitro (3-nitro-1-(4-nitrophenyl)-4-
pyridone 1H NMR (DMSO, 400 MHz): δ 9.18 (d, 1H, J = 2.5 Hz), 8.43 (d, 2H, J = 9.0 Hz), 8.26 (dd, 1H, J = 7.8, 2.5 Hz), 
7.99 (d, 2H, J = 9.1 Hz), 6.68 (d, 1H, J = 7.9 Hz)) impurities are present (ratios vary slightly upon repetition). IR (neat): 
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1H), 8.47 (d, 1H, J = 9.0 Hz), 8.05 (d, 1H, J = 9.1 Hz); 13C-APT NMR (DMSO, 101 MHz): δ 159.3, 147.6, 145.5, 142.1, 
141.6, 125.7, 125.1; HRMS: [M+H]+ calcd for C11H7N4O7 307.03093, found 307.03123. 
Phenyl 2-(3,5-dinitro-4-pyridone)-3-O-benzyl-4,6-O-benzylidene-2-deoxy-1-thio-β-D-
glucopyranoside (5). Free amine 16 (3.6 g, 8 mmol) and reagent 18 (2.7 g, 8.8 mmol, 1.1 
eq.) were dissolved in pyridine (48 mL) and AcOH (4 mL) and left to stir for 30 min. The 
mixture was diluted with EtOAc and washed with 1M aq. HCl (5x) and once with sat.aq. 
NaHCO3. The organic layer was dried (MgSO4), filtered and concentrated under reduced 
pressure. Column chromatography: DCM until all the nitroanaline had been removed, then 1% to 5% acetone in DCM. 
Yield 4.84 g, 7.8 mmol (98%) as a yellow solid. Rf: 0.21 (DCM), [α]  = 10.5° (c = 0.5, CHCl3); IR (thin film): 604, 696, 
746, 989, 1055, 1094, 1211, 1300, 1329, 1516, 1674, 2856, 2926, 3034, 3059; 1H NMR (Acetone-d6, 400 MHz, HH-
COSY, HSQC): δ 8.74 (s, 2H, CH pyridone), 7.63 – 7.54 (m, 2H, CHarom), 7.51 – 7.39 (m, 5H, CHarom), 7.39 – 7.31 (m, 3H, 
CHarom), 7.21 – 7.14 (m, 3H, CHarom), 7.14 – 7.07 (m, 2H, CHarom), 5.84 (s, 1H, CHPh), 5.73 (d, 1H, J = 10.4 Hz, H-1), 4.84 
(d, 1H, J = 12.1 Hz, CHH Bn), 4.62 (d, 1H, J = 12.1 Hz, CHH Bn), 4.55 – 4.47 (m, 1H, H-3), 4.44 – 4.39 (m, 1H, H-6), 4.39 
(t, 1H, J = 8.9 Hz, H-2), 4.06 – 3.91 (m, 3H, H-4, H-5, H-6); 13C-APT NMR (Acetone-d6, 101 MHz, HSQC): δ 159.9 (C=O 
pyridone), 143.1 (Cq NO2), 138.5, 137.8 (Cq), 133.4 (CHarom), 131.7 (Cq SPh), 130.3, 129.7, 129.5, 129.2, 129.0, 129.0, 
127.0 (CHarom), 102.0 (CHPh), 85.9 (C-1), 83.0 (C-4), 77.0 (C-3), 74.7 (CH2 Bn), 71.6 (C-2), 70.9 (C-5), 68.8 (C-6); HRMS: 
[M+H]+ calcd for C31H28N3O9S 618.15408 found 618.15375. 
Trifluoromethanesulfonyl 2,3-di-O-benzyl-4,6-O-benzylidene-α-D-glucopyranoside (19).9 1H NMR 
(CD2Cl2, T = 213 K,  400 MHz, HH-COSY, HSQC): δ 6.08 (d, 1H, J = 3.5 Hz, H-1), 5.59 (s, 1H, CHPh), 
4.89 (d, 1H, J = 11.0 Hz, CHH Bn), 4.85 – 4.69 (m, 3H, CHH Bn, CH2 Bn), 4.29 (dd, 1H, J = 10.3, 4.8 
Hz, H-6), 4.09 – 3.94 (m, 2H, H-3, H-5), 3.86 – 3.70 (m, 3H, H-2, H-4, H-6); 13C-APT NMR (CD2Cl2, T = 213 K, 101 MHz, 
HSQC): δ 106.1 (C-1), 100.8 (CHPh), 79.6 (C-4), 77.0 (C-3), 76.3 (C-2), 75.0, 74.1 (CH2 Bn), 67.4 (C-6), 65.8 (C-5). 
Trifluoromethanesulfonyl 2-azido-3-O-benzyl-4,6-O-benzylidene-2-deoxy-α-D-glucopyranoside 
(20). 1H NMR (CD2Cl2, T = 243 K, 400 MHz, HH-COSY, HSQC): δ 6.08 (d, 1H, J = 3.5 Hz, H-1), 5.64 
(s, 1H, CHPh), 4.98 (d, 1H, J = 10.6 Hz, CHH Bn), 4.78 (d, 1H, J = 10.6 Hz, CHH Bn), 4.32 (dd, 1H, 
J = 10.4, 4.9 Hz, H-6), 4.11 – 4.00 (m, 2H, H-3, H-5), 3.94 – 3.86 (m, 2H, H-2, H-4), 3.82 (t, 1H, J 
= 10.3 Hz, H-6); 13C-APT NMR (CD2Cl2, T = 243 K, 101 MHz, HSQC): δ 137.2, 136.7 (Cq), 130.5, 
128.4, 128.4, 125.9 (CHarom), 105.0 (C-1), 101.3 (CHPh), 80.6 (C-4), 76.4 (C-3), 75.3 (CH2 Bn), 67.6 (C-6), 66.2 (C-5), 61.4 
(C-2). 
Trifluoromethanesulfonyl 2-azido-3-O-benzoyl-4,6-O-benzylidene-2-deoxy-α-D-glucopyranoside 
(21). 1H NMR (CD2Cl2, T = 243 K , 400 MHz, HH-COSY, HSQC): δ 6.23 (d, 1H, J = 3.5 Hz, H-1), 5.80 
(t, 1H, J = 10.0 Hz, H-3), 5.54 (s, 1H, CHPh), 4.36 (dd, 1H, J = 10.4, 4.9 Hz, H-6), 4.21 (td, 1H, J = 
9.9, 4.9 Hz, H-5), 4.12 (dd, 1H, J = 10.2, 3.5 Hz, H-2), 3.98 (t, 1H, J = 9.8 Hz, H-4), 3.86 (t, 1H, J = 10.3 Hz, H-6); 13C-APT 
NMR (CD2Cl2, T = 243 K, 101 MHz, HSQC): δ 104.5 (C-1), 101.8 (CHPh), 77.5 (C-4), 69.3 (C-3), 67.6 (C-6), 66.4 (C-5), 
60.9 (C-2). 
Trifluoromethanesulfonyl 2-azido-3-O-benzyl-2-deoxy-4,6-O-di-tert-butylsilylidene-α-D-
glucopyranoside (22). 1H NMR (CD2Cl2, T = 233 K, 400 MHz, HH-COSY, HSQC, HMBC): δ 6.00 (d, 
1H, J = 3.4 Hz, H-1), 5.08 (d, 1H, J = 10.1 Hz, CHH Bn), 4.81 (d, 1H, J = 10.2 Hz, CHH Bn), 4.15 – 
4.06 (m, 2H, H-4, H-6), 3.95 – 3.84 (m, 3H, H-3, H-5, H-6), 3.79 (dd, 1H, J = 10.1, 3.4 Hz, H-2), 1.07 (s, 9H, CH3 tBu), 1.00 
(s, 9H, CH3 tBu); 13C-APT NMR (CD2Cl2, T = 233 K, 101 MHz, HSQC, HMBC): δ 118.9 (q, J = 317.6 Hz, CF3), 104.8 (C-1), 
78.8 (C-3), 76.9 (C-4), 75.7 (CH2 Bn), 70.0 (C-5), 65.3 (C-6), 60.6 (C-2), 27.0, 26.4 (CH3 tBu), 22.5, 19.7 (Cq tBu); 13C-
HMBC NMR (CD2Cl2, 101 MHz): δ 104.8 (JC1-H1 = 187 Hz, C-1). 
3-O-benzyl-4,6-O-benzylidene-2-deoxy-2-(3,5-dinitro-4-pyridone)-D-glucal (24). Off-white 
solid. Rf: 0.20 (7/3 pentane/EtOAc). [α]  = +85.9° (c = 0.32, DCM); IR (thin film): 698, 720, 
753, 1007, 1059, 1095, 1192, 1247, 1304, 1351, 1516, 1679, 2880, 2924, 3072; 1H NMR 
(Acetone-d6, 500 MHz, HH-COSY, HSQC): δ 8.72 (s, 2H, CH pyridone), 7.62 – 7.53 (m, 2H, 
CHarom), 7.49 – 7.37 (m, 4H, CHarom, H-1), 7.29 – 7.14 (m, 5H, CHarom), 5.88 (s, 1H, CHPh), 
4.93 – 4.88 (m, 2H, CHH Bn, H-3), 4.68 (d, 1H, J = 11.8 Hz, CHH Bn), 4.46 (dd, 1H, J = 10.5, 5.2 Hz, H-6), 4.37 (dd, 1H, J 
= 10.4, 6.9 Hz, H-4), 4.30 (td, 1H, J = 10.2, 5.1 Hz, H-5), 4.03 (t, 1H, J = 10.3 Hz, H-6); 13C-APT NMR (Acetone-d6, 101 










129.1, 129.0, 128.8, 127.0 (CHarom), 122.1 (C-2), 101.9 (CHPh), 80.2 (C-4), 74.7 (CH2 Bn), 74.6 (C-3), 70.7 (C-5), 68.2 (C-
6); HRMS: [M+H]+ calcd for C25H22N3O9 508.13506, found 508.13465. 
Ethyl 2-azido-3-O-benzyl-2-deoxy-4,6-O-di-tert-butylsilylidene-β-D-glucopyranoside (2A). 
Donor 2 and ethanol were condensed using the general procedure for Tf2O/Ph2SO 
mediated glycosylations and purified by flash column chromatography (0% to 5% Et2O in 
pentane) to yield glycosylation product 2A (30 mg, 65 µmol, 65%, α:β = <1:20) as a 
colorless oil. Rf: 0.35 (5% Et2O in pentane). [α]  = -69.6° (c = 0.5, CHCl3); IR (neat): 652, 
768, 827, 962, 1082, 1161, 1474, 2112, 2859, 2932; 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC): δ 7.46 – 7.40 (m, 2H, 
CHarom), 7.39 – 7.27 (m, 3H, CHarom), 4.99 (d, 1H, J = 11.0 Hz, CHH Bn), 4.81 (d, 1H, J = 10.9 Hz, CHH Bn), 4.31 (dd, 1H, 
J = 7.7, 1.7 Hz, H-1), 4.16 (dd, 1H, J = 10.3, 5.0 Hz, H-6), 3.98 – 3.87 (m, 3H, CHH-CH3 Et, H-4, H-6), 3.61 (dq, 1H, J = 9.5, 
7.1 Hz, CHH-CH3 Et), 3.41 – 3.28 (m, 3H, H-2, H-3, H-5), 1.26 (t, 3H, J = 7.1 Hz, CH3 Et), 1.08 (s, 9H, CH3 tBu), 1.01 (s, 
9H, CH3 tBu); 13C-APT NMR (CDCl3, 101 MHz, HSQC): δ 138.3 (Cq), 128.5, 128.4, 128.0 (CHarom), 102.1 (C-1), 82.4 (C-3), 
78.1 (C-4), 75.4 (CH2 Bn), 70.5 (C-5), 66.4 (C-6), 66.1 (CH2 Et), 65.6 (C-2), 27.6, 27.2 (CH3 tBu), 22.8, 20.1 (Cq tBu), 15.2 
(CH3 Et); HRMS: [M-N2+H]+ calcd for C23H38NO5Si 436.25138, found 436.25132. 
Cyclohexyl 2-azido-3-O-benzyl-2-deoxy-4,6-O-di-tert-butylsilylidene-β-D-
glucopyranoside (2B). Donor 2 and cyclohexanol were condensed using the general 
procedure for Tf2O/Ph2SO mediated glycosylations and purified by flash column 
chromatography (4/1 to 0/1 pentane/toluene) to yield glycosylation product 2B (40 mg, 
77 µmol, 77%, α:β = <1 : 20) as a colorless oil. Rf: 0.43 (5% Et2O in pentane). [α]  = -
44.3° (c = 1.0, CHCl3); IR (thin film): 696, 768, 827, 961, 1080, 1163, 1364, 2112, 2859, 2934; 1H NMR (CDCl3, 400 MHz, 
HH-COSY, HSQC): δ 7.45 – 7.40 (m, 2H, CHarom), 7.38 – 7.27 (m, 3H, CHarom), 4.97 (d, 1H, J = 11.1 Hz, CHH Bn), 4.81 (d, 
1H, J = 11.1 Hz, CHH Bn), 4.42 (d, 1H, J = 7.8 Hz, H-1), 4.15 (dd, 1H, J = 10.3, 5.0 Hz, H-6), 3.99 – 3.89 (m, 2H, H-3, H-
6), 3.64 (tt, 2H, J = 9.2, 3.8 Hz, CH Cy), 3.40 – 3.24 (m, 3H, H-2, H-4, H-5), 1.96 – 1.83 (m, 2H, CH2 Cy), 1.80 – 1.71 (m, 
2H, CH2 Cy), 1.55 – 1.48 (m, 1H, CH2 Cy), 1.47 – 1.37 (m, 2H, CH2 Cy), 1.34 – 1.20 (m, 3H, CH2 Cy), 1.08 (s, 9H, tBu), 
1.01 (s, 9H, tBu); 13C-APT NMR (CDCl3, 101 MHz, HSQC): δ 138.4 (Cq), 128.5, 128.3, 127.9 (CHarom), 100.7 (C-1), 82.3 
(C-4), 78.3 (CH Cy), 78.0 (C-3), 75.4 (CH2 Bn), 70.5 (C-5), 66.4 (C-6), 65.8 (C-2), 33.6, 31.7 (CH2 Cy), 27.6, 27.2 (CH3 tBu), 
25.6 (CH2 Cy), 24.1, 23.9 (Cq tBu), 22.8, 20.1 (CH2 Cy); HRMS: [M-N2+H]+ calcd for C27H44NO5Si 490.29833, found 
490.29811. 
Methyl 6-O-(2-azido-3-O-benzyl-2-deoxy-4,6-O-di-tert-butylsilylidene-α/β-ᴅ-
glucopyranosyl)-2,3,4-tri-O-benzyl-α-ᴅ-glucopyranoside (2C). Donor 2 and 
acceptor 25 were condensed using the general procedure for Tf2O/Ph2SO 
mediated glycosylations (for an additional 18 hours at -40°C) and purified by flash 
column chromatography (1/0 to 9/1 pentane/EtOAc) to yield glycosylation 
product 2C (81 mg, 92 µmol, 92%, α:β = 1:14) as a white solid. Rf: 0.42 (4/1 
pentane/EtOAc). [α]  = -18.6° (c = 1.0, CHCl3); IR (thin film): 654, 969, 735, 827, 962, 1028, 1070, 1161, 1362, 1454, 
2112, 2859, 2931; 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC, HMBC): δ 7.45 – 7.39 (m, 2H, CHarom), 7.38 – 7.25 (m, 
18H, CHarom), 4.99 (d, 1H, J = 11.0 Hz, CHH Bn), 4.98 (d, 1H, J = 10.9 Hz, CHH Bn), 4.94 (d, 1H, J = 11.1 Hz, CHH Bn), 4.85 
– 4.76 (m, 3H, CHH Bn, 2xCHH Bn), 4.66 (d, 1H, J = 11.1 Hz, CHH Bn), 4.64 (d, 1H, J = 12.1 Hz, CHH Bn), 4.60 (d, 1H, J = 
3.6 Hz, H-1), 4.17 (d, 1H, J = 7.9 Hz, H-1’), 4.15 – 4.10 (m, 1H, H-6’), 4.05 – 3.96 (m, 2H, H-3, H-6), 3.96 – 3.87 (m, 2H, 
H-4’, H-6’), 3.76 (ddd, 1H, J = 9.9, 4.2, 1.7 Hz, H-5), 3.70 (dd, 1H, J = 10.7, 4.2 Hz, H-6), 3.59 (t, 1H, J = 9.5 Hz, H-4), 3.54 
(dd, 1H, J = 9.6, 3.5 Hz, H-2), 3.40 (dd, 1H, J = 9.7, 7.9 Hz, H-2’), 3.37 – 3.26 (m, 5H, CH3 Ome, H-3’, H-5’), 1.07 (s, 9H, 
CH3 tBu), 1.01 (s, 9H, CH3 tBu); 13C-APT NMR (CDCl3, 101 MHz, HSQC, HMBC): δ 138.9, 138.6, 138.2, 138.1 (Cq), 128.6, 
128.5, 128.5, 128.4, 128.3, 128.1, 128.0, 128.0, 127.9, 127.8, 127.7 (CHarom), 102.2 (C-1’), 98.3 (C-1), 82.5 (C-3’), 82.2 
(C-3), 79.9 (C-2), 77.9 (C-4’), 77.7 (C-4), 75.9, 75.4, 75.0, 73.6 (CH2 Bn), 70.6 (C-5’), 69.7 (C-5), 68.6 (C-6), 66.3 (C-6’), 
65.6 (C-2’), 55.3 (OMe), 27.5, 27.1 (CH3 tBu), 22.8, 20.1 (Cq tBu); Diagnostic peaks α-anomer: 1H NMR (CDCl3, 400 
MHz): δ 4.87 (d, 1H, J = 3.6 Hz, H-1’), 4.52 (d, 1H, J = 3.4 Hz, H-1); 13C-APT NMR (CDCl3, 101 MHz): δ 98.1, 98.0, 68.3; 
HRMS: [M+NH4]+ calcd for C49H67N4O10Si 899.46210, found 899.46246. 
2-Fluoroethyl 2-azido-3-O-benzyl-2-deoxy-4,6-O-di-tert-butylsilylidene-α/β-D-
glucopyranoside (2D). Donor 2 and 2-fluoroethanol were condensed using the general 
procedure for Tf2O/Ph2SO mediated glycosylations and purified by flash column 
chromatography (1/0 to 0/1 pentane/toluene to 2% Et2O in toluene) to yield 
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(toluene). Reported as a 1.00 : 0.18 mixture of anomers: IR (neat): 654, 768, 827, 962, 1080, 1161, 1472, 2112, 2859, 
2932; 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC): δ 7.45 – 7.40 (m, 2.36H, CHarom), 7.39 – 7.27 (m, 3.54H, CHarom), 
5.06 (d, 0.18H, J = 10.7 Hz, CHH Bnα), 4.99 (d, 1H, J = 10.9 Hz, CHH Bnβ), 4.86 (d, 0.18H, J = 3.6 Hz, H-1α), 4.82 (d, 0.18H, 
J = 10.6 Hz, CHH Bnα), 4.82 (d, 1H, J = 10.9 Hz, CHH Bnβ), 4.71 – 4.61 (m, 1.18H, CHHFα, CHHFβ), 4.58 – 4.47 (m, 1.18H, 
CHHFα, CHHFβ), 4.37 (d, 1H, J = 7.6 Hz, H-1β), 4.17 (dd, 1H, J = 10.3, 5.1 Hz, H-6β), 4.12 – 3.78 (m, 5.26H, CH2-CH2Fα, 
CH2-CH2Fβ, H-3α, H-4α, H-4β, H-5α, H-6α, H-6α, H-6β), 3.44 – 3.29 (m, 3.18H, H-2α, H-2β, H-3β, H-5β), 1.09 (s, 1.62H, CH3 
tBuα), 1.08 (s, 9H, CH3 tBuβ), 1.03 (s, 1.62H CH3 tBuα), 1.01 (s, 9H, CH3 tBuβ); 13C-APT NMR (CDCl3, 101 MHz, HSQC): δ 
138.3 (Cq,α), 138.2 (Cq,β), 128.6 (CHarom Bnα), 128.5 (CHarom Bnβ), 128.5 (CHarom Bnα), 128.4 (CHarom Bnβ), 128.0 (CHarom 
Bnα,β), 102.4 (C-1β), 98.3 (C-1α), 82.7 (d, J = 170.0 Hz, CH2Fβ), 82.4 (d, J = 170.6 Hz, CH2Fα), 82.3 (C-3β), 79.3, 79.0 (C-3α, 
C-4α), 78.0 (C-4β), 75.6 (CH2 Bnα), 75.5 (CH2 Bnβ), 70.6 (C-5β), 69.0 (d, J = 20.3 Hz, CH2-CH2Fβ), 67.3 (d, J = 20.1 Hz, CH2-
CH2Fα), 66.8 (C-5α), 66.7 (C-6α), 66.3 (C-6β), 65.5 (C-2β), 62.5 (C-2α), 27.5, 27.1 (CH3 tBuα,β), 23.1 (Cq tBuα), 22.8 (Cq tBuβ),
20.1 (Cq tBuα), 20.1 (Cq tBuβ); HRMS: [M-N2+H]+ calcd for C23H37FNO5Si 454.24195, found 454.24188.
Methyl 4-O-(2-azido-3-O-benzyl-2-deoxy-4,6-O-di-tert-butylsilylidene-α/β-D-
glucopyranosyl)-2,3,6-tri-O-benzyl-α-ᴅ-glucopyranoside (2E). Donor 2 and acceptor 
26 were condensed using the general procedure for Tf2O/Ph2SO mediated 
glycosylations (for an additional 18 hours at -40°C) and purified by flash column 
chromatography (1/0 to 9/1 pentane/EtOAc) to yield glycosylation product 2E (72
mg, 82 µmol, 82%, α:β = 1:3) as a colorless oil. Rf: 0.23 and 0.41 (9/1 
pentane/EtOAc). IR (thin film): 654, 696, 735, 768, 827, 962, 1090, 1159, 1271, 1362, 1454, 2110, 2859, 2932; Data 
for the β-anomer: 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC, HMBC): δ 7.44 – 7.39 (m, 2H, CHarom), 7.39 – 7.21 (m, 
18H, CHarom), 4.98 (d, 1H, J = 10.8 Hz, CHH Bn), 4.83 – 4.74 (m, 4H, CHH Bn, CH2 Bn, CHH Bn), 4.68 (d, 1H, J = 11.9 Hz, 
CHH Bn), 4.62 (d, 1H, J = 12.2 Hz, CHH Bn) 4.59 (d, 1H, J = 3.6 Hz, H-1), 4.44 (d, 1H, J = 11.9 Hz, CHH Bn), 4.23 (d, 1H, J 
= 8.0 Hz, H-1’), 3.97 (dd, 1H, J = 10.6, 3.0 Hz, H-6), 3.94 – 3.73 (m, 5H, H-3, H-4, H-4’, H-5, H-6’), 3.71 – 3.66 (m, 1H, H-
6), 3.55 – 3.47 (m, 2H, H-2, H-6’), 3.38 (s, 3H, CH3 OMe), 3.27 – 3.21 (m, 1H, H-2’), 3.20 – 3.14 (m, 1H, H-3’), 3.06 (td, 
1H, J = 9.9, 5.1 Hz, H-5’), 1.06 (s, 9H, CH3 tBu), 0.97 (s, 9H, CH3 tBu); 13C-APT NMR (CDCl3, 101 MHz, HSQC, HMBC): δ 
139.4, 138.4, 138.1, 137.9 (Cq), 128.5, 128.5, 128.5, 128.4, 128.4, 128.2, 128.1, 128.0, 128.0, 127.9, 127.4, 127.3 
(CHarom), 101.0 (C-1’), 98.4 (C-1), 82.6 (C-3’), 80.2 (C-3), 79.2 (C-2), 78.1 (C-4’), 77.0 (C-4), 75.3, 75.3, 73.6, 73.6 (CH2 
Bn), 70.2 (C-5’), 69.7 (C-5), 68.3 (C-6), 66.2 (C-6’), 66.1 (C-2’), 55.4 (OMe), 27.6, 27.1 (CH3 tBu), 22.7, 20.0 (Cq tBu); 
Diagnostic peaks α-anomer: 1H NMR (CDCl3, 400 MHz): δ 5.67 (d, 1H, J = 4.0 Hz, H-1), 5.11 (d, 1H, J = 10.6 Hz, CHH Bn), 
5.06 (d, 1H, J = 10.6 Hz, CHH Bn), 4.87 (d, 1H, J = 10.6 Hz, CHH Bn), 4.79 (d, 1H, J = 10.6 Hz, CHH Bn), 4.75 (d, 1H, J = 
12.0 Hz, CHH Bn), 4.09 (t, 1H, J = 9.0 Hz, H-3), 3.56 (dd, 1H, J = 9.6, 3.5 Hz, H-2), 3.38 (s, CH3 OMe), 3.21 (dd, 1H, J = 
10.2, 4.0 Hz, H-2’), 1.06 (s, 9H, CH3 tBu), 1.04 (s, 9H, CH3 tBu); 13C-APT NMR (CDCl3, 101 MHz): δ 138.8, 138.3, 138.2, 
138.0, 128.6, 128.4, 128.3, 128.1, 128.0, 128.0, 128.0, 127.9, 127.7, 127.6, 127.4, 127.3, 97.9, 97.7 (C-1, C-1’), 82.1 
(C-3), 80.6 (C-2), 79.1, 79.0, 75.6, 75.1, 73.7, 73.4, 69.6, 69.2, 67.5, 66.5, 62.3 (C-2’), 55.4, 27.6, 27.2, 22.8, 20.1; HRMS: 
[M+NH4]+ calcd for C49H67N4O10Si 899.46210, found 899.46246. 
Methyl (methyl 4-O-[2-azido-3-O-benzyl-2-deoxy-4,6-O-di-tert-butylsilylidene-α/β-
D-glucopyranosyl]-2,3-di-O-benzyl-α-ᴅ-glucopyranosyl uronate) (2F). Donor 2 and 
acceptor 27 were condensed using the general procedure for Tf2O/Ph2SO 
mediated glycosylations (for an additional 18 hours at -40°C) and purified by flash
column chromatography (1/0 to 9/1 pentane/EtOAc) to yield glycosylation 
product 2F (69 mg, 84 µmol, 84%, α:β = 3.3:1) as a white solid. Rf: 0.36 and 0.39 
(9/1 pentane/EtOAc). IR (thin film): 654, 696, 735, 827, 1042, 1144, 1387, 1751, 2108, 2859, 2934; Data for the α-
anomer: 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC, HMBC): δ 7.43 – 7.38 (m, 2H, CHarom), 7.37 – 7.25 (m, 13H, CHarom), 
5.45 (d, 1H, J = 4.1 Hz, H-1’), 5.07 – 5.02 (m, 2H, 2xCHH Bn), 4.90 (d, 1H, J = 10.6 Hz, CHH Bn), 4.84 – 4.78 (m, 1H, CHH 
Bn), 4.75 (d, 1H, J = 12.0 Hz, CHH Bn), 4.59 (d, 1H, J = 12.2 Hz, CHH Bn), 4.57 (d, 1H, J = 3.5 Hz, H-1), 4.21 – 4.17 (m, 
1H, H-5), 4.09 – 4.01 (m, 3H, H-3, H-4, H-6’), 3.91 – 3.85 (m, 1H, H-4’), 3.83 – 3.73 (m, 5H, CH3 CO2Me, H-3’, H-6’), 3.62 
(td, 1H, J = 10.1, 5.0 Hz, H-5’), 3.58 – 3.53 (m, 1H, H-2), 3.41 (s, 3H, CH3 OMe), 3.23 (dd, 1H, J = 10.2, 4.1 Hz, H-2’), 1.07 
(s, 9H, CH3 tBu), 1.05 (s, 9H, CH3 tBu); 13C-APT NMR (CDCl3, 101 MHz, HSQC, HMBC): δ 169.2 (C=O CO2Me), 138.7, 
138.2, 137.8 (Cq), 128.7, 128.5, 128.5, 128.5, 128.3, 128.2, 128.0, 127.7, 127.6 (CHarom), 98.5, 98.4 (C-1, C-1’), 81.0 (C-
3), 79.9 (C-2), 79.0, 79.0 (C-3’, C-4’), 76.2 (C-4), 75.5, 75.4, 73.6 (CH2 Bn), 70.2 (C-5), 67.0 (C-5’), 66.4 (C-6’), 62.4 (C-
2’), 55.9 (OMe), 52.9 (CO2Me), 27.6, 27.2 (CH3 tBu), 22.9, 20.0 (Cq tBu); Diagnostic peaks β-anomer: 1H NMR (CDCl3, 
400 MHz): δ 4.98 (d, 1H, J = 10.9 Hz, CHH Bn), 4.39 (d, 1H, J = 7.7 Hz, H-1’), 4.02 – 3.96 (m, 1H), 3.82 (s, 3H, CH3 CO2Me), 
3.52 (dd, 1H, J = 9.5, 3.6 Hz, H-2), 1.05 (s, 9H, CH3 tBu), 0.97 (s, 9H, CH3, tBu); 13C-APT NMR (CDCl3, 101 MHz): δ 170.2, 























79.4, 78.8, 78.0, 75.4, 73.9, 70.4, 69.9, 66.1, 55.9, 52.8, 27.5, 27.1, 22.8, 20.0; HRMS: [M+NH4]+ calcd for C43H61N4O11Si 
837.41006, found 837.41042. 
2,2-Difluoroethyl 2-azido-3-O-benzyl-2-deoxy-4,6-O-di-tert-butylsilylidene-α/β-D-
glucopyranoside (2G). Donor 2 and 2,2-difluoroethanol were condensed using the 
general procedure for Tf2O/Ph2SO mediated glycosylations and purified by flash column 
chromatography (1/0 to 0/1 pentane/toluene to 2% Et2O in toluene) to yield 
glycosylation product 2G (38.1 mg, 76 µmol, 76%, α:β = 2.7:1) in two fractions (24.3 mg 
α only, 13.8 mg α:β = 0.3:1) as white solids. Rf: 0.43 β, 0.31 α (toluene). IR (neat): 654, 766, 826, 1070, 1474, 2108, 
2860, 2934; Data for the α-anomer: [α]  = +35.6° (c = 0.86, CHCl3); 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC): δ 
7.45 – 7.40 (m, 2H, CHarom), 7.39 – 7.27 (m, 3H, CHarom), 5.95 (tt, 1H, J = 55.2, 4.1 Hz, CHF2), 5.06 (d, 1H, J = 10.6 Hz, 
CHH Bn), 4.85 (d, 1H, J = 3.6 Hz, H-1), 4.82 (d, 1H, J = 10.7 Hz, CHH Bn), 4.13 – 4.08 (m, 1H, H-6), 3.98 – 3.92 (m, 1H, 
H-3/4), 3.92 – 3.72 (m, 5H, CH2-CHF2, H-3/4, H-5, H-6), 3.35 (dd, 1H, J = 10.1, 3.6 Hz, H-2), 1.09 (s, 9H, CH3 tBu), 1.03 
(s, 9H, CH3 tBu); 13C-APT NMR (CDCl3, 101 MHz, HSQC): δ 138.1 (Cq), 128.6, 128.5, 128.1 (CHarom), 113.8 (t, J = 241.6 
Hz, CHF2), 98.7 (C-1), 79.0, 78.9 (C-3, C-4), 75.7 (CH2 Bn), 67.3 (t, J = 28.6 Hz, CH2-CHF2), 67.1 (C-5), 66.6 (C-6), 62.4 (C-
2), 27.5, 27.1 (CH3 tBu), 22.8, 20.1 (Cq tBu); Data for the β-anomer: 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC): δ 7.44 
– 7.39 (m, 2H, CHarom), 7.38 – 7.29 (m, 3H, CHarom), 5.92 (tdd, 1H, J = 55.3, 5.1, 3.4 Hz, CHF2), 4.99 (d, 1H, J = 10.9 Hz, 
CHH Bn), 4.81 (d, 1H, J = 11.0 Hz, CHH Bn), 4.35 (s, 1H, J = 7.7 Hz, H-1), 4.17 (dd, 1H, J = 10.3, 5.0 Hz, H-6), 4.02 – 3.74 
(m, 4H, CH2-CHF2, H-4, H-6), 3.42 – 3.30 (m, 3H, H-2, H-3, H-5), 1.09 (s, 9H, CH3 tBu), 1.01 (s, 9H, CH3, tBu); 13C-APT 
NMR (CDCl3, 101 MHz, HSQC): δ 138.1 (Cq), 128.5, 128.4, 128.1 (CHarom), 114.1 (t, J = 241.4 Hz, CHF2), 102.5 (C-1), 82.2 
(C-3), 77.9 (C-4), 75.5 (CH2 Bn), 70.7 (C-5), 68.8 (dd, J = 29.3, 28.8 Hz, CH2-CHF2), 66.2 (C-6), 65.4 (C-2), 27.5, 27.1 (CH3 
tBu), 22.8, 20.1 (Cq tBu); HRMS: [M-N2+H]+ calcd for C23H36F2NO5Si 472.23253, found 472.23239. 
Methyl 4-O-(2-azido-3-O-benzyl-2-deoxy-4,6-O-di-tert-butylsilylidene-α/β-D-
glucopyranosyl)-2,3,6-tri-O-benzyl-β-ᴅ-galactopyranoside (2H). Donor 2 and 
acceptor 28 were condensed using the general procedure for Tf2O/Ph2SO 
mediated glycosylations (for an additional 18 hours at -40°C) and purified by flash 
column chromatography (1/0 to 9/1 pentane/EtOAc) to yield glycosylation 
product 2H (46 mg, 52 µmol, 52%, α:β = 7:1) as a colorless oil. Rf: 0.33 and 0.51 
(9/1 pentane/EtOAc). IR (thin film): 652, 696, 735, 826, 1001, 1036, 1206, 1364, 1454, 2108, 2859, 2932; Data for the 
α-anomer: 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC, HMBC): δ 7.46 – 7.41 (m, 2H, CHarom), 7.41 – 7.23 (m, 18H, 
CHarom), 5.10 (d, 1H, J = 10.3 Hz, CHH Bn), 4.89 – 4.81 (m, 3H, CHH Bn, 2xCHH Bn), 4.79 (d, 1H, J = 3.7 Hz, H-1’), 4.72 
(d, 1H, J = 10.6 Hz, CHH Bn), 4.68 (d, 1H, J = 13.0 Hz, CHH Bn), 4.58 – 4.44 (m, 3H, CH2 Bn, H-5’), 4.23 (d, 1H, J = 7.6 Hz, 
H-1), 4.07 – 3.99 (m, 2H, H-4, H-6), 3.99 – 3.88 (m, 3H, H-3’, H-4’, H-6’), 3.76 (t, 1H, J = 10.1 Hz, H-6’), 3.67 – 3.58 (m, 
2H, H-2, H-6), 3.56 (s, 3H, CH3 OMe), 3.48 (dd, 1H, J = 8.9, 5.5 Hz, H-5), 3.38 (dd, 1H, J = 10.0, 2.9 Hz, H-3), 3.33 (dd, 
1H, J = 9.7, 3.7 Hz, H-2’), 1.06 (s, 9H, CH3 tBu), 1.02 (s, 9H, CH3 tBu); 13C-APT NMR (CDCl3, 101 MHz, HSQC, HMBC): δ 
138.8, 138.4, 138.2, 137.7 (Cq), 128.6, 128.6, 128.5, 128.5, 128.5, 128.3, 128.2, 127.9, 127.8 (CHarom), 105.1 (C-1), 99.2 
(C-1’), 79.9, 79.9 (C-2, C-3’), 79.6, 79.4 (C-3, C-4’), 75.7, 75.6 (CH2 Bn), 75.0 (C-4), 73.6 (CH2 Bn), 72.9 (C-5), 72.6 (CH2 
Bn), 67.1, 67.0 (C-6, C-6’), 66.9 (C-5’), 63.2 (C-2’), 57.5 (OMe), 27.5, 27.3 (CH3 tBu), 22.7, 20.2 (Cq tBu); Diagnostic peaks 
β-anomer: 1H NMR (CDCl3, 400 MHz): δ 4.94 (d, 0.14H, J = 11.1 Hz, CHH Bn), 4.27 (d, 0.14H, J = 7.7 Hz, H-1), 3.22 – 
3.16 (m, 0.28H), 3.20 – 3.09 (m, 2H); 13C-APT NMR (CDCl3, 101 MHz): δ 105.1 (C-1), 102.0 (C-1’), 82.3, 78.0, 75.4, 75.3, 
73.7, 73.7, 73.5, 73.4, 70.4, 69.6, 66.4, 65.6, 57.3, 27.6, 27.2, 22.8, 20.1; HRMS: [M+NH4]+ calcd for C49H67N4O10Si 
899.46210, found 899.46243. 
Methyl 2-O-(2-azido-3-O-benzyl-2-deoxy-4,6-O-di-tert-butylsilylidene-α-D-
glucopyranosyl)-3-O-benzyl-4,6-O-benzylidene-α-ᴅ-mannopyranoside (2I). Donor 2 
and acceptor 29 were condensed using the general procedure for Tf2O/Ph2SO 
mediated glycosylations (for an additional 18 hours at -40°C) and purified by flash 
column chromatography (1/0 to 9/1 pentane/EtOAc) to yield glycosylation product 
2I (67 mg, 85 µmol, 85%, α:β = > 20:1) as a white solid. Rf: 0.54 (9/1 pentane/EtOAc). [α]  = +44.3° (c = 1.34, CHCl3); IR (thin film): 696, 827, 937, 1040, 1088, 1130, 1364, 
2108, 2859, 2957; Data for the α-anomer: 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC, HMBC): δ 7.54 – 7.47 (m, 2H, 
CHarom), 7.46 – 7.41 (m, 2H, CHarom), 7.41 – 7.22 (m, 11H, CHarom), 5.65 (s, 1H, CHPh), 5.23 (d, 1H, J = 3.6 Hz, H-1’), 5.09 
(d, 1H, J = 10.6 Hz, CHH Bn), 4.89 – 4.82 (m, 2H, CHH Bn, CHH Bn), 4.74 – 4.65 (m, 2H, CHH Bn, H-1), 4.31 – 4.21 (m, 
2H, H-4, H-6), 4.11 – 3.92 (m, 5H, H-2, H-3, H-3’, H-4’, H-6’), 3.92 – 3.76 (m, 4H, H-5, H-5’, H-6, H-6’), 3.36 (s, 3H, CH3 
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138.6, 138.4, 137.7 (Cq), 129.0, 128.5, 128.5, 128.4, 128.3, 128.3, 128.0, 127.6, 127.5, 127.4, 126.2, 126.1 (CHarom), 
101.7 (CHPh), 101.0 (C-1), 99.4 (C-1’), 79.3 (C-4), 79.1, 78.9 (C-3’, C-4’), 76.0, 75.6 (C-2, C-3), 75.6, 73.0 (CH2 Bn), 69.0 
(C-6), 67.2 (C-5’), 66.6 (C-6’), 64.1 (C-5), 62.6 (C-2’), 55.2 (CH3 OMe), 27.5, 27.2 (CH3 tBu), 22.8, 20.2 (Cq tBu); Diagnostic 
peaks β-anomer: 1H NMR (CDCl3, 400 MHz): δ 5.60 (s, 1H, CHPh), 4.98 (d, 1H, J = 11.3 Hz, CHH Bn), 4.39 (d, 1H, J = 8.2 
Hz, H-1’), 3.57 – 3.48 (m, 1H); 13C-APT NMR (CDCl3, 101 MHz): δ 101.6, 99.6, 81.8, 78.5, 77.8, 76.4, 75.2, 74.4, 72.3, 
70.9, 65.7, 55.1, 27.5, 27.1; HRMS: [M+NH4]+ calcd for C42H59N4O10Si 807.39950, found 807.39931. 
2,2,2-Trifluoroethyl 2-azido-3-O-benzyl-2-deoxy-4,6-O-di-tert-butylsilylidene-α-D-
glucopyranoside (2J). Donor 2 and 2,2,2-trifluoroethanol were condensed using the 
general procedure for Tf2O/Ph2SO mediated glycosylations (for an additional 30 min at -
40°C) and purified by flash column chromatography (1/0 to 0/1 pentane/toluene to 2% 
Et2O in toluene) to yield glycosylation product 2J (42.4 mg, 82 µmol, 82%, α:β = >20:1) as 
a colorless oil. Rf: 0.36 (toluene). [α]  = +32.6° (c = 1.0, CHCl3); IR (neat): 654, 766, 826, 1036, 1082, 1159, 1279, 1472, 
2108, 2859, 2930; 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC): δ 7.45 – 7.39 (m, 2H, CHarom), 7.38 – 7.27 (m, 3H, CHarom), 
5.07 (d, 1H, J = 10.6 Hz, CHH Bn), 4.88 (d, 1H, J = 3.6 Hz, H-1), 4.82 (d, 1H, J = 10.6 Hz, CHH Bn), 4.14 – 4.07 (m, 1H, H-
6), 4.03 – 3.93 (m, 3H, CH2-CF3, H-4), 3.92 – 3.80 (m, 3H, H-3, H-5, H-6), 3.36 (dd, 1H, J = 10.0, 3.6 Hz, H-2), 1.09 (s, 9H, 
CH3 tBu), 1.03 (s, 9H, CH3 tBu); 13C-APT NMR (CDCl3, 101 MHz, HSQC): δ 138.1 (Cq), 128.6, 128.5, 128.1 (CHarom), δ 
123.5 (q, J = 278.4 Hz, CF3), 98.8 (C-1), 78.9 (C-3), 78.8 (C-4), 75.7 (CH2 Bn), 67.4 (C-5), 66.5 (C-6), 65.2 (q, J = 35.4 Hz, 
CH2-CF3), 62.2 (C-2), 27.5, 27.1 (CH3 tBu), 22.8, 20.1 (Cq tBu); HRMS: [M-N2+H]+ calcd for C23H35F3NO5Si 490.22311, 
found 490.22292. 
1,1,1,3,3,3-Hexafluoro-2-propyl 2-azido-3-O-benzyl-2-deoxy-4,6-O-di-tert-butylsilylidene-α-
D-glucopyranoside (2K). Donor 2 and 1,1,1,3,3,3-hexafluoro-2-propanol were condensed 
using the general procedure for Tf2O/Ph2SO mediated glycosylations (for an additional 72 
hours at -40°C) and purified by flash column chromatography (4/1 to 0/1 pentane/toluene) 
to yield glycosylation product 2K (20 mg, 34 µmol, 34%, α:β = >20:1) as a white solid. Rf: 
0.38 (9/1 pentane/Et2O). [α]  = +31.2° (c = 0.50, CHCl3); IR (thin film): 689, 827, 1030, 
1098, 1221, 1288, 1368, 2112, 2860, 2934; 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC, HMBC, NOESY): δ 7.45 – 7.28 
(m, 5H, CHarom), 5.12 – 5.04 (m, 2H, CHH Bn, H-1), 4.83 (d, 1H, J = 10.5 Hz, CHH Bn), 4.40 (hept, 1H, J = 5.7 Hz, CH HFIP), 
4.09 (dd, 1H, J = 9.4, 4.0 Hz, H-6), 4.03 – 3.91 (m, 2H, H-4, H-5), 3.91 – 3.83 (m, 2H, H-3, H-6), 3.42 (dd, 1H, J = 10.2, 
3.8 Hz, H-2), 1.08 (s, 9H, CH3 tBu), 1.03 (s, 9H, CH3 tBu); 13C-APT NMR (CDCl3, 101 MHz, HSQC, HMBC): δ 138.0 (Cq), 
128.6, 128.5, 128.2 (CHarom), 100.4 (C-1), 78.7 (C-3), 78.4 (C-4), 75.8 (CH2 Bn), 73.3 (p, J = 33.2 Hz), 68.1 (C-5), 66.1 (C-
6), 61.9 (C-2), 27.5, 27.0 (CH3 tBu), 22.8, 20.1 (Cq tBu); HRMS: [M-N2+H]+ calcd for C24H34F6NO5Si 558.21050, found 
558.21009. 
Ethyl 2-azido-3-O-benzyl-4,6-O-benzylidene-2-deoxy-β-D-glucopyranoside (3A). Donor 3 and 
ethanol were condensed using the general procedure for Tf2O/Ph2SO mediated 
glycosylations and purified by flash column chromatography (1/0 to 0/1 hexane/toluene to 
5% EtOAc in toluene) to yield glycosylation product 3A (34.3 mg, 83 µmol, 83%, α:β = <1:20) as a white solid. Rf: 0.58 
(9/1 toluene/EtOAc). [α]  = -79.6° (c = 0.69, CHCl3); IR (neat): 692, 993, 1098, 1186, 1267, 1365, 1452, 2111, 2878, 
2979; 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC): δ 7.50 – 7.46 (m, 2H, CHarom), 7.41 – 7.28 (m, 8H, CHarom), 5.57 (s, 
1H, CHPh), 4.91 (d, 1H, J = 11.2 Hz, CHH Bn), 4.79 (d, 1H, J = 11.3 Hz, CHH Bn), 4.37 (d, 1H, J = 8.2 Hz, H-1), 4.34 (dd, 
1H, J = 10.6, 5.0 Hz, H-6), 3.96 (dq, 1H, J = 9.7, 7.1 Hz, CHH Et), 3.80 (t, 1H, J = 10.3 Hz, H-6), 3.70 (t, 1H, J = 9.0 Hz, H-
4), 3.66 (dq, 1H, J = 9.7, 7.2 Hz, CHH Et), 3.54 (t, 1H, J = 9.3 Hz, H-3), 3.44 (dd, 1H, J = 9.5, 8.0 Hz, H-2), 3.39 (td, 2H, J 
= 9.8, 5.0 Hz, H-5), 1.29 (t, 3H, J = 7.1 Hz, CH3 Et); 13C-APT NMR (CDCl3, 101 MHz, HSQC): δ 138.0, 137.2 (Cq), 129.2, 
128.5, 128.4, 128.3, 128.0, 126.1 (CHarom), 102.5 (C-1), 101.4 (CHPh), 81.7 (C-4), 79.1 (C-3), 75.0 (CH2 Bn), 68.7 (C-6), 
66.3 (CH2 Et), 66.3, 66.2 (C-2, C-5), 15.2 (CH3 Et); 13C-HMBC-GATED NMR (CDCl3, 101 MHz): δ 102.5 (JC1,H1 = 161 Hz, C-
1); HRMS: [M+NH4]+ calcd for C22H29N4O5 429.21325, found 429.21321. 
Cyclohexyl 2-azido-3-O-benzyl-4,6-O-benzylidene-2-deoxy-β-D-glucopyranoside (3B). 
Donor 3 and cyclohexanol were condensed using the general procedure for Tf2O/Ph2SO 
mediated glycosylations and purified by flash column chromatography (1/1 to 0/1 
hexane/toluene to 5% EtOAc in toluene) to yield glycosylation product 3B (43 mg, 93 
µmol, 93%, α:β = <1:20) as a white solid. Rf: 0.23 (toluene). [α]  = -60.5° (c = 0.86, DCM); IR (neat): 696, 748, 998, 
1092, 1275, 1365, 1452, 2108, 2858, 2933; Data for the β-anomer: 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC): δ 7.50 




= 11.4 Hz, CHH Bn), 4.47 (d, 1H, J = 7.8 Hz, H-1), 4.32 (dd, 1H, J = 10.5, 5.0 Hz, H-6), 3.79 (t, 1H, J = 10.3 Hz, H-6), 3.74 
– 3.64 (m, 2H, H-4, CH Cyc), 3.50 (t, 1H, J = 9.2 Hz, H-3), 3.44 (dd, 1H, J = 9.6, 7.8 Hz, H-2), 3.36 (td, 1H, J = 9.7, 5.0 Hz, 
H-5), 1.99 – 1.87 (m, 2H, CH2 Cyc), 1.82 – 1.72 (m, 2H, J = 15.2, 4.4 Hz, CH2 Cyc), 1.56 – 1.37 (m, 3H, CH2 Cyc), 1.36 – 
1.20 (m, 3H, CH2 Cyc); 13C-APT NMR (CDCl3, 101 MHz, HSQC): δ 138.0, 137.3 (Cq), 129.1, 128.5, 128.4, 128.3, 127.9, 
126.1 (CHarom), 101.4 (CHPh), 101.0 (C-1), 81.6 (C-4), 79.0 (C-3), 78.5 (CH Cyc), 75.0 (CH2 Bn), 68.8 (C-6), 66.5 (C-2), 
66.3 (C-5), 33.6, 31.8, 25.6, 24.1, 23.9 (CH2 Cyc); Diagnostic peaks α-anomer: 1H NMR (CDCl3, 400 MHz): δ 5.59 (s, 
0.04H, CHPh), 5.03 (d, 0.04H, J = 3.7 Hz, H-1), 4.12 (t, 0.04H, J = 9.5 Hz, H-3), 4.00 (td, 0.04H, J = 9.9, 4.8 Hz, H-5), 3.28 
(dd, 0.04H, J = 10.0, 3.7 Hz, H-2); 13C-APT NMR (CDCl3, 101 MHz): δ 101.4 (CHPh), 97.1 (C-1), 76.0 (C-3), 63.8 (C-2), 
62.9 (C-5); HRMS: [M+NH4]+ calcd for C26H35N4O5 483.26020 found 483.25991. 
Methyl 6-O-(2-azido-3-O-benzyl-4,6-O-benzylidene-2-deoxy-β-ᴅ-glucopyranosyl)-
2,3,4-tri-O-benzyl-α-ᴅ-glucopyranoside (3C). Donor 3 and acceptor 25 were 
condensed using the general procedure for Tf2O/Ph2SO mediated glycosylations 
(for an additional 18 h at -40°C) and purified by flash column chromatography (19/1 
to 4/1 pentane/EtOAc) to yield glycosylation product 3C (73.7 mg, 89 µmol, 89%, α:β = <1:20) as a white solid. Rf: 0.42 
(4/1 pentane/EtOAc). Spectroscopic data were in accord with those previously reported.38 [α]  = -32.2° (c = 1.0, 
CHCl3); IR (neat): 696, 737, 999, 1028, 1070, 1090, 1277, 1362, 1497, 2108, 2876, 2926; 1H NMR (CDCl3, 400 MHz, HH-
COSY, HSQC, HMBC): δ 7.47 (dd, 2H, J = 7.3, 2.5 Hz, CHarom), 7.42 – 7.25 (m, 23H, CHarom), 5.55 (s, 1H, CHPh), 4.99 (d, 
1H, J = 10.9 Hz, CHH 3-OBn), 4.95 (d, 1H, J = 11.2 Hz, CHH 4-OBn), 4.91 (d, 1H, J = 11.2 Hz, CHH 3’-OBn), 4.85 – 4.76 
(m, 3H, CHH 3-OBn, CHH 2-OBn, CHH 3’-OBn), 4.70 – 4.63 (m, 2H, CHH 4-OBn, CHH 2-OBn), 4.61 (d, 1H, J = 3.6 Hz, H-
1), 4.30 (dd, 1H, J = 10.5, 5.0 Hz, H-6’), 4.23 (d, 1H, J = 7.9 Hz, H-1’), 4.07 (d, 1H, J = 8.9 Hz, H-6), 4.00 (t, 1H, J = 9.3 Hz, 
H-3), 3.81 – 3.72 (m, 3H, H-5, H-6, H-6’), 3.69 (t, 1H, J = 9.1 Hz, H-4’), 3.60 (t, 1H, J = 9.3 Hz, H-4), 3.59 – 3.46 (m, 3H, 
H-2, H-2’, H-3’), 3.37 (s, 3H, CH3 OMe), 3.36 – 3.29 (m, 1H, H-5’); 13C-APT NMR (CDCl3, 101 MHz, HSQC, HMBC): δ 
138.8, 138.5, 138.2, 137.8, 137.2 (Cq), 129.2, 128.6, 128.5, 128.5, 128.4, 128.3, 128.3, 128.1, 128.1, 128.0, 127.9, 
127.9, 127.7, 126.1 (CHarom), 102.4 (C-1’), 101.4 (CHPh), 98.4 (C-1), 82.2 (C-3), 81.5 (C-4’), 79.8 (C-2), 79.3 (C-3’), 77.6 
(C-4), 75.9 (CH2 3-OBn), 75.0, 75.0 (CH2 3’-OBn, 4-OBn), 73.6 (CH2 2-OBn), 69.6 (C-5), 68.7, 68.6 (C-6, C-6’), 66.3 (C-5’), 
66.1 (C-2’), 55.4 (OMe); HRMS: [M+NH4]+ calcd for C48H55N4O10 847.39127, found 847.39224. 
2-Fluoroethyl 2-azido-3-O-benzyl-4,6-O-benzylidene-2-deoxy-α/β-D-glucopyranoside (3D). 
Donor 3 and 2-fluoroethanol were condensed using the general procedure for 
Tf2O/Ph2SO mediated glycosylations and purified by flash column chromatography (1/0 
to 0/1 pentane/toluene to 5% EtOAc in toluene) to yield glycosylation product 3D (38.5 mg, 90 µmol, 90%, α:β = 1:6.7) 
as a white solid. Rf: 0.40 (19/1 toluene/EtOAc). IR (neat): 696, 748, 996, 1028, 1072, 1091, 1174, 1276, 1368, 1454, 
2108, 2873, 2917; Data for the β-anomer: 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC): δ 7.50 – 7.46 (m, 2H, CHarom), 
7.41 – 7.36 (m, 5H, CHarom), 7.36 – 7.25 (m, 3H, CHarom), 5.57 (s, 1H, CHPh), 4.91 (d, 1H, J = 11.2 Hz, CHH Bn), 4.79 (d, 
1H, J = 11.3 Hz, CHH Bn), 4.69 – 4.64 (m, 1H, CHHF), 4.55 (dt, 1H, J = 4.6, 2.9 Hz, CHHF), 4.42 (d, 1H, J = 7.9 Hz, H-1), 
4.34 (dd, 1H, J = 10.5, 5.0 Hz, H-6), 4.11 (ddd, 0.5H, J = 12.2, 4.8, 2.9 Hz, CHH-CFH2), 4.03 (ddd, 0.5H, J = 12.2, 4.7, 3.0 
Hz, CHH-CFH2), 3.92 (ddd, 0.5H, J = 12.2, 5.9, 3.2 Hz, CHH-CFH2), 3.86 (ddd, 0.5H, J = 12.2, 6.0, 3.3 Hz, CHH-CFH2), 3.80 
(t, 1H, J = 10.3 Hz, H-6), 3.71 (t, 1H, J = 9.2 Hz, H-4), 3.56 (t, 1H, J = 9.2 Hz, H-3), 3.48 (dd, 1H, J = 9.5, 7.9 Hz, H-2), 3.39 
(td, 1H, J = 9.7, 4.9 Hz, H-5); 13C-APT NMR (CDCl3, 101 MHz, HSQC): δ 137.8, 137.1 (Cq), 129.2, 128.5, 128.4, 128.3, 
128.0, 126.1 (CHarom), 102.7 (C-1), 101.4 (CHPh), 82.6 (d, J = 170.1 Hz, CFH2), 81.5 (C-4), 79.0 (C-3), 75.1 (CH2 Bn), 69.3 
(d, J = 20.1 Hz, CH2-CFH2), 68.6 (C-6), 66.3 (C-5), 66.1 (C-2); 13C-HMBC-GATED NMR (CDCl3, 101 MHz): δ 102.7 (JC1,H1 = 
162 Hz, C-1); Diagnostic peaks α-anomer: 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC): δ 5.58 (s, 0.15H, CHPh), 4.96 (d, 
0.15H, J = 10.9 Hz, CHH Bn), 4.95 (d, 0.15H, J = 3.7 Hz, H-1), 4.81 (d, 0.15H, J = 11.0 Hz, CHH Bn), 4.29 (dd, 0.15H, J = 
10.2, 4.9 Hz, H-6); 13C-APT NMR (CDCl3, 101 MHz, HSQC): δ 101.5 (CHPh), 98.8 (C-1), 82.8 (C-4), 76.2 (C-3), 75.2 (CH2 
Bn), 68.9 (C-6), 63.0, 62.9 (C-2, C-5); 13C-HMBC-GATED NMR (CDCl3, 101 MHz): δ 98.8 (JC1,H1 = 172 Hz, C-1); HRMS: 
[M+NH4]+ calcd for C22H28FN4O5 447.20382 found 447.20355. 
Methyl 4-O-(2-azido-3-O-benzyl-4,6-O-benzylidene-2-deoxy-α/β-ᴅ-glucopyranosyl)-
2,3,6-tri-O-benzyl-α-ᴅ-glucopyranoside (3E). Donor 3 and acceptor 26 were 
condensed using the general procedure for Tf2O/Ph2SO mediated glycosylations 
(for an additional 18 h at -40°C) and purified by flash column chromatography (19/1 
to 4/1 pentane/EtOAc) to yield glycosylation product 3E (73.3 mg, 88 µmol, 88%, α:β = 1:7) as a white solid. Rf: 0.51 
α, 0.43 β (4/1 pentane/EtOAc). IR (neat): 696, 737, 1049, 1092, 1362, 1454, 2110, 2868; Data for the β-anomer: 1H 
NMR (CDCl3, 400 MHz, HH-COSY, HSQC, TOCSY): δ 7.68 – 7.60 (m, 2H, CHarom), 7.52 – 7.18 (m, 23H, CHarom), 5.47 (s, 
1H, CHPh), 4.89 (d, 1H, J = 11.2 Hz, CHH Bn), 4.87 (d, 1H, J = 10.9 Hz, CHH Bn), 4.81 (d, 1H, J = 10.9 Hz, CHH Bn), 4.78 
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(d, 1H, J = 12.2 Hz, CHH Bn), 4.75 (d, 1H, J = 11.2 Hz, CHH Bn), 4.71 (d, 1H, J = 12.0 Hz, CHH Bn), 4.63 (d, 1H, J = 12.1 
Hz, CHH Bn), 4.60 (d, 1H, J = 3.7 Hz, H-1), 4.41 (d, 1H, J = 12.0 Hz, CHH Bn), 4.19 (d, 1H, J = 7.6 Hz, H-1’), 4.11 (dd, 1H, 
J = 10.6, 5.0 Hz, H-6’), 4.00 – 3.90 (m, 2H, H-4, H-6), 3.85 (t, 1H, J = 9.3 Hz, H-3), 3.75 (dt, 1H, J = 9.8, 2.4 Hz, H-5), 3.69 
(dd, 1H, J = 10.8, 1.9 Hz, H-6), 3.56 (t, 1H, J = 9.0 Hz, H-4’), 3.51 (dd, 1H, J = 9.5, 3.7 Hz, H-2), 3.45 – 3.38 (m, 4H, H-6’, 
CH3 OMe), 3.36 – 3.27 (m, 2H, H-2’, H-3’), 3.00 (td, 1H, J = 9.8, 5.0 Hz, H-5’); 13C-APT NMR (CDCl3, 101 MHz, HSQC): δ 
139.3, 138.3, 137.8, 137.8, 137.3 (Cq), 131.1, 129.4, 128.6, 128.4, 128.3, 128.2, 128.2, 128.1, 128.1, 127.9, 127.9, 
127.6, 126.0, 124.8 (CHarom), 101.3, 101.2 (CHPh, C-1’), 98.4 (C-1), 81.7 (C-4’), 80.1 (C-3), 79.2 (C-3’), 79.0 (C-2), 76.9 
(C-4), 75.4, 74.7, 73.6, 73.5 (CH2 Bn), 69.7 (C-5), 68.6 (C-6’), 68.0 (C-6), 66.6 (C-2’), 65.8 (C-5’), 55.4 (OMe); Diagnostic 
peaks α-anomer: 1H NMR (CDCl3, 400 MHz): δ 5.71 (d, 1H, J = 4.0 Hz, H-1’), 5.53 (s, 1H, CHPh), 5.11 (d, 1H, J = 10.7 Hz, 
CHH Bn), 4.95 (d, 1H, J = 10.9 Hz, CHH Bn); 13C-APT NMR (CDCl3, 101 MHz): δ 98.1, 97.8, 82.7, 82.1, 80.5, 76.2, 75.1, 
73.3, 73.0, 69.4, 69.1, 68.7, 63.4, 62.9; HRMS: [M+Na]+ calcd for C48H51N3O10Na 852.34667, found 852.34668. 
Methyl (Methyl 4-O-[2-azido-3-O-benzyl-4,6-O-benzylidene-2-deoxy-α/β-ᴅ-
glucopyranosyl]-2,3-di-O-benzyl-α-ᴅ-glucopyranosyl uronate) (3F). Donor 3 and 
acceptor 27 were condensed using the general procedure for Tf2O/Ph2SO mediated 
glycosylations (for an additional 18 h at -40°C) and purified by flash column 
chromatography (19/1 to 4/1 pentane/EtOAc) to yield glycosylation product 3F (71.8 mg, 93 µmol, 93%, α:β = 1.1:1) 
as a white solid. Rf: 0.54 (4/1 pentane/EtOAc). Spectroscopic data were in accord with those previously reported.21 IR 
(neat): 696, 735, 914, 989, 1028, 1045, 1090, 1267, 1369, 1454, 1749, 2108, 2870, 2916; Reported as a 1 : 1 mixture 
of anomers: 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC, HMBC): δ 7.48 – 7.41 (m, 4H, CHarom), 7.41 – 7.24 (m, 36H, 
CHarom), 5.53 (s, 1H, CHPhα), 5.51 (d, 1H, J = 3.9 Hz, H-1’α), 5.47 (s, 1H, CHPhβ), 5.04 (d, 1H, J = 10.5 Hz, CHH Bn), 4.94 
(d, 1H, J = 11.0 Hz, CHH Bn), 4.91 – 4.82 (m, 4H, 2xCHH Bn, 2xCHH Bn), 4.81 – 4.72 (m, 4H, 2xCHH Bn, 2xCHH Bn), 4.64 
– 4.58 (m, 2H, 2xCHH Bn), 4.57 (d, 2H, J = 3.5 Hz, H-1α,β), 4.43 (d, 1H, J = 8.1 Hz, H-1’β), 4.26 (dd, 1H, J = 10.3, 4.8 Hz, 
H-6’α), 4.24 – 4.19 (m, 2H, H-5α, H-5β), 4.09 – 3.99 (m, 4H, H-3β, H-4α, H-4β, H-6’β), 3.97 (t, 1H, J = 9.5 Hz, H-3’α), 3.89 
(t, 1H, J = 9.2 Hz, H-3α), 3.82 (s, 3H, CH3 CO2Me), 3.81 (s, 3H, CH3 CO2Me), 3.72 – 3.56 (m, 4H, H-2β, H-4’α, H-4’β, H-6’α), 
3.56 – 3.46 (m, 3H, H-2α, H-3’β, H-5’α), 3.46 – 3.38 (m, 7H, 2xCH3 OMe, H-6’β), 3.36 – 3.29 (m, 2H, H-2’α, H-2’β), 3.26 
(td, 1H, J = 9.7, 5.0 Hz, H-5’β); 13C-APT NMR (CDCl3, 101 MHz, HSQC, HMBC): δ 170.0, 170.0 (C=O CO2Me), 139.1, 138.5, 
138.0, 137.9, 137.9, 137.8, 137.4, 137.2 (Cq), 129.2, 129.1, 128.7, 128.6, 128.5, 128.5, 128.4, 128.3, 128.3, 128.3, 
128.3, 128.2, 128.1, 128.0, 128.0, 127.8, 127.7, 127.5, 127.4, 126.1, 126.1 (CHarom), 102.3 (C-1’β), 101.4 (CHPhβ), 101.3 
(CHPhα), 98.9, 98.6 (C-1α, C-1β), 98.5 (C-1’ α), 82.4 (C-4’α), 81.6 (C-4’β), 81.1 (C-3β), 79.6 (C-2β, C-4β), 79.5 (C-3α), 79.4 
(C-3’β), 78.7 (C-2α), 76.3 (C-3’α), 75.6 (CH2 Bn), 75.5 (C-4α), 75.1, 75.0, 73.9, 73.7 (CH2 Bn), 70.0, 69.9 (C-5α, C-5β), 68.5, 
68.5 (C-6α, C-6β), 66.7 (C-2’β), 66.2 (C-5’β), 63.0 (C-5’α), 62.8 (C-2’α), 55.9, 55.9 (OMe), 53.0, 52.8 (CO2Me); HRMS: 
[M+NH4]+ calcd for C42H49N4O11 785.33923, found 785.34007. 
2,2-Difluoroethyl 2-azido-3-O-benzyl-4,6-O-benzylidene-2-deoxy-α/β-D-glucopyranoside 
(3G). Donor 3 and 2,2-difluoroethanol were condensed using the general procedure for 
Tf2O/Ph2SO mediated glycosylations and purified by flash column chromatography (1/0 
to 0/1 pentane/toluene to 5% EtOAc in toluene) to yield glycosylation product 3G (28.8 
mg, 64 µmol, 64%, α:β = 2.9:1) as a white solid. Rf: 0.15 and 0.18 (toluene). IR (neat): 698, 747, 998, 1070, 1093, 1372, 
1454, 2109, 2867, 2934; Reported as a 1 : 0.35 mixture of anomers: 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC): δ 
7.52 – 7.45 (m, 2.70H, CHarom), 7.43 – 7.26 (m, 10.80H, CHarom), 5.95 (tt, 1H, J = 55.2, 4.2 Hz, CF2Hα), 5.94 (tt, 0.35H, J 
= 55.3, 3.8 Hz, CF2Hβ), 5.58 (s, 1H, CHPhα), 5.57 (s, 0.35H, CHPhβ), 4.96 (d, 1H, J = 10.9 Hz, CHH Bnα), 4.93 (d, 1H, J = 
3.9 Hz, H-1α), 4.92 (d, 0.35H, J = 11.3 Hz, CHH Bnβ), 4.80 (d, 1H, J = 11.0 Hz, CHH Bnα), 4.79 (d, 0.35H, J = 11.3 Hz, CHH 
Bnβ), 4.40 (d, 0.35H, J = 7.9 Hz, H-1β), 4.34 (dd, 0.35H, J = 10.5, 5.0 Hz, H-6β), 4.29 (dd, 1H, J = 10.2, 4.8 Hz, H-6α), 4.08 
(t, 1H, J = 9.5 Hz, H-3α), 4.02 – 3.67 (m, 6.4H, H-4α, H-4β, H-5α, H-6α, H-6β, CH2-CF2Hα, CH2-CF2Hβ), 3.56 (t, 0.35H, J = 9.2 
Hz, H-3β), 3.50 – 3.35 (m, 1.70H, H-2α, H-2β, H-5β); 13C-APT NMR (CDCl3, 101 MHz, HSQC): δ 137.8, 137.8, 137.1, 137.1 
(Cq), 129.4, 129.3, 129.1, 128.6, 128.5, 128.5, 128.4, 128.1, 126.1 (CHarom), 114.0 (t, J = 241.5 Hz, CF2Hβ), 113.8 (t, J = 
241.6 Hz, CF2Hα), 102.8 (C-1β), 101.6 (CHPhα), 101.5 (CHPhβ), 99.3 (C-1α), 82.6 (C-4α), 81.4 (C-4β), 78.9 (C-3β), 76.0 (C-
3α), 75.3 (CH2 Bnα), 75.1 (CH2 Bn), 69.0 (t, J = 29.0 Hz, CH2-CF2Hβ), 68.8 (C-6), 68.5 (C-6), 67.5 (t, J = 28.7 Hz, CH2-CF2Hα), 





2,3,6-tri-O-benzyl-β-ᴅ-galactopyranoside (3H). Donor 3 and acceptor 28 were 
condensed using the general procedure for Tf2O/Ph2SO mediated glycosylations 
(for an additional 18 h at -40°C) and purified by flash column chromatography (19/1 
to 4/1 pentane/EtOAc) to yield glycosylation product 3H (62.2 mg, 75 µmol, 75%, 
α:β = 9:1) as a white solid. Rf: 0.52 (4/1 pentane/EtOAc). IR (neat): 696, 735, 995, 1030, 1072, 1090, 1368, 1454, 1497, 
2106, 2862, 2920; Data for the α-anomer: 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC, HMBC): δ 7.50 – 7.46 (m, 2H, 
CHarom), 7.42 – 7.25 (m, 23H, CHarom), 5.51 (s, 1H, CHPh), 4.98 (d, 1H, J = 10.7 Hz, CHH 3’-OBn), 4.90 (d, 1H, J = 11.0 Hz, 
CHH 2-OBn), 4.88 (d, 1H, J = 3.7 Hz, H-1’), 4.84 – 4.76 (m, 3H, CHH 2-OBn, CHH 3’-OBn, CHH 3-OBn), 4.69 (d, 1H, J = 
12.4 Hz, CHH 3-OBn), 4.59 – 4.51 (m, 2H, CH2 6-OBn), 4.30 (td, 1H, J = 10.1, 4.9 Hz, H-5’), 4.25 (d, 1H, J = 7.6 Hz, H-1), 
4.14 – 4.07 (m, 2H, H-3’, H-4), 4.03 (t, 1H, J = 8.9 Hz, H-6), 3.80 (dd, 1H, J = 10.2, 4.9 Hz, H-6’), 3.70 – 3.60 (m, 3H, H-
2, H-4’, H-6), 3.55 (s, 3H, CH3 OMe), 3.54 – 3.48 (m, 2H, H-5, H-6’), 3.44 – 3.36 (m, 2H, H-2’, H-3); 13C-APT NMR (CDCl3, 
101 MHz, HSQC, HMBC): δ 138.7, 138.3, 138.1, 137.7, 137.6 (Cq), 129.0, 128.6, 128.5, 128.5, 128.4, 128.3, 128.3, 
128.3, 128.2, 128.0, 127.7, 127.6, 126.1 (CHarom), 105.3 (C-1), 101.2 (CHPh), 99.4 (C-1’), 83.1 (C-4’), 80.1 (C-3), 78.9 
(C-2), 77.0 (C-3’), 75.3 (CH2 3’-OBn), 75.1 (CH2 2-OBn), 74.7 (C-4), 73.6 (CH2 6-OBn), 73.0 (CH2 3-OBn), 72.9 (C-5), 68.9 
(C-6’), 67.1 (C-6), 63.8 (C-2’), 62.9 (C-5’), 57.4 (OMe); Diagnostic peaks β-anomer: 1H NMR (CDCl3, 400 MHz): δ 5.54 
(s, 1H, CHPh), 3.92 (dd, 1H, J = 9.7, 7.7 Hz, H-2), 3.76 – 3.71 (m, 1H, H-6), 3.22 (td, 1H, J = 9.7, 4.8 Hz, H-5’); 13C-APT 
NMR (CDCl3, 101 MHz): δ 105.1 (C-1), 102.6 (C-1’), 101.4, 81.5, 81.3, 79.5, 79.0, 74.0, 73.4, 69.4, 68.6, 66.3, 66.0, 57.4; 
HRMS: [M+NH4]+ calcd for C48H55N4O10 847.39127, found 847.39206. 
Methyl 2-O-(2-azido-3-O-benzyl-4,6-O-benzylidene-2-deoxy-α/β-ᴅ-glucopyranosyl)-3-O-
benzyl-4,6-O-benzylidene-α-ᴅ-mannopyranoside (3I). Donor 3 and acceptor 29 were 
condensed using the general procedure for Tf2O/Ph2SO mediated glycosylations (for an 
additional 18 h at -40°C) and purified by flash column chromatography (19/1 to 4/1 
pentane/EtOAc) to yield glycosylation product 3I (54.7 mg, 74 µmol, 74%, α:β = 9:1) as a 
white solid. Rf: 0.74 (7/2 pentane/EtOAc). IR (neat): 696, 746, 997, 1036, 1074, 1090, 1128, 1371, 1454, 2106, 2862, 
2922; Data for the α-anomer: 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC, HMBC): δ 7.54 – 7.47 (m, 4H, CHarom), 7.44 
– 7.25 (m, 16H, CHarom), 5.66 (s, 1H, CHPh), 5.60 (s, 1H, CHPh’), 5.39 (d, 1H, J = 3.7 Hz, H-1’), 5.00 (d, 1H, J = 11.0 Hz, 
CHH Bn), 4.90 (d, 1H, J = 12.2 Hz, CHH Bn), 4.84 (d, 1H, J = 10.9 Hz, CHH Bn), 4.73 – 4.66 (m, 2H, H-1, CHH Bn), 4.34 – 
4.24 (m, 3H, H-4, H-6, H-6’), 4.17 (dd, 1H, J = 10.2, 9.0 Hz, H-3’), 4.09 (dd, 1H, J = 3.1, 1.7 Hz, H-2), 4.00 (dd, 1H, J = 9.9, 
3.1 Hz, H-3), 3.95 – 3.86 (m, 2H, H-5’, H-6), 3.83 – 3.70 (m, 3H, H-4’, H-5, H-6’), 3.36 (s, 3H, CH3 OMe), 3.32 (dd, 1H, J 
= 10.2, 3.8 Hz, H-2’); 13C-APT NMR (CDCl3, 101 MHz, HSQC, HMBC): δ 138.7, 138.0, 137.7, 137.2 (Cq), 129.2, 129.0, 
128.6, 128.5, 128.4, 128.3, 128.2, 128.0, 127.6, 127.4, 126.2, 126.0 (CHarom), 101.7 (CHPh), 101.5 (CHPh’), 101.0 (C-1), 
99.8 (C-1’), 82.9 (C-4’), 79.4 (C-4), 75.9 (C-3), 75.6 (C-3’), 75.5 (C-2), 75.3, 73.3 (CH2 Bn), 69.0, 68.9 (C-6, C-6’), 64.1 (C-
5), 63.3 (C-5’), 63.0 (C-2’), 55.0 (OMe); Diagnostic peaks β-anomer: 1H NMR (CDCl3, 400 MHz): δ 4.43 (d, 0.1H, J = 8.0 
Hz, H-1’), 3.62 (dd, 0.1H, J = 9.6, 8.0 Hz, H-2’), 3.51 (t, 0.1H, J = 9.3 Hz, H-4); 13C-APT NMR (CDCl3, 101 MHz): δ 102.0 
(C-1’), 78.5 (C-4), 66.4 (C-2’); HRMS: [M+NH4]+ calcd for C41H47N4O10 755.32867, found 755.32921. 
2,2,2-Trifluoroethyl 2-azido-3-O-benzyl-4,6-O-benzylidene-2-deoxy-α-D-glucopyranoside 
(3J). Donor 3 and 2,2,2-trifluoroethanol were condensed using the general procedure for 
Tf2O/Ph2SO mediated glycosylations (for an additional 1 h at -40°C) and purified by flash 
column chromatography (1/0 to 0/1 pentane/toluene to 5% EtOAc in toluene) to yield glycosylation product 3J (44 
mg, 94 µmol, 94%, α:β = >20:1) as a colorless oil. Rf: 0.24 (toluene). [α]  = +25.9° (c = 0.88, DCM); IR (neat): 697, 747, 
1001, 1034, 1090, 1165, 1279, 1373, 2108, 2865, 2934; Data for the α-anomer: 1H NMR (CDCl3, 400 MHz, HH-COSY, 
HSQC): δ 7.51 – 7.48 (m, 2H, CHarom), 7.42 – 7.28 (m, 8H, CHarom), 5.58 (s, 1H, CHPh), 4.99 – 4.94 (m, 2H, CHH Bn, H-
1), 4.80 (d, 1H, J = 10.9 Hz, CHH Bn), 4.29 (dd, 1H, J = 10.2, 4.8 Hz, H-6), 4.10 (dd, 1H, J = 10.0, 9.0 Hz, H-3), 3.98 (qd, 
2H, J = 8.5, 3.1 Hz, CH2-CF3), 3.91 (td, 1H, J = 9.9, 4.8 Hz, H-5), 3.79 – 3.70 (m, 2H, H-4, H-6), 3.43 (dd, 1H, J = 10.0, 3.7 
Hz, H-2); 13C-APT NMR (CDCl3, 101 MHz, HSQC): δ 137.8, 137.1 (Cq), 129.3, 128.6, 128.5, 128.3, 128.1, 126.1 (CHarom), 
123.5 (q, J = 278.5 Hz), 101.6 (CHPh), 99.4 (C-1), 82.5 (C-4), 75.9 (C-3), 75.3 (CH2 Bn), 68.7 (C-6), 65.4 (q, J = 35.4 Hz), 
63.5 (C-5), 62.7 (C-2); 13C-HMBC-GATED NMR (CDCl3, 101 MHz): δ 102.5 (JC1,H1 = 173 Hz, C-1); Diagnostic peaks β-
anomer: 1H NMR (CDCl3, 400 MHz): δ 4.44 (d, 0.03H, J = 7.9 Hz, H-1), 4.34 (dd, 0.03H, J = 10.8, 5.3 Hz, H-6), 3.56 (t, 
0.03H, J = 9.2 Hz), 3.48 (dd, 0.03H, J = 10.0, 7.9 Hz, H-2); 13C-HMBC-GATED NMR (CDCl3, 101 MHz): δ 102.4 (JC-H = 150 














glucopyranoside (3K). Donor 3 and 1,1,1,3,3,3-hexafluoroisopropanol were condensed 
using the general procedure for Tf2O/Ph2SO mediated glycosylations (for an additional 72 h 
at -40°C) and purified by flash column chromatography (1/0 to 9/1 pentane/EtOAc) to yield 
glycosylation product 3K (28.1 mg, 53 µmol, 53%, α:β = >20:1) as a colorless oil. [α]  = +25.8° (c = 0.5, CHCl3); IR 
(neat): 689, 748, 999, 1092, 1196, 1219, 1287, 1368, 2108, 2868, 2928; 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC): δ 
7.54 – 7.45 (m, 2H, CHarom), 7.44 – 7.27 (m, 8H, CHarom), 5.59 (s, 1H, CHPh), 5.13 (d, 1H, J = 3.9 Hz, H-1), 4.99 (d, 1H, J 
= 10.8 Hz, CHH Bn), 4.82 (d, 1H, J = 10.8 Hz, CHH Bn), 4.40 (hept, 1H, J = 5.9 Hz, CH HFIP), 4.26 (dd, 1H, J = 10.3, 4.9 
Hz, H-6), 4.10 (dd, 1H, J = 10.0, 9.1 Hz, H-3), 3.98 (td, 1H, J = 10.0, 4.9 Hz, H-5), 3.80 – 3.73 (m, 2H, H-4, H-6), 3.51 (dd, 
1H, J = 10.1, 3.9 Hz, H-2); 13C-APT NMR (CDCl3, 101 MHz, HSQC): δ 137.6, 136.9 (Cq), 129.3, 128.6, 128.5, 128.4, 128.2, 
126.1 (CHarom), 120.9 (q, J = 283 Hz, CF3), 101.6 (CHPh), 101.0 (C-1), 82.1 (C-4), 75.9 (C-3), 75.5 (CH2 Bn), 74.0, 73.7 
(hept, J = 32.8 Hz, CH HFIP), 68.3 (C-6), 64.2 (C-5), 62.5 (C-2); HRMS: [M+H]+ calcd for C23H21F6N3O5 534.14582, found 
534.14569. 
Ethyl 2-azido-3-O-benzoyl-4,6-O-benzylidene-2-deoxy-β-D-glucopyranoside (4A). Donor 4 
and ethanol were condensed using the general procedure for Tf2O/Ph2SO mediated 
glycosylations and purified by flash column chromatography (1/1/0 to 0/1/0 to 0/19/1 
pentane/toluene/EtOAc) to yield glycosylation product 4A (36 mg, 85 µmol, 85%, α:β = <1:20) as a white solid. Rf: 0.44 
(19/1 toluene/EtOAc). [α]  = -53.7° (c = 1.04, DCM); IR (thin film): 709, 1001, 1026, 1070, 1094, 1180, 1263, 1375, 
1726, 2110, 2872; Data for the β-anomer: 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC): δ 8.11 – 8.05 (m, 2H, CHarom), 
7.60 – 7.55 (m, 1H, CHarom), 7.48 – 7.43 (m, 2H, CHarom), 7.40 – 7.35 (m, 2H, CHarom), 7.32 – 7.27 (m, 3H, CHarom), 5.50 
(s, 1H, CHPh), 5.40 (t, 1H, J = 9.8 Hz, H-3), 4.59 (d, 1H, J = 7.9 Hz, H-1), 4.38 (dd, 1H, J = 10.6, 5.0 Hz, H-6), 4.02 (dq, 1H, 
J = 9.5, 7.1 Hz, CHH Et), 3.83 (t, 1H, J = 10.3 Hz, H-6), 3.80 – 3.67 (m, 2H, H-4, CHH Et), 3.64 (dd, 1H, J = 10.0, 7.9 Hz, 
H-2), 3.56 (td, 1H, J = 9.7, 5.0 Hz, H-5), 1.32 (t, 3H, J = 7.1 Hz, CH3 Et); 13C-APT NMR (CDCl3, 101 MHz, HSQC): δ 165.5 
(C=O Bz), 136.9 (Cq), 133.4, 130.1 (CHarom), 129.7 (Cq), 129.2, 128.6, 128.3, 126.2 (CHarom), 102.8 (C-1), 101.6 (CHPh), 
79.0 (C-4), 71.8 (C-3), 68.7 (C-6), 66.6, 66.6 (C-5, CH2 Et), 65.0 (C-2), 15.2 (CH3 Et); Diagnostic peaks α-anomer: 1H NMR 
(CDCl3, 400 MHz, HH-COSY, HSQC): δ 5.88 (t, 0.03H, J = 9.9 Hz, H-3), 5.53 (s, 0.03H, CHPh), 5.06 (d, 0.03H, J = 3.6 Hz, 
H-1), 4.32 (dd, 0.03H, J = 10.4, 4.9 Hz, H-6), 3.32 (dd, 0.03H, J = 10.3, 3.6 Hz, H-2); HRMS: [M+NH4]+ calcd for C22H27N4O6 
443.19251 found 443.19234. 
Cyclohexyl 2-azido-3-O-benozyl-4,6-O-benzylidene-2-deoxy-β-D-glucopyranoside (4B). 
Donor 4 and cyclohexanol were condensed using the general procedure for Tf2O/Ph2SO 
mediated glycosylations and purified by flash column chromatography (1/1/0 to 0/1/0 
to 0/19/1 pentane/toluene/EtOAc) to yield glycosylation product 4B (43.6 mg, 91 µmol, 
91%, α:β = <1:20) as a white solid. Rf: 0.18 (toluene). [α]  = -41.2° (c = 0.87, DCM); IR (thin film): 613, 708, 999, 1096, 
1263, 1730, 2110, 2859, 2934; 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC): δ 8.11 – 8.05 (m, 2H, CHarom), 7.61 – 7.54 
(m, 1H, CHarom), 7.49 – 7.42 (m, 2H, CHarom), 7.41 – 7.35 (m, 2H, CHarom), 7.31 – 7.27 (m, 3H, CHarom), 5.50 (s, 1H, CHPh), 
5.38 (t, 1H, J = 9.9 Hz, H-3), 4.70 (d, 1H, J = 7.9 Hz, H-1), 4.37 (dd, 1H, J = 10.6, 5.0 Hz, H-6), 3.89 – 3.71 (m, 3H, H-4, H-
6, CHO Cyc), 3.64 (dd, 1H, J = 10.1, 7.9 Hz, H-2), 3.55 (td, 1H, J = 9.8, 5.0 Hz, H-5), 2.04 – 1.90 (m, 2H, 2xCHH Cyc), 1.85 
– 1.73 (m, 2H, 2xCHH Cyc), 1.58 – 1.40 (m, 3H, CHH Cyc, 2xCHH Cyc), 1.39 – 1.20 (m, 3H, 3xCHH Cyc); 13C-APT NMR 
(CDCl3, 101 MHz, HSQC): δ 165.5 (C=O Bz), 136.9 (Cq), 133.4, 130.0 (CHarom), 129.7 (Cq), 129.2, 128.5, 128.3, 126.2 
(CHarom), 101.6 (CHPh), 101.2 (C-1), 79.0 (C-4), 78.8 (CH Cyc), 71.8 (C-3), 68.7 (C-6), 66.6 (C-5), 65.2 (C-2), 33.7, 31.7, 
25.6, 24.1, 23.9 (CH2 Cyc); HRMS: [M+NH4]+ calcd for C26H33N4O6 497.23946 found 497.23932. 
Methyl 6-O-(2-azido-3-O-benzoyl-4,6-O-benzylidene-2-deoxy-α/β-ᴅ-
glucopyranosyl)-2,3,4-tri-O-benzyl-α-ᴅ-glucopyranoside (4C). Donor 4 and acceptor 
25 were condensed using the general procedure for Tf2O/Ph2SO mediated 
glycosylations (for an additional 18 h at -40°C) and purified by flash column 
chromatography (19/1 to 3/1 pentane/EtOAc) to yield glycosylation product 4C (67 mg, 79 µmol, 79%, α:β = 1:14) as 
a white solid. Rf: 0.24 (4/1 pentane/EtOAc). [α]  = -17.5° (c = 1.34, CHCl3); IR (thin film): 696, 748, 1002, 1028, 1068, 
1092, 1263, 1313, 1369, 1452, 1730, 2110, 2872, 2918; Data for the β-anomer: 1H NMR (CDCl3, 400 MHz, HH-COSY, 
HSQC, HMBC): δ 8.09 – 8.04 (m, 2H, CHarom), 7.60 – 7.53 (m, 1H, CHarom), 7.48 – 7.41 (m, 2H, CHarom), 7.40 – 7.24 (m, 
20H, CHarom), 5.47 (s, 1H, CHPh), 5.42 (t, 1H, J = 9.8 Hz, H-3’), 5.00 (d, 1H, J = 10.9 Hz, CHH Bn), 4.95 (d, 1H, J = 11.1 Hz, 
CHH Bn), 4.84 (d, 1H, J = 11.0 Hz, CHH Bn), 4.80 (d, 1H, J = 12.2 Hz, CHH Bn), 4.68 – 4.63 (m, 2H, 2xCHH Bn), 4.61 (d, 
1H, J = 3.5 Hz, H-1), 4.43 (d, 1H, J = 8.0 Hz, H-1’), 4.33 (dd, 1H, J = 10.5, 5.0 Hz, H-6’), 4.12 (d, 1H, J = 9.1 Hz, H-6), 4.02 









Hz, H-4), 3.54 (dd, 1H, J = 9.7, 3.6 Hz, H-2), 3.49 (td, 1H, J = 9.8, 5.0 Hz, H-5’), 3.39 (s, 3H, CH3 OMe); 13C-APT NMR 
(CDCl3, 101 MHz, HSQC, HMBC): δ 165.4 (C=O), 138.7, 138.3, 138.2, 136.7 (CHarom), 133.5, 130.0 (CHarom), 129.4 (Cq 
Bz), 129.1, 128.6, 128.6, 128.5, 128.5, 128.3, 128.3, 128.1, 128.0, 128.0, 127.9, 127.9, 127.7, 126.1 (CHarom), 102.6 (C-
1’), 101.5 (CHPh), 98.3 (C-1), 82.1 (C-3), 79.8 (C-2), 78.7 (C-4’), 77.7 (C-4), 75.8, 75.0, 73.6 (CH2 Bn), 71.9 (C-3’), 69.7 
(C-5), 68.9 (C-6), 68.5 (C-6’), 66.6 (C-5’), 65.2 (C-2’), 55.4 (CH3 OMe); Diagnostic peaks α-anomer: 1H NMR (CDCl3, 400 
MHz): δ 5.79 (t, 0.07H, J = 9.9 Hz, H-3’), 5.50 (s, 0.07H, CHPh), 5.08 (d, 0.07H, J = 3.5 Hz, H-1’), 4.24 (dd, 0.07H, J = 10.3, 
4.8 Hz, H-6’), 3.41 (s, 0.21H, CH3 OMe); 13C-APT NMR (CDCl3, 101 MHz): δ 101.7 (CHPh), 99.3 (C-1’), 98.1 (C-1), 82.1, 
80.0, 79.7, 77.6, 75.8, 75.2, 70.0, 69.4, 67.0, 62.8, 62.1, 55.4; HRMS: [M+NH4]+ calcd for C48H53N4O11 861.37053, found 
861.37064. 
2-Fluoroethyl 2-azido-3-O-benzoyl-4,6-O-benzylidene-2-deoxy-α/β-D-glucopyranoside 
(4D). Donor 4 and 2-fluoroethanol were condensed using the general procedure for 
Tf2O/Ph2SO mediated glycosylations and purified by flash column chromatography 
(1/1/0 to 0/1/0 to 0/16/1 pentane/toluene/EtOAc) to yield glycosylation product 4D (36.6 mg, 83 µmol, 83%, α:β = 
1:6.5) as a white solid. Rf: 0.41 (19/1 toluene/EtOAc). IR (thin film): 700, 748, 879, 1001, 1026, 1070, 1093, 1179, 1261, 
1722, 2108, 2868; Data for the β-anomer: 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC): δ 8.10 – 8.05 (m, 2H, CHarom), 
7.61 – 7.54 (m, 1H, CHarom), 7.49 – 7.43 (m, 2H, CHarom), 7.41 – 7.36 (m, 2H, CHarom), 7.33 – 7.27 (m, 3H, CHarom), 5.50 
(s, 1H, CHPh), 5.41 (t, 1H, J = 9.8 Hz, H-3), 4.69 (ddt, 1H, J = 4.6, 3.2, 1.8 Hz, CHH-CH2F), 4.65 (d, 1H, J = 7.9 Hz, H-1), 
4.58 (ddt, 1H, J = 4.5, 3.3, 1.8 Hz, CHH-CH2F), 4.38 (dd, 1H, J = 10.5, 4.9 Hz, H-6), 4.14 (dddd, 1H, J = 30.3, 11.9, 4.6, 
3.1 Hz, CHHF), 3.95 (dddd, 1H, J = 27.1, 12.1, 5.5, 3.4 Hz, CHHF), 3.83 (t, 1H, J = 10.3 Hz, H-6), 3.79 (t, 1H, J = 9.5 Hz, 
H-4), 3.69 (dd, 1H, J = 10.0, 7.9 Hz, H-2), 3.57 (td, 1H, J = 9.7, 5.0 Hz, H-5); 13C-APT NMR (CDCl3, 101 MHz, HSQC): δ 
165.4 (C=O), 136.8 (Cq Ph), 133.5, 130.0 (CHarom), 129.5 (Cq Bz), 129.2, 128.6, 128.5, 128.3, 126.3, 126.2 (CHarom), 103.0 
(C-1), 101.6 (CHPh), 82.5 (d, J = 170.5 Hz, CH2F), 78.8 (C-4), 71.7 (C-3), 69.5 (d, J = 20.2 Hz, CH2-CH2F), 68.5 (C-6), 66.7 
(C-5), 64.9 (C-2); Diagnostic peaks α-anomer: 1H NMR (CDCl3, 400 MHz): δ 5.89 (t, 0.17H, J = 9.9 Hz, H-3), 5.53 (s, 
0.17H, CHPh), 5.12 (d, 0.17H, J = 3.6 Hz, H-1), 4.33 (dd, 0.17H, J = 10.4, 5.0 Hz, H-6), 3.38 (dd, 0.17H, J = 10.4, 3.6 Hz, 
H-2); 13C-APT NMR (CDCl3, 101 MHz): δ 101.8, 99.5 (C-1), 82.4 (d, J = 170.8 Hz), 79.6, 68.9, 67.8 (d, J = 20.2 Hz), 63.1, 
61.8; HRMS: [M+NH4]+ calcd for C22H26FN4O6 461.18309 found 461.18292. 
Methyl 4-O-(2-azido-3-O-benzoyl-4,6-O-benzylidene-2-deoxy-α/β-ᴅ-
glucopyranosyl)-2,3,6-tri-O-benzyl-α-ᴅ-glucopyranoside (4E). Donor 4 and acceptor 
26 were condensed using the general procedure for Tf2O/Ph2SO mediated 
glycosylations (for an additional 18 h at -40°C) and purified by flash column 
chromatography (19/1 to 4/1 pentane/EtOAc) to yield glycosylation product 4E (60 mg, 71 µmol, 71%, α:β = 1:6) as a 
white solid. Rf: 0.67 (4/1 pentane/EtOAc). IR (thin film): 696, 733, 914, 999, 1026, 1045, 1090, 1177, 1263, 1314, 1366, 
1452, 1730, 2108, 2866, 2899; Data for the β-anomer: 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC, HMBC): δ 8.10 – 
8.04 (m, 2H, CHarom), 7.61 – 7.53 (m, 1H, CHarom), 7.49 – 7.24 (m, 22H, CHarom), 5.40 (s, 1H, CHPh), 5.19 (t, 1H, J = 9.8 
Hz, H-3’), 4.90 (d, 1H, J = 10.8 Hz, CHH Bn), 4.83 (d, 1H, J = 10.8 Hz, CHH Bn), 4.81 – 4.73 (m, 2H, 2xCHH Bn), 4.67 – 
4.60 (m, 2H, CHH Bn, H-1), 4.42 (d, 1H, J = 12.0 Hz, CHH Bn), 4.31 (d, 1H, J = 8.0 Hz, H-1’), 4.17 (dd, 1H, J = 10.6, 5.0 
Hz, H-6’), 4.08 – 3.98 (t, 1H, J = 9.4 Hz, H-4), 3.96 (dd, 1H, J = 10.8, 2.4 Hz, H-6), 3.86 (t, 1H, J = 9.3 Hz, H-3), 3.79 – 3.74 
(m, 1H, H-5), 3.71 (dd, 1H, J = 10.7, 1.7 Hz, H-6), 3.61 (t, 1H, J = 9.5 Hz, H-4’), 3.54 (dd, 1H, J = 9.6, 3.7 Hz, H-2), 3.52 – 
3.45 (m, 2H, H-2’, H-6’), 3.39 (s, 3H, CH3 OMe), 3.08 (td, 1H, J = 9.7, 5.0 Hz, H-5’); 13C-APT NMR (CDCl3, 101 MHz, HSQC, 
HMBC): δ 165.3 (C=O), 139.3, 138.3, 137.6, 136.9 (Cq), 133.4, 129.9 (CHarom), 128.9 (Cq Bz), 128.6, 128.5, 128.5, 128.3, 
128.3, 128.2, 127.9, 127.8, 126.2 (CHarom), 101.5, 101.4 (CHPh, C-1’), 98.4 (C-1), 80.1 (C-3), 79.1 (C-2), 78.9 (C-4’), 76.8 
(C-4), 75.6, 73.7, 73.6 (CH2 Bn), 72.0 (C-3’), 69.7 (C-5), 68.6 (C-6’), 67.8 (C-6), 66.1 (C-5’), 65.6 (C-2’), 55.5 (OMe); 
Diagnostic peaks α-anomer: 1H NMR (CDCl3, 400 MHz): δ 5.91 (d, 0.17H, J = 3.9 Hz, H-1’), 5.80 (t, 0.17H, J = 10.0 Hz, 
H-3’), 5.47 (s, 0.17H, CHPh), 5.15 (d, 0.17H, J = 10.7 Hz, CHH Bn), 4.74 (d, 0.17H, J = 12.0 Hz, CHH Bn), 4.09 (t, 0.17H, J 
= 9.2 Hz), 3.29 (dd, 0.17H, J = 10.5, 3.9 Hz, H-2’); 13C-APT NMR (CDCl3, 101 MHz): δ 165.6, 138.6, 138.1, 137.9, 137.0, 
133.4, 130.0, 129.6, 129.0, 128.6, 128.6, 128.5, 128.4, 128.2, 128.1, 127.6, 127.6, 127.4, 101.6 (CHPh), 98.6 (C-1’), 
97.7 (C-1), 82.1, 80.7, 79.5, 75.0, 73.6, 73.3, 72.8, 69.5, 69.3, 68.9, 68.7, 63.7, 61.9, 55.5; HRMS: [M+NH4]+ calcd for 
C48H53N4O11 861.37053, found 861.37081. 
Methyl (Methyl 4-O-[2-azido-3-O-benzoyl-4,6-O-benzylidene-2-deoxy-α/β-ᴅ-
glucopyranosyl]-2,3-di-O-benzyl-α-ᴅ-glucopyranosyl uronate) (4F). Donor 4 and 
acceptor 27 were condensed using the general procedure for Tf2O/Ph2SO mediated 
glycosylations (for an additional 18 h at -40°C) and purified by flash column 
chromatography (19/1 to 4/1 pentane/EtOAc) to yield glycosylation product 4F (46 mg, 59 µmol, 59%, α:β = 1:1.4) as 
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a white solid. Rf: 0.56 (4/1 pentane/EtOAc). IR (thin film): 698, 750, 991, 1026, 1047, 1092, 1178, 1263, 1452, 1730, 
2110, 2868, 2938; Reported as a 0.7 : 1 mixture of anomers: 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC, HMBC): δ 
8.09 – 8.03 (m, 3.4H, CHarom), 7.61 – 7.52 (m, 1.7H, CHarom), 7.49 – 7.25 (m, 28.9H, CHarom), 5.76 (dd, 0.7H, J = 9.5, 10.3 
Hz, H-3’α), 5.70 (d, 0.7H, J = 3.9 Hz, H-1’α), 5.47 (s, 0.7H, CHPhα), 5.41 (s, 1H, CHPhβ), 5.36 (t, 1H, J = 9.8 Hz, H-3’β), 5.10 
(d, 0.7H, J = 10.6 Hz, CHH Bnα), 4.93 (d, 1H, J = 10.9 Hz, CHH Bnβ), 4.87 (d, 1H, J = 10.9 Hz, CHH Bnβ), 4.83 (d, 0.7H, J = 
10.6 Hz, CHH Bnα), 4.79 (d, 1H, J = 13.6 Hz, CHH Bnβ), 4.76 (d, 0.7H, J = 13.6 Hz, CHH Bnα), 4.66 – 4.62 (m, 2H, CHH Bnβ, 
H-1’β), 4.61 – 4.58 (m, 2.4H, CHH Bnα, H-1α, H-1β), 4.31 (dd, 0.7H, J = 10.0, 4.6 Hz, H-6’α), 4.28 (d, 0.7H, J = 9.7 Hz, H-
5α), 4.23 (d, 1H, J = 9.9 Hz, H-5β), 4.19 – 4.06 (m, 3.4H, H-3α, H-4α, H-4β, H-6’β), 3.91 (t, 1H, J = 9.2 Hz, H-3), 3.85 (s, 
2.1H, CH3 CO2Meα), 3.83 (s, 3H, CH3 CO2Meβ), 3.79 – 3.59 (m, 3.8H, H-2α, H-4’α, H-4’β, H-5’α, H-6’α), 3.59 – 3.44 (m, 4H, 
H-2β, H-2’β, H-5’β, H-6’β), 3.43 (s, 3H, CH3 OMeβ), 3.42 (s, 2.1H, CH3 OMeα), 3.31 (dd, 1H, J = 10.4, 3.9 Hz, H-2’α); 13C-
APT NMR (CDCl3, 101 MHz, HSQC, HMBC): δ 170.2, 169.9 (C=O CO2Me), 165.5, 165.3 (C=O Bz), 139.1, 138.4, 138.0, 
137.7, 137.0, 136.8 (Cq Bn, CHPh), 133.4, 133.4, 130.0, 130.0 (CHarom), 129.5, 129.5 (Cq Bz), 129.1, 129.1, 128.7, 128.6, 
128.5, 128.5, 128.5, 128.3, 128.3, 128.2, 128.1, 127.8, 127.7, 127.6, 127.5, 126.2, 126.2 (CHarom), 102.3 (C-1’β), 101.7 
(CHPhα), 101.5 (CHPhβ), 99.0 (C-1’α), 98.8 (C-1β), 98.5 (C-1α), 81.1 (C-3α), 79.9 (C-2α), 79.5, 79.5 (C-3β, C-4β), 79.2 (C-
4’α), 78.9, 78.7 (C-2β, C-4’β), 75.7, 75.4 (CH2 Bn), 75.2 (C-4α), 73.9, 73.6 (CH2 Bn), 71.9 (C-3’β), 69.8, 69.8 (C-5α, C-5β), 
69.6 (C-3’α), 68.5, 68.4 (C-6’α, C-6’β), 66.5 (C-5’β), 65.6 (C-2’β), 63.2 (C-5’α), 61.7 (C-2’α), 56.0, 56.0 (CH3 OMe), 53.1, 
53.0 (CH3 CO2Me); HRMS: [M+NH4]+ calcd for C42H47N4O12 799.31850, found 799.31869. 
2,2-Difluoroethyl 2-azido-3-O-benzoyl-4,6-O-benzylidene-2-deoxy-α/β-D-
glucopyranoside (4G). Donor 4 and 2,2-difluoroethanol were condensed using the 
general procedure for Tf2O/Ph2SO mediated glycosylations and purified by flash column 
chromatography (1/1/0 to 0/1/0 to 0/19/1 pentane/toluene/EtOAc) to yield 
glycosylation product 4G (38.6 mg, 84 µmol, 84%, α:β = 2.7:1) as a white solid. Rf: 0.49 (19/1 toluene/EtOAc). IR (thin 
film): 709, 997, 1026, 1069, 1094, 1265, 1726, 2108, 2870; Data for the α-anomer: 1H NMR (CDCl3, 400 MHz, HH-
COSY, HSQC): δ 8.11 – 8.05 (m, 2H, CHarom), 7.63 – 7.53 (m, 1H, CHarom), 7.50 – 7.36 (m, 4H, CHarom), 7.34 – 7.27 (m, 
3H, CHarom), 6.02 (tt, 1H, J = 55.1, 4.2 Hz, CHF2), 5.91 – 5.81 (m, 1H, H-3), 5.53 (s, 1H, CHPh), 5.11 (d, 1H, J = 3.6 Hz, H-
1), 4.33 (dd, 1H, J = 10.4, 4.9 Hz, H-6), 4.07 (ddd, 1H, J = 14.8, 6.4, 3.7 Hz, H-5), 3.99 – 3.77 (m, 4H, H-4, H-6), 3.42 (dd, 
1H, J = 10.4, 3.6 Hz, H-2); 13C-APT NMR (CDCl3, 101 MHz, HSQC): δ 165.5 (C=O Bz), 136.8 (Cq), 133.5, 130.1 (CHarom), 
129.5 (Cq Bz), 128.5, 128.3, 126.2 (CHarom), 113.7 (t, J = 241.7 Hz, CHF2), 101.8 (CHPh), 99.8 (C-1), 79.4 (C-4), 69.3 (C-
3), 68.7 (C-6), 67.6 (t, J = 29.0 Hz, CH2-CHF2), 63.5 (C-5), 61.8 (C-2); Data for the β-anomer: 1H NMR (CDCl3, 400 MHz): 
δ 5.97 (tdd, 0.37H, J = 55.2, 4.8, 3.5 Hz, CHF2), 5.51 (s, 0.37H, CHPh), 5.42 (t, 0.37H, J = 9.8 Hz, H-3), 4.63 (d, 0.37H, J 
= 7.9 Hz, H-1), 4.38 (dd, 0.37H, J = 10.5, 5.0 Hz, H-6), 4.12 – 3.99 (m, 0.37H, CHH-CHF2), 3.98 – 3.76 (m, 1.11H, CHH-
CHF2, H-4, H-6), 3.69 (dd, 0.37H, J = 10.0, 7.9 Hz, H-2), 3.58 (td, 0.37H, J = 9.8, 5.0 Hz, H-5); 13C-APT NMR (CDCl3, 101 
MHz): δ 165.4, 136.7, 133.5, 130.0, 129.4, 129.2, 128.6, 126.2, 113.8 (t, J = 241.5 Hz), 103.1, 101.7, 78.7 (C-4), 71.5 
(C-3), 69.1 (t, J = 29.0 Hz, CH2-CHF2), 68.4 (C-6), 66.8 (C-5), 64.9 (C-2); HRMS: [M+H]+ calcd for C22H22F2N3O6 462.14712, 
found 462.14699. 
Methyl 4-O-(2-azido-3-O-benzoyl-4,6-O-benzylidene-2-deoxy-α/β-ᴅ-
glucopyranosyl)-2,3,6-tri-O-benzyl-β-ᴅ-galactopyranoside (4H). Donor 4 and 
acceptor 28 were condensed using the general procedure for Tf2O/Ph2SO mediated 
glycosylations (for an additional 18 h at -40°C) and purified by flash column 
chromatography (19/1 to 4/1 pentane/EtOAc) to yield glycosylation product 4H (43 
mg, 52 µmol, 52%, α:β = 4:1) as a white solid. Rf: 0.36 (4/1 pentane/EtOAc). IR (thin film): 698, 737, 997, 1072, 1094, 
1265, 1452, 1730, 2106, 2862, 2930; Data for the α-anomer: 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC, HMBC): δ 
8.12 – 8.05 (m, 2H, CHarom), 7.57 (t, 1H, J = 7.4 Hz, CHarom), 7.45 (t, 2H, J = 7.7 Hz, CHarom), 7.42 – 7.20 (m, 20H, CHarom), 
5.85 (t, 1H, J = 9.9 Hz, H-3’), 5.44 (s, 1H, CHPh), 5.07 (d, 1H, J = 3.9 Hz, H-1’), 4.93 (d, 1H, J = 11.0 Hz, CHH Bn), 4.84 (d, 
1H, J = 10.9 Hz, CHH Bn), 4.79 (d, 1H, J = 12.4 Hz, CHH Bn), 4.74 (d, 1H, J = 12.4 Hz, CHH Bn), 4.55 (s, 2H, CH2 Bn), 4.46 
(td, 1H, J = 9.9, 4.9 Hz, H-5’), 4.26 (d, 1H, J = 7.6 Hz, H-1), 4.17 (d, 1H, J = 3.1 Hz, H-4), 3.93 (t, 1H, J = 9.1 Hz, H-6), 3.85 
(dd, 1H, J = 10.2, 5.0 Hz, H-6’), 3.81 – 3.70 (m, 2H, H-2, H-4’), 3.64 (dd, 2H, J = 9.1, 5.4 Hz, H-6), 3.57 – 3.50 (m, 5H, CH3 
OMe, H-5, H-6’), 3.47 (dd, 1H, J = 10.4, 3.9 Hz, H-2’), 3.42 (dd, 1H, J = 10.0, 3.0 Hz, H-3); 13C-APT NMR (CDCl3, 101 MHz, 
HSQC, HMBC): δ 165.3 (C=O Bz), 138.7, 138.3, 137.6, 137.2 (Cq), 133.3, 130.0 (CHarom), 129.8 (Cq), 128.9, 128.7, 128.6, 
128.6, 128.5, 128.5, 128.4, 128.4, 128.3, 128.2, 128.2, 128.1, 127.9, 127.7, 127.6, 127.6, 126.3, 126.2 (CHarom), 105.2 
(C-1), 101.4 (CHPh), 99.4 (C-1’), 80.0 (C-4’), 79.8 (C-3), 79.0 (C-2), 75.2 (CH2 Bn), 74.4 (C-4), 73.6, 73.2 (CH2 Bn), 72.6 
(C-5), 70.2 (C-3’), 68.8 (C-6’), 67.1 (C-6), 62.8, 62.7 (C-2’, C-5’), 57.0 (OMe); Diagnostic peaks β-anomer: 1H NMR (CDCl3, 













2.7 Hz, H-4); 13C-APT NMR (CDCl3, 101 MHz): δ 105.1 (C-1), 102.7 (C-1’), 101.5 (CHPh), 81.2, 79.6, 78.9, 75.3, 74.6, 
73.9, 73.6, 73.3, 71.7, 69.4, 68.5, 66.2, 65.0, 57.3; HRMS: [M+NH4]+ calcd for C48H53N4O11 861.37053, found 861.37067. 
Methyl 2-O-(2-azido-3-O-benzoyl-4,6-O-benzylidene-2-deoxy-α/β-ᴅ-glucopyranosyl)-3-O-
benzyl-4,6-O-benzylidene-α-ᴅ-mannopyranoside (4I). Donor 4 and acceptor 29 were 
condensed using the general procedure for Tf2O/Ph2SO mediated glycosylations (for an 
additional 18 h at -40°C) and purified by flash column chromatography (19/1 to 3/1 
pentane/EtOAc) to yield glycosylation product 4I (55 mg, 73 µmol, 73%, α:β = 5:1) as a 
white solid. Rf: 0.36 (4/1 pentane/EtOAc). IR (thin film): 671, 750, 1037, 1092, 1265, 1373, 1730, 2108, 2913; 1H NMR 
(CDCl3, 400 MHz, HH-COSY, HSQC, HMBC): δ 8.15 – 8.04 (m, 2H, CHarom), 7.59 – 7.53 (m, 1H, CHarom), 7.53 – 7.25 (m, 
17H, CHarom), 5.92 (dd, 1H, J = 10.4, 9.5 Hz, H-3’), 5.67 (s, 1H, CHPh), 5.54 (s, 1H, CHPh’), 5.51 (d, 1H, J = 3.8 Hz, H-1’), 
4.94 (d, 1H, J = 12.2 Hz, CHH Bn), 4.73 (d, 1H, J = 1.5 Hz, H-1), 4.69 (d, 1H, J = 12.2 Hz, CHH Bn), 4.39 (t, 1H, J = 9.7 Hz, 
H-4), 4.32 (dd, 1H, J = 10.4, 4.9 Hz, H-6’), 4.27 (dd, 1H, J = 10.3, 4.7 Hz, H-6), 4.14 (dd, 1H, J = 3.1, 1.6 Hz, H-2), 4.06 – 
3.99 (m, 2H, H-3, H-5’), 3.95 (t, 1H, J = 10.3 Hz, H-6), 3.86 – 3.77 (m, 3H, H-4’, H-5, H-6’), 3.38 – 3.33 (m, 4H, CH3 OMe, 
H-2’); 13C-APT NMR (CDCl3, 101 MHz, HSQC): δ 165.5 (C=O Bz), 138.8, 137.7, 136.8 (Cq), 133.4, 130.1 (CHarom), 129.6 
(Cq), 129.2, 128.9, 128.5, 128.4, 128.3, 128.3, 128.3, 128.3, 127.6, 127.6, 127.4, 126.2, 126.2, 126.2, 126.1 (CHarom), 
101.7, 101.6 (CHPh), 100.9 (C-1), 100.1 (C-1’), 79.7 (C-4’), 79.5 (C-4), 75.9, 75.9 (C-2, C-3), 73.6 (CH2 Bn), 69.2 (C-3’), 
68.9 (C-6), 68.8 (C-6’), 64.1 (C-5), 63.3 (C-5’), 61.9 (C-2’), 54.9 (OMe); Diagnostic peaks β-anomer: 1H NMR (CDCl3, 400 
MHz): δ 5.60 (s, 0.2H, CHPh), 5.50 (s, 0.2H, CHPh), 5.40 (t, 0.2H, J = 9.8 Hz, H-3’), 4.87 (d, 0.2H, J = 1.4 Hz, H-1), 4.80 
(d, 0.2H, J = 12.3 Hz, CHH Bn), 3.57 (td, 0.2H, J = 9.9, 4.3 Hz), 3.40 (s, 0.6H, CH3 OMe); 13C-APT NMR (CDCl3, 101 MHz): 
δ 101.8 (C-1’), 100.0 (CHPh), 99.4 (C-1), 78.7, 78.5, 76.4, 74.4, 72.4, 71.5, 68.9, 68.5, 66.9, 65.1, 64.2, 55.2; HRMS: 
[M+NH4]+ calcd for C41H45N4O11 769.30793, found 769.30780. 
2,2,2-Trifluoroethyl 2-azido-3-O-benzoyl-4,6-O-benzylidene-2-deoxy-α-D-glucopyranoside 
(4J). Donor 4 and 2,2,2-trifluoroethanol were condensed using the general procedure for 
Tf2O/Ph2SO mediated glycosylations (for an additional 30 min at -40°C) and purified by flash 
column chromatography (19/1 to 17/3 pentane/EtOAc) to yield glycosylation product 4J (41 mg, 86 µmol, 86%, α:β = 
>20:1) as a white solid. Rf: 0.15 (toluene). [α]  = +78.9° (c = 1.03, CHCl3); IR (thin film): 702, 989, 1085, 1177, 1275, 
1717, 2112, 2864; 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC): δ 8.13 – 8.03 (m, 2H, CHarom), 7.60 – 7.53 (m, 1H, CHarom), 
7.48 – 7.38 (m, 4H, CHarom), 7.33 – 7.28 (m, 3H, CHarom), 5.87 (t, 1H, J = 10.0 Hz, H-3), 5.53 (s, 1H, CHPh), 5.14 (d, 1H, J 
= 3.6 Hz, H-1), 4.33 (dd, 1H, J = 10.4, 4.9 Hz, H-6), 4.14 – 3.97 (m, 4H, CH2CF3, H-5), 3.84 (t, 1H, J = 9.5 Hz, H-4), 3.80 
(t, 1H, J = 10.3 Hz, H-6), 3.44 (dd, 1H, J = 10.4, 3.6 Hz, H-2); 13C-APT NMR (CDCl3, 101 MHz, HSQC): δ 165.5 (C=O), 136.7 
(Cq), 133.5, 130.0 (CHarom), 129.5 (Cq Bz), 129.2, 128.5, 127.6, 126.2 (CHarom), 123.42 (q, J = 278.6 Hz), 101.8 (CHPh), 
99.9 (C-1), 79.3 (C-4), 69.1 (C-3), 68.6 (C-6), 65.41 (q, J = 35.6 Hz), 63.7 (C-5), 61.6 (C-2); HRMS: [M+NH4]+ calcd for 
C22H24F3N4O6 497.16425 found 497.16425. 
Ethyl 3-O-benzyl-4,6-O-benzylidene-2-deoxy-2-(3,5-dinitro-4-pyridone)-β-D-
glucopyranoside (5A). Donor 5 and ethanol were condensed using the general procedure 
for Tf2O/Ph2SO mediated glycosylations (for an additional 1 hour at -40°C) and purified by 
flash column chromatography (19/1 to 8/2 pentane/EtOAc) to yield glycosylation product 
5A (32 mg, 59 µmol, 59%, α:β = <1:20) as a yellow solid alongside donor 5 (14 mg). Rf: 0.60 
(7/3 pentane/EtOAc). [α]  = +156.9° (c = 0.64, CHCl3); IR (thin film): 698, 998, 1093, 1213, 1303, 1330, 1516, 1679, 
2930; 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC): δ 8.58 (s, 2H, CH pyridone), 7.56 (dd, 2H, J = 7.4, 2.2 Hz, CHarom), 
7.45 – 7.38 (m, 3H, CHarom), 7.06 – 6.97 (m, 5H, CHarom), 5.66 (s, 1H, CHPh), 5.32 (d, 1H, J = 8.3 Hz, H-1), 4.70 (d, 1H, J 
= 11.7 Hz, CHH Bn), 4.57 (dd, 1H, J = 10.2, 8.7 Hz, H-3), 4.53 (d, 1H, J = 11.6 Hz, CHH Bn), 4.43 (dd, 1H, J = 10.3, 4.6 Hz, 
H-6), 3.99 – 3.81 (m, 4H, CHH Et, H-4, H-5, H-6), 3.72 (dd, 1H, J = 10.3, 8.3 Hz, H-2), 3.60 (dq, 1H, J = 9.9, 7.1 Hz, CHH 
Et), 1.08 (t, 3H, J = 7.1 Hz, CH3 Et); 13C-APT NMR (CDCl3, 101 MHz, HSQC): δ 160.6 (C=O pyridone), 141.7 (Cq NO2 
pyridone), 141.4 (CH pyridone), 137.1, 136.6 (Cq), 129.4, 128.9, 128.7, 128.5, 128.5, 126.3 (CHarom), 101.9 (CHPh), 99.3 
(C-1), 82.8 (C-4), 75.4 (C-3), 74.9 (CH2 Bn), 73.8 (C-2), 68.7 (C-6), 66.5 (CH2 Et), 65.7 (C-5), 15.1 (CH3 Et); HRMS: [M+H]+ 
calcd for C27H28N3O10 554.17692, found 554.17642. 
Cyclohexyl 3-O-benzyl-4,6-O-benzylidene-2-deoxy-2-(3,5-dinitro-4-pyridone)-β-D-
glucopyranoside (5B). Donor 5 and cyclohexanol were condensed using the general 
procedure for Tf2O/Ph2SO mediated glycosylations (for an additional 1 hour at -40°C) 
and purified by flash column chromatography (19/1 to 8/2 pentane/EtOAc) to yield 51 
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5B, 63 µmol, 63%, α:β = <1:20) as a yellow solid. Rf: 0.75 (7/3 pentane/EtOAc). Rf: 0.55 (7/3 pentane/EtOAc); IR: (thin 
film): 697, 718, 749, 789, 910, 997, 1092, 1212, 1302, 1330, 1516, 1623, 1674, 2931; 1H NMR (CDCl3, 400 MHz, HH-
COSY, HSQC): δ 8.60 (s, 2H, CH pyridone), 7.56 (d, 2H, J = 4.7 Hz, CHarom), 7.48 – 7.33 (m, 3H, CHarom), 7.10 – 6.96 (m, 
5H, CHarom), 5.65 (s, 1H, CHPh), 5.41 (d, 1H, J = 8.2 Hz, H-1), 4.71 (d, 1H, J = 11.7 Hz, CHH Bn), 4.66 – 4.50 (m, 2H, CHH 
Bn, H-3), 4.44 (dd, 1H, J = 10.6, 5.2 Hz, H-6), 3.98 – 3.80 (m, 3H, H-4, H-5, H-6), 3.79 – 3.61 (m, 2H, CH Cy, H-2), 1.91 – 
1.77 (m, 1H, CH2 Cy), 1.71 – 1.54 (m, 2H, CH2 Cy), 1.54 – 1.45 (m, 1H, CH2 Cy), 1.43 – 0.96 (m, 6H, CH2 Cy); 13C-APT 
NMR (CDCl3, 101 MHz, HSQC): δ 160.5 (C=O pyridone), 141.6 (Cq NO2 pyridone), 141.4 (CH pyridone), 137.1, 136.7 
(Cq), 128.8, 128.6, 128.4, 126.3 (CHarom), 101.9 (CHPh), 98.1 (C-1), 82.7 (C-4), 78.8 (CH Cy), 75.6 (C-3), 74.8 (CH2 Bn), 
74.0 (C-2), 68.8 (C-6), 65.7 (C-5), 33.3, 31.7, 25.3, 23.9, 23.6 (CH2 Cy); HRMS: [M+H]+ calcd for C31H34N3O10 608.22387, 
found 608.22352. 
Methyl 6-O-(3-O-benzyl-4,6-O-benzylidene-2-deoxy-2-(3,5-dinitro-4-pyridone)-β-ᴅ-
glucopyranosyl)-2,3,4-tri-O-benzyl-α-ᴅ-glucopyranoside (5C). Donor 5 and acceptor 
25 were condensed using the general procedure for Tf2O/Ph2SO mediated 
glycosylations (for an additional 18 hours at -40°C) and purified by flash column 
chromatography (9/1 to 7/3 pentane/EtOAc) to yield glycosylation product 5C (55 
mg, 54 µmol, 54%, α:β = <1:20) as a yellow solid. Rf: 0.45 (7/3 pentane/EtOAc). [α]  = +90.5° (c = 0.92, CHCl3); IR (thin 
film): 698, 1001, 1069, 1094, 1213, 1331, 1454, 1522, 1678, 2868; 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC, HMBC): 
δ 8.19 (s, 2H, CH pyridone), 7.54 (dd, 2H, J = 7.6, 2.1 Hz, CHarom), 7.45 – 7.38 (m, 3H, CHarom), 7.34 – 7.22 (m, 13H, 
CHarom), 7.20 – 7.12 (m, 5H, CHarom), 7.04 (dd, 2H, J = 6.6, 2.9 Hz, CHarom), 5.66 (s, 1H, CHPh), 4.92 (d, 1H, J = 11.0 Hz, 
CHH Bn), 4.85 (d, 1H, J = 8.3 Hz, H-1’), 4.83 – 4.66 (m, 2H, 2xCHH Bn), 4.72 (d, 1H, J = 10.9 Hz, CHH Bn), 4.69 (d, 1H, J 
= 12.0 Hz, CHH Bn), 4.60 (d, 1H, J = 12.2 Hz, CHH Bn), 4.60 (d, 1H, J = 12.0 Hz, CHH Bn), 4.46 (d, 1H, J = 3.4 Hz, H-1), 
4.39 (dd, 1H, J = 10.6, 5.0 Hz, H-6’), 4.34 (d, 1H, J = 11.3 Hz, CHH Bn), 4.10 (t, 1H, J = 7.9 Hz, H-3’), 4.01 (dd, 1H, J = 
10.8, 1.8 Hz, H-6), 3.91 (t, 1H, J = 9.2 Hz, H-3), 3.89 – 3.82 (m, 2H, H-4’, H-6), 3.77 – 3.69 (m, 2H, H-2’, H-5), 3.65 (td, 
1H, J = 9.7, 5.0 Hz, H-5’), 3.52 (dd, 1H, J = 10.8, 7.1 Hz, H-6), 3.39 (dd, 1H, J = 9.6, 3.5 Hz, H-2), 3.21 (s, 3H, CH3 OMe), 
3.13 (dd, 1H, J = 9.9, 8.9 Hz, H-4); 13C-APT NMR (CDCl3, 101 MHz, HSQC, HMBC): δ 159.4 (C=O pyridone), 141.7 (Cq 
NO2 pyridone), 140.2 (CH pyridone), 138.6, 138.0, 138.0, 136.7, 135.8 (Cq), 129.5, 129.1, 129.0, 128.6, 128.5, 128.5, 
128.5, 128.2, 128.1, 128.0, 128.0, 127.9, 127.7, 127.6, 126.1 (CHarom), 101.8 (CHPh), 100.1 (C-1’), 97.9 (C-1), 82.3 (C-
4’), 81.6 (C-3), 79.8 (C-2), 78.2 (C-4), 75.7, 74.8, 74.3, (CH2 Bn), 74.0 (C-3’), 73.3 (CH2 Bn), 72.7 (C-2’), 70.4 (C-6), 69.3 
(C-5), 68.4 (C-6’), 66.1 (C-5’), 55.1 (OMe); 13C-HMBC-GATED NMR (CDCl3, 101 MHz): δ 100.1 (J = 163 Hz, C-1’); HRMS: 
[M+H]+ calcd for C53H54N3O15 972.35494, found 972.35546. 
2-Fluoroethyl 3-O-benzyl-4,6-O-benzylidene-2-deoxy-2-(3,5-dinitro-4-pyridone)-β-D-
glucopyranoside (5D). Donor 5 and 2-fluoroethanol were condensed using the general 
procedure for Tf2O/Ph2SO mediated glycosylations (for an additional 1 hour at -40°C) 
and purified by flash column chromatography (19/1 to 8/2 pentane/EtOAc) to yield 
glycosylation product 5D (24 mg, 43 µmol, 43%, α:β = <1:20) as a yellow solid alongside 
donor 5 (15.6 mg). Rf: 0.42 (3/2 pentane/EtOAc). [α]  = +142.9° (c = 0.48, CHCl3); IR (thin film): 698, 752, 1070, 1096, 
1213, 1304, 1331, 1518, 1680, 2870, 3064; 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC): δ 8.58 (s, 2H, CH pyridone), 
7.63 – 7.49 (m, 2H, CHarom), 7.47 – 7.36 (m, 3H, CHarom), 7.09 – 6.96 (m, 5H, CHarom), 5.66 (s, 1H, CHPh), 5.46 (d, 1H, J 
= 8.3 Hz, H-1), 4.71 (d, 1H, J = 11.7 Hz, CHH Bn), 4.57 (dd, 1H, J = 10.3, 8.7 Hz, H-3), 4.53 (d, 1H, J = 11.7 Hz, CHH Bn), 
4.48 – 4.42 (m, 2H, CHHF, H-6), 4.33 (t, 1H, J = 4.1 Hz, CHHF), 4.09 – 3.81 (m, 5H, CH2-CH2F, H-4, H-5, H-6), 3.77 (dd, 
1H, J = 10.3, 8.4 Hz, H-2); 13C-APT NMR (CDCl3, 101 MHz, HSQC): δ 160.6 (C=O pyridone), 141.5, 141.5 (Cq NO2, CH 
pyridone), 137.0, 136.6 (Cq), 129.4, 129.0, 128.7, 128.6, 128.5, 126.3 (CHarom), 101.9 (CHPh), 99.8 (C-1), 82.7 (C-4), 
82.5 (d, J = 169.4 Hz, CH2F), 75.3 (C-3), 74.9 (CH2 Bn), 73.6 (C-2), 69.5 (d, J = 19.5 Hz, CH2-CH2F), 68.6 (C-6), 65.8 (C-5); 
HRMS: [M+H]+ calcd for C27H27FN3O10 572.16760, found 572.16705. 
Methyl 4-O-(3-O-benzyl-4,6-O-benzylidene-2-deoxy-2-(3,5-dinitro-4-pyridone)-β-ᴅ-
glucopyranosyl)-2,3,6-tri-O-benzyl-α-ᴅ-glucopyranoside (5E). Donor 5 and acceptor 
26 were condensed using the general procedure for Tf2O/Ph2SO mediated 
glycosylations (for an additional 18 hours at -40°C) and purified by flash column 
chromatography (9/1 to 7/3 pentane/EtOAc) to yield glycosylation product 5E (54 
mg, 56 µmol, 56%, α:β = <1:20) as a yellow solid. Rf: 0.37 (7/3 pentane/EtOAc). [α]  = +83.3° (c = 0.84, CHCl3); IR (thin 
film): 696, 734, 997, 1028, 1039, 1092, 1209, 1302, 1327, 1454, 1522, 1682, 2862, 2900, 3030, 3065; 1H NMR (CDCl3, 
500 MHz, HH-COSY, HSQC, HMBC, NOESY): δ 7.74 (s, 2H, CH pyridone), 7.57 – 7.53 (m, 2H, CHarom), 7.49 – 7.38 (m, 




Bn), 4.77 (d, 1H, J = 12.1 Hz, CHH Bn), 4.74 (d, 1H, J = 12.3 Hz, CHH Bn), 4.69 (d, 1H, J = 11.7 Hz, CHH Bn), 4.66 (d, 1H, 
J = 12.0 Hz, CHH Bn), 4.63 (d, 1H, J = 12.1 Hz, CHH Bn), 4.56 (d, 1H, J = 12.3 Hz, CHH Bn), 4.54 (d, 1H, J = 3.6 Hz, H-1), 
4.35 (d, 1H, J = 8.2 Hz, H-1’), 4.27 – 4.20 (m, 2H, CHH Bn, H-6’), 3.92 (t, 1H, J = 9.5 Hz, H-4), 3.70 (t, 1H, J = 9.3 Hz, H-
3), 3.67 (t, 1H, J = 9.0 Hz, H-4’), 3.58 (t, 1H, J = 10.4 Hz, H-6’), 3.53 – 3.45 (m, 2H, H-2, H-3’), 3.43 (dd, 1H, J = 11.4, 1.5 
Hz, H-6), 3.40 – 3.34 (m, 1H, H-5), 3.31 (s, 2H, CH3 OMe), 3.18 (dd, 1H, J = 10.5, 8.3 Hz, H-2’), 3.04 (dd, 1H, J = 11.3, 
2.6 Hz, H-6), 2.92 (td, 1H, J = 9.8, 5.1 Hz, H-5’); 13C-APT NMR (CDCl3, 126 MHz, HSQC, HMBC): δ 159.3 (C=O pyridone), 
141.8 (Cq NO2 pyridone), 139.6 (CH pyridone), 139.4, 138.1, 137.8, 136.8, 135.7 (Cq), 129.6, 129.3, 129.2, 129.0, 128.9, 
128.6, 128.6, 128.5, 128.4, 128.1, 128.1, 127.8, 126.1 (CHarom), 101.8 (CHPh), 98.1 (C-1), 97.6 (C-1’), 82.4 (C-4’), 79.7 
(C-2), 79.2 (C-3), 75.3 (CH2 Bn), 74.4 (C-4), 73.9, 73.6, 73.5 (CH2 Bn), 73.0 (C-3’), 72.5 (C-2’), 69.2 (C-5), 68.4 (C-6’), 68.1 
(C-6), 65.6 (C-5’), 55.7 (OMe); HRMS: [M+H]+ calcd for C53H54N3O15 972.35494, found 972.35519. 
Methyl (Methyl 4-O-[3-O-benzyl-4,6-O-benzylidene-2-deoxy-2-(3,5-dinitro-4-
pyridone)-α/β-ᴅ-glucopyranosyl]-2,3-di-O-benzyl-α-ᴅ-glucopyranosyl uronate) (5F). 
Donor 5 and acceptor 27 were condensed using the general procedure for 
Tf2O/Ph2SO mediated glycosylations (for an additional 18 hours at -40°C) and 
purified by flash column chromatography (9/1 to 7/3 pentane/EtOAc) to yield 
glycosylation product 5F (27 mg, 30 µmol, 30%, α:β = 1:3.6) as a yellow solid. Rf: 0.51 (7/3 pentane/EtOAc). IR (thin 
film): 648, 698, 733, 789, 910, 995, 1090, 1171, 1209, 1302, 1331, 1454, 1520, 1678, 1744, 2932; Data for the β-
anomer: 1H NMR (CDCl3, 500 MHz, HH-COSY, HSQC, HMBC): δ 8.06 (s, 2H, CH pyridone), 7.50 (dd, 2H, J = 7.3, 2.0 Hz, 
CHarom), 7.45 – 7.35 (m, 6H, CHarom), 7.33 – 7.18 (m, 9H, CHarom), 7.03 (dd, 2H, J = 6.9, 2.2 Hz, CHarom), 6.96 (dd, 1H, J = 
14.5, 6.9 Hz, CHarom), 5.55 (s, 1H, CHPh), 5.17 (d, 1H, J = 8.2 Hz, H-1’), 4.92 (d, 1H, J = 11.3 Hz, CHH Bn), 4.82 – 4.72 (m, 
3H, CHH Bn, 2xCHH Bn), 4.61 – 4.55 (m, 2H, 2xCHH Bn), 4.51 (d, 1H, J = 3.3 Hz, H-1), 4.14 (dd, 1H, J = 10.6, 4.8 Hz, H-
6’), 3.97 – 3.88 (m, 2H, H-3’, H-4), 3.83 (d, 1H, J = 9.7 Hz, H-5), 3.82 – 3.73 (m, 2H, H-3, H-4’), 3.54 – 3.43 (m, 6H, CH3 
CO2Me, H-2, H-2’, H-5’), 3.42 – 3.36 (m, 4H, CH3 OMe, H-6’); 13C-APT NMR (CDCl3, 126 MHz, HSQC, HMBC): δ 170.0 
(C=O CO2Me), 159.5 (C=O pyridone), 141.5 (Cq NO2 pyridone), 140.4 (CH pyridone), 139.1, 137.8, 136.7, 135.7 (Cq), 
129.5, 129.2, 129.2, 129.1, 129.0, 128.9, 128.7, 128.7, 128.6, 128.5, 128.4, 128.2, 128.2, 127.7, 127.7, 126.1, 126.0, 
125.7 (CHarom), 101.7 (CHPh), 98.8 (C-1’), 98.3 (C-1), 82.3 (C-4’), 79.1 (C-3), 78.8 (C-2), 77.8 (C-4), 75.5, 74.2 (CH2 Bn), 
74.0 (C-3’), 73.7 (CH2 Bn), 72.9 (C-2’), 68.8 (C-5), 68.2 (C-6’), 65.9 (C-5’), 56.1 (OMe), 52.9 (CO2Me); 13C-HMBC-GATED 
NMR (CDCl3, 101 MHz): δ 98.8 (J = 167 Hz, C-1’); Diagnostic peaks α-anomer: 1H NMR (CDCl3, 500 MHz, HH-COSY, 
HSQC): δ 5.74 (d, 0.28H, J = 3.9 Hz, H-1’), 5.61 (s, 0.28H, CHPh), 5.03 (d, 0.28H, J = 12.7 Hz, CHH Bn), 4.70 (d, 0.28H, J 
= 12.3 Hz), 4.62 (d, 0.28H, J = 12.2 Hz, CHH Bn), 4.46 (d, 0.28H, J = 12.3 Hz, CHH Bn), 4.37 (dd, 0.28H, J = 10.5, 4.9 Hz, 
H-6’), 4.29 (d, 0.28H, J = 9.9 Hz, H-5), 4.08 (t, 0.28H, J = 9.4 Hz), 3.69 (dd, 0.28H, J = 10.6, 3.9 Hz, H-2’); 13C-APT NMR 
(CDCl3, 126 MHz, HSQC): δ 169.7, 159.2, 141.2, 101.8 (CHPh), 96.8 (C-1’), 82.6, 80.7, 79.8, 74.5, 74.4, 73.1, 72.2, 69.6, 
69.5, 68.1, 63.0, 56.1, 53.3; 13C-HMBC-GATED NMR (CDCl3, 101 MHz): δ 96.8 (J = 181 Hz, C-1’); HRMS: [M+H]+ calcd 
for C47H48N3O16 910.30291, found 910.30315. 
2,2-Difluoroethyl 3-O-benzyl-4,6-O-benzylidene-2-deoxy-2-(3,5-dinitro-4-pyridone)-α/β-
D-glucopyranoside (5G). Donor 5 and 2,2-difluoroethanol were condensed using the 
general procedure for Tf2O/Ph2SO mediated glycosylations (for an additional 1 hour at -
40°C) and purified by flash column chromatography (19/1 to 8/2 pentane/EtOAc) to yield 
glycosylation product 5G (17.3 mg, 29 µmol α anomer, 17.8 mg 30 µmol β anomer. α:β 
= 1:1, 59%) as a yellow solids alongside donor 5 (11 mg). Rf: 0.12 and 0.30 (7/3 pentane/EtOAc). IR (thin film): 698, 
997, 1069, 1094, 1211, 1300, 1339, 1520, 1684, 2922; Data for the α-anomer: 1H NMR (Acetone-d6, 400 MHz, HH-
COSY, HSQC): δ 8.91 (s, 2H, CH pyridone), 7.61 – 7.53 (m, 2H, CHarom), 7.48 – 7.37 (m, 3H, CHarom), 7.25 – 7.10 (m, 5H, 
CHarom), 6.16 (tt, 1H, J = 55.0, 3.7 Hz, CHF2), 5.83 (s, 1H, CHPh), 5.56 (d, 1H, J = 3.7 Hz, H-1), 4.91 (d, 1H, J = 11.9 Hz, 
CHH Bn), 4.79 (dd, 1H, J = 10.7, 3.7 Hz, H-2), 4.71 – 4.62 (m, 2H, CHH Bn, H-3), 4.37 (dd, 1H, J = 10.1, 4.9 Hz, H-6), 4.18 
– 4.06 (m, 2H, CHH-CHF2, H-5), 4.03 (dd, 1H, J = 9.6, 8.6 Hz, H-4), 3.96 – 3.83 (m, 2H, CHH-CHF2, H-6); 13C-APT NMR 
(Acetone-d6, 101 MHz, HSQC): δ 160.0 (C=O pyridone), 142.9 (Cq NO2 pyridone), 142.6 (CH pyridone), 138.6, 138.5 
(Cq), 129.8, 129.2, 129.0, 129.0, 128.9, 127.0 (CHarom), 115.0 (t, J = 239.2 Hz, CHF2), 102.1 (CHPh), 98.8 (C-1), 83.5 (C-
4), 75.0 (CH2 Bn), 74.7 (C-3), 69.9 (C-2), 68.9 (C-6), 67.93 (t, J = 27.3 Hz, CH2-CHF2), 63.9 (C-5); Data for the β-anomer: 
1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC): δ 8.67 (s, 2H, CH pyridone), 7.60 – 7.52 (m, 2H, CHarom), 7.46 – 7.37 (m, 
3H, CHarom), 7.03 – 6.93 (m, 5H, CHarom), 5.75 (tt, 1H, J = 54.9, 3.9 Hz, CHF2), 5.65 (s, 1H, CHPh), 5.59 (d, 1H, J = 8.3 Hz, 
H-1), 4.76 – 4.64 (m, 2H, CHH Bn, H-3), 4.50 (d, 1H, J = 11.6 Hz, CHH Bn), 4.45 (dd, 1H, J = 10.4, 4.9 Hz, H-6), 4.05 (td, 
1H, J = 9.7, 5.0 Hz, H-5), 4.00 – 3.80 (m, 4H, CH2-CHF2, H-4, H-6), 3.77 (dd, 1H, J = 10.3, 8.4 Hz, H-2); 13C-APT NMR 
(CDCl3, 101 MHz, HSQC): δ 160.9 (C=O pyridone), 141.7 (Cq NO2 pyridone), 141.5 (CH pyridone), 137.0, 136.7 (Cq), 
129.4, 128.8, 128.6, 128.5, 128.4, 126.4 (CHarom), 113.4 (t, J = 241.5 Hz, 102.0 (CHPh), 99.9 (C-1), 82.6 (C-4), 75.5 (C-
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3), 75.1 (CH2 Bn), 73.7 (C-2), 68.9 (t, J = 27.8 Hz, CH2-CHF2), 68.6 (C-6), 65.8 (C-5); HRMS: [M+H]+ calcd for C27H26F2N3O10 
590.15808, found 590.15741. 
Methyl 4-O-(3-O-benzyl-4,6-O-benzylidene-2-deoxy-2-(3,5-dinitro-4-pyridone)-
β-ᴅ-glucopyranosyl)-2,3,6-tri-O-benzyl-β-ᴅ-galactopyranoside (5H). Donor 5 and 
acceptor 28 were condensed using the general procedure for Tf2O/Ph2SO 
mediated glycosylations (for an additional 18 hours at -40°C) and purified by 
flash column chromatography (9/1 to 7/3 pentane/EtOAc) to yield glycosylation 
product 5H (51 mg, 52 µmol, 52%, α:β = <1:20) as a yellow solid. Rf: 0.49 (7/3 pentane/EtOAc). [α]  = +35.5° (c = 0.85, 
CHCl3); IR (thin film): 698, 750, 999, 1072, 1094, 1213, 1454, 1522, 1682, 2868; 1H NMR (CDCl3, 400 MHz, HH-COSY, 
HSQC, HMBC): δ 8.20 (s, 2H, CH pyridone), 7.55 – 7.49 (m, 2H, CHarom), 7.47 – 7.40 (m, 3H, CHarom), 7.40 – 7.15 (m, 
18H, CHarom), 7.07 – 7.00 (m, 2H, CHarom), 5.63 (s, 1H, CHPh), 5.03 (d, 1H, J = 8.3 Hz, H-1’), 4.80 (d, 1H, J = 12.2 Hz, CHH 
Bn), 4.64 (d, 1H, J = 10.4 Hz, CHH Bn), 4.61 (d, 1H, J = 12.3 Hz, CHH Bn), 4.57 (d, 1H, J = 12.2 Hz, CHH Bn), 4.50 (s, 2H, 
CH2 Bn), 4.47 (d, 1H, J = 12.3 Hz, CHH Bn), 4.29 (d, 1H, J = 10.4 Hz, CHH Bn), 4.20 (dd, 1H, J = 10.5, 5.0 Hz, H-6’), 4.13 
(d, 1H, J = 7.6 Hz, H-1), 3.91 (d, 1H, J = 2.6 Hz, H-4), 3.88 – 3.78 (m, 2H, H-3’, H-4’), 3.74 (t, 1H, J = 10.3 Hz, H-6’), 3.70 
(dd, 1H, J = 9.9, 8.4 Hz, H-2’), 3.66 – 3.52 (m, 2H, H-6, H-6), 3.46 (s, 4H, CH3 OMe, H-5), 3.41 – 3.33 (m, 2H, H-3, H-5’), 
2.93 (dd, 1H, J = 9.6, 7.6 Hz, H-2); 13C-APT NMR (CDCl3, 101 MHz, HSQC, HMBC): δ 159.4 (Cq pyridone), 141.6 (Cq NO2 
pyridone), 140.5 (CH pyridone), 138.2, 138.0, 137.6, 136.6, 135.6 (Cq), 129.6, 129.3, 129.1, 129.1, 128.9, 128.7, 128.6, 
128.6, 128.4, 128.4, 128.1, 128.0, 127.7, 127.5, 126.1 (CHarom), 104.8 (C-1), 101.8 (CHPh), 99.6 (C-1’), 82.3 (C-4’), 80.2, 
80.2 (C-2, C-3), 75.4 (CH2 Bn), 74.6 (C-4), 74.5, 74.4 (CH2 Bn), 74.2 (C-3’), 73.5 (CH2 Bn), 72.5 (C-5), 72.3 (C-2’), 68.6 (C-
6), 68.2 (C-6’), 66.2 (C-5’), 57.3 (OMe); 13C-HMBC-GATED NMR (CDCl3, 101 MHz): δ 104.8 (J = 159 Hz, C-1), 99.6 (J = 
165 Hz, C-1’); HRMS: [M+H]+ calcd for C53H54N3O15 972.35494, found 972.35542. 
Methyl 2-O-(3-O-benzyl-4,6-O-benzylidene-2-deoxy-2-(3,5-dinitro-4-pyridone)-α/β-ᴅ-
glucopyranosyl)-3-O-benzyl-4,6-O-benzylidene-α-ᴅ-mannopyranoside (5I). Donor 5 
and acceptor 29 were condensed using the general procedure for Tf2O/Ph2SO 
mediated glycosylations (for an additional 18 hours at -40°C) and purified by flash 
column chromatography (9/1 to 7/3 pentane/EtOAc) to yield glycosylation product 5I 
(47 mg, 53 µmol, 53%, α:β = 1:1.3) as a yellow solid. Rf: 0.34 and 0.49 (7/3 
pentane/EtOAc). IR: (thin film): 646, 696, 731, 789, 908, 997, 1090, 1123, 1211, 1302, 1333, 1454, 1518, 1624, 1674, 
2910; Reported as a 0.8 : 1 mixture of anomers. 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC, HMBC): δ 8.48 (s, 2H, 
pyridoneβ), 8.33 (s, 1.6H, pyridoneα), 7.58 – 7.26 (m, 22.8H, CHarom), 7.23 – 7.01 (m, 11.8H, CHarom), 6.99 – 6.94 (m, 
1.6H, CHarom), 5.67 (s, 1.8H, CHPh’α, CHPh’β), 5.62 (s, 0.8H, CHPhα), 5.53 (s, 1H, CHPhβ), 5.27 (d, 0.8H, J = 3.9 Hz, H-1’α), 
5.24 (d, 1H, J = 8.3 Hz, H-1’β), 4.84 (d, 1H, J = 12.1 Hz, CHH Bnβ), 4.79 (d, 0.8H, J = 12.2 Hz, CHH Bnα), 4.75 (d, 1H, J = 
12.1 Hz, CHH Bnβ), 4.70 (d, 1H, J = 12.2 Hz, CHH Bnβ), 4.67 (d, 0.8H, J = 1.1 Hz, H-1α), 4.64 (d, 1H, J = 12.1 Hz, CHH Bnβ), 
4.57 (d, 0.8H, J = 12.2 Hz, CHH Bnα), 4.52 (d, 0.8H, J = 11.1 Hz, CHH Bnα), 4.50 (dd, 1H, J = 10.3, 8.2 Hz, H-3’β), 4.46 – 
4.41 (m, 1H, H-6’β), 4.33 (d, 0.8H, J = 11.1 Hz, CHH Bnα), 4.34 – 4.26 (m, 1.6H, H-6α, H-6’α), 4.22 – 4.15 (m, 2.8H, H-1β, 
H-2β, H-3’α), 4.10 – 3.96 (m, 4.4H, H-2α, H-2’α, H-2’β, H-5’α, H-6β), 3.95 – 3.83 (m, 8.2H, H-3α, H-3β, H-4β, H-4’α, H-4’β, 
H-5’β, H-6α, H-6’α, H-6’β), 3.81 – 3.74 (m, 1.6H, H-4α, H-5α), 3.61 (dq, 1H, J = 9.0, 4.5 Hz, H-5β), 3.50 (t, 1H, J = 10.3 Hz, 
H-6β), 3.38 (s, 2.4H, CH3 OMeα), 3.15 (s, 3H, CH3 OMeβ); 13C-APT NMR (CDCl3, 101 MHz, HSQC, HMBC): δ 159.9, 159.7 
(C=O pyridone), 142.1 (CH pyridoneα), 141.7 (Cq NO2 pyridone), 140.9 (CH pyridoneβ), 140.8 (Cq NO2 pyridone), 138.2, 
137.6, 137.4, 137.4, 136.8, 136.6, 136.5, 136.0 (Cq), 129.6, 129.4, 129.1, 129.0, 128.9, 128.8, 128.7, 128.6, 128.5, 
128.4, 128.4, 128.3, 128.3, 127.8, 127.8, 127.6, 126.2, 126.1, 126.1 (CHarom), 101.9, 101.8 (CHPh’α,β), 101.6, 101.6 
(CHPhα,β), 100.7 (C-1α), 99.8 (C-1’α), 99.2 (C-1β), 98.8 (C-1’β), 83.1 (C-4’α), 82.4 (C-4’β), 79.6 (C-4α), 79.1 (C-2α), 78.5 (C-
4β), 76.1 (C-2β), 75.0 (C-3α), 74.5, 74.5, 74.3 (CH2 Bn), 74.2 (C-3β, C-3’β), 72.9 (C-2’β), 72.7 (CH2 Bn), 72.5 (C-3’α), 69.9 
(C-2’α), 68.5, 68.5, 68.4 (C-6α,β, C-6’α,β), 66.1 (C-5’β), 63.7 (C-5β), 63.3 (C-5α), 63.1 (C-5’α), 55.1, 55.1 (OMe); 13C-HMBC-
GATED NMR (CDCl3, 101 MHz): δ 99.8 (J = 176 Hz, C-1’α), 98.8 (J = 164 Hz, C-1’β); HRMS: [M+H]+ calcd for C46H46N3O15 
880.29234, found 880.29252. 
2,2,2-Trifluoroethyl 3-O-benzyl-4,6-O-benzylidene-2-deoxy-2-(3,5-dinitro-4-pyridone)-
α/β-D-glucopyranoside (5J). Donor 5 and 2,2,2-trifluoroethanol were condensed using the 
general procedure for Tf2O/Ph2SO mediated glycosylations (for an additional 1 hour at -
40°C) and purified by flash column chromatography (19/1 to 8/2 pentane/EtOAc) to yield 
glycosylation product 5J (28 mg, 46 µmol α anomer and 7 mg, 12 µmol β anomer. α:β = 
4:1, 58%) as a yellow solids alongside glucal 24 (4 mg) and donor 5 (13 mg). Rf: 0.15 and 0.67 (7/3 pentane/EtOAc). IR 
















anomer: 1H NMR (Acetone-d6, 400 MHz, HH-COSY, HSQC): δ 8.92 (s, 2H, CH pyridone), 7.60 – 7.54 (m, 2H, CHarom), 
7.47 – 7.37 (m, 3H, CHarom), 7.24 – 7.13 (m, 5H, CHarom), 5.84 (s, 1H, CHPh), 5.65 (d, 1H, J = 3.7 Hz, H-1), 4.92 (d, 1H, J 
= 11.8 Hz, CHH Bn), 4.84 (dd, 1H, J = 10.7, 3.7 Hz, H-2), 4.73 (dd, 1H, J = 10.7, 8.4 Hz, H-3), 4.70 (d, 1H, J = 11.8 Hz, CHH 
Bn), 4.51 – 4.38 (m, 1H, CHH-CF3), 4.38 (dd, 1H, J = 10.1, 4.7 Hz, H-6), 4.30 – 4.17 (m, 1H, CHH-CF3), 4.12 (dd, 1H, J = 
9.8, 4.7 Hz, H-5), 4.09 – 4.02 (m, 1H, H-4), 3.93 (t, 1H, J = 10.0 Hz, H-6); 13C-APT NMR (Acetone-d6, 101 MHz, HSQC): δ 
160.0 (C=O pyridone), 142.9 (Cq NO2 pyridone), 142.6 (CH pyridone), 138.6, 138.5 (Cq), 129.8, 129.2, 129.0, 129.0, 
128.9, 127.0 (CHarom), 124.72 (q, J = 277.4 Hz, CF3), 102.1 (CHPh), 98.8 (C-1), 83.4 (C-4), 75.1 (CH2 Bn), 74.6 (C-3), 69.8 
(C-2), 68.8 (C-6), 65.84 (q, J = 35.0 Hz, CH2-CF3), 64.1 (C-5); Diagnostic peaks β-anomer: 1H NMR (CDCl3, 400 MHz, HH-
COSY, HSQC): δ 8.61 (s, 2H, CH pyridone), 7.56 (dd, 2H, J = 6.6, 2.9 Hz, CHarom), 7.41 (dd, 3H, J = 5.0, 1.7 Hz, CHarom), 
7.00 (s, 5H, CHarom), 5.66 (s, 1H, CHPh), 5.58 (d, 1H, J = 8.3 Hz, H-1), 4.75 – 4.62 (m, 2H, CHH Bn, H-3), 4.52 (d, 1H, J = 
11.7 Hz, CHH Bn), 4.46 (dd, 1H, J = 10.5, 4.8 Hz, H-6), 4.17 – 3.99 (m, 3H, CH2-CF3, H-5), 3.91 – 3.82 (m, 2H, H-4, H-6), 
3.78 (dd, 1H, J = 10.0, 8.5 Hz, H-2); HRMS: [M+H]+ calcd for C27H25F3N3O10 608.14865, found 608.14825. 
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Both α- and β-linked glucosamine residues are widespread in naturally occurring 
carbohydrates.1–5 While β-glucosamine linkages can be reliably installed using 
anchimeric assistance of a participating N-protecting group, the installation of the α-
glucosamine bond commonly hinges on the use of a non-participating N-protecting 
group, where the azide is most commonly employed.6–8 In chapters 3 and 4, a set of 
fluorinated model acceptors was introduced to investigate how the stereoselectivity of 
glycosylations of 4,6-tethered glucosazide donors relates to acceptor nucleophilicity. This 
approach revealed that the combination of a reactive donor glycoside and a weak 
nucleophile led to α-selective glycosylation reactions. In the current chapter, the 
stereoselectivity of glycosylations of a 3,4-tethered glucosazide donor is studied in 
relation to the nucleophilicity of the acceptor. The reactivity of the donor is assessed 
using Variable-Temperature NMR (VT-NMR) and competition experiments, followed 
by a series of glycosylations. The set of partially fluorinated model acceptors and a panel 
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of carbohydrate acceptors, introduced in the previous chapters, are used to map 
reactivity-stereoselectivity relationships to provide a basis for α-glucosaminylation 
reactions. 9–12 
Results and discussion 
In an extension of the glucosazide donors described in the previous chapter, the butane 
diacetal (BDA)13–15 protected glucosazide donor 1 is glycosylated with the range of 
acceptors depicted in Figure 1 to investigate how the stereoselectivity of glycosylations 
of donor 1 depends on the reactivity of these acceptors. Benzylidene glucose donor 2 and 
benzylidene glucosazide donor 3 serve as a direct comparison for the reactivity and 
selectivity of donor 1. The 3,4-O-BDA protecting group locks the donor in a trans-
decalin constellation, conformationally disarming the system, as is also the case for the 
4,6-O-benzylidene in donors 2 and 3. Severe conformational changes are prohibited, and 
the number of possible glycosylation reaction itineraries restricted.16–18 The difference in 
electronic properties between the BDA group and the benzylidene acetal can be found in 
the rotational freedom of the C-6-substituent. In donor 1 the C-6–O-6 bond is not 
retained in its most electron withdrawing tg-conformation, as in donor 2 and 3 (Figure 
1C).18–20 The BDA protected donor 1 is therefore expected to be more reactive than 
benzylidene glucosazide donor 3. This has previously been demonstrated in the manno-
series by Crich and co-workers, who reported highly α-selective mannosylations with 
BDA-protected mannosyl donors. They related this to the higher reactivity of the BDA 
donor over the benzylidene donor and therefore a shift in the glycosylation reaction 
mechanism continuum from the β-selective SN2-side for the latter donor to the α-
selective SN1-side for the former donor.21 In contrast, glycosylations of the related 3,4-O-
BDA-glucosyl donors proceeded with β-selectivity, which they interpreted to arise from 
an SN2-type reaction on the relatively stable α-triflate. Collapse into the α-selective 
oxocarbeniun ion intermediate was prevented by the steric hindrance of the BDA-OMe 
group with the large C-2-OBn group (See Figure 3).22 It may be hypothesized that the 
smaller 2-azido group in donor 1 does not experience this unfavorable steric effect 
allowing for the easier formation of the oxocarbenium intermediate. On the other hand, 
Chapter 4 has revealed the azide to promote SN2-type reactions as a result of its electron 
withdrawing nature. 





Figure 1. (A) Glycoside donors and (B) acceptors used in the glycosylation study of this chapter. (C) Newman 
projections of the three staggered rotamer conformations along the C-5–C-6 bond. 
 
Donor 1 is synthesized from acetylated thioglycoside 15 (Scheme 1), by alkaline 
hydrolysis of the TCA and acetyl groups followed by diazotransfer to give the crude 
glucosazide 16. Installation of the BDA and benzyl groups gave donor 1 in good overall 
yield. 
 
Scheme 1. Synthesis of BDA-donor 1. 
 
Reagents and conditions: (a) i. K2CO3, EtOH, H2O; ii. CuSO4⋅5H2O, imidazole-1-sulfonyl azide hydrochloride23; 
(b) 2,3-butadione, trimethyl orthoformate, CSA, MeOH, 64% (three steps); (c) BnBr, NaH, DMF, 85%. 
 
The activation of donor 1 was studied by VT-NMR.24 To this end donor 1 was 
treated with Ph2SO/Tf2O in the presence of TTBP in deuterated DCM.25 Figure 2A 
displays the spectra of the reaction mixture at a range of temperatures. Interestingly, 
various species are generated upon activation, the two most predominant of which were 
assigned as the α-anomeric triflate 18 (labelled ◊, 1H δ = 6.09 ppm, JH-1–H-2 = 3.3 Hz, 13C 
δ = 105.8 ppm) and β-oxosulfonium triflate (labelled *, 1H δ = 5.56 ppm, JH-1–H-2 = 7.6 
Hz, 13C δ = 103.8 ppm) in a 3:1 ratio. Using either an equimolar amount or an excess of 










































































































oxosulfonium triflate 19 (Figure 2B depicts the 19F-NMR spectrum of the activation 
mixture using an excess Ph2SO, showing full consumption of the anomeric triflate). 
When the sample (with 1.3 equivalents Ph2SO) was heated to -50°C the signal of the β-
oxosulfonium triflate disappeared irreversibly. Decomposition of the anomeric triflate 
started around -20°C, similar to the triflates reported in Chapter 4, and no specific 
product could be identified. The immediate formation of the β-oxosulfonium triflate, 
and the complete conversion of the anomeric triflate to this species when an excess of 
Ph2SO is used, hints at the relatively high reactivity of the donor, in line with the 





Figure 2. NMR activation study of donor 1. (A) 1.3 eq. Ph2SO, 1.3 eq. Tf2O. The behavior of triflate 18 (◊) and 
oxosulfonium triflate 19 (*) between -80°C -10°C. (B) 19F-NMR showing triflate 18 (◊) and its absence when 5 




























The relative reactivity of the BDA protected glucosazide versus its benzylidene 
counterpart was evaluated in a set of competition experiments (Table 1). The 
thioglycosides and acceptor 10 were mixed and made to compete for a limiting amount 
of NIS. This experiment revealed the BDA donor 1 to be six times more reactive than 
donor 3 towards NIS and, somewhat surprisingly given the stronger electron 
withdrawing capacity of the azide, two times more reactive than 2. Apparently the 
combined disarming effect of the azide and BDA group, previously found to be semi-
disarming,26,27 is smaller than the disarming effect of the benzylidene group in donor 2.  
 









I : II 
Recovered 
donora I : II 
Yielda 
% 
α : β 
1 1 2 0.1 M DCM 1C/2C 
2 : 1 
1 : 1.4 75% 1C; 1 : 6 
2C; 1 : 1 
2 1 3 0.1 M DCM 1C/3C 
6 : 1 
1 : 10 99% 
1C; 1 : 6 
3C; 1 : 3 
3 2 3 0.05 M DCMb 2C/3C 
1 : 0 
0 : 1 80% 1C; 1.5 : 1 
aIsolated ratios after size-exclusion chromatography, and yield of the disaccharide fraction. bReference relative 
reactivity between 2 and 3 (Chapter 4); selectivity increases with dilution. 
 
Next, the BDA glucosazide donor 1 was glycosylated with the set of fluorinated 
model nucleophiles and a selection of carbohydrate acceptors. The results of the 
glycosylations are listed in Table 2 and compared with the glycosylation results of donors 
2 and 3. The reactions were carried out by preactivating the donor from -78°C to -50°C 
to remove the contribution of the oxosulfonium triflate on the stereoselectivity of the 
reaction. Despite the high reactivity observed in the competition and activation 
experiments, indicating that oxocarbenium ion character readily develops at the 
anomeric center, the reactions of donor 1 are very β-selective. It is not surprising to find 
the strong nucleophiles cyclohexanol 4, ethanol 5 and carbohydrate acceptor 10 to react 
with full β-selectivity, but the other acceptors, especially trifluoroethanol 8 and axially 
orientated nucleophiles 13 and 14, react with unexpected low α-selectivity.  
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Table 2. Glycosylations of donors 1-3 with model acceptors 4-9 and carbohydrate acceptors 10-14. Ordered by 
their overall β- to α-selectivity. 











1 : 5.1 
3A 
93 % 
< 1 : 20 
1A 
87 % 




1 : 10 
3B 
83 % 
< 1 : 20 
1B 
90 % 




1 : 2.8 
3C 
90 % 
1 : 6.7 
1C 
97 % 




5 : 1 
3D 
64 % 
2.9 : 1 
1D 
84 % 




> 20 : 1
3E 
94 % 
> 20 : 1
1E 
87 % 




> 20 : 1
3F 
53 % 
> 20 : 1
1Fc 
18% 




1 : 2.7 
3G 
89 % 
< 1 : 20 
1G 
86 % 




1 : 1 
3H 
88 % 
1 : 7 
1H 
93 % 




5 : 1 
3I 
93 % 
1.1 : 1 
1I 
83 % 




> 20 : 1
3J 
75 % 
9 : 1 
1J 
86 % 




> 20 : 1
3K 
74 % 
9 : 1 
1K 
93 % 
1 : 1.7 
aGlycosylation results of donors 2 and 3, are also reported in Chapter 3 and 4 of this thesis, respectively. bRatio 
and yield of isolated product after column chromatography, anomers were not separated. cα,β-Trehalose 24 


























The high β-selectivity for donor 1 under preactivation conditions is also apparent 
when compared with the previously reported C-2–OBn analogue.22 Condensation (See 
Figure 3) of donor 20 and acceptor 11 provided an anomeric mixture (α/β, 1:4), whereas 
glycosylation of 1 and 11 led to a much higher β-selectivity (1H; α/β, 1:15). This 
observation is consistent with the scenario drawn in Chapter 4: the 2-azido group 
promotes an SN2 pathway (via triflate 18) due to additional electron-withdrawing from 
the anomeric center. Although the high β-selectivity appears contradictory to the high 
reactivity of the donor, it may also be that the BDA glucosazide oxocarbenium ion 22 (as 
part of a close ion pair) takes up a conformation favoring attack from the β-side.  
 
 
Figure 3. Reactive species at play in the glycosylation reactions of donors 1 and 20.  
 
Conclusions 
Condensations of butane diacetal (BDA) protected glucosazide donor 1 have been 
studied using the set of fluorinated model acceptors introduced in Chapters 3 and 4. The 
BDA protecting group in combination with the 2-azido functionality is highly β-
directing in glycosylations without the need for a C-2 participating group. Despite the 
high β-selectivity, the model acceptors show the anticipated trend of reactivity of the 
acceptor versus glycosylation stereoselectivity, with less reactive acceptors providing 
more α-products as was established in Chapters 3 and 4, to provide yet another example 
of the importance of the reactivity of the acceptor in a glycosylation reaction. The exact 
underlying mechanism that causes the high β-selectivity has yet to be fully elucidated, 
but based on precedent, the high β-selective for donor 1 may arise from an SN2-like 
substitution of the anomeric α-triflate. How this exactly relates to the high reactivity of 






General procedure for Tf2O/Ph2SO mediated glycosylations: Donor (0.1 mmol), Ph2SO (26 mg, 0.13 mmol, 1.3 eq.) and 
TTBP29 (62 mg, 0.25 mmol, 2.5 eq.) were coevaporated twice with dry toluene and dissolved in dry DCM (2 mL, 0.05 
M donor). Activated 3Å molecular sieves (rods, size 1/16 in.) were added, and the reaction mixture stirred for 1 h at 
room temperature under a nitrogen atmosphere. The solution was cooled to -78°C and Tf2O (22 μl, 0.13 mmol, 1.3 
eq.) was added. The reaction mixture was allowed to warm to -50°C followed by recooling to -78°C and addition of 
the acceptor (0.2 mmol, 2 eq.) in DCM (0.4 mL, 0.5 M). The reaction mixture was allowed to warm to -40°C in 
approximately 90 min and stirred for an additional 0-18 h depending on the acceptor. The reaction was quenched 
with Et3N (0.1 mL, 0.72 mmol, 5.5 eq.) at -40 °C and diluted with DCM. The solution was transferred to a separatory 
funnel and water was added, the layers were separated and the water phase extracted once more with DCM. The 
combined organic layers were dried over MgSO4, filtered, and concentrated in vacuo. Purification by silica gel flash 
column chromatography and when needed, sephadexTM LH-20 size exclusion chromatography yielded the 
glycosylation product as a mixture of anomers. 
General procedure for the NIS/TfOH mediated competition experiments: Donor I (0.1 mmol, 1 eq.), donor II (0.1 mmol, 
1 eq.) and acceptor 25 (0.2 mmol, 2 eq.) were together coevaporated with dry toluene (2x). Dry DCM (4 mL, donor 
concentration 0.1 M), a Teflon stirring bar and 3Å activated molecular sieves (rods, size 1/16 in.) were added and the 
mixture was stirred under a nitrogen atmosphere for 1 h at room temperature. The mixture was cooled to -40°C and 
NIS (0.1 mmol, 1 eq.) was added. TfOH (50 µL of a freshly prepared 0.2 M stock solution in dry DCM, 0.1 eq.) was 
added and the mixture was allowed to warm to 0°C in 3 hours. Et3N (0.1 mL) was added and the mixture was diluted 
with EtOAc, washed with sat. aq. NaS2O3 and brine, dried over Na2SO4 and concentrated in vacuo. Size exclusion 
chromatography (Sephadex LH-20, 1/1 DCM/MeOH) enabled isolation of the disaccharide products and the 
monosaccharide rests, which were both analysed with NMR spectroscopy. The yield of the disaccharide fraction was 
determined. 
General procedure for the low temperature NMR experiments: A mixture of donor (30 µmol) and Ph2SO (39 µmol) was 
coevaporated with dry toluene twice (for the activation of donor 1 also TTBP (75 µmol) was added). Under a nitrogen 
atmosphere, CD2Cl2 (0.6 mL) was added and the mixture transferred to a nitrogen flushed NMR tube and closed with 
a NMR tube septum. The NMR magnet was cooled to -80°C, locked and shimmed and the sample was measure prior 
to activation. In a long narrow cold bath (EtOH, -85°C) the sample was treated with Tf2O (39 µmol), shaken thrice and 
cooled again after every shake. The cold sample was wiped dry and quickly inserted back in the cold magnet. The first 
1H NMR spectrum was immediately recorded. The sample was then reshimmed and spectra were recorded in 10°C 
intervals with at least 5 min equilibration time for every temperature.  
Phenyl 2-azido-2-deoxy-3,4-O-(2,3-dimethoxybutane-2,3-diyl)-1-thio-β-D-glucopyranoside (17). 
To a solution of crude triol 16 (synthesized as described in Chapter 4) (≤15 mmol) in dry MeOH 
(100 mL) was added butadione (2.0 mL, 22.5 mmol, 1.5 eq.), trimethyl orthoformate (9.8 mL, 
90 mmol, 6 eq.) and CSA (523 mg, 2.25 mmol, 0.15 eq.) and the solution was refluxed 
overnight. Et3N was added (1 mL) and the volatiles were removed in vacuo. Crystallization from EtOAc/petroleum 
ether yielded the tiles compound as a white solid (3.94 g, 9.56 mmol, 64% over three steps). Spectroscopic data were 
in accord with those previously reported.30 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC): δ 7.62 – 7.54 (m, 2H, CHarom), 
7.41 – 7.34 (m, 3H, CHarom), 4.47 (d, 1H, J = 9.9 Hz, H-1), 3.91 (ddd, 1H, J = 12.0, 5.6, 2.6 Hz, H-6), 3.81 – 3.70 (m, 2H, 
H-3, H-6), 3.66 (t, 1H, J = 9.7 Hz, H-4), 3.55 (ddd, 1H, J = 9.6, 4.5, 2.7 Hz, H-5), 3.43 (t, 1H, J = 9.8 Hz, H-2), 3.35 (s, 3H, 
CH3 OMe), 3.27 (s, 3H, CH3 OMe), 2.02 (dd, 1H, J = 7.6, 5.9 Hz, 6-OH), 1.35 (s, 3H, CH3 Me), 1.31 (s, 3H, CH3 Me); 13C-
APT NMR (CDCl3, 101 MHz, HSQC): δ 133.9 (CHarom), 130.7 (Cq SPh), 129.3, 128.9 (CHarom), 100.3, 99.9 (Cq BDA), 86.2 
(C-1), 78.2 (C-5), 73.1 (C-3), 65.7 (C-4), 61.5 (C-2), 61.4 (C-6), 48.3, 48.2 (OMe), 17.7, 17.6 (Me). 
Phenyl 2-azido-6-O-benzyl-2-deoxy-3,4-O-(2,3-dimethoxybutane-2,3-diyl)-1-thio-β-D-
glucopyranoside (1). Compound 17 was dissolved in DMF (45 mL) and cooled to 0°C. NaH (60% 
dispersion in mineral oil, 540 mg, 13.5 mmol, 1.5 eq.) and BnBr (1.4 mL, 11.7 mmol, 1.3 eq.) 
were added and the mixture was stirred at r.t. until complete conversion was observed (TLC). 
Excess NaH was quenched with MeOH and the solution was reduced in volume under reduced pressure. H2O was 
added to the residue and extracted with Et2O twice and DCM once. Combined organic layers were washed with H2O 
and brine, dried with MgSO4, filtered and concentrated in vacuo. Flash column chromatography (1/0 to 9/1 
pentane/EtOAc) and subsequently recrystallized (EtOAc, excess petroleum ether) gave the title compound as a white 




solid in two batches (total yield 3.84 g, 7.66 mmol, 85%). Rf: 0.25 (19/1 pentane/EtOAc). m.p.: 146-149°C. ). [α]  = 
+72.2° (c = 1.0, CHCl3); IR (thin film): 689, 735, 752, 851, 885, 960, 1032, 1107, 1128, 1265, 1275, 1366, 1375, 1437, 
1452, 2110, 2868; 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC): δ 7.63 – 7.57 (m, 2H, CHarom), 7.36 – 7.27 (m, 5H, CHarom), 
7.26 – 7.21 (m, 3H, CHarom), 4.63 (d, 1H, J = 11.9 Hz, CHH Bn), 4.56 (d, 1H, J = 11.9 Hz, CHH Bn), 4.41 (d, 1H, J = 9.8 Hz, 
H-1), 3.83 – 3.68 (m, 4H, H-3, H-4, H-6, H-6), 3.66 – 3.60 (m, 1H, H-5), 3.41 (t, 1H, J = 9.8 Hz, H-2), 3.32 (s, 3H, CH3 
OMe), 3.17 (s, 3H, CH3 OMe), 1.32 (s, 3H, CH3 Me), 1.27 (s, 3H, CH3 Me); 13C-APT NMR (CDCl3, 101 MHz, HSQC): δ 
138.5 (Cq Bn), 134.2 (CHarom), 130.8 (Cq SPh), 129.2, 128.7, 128.4, 127.6, 127.5 (CHarom), 100.3, 99.9 (Cq BDA), 86.1 (C-
1), 78.1 (C-5), 73.6 (CH2 Bn), 73.3 (C-3), 68.3 (C-6), 65.7 (C-4), 61.4 (C-2), 48.3, 48.2 (OMe), 17.8, 17.7 (Me); HRMS: 
[M+NH4]+ calcd for C25H35N3O6S 519.22718, found 519.22695.  
Cyclohexyl 2-azido-6-O-benzyl-2-deoxy-3,4-O-(2,3-dimethoxybutane-2,3-diyl)-β-D-
glucopyranoside (1A). Donor 1 and cyclohexanol were condensed using the general 
procedure for Tf2O/Ph2SO mediated glycosylations (for an additional 18 hours at -40°C) 
and purified by flash column chromatography (1/0 to 9/1 pentane/EtOAc) to yield 
glycosylation product 1A (43 mg, 87 µmol, 87%, α:β = <1:20). Rf: 0.6 (9/1 pentane/EtOAc). [α]  = +98.6° (c = 1.08, 
CHCl3); IR (thin film): 698, 849, 891, 959, 1047, 1121, 1368, 1452, 2108, 2932; 1H NMR (CDCl3, 400 MHz, HH-COSY, 
HSQC): δ 7.35 – 7.26 (m, 5H, CHarom), 4.61 (d, 1H, J = 12.1 Hz, CHH Bn), 4.57 (d, 1H, J = 12.1 Hz, CHH Bn), 4.41 (d, 1H, 
J = 7.7 Hz, H-1), 3.76 (dd, 1H, J = 11.0, 1.6 Hz, H-6), 3.74 – 3.63 (m, 3H, CH Cy, H-4, H-6), 3.61 – 3.51 (m, 2H, H-3, H-5), 
3.43 (dd, 1H, J = 10.4, 7.7 Hz, H-2), 3.30 (s, 3H, CH3 OMe), 3.18 (s, 3H, CH3 OMe), 2.02 – 1.87 (m, 2H, CH2 Cy), 1.82 – 
1.71 (m, 2H, CH2 Cy), 1.58 – 1.37 (m, 3H, CH2 Cy), 1.33 (s, 3H, CH3 Me), 1.31 – 1.19 (m, 6H, CH3 Me, CH2 Cy); 13C-APT 
NMR (CDCl3, 101 MHz, HSQC): δ 138.4 (Cq), 128.4, 127.6, 127.6 (CHarom), 101.2 (C-1), 100.0, 99.8 (Cq BDA), 78.3 (CH 
Cy), 74.0 (C-5), 73.6 (CH2 Bn), 70.9 (C-3), 68.4 (C-6), 66.5 (C-4), 63.0 (C-2), 48.1, 48.1 (CH3 OMe), 33.7, 31.8, 25.6, 24.1, 
24.0 (CH2 Cy), 17.7, 17.7 (CH3 Me); HRMS: [M+NH4]+ calcd for C25H41N4O7 509.29698, found 509.29668. 
Ethyl 2-azido-6-O-benzyl-2-deoxy-3,4-O-(2,3-dimethoxybutane-2,3-diyl)-β-D-
glucopyranoside (1B). Donor 1 and ethanol were condensed using the general procedure 
for Tf2O/Ph2SO mediated glycosylations (for an additional 30 min at -40°C) and purified by 
flash column chromatography (1/0 to 9/1 pentane/EtOAc) to yield glycosylation product 1B 
(39.7 mg, 90 µmol, 90%, α:β = <1:20). Rf: 0.48 (9/1 pentane/EtOAc). [α]  = +105.2° (c = 0.85, CHCl3); IR (thin film): 
698, 849, 1047, 1115, 1375, 2108, 2927; 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC): δ 7.39 – 7.24 (m, 5H, CHarom), 
4.61 (d, 1H, J = 12.2 Hz, CHH Bn), 4.57 (d, 1H, J = 12.2 Hz, CHH Bn), 4.31 (d, 1H, J = 7.7 Hz, H-1), 3.98 (dq, 1H, J = 9.5, 
7.1 Hz, CHH Et), 3.76 (dd, 1H, J = 10.9, 1.7 Hz, H-6), 3.71 – 3.64 (m, 2H, H-5, H-6), 3.64 – 3.55 (m, 3H, H-3, H-4, CHH 
Et), 3.46 (dd, 1H, J = 10.5, 7.7 Hz, H-2), 3.31 (s, 3H, CH3 OMe BDA), 3.18 (s, 3H, CH3 OMe BDA), 1.34 (s, 3H, CH3 Me 
BDA), 1.28 (t, 4H, J = 7.1 Hz, CH3 Et), 1.27 (s, 3H, CH3 Me BDA); 13C-APT NMR (CDCl3, 101 MHz, HSQC): δ 138.2 (Cq), 
128.4, 127.6 (CHarom), 102.4 (C-1), 100.1, 99.8 (Cq BDA), 74.0 (C-3/C-4), 73.6 (CH2 Bn), 71.0 (C-3/C-4), 68.3 (C-6), 66.3 
(C-5), 66.0 (CH2 Et), 62.6 (C-2), 48.2, 48.1 (OMe BDA), 17.7, 17.7 (Me BDA), 15.2 (CH3 Et); HRMS: [M+NH4]+ calcd for 
C21H35N4O7 455.25003, found 455.24975. 
2-Fluoroethyl 2-azido-6-O-benzyl-2-deoxy-3,4-O-(2,3-dimethoxybutane-2,3-diyl)-β-D-
glucopyranoside (1C). Donor 1 and 2-fluoroethanol were condensed using the general 
procedure for Tf2O/Ph2SO mediated glycosylations (for an additional 30 min at -40°C) 
and purified by flash column chromatography (1/0 to 9/1 pentane/EtOAc) to yield 
glycosylation product 1C (44 mg, 97 µmol, 97%, α:β = 1:20). Rf: 0.30 (9/1 pentane/EtOAc). [α]  = +96.4° (c = 1.10, 
CHCl3); IR (thin film): 698, 881, 1049, 1113, 1375, 1454, 2110, 2949; 1H NMR (CDCl3, 500 MHz, HH-COSY, HSQC): δ 
7.35 – 7.27 (m, 5H, CHarom), 4.71 – 4.62 (m, 1H, CHHF), 4.62 – 4.52 (m, 3H, CHHF, CH2 Bn), 4.36 (d, 1H, J = 7.7 Hz, H-
1), 4.08 (dddd, 1H, J = 31.8, 12.2, 4.7, 2.6 Hz, CHH-CH2F), 3.88 (dddd, 2H, J = 25.2, 12.1, 6.8, 2.7 Hz, CHH-CH2F), 3.76 
(dd, 1H, J = 11.0, 1.7 Hz, H-6), 3.72 (t, 1H, J = 10.0 Hz, H-4), 3.68 (dd, 1H, J = 11.0, 5.3 Hz, H-6), 3.65 – 3.56 (m, 2H, H-
3, H-5), 3.50 (dd, 1H, J = 10.5, 7.7 Hz, H-2), 3.31 (s, 3H, CH3 OMe), 3.19 (s, 3H, CH3 OMe), 1.34 (s, 3H, CH3 Me), 1.28 (s, 
3H, CH3 Me); 13C-APT NMR (CDCl3, 126 MHz, HSQC): δ 138.2 (Cq), 128.4, 127.7, 127.6 (CHarom), 102.7 (C-1), 100.1, 99.8 
(Cq BDA), 82.7 (d, J = 169.9 Hz, CH2F), 74.1 (C-5), 73.6 (CH2 Bn), 71.0 (C-3), 69.0 (d, J = 20.3 Hz, CH2-CH2F), 68.2 (C-6), 
66.2 (C-4), 62.6 (C-2), 48.2, 48.2 (OMe), 17.7, 17.7 (Me); HRMS: [M+NH4]+ calcd for C21H34FN4O7 473.24060, found 
473.24041. 
2,2-Difluoroethyl 2-azido-6-O-benzyl-2-deoxy-3,4-O-(2,3-dimethoxybutane-2,3-diyl)-α/β-
D-glucopyranoside (1D). Donor 1 and 2,2-difluoroethanol were condensed using the 




40°C) and purified by flash column chromatography (1/0 to 9/1 pentane/EtOAc) to yield glycosylation product 1D (40 
mg, 84 µmol, 84%, α:β = 1:3.5). Rf: 0.60 (9/1 pentane/EtOAc). IR (thin film): 698, 735, 849, 883, 1030, 1107, 1265, 
1373, 1454, 2108, 2926; Data for the β-anomer: 1H NMR (CDCl3, 500 MHz, HH-COSY, HSQC): δ 7.38 – 7.27 (m, 5H, 
CHarom), 6.10 – 5.82 (m, 1H, CHF2), 4.62 – 4.54 (m, 2H, CH2 Bn), 4.34 (d, 1H, J = 7.7 Hz, H-1), 4.05 – 3.93 (m, 1H, CHH-
CHF2), 3.90 – 3.78 (m, 1H, CHH-CHF2,), 3.77 – 3.65 (m, 3H, H-4, H-6, H-6), 3.64 – 3.56 (m, 2H, H-3, H-5), 3.49 (dd, 1H, 
J = 10.5, 7.7 Hz, H-2), 3.30 (s, 3H, CH3 OMe), 3.19 (s, 3H, CH3 OMe), 1.34 (s, 3H, CH3 Me), 1.28 (s, 3H, CH3 Me); 13C-APT 
NMR (CDCl3, 126 MHz, HSQC): δ 138.1 (Cq), 128.5, 127.8, 127.6 (CHarom), 114.2 (dd, J = 241.8, 240.8 Hz, CHF2), 102.9 
(C-1), 100.1, 99.9 (Cq BDA), 74.2 (C-5), 73.7 (CH2 Bn), 70.9 (C-3), 68.8 (dd, J = 30.3, 28.1 Hz, CH2-CHF2), 68.1 (C-6), 66.0 
(C-4), 62.6 (C-2), 48.2, 48.2 (OMe), 17.7, 17.7 (Me); Diagnostic peaks α-anomer: 1H NMR (CDCl3, 500 MHz): δ 4.97 (d, 
0.3H, J = 3.6 Hz, H-1), 4.25 (dd, 0.3H, J = 10.8, 9.7 Hz, H-3), 3.39 (dd, 0.3H, J = 10.9, 3.6 Hz, H-2), 3.37 (s, 0.9H, CH3 
OMe), 1.35 (s, 0.9H, CH3 Me), 1.30 (s, 0.9H, CH3 Me); 13C-APT NMR (CDCl3, 126 MHz, HSQC): δ 137.9, 128.4, 127.7, 
127.6, 113.8 (t, J = 241.5 Hz), 100.2, 100.1 (Cq BDA), 99.4 (C-1), 73.7 (CH2 Bn), 70.0 (C-5), 67.7 (C-6), 67.6 (t, J = 29.0 
Hz, CH2-CHF2), 67.4 (C-3), 66.3 (C-4), 60.0 (C-2), 48.6, 17.9, 17.8; HRMS: [M+NH4]+ calcd for C21H33F2N4O7 491.23118, 
found 491.23061. 
2,2,2-trifluoroethyl 2-azido-6-O-benzyl-2-deoxy-3,4-O-(2,3-dimethoxybutane-2,3-diyl)-
α/β-D-glucopyranoside (1E). Donor 1 and 2,2,2-trifluoroethanol were condensed using the 
general procedure for Tf2O/Ph2SO mediated glycosylations (for an additional 30 min at -
40°C) and purified by flash column chromatography (1/0 to 9/1 pentane/EtOAc) to yield 
glycosylation product 1E (43 mg, 87 µmol, 87%, α:β = 2.5:1). Rf: 0.35 9/1 (pentane/EtOAc). IR (thin film): 673, 737, 851, 
885, 972, 1030, 1111, 1279, 1377, 2108, 2949; Data for the α-anomer: 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC, 
HMBC): δ 7.38 – 7.24 (m, 5H, CHarom), 5.01 (d, 1H, J = 3.6 Hz, H-1), 4.60 – 4.55 (m, 2H, CH2 Bn), 4.28 (dd, 1H, J = 10.9, 
9.5 Hz, H-3), 4.01 – 3.91 (m, 3H, CH2CF3, H-5), 3.89 – 3.82 (m, 1H, H-4), 3.78 – 3.66 (m, 2H, H-6, H-6), 3.41 – 3.35 (m, 
4H, CH3 OMe, H-2), 3.19 (s, 3H, CH3 OMe), 1.35 (s, 3H, CH3 Me), 1.30 (s, 3H, CH3 Me); 13C-APT NMR (CDCl3, 101 MHz, 
HSQC, HMBC): δ 137.9 (Cq), 128.4, 127.8, 127.6 (CHarom), 123.5 (q, J = 278.4 Hz, CF3), 100.2, 100.1 (Cq BDA), 99.3 (C-
1), 73.7 (CH2 Bn), 70.3 (C-5), 67.6 (C-6), 67.2 (C-3), 66.2 (C-4), 65.1 (q, J = 35.3 Hz, CH2CF3), 59.8 (C-2), 48.6, 48.2 (OMe), 
17.8, 17.8 (Me); Diagnostic peaks β-anomer: 1H NMR (CDCl3, 400 MHz): δ 4.38 (d, 0.38H, J = 7.6 Hz, H-1), 4.16 (dq, 
0.38H, J = 12.5, 8.7 Hz, CHH-CF3), 3.65 – 3.56 (m, 2H, H-3, H-5), 3.50 (dd, 0.38H, J = 10.5, 7.6 Hz, H-2), 3.30 (s, 1.14H), 
1.34 (s, 1.14H), 1.28 (s, 1.14H); 13C-APT NMR (CDCl3, 101 MHz): δ 102.4 (C-1), 100.2, 99.9, 74.4, 70.7, 68.0, 66.5, 66.0 
(q, J = 35.1 Hz), 62.6, 48.2, 48.2, 17.7, 17.6; HRMS: [M+NH4]+ calcd for C21H32F3N4O7 509.22176, found 509.22116. 
1,1,1,3,3,3-Hexafluoro-2-propyl 2-azido-6-O-benzyl-2-deoxy-3,4-O-(2,3-dimethoxybutane-
2,3-diyl)-α-D-glucopyranoside (1F). Donor 1 and hexafluoro-iso-propanol were condensed 
using the general procedure for Tf2O/Ph2SO mediated glycosylations (for an additional 120 
hours at -40°C) and purified by flash column chromatography (1/0 to 9/1 pentane/EtOAc) 
to yield glycosylation product 1F (10 mg, 18 µmol, 18%, α:β = >20:1). Rf: 0.7 (9/1 
pentane/EtOAc). [α]  = +182.1° (c = 0.52, CHCl3); 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC, HMBC): δ 7.36 – 7.28 
(m, 5H, CHarom), 5.17 (d, 1H, J = 3.9 Hz, H-1), 4.58 (d, 1H, J = 12.0 Hz, CHH Bn), 4.54 (d, 1H, J = 12.0 Hz, CHH Bn), 4.44 
(hept, 1H, J = 5.8 Hz, CH HFIP), 4.23 (dd, 1H, J = 11.1, 9.6 Hz, H-3), 4.02 (ddd, 1H, J = 10.0, 3.5, 2.0 Hz, H-5), 3.92 (t, 1H, 
J = 9.9 Hz, H-4), 3.78 (dd, 1H, J = 11.2, 3.5 Hz, H-6), 3.64 (dd, 1H, J = 11.1, 2.0 Hz, H-6), 3.46 (dd, 1H, J = 11.0, 3.9 Hz, 
H-2), 3.38 (s, 3H, CH3 OMe), 3.20 (s, 3H, CH3 OMe), 1.36 (s, 3H, CH3 Me), 1.31 (s, 3H, CH3 Me); 13C-APT NMR (CDCl3, 
101 MHz, HSQC, HMBC): δ 137.8 (Cq Bn), 128.5, 127.8, 127.6 (CHarom Bn), 101.1 (C-1), 100.3, 100.2 (Cq BDA), 73.8 (CH2 
Bn), 73.3 (CH HFIP), 71.3 (C-5), 67.2 (C-6), 66.9 (C-3), 65.9 (C-4), 59.8 (C-2), 48.8, 48.3 (OMe), 17.8, 17.8 (Me); HRMS: 
[M+NH4]+ calcd for C22H31F6N4O7 577.20914, found 577.20899. 
 Methyl 6-O-(2-azido-6-O-benzyl-2-deoxy-3,4-O-(2,3-dimethoxybutane-2,3-diyl)-β-
D-glucopyranosyl)-2,3,4-tri-O-benzyl-α-ᴅ-glucopyranoside (1G). Donor 1 and 
acceptor 10 were condensed using the general procedure for Tf2O/Ph2SO mediated 
glycosylations (for an additional 18 hours at -40°C) and purified by flash column 
chromatography (19/1 to 3/1 pentane/EtOAc) to yield glycosylation product 1G (74 
mg, 86 µmol, 86%, α:β = <1:20). Rf: 0.41 (4/1 pentane/EtOAc). [α]  = +54.9° (c = 1.85, CHCl3); IR (thin film): 696, 735, 
849, 962, 1107, 1134, 1369, 1454, 2108, 2907; 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC, HMBC): δ 7.38 – 7.24 (m, 
20H, CHarom), 4.98 (d, 1H, J = 10.9 Hz, CHH Bn), 4.92 (d, 1H, J = 11.1 Hz, CHH Bn), 4.84 – 4.76 (m, 2H, CHH Bn, CHH Bn), 
4.66 (d, 1H, J = 11.0 Hz, CHH Bn), 4.65 (d, 1H, J = 12.1 Hz, CHH Bn), 4.62 (d, 1H, J = 3.5 Hz, H-1), 4.58 (d, 1H, J = 12.1 
Hz, CHH Bn), 4.53 (d, 1H, J = 12.2 Hz, CHH Bn), 4.20 (d, 1H, J = 7.7 Hz, H-1’), 4.12 (dd, 1H, J = 10.9, 1.6 Hz, H-6), 4.00 (t, 
1H, J = 9.3 Hz, H-3), 3.83 – 3.77 (m, 1H, H-5), 3.76 – 3.63 (m, 4H, H-4’, H-6, H-6’, H-6’), 3.63 – 3.52 (m, 4H, H-2, H-3’, 




H-4, H-5’), 3.50 (dd, 1H, J = 10.3, 7.7 Hz, H-2’), 3.38 (s, 3H, CH3 OMe), 3.30 (s, 3H, CH3 OMe BDA), 3.16 (s, 3H, CH3 OMe 
BDA), 1.33 (s, 3H, CH3 Me), 1.26 (s, 3H, CH3 Me); 13C-APT NMR (CDCl3, 101 MHz, HSQC, HMBC): δ 138.8, 138.5, 138.3, 
138.2 (Cq), 128.5, 128.5, 128.5, 128.4, 128.2, 128.2, 128.1, 128.0, 127.8, 127.8, 127.6, 127.6, 127.5 (CHarom), 102.7 (C-
1’), 100.1, 99.8 (Cq BDA), 98.2 (C-1), 82.2 (C-3), 79.9 (C-2), 77.7 (C-4), 75.8, 74.9 (CH2 Bn), 74.3 (C-5), 73.6, 73.5 (CH2 
Bn), 71.3 (C-3’), 69.8 (C-5), 68.6 (C-6), 68.3 (C-6’), 66.2 (C-4’), 62.8 (C-2’), 55.3 (CH3 OMe), 48.1, 48.1 (CH3 OMe BDA), 
17.7, 17.6 (CH3 Me BDA); HRMS: [M+NH4]+ calcd for C47H61N4O12 873.42805, found 873.42812. 
Methyl 4-O-(2-azido-6-O-benzyl-2-deoxy-3,4-O-(2,3-dimethoxybutane-2,3-diyl)-α/β-
D-glucopyranosyl)-2,3,6-tri-O-benzyl-α-ᴅ-glucopyranoside (1H). Donor 1 and 
acceptor 11 were condensed using the general procedure for Tf2O/Ph2SO mediated 
glycosylations (for an additional 18 hours at -40°C) and purified by flash column 
chromatography (19/1 to 4/1 pentane/EtOAc) to yield glycosylation product 1H (80 
mg, 93 µmol, 93%, α:β = 1:15). Rf: 0.51 (4/1 pentane/EtOAc). IR (thin film): 696, 737, 1045, 1109, 1134, 1368, 1454, 
1497, 2108, 2900; Data for the β-anomer: 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC, HMBC): δ 7.37 – 7.19 (m, 20H, 
CHarom), 5.00 (d, 1H, J = 11.4 Hz, CHH Bn), 4.80 (d, 1H, J = 11.4 Hz, CHH Bn), 4.74 (d, 1H, J = 12.2 Hz, CHH Bn), 4.62 (d, 
1H, J = 12.0 Hz, CHH Bn), 4.58 (d, 1H, J = 12.1 Hz, CHH Bn), 4.57 (d, 1H, J = 3.8 Hz, H-1), 4.52 (d, 1H, J = 12.1 Hz, CHH 
Bn), 4.48 (d, 1H, J = 12.4 Hz, CHH Bn), 4.35 (d, 1H, J = 7.8 Hz, H-1’), 4.33 (d, 1H, J = 12.2 Hz, CHH Bn), 4.00 – 3.94 (m, 
1H, H-4), 3.91 (t, 1H, J = 9.1 Hz, H-3), 3.87 (dd, 1H, J = 10.8, 3.3 Hz, H-6), 3.81 – 3.76 (m, 1H, H-5), 3.71 (dd, 1H, J = 
10.8, 1.6 Hz, H-6), 3.68 (t, 1H, J = 9.6 Hz, H-4’), 3.63 (dd, 1H, J = 11.1, 1.4 Hz, H-6’), 3.55 (t, 1H, J = 10.0 Hz, H-3’), 3.48 
– 3.35 (m, 7H, CH3 OMe, H-2, H-2’, H-5’, H-6’), 3.32 (s, 3H, CH3 OMe BDA), 3.17 (s, 3H, CH3 OMe BDA), 1.33 (s, 3H, CH3 
Me BDA), 1.26 (s, 3H, CH3 Me BDA); 13C-APT NMR (CDCl3, 101 MHz, HSQC, HMBC): δ 139.5, 138.6, 138.3, 137.9 (Cq), 
128.6, 128.5, 128.4, 128.4, 128.3, 128.2, 128.2, 128.1, 127.8, 127.8, 127.8, 127.8, 127.6, 127.5, 127.4, 127.3, 127.1 
(CHarom), 101.3 (C-1’), 100.1, 99.8 (Cq BDA), 98.4 (C-1), 80.3 (C-3), 79.1 (C-2), 76.7 (C-4), 75.4 (CH2 Bn), 74.3 (C-5’), 73.7, 
73.5 (CH2 Bn), 71.6 (C-3’), 69.8 (C-5), 68.4 (C-6), 68.1 (C-6’), 66.2 (C-4’), 63.5 (C-2’), 55.3 (OMe), 48.2, 48.1 (OMe BDA), 
17.7, 17.6 (Me BDA); Diagnostic peaks α-anomer: 1H NMR (CDCl3, 400 MHz): δ 5.72 (d, 0.1H, J = 4.1 Hz, H-1’), 5.09 (d, 
0.1H, J = 10.5 Hz, CHH Bn), 4.84 (d, 0.1H, J = 10.5 Hz, CHH Bn), 4.17 – 4.11 (m, 0.1H), 4.06 (d, 0.1H, J = 9.1 Hz); 13C-APT 
NMR (CDCl3, 101 MHz): δ 100.0 (Cq BDA), 98.6 (C-1’), 97.7 (C-1), 82.0, 80.6, 75.1, 74.2, 73.3, 70.2, 60.0, 55.4, 48.6; 
HRMS: [M+NH4]+ calcd for C47H61N4O12 873.42805, found 873.42783. 
Methyl (Methyl 4-O-[2-azido-6-O-benzyl-2-deoxy-3,4-O-(2,3-dimethoxybutane-2,3-
diyl)-α/β-D-glucopyranosyl]-2,3-di-O-benzyl-α-ᴅ-glucopyranosyl uronate) (1I). Donor 
1 and acceptor 12 were condensed using the general procedure for Tf2O/Ph2SO 
mediated glycosylations (for an additional 18 hours at -40°C) and purified by flash 
column chromatography (19/1 to 4/1 pentane/EtOAc) to yield glycosylation 
product 1I (66 mg, 83 µmol, 83%, α:β = 1.5:1). Rf: 0.44 and 0.47 (4/1 pentane/EtOAc). IR (thin film): 698, 735, 1043, 
1107, 1454, 1749, 2108, 2949; Reported as a 1 : 0.7 mixture of anomers: 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC, 
HMBC): δ 7.34 – 7.21 (m, 31H), 5.58 (d, 1H, J = 3.8 Hz, H-1’α), 5.05 – 4.98 (m, 1.7H, CHH Bn α, CHH Bnβ), 4.85 (d, 1H, J 
= 10.5 Hz, CHH Bnα), 4.82 – 4.71 (m, 2.4H, CHH Bnα, CHH Bnβ, CHH Bnβ), 4.62 – 4.53 (m, 4.4H, CHH Bnα, CHH Bnα CHH 
Bnβ, H-1α, H-1β), 4.50 (d, 1H, J = 12.0 Hz, CHH Bnα), 4.43 (d, 0.7H, J = 12.2 Hz, CHH Bnβ), 4.38 (d, 0.7H, J = 7.8 Hz, H-
1’β), 4.34 (d, 0.7H, J = 12.1 Hz, CHH Bnβ), 4.23 (d, 0.7H, J = 9.8 Hz, H-5β), 4.18 (d, 1H, J = 9.4 Hz, H-5α), 4.13 (dd, 1H, J = 
10.9, 9.7 Hz, H-3’α), 4.08 – 4.00 (m, 2.7H, H-3α, H-4α, H-4β), 3.93 (t, 0.7H, J = 9.1 Hz, H-3β), 3.83 (t, 1H, J = 10.0 Hz, H-
4’α), 3.81 (s, 2.1H, CH3 CO2Meβ), 3.73 – 3.67 (m, 4.7H, CH3 CO2Meα, H-4’β, H-6’α), 3.61 – 3.44 (m, 6.5H, H-2α, H-2β, H-
3’β, H-5’α, H-5’β, H-6’α, H-6’β, H-6’β), 3.41 – 3.36 (m, 5.8H, CH3 OMeα, CH3 OMeβ, H-2’β), 3.35 (s, 3H, CH3 OMe BDAα), 
3.30 – 3.26 (m, 3.1H, CH3 OMe BDAβ, H-2’), 3.16 (s, 2.1H, CH3 OMe BDAβ), 3.15 (s, 3H, CH3 OMe BDAα), 1.32 (s, 5.1H, 
CH3 Me BDAα, CH3 Me BDAβ), 1.25 (s, 2.1H, CH3 Me BDAβ), 1.23 (s, 3H, CH3 Me BDAα); 13C-APT NMR (CDCl3, 101 MHz, 
HSQC, HMBC): δ 170.1, 169.9 (C=O), 139.3, 138.5, 138.4, 138.1, 138.1, 137.8 (Cq), 128.6, 128.5, 128.5, 128.4, 128.3, 
128.3, 128.2, 128.2, 128.0, 128.0, 128.0, 127.8, 127.7, 127.7, 127.6, 127.6, 127.6, 127.5, 127.4, 127.4, 127.2 (CHarom), 
102.1 (C-1’β), 100.1, 99.8, 99.8 (Cq BDA), 98.9 (C-1β), 98.6 (C-1α), 98.3 (C-1’α), 81.3 (C-3α), 79.8 (C-3β), 79.6 (C-2α), 79.0 
(C-4β), 78.6 (C-2β), 75.5, 75.4 (CH2 Bn), 74.9 (C-4α), 74.4 (C-5’β), 73.9, 73.8, 73.7, 73.5 (CH2 Bn), 71.3 (C-3’β), 70.1 (C-
5α), 70.0 (C-5’α), 69.9 (C-5β), 68.0 (C-6’β), 67.4 (C-3’α), 67.3 (C-6’α), 66.0 (C-4’β), 65.8 (C-4’α), 63.4 (C-2’α), 60.1 (C-2’β), 
55.9, 55.8 (OMe), 52.7, 52.7 (CO2 Me), 48.4, 48.2, 48.1, 48.1 (OMe BDA), 17.9, 17.7, 17.7, 17.6 (Me BDA); HRMS: 














D-glucopyranosyl)-2,3,6-tri-O-benzyl-β-ᴅ-galactopyranoside (1J). Donor 1 and 
acceptor 13 were condensed using the general procedure for Tf2O/Ph2SO mediated 
glycosylations (for an additional 18 hours at -40°C) and purified by flash column 
chromatography (19/1 to 4/1 pentane/EtOAc) to yield glycosylation product 1J (74 
mg, 86 µmol, 86%, α:β = 1:1.7). Rf: 0.48 and 0.54 (4/1 pentane/EtOAc). IR (thin film): 696, 737, 1034, 1109, 1368, 1454, 
2108, 2930; Reported as a 1 : 1.5 mixture of anomers: 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC, HMBC): δ 7.42 – 
7.19 (m, 50H, CHarom), 4.99 (d, 1H, J = 3.9 Hz, H-1’α), 4.90 (d, 1H, J = 10.9 Hz, CHH Bnα), 4.90 – 4.83 (m, 3H, 2xCHH Bnβ), 
4.79 (d, 1H, J = 10.9 Hz, CHH Bnα), 4.75 – 4.71 (m, 4H, CHH Bnβ, CHH Bnα, H-1’β), 4.66 (d, 1.5H, J = 12.2 Hz, CHH Bnβ), 
4.62 (d, 1H, J = 12.5 Hz, CHH Bnα), 4.53 (s, 2H, CH2 Bnα), 4.49 (s, 3H, CH2 Bnβ), 4.48 – 4.40 (m, 4H, CH2 Bnβ, CHH Bnα), 
4.32 (d, 1H, J = 12.2 Hz, CHH Bnα), 4.28 (d, 1.5H, J = 7.8 Hz, H-1β), 4.27 – 4.21 (m, 2H, H-3’α, H-5’α), 4.23 (d, 1H, J = 7.6 
Hz, H-1α), 4.14 (d, 1H, J = 3.0 Hz, H-4α), 4.09 (d, 1.5H, J = 2.6 Hz, H-4β), 3.98 – 3.87 (m, 3.5H, H-2β, H-4’α, H-6α), 3.82 
(dd, 1.5H, J = 10.5, 4.7 Hz, H-6’β), 3.75 – 3.55 (m, 14H, CH3 OMeβ, H-2α, H-4’β, H-5’β, H-6’β, H-6α, H-6β, H-6β), 3.54 – 
3.40 (m, 11H, CH3 OMeα, H-2’β, H-3β, H-3’β, H-5α, H-5β, H-6’α), 3.40 – 3.33 (m, 5H, CH3 OMe BDAα, H-2’α, H-3α), 3.31 (s, 
4.5H, CH3 OMe BDAβ), 3.18 – 3.10 (m, 8.5H, CH3 OMe BDAα,β, H-6’α), 1.34 (s, 3H, CH3 Me BDAα), 1.34 (s, 4.5H, CH3 Me 
BDAβ), 1.29 (s, 3H, CH3 Me BDAα), 1.27 (s, 4.5H, CH3 Me BDAβ); 13C-APT NMR (CDCl3, 101 MHz, HSQC, HMBC): δ 138.9, 
138.8, 138.6, 138.5, 138.5, 138.3, 138.2, 137.6 (Cq), 128.6, 128.4, 128.4, 128.4, 128.3, 128.3, 128.2, 128.2, 128.2, 
128.1, 127.6, 127.6, 127.6, 127.6, 127.5, 127.5, 127.5, 127.5, 127.3, 127.2 (CHarom), 105.3 (C-1α), 105.1 (C-1β), 102.5 
(C-1’β), 100.1, 100.0, 99.9, 99.8 (Cq BDA), 99.4 (C-1’α), 81.3 (C-3β), 80.2 (C-3α), 79.5 (C-2β) , 79.0 (C-2α), 75.2, 75.0 (CH2 
Bn), 74.1 (C-4α), 73.9 (C-5’β), 73.9 (C-5β), 73.7 (CH2 Bn), 73.6 (C-4β), 73.6, 73.6, 73.5, 73.4 (CH2 Bn), 73.0 (C-5α), 72.9 
(CH2 Bn), 70.7 (C-3’β), 70.3 (C-6’β), 69.5 (C-5’α), 68.5 (C-6β), 68.0 (C-3’α), 67.2, 67.1 (C-6α, C-6’α), 66.2 (C-4’β), 66.0 (C-
4’α), 62.7 (C-2’β), 60.9 (C-2’α), 57.3, 57.2 (OMe), 48.7, 48.2, 48.1, 48.1 (OMe BDA), 17.9, 17.9, 17.7, 17.7 (Me BDA); 
HRMS: [M+NH4]+ calcd for C47H61N4O12 873.42805, found 873.42801. 
Methyl 2-O-(2-azido-6-O-benzyl-2-deoxy-3,4-O-(2,3-dimethoxybutane-2,3-diyl)-α/β-D-
glucopyranosyl)-3-O-benzyl-4,6-O-benzylidene-α-ᴅ-mannopyranoside (1K). Donor 1 and 
acceptor 14 were condensed using the general procedure for Tf2O/Ph2SO mediated 
glycosylations (for an additional 18 hours at -40°C) and purified by flash column 
chromatography (19/1 to 4/1 pentane/EtOAc) to yield glycosylation product 1K (71 mg, 
93 µmol, 93%, α:β = 1:1.7). Rf: 0.45 (4/1 pentane/EtOAc).IR (thin film): 698, 1038, 1109, 
1126, 1375, 1454, 2110, 2912; Data for the β-anomer: 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC, HMBC): δ 7.52 – 
7.47 (m, 2H, CHarom), 7.40 – 7.32 (m, 3H, CHarom), 7.30 – 7.19 (m, 10H, CHarom), 5.60 (s, 1H, CHPh), 4.86 – 4.78 (m, 2H, 
CHH Bn, H-1), 4.64 (d, 1H, J = 12.5 Hz, CHH Bn), 4.54 (d, 1H, J = 12.0 Hz, CHH Bn), 4.49 (d, 1H, J = 11.9 Hz, CHH Bn), 
4.41 (d, 1H, J = 7.3 Hz, H-1’), 4.29 (dd, 1H, J = 3.3, 1.5 Hz, H-2), 4.24 (dd, 1H, J = 10.0, 4.6 Hz, H-6), 4.16 (t, 1H, J = 9.7 
Hz, H-4), 3.93 (dd, 1H, J = 10.1, 3.4 Hz, H-3), 3.86 (t, 1H, J = 10.2 Hz, H-6), 3.82 – 3.61 (m, 6H, H-2’, H-4’, H-5, H-5’, H-
6’, H-6’), 3.57 (dd, 1H, J = 10.8, 7.9 Hz, H-3’), 3.37 (s, 3H, CH3 OMe), 3.30 (s, 3H, CH3 OMe BDA), 3.18 (s, 3H, CH3 OMe 
BDA), 1.34 (s, 3H, CH3 Me BDA), 1.28 (s, 3H, CH3 Me BDA); 13C-APT NMR (CDCl3, 101 MHz, HSQC, HMBC): δ 138.5, 
138.1, 137.8 (Cq), 128.4, 128.3, 128.2, 127.8, 127.6, 127.4, 127.3, 126.2, 126.2 (CHarom), 101.6 (CHPh), 101.4 (C-1’), 
100.0, 99.8 (Cq BDA), 99.3 (C-1), 78.1 (C-4), 74.7 (C-2), 74.4 (C-5’), 73.8 (CH2 Bn), 73.7 (C-3), 71.0 (CH2 Bn), 70.5 (C-3’), 
68.9, 68.8 (C-6, C-6’), 66.4 (C-4’), 64.2 (C-5), 63.0 (C-2’), 55.0 (OMe), 48.1 (OMe BDA), 17.7, 17.7 (Me BDA); Data for 
the α-anomer: 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC, HMBC): δ 7.51 – 7.43 (m, 2H, CHarom), 7.40 – 7.23 (m, 13H, 
CHarom), 5.62 (s, 1H, CHPh), 5.35 (d, 1H, J = 3.8 Hz, H-1’), 4.88 (d, 1H, J = 12.4 Hz, CHH Bn), 4.75 (d, 1H, J = 1.3 Hz, H-1), 
4.69 (d, 1H, J = 12.4 Hz, CHH Bn), 4.57 (s, 2H, CH2 Bn), 4.32 (dd, 1H, J = 10.9, 9.6 Hz, H-3’), 4.30 – 4.22 (m, 2H, H-4, H-
6), 4.10 (dd, 1H, J = 3.0, 1.7 Hz, H-2), 4.03 (ddd, J = 10.2, 5.0, 1.7 Hz, 1H, H-5’), 3.96 (dd, 1H, J = 9.9, 3.1 Hz, H-3), 3.85 
(t, 1H, J = 10.2 Hz, H-6), 3.80 – 3.66 (m, 4H, H-4’, H-5, H-6’, H-6’), 3.42 (s, 3H, CH3 OMe BDA), 3.25 – 3.17 (m, 7H, CH3 
OMe BDA, CH3 OMe, H-2’), 1.36 (s, 3H, CH3 Me BDA), 1.32 (s, 3H, CH3 Me BDA); 13C-APT NMR (CDCl3, 101 MHz, HSQC, 
HMBC): δ 138.8, 138.0, 137.8 (Cq), 128.9, 128.8, 128.3, 128.2, 127.7, 127.7, 127.6, 127.4, 126.2 (CHarom), 101.6 (CHPh), 
100.9 (C-1), 100.2 (C-1’), 100.1, 100.0 (Cq BDA), 79.5 (C-4), 76.1 (C-2), 75.5 (C-3), 73.7, 73.1 (CH2 Bn), 70.0 (C-5’), 69.0 
(C-6), 68.2 (C-6’), 66.9 (C-4’), 66.5 (C-3’), 63.9 (C-5), 60.1 (C-2’), 54.8 (OMe), 48.7, 48.2 (OMe BDA), 17.9, 17.8 (Me 
BDA); HRMS: [M+NH4]+ calcd for C40H53N4O12 781.36545, found 781.36550. 
Trifluoromethanesulfonyl 2-azido-6-O-benzyl-2-deoxy-3,4-O-(2,3-dimethoxybutane-2,3-diyl)-α-D-
glucopyranoside (18). 1H NMR (CD2Cl2, T = 243 K, 500 MHz, HH-COSY, HSQC): δ 6.10 (d, 1H, J = 
3.3 Hz, H-1), 4.52 (d, 1H, J = 11.5 Hz, CHH Bn), 4.48 (d, 1H, J = 11.3 Hz, CHH Bn), 4.19 (t, 1H, J = 
10.2 Hz, H-3), 4.07 (d, 1H, J = 10.4 Hz, H-5), 4.01 (t, 1H, J = 9.9 Hz, H-4), 3.87 (dd, 1H, J = 10.8, 3.5 
















1.30 (s, 3H, CH3 Me), 1.25 (s, 3H, CH3 Me); 13C-APT NMR (CD2Cl2, 126 MHz, HSQC): δ 105.8 (C-1), 99.8, 99.6 (Cq BDA), 
73.2 (C-5), 72.9 (CH2 Bn), 67.5 (C-3), 65.9 (C-6), 63.6 (C-4), 58.6 (C-2), 48.3, 48.1 (OMe), 17.3, 17.2 (Me). 
1-(2-azido-6-O-benzyl-2-deoxy-3,4-O-[2,3-dimethoxybutane-2,3-diyl]-α-D-glucopyranosyl)-2-
azido-6-O-benzyl-2-deoxy-3,4-O-[2,3-dimethoxybutane-2,3-diyl]-β-D-glucopyranoside (24). IR 
(thin film): 698, 737, 883, 1032, 1107, 1134, 1263, 1279, 1375, 1454, 2108, 2926, 2947, 2994;1H 
NMR (CDCl3, 400 MHz, HH-COSY, HSQC): δ 7.36 – 7.21 (m, 10H, CHarom), 5.20 (d, 1H, J = 3.6 Hz, 
H-1’), 4.53 –  4.46 (m, 2H, CH2 Bn), 4.44 – 4.38 (m, 2H, CHH Bn, H-1), 4.35 – 4.28 (m, 2H, CHH 
Bn, H-3’), 4.23 (dt, 1H, J = 10.7, 2.4 Hz, H-5’), 3.93 (t, 1H, J = 10.0 Hz, H-4’), 3.74 – 3.52 (m, 8H, 
H-2, H-3, H-4, H-5, 2xH-6, 2xH-6’), 3.39 (dd, 1H, J = 7.3, 3.5 Hz, H-2’), 3.37 (s, 3H, CH3 OMe), 3.32 
(s, 3H, CH3 OMe), 3.21 (s, 3H, CH3 OMe), 3.16 (s, 3H, CH3 OMe), 1.35 (s, 3H, CH3 Me), 1.34 (s, 3H, CH3 Me), 1.29 (s, 3H, 
CH3 Me), 1.28 (s, 3H, CH3 Me); 13C-APT NMR (CDCl3, 101 MHz, HSQC): δ 138.3, 138.2 (Cq Bn), 128.5, 128.3, 127.7, 
127.6 (CHarom), 102.0 (C-1), 100.3, 100.2, 100.0, 99.9 (Cq BDA), 99.8 (C-1’), 74.4 (C-5), 73.6, 73.5 (CH2 Bn), 71.6 (C-3), 
70.6 (C-5’), 68.3 (C-6), 67.5 (C-3’), 67.4 (C-6’), 66.0  (C-4’), 65.9 (C-4), 63.3 (C-2), 60.1 (C-2’), 48.7, 48.2, 48.2, 48.2 
(OMe), 17.9, 17.8, 17.8, 17.7 (Me); HRMS: [M+NH4]+ calcd for C38H56N6O13 818.39306, found 818.39310. 
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Mapping glycosylation stereoselectivity 





The union of two carbohydrates to generate larger oligosaccharides is arguably one of 
the most important reactions in glycochemistry.1–4 Although the glycosylation reaction 
has been actively studied for more than half a century, many aspects that affect this 
reaction, both in terms of yield and stereoselectivity, remain enigmatic.5–10 The reactivity 
of the carbohydrate building blocks is one of the most important determinants that 
influence the outcome of a glycosylation reaction.11,12 The reactivity of donor glycosides 
has been very well documented: the relative reactivity value (RRV) of hundreds of 
thioglycosides has been established and hundreds of anomeric triflates and other 
covalent reactive species, key reactive intermediates formed in situ during the reaction, 
have been characterized.13–18 The reactivity of acceptor glycosides is less well understood 
and systematic studies investigating this important reaction parameter are extremely 
scarce.19–24 At the same time, it is common practice to change protecting groups on the 




glycosylation reaction.25–28 Often this is done in a time consuming, trial-and-error 
manner as well defined guidelines how to tune the reactivity of an acceptor and how this 
effects the glycosylation reaction are absent.29–31 
In Chapters 3 and 4 of this thesis the profound influence acceptor nucleophilicity 
has on the stereoselectivity of glycosylation reactions with 4,6-O-benzylidene protected 
glucose and glucosamine donors was demonstrated.32,33 In these studies a panel of 
partially fluorinated ethanols (ethanol, mono-, di- and trifluoroethanol) was used to 
reveal a donor’s stereoselectivity dependency on acceptor nucleophilicity and described 
the change in the underlying continuum of mechanisms (Scheme 1).21,34,35 An intimate 
relation between model acceptor reactivity and glycosylation stereoselectivity was 
evident. Whereas some donors are highly sensitive towards acceptor reactivity, other 
donors are more reluctant to changes in stereochemical outcome. They all have in 
common that eventually the poorest of O-nucleophiles lead them to converge to α-
selectivity. These results have been explained by stereoelectronic properties of both the 
donor and acceptor molecules. In a general sense, the strongest acceptors are able to 
substitute an anomeric leaving group (α-triflate) in an SN2-like substitution reaction. 
Somewhat weaker acceptors preferentially react with the more reactive β-triflate, and 
upon reducing acceptor reactivity further the mechanism shifts towards the SN1-side of 
the reactivity spectrum as increasingly stronger electrophiles are required. 
 
Scheme 1. General glycosylation mechanism, with distinct oxocarbenium ion conformations for the solvent-
















































Results and discussion 
Among the various donors evaluated in Chapters 3-5, the benzylidene glucose (A) and 
glucosazide donors (B) were identified to be the most susceptible to acceptor reactivity, 
based on the stereochemical results of the fluorinated ethanol model system and a few 
carbohydrate acceptors (See Table 1). An extension of the set of carbohydrate acceptors 
was envisioned, bearing protecting groups differing in electron-withdrawing properties 
to closely follow the trend set by the model nucleophiles, determined by the 
stereoselectivities in glycosylations with donors A and B. Simultaneously, the variety of 
acceptors can provide an accurate scale of relative acceptor reactivities to which any 

























1 : 10 
(68%) 




1 : 1 
(82%) 
1B 
1 : 7 
(88%) 
 
1 : 2.8 
(70%) 




2 : 1 
(85%) 
2B 
1 : 5 
(69%) 
 
5 : 1 
(70%) 




4 : 1 
(92%) 
3B 
1 : 1.1 
(67%) 
 
>20 : 1 
(64%) 




5 : 1 
(90%) 
4B 
1.1 : 1 
(93%) 
aRatios and yields of the isolated product after SiO2 and LH-20 size-exclusion chromatography, anomers were 
not separated. Ratios were determined by integration of representative signals for each anomer in the mixture 






















To keep steric and other structural effects to a minimum for comparison 
throughout the scope of acceptors, the primary focus was laid on a diverse set of C-4–
OH glucoside acceptors (Figure 1, 1-20). The other alcohol functions are protected as 
either O-benzyl or O-benzoyl groups, and in addition to these two groups, the primary 
alcohol is also either reduced or oxidized to give C-6-deoxy and C-6–CO2Me species 
respectively to provide for a difference in electron-withdrawing properties. The 
glycosylation method used throughout this study is based on preactivation of donors A 
and B in DCM with the Ph2SO/Tf2O activation couple in the presence of hindered weak 
base TTBP at -80°C36,37, followed by addition of a solution of the acceptor. Applying this 
protocol, the generation of an equilibrium of reactive species (Scheme 1) is ensured, 
enabling the rationalization of the stereoselectivity in terms of the set of reactive species, 
and furthermore avoids competitive alternative pathways present in the in situ activation 
scenarios (direct substitution of the activation thioglycoside, its ion pair or the first 
formed oxocarbenium ion conformer contribute to an increased complexity of the 
reaction mechanism).  
 
 
Figure 1. Donors and gluco C-4–OH acceptors used in this chapter. 
 
In Table 1 results previously obtained with the fluorinated model alcohols are 
directly compared with glycosylation results of 2,3-di-O-benzyl acceptors 1-4. A clear 
transition from β- to α-selectivity, following the electron-withdrawing tendency of the 
protecting group at the C-6 position, arises. The uronic acid having its electron-
withdrawing carbonyl function closer to the acceptor’s nucleophilic center than the 6-O-
benzoyl has, is more α-directing than the latter, which in turn gives higher α-selectivity 
than the 6-O-benzyl. Changing the configuration of the remote anomeric position of the 
acceptor to a β-glucoside (17-20), or protecting the C-2 position with a benzoyl (5-8) 
rather than a benzyl has no apparent effect on the glycosylation stereoselectivities (Table 





















5: R = CH2OBn
6: R = CH3
7: R = CH2OBz
8: R = CO2Me
9: R = CH2OBn
10: R = CH3
11: R = CH2OBz
12: R = CO2Me
13: R = CH2OBn
14: R = CH3
15: R = CH2OBz
16: R = CO2Me
17: R = CH2OBn
18: R = CH3
19: R = CH2OBz




















1: R = CH2OBn
2: R = CH3
3: R = CH2OBz
4: R = CO2Me






Table 2. Glycosylations of donor A and B with β-acceptors 17-20 and α-acceptors bearing a benzoyl on C-2 























1 : 1 
(79%) 
17B 




1 : 1.1 
(81%) 
5B 




1.1 : 1 
(87%) 
18B 
1 : 5.6 
(86%)  
6A 
1.1 : 1 
(86%) 
6B 




3.3 : 1 
(73%) 
19B 




3.5 : 1 
(88%) 
7B 




5 : 1 
(83%) 
20B 
1.2 : 1 
(85%)  
8A 
4.8 : 1 
(96%) 
8B 




>20 : 1 
(95%) 
9B 




>20 : 1 
(90%) 
13B 




>20 : 1 
(93%) 
10B 
14 : 1 
(81%)  
14A 
>20 : 1 
(83%) 
14B 




>20 : 1 
(95%) 
11B 




>20 : 1 
(91%) 
15B 




>20 : 1 
(86%) 
12B 
>20 : 1 
(93%)  
16A 
>20 : 1 
(84%) 
16B 




1 : 2.7 
(90%) 
21B 




3 : 1 
(86%) 
22B 





α-selectivity is found only by changing the C-3–OBn group to a C-3–OBz group (Table 
2, 9-12). Even the more β-selective donor B reacts with high to complete α-selectivity 
with the C-3–OBz acceptors (9-16). Only exchanging the two C–H bonds for a C=O 
bond, by replacing a benzyl ether for a benzoyl ester, a marked change in stereoselectivity 
is achieved. This effect is most pronounced at the nearby C-3 position, whereas position 
C-6 offers slight fine-tuning of the acceptor reactivity, and position C-2 has only a 
negligible influence. 42 
The concept of reactivity tuning of the acceptors works consistently well for C-4–
OH gluco-configured acceptors. The more reactive primary acceptors 21 and 22 (Table 
2) showed similar behavior and upon benzoylation significantly more α-product is 
obtained, however the C-6 nucleophilic position remains too reactive to give complete 
α-selectivity. 
To examine the extent of influence the protecting group on the C-6 position 
exerts, more electronegative elements were introduced on the benzoyl aromatic ring 
(Table 3, 23-26).43 A series of mono-nitrobenzoyl esters were found to marginally 
increase α-selectivity, but acceptor 26 bearing a 2,6-dinitrobenzoyl group enhanced α-
selectivity even more than the uronic acid acceptor 4.44 
 









































The translation from a set of fluorinated model nucleophiles providing a reactivity-
selectivity glycosylation picture, to a selection of carbohydrate acceptors occurs without 
difficulty. These carbohydrate acceptors can be tuned in reactivity just like donors have 
been in the past by manipulation of their protecting groups, and their reactivity exploited 
in obtaining stereoselectivity in glycosylations. Everyday protecting- and functional 
groups were successfully used to moderate the reactivity of the glycosyl acceptors. The 
most electron-withdrawing groups turned the acceptor into a poor nucleophile and 
steered the glycosyation utilizing these acceptors to the α-product. The concept of 
acceptor reactivity tuning holds for all the example acceptors displayed in this chapter. 
By using this panel of reference acceptors and the two model donors, any other relevant 
acceptor can have its reactivity compared with the current set of acceptors and 







General experimental procedures: 
A: reductive opening benzylidene acetal. The benzylidene protected compound (1 eq.) was coevaporated with dry 
toluene (2x) and dissolved at r.t. in dry THF (0.07 M). NaCNBH3 (5 eq.) was added followed by drop-wise addition of a 
4 M HCl solution in 1,4-dioxane (5.2 eq. pH<4). After stirring for an additional hour, the reaction was quenched by the 
addition of ice water (40 mL/mmol) and extracted with DCM (2x 15 mL/mmol). The combined organic layers were 
washed with sat.aq. NaHCO3 and sat.aq. NaCl.  The organic fraction was dried (MgSO4), filtered, concentrated in vacuo, 
and purified by column chromatography (pentane/EtOAc mixtures). 
B: iodination-deoxygenation. To a 0°C solution of the diol (1 eq.) in pyridine (0.2 M) was added p-TsCl (1.5 eq.) and the 
reaction stirred until completion (TLC, 3-14 h). MeOH was added (1 mL/mmol), and the reaction mixture diluted with 
Et2O (15 mL/mmol). The organic layer was washed with 5 M aq. HCl (3x), H2O, sat.aq. NaHCO3, and sat.aq. NaCl. The 
organic fraction was dried (MgSO4), filtered and concentrated in vacuo. The crude compound was dissolved in 
butanone (0.2 M) and NaI (2 eq.) was added. The reaction mixture was heated for 3h at 80°C after which it was diluted 
with EtOAc and washed with 10% aq. Na2S2O3 and H2O. The organic fraction was dried (MgSO4), filtered, concentrated 
in vacuo, and purified by column chromatography (pentane/EtOAc mixtures). The intermediate iodo compound (1 
eq.) was coevaporated with dry toluene and dissolved in toluene (0.07 M) under a nitrogen atmosphere. AIBN (0.05 
eq.) and Bu3SnH (2 eq.) were added and the reaction refluxed (120°C) for 3-7 h. The cooled solution was diluted with 
EtOAc and washed with H2O and sat.aq. NaCl. The organic fraction was dried (MgSO4), filtered, concentrated in vacuo, 
and purified by column chromatography (pentane/EtOAc mixtures). 
C: regioselective benzoylation. To a 0°C solution of the diol (1 eq.) in DCM (0.35 M) was added pyridine (5 eq.) followed 
by a solution of benzoyl chloride (1.05 eq.) in DCM (1.6 M), slowly added over 15 min. After stirring overnight, the 
reaction mixture was diluted with DCM, washed with 1 M HCl (2x), H2O and sat.aq. NaHCO3. The organic fraction was 
dried (MgSO4), filtered, concentrated in vacuo, and purified by column chromatography (pentane/EtOAc mixtures). 
D: regioselective oxidation. To a 0°C solution of the diol (1 eq.) in DCM/H2O (5/1, v/v, 0.20 M) was added 
(diacetoxy)iodobenzene (2.5 eq.) and TEMPO (0.2 eq.). The mixture was vigorously stirred for 2-5 h, and quenched by 
the addition of 10% aq. Na2S2O3. The reaction mixture was extracted twice with DCM. The water layer was acidified 
(pH 1) with 1 M aq. HCl and extracted once with DCM. The combined organic layers were washed with H2O, then dried 
(MgSO4), filtered, and concentrated in vacuo. The crude carboxylic acid was coevaporated twice with dry toluene and 
dissolved in DMF (0.35 M). MeI (2 eq.) and K2CO3 (2 eq.) were added and stirred for 3 h. The reaction was quenched 
with AcOH (3 eq.), and diluted with H2O. The mixture was extracted thrice with EtOAc, and the combined organic 
layers were washed with H2O and sat.aq. NaCl. The organic fraction was dried (MgSO4), filtered, concentrated in vacuo, 
and purified by column chromatography (pentane/EtOAc mixtures). 
E: Tf2O/Ph2SO mediated pre-activation glycosylation. Donor (0.1 mmol), Ph2SO (26 mg, 0.13 mmol, 1.3 equiv), and tri-
tert-butylpyrimidine (TTBP) (62 mg, 0.25 mmol, 2.5 equiv) were coevaporated twice with dry toluene and dissolved in 
dry DCM (2 mL, 0.05 M donor). Activated 3 Å molecular sieves (rods, 1 /16 in. in size) were added, and the reaction 
mixture was stirred for 1 h at room temperature under a nitrogen atmosphere. The solution was cooled to −78 °C, 
and Tf2O (22 μL, 0.13 mmol, 1.3 equiv) was added. The reaction mixture was allowed to warm to −60 °C and then 
recooled to −78 °C, a er which the acceptor (0.2 mmol, 2 equiv) in DCM (0.4 mL, 0.5 M) was added. The reaction 
mixture was allowed to warm to −40 °C in approximately 90 min and s rred overnight at that temperature. The 
reaction was quenched with Et3N (0.1 mL, 0.72 mmol, 5.5 equiv) at −40 °C, and the mixture was diluted with DCM. 
The solution was transferred to a separatory funnel, water was added, the layers were separated, and the water phase 
was extracted once more with DCM. The combined organic layers were dried over MgSO4, filtered, and concentrated 
in vacuo. Purification by silica gel flash column chromatography and sephadex LH-20 size-exclusion chromatography 
yielded the glycosylation product as a mixture of anomers.  
  




Scheme S1: Synthesis of all C-4–OH acceptors.a,b 
 
aAcceptors 17-20 follow the same four procedures from the corresponding β-methyl glycoside, acceptors 23-25 follow 
procedure C with the appropriate nitrobenzoyl chloride. bAcceptor 2 was made via an alternative route. 
Methyl 2,3,6-tri-O-benzyl-α-D-glucopyranoside (1). Methyl 2,3-di-O-benzyl-4,6-O-benzylidene-α-D-
glucopyranoside32 (4.67 g, 10 mmol) was converted to the title compound 1 following general 
procedure A. Yield: 3.5 g, 7.5 mmol, 75%. Rf 0.20 (9/1 pentane/EtOAc). Spectroscopic data were in 
accord with those previously reported.32 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC): δ 7.40 – 7.24 (m, 15H, CHarom), 
5.00 (d, 1H, J = 11.4 Hz, CHH Bn), 4.77 (d, 1H, J = 12.1 Hz, CHH Bn), 4.73 (d, 1H, J = 11.4 Hz, CHH Bn), 4.66 (d, 1H, J = 
12.1 Hz, CHH Bn), 4.63 (s, 1H, H-1), 4.59 (d, 1H, J = 12.2 Hz, CHH Bn), 4.54 (d, 1H, J = 12.2 Hz, CHH Bn), 3.78 (t, 1H, J = 
9.1 Hz, H-3), 3.74 – 3.64 (m, 3H, H-5, H-6), 3.60 (td, 1H, J = 9.1, 2.3 Hz, H-4), 3.53 (dd, 1H, J = 9.5, 3.5 Hz, H-2), 3.38 (s, 
3H, CH3 OMe); 13C-APT NMR (CDCl3, 101 MHz, HSQC): δ 138.9, 138.2 (Cq), 128.7, 128.6, 128.6, 128.5, 128.3, 128.3, 
128.1, 128.1, 128.0, 127.8, 127.8 (CHarom), 98.3 (C-1), 81.6 (C-3), 79.7 (C-2), 75.6, 73.7, 73.3 (CH2 Bn), 70.9 (C-4), 70.0 
(C-5), 69.6 (C-6), 55.4 (OMe). 
Methyl 2,3-di-O-benzyl-6-deoxy-α-D-glucopyranoside (2). Methyl 2,3-di-O-benzyl-α-D-
glucopyranoside32 (581 mg,  1.5 mmol) and p-TsCl (343 mg, 1.8 mmol, 1.2 eq.) were dissolved in 
pyridine (3 mL) and stirred overnight. The reaction mixture was poured in 1 M aq. HCl and extracted 
twice with Et2O. The organic layers were washed with 1 M aq. HCl, H2O, and sat.aq. NaCl, then dried (MgSO4), filtered 
and concentrated under reduced pressure. The crude was coevaporated twice with dry toluene and 12 mL Et2O was 
added, followed by LiAlH4 (1 mL, 4 M in Et2O, 2.6 eq.) and refluxed for 4 h. The reaction was quenched by addition of 
EtOAc and 1 M aq. HCl. The reaction mixture was washed with 1 M aq. HCl, H2O and sat.aq. NaCl. The organic layer 
was dried (MgSO4), filtered, and concentrated in vacuo. Purificiation by column chromatography (5% to 30% EtOAc in 
pentane) gave the title compound 2 as an oil. (430 mg, 1.2 mmol, 80%). Rf 0.32 (3/1 pentane/EtOAc). Spectroscopic 
data were in accord with those previously reported.45 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC): δ 7.42 – 7.23 (m, 
10H, CHarom), 5.03 (d, 1H, J = 11.5 Hz, CHH Bn), 4.76 (d, 1H, J = 12.1 Hz, CHH Bn), 4.72 – 4.63 (m, 2H, 2xCHH Bn), 4.56 
(d, 1H, J = 3.5 Hz, H-1), 3.73 (t, 1H, J = 9.2 Hz, H-3), 3.69 – 3.54 (m, 1H, H-5), 3.55 – 3.48 (m, 1H, H-2), 3.37 (s, 3H, CH3 
OMe), 3.15 (t, 1H, J = 9.2 Hz, H-4), 2.19 (d, 1H, J = 18.3 Hz, 4-OH), 1.23 (d, 3H, J = 6.2 Hz, H-6); 13C-APT NMR (CDCl3, 
101 MHz, HSQC): δ 138.8, 138.1 (Cq), 128.8, 128.6, 128.2, 128.1, 128.1, 128.1 (CHarom), 98.1 (C-1), 81.4 (C-3), 80.2 (C-
2), 75.4 (CH2 Bn), 75.4 (C-4), 73.1 (CH2 Bn) , 66.9 (C-5), 55.2 (OMe), 17.8 (C-6). 
Methyl 2,3-di-O-benzyl-6-O-benzoyl-α-D-glucopyranoside (3). Methyl 2,3-di-O-benzyl-α-D-
glucopyranoside32 (3.37 g, 9 mmol) was converted to the title compound 3 following general 
procedure C. Yield: 3.94 g, 8.24 mmol, 92%. Rf 0.18 (4/1 pentane/EtOAc). Spectroscopic data were 
in accord with those previously reported.45 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC): δ 8.03 (d, 2H, J = 7.6 Hz, CHarom), 
7.59 – 7.26 (m, 13H, CHarom), 5.01 (dd, 1H, J = 11.3, 2.1 Hz, CHH Bn), 4.83 – 4.72 (m, 2H, CHH Bn, CHH Bn), 4.70 – 4.54 
(m, 3H, H-1, CHH Bn, H-6), 4.51 (d, 1H, J = 11.7 Hz, H-6), 3.91 – 3.79 (m, 2H, H-5, H-3), 3.60 – 3.49 (m, 2H, H-4, H-2), 
3.40 (s, 3H, CH3 OMe), 2.64 (s, 1H, 4-OH); 13C-APT NMR (CDCl3, 101 MHz, HSQC): δ 166.9 (C=O), 138.7, 138.1 (Cq), 
133.3, 129.8, 128.8, 128.6, 128.5, 128.2, 128.2, 128.1, 128.1 (CHarom), 98.3 (C-1), 81.3 (C-3), 79.8 (C-2), 75.8, 73.3 (CH2 




Methyl (methyl 2,3-di-O-benzyl-α-D-glucopyranosyl uronate) (4). Methyl 2,3-di-O-benzyl-α-D-
glucopyranoside32 (6.95 g, 18.6 mmol) was converted to the title compound 4 following general 
procedure D. Yield: 3.84 g, 9.54 mmol, 52%. Spectroscopic data were in accord with those 
previously reported.32 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC): δ 7.39 – 7.26 (m, 10H, CHarom), 4.92 (d, 1H, J = 11.3 
Hz, CHH Bn), 4.81 (d, 1H, J = 11.4 Hz, CHH Bn), 4.79 (d, 1H, J = 12.1 Hz, CHH Bn), 4.67 – 4.62 (m, 2H, CHH Bn, H-1), 4.15 
(d, 1H, J = 8.9 Hz, H-5), 3.87 – 3.76 (m, 5H, H-3, H-4, CH3 CO2Me), 3.53 (dd, 1H, J = 8.9, 3.4 Hz, H-2), 3.42 (s, 3H, CH3 
OMe), 2.89 (bs, 1H, 4-OH); 13C-APT NMR (CDCl3, 101 MHz, HSQC): δ 170.8 (C=O CO2Me), 138.7, 138.0 (Cq), 128.6, 
128.3, 128.1, 128.0, 127.9 (CHarom), 98.8 (C-1), 80.5 (C-3), 78.6 (C-2), 75.6, 73.7 (CH2 Bn), 71.9 (C-4), 70.6 (C-5), 56.0 
(OMe), 52.8 (CO2Me); HRMS: [M+Na]+ calcd for C22H26O7Na 425.15707, found 425.15649. 
Methyl 2-O-benzoyl-3,6-di-O-benzyl-α-D-glucopyranoside (5). Methyl 2-O-benzoyl-3-O-benzyl-4,6-
O-benzylidene-α-D-glucopyranoside46 (3.36 g, 7 mmol) was converted to the title compound 5 
following general procedure A. Yield: 3.07 g, 6.42 mmol, 92%. Rf 0.38 (4/1 pentane/EtOAc). 
Spectroscopic data were in accord with those previously reported.47 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC): δ 
8.12 – 8.03 (m, 2H, CHarom), 7.62 – 7.15 (m, 13H, CHarom), 5.09 (dd, 1H, J = 9.7, 3.6 Hz, H-2), 5.05 (d, 1H, J = 3.7 Hz, H-
1), 4.86 (d, 1H, J = 11.4 Hz, CHH Bn), 4.74 (d, 1H, J = 11.4 Hz, CHH Bn), 4.64 (d, 1H, J = 12.1 Hz, CHH Bn), 4.58 (d, 1H, J 
= 12.1 Hz, CHH Bn), 4.02 (dd, 1H, J = 9.7, 8.2 Hz, H-3), 3.86 – 3.71 (m, 4H, H-5, H-6, H-4, H-6), 3.38 (s, 3H, CH3 OMe), 
2.62 (d, 1H, J = 2.4 Hz, 4-OH); 13C-APT NMR (CDCl3, 101 MHz, HSQC): δ 166.0 (C=O), 138.4, 138.0 (Cq), 133.5, 133.4, 
129.9 (CHarom), 129.8 (Cq), 128.6, 128.6, 128.5, 128.0, 128.0, 127.8, 127.8, 127.1 (CHarom), 97.4 (C-1), 79.8 (C-3), 75.3 
(CH2 Bn), 74.0 (C-2), 73.8 (CH2 Bn), 71.6 (C-5), 69.9 (C-4), 69.8 (C-6), 55.4 (OMe). 
Methyl 2-O-benzoyl-3-O-benzyl-6-deoxy-α-D-glucopyranoside (6). Methyl 2-O-benzoyl-3-O-benzyl-
4,6-O-benzylidene-α-D-glucopyranoside46 (5.56 g, 17.96 mmol, 1 eq.) was dissolved in 100 ml 
MeOH and p-TsOH⋅H2O (0.35 g) was added. The reaction mixture was stirred at 50°C for 3 h, after 
which it was quenched by addition of Et3N (0.25 ml) and concentrated in vacuo. The crude product was purified by 
column chromatography (2:1 to 4:6 pentane/EtOAc) to yield Methyl 2-O-benzoyl-3-O-benzyl-α-D-glucopyranoside as 
a white solid (5.98 g, 15.39 mmol, 86%). Rf 0.26 (4/6 pentane/EtOAc).  1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC): δ 
8.13 – 8.04 (m, 2H, CHarom), 7.63 – 7.56 (m, 1H, CHarom), 7.51 – 7.42 (m, 2H, CHarom), 7.31 – 7.19 (m, 5H, CHarom), 5.08 
– 5.01 (m, 2H, H-1, H-2), 4.88 (dd, 1H, J = 11.4, 1.0 Hz, CHH Bn), 4.70 (dd, 1H, J = 11.4, 0.9 Hz, CHH Bn), 4.07 – 4.00 (m, 
1H, H-3), 3.91 – 3.78 (m, 2H, H-6, H-6), 3.77 – 3.67 (m, 2H, H-4, H-5), 3.38 (s, 3H, CH3 OMe), 2.13 (d, 1H, J = 10.0 Hz, 
4-OH); 13C-APT NMR (CDCl3, 101 MHz, HSQC): δ 166.1 (C=O), 138.3 (Cq), 133.5, 130.0 (CHarom), 129.7 (Cq), 128.7, 128.7, 
128.1, 128.0 (CHarom), 97.5 (C-1), 79.9 (C-3), 75.4 (CH2 Bn), 74.2 (C-2), 70.9 (C-4), 70.7 (C-5), 62.5 (C-6), 55.5 (OMe). 
HRMS: [M+Na]+ calcd for C21H24O7Na 411.1414, found 411.1421. Methyl 2-O-benzoyl-3-O-benzyl-α-D-
glucopyranoside (3.01 g, 7.75 mmol) was converted to the 6-iodo intermediate following general procedure B. Yield: 
3.21 g, 6.43 mmol, 83%. Rf 0.64 (3/1 pentane/EtOAc). Spectroscopic data were in accord with those previously 
reported.48 1H NMR (CDCl3, 400 MHz, HH-COSY): δ 8.13 – 8.06 (m, 2H, CHarom), 7.64 – 7.26 (m, 8H, CHarom), 5.12 – 5.03 
(m, 2H, H-2, H-1), 4.88 (d, 1H, J = 11.4 Hz, CHH Bn), 4.65 (d, 1H, J = 11.4 Hz, CHH Bn), 4.02 (dd, 1H, J = 9.6, 8.1 Hz, H-
3), 3.59 (dd, 1H, J = 10.6, 2.1 Hz, H-6), 3.56 – 3.52 (m, 1H, H-5), 3.52 – 3.46 (m, 1H, H-4), 3.44 (s, 3H, CH3 OMe), 3.34 
(dd, 1H, J = 10.5, 6.4 Hz, H-6), 2.33 (d, 1H, J = 2.5 Hz, 4-OH). Subsequent deoxygenation gave the title compound 6. 
Yield: 2.03 g, 5.45 mmol, 85%. [α]  = +112.3° (c = 0.90, CHCl3); IR (thin film): 712, 1027, 1051, 1108, 1271, 1452, 1721, 
2933, 3486; 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC): δ 8.13 – 8.06 (m, 2H, CHarom), 7.62 – 7.55 (m, 1H, CHarom), 
7.50 – 7.42 (m, 2H, CHarom), 7.29 – 7.24 (m, 5H, CHarom), 5.08 (dd, 1H, J = 9.9, 3.7 Hz, H-2), 4.98 (d, 1H, J = 3.7 Hz, H-1), 
4.87 (d, 1H, J = 11.4 Hz, CHH Bn), 4.68 (d, 1H, J = 11.4 Hz, CHH Bn), 3.97 (dd, 1H, J = 9.9, 8.9 Hz, H-3), 3.76 (dq, 1H, J = 
9.6, 6.2 Hz, H-5), 3.37 (s, 3H, CH3 OMe), 3.33 (dd, 1H, J = 9.2, 2.7 Hz, H-4), 2.32 (d, 1H, J = 2.8 Hz, 4-OH), 1.32 (d, 3H, J 
= 6.2 Hz, H-6); 13C-APT NMR (CDCl3, 101 MHz, HSQC): δ 166.0 (C=O), 138.3 (Cq), 133.4, 129.9 (CHarom), 129.8 (Cq), 128.7, 
128.6, 128.1, 128.1 (CHarom), 97.3 (C-1), 80.0 (C-3), 75.6 (C-4), 75.3 (CH2 Bn), 74.6 (C-2), 67.0 (C-5), 55.3 (OMe), 17.7 
(C-6); HRMS: [M+Na]+ calcd for C21H24O6Na 395.1465, found 395.1472. 
Methyl 2,6-di-O-benzoyl-3-O-benzyl-α-D-glucopyranoside (7). Methyl 2-O-benzoyl-3-O-benzyl-α-D-
glucopyranoside (0.93 g, 2.4 mmol) was converted to the title compound 7 following general 
procedure C. Yield: 1.25 g, 2.4 mmol, 100%. Rf 0.25 (4/1 pentane/EtOAc). Spectroscopic data were 
in accord with those previously reported.45 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC): δ 8.13 – 8.01 (m, 4H, CHarom), 
7.62 – 7.17 (m, 11H, CHarom), 5.11 – 5.04 (m, 2H, H-1, H-2), 4.87 (d, 1H, J = 11.3 Hz, CHH Bn), 4.78 – 4.70 (m, 2H, CHH 
Bn, H-6), 4.54 (dd, 1H, J = 12.1, 2.2 Hz, H-6), 4.07 (t, 1H, J = 9.0 Hz, H-3), 3.97 (ddd, 1H, J = 10.0, 4.5, 2.1 Hz, H-5), 3.70 
(t, 1H, J = 9.4 Hz, H-4), 3.40 (s, 3H, CH3 OMe), 2.83 (s, 1H, 4-OH); 13C-APT NMR (CDCl3, 101 MHz, HSQC): δ 167.1, 166.0 




(C=O), 138.2 (Cq), 133.5, 133.4, 130.0, 129.9, 129.8 (CHarom), 129.7 (Cq), 128.7, 128.6, 128.1, 128.1 (CHarom), 97.5 (C-
1), 79.6 (C-3), 75.6 (CH2 Bn), 74.0 (C-2), 70.4 (C-4), 69.7 (C-5), 63.6 (C-6), 55.5 (OMe). 
Methyl (methyl 2-O-benzoyl-3-O-benzyl-α-D-glucopyranosyl uronate) (8). Methyl 2-O-benzoyl-3-O-
benzyl-α-D-glucopyranoside (1.55 g, 4 mmol) was converted to the title compound 8 following 
general procedure D. Yield: 1.01 g, 2.4 mmol, 61%. [α]  = +137.4° (c = 0.95, CHCl3); IR (thin film): 
711, 1028, 1046, 1105, 1270, 1452, 1723, 1749, 2937, 3508;  1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC): δ 8.08 – 
8.02 (m, 2H, CHarom), 7.62 – 7.18 (m, 9H, CHarom), 5.14 (d, 1H, J = 3.6 Hz, H-1), 5.08 (dd, 1H, J = 9.6, 3.6 Hz, H-2), 4.84 
(s, 2H, CH2 Bn), 4.24 (d, 1H, J = 9.6 Hz, H-5), 4.05 (dd, 1H, J = 9.7, 8.6 Hz, H-3), 3.98 (td, 1H, J = 9.2, 1.9 Hz, H-4), 3.86 
(s, 3H, CH3 CO2Me), 3.43 (s, 3H, CH3 OMe), 3.03 (s, 1H, 4-OH); 13C-APT NMR (CDCl3, 101 MHz, HSQC): δ 170.8 (C=O 
CO2Me), 166.0 (C=O OBz), 138.3 (Cq), 133.5, 130.0 (CHarom), 129.6 (Cq), 128.6, 128.6, 128.1, 127.9 (CHarom), 97.8 (C-1), 
78.6 (C-3), 75.4 (CH2 Bn), 73.1 (C-2), 72.4 (C-4), 70.2 (C-5), 56.0 (OMe), 53.0 (CO2Me); HRMS: [M+Na]+ calcd for 
C22H24O8Na 439.1363, found 439.1374. 
Methyl 3-O-benzoyl-2,6-di-O-benzyl-α-D-glucopyranoside (9). Methyl 3-O-benzoyl-2-O-benzyl-4,6-
O-benzylidene-α-D-glucopyranoside47 (3.34 g, 7 mmol) was converted to the title compound 9 
following general procedure A. Yield: 2.11 g, 4.40 mmol, 63%. Rf 0.20 (4/1 pentane/EtOAc). 
Spectroscopic data were in accord with those previously reported.47 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC): δ 
8.07 – 8.00 (m, 2H, CHarom), 7.64 – 7.21 (m, 13H, CHarom), 5.50 (ddd, 1H, J = 9.9, 7.5, 1.3 Hz, H-3), 4.75 (d, 1H, J = 3.5 
Hz, H-1), 4.69 – 4.52 (m, 4H, 2xCH2 Bn), 3.86 – 3.66 (m, 5H, H-2, H-4, H-5, H-6, H-6), 3.42 (s, 3H, CH3 OMe), 3.01 – 2.91 
(m, 1H, 4-OH); 13C-APT NMR (CDCl3, 101 MHz, HSQC): δ 167.7 (C=O), 138.0, 137.8 (Cq), 133.4, 130.1, 129.8, 128.5, 
128.5, 128.1, 128.1, 127.8, 127.8 (CHarom), 98.0 (C-1), 76.6 (C-2), 76.4 (C-3), 73.8 (CH2 Bn), 73.1 (CH2 Bn), 70.5 (C-4), 
70.5 (C-5), 69.3 (C-6), 55.5 (OMe). 
Methyl 2-O-benzyl-3-O-benzoyl-6-deoxy-α-D-glucopyranoside (10). Methyl 3-O-benzoyl-2-O-
benzyl-α-D-glucopyranoside49 (3.63 g, 9.34 mmol) was converted to the 6-iodo intermediate 
following general procedure B. Yield: 3.89 g, 7.80 mmol, 84%). 1H NMR (CDCl3, 400 MHz, HH-COSY, 
HSQC): δ 8.06 – 7.99 (m, 2H, CHarom), 7.65 – 7.23 (m, 8H, CHarom), 5.47 (dd, 1H, J = 9.8, 8.5 Hz, H-3), 4.75 (d, 1H, J = 3.6 
Hz, H-1), 4.69 (d, 1H, J = 12.4 Hz, CHH Bn), 4.63 (d, 1H, J = 12.4 Hz, CHH Bn), 3.69 (dd, 1H, J = 9.8, 3.6 Hz, H-6), 3.61 
(dd, 1H, J = 10.7, 2.3 Hz, H-2), 3.57 – 3.52 (m, 1H, H-5), 3.52 – 3.48 (m, 1H, H-4), 3.48 (s, 3H, CH3 OMe), 3.34 (dd, 1H, 
J = 10.6, 6.4 Hz, H-6), 3.19 (dq, 1H, J = 5.0, 1.6 Hz, 4-OH); 13C-APT NMR (CDCl3, 101 MHz, HSQC): δ 168.1 (C=O), 137.7, 
133.7(Cq), 130.1, 128.6, 128.1 (CHarom), 97.9 (C-1), 76.7 (C-2), 76.1 (C-3), 74.0 (C-4), 73.2 (CH2 Bn), 70.5 (C-5), 60.5 (C-
6), 55.8 (OMe), 7.0 (C-6). Subsequent deoxygenation gave the title compound 10. Yield: 1.08 g, 2.90 mmol, 37%. [α]  = +93.3° (c = 1.0, CHCl3); IR (thin film): 710, 748, 988, 1053, 1103, 1269, 1369, 1450, 1720, 2909, 3460; 1H NMR 
(CDCl3, 400 MHz, HH-COSY, HSQC): δ 8.06 – 7.99 (m, 2H, CHarom), 7.64 – 7.22 (m, 8H, CHarom), 5.43 (t, 1H, J = 9.5 Hz, 
H-3), 4.71 – 4.61 (m, 3H, CH2 Bn, H-1), 3.77 (dq, 1H, J = 9.5, 6.2 Hz, H-5), 3.68 (dd, 1H, J = 9.8, 3.6 Hz, H-2), 3.42 (s, 3H, 
CH3 OMe), 3.34 (td, 1H, J = 9.3, 5.3 Hz, H-4), 2.82 (d, 1H, J = 5.3 Hz, 4-OH), 1.31 (d, 3H, J = 6.2 Hz, H-6); 13C-APT NMR 
(CDCl3, 101 MHz, HSQC): δ 168.1 (C=O), 137.8, 133.5 (Cq), 130.1 (CHarom), 129.8 (Cq), 128.6, 128.1, 128.1 (CHarom), 97.8 
(C-1), 76.9 (C-2), 76.7 (C-3), 75.7 (C-4), 73.1 (CH2 Bn), 67.6 (C-5), 55.4 (OMe), 17.7 (C-6); HRMS: [M+NH4]+ calcd for 
C21H28NO6 390.19111, found 390.19132. 
Methyl 2-O-benzyl-3,6-di-O-benzoyl-α-D-glucopyranoside (11). Methyl 3-O-benzoyl-2-O-benzyl-α-
D-glucopyranoside49 (1.36 g, 3.5 mmol) was converted to the title compound 11 following general 
procedure C. Yield: 1.47 g, 3.0 mmol, 85%. Rf 0.28 (4/1 pentane/EtOAc). [α]  = +78.4° (c = 1.13, 
CHCl3); IR (thin film): 709, 1051, 1070, 1097, 1107, 1275, 1452, 1724, 1749, 2945, 3493; 1H NMR (CDCl3, 400 MHz, 
HH-COSY, HSQC): δ 8.08 – 8.02 (m, 4H, CHarom), 7.65 – 7.54 (m, 2H, CHarom), 7.49 – 7.41 (m, 4H, CHarom), 7.30 – 7.22 
(m, 5H, CHarom), 5.54 (t, 1H, J = 9.5 Hz, H-3), 4.76 (d, 1H, J = 3.5 Hz, H-6), 4.73 – 4.63 (m, 3H, CHH Bn, H-1, H-6), 4.63 – 
4.54 (m, 1H, CHH Bn ), 4.02 (ddd, 1H, J = 10.0, 5.1, 2.3 Hz, H-5), 3.73 – 3.61 (m, 2H, H-2, H-4), 3.44 (s, 3H, CH3 OMe), 
3.35 – 3.20 (m, 1H, 4-OH); 13C-APT NMR (CDCl3, 101 MHz, HSQC): δ 167.8, 166.9 (C=O), 137.8 (Cq), 133.5, 130.1, 129.9 
(CHarom), 129.7 (Cq), 128.6, 128.6, 128.5, 128.1, 128.1 (CHarom), 97.9 (C-1), 76.7 (C-2), 76.1 (C-3), 73.2 (CH2 Bn), 70.2 
(C-4), 70.1 (C-5), 63.8 (C-6), 55.5 (OMe); HRMS: [M+Na]+ calcd for C28H28O8Na 515.1676, found 515.1680. 
Methyl (methyl 2-O-benzyl-3-O-benzoyl-α-D-glucopyranosyl uronate) (12). Methyl 3-O-benzoyl-2-O-
benzyl-α-D-glucopyranoside49 (2.14 g, 5.5 mmol) was converted to the title compound 12 following 
general procedure D. Yield: 1.70 g, 4.08 mmol, 74%. [α]  = +65.6° (c = 1.0, CHCl3);  IR (thin film): 




8.00 (m, 2H, CHarom), 7.62 – 7.56 (m, 1H, CHarom), 7.50 – 7.41 (m, 2H, CHarom), 7.28 – 7.22 (m, 5H, CHarom), 5.58 (t, 1H, 
J = 9.3 Hz, H-3), 4.79 (d, 1H, J = 3.4 Hz, H-1), 4.67 (d, 1H, J = 12.4 Hz, CHH Bn), 4.61 (d, 1H, J = 12.4 Hz, CHH Bn), 4.28 
(d, 1H, J = 9.5 Hz, H-5), 3.96 (td, 1H, J = 9.4, 2.7 Hz, H-4), 3.80 (s, 3H, CH3 CO2Me), 3.70 (dd, 1H, J = 9.6, 3.4 Hz, H-2), 
3.47 (s, 3H, CH3 OMe), 3.28 (d, 1H, J = 4.3 Hz, 4-OH); 13C-APT NMR (CDCl3, 101 MHz, HSQC): δ 170.4 (C=O CO2Me), 
166.8 (C=O OBz), 137.6 (Cq), 133.4, 130.0 (CHarom), 129.7(Cq), 129.5, 128.6, 128.5, 128.2 (CHarom), 98.4 (C-1), 76.0 (C-
2), 74.3 (C-3), 73.3 (CH2 Bn), 71.0 (C-4), 70.9 (C-5), 56.1 (OMe), 52.9 (CO2Me); HRMS: [M+NH4]+ calcd for C21H28NO6 
479.20643, found 479.20618. 
Methyl 2,3-di-O-benzoyl-6-O-benzyl-α-D-glucopyranoside (13). Methyl 2,3-di-O-benzoyl-4,6-O-
benzylidene-α-D-glucopyranoside50 (4.68 g, 9.54 mmol) was converted to the title compound 13 
following general procedure A. Yield: 3.74 g, 7.62 mmol, 80%. Rf 0.30 (4/1 pentane/EtOAc). 
Spectroscopic data were in accord with those previously reported.51 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC): δ 
8.02 – 7.94 (m, 4H, CHarom), 7.55 – 7.27 (m, 11H, CHarom), 5.74 (dd, 1H, J = 10.1, 8.4 Hz, H-3), 5.26 (dd, 1H, J = 10.2, 3.7 
Hz, H-2), 5.13 (d, 1H, J = 3.7 Hz, H-1), 4.67 (d, 1H, J = 12.0 Hz, CHH Bn), 4.61 (d, 1H, J = 12.0 Hz, CHH Bn), 4.03 – 3.91 
(m, 2H, H-5, H-4), 3.86 (dd, 1H, J = 10.4, 3.9 Hz, H-6), 3.81 (dd, 1H, J = 10.4, 3.4 Hz, H-6), 3.43 (s, 3H, CH3 OMe), 3.02 
(d, 1H, J = 3.5 Hz, 4-OH); 13C-APT NMR (CDCl3, 101 MHz, HSQC): δ 167.5, 166.1 (C=O), 137.0 (Cq), 133.5, 133.1, 130.0 
(CHarom), 129.9, 129.2 (Cq), 128.6, 128.4, 128.3, 126.3 (CHarom), 97.2 (C-1), 74.3 (C-3), 73.9 (CH2 Bn), 71.6 (C-2), 70.8 
(C-4), 70.3 (C-5), 69.6 (C-6), 55.6 (OMe). 
Methyl 2,3-di-O-benzoyl-6-deoxy-α-D-glucopyranoside (14). Methyl 2,3-di-O-benzoyl-α-D-
glucopyranoside50 (1.49 g, 3.7 mmol) was converted to the 6-iodo intermediate following general 
procedure B. Yield: 1.38 g, 2.7 mmol, 73%. 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC): δ 8.01 – 
7.93 (m, 4H, CHarom), 7.55 – 7.48 (m, 2H, CHarom), 7.41 – 7.34 (m, 4H, CHarom), 5.69 (dd, 1H, J = 10.1, 8.7 Hz, H-3), 5.29 
(dd, 1H, J = 10.1, 3.7 Hz, H-2), 5.12 (d, 1H, J = 3.7 Hz, H-1), 3.76 – 3.63 (m, 3H, H-4, H-5, H-6), 3.49 (s, 3H, CH3 OMe), 
3.46 – 3.41 (m, 1H, H-6), 3.29 – 3.12 (m, 1H, 4-OH); 13C-APT NMR (CDCl3, 101 MHz, HSQC): δ 168.0, 166.0 (C=O), 133.8, 
133.6, 130.0, 130.0 (CHarom), 129.2, 129.0 (Cq), 128.6, 128.6 (CHarom), 97.2 (C-1), 74.4 (C-3), 73.9 (C-4), 71.3 (C-2), 70.6 
(C-5), 55.8 (OMe), 6.5 (C-6). Subsequent deoxygenation gave the title compound 14. Yield: 0.43 g, 1.12 mmol, 41%. 
Spectroscopic data were in accord with those previously reported.52 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC): δ 
8.02 – 7.93 (m, 4H, CHarom), 7.56 – 7.47 (m, 2H, CHarom), 7.42 – 7.32 (m, 4H, CHarom), 5.65 (dd, 1H, J = 10.2, 9.2 Hz, H-
3), 5.27 (dd, 1H, J = 10.1, 3.7 Hz, H-2), 5.05 (d, 1H, J = 3.6 Hz, H-1), 3.89 (dq, 1H, J = 9.5, 6.2 Hz, H-5), 3.55 (td, 1H, J = 
9.3, 5.0 Hz, H-4), 3.43 (s, 3H, CH3 OMe), 2.84 (d, 1H, J = 5.1 Hz, 4-OH), 1.40 (d, 3H, J = 6.2 Hz, CH3-6); 13C-APT NMR 
(CDCl3, 101 MHz, HSQC): δ 167.9, 166.1 (C=O), 133.6, 133.5, 130.0 (CHarom), 130.0, 129.3 (Cq), 128.6, 128.5 (CHarom), 
97.1 (C-1), 75.4 (C-4), 74.8 (C-3), 71.7 (C-2), 67.7 (C-5), 55.4 (OMe), 17.6 (C-6). 
Methyl 2,3,6-tri-O-benzoyl-α-D-glucopyranoside (15). Methyl 2,3-di-O-benzoyl-α-D-
glucopyranoside50 (2.84 g, 7 mmol) was converted to the title compound 15 following general 
procedure C. Yield: 2.3 g, 4.5 mmol, 66%. Rf 0.27 (4/1 pentane/EtOAc). Spectroscopic data were in 
accord with those previously reported.53 1H NMR (400 MHz, CDCl3) δ 8.14 – 8.05 (m, 2H, CHarom), 8.03 – 7.93 (m, 4H, 
CHarom), 7.64 – 7.12 (m, 9H, CHarom), 5.79 (dd, 1H, J = 10.1, 9.2 Hz, H-3), 5.27 (dd, 1H, J = 10.2, 3.6 Hz, H-2), 5.14 (d, 1H, 
J = 3.6 Hz, H-1), 4.81 (dd, 1H, J = 12.1, 4.5 Hz, H-6), 4.63 (dd, 1H, J = 12.2, 2.3 Hz, H-6), 4.12 (ddd, 1H, J = 9.9, 4.5, 2.2 
Hz, H-5), 3.88 (t, 1H, J = 9.6 Hz, H-4), 3.46 (s, 3H, CH3 OMe), 3.39 (s, 1H, 4-OH). 13C-APT NMR (CDCl3, 101 MHz, HSQC): 
δ 167.5, 167.1, 166.1 (C=O), 133.6, 133.5, 133.5, 130.0, 130.0 (CHarom), 129.7, 129.3, 129.2 (Cq), 128.6, 128.6, 128.5 
(CHarom), 97.2 (C-1), 74.0 (C-3), 71.4 (C-2), 70.2 (C-5), 69.8 (C-4), 63.6 (C-6), 55.6 (OMe).  
Methyl (methyl 2,3-di-O-benzoyl-α-D-glucopyranosyl uronate) (16). Methyl 2,3-di-O-benzoyl-α-D-
glucopyranoside50 (0.72 g, 1.8 mmol) was converted to the title compound 16 following general 
procedure D. Yield: 0.57 g, 1.49 mmol, 83%. [α]  = +111.4° (c = 0.83, CHCl3); IR (thin film): 710, 
1026, 1064, 1270, 1452, 1701, 1719, 2895, 3486;  1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC): δ 8.03 – 7.92 (m, 4H, 
CHarom), 7.55 – 7.30 (m, 6H, CHarom), 5.85 (ddd, 1H, J = 11.2, 9.1, 1.7 Hz, H-3), 5.27 – 5.20 (m, 2H, H-1 H-2), 4.37 (d, 1H, 
J = 9.8 Hz, H-5), 4.16 (td, 1H, J = 9.6, 3.5 Hz, H-4), 3.88 (s, 3H, CH3 CO2Me), 3.49 (s, 3H, CH3 OMe), 3.34 (d, 1H, J = 3.7 
Hz, 4-OH). 13C-APT NMR (CDCl3, 101 MHz, HSQC): δ 170.4 (C=O CO2Me), 166.7, 166.0 (C=O Bz), 133.6, 133.5, 130.0, 
130.0 (CHarom), 129.4, 129.1 (Cq), 128.6, 128.5 (CHarom), 97.6 (C-1), 72.4 (C-3), 71.2 (C-2), 70.9 (C-4), 70.4 (C-5), 56.1 
(OMe), 53.1 (CO2Me); HRMS: [M+Na]+ calcd for C22H22O9Na 453.1156, found 453.1165. 
Methyl 2,3,6-tri-O-benzyl-β-D-glucopyranoside (17). Methyl 2,3-di-O-benzyl-4,6-O-benzylidene-















general procedure A. Yield: 0.45 g, 0.96 mmol, 64%. Spectroscopic data were in accord with those previously 
reported.54 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC): δ 7.39 – 7.22 (m, 15H, CHarom), 4.94 – 4.90 (m, 2H, 2xCHH Bn), 
4.73 – 4.69 (m, 2H, 2xCHH Bn), 4.63 – 4.53 (m, 2H, CH2 Bn), 4.33 (d, 1H, J = 7.4 Hz, H-1), 3.77 (dd, 1H, J = 10.4, 3.8 Hz, 
H-6), 3.70 (dd, 1H, J = 10.4, 5.3 Hz, H-6), 3.63 – 3.58 (m, 1H, H-5 ), 3.57 (s, 3H, CH3 OMe), 3.50 – 3.37 (m, 3H, H-3, H-
4, H-2), 2.55 (d, 1H, J = 2.1 Hz, 4-OH); 13C-APT NMR (CDCl3, 101 MHz, HSQC): δ 138.7, 138.6, 138.0 (Cq), 128.7, 128.5, 
128.5, 128.1, 128.1, 128.0, 127.8, 127.8, 127.8 (CHarom), 104.9 (C-1), 84.1 (C-3), 81.9 (C-2), 75.4 (CH2 Bn), 74.8(CH2 Bn), 
74.1 (C-4), 73.8 (CH2 Bn), 71.6 (C-5), 70.4 (C-6), 57.3 (OMe). 
Methyl 2,3-di-O-benzyl-6-deoxy-β-D-glucopyranoside (18). Methyl 2,3-di-O-benzyl-β-D-
glucopyranoside54 (1.18 g, 3.15 mmol) was converted to the 6-iodo intermediate55 following 
general procedure B. Yield: 1.03 g, 2.12 mmol, 67%. 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC): 
δ 7.44 – 7.18 (m, 10H, CHarom), 5.01 – 4.89 (m, 2H, 2xCHH Bn), 4.73 – 4.58 (m, 2H, 2xCHH Bn), 4.38 – 4.34 (m, 1H, H-
1), 3.61 (s, 3H, CH3 OMe), 3.56 (dd, 1H, J = 10.6, 2.4 Hz, H-6), 3.46 – 3.41 (m, 2H, H-3, H-4), 3.37 – 3.30 (m, 1H, H-5), 
3.25 (dd, 1H, J = 10.6, 7.8 Hz, H-2), 3.16 (ddd, 1H, J = 9.1, 7.8, 2.4 Hz, H-6), 2.18 (d, 1H, J = 2.4 Hz, OH). Subsequent 
deoxygenation gave the title compound 18. Yield: 0.43 g, 1.21 mmol, 57%. [α]  = -21.2° (c = 1.0, CHCl3); IR (thin film): 
698, 737, 988, 1065, 1146, 1354, 1454, 2905, 3345; 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC): δ 7.54 – 7.03 (m, 10H, 
CHarom), 5.00 – 4.91 (m, 2H, 2xCHH Bn), 4.74 – 4.61 (m, 2H, 2xCHH Bn), 4.33 – 4.27 (m, 1H, H-1), 3.57 (s, 3H, CH3 OMe), 
3.45 – 3.27 (m, 3H, H-3, H-2, H-5), 3.21 (ddt, 1H, J = 9.0, 6.7, 2.2 Hz, H-4), 1.31 (d, 3H, J = 6.1 Hz, CH3 6); 13C-APT NMR 
(CDCl3, 101 MHz, HSQC): δ 138.6 (Cq), 128.8, 128.5, 128.3, 128.1, 127.8 (CHarom), 104.8 (C-1), 84.0 (C-2), 82.4 (C-3), 
75.3 (CH2 Bn), 75.0 (C-4), 74.7 (CH2 Bn), 71.3 (C-5), 57.2 (OMe), 17.8 (C-6); HRMS: [M+Na]+ calcd for C21H26O5Na 
381.1672, found 381.1677. 
Methyl 2,3-di-O-benzyl-6-O-benzoyl-β-D-glucopyranoside (19). Methyl 2,3-di-O-benzyl-β-D-
glucopyranoside54 (0.56 g, 1.5 mmol) was converted to the title compound 19 following general 
procedure C. Yield: 0.70 g, 1.47 mmol, 98%. Spectroscopic data were in accord with those 
previously reported.56 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC): δ 8.08 – 8.01 (m, 2H, CHarom), 7.60 – 7.23 (m, 13H, 
CHarom), 4.99 – 4.89 (m, 2H, 2xCHH Bn), 4.77 – 4.67 (m, 2H, 2xCHH Bn), 4.67 – 4.53 (m, 2H, H-6), 4.37 (d, 1H, J = 7.5 
Hz, H-1), 3.62 – 3.53 (m, 5H, H-4, CH3 OMe, H-5), 3.50 (td, 1H, J = 8.1, 7.2, 1.3 Hz, H-2), 3.42 (dd, 1H, J = 8.9, 7.5 Hz, H-
3), 2.64 (s, 1H, OH); 13C-APT NMR (CDCl3, 101 MHz, HSQC): δ 167.0 (C=O) 138.5, 133.3 (Cq), 130.0, 129.9 (CHarom), 
128.8 (Cq), 128.5, 128.5, 128.3, 128.2, 128.1, 127.9 (CHarom), 105.0 (C-1), 83.8 (C-2), 81.9 (C-3), 75.6, 74.8 (CH2 Bn), 
73.7 (C-4), 70.1 (C-5), 63.9 (C-6), 57.3 (OMe). 
Methyl (methyl 2,3-di-O-benzoyl-β-D-glucopyranosyl uronate) (20). Methyl 2,3-di-O-benzyl-β-D-
glucopyranoside54 (745 mg, 2.0 mmol) was converted to the title compound 20 following general 
procedure D. Yield: 689 g, 1.71 mmol, 85%. Spectroscopic data were in accord with those 
previously reported.57 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC): δ 7.37 – 7.21 (m, 10H, CHarom), 4.92 – 4.84 (m, 2H, 
2xCHH Bn), 4.80 (d, 1H, J = 11.3 Hz, CHH Bn), 4.68 (d, 1H, J = 11.1 Hz, CHH Bn), 4.34 (d, 1H, J = 7.5 Hz, H-1), 3.87 – 3.79 
(m, 2H, H-3, H-4), 3.76 (s, 3H, CH3 CO2Me), 3.55 (s, 3H, CH3 OMe), 3.50 (ddd, 1H, J = 8.6, 6.7, 1.6 Hz, H-5), 3.42 (dd, 
1H, J = 9.1, 7.5 Hz, H-2), 3.09 (s, 1H, 4-OH);  13C-APT NMR (CDCl3, 101 MHz, HSQC): δ 169.7 (C=O CO2Me), 138.4, 138.3 
(Cq), 128.4, 128.3, 128.0, 127.9, 127.7, 127.7 (CHarom), 104.9 (C-1), 83.0 (C-5), 81.1 (C-2), 75.3, 74.7 (CH2 Bn), 74.3, 
71.7 (C-3, C-4), 57.4 (OMe), 52.7 (CO2Me). 
Methyl 2,3-di-O-benzyl-6-O-(4-nitrobenzoyl)-α-ᴅ-glucopyranoside (23). Methyl 2,3-di-O-
benzyl-α-D-glucopyranoside32 (374 mg, 1.0 mmol, 1 eq.) was converted to the title 
compound 23 following general procedure C (4-nitrobenzoyl chloride; 195 μL, 1.05 mmol, 
1.05 eq.). Yield: 460 mg, 0.88 mmol, 88%. [α]  = +28.3° (c = 0.6, CHCl3); IR (thin film): 698, 
719, 739, 1057, 1103, 1277, 1346, 1454, 1528, 1607, 1726, 2912, 3505; 1H NMR (CDCl3, 
500 MHz, HH-COSY, HSQC): δ 8.30 – 8.26 (m, 2H, CHarom pNO2Bz), 8.21 – 8.17 (m, 2H, CHarom pNO2Bz), 7.39 – 7.30 (m, 
10H, CHarom Bn), 5.04 (d, 1H, J = 11.3 Hz, CHH Bn), 4.79 (d, 1H, J = 12.2 Hz, CHH Bn), 4.73 (d, 1H, J = 11.3 Hz, CHH Bn), 
4.68 (d, 1H, J = 12.1 Hz, CHH Bn), 4.64 (d, 1H, J = 3.5 Hz, H-1), 4.63 – 4.56 (m, 2H, H-6, H-6), 3.90 (ddd, 1H, J = 10.0, 
4.6, 2.7 Hz, H-5), 3.83 (t, 1H, J = 9.2 Hz, H-3), 3.54 (dd, 1H, J = 9.5, 3.6 Hz, H-2), 3.52 (ddd, 1H, J = 10.0, 8.9, 2.7 Hz, H-
4), 3.40 (s, 3H, CH3 OMe), 2.43 (d, 1H, J = 2.8 Hz, 4-OH); 13C-APT NMR (CDCl3, 126 MHz, HSQC): δ 164.8 (C=O), 150.8 
(Cq NO2), 138.6, 138.0, 135.3 (Cq), 131.0, 128.9, 128.7, 128.3, 128.2, 123.7 (CHarom), 98.3 (C-1), 81.3 (C-3), 79.8 (C-2), 
75.8, 73.3 (CH2 Bn), 70.1 (C-4), 69.3 (C-5), 64.7 (C-6), 55.5 (OMe); HRMS: [M+Na]+ calcd for C28H29NO9Na 546.1740, 








Methyl 2,3-di-O-benzyl-6-O-(3-nitrobenzoyl)-α-ᴅ-glucopyranoside (24). Methyl 2,3-di-O-
benzyl-α-D-glucopyranoside32 (300 mg, 0.8 mmol, 1 eq.) was converted to the title 
compound 24 following general procedure C (3-nitrobenzoyl chloride; 227 mg, 1.7 mmol, 
1.6 eq.). Yield: 375 mg, 0.72 mmol, 90% (included 5% fully protected glycoside). [α]  = 
+22.2° (c = 0.67, CHCl3); IR (thin film): 698, 718, 741, 1059, 1121, 1261, 1294, 1350, 1454,
1533, 1616, 1728, 2920, 3520; 1H NMR (CDCl3, 500 MHz, HH-COSY, HSQC): δ 8.83 (ddd, 1H, J = 2.2, 1.6, 0.4 Hz, CHarom 
NO2Bz), 8.39 (ddd, 1H, J = 8.2, 2.3, 1.1 Hz, CHarom NO2Bz), 8.33 (ddd, 1H, J = 7.7, 1.6, 1.2 Hz, CHarom NO2Bz), 7.62 (td, 
1H, J = 8.0, 0.4 Hz, CHarom NO2Bz), 7.40 – 7.27 (m, 10H, CHarom Bn), 5.02 (d, 1H, J = 11.4 Hz, CHH Bn), 4.78 (d, 1H, J = 
12.1 Hz, CHH Bn), 4.74 (d, 1H, J = 11.4 Hz, CHH Bn), 4.67 (d, 1H, J = 12.1 Hz, CHH Bn), 4.65 (d, 1H, J = 3.6 Hz, H-1), 4.61 
– 4.58 (m, 2H, H-6, H-6), 3.91 (dt, 1H, J = 10.0, 3.9 Hz, H-5), 3.86 – 3.80 (m, 1H, H-3), 3.55 (dd, 1H, J = 9.5, 3.6 Hz, H-2), 
3.53 – 3.48 (m, 1H, H-4), 3.42 (s, 3H, CH3 OMe), 2.59 (d, 1H, J = 2.7 Hz, 4-OH); 13C-APT NMR (CDCl3, 126 MHz, HSQC):
δ 164.6 (C=O), 148.3 (Cq NO2), 138.6, 138.0 (Cq Bn), 135.4 (CHarom), 131.7 (Cq Bz), 129.7, 128.7, 128.6, 128.2, 128.2,
128.1, 128.1, 128.1, 128.1, 127.6, 124.7 (CHarom), 98.2 (C-1), 81.2 (C-3), 79.8 (C-2), 75.6, 73.3 (CH2 Bn), 70.2 (C-4), 69.3 
(C-5), 64.8 (C-6), 55.4 (OMe); HRMS: [M+Na]+ calcd for C28H29NO9Na 546.1740, found 546.1752. 
Methyl 2,3-di-O-benzyl-6-O-(2-nitrobenzoyl)-α-ᴅ-glucopyranoside (25). Methyl 2,3-di-O-benzyl-
α-D-glucopyranoside32 (374 mg, 1.0 mmol, 1 eq.) was converted to the title compound 25 
following general procedure C (2-nitrobenzoyl chloride; 140 μL, 1.05 mmol, 1.05 eq.). Yield: 450 
mg, 0.86 mmol, 86%. [α]  = +15.8° (c = 0.6, CHCl3); IR (thin film): 698, 737, 1059, 1117, 1257, 
1292, 1350, 1533, 1734, 2907, 3503; 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC): δ 7.85 – 7.81 
(m, 1H, CHarom NO2Bz), 7.74 – 7.70 (m, 1H, CHarom NO2Bz), 7.64 – 7.55 (m, 2H, CHarom NO2Bz), 
7.39 – 7.25 (m, 10H, CHarom Bn), 4.99 (d, 1H, J = 11.4 Hz, CHH Bn), 4.78 – 4.73 (m, 2H, CHH Bn, CHH Bn), 4.64 (d, 1H, J 
= 12.0 Hz, CHH Bn), 4.62 (d, 1H, J = 3.5 Hz, H-1), 4.54 (d, 2H, J = 3.7 Hz, H-6, H-6), 3.86 – 3.78 (m, 2H, H-3, H-5), 3.51 
(dd, 1H, J = 9.6, 3.5 Hz, H-2), 3.52 – 3.42 (m, 1H, H-4), 3.36 (s, 3H, CH3 OMe), 2.65 (bs, 1H, 4-OH); 13C-APT NMR (CDCl3, 
101 MHz, HSQC): δ 165.3 (C=O), 148.3 (Cq-NO2), 138.6, 137.9 (Cq Bn), 132.8, 132.0, 130.0, 128.6, 128.4, 128.0, 128.0, 
127.9, 127.8 (CHarom), 127.1 (Cq Bz), 123.8 (CHarom), 98.1 (C-1), 81.1 (C-3), 79.5 (C-2), 75.4, 73.2 (CH2 Bn), 69.9 (C-4), 
69.0 (C-5), 65.3 (C-6), 55.4 (OMe); HRMS: [M+Na]+ calcd for C28H29NO9Na 546.1740, found 546.1755. 
Methyl 2,3-di-O-benzyl-6-O-(2,6-dinitrobenzoyl)-α-ᴅ-glucopyranoside (26). Methyl 2,3-di-O-
benzyl-α-D-glucopyranoside32 (145 mg, 0.39 mmol, 1 eq.) was dissolved in 1.5 mL DCM and 
cooled to 0°C. To this solution was added 2,6-dinitrobenzoic acid (synthesized by K2Cr2O7/H2SO4 
oxidation of 2,6-dinitrotoluene)58 (123 mg, 0.58 mmol, 1.5 eq.), Ph3P (202 mg, 0.77 mmol, 2 
eq.), and DEAD (~40% in toluene, ~0.8 mmol, 2 eq.). The reaction was stirred at room 
temperature for 2 days. The reaction mixture was diluted with H2O and extracted with DCM 
twice. The combined organic layers were washed with sat. aq. NaHCO3, and brine, then dried (MgSO4), filtered, and 
concentrated under reduced pressure. Flash column chromatography (8/2 to 7/3 pentane/EtOAc) and size-exclusion 
chromatography (Sephadex LH-20, 1/1 MeOH/DCM) provide the title compound as a yellow oil. Yield: 165 mg, 0.29 
mmol, 74%. [α]  = +22.5° (c = 1.25, CHCl3); IR (thin film): 698, 714, 743, 918, 1057, 1279, 1454, 1582, 1748, 2920, 
3493; 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC, HMBC): δ 8.46 (d, 2H, J = 8.3 Hz, CHarom NO2Bz), 7.79 (t, 1H, J = 8.3 
Hz, CHarom NO2Bz), 7.39 – 7.26 (m, 10H, CHarom Bn), 5.00 (d, 1H, J = 11.4 Hz, CHH Bn), 4.79 (dd, 1H, J = 11.9, 4.8 Hz, H-
6), 4.77 – 4.73 (m, 2H, CHH Bn, CHH Bn), 4.66 – 4.60 (m, 3H, CHH Bn, H-1, H-6), 3.89 (ddd, 1H, J = 10.0, 4.8, 2.1 Hz, H-
5), 3.86 – 3.76 (m, 1H, H-3), 3.57 – 3.50 (m, 1H, H-4), 3.49 (dd, 1H, J = 9.6, 3.5 Hz, H-2), 3.37 (s, 3H, CH3 OMe), 2.51 (d, 
1H, J = 3.3 Hz, 4-OH); 13C-APT NMR (CDCl3, 101 MHz, HSQC, HMBC): δ 162.6 (C=O), 146.8 (Cq NO2), 138.7, 138.0 (Cq 
Bn), 131.2, 129.8, 128.7, 128.5, 128.1, 128.1, 128.0, 128.0 (CHarom), 125.6 (Cq Bz), 98.3 (C-1), 81.3 (C-3), 79.6 (C-2), 
75.6, 73.2 (CH2 Bn), 69.8 (C-4), 69.0 (C-5), 66.2 (C-6), 55.6 (OMe); HRMS: [M+Na]+ calcd for C28H28N2O11Na 591.1591, 
found 591.1602.  
Methyl 4-O-(2,3-di-O-benzyl-4,6-O-benzylidene-α/β-D-glucopyranosyl)-2,3,6-tri-O-
benzyl-α-D-glucopyranoside (1A). Donor A and acceptor 1 were condensed using the 
general procedure for Tf2O/Ph2SO mediated glycosylations (E) yielding product 1A 
(73 mg, 82 μmol, 82%, α:β = 1:1) as a white solid. Rf: 0.55 (4/1 pentane/EtOAc); 
Spectroscopic data were in accord with those previously reported.32  1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC, 
HMBC): δ 7.52 – 7.45 (m, 4H, CHarom), 7.44 – 7.18 (m, 56H, CHarom), 5.75 (d, 1H, J = 3.8 Hz, H-1’α), 5.52 (s, 1H, CHPhα), 
5.49 (s, 1H, CHPhβ), 5.04 (d, 1H, J = 11.7 Hz, CHH Bn), 4.95 – 4.87 (m, 3H, 3xCHH Bn), 4.84 – 4.51 (m, 17H, 4xCHH Bn, 
5xCH2 Bn CHH Bn, H-1α, H-1β), 4.36 (d, 1H, J = 7.8 Hz, H-1’β), 4.30 (d, 1H, J = 12.0 Hz, CHH Bn), 4.19 (dd, 1H, J = 10.5, 
5.0 Hz, H-6’β), 4.15 – 4.09 (m, 3H, H-3α, H-4α, H-6’α), 3.99 (t, 1H, J = 9.3 Hz, H-3’α), 3.94 (t, 1H, J = 9.4 Hz, H-4β), 3.90 – 




3.78 (m, 5H, H-2β, H-5α, H-5’α, H-6α, H-6β), 3.69 – 3.41 (m, 11H, H-2α, H-2’α, H-3β, H-3’β, H-4’α, H-4’β, H-5β, H-6α, H-6β, 
H-6’α, H-6’β), 3.40 – 3.31 (m, 7H, CH3 OMeα, CH3 OMeβ, H-2’β), 3.10 (td, 1H, J = 9.5, 4.9 Hz, H-5’β); 13C-APT NMR (CDCl3, 
101 MHz, HSQC, HMBC): δ 139.4, 139.0, 138.7, 138.6, 138.5, 138.4, 138.2, 138.0, 137.9, 137.9, 137.6, 137.5 (Cq), 
129.0, 128.9, 128.6, 128.5, 128.5, 128.4, 128.3, 128.3, 128.3, 128.2, 128.2, 128.2, 128.1, 128.1, 128.0, 128.0, 127.9, 
127.8, 127.7, 127.7, 127.5, 127.5, 127.4, 127.3, 126.8, 126.1, 126.1 (CHarom), 102.9 (C-1’β), 101.2 (CHPhα,β), 98.5, 97.8 
(C-1α, C-1β), 97.2 (C-1’α), 82.7 (C-2’β), 82.4 (C-4’α), 82.2 (C-3α), 81.8 (C-4’β), 81.0 (C-3’β), 80.3 (C-2β), 80.3, 78.9 (C-2α, C-
3’α), 78.8 (C-2’α, C-3β), 76.9 (C-4β), 75.6, 75.5, 75.4, 75.0, 74.4, 73.9, 73.7, 73.4, 73.4 (CH2 Bn), 71.6 (C-4α), 70.0 (C-5β), 
69.4 (C-5α), 69.0, 68.9, 68.8 (C-6α, C-6’α, C-6’β), 67.7 (C-6β), 65.8 (C-5’β), 63.4 (C-5’α), 55.5 (OMeβ), 55.3 (OMeα); HRMS: 
[M+NH4]+ calcd for C55H62O11N 912.43174, found 912.43282. 
Methyl 4-O-(2-azido-3-O-benzyl-4,6-O-benzylidene-2-deoxy-α/β-D-glucopyranosyl)-
2,3,6-tri-O-benzyl-α-ᴅ-glucopyranoside (1B). Donor B and acceptor 1 were 
condensed using the general procedure for Tf2O/Ph2SO mediated glycosylations (E) 
yielding product 1B (mg, 88 μmol, 88% , α:β = 1:7) as a white solid. Rf 0.51 α, 0.43 β 
(4:1 pentane/ EtOAc). Spectroscopic data were in accord with those previously reported.11 IR (thin film): 696, 737, 
1049, 1092, 1362, 1454, 2110, 2868. Data for the β-anomer: 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC, TOCSY): δ 
7.68−7.60 (m, 2H, CHarom), 7.52−7.18 (m, 23H, CHarom), 5.47 (s, 1H, CHPh), 4.89 (d, 1H, J = 11.2 Hz, CHH Bn), 4.87 (d, 
1H, J = 10.9 Hz, CHH Bn), 4.81 (d, 1H, J = 10.9 Hz, CHH Bn), 4.78 (d, 1H, J = 12.2 Hz, CHH Bn), 4.75 (d, 1H, J = 11.2 Hz, 
CHH Bn), 4.71 (d, 1H, J = 12.0 Hz, CHH Bn), 4.63 (d, 1H, J = 12.1 Hz, CHH Bn), 4.60 (d, 1H, J = 3.7 Hz, H-1), 4.41 (d, 1H, 
J = 12.0 Hz, CHH Bn), 4.19 (d, 1H, J = 7.6 Hz, H-1′), 4.11 (dd, 1H, J = 10.6, 5.0 Hz, H-6′), 4.00 − 3.90 (m, 2H, H-4, H-6), 
3.85 (t, 1H, J = 9.3 Hz, H-3), 3.75 (dt, 1H, J = 9.8, 2.4 Hz, H-5), 3.69 (dd, 1H, J = 10.8, 1.9 Hz, H- 6), 3.56 (t, 1H, J = 9.0 
Hz, H-4′), 3.51 (dd, 1H, J = 9.5, 3.7 Hz, H-2), 3.45−3.38 (m, 4H, H-6′, CH3 OMe), 3.36−3.27 (m, 2H, H-2′, H-3′), 3.00 (td, 
1H, J = 9.8, 5.0 Hz, H-5′). 13C-APT NMR (CDCl3, 101 MHz, HSQC): δ 139.3, 138.3, 137.8, 137.8, 137.3 (Cq), 131.1, 129.4, 
128.6, 128.4, 128.3, 128.2, 128.2, 128.1, 128.1, 127.9, 127.9, 127.6, 126.0, 124.8 (CHarom), 101.3, 101.2 (CHPh, C-1′), 
98.4 (C-1), 81.7 (C-4′), 80.1 (C-3), 79.2 (C-3′), 79.0 (C-2), 76.9 (C-4), 75.4, 74.7, 73.6, 73.5 (CH2 Bn), 69.7 (C-5), 68.6 (C-
6′), 68.0 (C-6), 66.6 (C-2′), 65.8 (C-5′), 55.4 (OMe). Diagnostic peaks for the α-anomer: 1H NMR (CDCl3, 400 MHz): δ 
5.71 (d, 1H, J = 4.0 Hz, H-1′), 5.53 (s, 1H, CHPh), 5.11 (d, 1H, J = 10.7 Hz, CHH Bn), 4.95 (d, 1H, J = 10.9 Hz, CHH Bn). 
13C-APT NMR (CDCl3, 101 MHz): δ 98.1, 97.8, 82.7, 82.1, 80.5, 76.2, 75.1, 73.3, 73.0, 69.4, 69.1, 68.7, 63.4, 62.9; HRMS: 
[M+Na]+ calcd for C48H51N3O10Na 852.34667, found 852.34668. 
Methyl 4-O-(2,3-di-O-benzyl-4,6-O-benzylidene-α/β-D-glucopyranosyl)-2,3-di-O-
benzyl-6-deoxy-α-D-glucopyranoside (2A). Donor A and acceptor 2 were condensed 
using the general procedure for Tf2O/Ph2SO mediated glycosylations (E) yielding 
product 2A (67 mg, 85 μmol, 85%, α:β = 2:1) as a colorless oil. Rf: 0.50 (4/1 
pentane/EtOAc); IR (thin film): 698, 737, 910, 995, 1029, 1049, 1088, 1369, 1454, 2870, 3032; Data reported for a 2:1 
mixture of anomers. 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC, HMBC): δ 7.65 – 6.84 (m, 37.5H, CHarom), 5.76 (d, 1H, 
J = 4.1 Hz, H-1’α), 5.55 (s, 1H, CHPhα), 5.50 (s, 0.5H, CHPhβ), 5.02 (d, 1H, J = 11.8 Hz, CHH Bnα ), 4.96 – 4.88 (m, 2H, 
2xCHH Bnβ, CHH Bnα), 4.87 – 4.81 (m, 1.5H, CHH Bnβ, CHH Bnα), 4.81 – 4.62 (m, 6.0H, CHH Bnβ, 2xCHH Bnα, 2xCH2 Bnβ, 
CH2 Bnα, H-1’β), 4.55 (d, 1H, J = 12.0 Hz, CHH Bnα), 4.57 – 4.47 (m, 2.5H, CHH Bnα, H-1α, H-1β), 4.26 (dd, 1H, J = 10.3, 
4.8 Hz, H-6’α), 4.16 (dd, 1H, J = 10.5, 5.0 Hz, H-6’β), 4.08 – 3.99 (m, 2H, H-3α, H-3’α), 3.98 – 3.78 (m, 2H, H-5α, H-5’α), 
3.78 – 3.66 (m, 2H, H-4’β, H-6’α, H-5β), 3.63 (m, 2H, m, H-4α, H-4’α), 3.58 – 3.50 (m, 2.5H, H-2’α, H-2α, H-2β), 3.50 – 3.40 
(m, 1.5H, H-6’β,  H-4β, H-2’β), 3.39 (s, 1.5H, CH3 OMeβ), 3.37 (s, 3H, CH3 OMeα), 3.29 (td, 0.5H, J = 9.7, 4.9 Hz, H-5’β), 
1.34 (d, 3H, J = 6.2 Hz, H-6α), 1.27 (d, 1.5H, J = 6.4 Hz, H-6β); 13C-APT NMR (CDCl3, 101 MHz, HSQC, HMBC): δ 139.1, 
138.7, 138.6, 138.4, 138.3, 138.0, 137.4 (Cq), 129.0, 129.0, 128.5, 128.4, 128.3, 128.1, 127.7, 127.2, 126.6, 126.1, 
126.1(CHarom), 103.7(C-1’β), 101.2(CHPhα), 101.2 (CHPhβ), 98.1 (C-1β) , 97.9 (C-1’α), 97.6 (C-1α), 83.8 (C-4β), 82.8 (C-2’β), 
82.3 (C-4α), 81.8 (C-3α), 81.4 (C-4’β), 80.7 (C-2’α), 80.0 (C-3β), 79.5 (C-3’β), 79.0 (C-3’α), 78.8 (C-4’α), 78.3 (C-2α), 75.8, 
75.5, 75.4, 75.2, 74.2, 74.0, 73.6, 73.3 (CH2 Bn), 68.9 (C-6’α), 68.8 (C-6’β), 66.6 (C-5β), 66.0 (C-5’β), 65.7 (C-5α), 63.3 (C-
5’α), 55.4 (OMeβ), 55.2 (OMeα), 19.2 (C-6α), 18.0 (C-6β); HRMS: [M+NH4]+ calcd for C48H56NO10 806.38987, found 
806.39030.  
Methyl 4-O-(2-azido-3-O-benzyl-4,6-O-benzylidene-2-deoxy-α/β-D-glucopyranosyl)-
2,3-di-O-benzyl-6-deoxy-α-ᴅ-glucopyranoside (2B). Donor B and acceptor 2 were 
condensed using the general procedure for Tf2O/Ph2SO mediated glycosylations (E) 
yielding product 2B (50 mg, 69 μmol, 69%, α:β = 1:5) as a white solid. Rf: 0.50 (4/1 
pentane/EtOAc); IR (thin film): 698, 737, 999, 1049, 1092, 1177, 1277, 1366, 1454, 2110, 2912, 3032; Data for the β-




4.69 (m, 5H, 2xCH2 Bn, CHH Bn), 4.66 – 4.58 (m, 1H, CHH Bn), 4.54 – 4.46 (m, 2H, H-1, H-1’), 4.07 – 3.98 (m, 1H, H-6’), 
3.89 – 3.82 (m, 1H, H-3), 3.79 (dd, 1H, J = 9.7, 6.2 Hz, H-5), 3.63 (t, 1H, J = 9.1 Hz, H-4’), 3.57 (t, 1H, J = 9.1 Hz, H-3’), 
3.51 – 3.48 (m, 1H, H-2), 3.48 – 3.39 (m, 3H, H-6’, H-2’, H-4), 3.38 (s, 3H, CH3 OMe), 3.25 – 3.16 (m, 1H, H-5’), 1.35 (d, 
3H, J = 6.2 Hz, H-6); 13C-APT NMR (CDCl3, 101 MHz, HSQC, HMBC): δ 139.4, 138.3, 137.8, 137.2 (Cq), 129.2, 128.5, 
128.4, 128.3, 128.3, 128.2, 128.0, 128.0, 127.4, 127.2, 126.1 (CHarom), 102.4 (C-1’), 101.3 (CHPh), 97.9 (C-1), 84.0 (C-
4), 81.7 (C-4’), 80.1 (C-3), 79.7 (C-2), 79.5 (C-3’), 75.3, 75.0, 73.5 (CH2 Bn), 68.5 (C-6’), 67.2 (C-2’), 66.2 (C-5), 66.2 (C-
5’), 55.3 (OMe), 18.1 (C-6); Diagnostic peaks for the α-anomer: 1H NMR (CDCl3, 400 MHz): δ 5.66 (d, 1H, J = 4.2 Hz, H-
1’), 5.57 (s, 1H, CHPh), 5.10 (d, 1H, J = 10.6 Hz), 4.98 (d, 1H, J = 10.9 Hz), 4.22 (dd, 1H, J = 10.4, 4.9 Hz, H-6’), 3.92 (td, 
1H, J = 10.1, 4.9 Hz, H-5’), 3.31 (dd, 1H, J = 10.1, 4.2 Hz, H-2’), 1.30 (d, 3H, J = 6.2 Hz, H-6); 13C-APT NMR (CDCl3, 101 
MHz): δ 101.3, 98.8, 97.7, 82.6, 80.9, 79.9, 76.3, 75.2, 75.1, 73.3, 68.6, 65.5, 63.3, 62.8, 18.8; HRMS: [M+NH4]+ calcd 
for C41H49N4O9 741.34941, found 741.34989.  
Methyl 4-O-(2,3-di-O-benzyl-4,6-O-benzylidene-α/β-D-glucopyranosyl)-2,3-di-O-
benzyl-6-O-benzoyl-α-D-glucopyranoside (3A). Donor A and acceptor 3 were 
condensed using the general procedure for Tf2O/Ph2SO mediated glycosylations (E) 
yielding product 3A (84 mg, 92 μmol, 92%, α:β = 5:1) as a colorless oil. Rf: 0.49 (4/1 
pentane/EtOAc); IR (thin film): 737, 999, 1026, 1049, 1092, 1273, 1454, 1721, 2928; Data for the α-anomer: 1H NMR 
(CDCl3, 400 MHz, HH-COSY, HSQC, HMBC): δ 8.10 – 8.00 (m, 2H, CHarom), 7.59 – 7.11 (m, 28H, CHarom), 5.73 (d, 1H, J = 
4.0 Hz, H-1’α ), 5.47 (s, 1H, CHPh), 4.99 (d, 1H, J = 11.5 Hz, CHH Bn), 4.89 (d, 1H, J = 11.1 Hz, CHH Bn), 4.80 (d, 1H, J = 
8.3 Hz, CHH Bn), 4.76 – 4.69 (m, 3H, 2xCHH Bn, H-6), 4.66 (d, 1H, J = 8.7 Hz, CHH Bn), 4.60 (d, 1H, J = 3.5 Hz, H-1), 4.59 
– 4.50 (m, 3H, 2xCHH Bn, H-6), 4.16 – 4.08 (m, 1H, H-3), 4.07 (m, 4H, H-5, H-3’, H-4, H-6’), 3.81 (td, 1H, J = 9.9, 4.7 Hz, 
H-5’), 3.63 – 3.52 (m, 4H, H-2, H-4’, H-6’, H-2’), 3.39 (s, 3H, CH3 OMe); 13C-APT NMR (CDCl3, 101 MHz, HSQC, HMBC): 
δ 166.2 (C=O), 138.9, 138.6, 137.8, 137.4 (Cq), 133.2 (CHarom), 129.9 (Cq), 129.8, 128.9, 128.5, 127.7, 126.9, 126.2, 
126.1 (CHarom), 101.3 (CHPh), 98.2 (C-1’), 97.6 (C-1), 82.4 (C-2), 81.7 (C-3), 80.4 (C-4’) , 78.7 (C-3’), 78.7 (C-2’), 75.3, 
74.6, 74.2 (CH2 Bn), 73.7 (C-4), 73.4 (CH2 Bn), 68.8 (C-6’), 68.1 (C-5), 63.7 (C-5’), 62.8 (C-6), 55.4 (OMe); Diagnostic 
peaks β-anomer: 1H NMR (CDCl3, 400 MHz): δ 7.99 – 7.94 (m, 2H), 5.51 (s, 1H), 4.46 (dd, 1H, J = 12.1, 4.7 Hz), 4.19 (dd, 
1H, J = 10.5, 5.0 Hz), 3.32 – 3.18 (m, 1H, H-5’β); 13C-APT NMR (CDCl3, 101 MHz): δ 166.0, 139.1, 138.3, 138.2, 137.3, 
129.6, 128.3, 127.3, 103.3, 101.2, 98.0, 82.7, 81.4, 80.1, 77.8, 75.8, 68.7, 66.1, 63.7, 41.1; HRMS: [M+NH4]+ calcd for 
C55H60NO12 926.41100, found 926.41196.  
Methyl 4-O-(2-azido-3-O-benzyl-4,6-O-benzylidene-2-deoxy-α/β-D-glucopyranosyl)-
2,3-di-O-benzyl-6-O-benzoyl-α-ᴅ-glucopyranoside (3B). Donor B and acceptor 3 were 
condensed using the general procedure for Tf2O/Ph2SO mediated glycosylations (E) 
yielding product 3B (61 mg, 67 μmol, 67%, α:β = 1:1.1) as a colorless oil. Rf: 0.50 
(4/1 pentane/EtOAc); IR (thin film): 698, 741, 914, 999, 1030, 1092, 1273, 1369, 1454, 1721, 2110, 2870, 3032; Data 
reported for a 0.9:1 mixture of anomers. 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC, HMBC): δ 8.04 (ddd, 3.8H, J = 8.4, 
6.7, 1.4 Hz, CHarom), 7.61 – 7.15 (m, 43.7H, CHarom), 5.71 (d, 0.9H, J = 4.2 Hz, H-1’α), 5.50 (s, 0.9H, CHPhα), 5.49 (s, 1H, 
CHPhβ), 5.13 (d, 1H, J = 10.4 Hz, CHH Bn), 5.00 – 4.83 (m, 5H, CHH Bn, 2xCH2 Bn, CHH Bn), 4.83 – 4.68 (m, 4.9H, H-6α, 
H-6β, CHH Bn, 2xCHH Bn), 4.68 – 4.54 (m, 4.8H, 2xCHH Bn, H-6α, H-1α, H-1β), 4.51 – 4.40 (m, 2H, H-6β, H-1’β), 4.13 (dd, 
1H, J = 9.5, 8.4 Hz, H-3β), 4.08 – 3.88 (m, 7.5H, H-3α, H-3’α, H-4β, H-4α, H-5α, H-5β, H-6’α, H-6’β), 3.83 (td, 0.9H, J = 9.9, 
4.8 Hz, H-5’α), 3.71 – 3.51 (m, 5H, H-2α, H-2β, H-3’β, H-4’β H-4’β, H-6’α), 3.49 (t, 1H, J = 10.3 Hz, H-6’β), 3.46 – 3.41 (m, 
1H, H-2’β), 3.41 (s, 3H, CH3 OMeβ), 3.40 (s, 2.7H, CH3 OMeα), 3.35 (dd, 0.9H, J = 10.1, 4.2 Hz, H-2’α), 3.22 – 3.10 (m, 1H, 
H-5’β); 13C-APT NMR (CDCl3, 101 MHz, HSQC, HMBC): δ 166.2, 166.1 (C=O), 139.1, 138.6, 138.2, 137.9, 137.8, 137.7, 
137.2, 137.1 (Cq), 133.4, 133.3 (CHarom), 129.9 (Cq), 129.7, 129.2, 129.1, 128.7, 128.6, 128.6, 128.6, 128.5, 128.5, 128.4, 
128.3, 128.3, 128.3, 128.2, 128.2, 128.1, 128.0, 128.0, 127.9, 127.8, 127.6, 127.5, 126.1, 126.0 (CHarom), 102.0 (C-1’β), 
101.4 (CHPhα), 101.3 (CHPhβ), 99.0 (H-1α), 98.0, 97.7 (C-1α, C-1β), 82.7 (C-4’α), 81.6, 81.6 (C-3β, C-4’β), 80.8 (C-2α), 80.1 
(C-3α), 79.7 (C-3’β), 79.6, (C-2β), 78.0 (C-4β), 76.1 (C-3’α), 75.7, 75.3, 75.2, 75.1 (CH2 Bn), 74.9 (C-4α), 73.6, 73.4 (CH2 
Bn), 68.6, 68.5 (C-6’α,β) , 68.5, 68.0 (C-5α, C-5β), 66.8 (C-2’β), 66.3 (C-5’β), 63.7 (C-5’α), 63.5 (C-6β), 63.1 (C-6α), 62.8 (C-
2’α), 55.6 (OMeβ), 55.5 (OMeα); HRMS: [M+Na]+ calcd for C48H49N3O11Na 866.3290, found 866.3259. 
Methyl (methyl 4-O-(2,3-di-O-benzyl-4,6-O-benzylidene-α/β-D-glucopyranosyl)-2,3-
di-O-benzyl-α-D-glucopyranosyl uronate) (4A). Donor A and acceptor 4 were 
condensed using the general procedure for Tf2O/Ph2SO mediated glycosylations (E) 
yielding product 4A (75.2 mg, 90 µmol, 90%, α:β = 5:1) as a white solid. Rf: 0.77 (7/3 
pentane/EtOAc); Spectroscopic data were in accord with those previously reported.32  IR (thin film): 694, 732, 912, 
988, 1026, 1043, 1074, 1086, 1358, 1454, 1749, 28866, 2932; Data for the α-anomer: 1H NMR (CDCl3, 400 MHz, HH-




COSY, HSQC, HMBC): δ 7.48 – 7.43 (m, 2H, CHarom), 7.40 – 7.16 (m, 23H, CHarom), 5.51 (s, 1H, CHPh), 5.44 (d, 1H, J = 
3.8 Hz, H-1’), 4.95 – 4.86 (m, 3H, CH2 Bn, CHH Bn), 4.78 (d, 1H, J = 11.2 Hz, CHH Bn), 4.71 (d, 1H, J = 12.1 Hz, CHH Bn), 
4.67 (d, 1H, J = 12.0 Hz, CHH Bn), 4.59 – 4.53 (m, 3H, 2xCHH Bn, H-1), 4.28 (dd, 1H, J = 6.5, 3.8 Hz, H-6’), 4.25 (d, 1H, J 
= 9.5 Hz, H-5), 4.11 (t, 1H, J = 9.1 Hz, H-4), 4.05 (t, 1H, J = 8.9 Hz, H-3), 3.98 (t, 1H, J = 9.1 Hz, H-3’), 3.76 (s, 3H, CH3 
CO2Me), 3.64 (t, 1H, J = 10.0 Hz, H-6’), 3.61 – 3.54 (m, 3H, H-2, H-4’, H-5’), 3.48 (dd, 1H, J = 5.6, 3.9 Hz, H-2’), 3.40 (s, 
3H, CH3 OMe); 13C-APT NMR (CDCl3, 101 MHz, HSQC, HMBC): δ 170.1 (C=O CO2Me), 139.0, 138.6, 138.0, 137.8, 137.6 
(Cq), 129.0, 128.6, 128.4, 128.4, 128.3, 128.3, 128.3, 128.2, 128.1, 128.1, 127.8, 127.7, 127.7, 127.3, 127.0, 126.1 
(CHarom), 101.3 (CHPh), 98.6 (C-1), 98.4 (C- 1’), 82.0 (C-4’), 80.8 (C-3), 79.2 (C-2), 78.7 (C-2’), 78.4 (C-3’), 76.1 (C-4), 
75.3, 75.0, 73.7, 73.7 (CH2 Bn), 70.3 (C-5), 68.6 (C-6’), 63.1 (C-5’), 55.8 (OMe), 52.9 (CO2Me); 13C-HMBC NMR (CDCl3, 
101 MHz): δ 98.4 (JC1’,H1’ = 174 Hz, C-1’α); Diagnostic peaks β-anomer: 1H NMR (CDCl3, 400 MHz): δ 5.47 (s, 1H, CHPh), 
4.62 (d, 1H, J = 12.1 Hz), 3.87 (dd, 1H, J = 9.6, 8.4 Hz), 3.50 (s, 3H, CH3 CO2Me), 3.44 (s, 0.54H, CH3 OMe), 3.38 – 3.28 
(m, 2H, H-2’, H-5’); 13CAPT NMR (CDCl3, 101 MHz): δ 170.1, 139.2, 138.6, 138.2, 137.4, 129.0, 128.5, 128.3, 128.1, 
127.7, 127.5, 126.1, 102.9 (C- 1’), 101.2 (CHPh), 99.0 (C-1), 82.3, 81.8, 81.3, 79.6, 78.5, 78.2, 75.6, 75.5, 75.2, 73.9, 
70.0, 68.8, 65.9, 55.9, 52.7; 13C-HMBC NMR (CDCl3, 101 MHz): δ 102.9 (JC1’,H1’ = 164 Hz, C-1’β); HRMS: [M+Na]+ calcd 
for C49H52O12Na 855.33510, found 855.33496.  
Methyl (methyl 4-O-(2-azido-3-O-benzyl-4,6-O-benzylidene-2-deoxy-α/β-D-
glucopyranosyl)-2,3-di-O-benzyl-α-ᴅ-glucopyranosyl uronate (4B). Donor B and 
acceptor 4 were condensed using the general procedure for Tf2O/Ph2SO mediated 
glycosylations (E) yielding product 4B (mg, 93 μmol, 93%, α:β = 1.1 :1) as a white 
solid. Rf 0.54 (4:1 pentane/EtOAc). Spectroscopic data were in accord with those previously reported.11 IR (thin film): 
696, 735, 914, 989, 1028, 1045, 1090, 1267, 1369, 1454, 1749, 2108, 2870, 2916. Data reported for a 1:1 mixture of 
anomers: 1H NMR (CDCl3, 400 MHz, H−H COSY, HSQC, HMBC): δ 7.48−7.41 (m, 4H, CHarom), 7.41−7.24 (m, 36H, CHarom), 
5.53 (s, 1H, CHPhα), 5.51 (d, 1H, J = 3.9 Hz, H-1′α), 5.47 (s, 1H, CHPhβ), 5.04 (d, 1H, J = 10.5 Hz, CHH Bn), 4.94 (d, 1H, J 
= 11.0 Hz, CHH Bn), 4.91−4.82 (m, 4H, 2xCHH Bn, 2xCHH Bn), 4.81−4.72 (m, 4H, 2xCHH Bn, 2xCHH Bn), 4.64−4.58 (m, 
2H, 2xCHH Bn), 4.57 (d, 2H, J = 3.5 Hz, H-1α,β), 4.43 (d, 1H, J = 8.1 Hz, H-1′β), 4.26 (dd, 1H, J = 10.3, 4.8 Hz, H-6′α), 
4.24−4.19 (m, 2H, H-5α, H-5β), 4.09−3.99 (m, 4H, H-3β, H-4α, H-4β, H-6′β), 3.97 (t, 1H, J = 9.5 Hz, H-3′α), 3.89 (t, 1H, J = 
9.2 Hz, H-3α), 3.82 (s, 3H, CH3 CO2Me), 3.81 (s, 3H, CH3 CO2Me), 3.72−3.56 (m, 4H, H-2β, H-4′α, H-4′β, H-6′α), 3.56−3.46 
(m, 3H, H-2α, H-3′β, H-5′α), 3.46−3.38 (m, 7H, 2×CH3 OMeα,β, H-6′β), 3.36−3.29 (m, 2H, H-2′α, H-2′β), 3.26 (td, 1H, J = 
9.7, 5.0 Hz, H-5′β). 13C-APT NMR (CDCl3, 101 MHz, HSQC, HMBC): δ 170.0, 170.0 (C=O), 139.1, 138.5, 138.0, 137.9, 
137.9, 137.8, 137.4, 137.2 (Cq), 129.2, 129.1, 128.7, 128.6, 128.5, 128.5, 128.4, 128.3, 128.3, 128.3, 128.3, 128.2, 
128.1, 128.0, 128.0, 127.8, 127.7, 127.5, 127.4, 126.1, 126.1 (CHarom), 102.3 (C-1′β), 101.4 (CHPhβ), 101.3 (CHPhα), 
98.9, 98.6 (C-1α, C-1β), 98.5 (C-1′α), 82.4 (C-4′α), 81.6 (C-4′β), 81.1 (C-3β), 79.6 (C-2β, C-4β), 79.5 (C-3α), 79.4 (C-3′β), 78.7 
(C-2α), 76.3 (C-3′α), 75.6 (CH2 Bn), 75.5 (C-4α), 75.1, 75.0, 73.9, 73.7 (CH2 Bn), 70.0, 69.9 (C-5α, C-5β), 68.5, 68.5 (C-6α, 
C-6β), 66.7 (C-2′β), 66.2 (C-5′β), 63.0 (C-5′α), 62.8 (C-2′α), 55.9, 55.9 (OMe), 53.0, 52.8 (CO2Me); HRMS: [M+NH4]+ calcd 
for C42H49N4O11 785.33923, found 785.34007. 
Methyl 4-O-(2,3-di-O-benzyl-4,6-O-benzylidene-α/β-ᴅ-glucopyranosyl)-2-O-benzoyl-
3,6-di-O-benzyl-α-ᴅ-glucopyranoside (5A). Donor A and acceptor 5 were condensed 
using the general procedure for Tf2O/Ph2SO mediated glycosylations (E) yielding 
product 5A (74 mg, 81 μmol, 81%, α:β = 1:1.1) as a white solid. Rf: 0.50 (4/1 
pentane/EtOAc); IR (thin film): 696, 737, 916, 995, 1047, 1088, 1271, 1366, 1452, 1721, 2926; Data reported for a 
1:1.1 mixture of anomers: 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC, HMBC): δ 8.02 (td, 4H, J = 8.2, 1.4 Hz, CHarom), 
7.60 – 6.99 (m, 56H, CHarom), 5.64 (d, 1H, J = 3.8 Hz, H-1’α), 5.54 (s, 1H, CHPhα), 5.49 (s, 1.1H, CHPhβ), 5.18 (dd, 1H, J = 
9.7, 3.7 Hz, H-2α), 5.11 – 5.02 (m, 3.2H, H-2β, H-1β, H-1α), 4.96 – 4.55 (m, 15.7H, 7xCH2 Bn, CHH Bnβ), 4.45 (d, 1.1H, J = 
7.8 Hz, H-1’β), 4.38 (d, 1.1H, J = 12.0 Hz, CHH Bnβ), 4.32 (t, 1H, J = 9.2 Hz, H-3α), 4.25 (t, 1H, J = 9.0 Hz, H-4α), 4.21 – 
4.08 (m, 3.2H, H-6α, H-6’β, H-3β), 4.08 – 3.99 (m, 2.1H, H-3’α, H-3β), 3.99 – 3.82 (m, 4.1H, H-5’α, H-6α, H-6β, H-5α), 3.78 
– 3.66 (m, 2.2H, H-6α, H-5β), 3.63 – 3.49 (m, 6.3H, H-6β, H-4’β, H-4β, H-4’α, H-6α, H-2’α), 3.45 (t, 1.1H, J = 10.3 Hz, H-6’β), 
3.41 – 3.38 (m, 7.4H, H-2’β, CH3 OMeβ, CH3 OMeα), 3.20 – 3.09 (m, 1.1H, H-5’β); 13C-APT NMR (CDCl3, 101 MHz, HSQC, 
HMBC): δ 166.0, 165.9 (C=O), 138.8, 138.8, 138.6, 138.5, 138.3, 138.3, 138.1, 138.0, 137.7 (Cq), 133.3, 133.2, 129.9, 
129.9 (CHarom), 129.7 (Cq), 129.1, 129.0, 128.6, 128.5, 128.4, 128.4, 128.4, 128.4, 128.3, 128.3, 128.2, 128.2, 128.1, 
128.0, 128.0, 127.9, 127.9, 127.8, 127.8, 127.7, 127.6, 127.6, 127.5, 127.4, 127.0, 126.2 (CHarom), 103.0 (C-1’β), 101.2 
(CHPhα, β), 97.7 (C-1’α), 97.3 (C-1α), 97.0 (C-1β), 82.7 (C-2’β), 82.4 (C-4’α), 81.9 (C-4’β), 81.1 (C-3’β), 80.6 (C-3α), 79.0 (C-
2’α), 78.8 (C-3’α), 77.9 (C-3β), 76.9 (C-4β), 75.6, 75.4, 75.3, 75.1 (CH2 Bn), 74.2 (C-2α), 74.1, 73.8, 73.6, 73.5 (CH2 Bn), 
73.4 (C-2β), 72.7 (C-4α), 70.3 (C-5β), 69.8 (C-5α), 69.0, 68.8, 68.8  (C-6’α,β, C-6β), 67.6 (C-6α), 65.8 (C-5’β), 63.5 (C-5’α), 





2-O-benzoyl-3,6-di-O-benzyl-α-ᴅ-glucopyranoside (5B). Donor B and acceptor 5 were 
condensed using the general procedure for Tf2O/Ph2SO mediated glycosylations (E) 
yielding product 5B (74 mg, 88 μmol, 88%, α:β = 1:6) as a light yellow oil. Rf: 0.50 
(4/1 pentane/EtOAc);  IR (thin film): 698, 737, 999, 1092, 1173, 1273, 1366, 1454, 1721, 2110, 2870; Data for the β-
anomer: 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC, HMBC): δ 8.05 – 7.98 (m, 2H, CHarom), 7.60 – 7.10 (m, 23H, CHarom), 
5.47 (s, 1H, CHPh), 5.12 – 5.03 (m, 2H, H-1, H-2), 4.90 (d, 1H, J = 11.2 Hz, CHH Bn), 4.85 (d, 1H, J = 11.0 Hz, CHH Bn), 
4.78 (d, 1H, J = 4.3 Hz, CHH Bn), 4.75 (d, 1H, J = 3.5 Hz, CHH Bn), 4.70 (d, 1H, J = 11.0 Hz, CHH Bn), 4.47 (d, 1H, J = 12.0 
Hz, CHH Bn), 4.29 – 4.24 (m, 1H, H-1’), 4.17 – 4.00 (m, 4H, H-3, H-6’, H-3’, H-6), 3.86 (dt, 1H, J = 9.4, 2.3 Hz, H-5), 3.77 
(dd, 1H, J = 11.0, 1.8 Hz, H-6), 3.60 – 3.54 (m, 1H, H-4’), 3.44 – 3.34 (m, 2H, H-3’, H-6’, H-2’, CH3 OMe), 3.03 (td, 1H, J 
= 9.8, 5.0 Hz, H-5’); 13C-APT NMR (CDCl3, 101 MHz, HSQC, HMBC): δ 165.9 (C=O), 138.7, 137.9, 137.3 (Cq), 133.3, 129.9 
(CHarom), 129.8 (Cq), 129.2, 128.7, 128.5, 128.5, 128.4, 128.4, 128.3, 128.3, 128.2, 128.1, 128.0, 127.7, 127.5, 126.1 
(CHarom), 101.3, 101.3 (C-1’, CHPh), 97.3 (C-1), 81.8 (C-4’), 79.2 (C-3’), 77.9 (C-3), 76.9 (C-4), 75.3, 74.9, 73.6 (CH2 Bn), 
73.5 (C-2), 70.0 (C-5), 68.6 (C-6’), 67.9 (C-6), 66.7 (C-2’), 65.9 (C-5’), 55.5 (OMe); Diagnostic peaks for the α-anomer: 
1H NMR (CDCl3, 400 MHz): δ 8.11 – 8.06 (m, 2H), 5.68 (d, 1H, J = 4.0 Hz, H-1’), 5.55 (s, 1H, CHPh), 5.17 (dd, 1H, J = 9.8, 
3.6 Hz, H-2), 4.98 (d, 1H, J = 10.9 Hz), 4.33 (dd, 1H, J = 9.8, 8.7 Hz), 3.67 (t, 1H, J = 9.3 Hz); 13C-APT NMR (CDCl3, 101 
MHz): δ 165.9, 138.2, 137.9, 137.4, 133.4, 129.6, 129.1, 128.6, 127.6, 98.2, 97.1, 82.7, 80.9, 76.3, 75.2, 75.0, 74.7, 
69.7, 69.1, 68.8, 63.5, 62.9; HRMS: [M+NH4]+ calcd for C48H51N4O12 861.37053, found 861.37082. 
Methyl 4-O-(2,3-di-O-benzyl-4,6-O-benzylidene-α/β-ᴅ-glucopyranosyl)-2-O-benzoyl-
3-O-benzyl-6-deoxy-α-ᴅ-glucopyranoside (6A). Donor A and acceptor 6 were 
condensed using the general procedure for Tf2O/Ph2SO mediated glycosylations (E) 
yielding product 6A (69 mg, 86 μmol, 86%, α:β = 1.1:1) as a white solid. Rf: 0.55 (4/1 
pentane/EtOAc); IR (thin film): 696, 737, 995, 1051, 1086, 1273, 1366, 1452, 1720, 2932; Data reported for a 1.1:1 
mixture of anomers: 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC): δ 8.05 – 8.01 (m, 2H, CHarom), 8.01 – 7.95 (m, 2.2H, 
CHarom), 7.60 – 7.16 (m, 42.8H, CHarom), 7.14 – 7.08 (m, 3.3H, CHarom), 7.04 – 6.97 (m, 2.2H, CHarom), 5.66 (d, 1.1H, J = 
4.0 Hz, H-1’α), 5.57 (s, 1.1H, CHPhα), 5.50 (s, 1H, CHPhβ), 5.12 (dd, 1.1H, J = 9.9, 3.7 Hz, H-2α), 5.06 (dd, 1H, J = 10.0, 
3.8 Hz, H-2β) 4.97 (d, 1.1H, J = 3.8 Hz, H-1β), 4.95 (d, 1H, J = 4.0 Hz, H-1β), 4.95 – 4.70 (m, 11.5H, 2xCH2 Bnα, 3xCH2 Bnβ, 
CHH Bnα), 4.67 (d, 1H, J = 7.7 Hz, H-1’β), 4.57 (d, 1.1H, J = 11.8 Hz, CHH Bnα), 4.33 – 4.22 (m, 2.2H, H-3α, H-6’α), 4.18 
(dd, 1H, J = 10.4, 4.8 Hz, H-6’β), 4.12 – 4.00 (m, 2.1H, H-3’α, H-3β), 4.03 – 3.89 (m, 2.2H, H-5α, H-5’α), 3.85 – 3.74 (m, 
2H, H-3β, H-5β), 3.74 (t, 1.1H, J = 10.3 Hz, H-6’α), 3.68 (dd, 1.1H, J = 9.5, 8.6 Hz, H-4α), 3.68 – 3.61 (m, 2.1H, H-4’α, H-
4’β), 3.58 (dd, 1H, J = 9.7, 8.8 Hz, H-4β), 3.56 (dd, 1.1H, J = 9.5, 4.1 Hz, H-2α), 3.48 (dd, 1H, J = 8.8, 7.7 Hz, H-2’β), 3.45 
(t, 1H, J = 10.2 Hz, H-6’β), 3.38 (s, 3H, CH3 OMeβ), 3.36 (s, 3.3H, CH3 OMeα), 3.32 (dt, 0.9H, J = 9.7, 4.8 Hz, H-5’β), 1.42 
(d, 3H, J = 6.2 Hz, H-6α), 1.36 (d, 2.7H, J = 6.3 Hz, H-6β); 13C-APT NMR (CDCl3, 101 MHz, HSQC, HMBC): δ 166.0 (C=O), 
138.8, 138.7, 138.6, 138.4, 138.3, 138.1, 137.4 (Cq), 133.3, 133.3 (CHarom), 129.9 (Cq), 129.9, 129.1, 129.0, 128.5, 128.5, 
128.4, 128.4, 128.4, 128.4, 128.4, 128.4, 128.3, 128.2, 128.2, 128.1, 127.9, 127.8, 127.8, 127.7, 127.7, 127.5, 127.3, 
126.7, 126.1, 126.1 (CHarom), 103.8 (C-1’β), 101.2 (CHPhα), 101.2 (CHPhβ), 98.3 (C-1’α), 97.0 (C-1β), 96.9 (C-1α), 83.6 (C-
4β), 82.9 (C-2’β), 82.3 (C-4’α), 81.8 (C-4’β) , 81.4 (C-3’β), 80.3 (C-3α), 79.2 (C-3’α), 78.9 (C-4α), 78.9 (C-2’α), 77.8 (C-3β), 
75.8, 75.4, 75.3 (CH2 Bn), 74.7 (C-2α), 74.0 (CH2 Bn), 73.8 (C-2β), 68.9 (C-6’α), 68.8 (C-6’β), 66.8 (C-5β), 66.0 (C-5’β), 65.9 
(C-5α), 63.4 (C-5’α), 55.4 (OMeβ), 55.2 (OMeα) , 19.1 (C-6α), 17.9 (C-6β); HRMS: [M+NH4]+ calcd for C48H54NO11 
820.36914, found 820.36967.  
Methyl 4-O-(2-azido-3-O-benzyl-4,6-O-benzylidene-2-deoxy-α/β-D-glucopyranosyl)-
2-O-benzoyl-3-O-benzyl-6-deoxy-α-ᴅ-glucopyranoside (6B). Donor B and acceptor 6 
were condensed using the general procedure for Tf2O/Ph2SO mediated 
glycosylations (E) yielding product 6B (65 mg, 88 μmol, 88%, α:β = 1:5) as a colorless 
oil. Rf: 0.76 (4/1 pentane/EtOAc); IR (thin film): 698, 737, 995, 1092, 1273, 1366, 1454, 1721, 2110, 2878; Data for the 
β-anomer: 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC, HMBC): δ 8.05 – 7.98 (m, 2H, CHarom), 7.60 – 7.11 (m, 18H, 
CHarom), 5.49 (s, 1H, CHPh), 5.06 (dd, 1H, J = 10.0, 3.7 Hz, H-2), 4.97 (d, 1H, J = 3.8 Hz, H-1), 4.94 – 4.82 (m, 2H, 2xCHH 
Bn), 4.79 (d, 1H, J = 11.2 Hz, CHH Bn), 4.74 (d, 1H, J = 11.1 Hz, CHH Bn), 4.53 (d, 1H, J = 8.1 Hz, H-1’), 4.12 – 4.01 (m, 
2H, H-6’, H-3), 3.89 (qd, 1H, J = 6.3, 3.4 Hz, H-5), 3.65 (t, 1H, J = 9.0 Hz, H-4’), 3.62 – 3.52 (m, 2H, H-3’, H-4), 3.49 – 
3.40 (m, 2H, H-2’, H-6’), 3.37 (s, 3H, CH3 OMe), 3.25 (td, 1H, J = 9.6, 4.9 Hz, H-5’), 1.43 (d, 3H, J = 6.2 Hz, H-6); 13C-APT 
NMR (CDCl3, 101 MHz, HSQC, HMBC): δ 166.0 (C=O), 138.7, 137.8, 137.2 (Cq), 133.3, 129.9 (CHarom), 129.8 (Cq), 129.2, 
128.6, 128.6, 128.5, 128.4, 128.4, 128.3, 128.3, 128.0, 127.7, 127.5, 127.4, 126.1 (CHarom), 102.4 (C-1’), 101.3 (CHPh), 
96.9 (C-1), 83.8 (C-4), 81.7 (C-4’), 79.4 (C-3’), 78.1 (C-3), 75.3, 75.1 (CH2 Bn), 74.0 (C-2), 68.5 (C-6’), 67.2 (C-2’), 66.4 
(C-5), 66.2 (C-5’), 55.4 (OMe), 18.0 (CO2Me); Diagnostic peaks for the α-anomer: 1H NMR (CDCl3, 400 MHz): δ 8.11 – 




8.06 (m, 2H), 5.62 (d, 1H, J = 4.2 Hz, H-1’), 5.58 (s, 1H, CHPh), 5.12 (dd, 1H, J = 9.8, 3.7 Hz, H-2), 4.31 – 4.23 (m, 2H), 
3.78 – 3.66 (m, 2H) 1.39 (d, 3H, J = 6.2 Hz); 13C-APT NMR (CDCl3, 101 MHz): δ 166.0, 138.1, 137.9, 137.2, 133.5, 129.6, 
127.7, 126.0, 98.8, 82.6, 80.4, 80.1, 76.4, 75.2, 75.0, 68.6, 65.6, 63.4, 62.8, 18.8; HRMS: [M+Na]+ calcd for 
C41H43N3O10Na 760.2841, found 760.2853. 
Methyl 4-O-(2,3-di-O-benzyl-4,6-O-benzylidene-α/β-ᴅ-glucopyranosyl)-2,6-di-O-
benzoyl-3-O-benzyl-α-ᴅ-glucopyranoside (7A). Donor A and acceptor 7 were 
condensed using the general procedure for Tf2O/Ph2SO mediated glycosylations (E) 
yielding product 7A (81 mg, 88 μmol, 88%, α:β = 3.5:1) as a white solid. Rf: 0.67 (4/1 
pentane/EtOAc); IR (thin film): 698, 712, 737, 995, 1026, 1090, 1271, 1371, 1452, 1720, 2920; Data for the α-anomer: 
1H NMR (CDCl3, 500 MHz, HH-COSY, HSQC, HMBC): δ 8.12 – 8.06 (m, 2H, CHarom), 8.01 – 7.97 (m, 2H, CHarom), 7.61 – 
6.99 (m, 26H, CHarom), 5.57 (d, 1H, J = 3.9 Hz, H-1’α), 5.49 (s, 1H, CHPh), 5.17 (dd, 1H, J = 9.9, 3.7 Hz, H-2), 5.02 (d, 1H, 
J = 3.5 Hz, H-1), 4.96 – 4.88 (m, 1H, CHH Bn), 4.87 – 4.82 (m, 1H, CHH Bn), 4.81 – 4.71 (m, 4H, CHH Bn, 2xCHH Bn, H-
6), 4.65 – 4.55 (m, 2H, H-6, CHH Bn), 4.33 (ddd, 1H, J = 9.9, 6.5, 1.7 Hz, H-3), 4.17 – 4.02 (m, 4H, H-4, H-6’, H-5, H-3’), 
3.88 (td, 1H, J = 9.8, 4.7 Hz, H-5’), 3.63 – 3.57 (m, 2H, H-6’, H-4’), 3.55 (dd, 1H, J = 9.5, 3.9 Hz, H-2’), 3.40 (s, 3H, CH3 
OMe); 13C-APT NMR (CDCl3, 126 MHz, HSQC, HMBC): δ 166.2, 165.9 (C=O), 138.7, 138.3, 138.2, 137.5 (Cq), 133.4, 
133.3 (CHarom), 129.9 (Cq), 129.9, 129.7 (CHarom), 129.6 (Cq), 129.0, 128.6, 128.5, 128.4, 128.3, 128.3, 128.1, 127.9, 
127.7, 127.7, 127.4, 127.0, 126.2 (CHarom), 101.4 (CHPh), 98.9 (C-1’), 97.0 (C-1), 82.4 (C-4’), 80.2 (C-3), 78.8 (C-2’), 78.7 
(C-3’), 75.3 (CH2 Bn) , 75.1 (C-4), 74.5 (CH2 Bn) , 74.1 (C-2), 74.1 (CH2 Bn), 68.9 (C-6’), 68.4 (C-5), 63.8 (C-5’), 63.7 (C-
6), 55.5 (OMe); Diagnostic peaks for the β-anomer: 1H NMR (CDCl3, 500 MHz): δ 8.06 – 8.01 (m, 2H), 5.50 (s, 1H, CHPh), 
5.08 (dd, 1H, J = 9.3, 3.8 Hz, H-2), 4.53 (dd, 1H, J = 12.1, 4.5 Hz, H-6), 3.76 (t, 1H, J = 9.0 Hz, H-3’), 3.27 (td, 1H, J = 9.1, 
8.4, 4.3 Hz, H-5’); 13C-APT NMR (CDCl3, 126 MHz): δ 166.0, 165.9 (C=O), 138.5, 138.5, 137.3, 133.4, 130.0, 130.0, 129.8, 
129.1, 128.6, 128.4, 128.1, 127.8, 127.8, 127.7, 126.1 (CHarom), 103.4 (C-1’), 101.2 (CHPh), 97.1 (C-1), 82.8 (C-2’), 81.8 
(C-4’), 81.4 (C-3’), 77.9, 77.8 (C-3, C-4), 75.9, 75.6, 75.3 (CH2 Bn), 73.4 (C-2), 68.9 (C-5), 68.8 (C-6’), 66.2 (C-5’), 62.7 (C-
6), 55.5 (OMe); HRMS: [M+NH4]+ calcd for C55H58NO13 940.39027, found 940.39106.  
Methyl 4-O-(2-azido-3-O-benzyl-4,6-O-benzylidene-2-deoxy-α/β-D-glucopyranosyl)-
2,6-di-O-benzoyl-3-O-benzyl-α-ᴅ-glucopyranoside (7B). Donor B and acceptor 7 were 
condensed using the general procedure for Tf2O/Ph2SO mediated glycosylations (E) 
yielding product 7B (75 mg, 87 μmol, 87%, α:β = 1.3:1) as a colorless oil. Rf: 0.66 
(4/1 pentane/EtOAc); IR (thin film): 698, 737, 918, 995, 1026, 1092, 1173, 1269, 1369, 1450, 1721, 2110, 2866; Data 
reported for a 1.3:1 mixture of anomers: 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC, HMBC): δ 8.14 – 7.98 (m, 9.2H, 
CHarom), 7.64 – 7.13 (m, 48.3H, CHarom), 5.67 (d, 1.3H, J = 4.1 Hz, H-1’α), 5.51 (s, 1.3H, CHPhα), 5.49 (s, 1H, CHPhβ), 5.18 
(dd, 1.3H, J = 9.8, 3.6 Hz, H-2α), 5.12 (dd, 1H, J = 9.6, 3.7 Hz, H-2β), 5.05 (d, 1H, J = 3.7 Hz, H-1β), 5.03 (d, 1.3H, J = 3.6 
Hz, H-1α), 4.98 (d, 1.3H, J = 10.9 Hz, CHH Bnα), 4.96 – 4.85 (m, 4.6H, CH2 Bnα, 2xCHH Bnβ), 4.80 – 4.73 (m, 5.6H, H-6β, 
2xCHH Bnβ, CHH Bnα H-6α, H-6β), 4.67 (dd, 1H, J = 12.2, 2.9 Hz, H-6β), 4.53 (dd, 1.3H, J = 12.0, 2.6 Hz, H-6α), 4.49 (d, 
1H, J = 8.0 Hz, H-1’β), 4.42 – 4.33 (m, 1.3H, H-3α), 4.21 – 4.13 (m, 1H, H-3β), 4.12 – 4.01 (m, 8.2H, H-3’α, H-4α, H-4β, H-
5β, H-5α, H-6’α, H-6’β), 3.87 (td, 1.3H, J = 9.9, 4.9 Hz, H-5’α), 3.72 – 3.53 (m, 4.6H, H-3’β, H-4’α, H-4’β, H-6’α), 3.51 – 3.40 
(m, 8.9H, H-2’β, H-6’β, CH3 OMeα, CH3 OMeβ), 3.36 (dd, 1.3H, J = 10.0, 4.1 Hz, H-2’α), 3.18 (td, 1H, J = 9.4, 4.9 Hz, H-
5’β); 13C-APT NMR (CDCl3, 101 MHz, HSQC, HMBC): δ 166.2, 166.2, 165.9, 165.9 (C=O), 138.4, 137.9, 137.8, 137.7, 
137.2, 137.1 (Cq), 133.6, 133.5, 133.4, 133.3 (CHarom), 129.9, 129.9 (Cq), 129.8 (CHarom), 129.8, 129.7 (Cq), 129.7, 129.5, 
129.2, 129.1, 128.7, 128.6, 128.6, 128.5, 128.5, 128.4, 128.4, 128.3, 128.3, 128.0, 127.8, 127.8, 127.7, 127.6, 126.2, 
126.0 (CHarom), 102.0 (C-1’β), 101.4 (CHPhα), 101.3 (CHPhβ), 99.0 (C-1’α), 97.1 (C-1α). 97.1 (C-1β), 82.6 (C-4’α), 81.7 (C-
4’β), 80.4 (C-3α), 79.7 (C-3’β), 78.1 (C-3β), 77.9 (C-4β), 76.2 (C-3’α), 75.6, 75.2 (CH2 Bn), 75.0(C-4α), 74.6 (C-2α), 73.5 (C-
2β), 68.6 (C-5β), 68.5, 68.5 (C-6’α, C-6’β), 68.1 (C-5α), 66.8 (C-2’β), 66.3 (C-5’β), 63.8 (C-5’α), 63.4 (C-6α), 62.9 (C-6β), 62.8 
(C-2’α), 55.6 (OMeα), 55.6 (OMeβ); HRMS: [M+NH4]+ calcd for C48H49N4O13 875.34980, found 875.35039. 
Methyl (methyl 4-O-(2,3-di-O-benzyl-4,6-O-benzylidene-α/β-ᴅ-glucopyranosyl)-2-O-
benzoyl-3-O-benzyl-α-ᴅ-glucopyranosyl uronate) (8A). Donor A and acceptor 8 were 
condensed using the general procedure for Tf2O/Ph2SO mediated glycosylations (E) 
yielding product 8A (81 mg, 96 μmol, 96%, α:β = 4.8 : 1) as a colorless oil. Rf: 0.57 
(4/1 pentane/EtOAc); IR (thin film): 698, 914, 995, 1045, 1088, 1200, 1267, 1369, 1452, 1722, 1751, 2938; Data for 
the α-anomer: 1H NMR (CDCl3, 500 MHz, HH-COSY, HSQC, HMBC): δ 8.00 – 7.94 (m, 2H, CHarom), 7.59 – 7.01 (m, 23H), 
5.54 (s, 1H, CHPh), 5.28 (d, 1H, J = 3.8 Hz, H-1’), 5.16 – 5.12 (m, 1H, H-2), 5.06 (d, 1H, J = 3.6 Hz, H-1), 4.95 – 4.68 (m, 
5H, 2xCH2 Bn, CHH Bn), 4.60 (d, 1H, J = 11.8 Hz, CHH Bn), 4.31 (dd, 1H, J = 8.9, 3.6 Hz, H-6’), 4.28 – 4.19 (m, 3H, H-3, 




H-4’), 3.52 (dd, 1H, J = 9.5, 3.8 Hz, H-2’), 3.41 (s, 3H, CH3 OMe); 13C-APT NMR (CDCl3, 126 MHz, HSQC, HMBC): δ 169.5 
(C=O CO2Me), 165.9 (C=O OBz), 138.6, 138.3, 138.0, 137.6 (Cq), 133.4 (CHarom), 130.0, 129.9 (CHarom), 129.6 (Cq), 129.0, 
128.5, 128.5, 128.4, 128.3, 128.2, 128.1, 128.0, 127.8, 127.7, 127.4, 127.4, 126.1 (CHarom), 101.3 (CHPh), 98.9 (C-1’), 
97.6 (C-1), 82.1 (C-4’), 79.0 (C-2), 78.4 (C-4), 78.2 (C-3’), 77.8 (C-3), 75.2, 74.9, 73.7 (CH2 Bn), 73.1 (C-2), 70.7 (C-5), 
68.6 (C-6’), 63.4 (C-5’), 55.9 (OMe), 52.8 (CO2Me); Diagnostic peaks for the β-anomer: 1H NMR (CDCl3, 500 MHz): δ 
8.05 – 8.00 (m, 1H), 5.46 (s, 1H, CHPh), 5.10 (dd, 1H, J = 9.4, 3.6 Hz, H-2), 4.09 (ddd, 1H, J = 9.4, 6.7, 1.5 Hz, H-3), 3.34 
(td, 1H, J = 9.6, 4.7 Hz, H-5’); 13C-APT NMR (CDCl3, 126 MHz): δ 169.7 (C=O), 138.6, 138.5, 137.4 (Cq), 129.8, 128.3, 
128.3, 128.1, 127.8, 127.7, 127.6, 126.1 (CHarom), 103.1 (C-1’), 101.2 (CHPh), 97.6 (C-1), 82.4 (C-2’), 81.8, 81.3, 78.0, 
77.0, 75.6 (C-3), 75.2, 72.6 (C-2), 70.4, 68.7, 65.9 (C-5’), 56.1 (OMe), 52.8 (CO2Me); HRMS: [M+NH4]+ calcd for 
C49H54NO13 864.35897, found 864.36009.  
Methyl (methyl 4-O-(2-azido-3-O-benzyl-4,6-O-benzylidene-2-deoxy-α/β-D-
glucopyranosyl)-2-O-benzoyl-3-O-benzyl-α-ᴅ-glucopyranosyl uronate) (8B). Donor B 
and acceptor 8 were condensed using the general procedure for Tf2O/Ph2SO 
mediated glycosylations (E) yielding product 8B (64 mg, 82 μmol, 82%, α:β = 1.18 : 
1) as a colorless oil. Rf: 0.73 (4/1 pentane/EtOAc); IR (thin film): 698, 737, 918, 991, 1045, 1092, 1200, 1265, 1366, 
1454, 1724, 1751, 2110, 2940; Data reported for a 1.18 : 1 mixture of anomers: 1H NMR (CDCl3, 400 MHz, HH-COSY, 
HSQC): δ 8.11 – 8.04 (m, 2H, CHarom), 8.04 – 7.97 (m, 2.2H, CHarom), 7.63 – 7.09 (m, 39.6H, CHarom), 5.55 (s, 1H), 5.48 
(d, 2H, J = 3.3 Hz), 5.16 (dd, 1H, J = 9.6, 3.6 Hz), 5.55 (s, 1.2H, CHPhα), 5.50 – 5.44 (m, 2.2H, H-1’α, CHPhβ), 5.16 (dd, 
1H, J = 9.6, 3.6 Hz, H-2α), 5.12 – 5.07 (m, 3.2H, H-1α, H-1β, H-2β), 4.96 (d, 1.2H, J = 11.0 Hz, CHH Bnα), 4.93 – 4.83 (m, 
4.4H, 2xCHH Bnβ, CH2 Bnα), 4.82 – 4.74 (m, 2.2H, CHH Bnα, CHH Bnβ), 4.73 (d, 1H, J = 11.1 Hz, CHH Bnβ), 4.51 (d, 1H, J 
= 8.1 Hz, H-1’β), 4.37 – 4.26 (m, 4.6H, H-5α, H-5β, H-3α, H-6’α), 4.26 – 4.16 (m, 2.2H, H-4α, H-4β), 4.16 – 4.05 (m, 2H, H-
3β,  H-6’β), 4.00 (dd, 1.2H, J = 10.0, 9.0 Hz, H-3’α), 3.86 (s, 3H, CH3 CO2Meβ), 3.85 (s, 3.6H, CH3 CO2Meα), 3.71 – 3.64 
(m, 2.4H, H-6’α, H-4’α), 3.63 – 3.50 (m, 3.2H, H-3’β, H-5’α, H-4’β), 3.47 – 3.33 (m, 8.8H, CH3 OMeα, CH3 OMeβ, H-2’α H-
2’β, H-6’β), 3.29 (td, 1H, J = 9.5, 4.8 Hz, H-5’β); 13C-APT NMR (CDCl3, 101 MHz, HSQC, HMBC): δ 169.7, 169.6 (C=O 
CO2Me), 165.9, 165.8 (C=O OBz), 138.4, 137.9, 137.9, 137.8, 137.4, 137.2 (Cq), 133.6, 133.4, 129.9, 129.9 (CHarom), 
129.6, 129.4 (Cq), 129.2, 129.1, 128.7, 128.5, 128.5, 128.5, 128.4, 128.4, 128.3, 128.3, 128.2, 128.0, 128.0, 127.8, 
127.8, 127.6, 127.6, 126.1, 126.1 (CHarom), 102.3 (C-1’β), 101.5 (CHPhα), 101.4 (CHPhβ), 98.6 (C-1’α), 97.7 (C-1α), 97.7 
(C-1β), 82.5 (C-4’α), 81.6 (C-3’β), 79.6 (C-3α), 79.4 (C-4’β), 79.3 (C-4β), 77.3 (C-3β), 76.4 (C-3’α), 75.7 (C-4α), 75.5, 75.4, 
75.1, 75.1 (CH2 Bn), 73.9 (C-2α), 72.9 (C-2β), 70.1 (C-5α), 70.0 (C-5β), 68.5 (C-6’α), 66.7(C-2’β), 66.2 (C-5’β), 63.2 (C-5’α), 
62.9 (C-2’α), 56.0 (OMeα,β), 53.1 (CO2Meα), 52.9 (CO2Meβ);  HRMS: [M+NH4]+ calcd C42H47N4O12 for 799.31850, found 
799.31937. 
Methyl 4-O-(2,3-di-O-benzyl-4,6-O-benzylidene-α-ᴅ-glucopyranosyl)-2,6-di-O-benzyl-
3-O-benzoyl-α-ᴅ-glucopyranoside (9A). Donor A and acceptor 9 were condensed using 
the general procedure for Tf2O/Ph2SO mediated glycosylations (E) yielding product 
9A (86 mg, 95 μmol, 95%, α:β = >20:1) as a colorless oil. Rf: 0.26 (4/1 pentane/EtOAc); [α]  = -0.9° (c = 1.0, CHCl3); IR (thin film): 696, 746, 912, 995, 1047, 1088, 1269, 1369, 
1452, 1728, 2924; 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC, HMBC): δ 8.09 – 8.02 (m, 2H, CHarom), 7.61 – 7.11 (m, 
28H, CHarom), 5.94 (t, 1H, J = 9.6 Hz, H-3), 5.46 (s, 1H, CHPh), 5.03 (d, 1H, J = 3.5 Hz, H-1’), 4.79 – 4.72 (m, 2H, H-1, CHH 
Bn), 4.63 – 4.50 (m, 5H, 2xCH2 Bn, CHH Bn), 4.40 (d, 1H, J = 12.1 Hz, CHH Bn), 4.21 (t, 1H, J = 9.4 Hz, H-4), 4.13 – 4.04 
(m, 2H, CHH Bn, H-6’), 3.97 – 3.88 (m, 3H, H-3’, H-5, H-6), 3.85 (dd, 1H, J = 9.9, 4.8 Hz, H-5’), 3.71 – 3.67 (m, 1H, H-6), 
3.65 (t, 1H, J = 3.0 Hz, H-2’), 3.55 (t, 1H, J = 10.2 Hz, H-6’), 3.44 (t, 1H, J = 9.7 Hz, H-4’), 3.41 (s, 3H, CH3 OMe), 3.26 (dd, 
1H, J = 9.4, 3.5 Hz, H-2’); 13C-APT NMR (CDCl3, 101 MHz, HSQC, HMBC): δ 165.4 (C=O), 138.8, 138.0, 137.9, 137.8, 
137.6 (Cq), 132.9 (CHarom), 130.7 (Cq), 129.9, 128.9, 128.5, 128.4, 128.4, 128.4, 128.3, 128.3, 128.3, 128.2, 128.1, 127.9, 
127.9, 127.8, 127.7, 127.6, 126.2 (CHarom), 101.3 (CHPh), 98.0 (C-1’), 97.7 (C-1), 81.9 (C-4), 78.8 (C-2’), 78.3 (C-3’), 77.2 
(C-2), 75.4 (CH2 Bn), 73.9 (C-3), 73.7 (C-4), 73.6, 72.9, 72.8 (CH2 Bn), 69.7 (C-5), 69.0 (C-6’), 68.3 (C-6), 63.6 (C-5’), 55.4 
(OMe); HRMS: [M+NH4]+ calcd for C55H60NO12 926.41100, found 926.41201. 
Methyl 4-O-(2-azido-3-O-benzyl-4,6-O-benzylidene-2-deoxy-α/β-D-glucopyranosyl)-
2,6-di-O-benzyl-3-O-benzoyl-α-ᴅ-glucopyranoside (9B). Donor B and acceptor 9 were 
condensed using the general procedure for Tf2O/Ph2SO mediated glycosylations (E) 
yielding product 9B (65 mg, 77 μmol, 77%, α:β = 6.7:1) as a light yellow oil. Rf: 0.28 
(4/1 pentane/EtOAc); [α]  = -25.5° (c = 1.0, CHCl3); IR (thin film): 698, 745, 995, 1092, 1165, 1269, 1369, 1454, 1732, 
2110, 2866; Data for the α-anomer: 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC, HMBC): δ 8.11 – 8.05 (m, 2H, CHarom), 
7.61 – 7.09 (m, 23H, CHarom), 5.85 (t, 1H, J = 9.6 Hz, H-3), 5.50 (s, 1H, CHPh), 5.04 (d, 1H, J = 3.7 Hz, H-1’), 4.82 (d, 1H, 




J = 10.6 Hz, CHH Bn), 4.75 (d, 1H, J = 3.5 Hz, H-1), 4.64 – 4.54 (m, 5H, CHH Bn, 2xCH2 Bn), 4.10 (dd, 1H, J = 10.3, 4.8 Hz, 
H-6),  4.05 (t, 1H, J = 9.5 Hz, H-4), 3.96 – 3.81 (m, 4H, H-3’, H-5’, H-5, H-6), 3.76 – 3.67 (m, 1H, H-6’), 3.64 – 3.57 (m, 
2H, H-2, H-6’), 3.56 (t, 1H, J = 9.3 Hz, H-4’), 3.42 (s, 3H, CH3 OMe), 3.23 (dd, 1H, J = 9.9, 3.7 Hz, H-2’); 13C-APT NMR 
(CDCl3, 101 MHz, HSQC, HMBC): δ 165.4 (C=O), 137.9, 137.8, 137.7, 137.2 (Cq), 132.8 (CHarom), 130.7 (Cq), 129.7, 129.1, 
128.7, 128.6, 128.5, 128.5, 128.4, 128.4, 128.3, 128.0, 127.9, 127.9, 127.8, 126.1 (CHarom), 101.5 (CHPh), 99.5 (C-1’), 
97.7 (C-1), 82.5 (C-4’), 77.1 (C-4), 76.7 (C-3’), 76.5 (C-2), 75.3, 73.7 (CH2 Bn), 73.5 (C-3), 72.8 (CH2 Bn), 69.6 (C-5), 68.8 
(C-6’), 68.7 (C-6), 63.8 (C-5’), 63.5 (C-2’), 55.6 (OMe); Diagnostic peaks for the β-anomer: 1H NMR (CDCl3, 400 MHz): 
δ 5.66 (dd, 1H, J = 10.0, 8.7 Hz, H-3), 5.19 (s, 1H, CHPh), 4.70 (d, 1H, J = 11.9 Hz, CHH Bn), 4.69 (d, 1H, J = 11.4 Hz, CHH 
Bn), 4.44 (d, 1H, J = 11.9 Hz, CHH Bn), 3.99 (dd, 1H, J = 10.8, 2.5 Hz, H-6) 2.87 (td, 1H, J = 9.3, 4.9 Hz, H-5’), 2.52 (t, 1H, 
J = 10.4 Hz, H-6’);  13C-APT NMR (CDCl3, 101 MHz): δ 101.5 (C-1’), 101.0 (CHPh), 98.0 (C-1), 81.2, 79.1, 76.1, 74.6, 73.7, 
72.8, 72.6, 69.4, 67.8, 67.6, 65.9, 65.7; HRMS: [M+NH4]+ calcd for C48H53N4O11 861.37053, found 861.37106. 
Methyl 4-O-(2,3-di-O-benzyl-4,6-O-benzylidene-α-ᴅ-glucopyranosyl)-2-O-benzyl-3-O-
benzoyl-6-deoxy-α-ᴅ-glucopyranoside (10A). Donor A and acceptor 10 were 
condensed using the general procedure for Tf2O/Ph2SO mediated glycosylations (E) 
yielding product 10A (67 mg, 83 μmol, 83%, α:β = >20:1) as a white solid. Rf: 0.38 (4/1 
pentane/EtOAc); [α]  = -3.6° (c = 1.0, CHCl3); IR (thin film): 698, 745, 995, 1053, 1092, 
1269, 1454, 1728, 2866; 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC, HMBC): δ 8.07 – 8.01 (m, 2H, CHarom), 7.62 – 7.06 
(m, 23H, CHarom), 5.98 – 5.87 (m, 1H, H-3), 5.48 (s, 1H, CHPh), 5.10 (d, 1H, J = 3.8 Hz, H-1’), 4.80 (d, 1H, J = 11.1 Hz, 
CHH Bn), 4.70 – 4.62 (m, 2H, H-1, CHH Bn), 4.57 (d, 1H, J = 12.5 Hz, CHH Bn), 4.52 (d, 1H, J = 12.5 Hz, CHH Bn), 4.42 (d, 
1H, J = 12.0 Hz, CHH Bn), 4.24 – 4.13 (m, 2H, H-6’, CHH Bn), 4.02 – 3.85 (m, 3H, H-3’, H-5, H-5’), 3.70 – 3.62 (m, 2H, H-
4’, H-6’), 3.62 – 3.55 (m, 1H, H-2), 3.49 (t, 1H, J = 9.5 Hz, H-4), 3.41 (s, 3H, CH3 OMe), 3.33 (dd, 1H, J = 9.5, 3.8 Hz, H-
2’), 1.36 (d, 3H, J = 6.2 Hz, H-6); 13C-APT NMR (CDCl3, 101 MHz, HSQC, HMBC): δ 165.2 (C=O), 138.7, 137.8, 137.4 (Cq), 
133.0 (CHarom), 130.6 (Cq), 129.9, 129.0, 128.5, 128.4, 128.3, 128.3, 128.2, 128.1, 127.9, 127.7, 127.6, 126.1 (CHarom), 
101.3 (CHPh), 98.1 (C-1’), 97.3 (C-1), 81.9 (C-4), 79.4 (C-4’), 78.5 (C-2’), 78.4 (C-3’), 77.6 (C-2), 75.5 (CH2 Bn), 73.9 (C-
3), 73.1, 72.6 (CH2 Bn), 68.9 (C-6’), 66.1 (C-5), 63.5 (C-5’), 55.3 (OMe), 18.7 (C-6); HRMS: [M+NH4]+ calcd for C48H54NO11 
820.36914, found 820.36983.  
Methyl 4-O-(2-azido-3-O-benzyl-4,6-O-benzylidene-2-deoxy-α-ᴅ-glucopyranosyl)-2-O-
benzyl-3-O-benzoyl-6-deoxy-α-ᴅ-glucopyranoside (10B). Donor B and acceptor 10 
were condensed using the general procedure for Tf2O/Ph2SO mediated glycosylations 
(E) yielding product 10B (60 mg, 81 μmol, 81%, α:β = 14:1) as a colorless oil. Rf: 0.25 
(4/1 pentane/EtOAc); [α]  = -30.0° (c = 1.0, CHCl3); IR (thin film): 698, 748, 995, 1053, 
1096, 1269, 1373, 1454, 1732, 2110, 2931; Data for the α-anomer: 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC, HMBC): 
δ 8.07 – 8.01 (m, 2H, CHarom), 7.61 – 7.09 (m, 18H, CHarom), 5.84 (t, 1H, J = 9.6 Hz, H-3), 5.53 (s, 1H, CHPh), 5.07 (d, 1H, 
J = 4.0 Hz, H-1’), 4.87 (d, 1H, J = 10.8 Hz, CHH Bn), 4.71 – 4.64 (m, 2H, CHH Bn, H-1), 4.61 – 4.47 (m, 2H, CH2 Bn), 4.21 
(dd, 1H, J = 10.4, 5.0 Hz, H-6’), 4.00 – 3.83 (m, 3H, H-3’, H-5’, H-5), 3.69 (t, 1H, J = 10.4 Hz, H-6’), 3.61 (t, 1H, J = 9.3 Hz, 
H-4’), 3.57 – 3.46 (m, 2H, H-2, H-4), 3.42 (s, 3H, CH3 OMe), 3.19 (dd, 1H, J = 10.0, 4.0 Hz, H-2’), 1.35 (d, 3H, J = 6.2 Hz, 
H-6); 13C-APT NMR (CDCl3, 101 MHz, HSQC, HMBC): δ 165.3 (C=O), 137.8, 137.7, 137.1 (Cq), 132.8 (CHarom), 130.6 (Cq), 
129.6, 129.1, 128.5, 128.4, 128.4, 128.4, 128.3, 128.0, 127.9, 127.9, 126.0 (CHarom), 101.3 (CHPh), 100.0 (C-1’), 97.5 
(C-1), 82.4 (C-4’), 82.4 (C-4), 77.4 (C-2), 76.6 (C-3’), 75.2 (CH2 Bn), 73.5 (C-3), 72.6 (CH2 Bn), 68.5 (C-6’), 65.7 (C-5), 63.5 
(C-5’), 63.0 (C-2’), 55.4 (OMe), 18.3 (C-6); Diagnostic peaks for the β-anomer: 1H NMR (CDCl3, 400 MHz): δ 5.66 (t, 1H, 
J = 9.5 Hz, H-3), 5.23 (s, 1H, CHPh), 3.04 (td, 1H, J = 9.7, 5.1 Hz, H-5’), 2.63 (t, 1H, J = 10.4 Hz, H-6’), 1.38 (d, 3H, J = 6.3 
Hz, H-6); 13C-APT NMR (CDCl3, 101 MHz): δ 102.6 (C-1’), 101.0 (CHPh), 97.5 (C-1), 83.3, 81.3, 81.1, 79.2, 74.8, 72.7, 
67.8, 66.4, 66.1, 65.9, 17.7; HRMS: [M+Na]+ calcd for C41H43N3O10Na 760.2841, found 760.2852. 
Methyl 4-O-(2,3-di-O-benzyl-4,6-O-benzylidene-α-ᴅ-glucopyranosyl)-2-O-benzyl-3,6-
di-O-benzoyl-α-ᴅ-glucopyranoside (11A). Donor A and acceptor 11 were condensed 
using the general procedure for Tf2O/Ph2SO mediated glycosylations (E) yielding 
product 11A (88 mg, 95 μmol, 95%, α:β = >20:1) as a white solid. Rf: 0.25 (4/1 
pentane/EtOAc); [α]  = +21.1° (c = 1.0, CHCl3); IR (thin film): 698, 712, 748, 995, 1026, 
1090, 1267, 1371, 1452, 1724; 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC): δ 8.12 – 8.06 (m, 2H, CHarom), 8.06 – 8.01 
(m, 2H, CHarom), 7.62 – 7.51 (m, 2H, CHarom), 7.46 – 7.32 (m, 9H, CHarom), 7.29 – 7.11 (m, 15H, CHarom), 5.99 (dd, 1H, J = 
9.9, 9.0 Hz, H-3), 5.42 (s, 1H, CHPh), 4.97 (d, 1H, J = 3.6 Hz, H-1’), 4.84 – 4.68 (m, 3H, H-1, H-6, CHH Bn), 4.67 – 4.51 
(m, 4H, CHH Bn, CH2 Bn, H-6), 4.36 (d, 1H, J = 12.2 Hz, CHH Bn), 4.15 (ddd, 1H, J = 10.0, 4.4, 2.1 Hz, H-5), 4.11 – 4.01 




H-2), 3.54 (t, 1H, J = 10.3 Hz, H-6’), 3.46 (d, 1H, J = 9.5 Hz, H-4’), 3.44 (s, 3H, CH3 OMe), 3.29 (dd, 1H, J = 9.5, 3.6 Hz, H-
2’); 13C-APT NMR (CDCl3, 101 MHz, HSQC, HMBC): δ 166.1, 165.3 (C=O), 138.7, 138.1, 137.7, 137.4 (Cq), 133.2, 133.0 
(CHarom), 130.7, 130.0 (Cq), 129.9, 129.8, 128.9, 128.5, 128.5, 128.4, 128.3, 128.2, 128.2, 128.2, 128.0, 127.9, 127.7, 
127.6, 126.2 (CHarom), 101.4 (CHPh), 99.2 (C-1’), 97.5 (C-1), 81.9 (C-4’), 78.5 (C-2’), 78.3 (C-3’), 77.3 (C-2), 75.9 (C-4), 
75.4 (CH2 Bn), 73.3 (C-3), 73.2 (CH2 Bn), 72.8 (CH2 Bn), 68.8 (C-6’), 68.6 (C-5), 63.9 (C-5’), 63.5 (C-6), 55.5 (OMe); HRMS: 
[M+NH4]+ calcd for C55H58NO13 940.39027, found 940.39105.  
Methyl 4-O-(2-azido-3-O-benzyl-4,6-O-benzylidene-2-deoxy-α-ᴅ-glucopyranosyl)-2-O-
benzyl-3,6-di-O-benzoyl-α-ᴅ-glucopyranoside (11B). Donor B and acceptor 11 were 
condensed using the general procedure for Tf2O/Ph2SO mediated glycosylations (E) 
yielding product 11B (73 mg, 85 μmol, 85%, α:β = >20:1) as a colorless oil. Rf: 0.31 
(4/1 pentane/EtOAc); [α]  = +0.6° (c = 1.0, CHCl3); IR (thin film): 748, 995, 1030, 
1096, 1169, 1269, 1315, 1373, 1450, 1724, 2110, 2924; 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC, HMBC): δ 8.08 (td, 
4H, J = 8.2, 1.4 Hz, CHarom), 7.61 – 7.10 (m, 21H, CHarom), 5.91 (t, 1H, J = 9.6 Hz, H-3), 5.49 (s, 1H, CHPh), 5.07 (d, 1H, J 
= 3.9 Hz, H-1’), 4.85 (d, 1H, J = 10.7 Hz, CHH Bn), 4.76 (d, 1H, J = 3.4 Hz, H-1), 4.72 (dd, 1H, J = 12.2, 2.1 Hz, H-6), 4.67 
(d, 1H, J = 10.7 Hz, CHH Bn), 4.63 – 4.53 (m, 2H, CH2 Bn), 4.50 (dd, 1H, J = 12.1, 4.7 Hz, H-6), 4.23 (dd, 1H, J = 10.4, 4.9 
Hz, H-6’), 4.12 (ddd, 1H, J = 9.9, 4.6, 2.0 Hz, H-5), 4.00 – 3.86 (m, 3H, H-3’, H-4, H-5’), 3.67 – 3.53 (m, 3H, H-4’, H-6’, H-
2), 3.45 (s, 3H, CH3 OMe), 3.25 (dd, 1H, J = 10.0, 3.9 Hz, H-2’); 13C-APT NMR (CDCl3, 101 MHz, HSQC, HMBC): δ 166.2, 
165.4 (C=O), 137.8, 137.1 (Cq), 133.3, 132.9 (CHarom), 130.5, 129.9 (Cq), 129.8, 129.1, 128.6, 128.5, 128.4, 128.3, 128.3, 
128.0, 127.9, 127.9, 126.1 (CHarom), 101.4 (CHPh), 100.5 (C-1’), 97.6 (C-1), 82.4 (C-4’), 77.8 (C-4), 77.2 (C-2), 76.6 (C-
3’), 75.2 (CH2 Bn), 73.2 (C-3), 72.7 (CH2 Bn), 68.5 (C-6’), 68.3 (C-5), 64.0 (C-5’), 63.6 (C-6), 63.2 (C-2’), 55.6 (OMe); 
HRMS: [M+NH4]+ calcd for C48H51N4O12 875.34980, found 875.35050. 
Methyl (methyl 4-O-(2,3-di-O-benzyl-4,6-O-benzylidene-α-ᴅ-glucopyranosyl)-2-O-
benzyl-3-O-benzoyl-α-ᴅ-glucopyranosyl uronate) (12A). Donor A and acceptor 12 were 
condensed using the general procedure for Tf2O/Ph2SO mediated glycosylations (E) 
yielding product 12A (73 mg, 86 μmol, 86%, α:β = >20:1) as a white solid. Rf: 0.40 (4/1 
pentane/EtOAc); [α]  = -18.4° (c = 1.0, CHCl3); IR (thin film): 698, 748, 914, 995, 1047, 
1088, 1201, 1267, 1452, 1732, 2931; 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC): δ 8.11 – 8.01 (m, 2H, CHarom), 7.59 
– 7.51 (m, 1H, CHarom), 7.47 – 7.33 (m, 7H, CHarom), 7.33 – 7.13 (m, 13H, CHarom), 7.09 – 7.02 (m, 2H, CHarom), 5.96 (t, 
1H, J = 9.6 Hz, H-3), 5.45 (s, 1H, CHPh), 4.93 (d, 1H, J = 3.7 Hz, H-1’), 4.80 (d, 1H, J = 11.1 Hz, CHH Bn), 4.75 (d, 1H, J = 
3.4 Hz, H-1), 4.69 (d, 1H, J = 11.1 Hz, CHH Bn), 4.61 – 4.52 (m, 2H, CH2 Bn), 4.40 – 4.28 (m, 2H, CHH Bn, H-5), 4.27 – 
4.16 (m, 2H, H-4, H-6’), 3.99 (d, 1H, J = 12.2 Hz, CHH Bn), 3.92 (t, 1H, J = 9.4 Hz, H-3’), 3.74 (s, 3H, CH3 CO2Me), 3.69 
(dd, 1H, J = 10.0, 3.4 Hz, H-2), 3.63 – 3.52 (m, 2H, H-5’, H-6’), 3.46 (s, 3H, CH3 OMe), 3.42 (d, 1H, J = 9.2 Hz, H-4’), 3.25 
(dd, 1H, J = 9.4, 3.7 Hz, H-2’); 13C-APT NMR (CDCl3, 101 MHz, HSQC, HMBC): δ 169.9 (C=O CO2Me), 165.1 (C=O OBz), 
138.7, 137.8, 137.5 (Cq), 133.1 (CHarom), 130.5 (Cq), 129.9, 129.0, 128.5, 128.5, 128.3, 128.3, 128.3, 128.2, 128.2, 128.2, 
128.1, 127.7, 127.6, 126.1 (CHarom), 101.3 (CHPh), 98.8 (C-1’), 98.4 (C-1), 81.6 (C-4’), 78.2 (C-2’), 78.0 (C-3’), 76.5 (C-
2), 76.1 (C-4), 75.4, 73.0, 72.8 (CH2 Bn), 72.7 (C-3), 70.5 (C-5), 68.5 (C-6’), 63.5 (C-5’), 55.9 (OMe), 52.9 (CO2Me); HRMS: 
[M+NH4]+ calcd for C49H54NO13 864.35897, found 864.36004.  
Methyl (methyl 4-O-(2-azido-3-O-benzyl-4,6-O-benzylidene-2-deoxy-α-ᴅ-
glucopyranosyl)-2-O-benzyl-3-O-benzoyl-α-ᴅ-glucopyranosyl uronate) (12B). Donor B 
and acceptor 12 were condensed using the general procedure for Tf2O/Ph2SO 
mediated glycosylations (E) yielding product 12B (73 mg, 93 μmol, 93%, α:β = >20:1) 
as a colorless oil. Rf: 0.33 (4/1 pentane/EtOAc); [α]  = -35.8° (c = 1.0, CHCl3); IR (thin 
film): 698, 748, 914, 995, 1045, 1092, 1200, 1265, 1373, 1454, 1732, 2110, 2936; 1H NMR (CDCl3, 400 MHz, HH-COSY, 
HSQC, HMBC): δ 8.09 – 7.99 (m, 2H, CHarom), 7.62 – 7.53 (m, 1H, CHarom), 7.52 – 7.42 (m, 4H, CHarom), 7.42 – 7.33 (m, 
3H, CHarom), 7.29 – 7.16 (m, 10H, CHarom), 5.87 (t, 1H, J = 9.7 Hz, H-3), 5.50 (s, 1H, CHPh), 4.96 (d, 1H, J = 3.8 Hz, H-1’), 
4.84 (d, 1H, J = 10.8 Hz, CHH Bn), 4.74 (d, 1H, J = 3.4 Hz, H-1), 4.67 (d, 1H, J = 10.8 Hz, CHH Bn), 4.60 – 4.51 (m, 2H, 
CH2 Bn), 4.30 (d, 1H, J = 9.8 Hz, H-5), 4.28 – 4.21 (m, 1H, H-6’), 4.12 (t, 1H, J = 9.5 Hz, H-4), 3.92 (dd, 1H, J = 10.0, 9.0 
Hz, H-3’), 3.79 (s, 3H, CH3 CO2Me), 3.73 – 3.59 (m, 3H, H-5’, H-6’, H-2), 3.55 (t, 1H, J = 9.0 Hz, H-4’), 3.46 (s, 3H, CH3 
OMe), 3.20 (dd, 1H, J = 9.9, 3.8 Hz, H-2’); 13C-APT NMR (CDCl3, 101 MHz, HSQC, HMBC): δ 169.4 (C=O CO2Me), 165.2 
(C=O OBz), 137.8, 137.5, 137.3 (Cq), 133.0 (CHarom), 130.4 (Cq), 129.7, 129.1, 128.5, 128.5, 128.4, 128.4, 128.2, 128.1, 
128.1, 127.9, 126.1 (CHarom), 101.5 (CHPh), 99.7 (C-1’), 98.5 (C-1), 82.3 (C-4’), 77.7 (C-4), 76.6 (C-3’), 76.4 (C-2), 75.2 
(CH2 Bn), 73.0 (CH2 Bn), 72.3 (C-3), 70.4 (C-5), 68.4 (C-6’), 63.5 (C-5’), 63.1 (C-2’), 56.0 (OMe), 52.9 (CO2Me); HRMS: 
[M+NH4]+ calcd for C42H47N4O12 799.31850, found 799.31924. 





benzoyl-6-O-benzyl-α-D-glucopyranoside (13A). Donor A and acceptor 13 were 
condensed using the general procedure for Tf2O/Ph2SO mediated glycosylations (E) 
yielding product 13A (83 mg, 90 μmol, 90%, α:β = >20:1) as a colorless oil. Rf: 0.53 
(4/1 pentane/EtOAc); [α]  = +33.1° (c = 1.0, CHCl3); IR (thin film): 698, 710, 748, 997, 1088, 1275, 1367, 1452, 1724, 
2934; 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC, HMBC): δ 8.03 – 7.91 (m, 4H, CHarom), 7.54 – 7.10 (m, 26H, CHarom), 
6.17 (dd, 1H, J = 10.2, 9.2 Hz, H-3), 5.48 (s, 1H, CHPh), 5.23 (dd, 1H, J = 10.2, 3.6 Hz, H-2), 5.18 (d, 1H, J = 3.6 Hz, H-1), 
5.05 (d, 1H, J = 3.5 Hz, H-1’), 4.78 (d, 1H, J = 11.1 Hz, CHH Bn), 4.67 – 4.56 (m, 3H, CH2 Bn, CHH Bn), 4.43 – 4.33 (m, 
2H, H-4, CHH Bn ), 4.12 (dd, 1H, J = 10.1, 4.8 Hz, H-6’), 4.07 (d, 1H, J = 12.3 Hz, CHH Bn), 4.05 – 3.97 (m, 2H, H-5, H-6), 
3.96 – 3.85 (m, 2H, H-3, H-5’), 3.74 (dd, 1H, J = 10.8, 1.6 Hz, H-6), 3.57 (t, 1H, J = 10.2 Hz, H-6’), 3.48 (t, 1H, J = 9.5 Hz, 
H-4’), 3.41 (s, 3H, CH3 OMe), 3.29 (dd, 1H, J = 9.4, 3.5 Hz, H-2’); 13C-APT NMR (CDCl3, 101 MHz, HSQC, HMBC): δ 166.1, 
165.7 (C=O), 138.8, 138.0, 138.0, 137.6 (Cq), 133.3, 133.0 (CHarom), 130.2 (Cq), 130.0, 129.8 (CHarom), 129.2 (Cq), 129.0, 
128.4, 128.4, 128.3, 128.3, 128.2, 128.1, 127.8, 127.8, 127.7, 127.6, 126.2 (CHarom), 101.3 (CHPh), 98.4 (C-1), 96.9 (C-
1’), 81.9 (C-4’), 78.7 (C-2’), 78.3 (C-3’), 75.4 (CH2 Bn), 73.9 (C-4), 73.6, 73.0 (CH2 Bn), 72.4 (C-2), 72.3 (C-3), 70.0 (C-5), 
69.0 (C-6’), 68.3 (C-6), 63.7 (C-5’), 55.4 (OMe); HRMS: [M+NH4]+ calcd for C55H58NO13 940.39027, found 940.39109.  
Methyl 4-O-(2-azido-3-O-benzyl-4,6-O-benzylidene-2-deoxy-α-ᴅ-glucopyranosyl)-
2,3-di-O-benzoyl-6-O-benzyl-α-ᴅ-glucopyranoside (13B). Donor B and acceptor 13 
were condensed using the general procedure for Tf2O/Ph2SO mediated 
glycosylations (E) yielding product 13B (80 mg, 93 μmol, 93%, α:β = 10:1) as a 
colorless oil. Rf: 0.36 (4/1 pentane/EtOAc); [α]  = +27.3° (c = 1.0, CHCl3); IR (thin film): 710, 748, 999, 1030, 1092, 
1277, 1728, 2110, 2932; Data for the α-anomer: 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC, HMBC): δ 8.05 – 7.92 (m, 
4H, CHarom), 7.56 – 7.19 (m, 21H, CHarom), 6.09 (dd, 1H, J = 10.2, 9.2 Hz, H-3), 5.53 (s, 1H, CHPh), 5.18 – 5.06 (m, 3H, H-
1, H-1’, H-2), 4.86 (d, 1H, J = 10.8 Hz, CHH Bn), 4.68 – 4.63 (m, 3H, CHH Bn, CH2 Bn), 4.25 (t, 1H, J = 9.5 Hz, H-4), 4.14 
(dd, 1H, J = 10.3, 4.9 Hz, H-6’), 4.00 (ddd, 1H, J = 10.2, 3.9, 2.0 Hz, H-5), 3.96 – 3.86 (m, 3H, H-3’, H-5’, H-6), 3.79 (dd, 
1H, J = 11.0, 1.8 Hz, H-6), 3.70 – 3.55 (m, 2H, H-6’, H-4’), 3.42 (s, 3H, CH3 OMe), 3.23 (dd, 1H, J = 10.0, 3.8 Hz, H-2’); 
13C-APT NMR (CDCl3, 101 MHz, HSQC, HMBC): δ 166.1, 165.6 (C=O), 138.1, 137.8, 137.2 (Cq), 133.4, 133.0, 130.1, 
129.6 (CHarom), 129.2 (Cq), 129.2, 128.5, 128.5, 128.5, 128.4, 128.3, 127.9, 127.8, 127.7 (CHarom), 101.5 (CHPh), 99.7 
(C-1’), 96.9 (C-1), 82.5 (C-4’), 76.6 (C-3’), 76.1 (C-4), 75.2, 73.8 (CH2 Bn), 72.4 (C-2), 72.3 (C-3), 69.8 (C-5), 68.8 (C-6’), 
68.8 (C-6), 63.8 (C-5’), 63.3 (C-2’), 55.6 (OMe); Diagnostic peaks β-anomer: 1H NMR (CDCl3, 400 MHz): δ 5.90 (dd, 1H, 
J = 10.2, 9.1 Hz, H-3), 5.22 (dd, 1H, J = 10.1, 3.7 Hz, H-2), 4.77 (d, 1H, J = 11.9 Hz, CHH Bn), 4.51 (d, 1H, J = 11.9 Hz, 
CHH Bn), 2.97 – 2.88 (m, 1H, H-5’), 2.58 (t, 1H, J = 10.4 Hz, H-6’); 13C-APT NMR (CDCl3, 101 MHz): δ 166.0, 165.5, 137.9, 
137.2, 133.1, 130.5, 130.0, 129.8, 129.3, 128.7, 128.2, 126.0, 101.6 (CHPh), 101.1 (C-1’), 97.1, 81.3, 79.1, 75.9, 74.7, 
71.9, 70.8, 69.7, 67.9, 67.6, 66.0, 65.7, 55.5; HRMS: [M+NH4]+ calcd for C48H51N4O12 875.34980, found 875.35038. 
Methyl 4-O-(2,3-di-O-benzyl-4,6-O-benzylidene-α-D-glucopyranosyl)-2,3-di-O-
benzoyl-6-deoxy-α-D-glucopyranoside (14A). Donor A and acceptor 14 were 
condensed using the general procedure for Tf2O/Ph2SO mediated glycosylations (E) 
yielding product 14A (68 mg, 83 μmol, 83%, α:β = >20:1) as a colorless oil. Rf: 0.50 
(4/1 pentane/EtOAc); [α]  = +37.1° (c = 1.0, CHCl3); IR (thin film): 696, 708, 748, 995, 1026, 1051, 1088, 1177, 1275, 
1452, 1722, 2934; 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC, HMBC): δ 8.01 – 7.92 (m, 4H, CHarom), 7.54 – 7.04 (m, 
21H, CHarom), 6.15 (dd, 1H, J = 10.2, 9.1 Hz, H-3), 5.51 (s, 1H, CHPh), 5.15 (dd, 1H, J = 10.2, 3.6 Hz, H-2), 5.10 (d, 1H, J 
= 3.8 Hz, H-1’), 5.07 (d, 1H, J = 3.6 Hz, H-1), 4.83 (d, 1H, J = 11.1 Hz, CHH Bn), 4.67 (d, 1H, J = 11.1 Hz, CHH Bn), 4.36 
(d, 1H, J = 12.1 Hz, CHH Bn), 4.25 (dd, 1H, J = 10.3, 4.9 Hz, H-6’), 4.16 (d, 1H, J = 12.1 Hz, CHH Bn), 4.06 (dq, 1H, J = 9.5, 
6.2 Hz, H-5), 4.02 – 3.90 (m, 2H, H-3’, H-5’), 3.80 (t, 1H, J = 9.3 Hz, H-4), 3.68 (t, 1H, J = 10.3 Hz, H-6’), 3.53 (t, 1H, J = 
9.5 Hz, H-4’), 3.40 (s, 3H, CH3 OMe), 3.35 (dd, 1H, J = 9.5, 3.8 Hz, H-2’), 1.45 (d, 3H, J = 6.2 Hz, H-6); 13C-APT NMR 
(CDCl3, 101 MHz, HSQC, HMBC): δ 166.2, 165.5 (C=O), 138.7, 137.9, 137.4 (Cq), 133.4, 133.1 (CHarom), 130.1 (Cq), 130.0, 
129.8 (CHarom), 129.2 (Cq), 129.0, 128.5, 128.5, 128.4, 128.3, 128.2, 128.1, 127.7, 127.7, 126.1 (CHarom), 101.3 (CHPh), 
98.7 (C-1’), 96.7 (C-1), 82.0 (C-4’), 79.8 (C-4), 78.5 (C-2’), 78.5 (C-3’), 75.5, 73.2 (CH2 Bn), 72.9 (C-2), 72.4 (C-3), 68.9 
(C-6’), 66.2 (C-5), 63.6 (C-5’), 55.3 (OMe), 18.6 (C-6); HRMS: [M+NH4]+ calcd for C48H52NO12 834.34840, found 
834.34900.  
Methyl 4-O-(2-azido-3-O-benzyl-4,6-O-benzylidene-2-deoxy-α-ᴅ-glucopyranosyl)-2,3-
di-O-benzoyl-6-deoxy-α-ᴅ-glucopyranoside (14B). Donor B and acceptor 14 were 
condensed using the general procedure for Tf2O/Ph2SO mediated glycosylations (E) 




pentane/EtOAc); [α]  = +22.9° (c = 1.0, CHCl3); IR (thin film): 710, 753, 999, 1030, 1057, 1092, 1177, 1277, 1369, 
1450, 1724, 2110, 2936; 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC, HMBC): δ 7.99 (dt, 4H, J = 8.3, 1.2 Hz, CHarom), 
7.54 – 7.18 (m, 16H, CHarom), 6.11 – 6.01 (m, 1H, H-3), 5.56 (s, 1H, CHPh), 5.15 (d, 1H, J = 4.0 Hz, H-1’), 5.09 – 5.02 (m, 
2H, H-1, H-2), 4.90 (d, 1H, J = 10.8 Hz, CHH Bn), 4.72 (d, 1H, J = 10.8 Hz, CHH Bn), 4.26 (dd, 1H, J = 10.3, 4.9 Hz, H-6’), 
4.06 – 3.89 (m, 3H, H-5, H-5’, H-3’), 3.77 – 3.68 (m, 2H, H-4, H-6’), 3.65 (t, 1H, J = 9.3 Hz, H-4’), 3.41 (s, 3H, CH3 OMe), 
3.20 (dd, 1H, J = 10.1, 4.0 Hz, H-2’), 1.44 (d, 3H, J = 6.2 Hz, H-6); 13C-APT NMR (CDCl3, 101 MHz, HSQC, HMBC): δ 166.2, 
165.5 (C=O), 137.8, 137.1 (Cq), 133.4, 133.0, 130.1 (CHarom), 130.1 (Cq), 129.5 (CHarom), 129.2 (Cq), 129.2, 128.5, 128.5, 
128.4, 128.3, 128.0, 126.0 (CHarom), 101.4 (CHPh), 100.1 (C-1’), 96.8 (C-1), 82.4 (C-4’), 82.1 (C-4), 76.5 (C-3’), 75.2 (CH2 
Bn), 72.8 (C-2), 72.3 (C-3), 68.5 (C-6’), 65.7 (C-5), 63.6 (C-5’), 62.9 (C-2’), 55.5 (OMe), 18.3 (C-6); HRMS: [M+NH4]+ calcd 
for C41H45N4O11 769.30793, found 769.30861. 
Methyl 4-O-(2,3-di-O-benzyl-4,6-O-benzylidene-α-D-glucopyranosyl)-2,3,6-tri-O-
benzoyl-α-D-glucopyranoside (15A). Donor A and acceptor 15 were condensed using 
the general procedure for Tf2O/Ph2SO mediated glycosylations (E) yielding product 
15A (85 mg, 91 μmol, 91%, α:β = >20:1) as a colorless oil. Rf: 0.47 (4/1 
pentane/EtOAc); [α]  = +43.5° (c = 1.0, CHCl3); IR (thin film): 710, 748, 997, 1028, 1090, 1271, 1452, 1724, 2936; 1H 
NMR (CDCl3, 400 MHz, HH-COSY, HSQC): δ 8.11 – 8.06 (m, 2H, CHarom), 8.03 – 7.95 (m, 4H, CHarom), 7.63 – 7.57 (m, 1H, 
CHarom), 7.52 – 7.41 (m, 6H, CHarom), 7.39 – 7.23 (m, 13H, CHarom), 7.19 – 7.14 (m, 3H, CHarom), 7.12 – 7.07 (m, 2H, 
CHarom), 6.21 (ddd, 1H, J = 10.2, 7.0, 1.8 Hz, H-3), 5.44 (s, 1H, CHPh), 5.27 (dd, 1H, J = 10.3, 3.6 Hz, H-2), 5.15 (d, 1H, J 
= 3.6 Hz, H-1), 4.94 (d, 1H, J = 3.6 Hz, H-1’), 4.85 – 4.75 (m, 2H, CHH Bn, H-6), 4.69 – 4.58 (m, 2H, CHH Bn, H-6), 4.30 
(d, 1H, J = 12.4 Hz, CHH Bn), 4.26 – 4.18 (m, 2H, H-5, H-4 ), 4.13 (dd, 1H, J = 10.2, 4.8 Hz, H-6’), 4.04 – 3.96 (m, 2H, 
CHH Bn, H-3’), 3.92 (td, 1H, J = 10.0, 4.8 Hz, H-5’), 3.57 (t, 1H, J = 10.3 Hz, H-6’), 3.49 (d, 1H, J = 9.5 Hz, H-4’), 3.44 (s, 
3H, CH3 OMe), 3.29 (dd, 1H, J = 9.5, 3.6 Hz, H-2’); 13C-APT NMR (CDCl3, 101 MHz, HSQC, HMBC): δ 166.2, 165.6 (C=O), 
138.7, 138.0, 137.4 (Cq), 133.5, 133.3, 133.1 (CHarom), 130.1 (Cq), 130.1 (CHarom), 129.9 (Cq), 129.8, 129.8 (CHarom), 
129.1 (Cq), 129.0, 128.6, 128.5, 128.5, 128.4, 128.4, 128.3, 128.2, 128.1, 127.8, 127.7, 126.2 (CHarom), 101.4 (CHPh), 
99.7 (C-1’), 96.9 (C-1), 81.9 (C-4’), 78.4 (C-2’), 78.4 (C-3’), 76.2 (C-4), 75.4 (CH2 Bn), 73.3 (CH2 Bn), 72.2 (C-2), 71.7 (C-
3), 68.8 (C-6’), 68.7 (C-5), 64.0 (C-5’), 63.4 (C-6), 55.6 (OMe); HRMS: [M+NH4]+ calcd for C55H56NO14 954.36953, found 
954.37046.  
Methyl 4-O-(2-azido-3-O-benzyl-4,6-O-benzylidene-2-deoxy-α-ᴅ-glucopyranosyl)-
2,3,6-tri-O-benzoyl-α-ᴅ-glucopyranoside (15B). Donor B and acceptor 15 were 
condensed using the general procedure for Tf2O/Ph2SO mediated glycosylations (E) 
yielding product 15B (60 mg, 69 μmol, 69%, α:β = >20:1) as a white solid. Rf: 0.42 (4/1 
pentane/EtOAc); [α]  = +38.5° (c = 1.0, CHCl3); IR (thin film): 710, 752, 999, 1030, 
1096, 1269, 1450, 1724, 2110, 2936; 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC, HMBC): δ 8.15 – 7.94 (m, 6H, CHarom), 
7.64 – 7.20 (m, 19H, CHarom), 6.14 (dd, 1H, J = 9.8, 8.7 Hz, H-3), 5.51 (s, 1H, CHPh), 5.20 – 5.08 (m, 3H, H-1, H-1’, H-2), 
4.89 (d, 1H, J = 10.8 Hz, CHH Bn), 4.75 (dd, 1H, J = 12.2, 2.0 Hz, H-6), 4.70 (d, 1H, J = 10.8 Hz, CHH Bn), 4.59 (dd, 1H, J 
= 12.2, 4.1 Hz, H-6), 4.28 (dd, 1H, J = 10.4, 4.8 Hz, H-6’), 4.22 (ddd, 1H, J = 10.1, 4.1, 1.9 Hz, H-5), 4.20 – 4.12 (m, 1H, 
H-4), 4.03 – 3.89 (m, 2H, H-3’, H-5’), 3.68 – 3.57 (m, 2H, H-6’, H-4’), 3.45 (s, 3H, CH3 OMe), 3.25 (dd, 1H, J = 10.0, 4.0 
Hz, H-2’); 13C-APT NMR (CDCl3, 101 MHz, HSQC, HMBC): δ 166.2, 166.1, 165.6 (C=O), 137.7, 137.1 (Cq), 133.5, 133.5, 
133.4, 133.1, 130.1 (CHarom), 130.0 (Cq), 129.9 (CHarom), 129.8 (Cq), 129.5, 129.1 (CHarom), 129.1 (Cq), 128.7, 128.6, 
128.5, 128.5, 128.4, 128.3, 128.0, 126.1 (CHarom), 101.4 (CHPh), 100.6 (C-1’), 96.9 (C-1), 82.4 (C-4’), 77.4 (C-4), 76.6 
(C-3’), 75.2 (CH2 Bn), 72.3 (C-2), 72.1 (C-3), 68.5 (C-6’), 68.2 (C-5), 64.0 (C-5’), 63.4 (C-6), 63.0 (C-2’), 55.7 (OMe); HRMS: 
[M+Na]+ calcd for C48H45N3O13Na 894.2845, found 894.2878. 
Methyl (methyl 4-O-(2,3-di-O-benzyl-4,6-O-benzylidene-α-D-glucopyranosyl)-2,3-di-O-
benzoyl-α-D-glucopyranosyl uronate) (16A). Donor A and acceptor 16 were condensed 
using the general procedure for Tf2O/Ph2SO mediated glycosylations (E) yielding 
product 16A (72 mg, 84 μmol, 84%, α:β = >20:1) as a colorless oil. Rf: 0.58 (4/1 
pentane/EtOAc); [α]  = +19.3° (c = 1.0, CHCl3); IR (thin film): 710, 748, 916, 997, 1049, 1090, 1271, 1452, 1732, 2938; 
1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC): δ 8.05 – 7.91 (m, 4H, CHarom), 7.53 – 7.43 (m, 4H, CHarom), 7.41 – 7.24 (m, 
12H, CHarom), 7.21 – 7.15 (m, 3H, CHarom), 7.07 – 7.02 (m, 2H, CHarom), 6.17 (dd, 1H, J = 10.2, 8.8 Hz, H-3), 5.48 (s, 1H, 
CHPh), 5.24 (dd, 1H, J = 10.1, 3.5 Hz, H-2), 5.20 (d, 1H, J = 3.5 Hz, H-1), 4.94 (d, 1H, J = 3.7 Hz, H-1’), 4.81 (d, 1H, J = 
11.2 Hz, CHH Bn), 4.70 (d, 1H, J = 11.2 Hz, CHH Bn), 4.45 (d, 1H, J = 9.7 Hz, H-5), 4.39 (dd, 1H, J = 9.7, 8.9 Hz, H-4), 4.34 
– 4.22 (m, 2H, CHH Bn, H-6’), 3.99 (d, 1H, J = 12.4 Hz, CHH Bn), 3.95 (t, 1H, J = 9.4 Hz, H-3’), 3.79 (s, 3H, CH3 CO2Me), 
3.72 – 3.64 (m, 1H, H-5), 3.64 – 3.56 (m, 1H, H-6’), 3.52 – 3.40 (m, 4H, H-4’, CH3 OMe), 3.28 (dd, 1H, J = 9.4, 3.7 Hz, H-




2’); 13C-APT NMR (CDCl3, 101 MHz, HSQC, HMBC): δ 169.4 (C=O CO2Me), 166.0, 165.4 (C=O OBz), 138.7, 137.9, 137.5 
(Cq), 133.5, 133.2, 130.1 (CHarom), 130.0 (Cq), 129.8 (CHarom), 129.0 (Cq), 129.0, 128.5, 128.4, 128.3, 128.2, 128.0, 127.7, 
127.7, 126.1 (CHarom), 101.3 (CHPh), 99.2 (C-1’), 97.5 (C-1), 81.6 (C-4’), 78.2 (C-2’), 78.0 (C-3’), 76.3 (C-4), 75.4, 72.8 
(CH2 Bn), 71.7 (C-2), 71.3 (C-3), 70.6 (C-5), 68.6 (C-6’), 63.6 (C-5’), 56.0 (OMe), 53.0 (CO2Me); HRMS: [M+NH4]+ calcd 
for C49H52NO14 878.33823, found 878.33866.  
Methyl (methyl 4-O-(2-azido-3-O-benzyl-4,6-O-benzylidene-2-deoxy-α-ᴅ-
glucopyranosyl)-2,3-di-O-benzoyl-α-ᴅ-glucopyranosyl uronate) (16B). Donor B and 
acceptor 16 were condensed using the general procedure for Tf2O/Ph2SO mediated 
glycosylations (E) yielding product 16B (79 mg, 99 μmol, 99%, α:β = >20:1) as a white 
solid. Rf: 0.51 (4/1 pentane/EtOAc); [α]  = +13.1° (c = 1.0, CHCl3); IR (thin film): 710, 
752, 995, 1092, 1269, 1369, 1450, 1728, 2110, 2936; 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC, HMBC): δ 8.03 – 7.94 
(m, 4H, CHarom), 7.54 – 7.19 (m, 16H, CHarom), 6.09 (dd, 1H, J = 10.2, 9.0 Hz, H-3), 5.53 (s, 1H, CHPh), 5.21 (d, 1H, J = 3.5 
Hz, H-1), 5.15 (dd, 1H, J = 10.2, 3.5 Hz, H-2), 5.06 (d, 1H, J = 3.9 Hz, H-1’), 4.87 (d, 1H, J = 10.8 Hz, CHH Bn), 4.70 (d, 1H, 
J = 10.8 Hz, CHH Bn), 4.45 – 4.26 (m, 3H, H-5, H-4, H-6’), 3.95 (dd, 1H, J = 10.0, 8.9 Hz, H-3’), 3.85 (s, 3H, CH3 CO2Me), 
3.75 – 3.63 (m, 2H, H-5’, H-6’), 3.59 (t, 1H, J = 9.1 Hz, H-4’), 3.47 (s, 3H, CH3 OMe), 3.22 (dd, 1H, J = 10.0, 3.8 Hz, H-2’); 
13C-APT NMR (CDCl3, 101 MHz, HSQC): δ 169.0 (C=O CO2Me), 166.0, 165.5 (C=O OBz), 137.8, 137.3 (Cq), 133.5, 133.2, 
130.1 (CHarom), 129.8 (Cq), 129.6, 129.2 (CHarom), 129.0 (Cq), 128.6, 128.5, 128.4, 128.3, 127.9, 126.1 (CHarom), 101.5 
(CHPh), 99.8 (C-1’), 97.6 (C-1), 82.4 (C-4’), 77.4 (C-4), 76.5 (C-3’), 75.2 (CH2 Bn), 71.8 (C-2), 71.1 (C-3), 70.3 (C-5), 68.5 
(C-6’), 63.6 (C-5’), 63.0 (C-2’), 56.1 (OMe), 53.0 (CO2Me); HRMS: [M+NH4]+ calcd for C42H45N4O13 813.29776, found 
813.29765. 
Methyl 4-O-(2,3-di-O-benzyl-4,6-O-benzylidene-α/β-D-glucopyranosyl)-2,3,6-tri-
O-benzyl-β-D-glucopyranoside (17A). Donor A and acceptor 17 were condensed 
using the general procedure for Tf2O/Ph2SO mediated glycosylations (E) yielding 
product 17A (71 mg, 79 μmol, 79%, α:β = 1:1) as a colorless oil. Rf: 0.67 (4/1 
pentane/EtOAc); IR (thin film): 698, 737, 910, 999, 1072, 1211, 1277, 1366, 1454, 2866; Data reported for a 1:1 
mixture of anomers: 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC, HMBC): δ 7.55 – 7.05 (m, 60H, CHarom), 5.71 (d, 1H, J 
= 3.9 Hz, H-1’α), 5.53 (s, 1H, CHPhα), 5.49 (s, 1H, CHPhβ), 5.00 – 4.84 (m, 6H, 6xCHH Bn), 4.84 – 4.66 (m, 9H, CH2 Bn, 
5xCHH Bn, 2xCHH Bn), 4.66 – 4.50 (m, 5H, 3xCHH Bn, CHH Bn, H-1’β), 4.38 (d, 1H, J = 12.1 Hz, CHH Bn), 4.34 (d, 1H, J 
= 7.8 Hz, H-1α), 4.29 (d, 1H, J = 7.7 Hz, H-1β), 4.23 – 4.14 (m, 2H, H-6’β, H-6α), 4.12 (dd, 1H, J = 9.7, 8.7 Hz, H-3’β), 4.02 
– 3.94 (m, 2H, H-3α, H-3β), 3.91 – 3.73 (m, 5H, H-5α, H-6β, H-6α, H-6α, H-3’α), 3.68 (dd, 1H, J = 10.9, 1.8 Hz, H-6β), 3.66 
– 3.52 (m, 12H, H-2α, H-4’β, H-4’α, H-4α, H-5β, H-6’α, CH3 OMeα, CH3 OMeβ), 3.51 – 3.28 (m, 6H, H-2’α, H-2β, H-2’β, H-3β, 
H-4β, H-6’β), 3.14 (td, 1H, J = 9.4, 4.9 Hz, H-5’β); 13C-APT NMR (CDCl3, 101 MHz, HSQC, HMBC): δ 139.1, 138.8, 138.8, 
138.6, 138.4, 138.3, 138.2, 137.9, 137.7, 137.5 (Cq), 129.1, 128.9, 128.5, 128.4, 128.4, 128.4, 128.4, 128.4, 128.3, 
128.3, 128.2, 128.1, 128.1, 127.9, 127.9, 127.8, 127.8, 127.7, 127.7, 127.7, 127.5, 127.3, 126.7, 126.1 (CHarom), 104.8 
(C-1β), 104.6 (C-1α), 102.9 (C-1’β), 101.2 (CHPhα,β), 97.3 (C-1’α), 84.9 (C-3’α), 82.9 (C-2α), 82.6 (C-2’β), 82.5, 82.4, 81.9, 
81.8, 81.2 (C-4α C-4’β C-5α C-2β C-4’α), 78.8, 78.8 (C-2’α C-3β), 76.9 (C-3α), 75.5, 75.5, 75.4, 75.1, 75.1 (CH2 Bn), 75.0 (C-
4β), 74.7, 74.3 (CH2 Bn), 73.9 (C-5β), 73.8, 73.5, 73.3 (CH2 Bn), 72.0 (C-3’β), 69.0 (C-6α), 68.9 (C-6’α,β) 68.0 (C-6β), 65.9 
(C-5’β), 63.4 (C-5’α), 57.2 (OMeα), 57.1 (OMeβ); HRMS: [M+NH4]+ calcd for C48H56NO10 912.43174, found 912.43238.  
Methyl 4-O-(2-azido-3-O-benzyl-4,6-O-benzylidene-2-deoxy-α/β-ᴅ-
glucopyranosyl)-2,3,6-tri-O-benzyl-β-ᴅ-glucopyranoside (17B). Donor B and 
acceptor 17 were condensed using the general procedure for Tf2O/Ph2SO 
mediated glycosylations (E) yielding product 17B (66 mg, 80 μmol, 80%, α:β = 
1:7) as a colorless oil. Rf: 0.78 (4/1 pentane/EtOAc); IR (thin film): 698, 737, 914, 999, 1092, 1277, 1366, 1454, 2110, 
2870; Data for the β-anomer: 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC, HMBC): δ 7.54 – 7.14 (m, 25H, CHarom), 5.47 
(s, 1H, CHPh), 4.90 – 4.82 (m, 3H, CH2 Bn, CHH Bn), 4.82 – 4.67 (m, 4H, CHH Bn, CH2 Bn, CHH Bn), 4.48 (d, 1H, J = 12.0 
Hz, CHH Bn), 4.35 (d, 1H, J = 7.8 Hz, H-1’), 4.30 (d, 1H, J = 7.7 Hz, H-1), 4.11 (dd, 1H, J = 10.5, 5.0 Hz, H-6’), 4.02 (t, 1H, 
J = 9.4 Hz, H-4), 3.99 – 3.92 (m, 1H, H-6), 3.82 (dd, 1H, J = 11.0, 1.8 Hz, H-6), 3.60 – 3.52 (m, 5H, CH3 OMe, H-3, H-4’), 
3.49 – 3.29 (m, 5H, H-2, H-2’, H-3’, H-5, H-6’), 3.01 (td, 1H, J = 9.8, 5.0 Hz, H-5’); 13C-APT NMR (CDCl3, 101 MHz, HSQC, 
HMBC): δ 139.1, 138.7, 138.1, 137.9, 137.3 (Cq), 129.2, 128.6, 128.5, 128.4, 128.3, 128.3, 128.1, 128.0, 128.0, 127.7, 
127.7, 127.5, 126.1 (CHarom), 104.8 (C-1), 101.3 (CHPh), 101.3 (C-1’), 82.8 (C-4’), 81.8 (C-2), 81.8 (C-3), 79.2 (C-3’), 76.9 
(C-4), 75.5, 75.0, 74.9 (CH2 Bn), 74.7 (C-5), 73.5 (CH2 Bn), 68.6 (C-6’), 68.2 (C-6), 66.7 (C-2’), 65.9 (C-5’), 57.3 (OMe); 
Diagnostic peaks for the α-anomer: 1H NMR (CDCl3, 400 MHz): δ 5.69 (d, 1H, J = 4.1 Hz, H-1’), 5.54 (s, 1H, CHPh), 5.07 




129.1, 128.5, 128.4, 128.2, 127.8, 127.6, 126.1, 104.7, 98.0, 85.0, 82.7, 76.2, 75.1, 74.3, 73.7, 73.1, 69.2, 68.8, 63.4, 
62.8, 57.1; HRMS: [M+NH4]+ calcd for C48H55N4O10 847.39127, found 847.39197. 
Methyl 4-O-(2,3-di-O-benzyl-4,6-O-benzylidene-α/β-D-glucopyranosyl)-2,3-di-O-
benzyl-6-deoxy-β-D-glucopyranoside (18A). Donor A and acceptor 18 were 
condensed using the general procedure for Tf2O/Ph2SO mediated glycosylations 
(E) yielding product 18A (69 mg, 87 μmol, 87%, α:β = 1.1:1) as a colorless oil. Rf: 
0.68 (4/1 pentane/EtOAc); IR (thin film): 698, 737, 999, 1030, 1072, 1454, 2870, 3032; Data reported for a 1.1:1 
mixture of anomers: 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC, HMBC): δ 7.53 – 7.06 (m, 47.5H, CHarom), 5.71 (d, 1H, 
J = 4.1 Hz, H-1’α), 5.55 (s, 1H, CHPhα), 5.52 (s, 0.9H, CHPhβ), 4.99 – 4.87 (m, 5H, 3xCHH Bn, CH2 Bn), 4.87 – 4.74 (m, 6H, 
2xCHH Bn, 2xCH2 Bn), 4.74 – 4.62 (m, 3.9H, CHH Bn, 2xCHH Bn, H-1’β), 4.57 (d, 1H, J = 10.9 Hz, CHH Bn), 4.52 (d, 1H, J 
= 11.7 Hz, CHH Bn), 4.34 – 4.28 (m, 1.9H,  H-1α, H-1β), 4.26 (dd, 1H, J = 10.3, 4.9 Hz, H-6’α), 4.18 (dd, 0.9H, J = 10.4, 4.9 
Hz, H-6’β), 4.02 (t, 1H, J = 9.3 Hz, H-3’α), 3.94 (td, 1H, J = 10.0, 4.8 Hz, H-5’α), 3.81 – 3.68 (m, 3H. H-3α, H-4α, H-6’α), 3.67 
– 3.58 (m, 4.7H, H-3’β, H-3β, H-4’β, H-5α, H-4’α), 3.57 (s, 3H, CH3 OMeα), 3.56 (s, 2.7H, CH3 OMeβ), 3.54 – 3.43 (m, 5.7H, 
H-2’α, H-2α, H-6’β, H-4β, H-5α, H-2’β), 3.43 – 3.35 (m, 1.8H, H-2β, H-5β), 3.31 (td, 0.9H, J = 9.7, 4.9 Hz, H-5’β), 1.42 (d, 3H, 
J = 5.8 Hz, H-6α), 1.38 (d, 2.7H, J = 6.1 Hz, H-6β); 13C-APT NMR (CDCl3, 101 MHz, HSQC, HMBC): δ 139.2, 139.0, 138.7, 
138.7, 138.5, 138.4, 138.2, 137.9, 137.4 (Cq), 129.1, 129.0, 128.4, 128.4, 128.4, 128.3, 128.3, 128.3, 128.1, 128.1, 
127.9, 127.8, 127.7, 127.7, 127.7, 127.7, 127.5, 127.2, 126.5, 126.1, 126.0 (CHarom), 104.5 (C-1β), 104.5 (C-1α), 103.7 
(C-1’β), 101.2 (CHPhα,β), 97.8 (C-1’α), 84.6 (C-3α), 83.2 (C-4β), 82.9, 82.7, 82.7, 82.3, 82.1 (C-3β C-3’β C-2β C-2’β C-2α), 
81.8 (C-4’β), 81.4 (C-4α), 78.9 (C-3’α), 78.7 (C-2’α), 78.2 (C-4’α), 75.7, 75.5, 75.4, 75.3, 75.0, 74.7, 74.0, 73.8 (CH2 Bn), 
71.4 (C-5β), 70.4 (C-5α), 68.9 (C-6’α), 68.8 (C-6’β), 66.0 (C-5’α), 63.3 (C-5’α), 57.2 (OMeα), 57.2 (OMeβ), 19.3 (C-6α), 18.1 
(C-6β); HRMS: [M+Na]+ calcd for C48H52O10Na 811.3453, found 811.3475.  
Methyl 4-O-(2-azido-3-O-benzyl-4,6-O-benzylidene-2-deoxy-α/β-ᴅ-
glucopyranosyl)-2,3-di-O-benzyl-6-deoxy-β-ᴅ-glucopyranoside (18B). Donor B and 
acceptor 18 were condensed using the general procedure for Tf2O/Ph2SO 
mediated glycosylations (E) yielding product 18B (62 mg, 86 μmol, 86%, α:β = 
1:5) as a white solid. Rf: 0.84 (4/1 pentane/EtOAc); IR (thin film): 698, 737, 999, 1072, 1169, 1277, 1366, 1454, 2110, 
2873; Data for the β-anomer: 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC): δ 7.54 – 7.11 (m, 20H, CHarom), 5.49 (s, 1H, 
CHPh), 4.91 (d, 1H, J = 11.3 Hz, CHH Bn), 4.87 (d, 1H, J = 11.1 Hz, CHH Bn), 4.85 – 4.81 (m, 2H, CH2 Bn), 4.77 (d, 1H, J 
= 11.2 Hz, CHH Bn), 4.68 (d, 1H, J = 11.0 Hz, CHH Bn), 4.52 (d, 1H, J = 8.1 Hz, H-1’), 4.30 (d, 1H, J = 7.8 Hz, H-1), 4.06 
(dd, 1H, J = 10.5, 5.0 Hz, H-6’), 3.63 (t, 1H, J = 9.1 Hz, H-4’), 3.60 – 3.50 (m, 5H, CH3 OMe, H-3, H-3’), 3.50 – 3.36 (m, 
6H, H-2, H-2’, H-4, H-5, H-6’), 3.22 (td, 1H, J = 9.6, 5.0 Hz, H-5’), 1.44 (d, 2H, J = 5.5 Hz, H-6); 13C-APT NMR (CDCl3, 101 
MHz, HSQC, HMBC): δ 139.1, 138.6, 137.8, 137.2 (Cq), 129.2, 128.5, 128.4, 128.4, 128.3, 128.3, 128.1, 128.0, 127.7, 
127.6, 127.5, 127.3, 126.1 (CHarom), 104.5 (C-1), 102.3 (C-1’), 101.3 (CHPh), 83.5 (C-4), 82.9 (C-3), 82.3 (C-2), 81.7 (C-
4’), 79.4 (C-3’), 75.4, 75.0, 74.9 (CH2 Bn), 71.0 (C-5), 68.5 (C-6’), 67.2 (C-2’), 66.2 (C-5’), 57.2 (OMe), 18.1 (C-6); 
Diagnostic peaks for the α-anomer: 1H NMR (CDCl3, 400 MHz): δ 5.64 (d, 1H, J = 4.2 Hz, (H-1’), 5.57 (s, 1H, CHPh), 5.08 
(d, 1H, J = 10.6 Hz, CHH Bn), 4.98 (d, 1H, J = 10.9 Hz, CHH Bn), 4.23 (dd, 1H, J = 10.4, 4.9 Hz, H-6’), 3.93 (td, 1H, J = 9.9, 
4.9 Hz, H-5’), 3.29 (dd, 1H, J = 10.1, 4.2 Hz, H-2’), 1.39 (d, 3H, J = 5.2 Hz, H-6); 13C-APT NMR (CDCl3, 101 MHz): δ 138.6, 
138.4, 137.9, 128.6, 128.2, 127.8, 126.0, 101.3, 98.6, 84.6, 83.1, 82.6, 79.5, 76.3, 75.2, 75.0, 74.7, 70.2, 68.6, 63.3, 
62.8, 57.2, 19.0; HRMS: [M+NH4]+ calcd for C41H49N4O9 741.34941, found 741.35004. 
Methyl 4-O-(2,3-di-O-benzyl-4,6-O-benzylidene-α/β-D-glucopyranosyl)-2,3-di-O-
benzyl-6-O-benzoyl-β-D-glucopyranoside (19A). Donor A and acceptor 19 were 
condensed using the general procedure for Tf2O/Ph2SO mediated glycosylations 
(E) yielding product 19A (66 mg, 73 μmol, 73%, α:β = 3:1) as a white solid. Rf: 
0.65 (4/1 pentane/EtOAc); IR (thin film): 698, 999, 1030, 1088, 1273, 1454, 1721, 2862, 3032; Data for the α-anomer: 
1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC, HMBC): δ 8.13 – 8.03 (m, 2H, CHarom), 7.60 – 7.01 (m, 28H, CHarom), 5.65 
(d, 1H, J = 4.0 Hz, H-1’), 5.46 (s, 1H, CHPh), 4.95 – 4.65 (m, 7H, 2xCHH Bn, 2xCH2 Bn, H-6), 4.65 – 4.50 (m, 3H, 2x CHH 
Bn, H-6), 4.38 (d, 1H, J = 7.7 Hz, H-1), 4.12 – 4.00 (m, 3H, H-4’, H-6’, H-5’), 3.87 – 3.74 (m, 3H, H-3, H-5, H-3’), 3.62 – 
3.45 (m, 7H, H-2’, H-2, H-4, H-6’, CH3 OMe); 13C-APT NMR (CDCl3, 101 MHz, HSQC, HMBC): δ 166.2 (C=O), 138.8, 138.6, 
138.3, 138.0, 137.4 (Cq), 133.2 (CHarom), 130.0 (Cq), 129.9, 129.7, 129.0, 128.5, 128.5, 128.4, 128.4, 128.4, 128.3, 128.2, 
128.1, 127.8, 127.7, 126.8, 126.2 (CHarom), 104.5 (C-1), 101.4 (CHPh), 98.3 (C-1’), 84.5 (C-3), 82.4 (C-4), 82.4 (C-2), 78.8 
(C-5’), 78.6 (C-2’), 75.3, 74.7, 74.3 (CH2 Bn), 74.2 (C-4’), 74.1 (CH2 Bn), 72.6 (C-3’), 68.9 (C-6’), 63.8 (C-6), 63.7 (C-5), 
57.2 (OMe); Diagnostic peaks for the β-anomer: 1H NMR (CDCl3, 400 MHz): δ 5.50 (s, 1H, CHPh), 4.47 (dd, 1H, J = 12.0, 
4.9 Hz), 4.33 (d, 1H, J = 7.7 Hz, H-1), 4.19 (dt, 1H, J = 9.3, 4.6 Hz), 3.72 (d, 1H, J = 8.9 Hz), 3.67 – 3.62 (m, 1H), 3.44 – 




3.39 (m, 1H, H-2’), 3.23 (td, 1H, J = 9.7, 5.0 Hz, H-5’); 13C-APT NMR (CDCl3, 101 MHz): δ 166.0, 138.8, 138.6, 138.5, 
138.2, 137.3, 133.3, 129.7, 129.0, 128.5, 128.0, 127.4, 126.1, 104.6 (C-1), 103.1 (C-1’), 101.2 (CHPh), 82.7, 82.6, 81.8, 
81.4, 77.4, 75.8, 75.7, 75.3, 75.0, 73.3, 66.1, 62.9; HRMS: [M+Na]+ calcd for C55H56O12Na 931.3664, found 931.3695.  
Methyl 4-O-(2-azido-3-O-benzyl-4,6-O-benzylidene-2-deoxy-α/β-ᴅ-
glucopyranosyl)-2,3,6-tri-O-benzyl-β-ᴅ-glucopyranoside (19B). Donor B and 
acceptor 19 were condensed using the general procedure for Tf2O/Ph2SO 
mediated glycosylations (E) yielding product 19B (59 mg, 70 μmol, 70%, α:β = 
1:1.2) as a colorless oil. Rf: 0.59 (4/1 pentane/EtOAc); IR (thin film): 698, 737, 999, 1030, 1069, 1092, 1273, 1369, 1454, 
1721, 2110, 2870, 3032; Data reported for a 1:1.2 mixture of anomers: 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC): δ 
8.10 – 8.00 (m, 4.4H, CHarom), 7.61 – 7.18 (m, 50.6H, CHarom), 5.68 (d, 1H, J = 4.2 Hz, H-1’α), 5.49 (s, 1H, CHPhα), 5.48 
(s, 1.2H, CHPhβ), 5.10 (d, 1H, J = 10.5 Hz, CHH Bnα), 4.95 (d, 1H, J = 11.0 Hz, CHH Bnα), 4.94 (d, 1H, J = 11.0 Hz, CHH 
Bnα), 4.92 – 4.82 (m, 7H, 2xCHH Bnβ, CH2 Bnβ, CHH Bnα, H-6β), 4.80 – 4.72 (m, 3.2H, CHH Bnα, CHH Bnβ, H-6α), 4.70 (d, 
1.2H, J = 11.0 Hz,, CHH Bnβ), 4.68 (d, 1H, J = 11.0 Hz, CHH Bnα), 4.57 (dd, 1H, J = 12.2, 4.4 Hz, H-6β), 4.51 – 4.43 (m, 
2.2H, H-1’β, H-6α), 4.43 – 4.33 (m, 2.2H, H-1α, H-1β), 4.09 – 3.92 (m, 5.4H, H-3’α, H-4α, H-4β, H-6’α, H-6’β), 3.88 – 3.77 
(m, 2.2H, H-3β, H-5’α), 3.76 – 3.60 (m, 5.4H, H-3α, H-4’α, H-4’β, H-5α, H-5β), 3.60 – 3.39 (m, 13.4H, CH3 OMeα, CH3 OMeβ, 
H-2α, H-2β, H-2’β, H-3’β, H-6’α, H-6’β), 3.31 (dd, 1H, J = 10.1, 4.1 Hz, H-2’α), 3.13 (td, 1.2H, J = 9.6, 5.0 Hz, H-5’β); 13C-APT 
NMR (CDCl3, 101 MHz, HSQC, HMBC): δ 166.1 (C=O), 138.8, 138.5, 138.4, 138.3, 137.8, 137.7, 137.2, 137.1 (Cq), 133.4, 
133.3, 129.9 (CHarom), 129.9 (Cq), 129.7, 129.2, 129.1, 128.6, 128.6, 128.5, 128.5, 128.5, 128.5, 128.4, 128.3, 128.3, 
128.2, 128.1, 128.0, 127.9, 127.8, 127.7, 127.7, 127.5, 126.2, 126.0 (CHarom), 104.7 (C-1β), 104.6 (C-1α), 101.9 (C-1’β), 
101.4 (CHPhα), 101.3 (CHPhβ), 98.8 (C-1’α), 84.5 (C-3β), 82.8 (C-2β), 82.7 (C-4’α), 82.6 (C-3α), 81.9 (C-2β), 81.6 (C-4’β), 
79.6 (C-3’β), 77.7 (C-4β), 76.0 (C-3’α), 75.7, 75.1, 75.1, 75.0 (CH2 Bn), 74.8 (C-4α), 74.7, 74.7 (CH2 Bn), 73.0 (C-5β), 72.3 
(C-5α), 68.5 (C-6α,β), 66.8 (C-2’β), 66.3 (C-5’β), 63.7 (C-5’α), 63.6 (C-6α), 63.1 (C-6β), 62.8(C-2’α),, 57.3 (OMeβ), 57.2 
(OMeα); HRMS: [M+Na]+ calcd for C48H49N3O11Na 866.3289, found 866.3259.  
Methyl 4-O-(2,3-di-O-benzyl-4,6-O-benzylidene-α/β-D-glucopyranosyl)-2,3-di-O-
benzyl-β-D-glucopyranosyl uronate) (20A). Donor A and acceptor 20 were 
condensed using the general procedure for Tf2O/Ph2SO mediated glycosylations 
(E) yielding product 20A (69 mg, 83 μmol, 83%, α:β = 5:1) as a white solid. Rf: 
0.75 (4/1 pentane/EtOAc); IR (thin film): 698, 737, 995, 1030, 1207, 1454, 1751, 2866, 3032; Data for the α-anomer: 
1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC, HMBC): δ 7.50 – 7.08 (m, 25H, CHarom), 5.51 (s, 1H, CHPh), 5.38 (d, 1H, J = 
3.8 Hz, H-1’), 4.94 – 4.75 (m, 4H, 2xCHH Bn, CH2 Bn), 4.67 – 4.50 (m, 4H, 2xCHH Bn, CH2 Bn), 4.36 (d, 1H, J = 7.6 Hz, H-
1), 4.32 – 4.25 (m, 1H, H-6’), 4.19 (t, 1H, J = 9.0 Hz, H-4), 4.00 (d, 1H, J = 9.5 Hz, H-5), 3.78 (s, 3H, CH3 CO2Me), 3.75 (t, 
1H, J = 8.9 Hz, H-3), 3.65 – 3.55 (m, 3H, H-6’, H-5’, H-4’), 3.54 (s, 3H, CH3 OMe), 3.52 – 3.43 (m, 3H, H-3’, H-2, H-2’);  
13C-APT NMR (CDCl3, 101 MHz, HSQC, HMBC): δ 169.0 (C=O), 138.7, 138.6, 138.2, 137.9, 137.5 (Cq), 129.0, 128.4, 
128.4, 128.4, 128.3, 128.3, 128.3, 128.2, 128.1, 127.9, 127.8, 127.7, 127.7, 127.3, 127.0, 126.1 (CHarom), 104.9 (C-1), 
101.3 (CHPh), 98.4 (C-1’), 83.4 (C-3), 82.0 (C-4’), 81.5 (C-2), 78.6 (C-2’), 78.4 (C-3’), 76.3 (C-4), 75.3 (CH2 Bn), 74.8 (C-
5), 74.8, 74.7, 73.6 (CH2 Bn), 68.6 (C-6’), 63.2 (C-5’), 57.5 (OMe), 52.9 (CO2Me); Diagnostic peaks for the β-anomer: 1H 
NMR (CDCl3, 400 MHz): δ 5.48 (s, 1H, CHPh), 4.39 (d, 1H, J = 7.6 Hz), 3.91 (d, 1H, J = 9.4 Hz), 3.41 – 3.29 (m, 1H); 13C-
APT NMR (CDCl3, 101 MHz): δ 169.1, 138.9, 138.5, 138.5, 138.5, 137.4, 129.0, 127.6, 126.1, 105.0, 102.8, 101.2, 82.3, 
81.8, 81.3, 78.0, 75.6, 75.4, 75.0, 74.8, 74.5, 68.8, 66.0, 52.7; HRMS: [M+Na]+ calcd for C49H52O12Na 855.3351, found 
855.3370.  
Methyl (methyl 4-O-(2-azido-3-O-benzyl-4,6-O-benzylidene-2-deoxy-α/β-ᴅ-
glucopyranosyl)-2,3-di-O-benzyl-β-ᴅ-glucopyranosyl uronate) (20B). Donor B and 
acceptor 20 were condensed using the general procedure for Tf2O/Ph2SO 
mediated glycosylations (E) yielding product 20B (65 mg, 85 μmol, 85%, α:β = 
1.2:1) as a white solid. Rf: 0.55 (4/1 pentane/EtOAc); IR (thin film): 698, 741, 999, 1030, 1211, 1277, 1369, 1454, 1751, 
2110, 2870, 2932; Data reported for a 1.2:1 mixture of anomers: 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC, HMBC): 
δ 7.51 – 7.19 (m, 36H, CHarom), 5.53 (s, 1H, CHPhα), 5.50 (d, 1H, J = 3.9 Hz, H-1’α), 5.48 (s, 0.8H, CHPhβ), 5.01 (d, 1H, J 
= 10.6 Hz, CHH Bn), 4.92 – 4.72 (m, 9H, CHH Bn, 4xCH2 Bn), 4.69 (d, 1H, J = 4.8 Hz, CHH Bn), 4.66 (d, 1H, J = 4.8 Hz, 
CHH Bn), 4.46 (d, 0.8H, J = 8.1 Hz, H-1’β), 4.42 – 4.34 (m, 1.8H, H-1β, H-1α), 4.27 (dd, 1H, J = 10.3, 4.8 Hz, H-6’α), 4.19 – 
4.04 (m, 2.8H, H-3α, H-5α, H-6’β), 4.01 – 3.91 (m, 2.8H, H-5β, H-4α, H-3’α), 3.85 (s, 2.4H, CH3 CO2Meβ), 3.83 (s, 3H, CH3 
OMeα), 3.76 (t, 1H, J = 8.9 Hz, H-3β), 3.70 – 3.63 (m, 2H, H-6’α, H-4’α), 3.59 (dd, 0.8H, J = 9.1, 1.6 Hz, H-4’β), 3.56 (s, 
5.4H, CH3 OMeα,β), 3.54 – 3.51 (m, 1.8H, H-2α, H-4β)  3.51 – 3.47 (m, 0.8H, H-2β), 3.47 – 3.40 (m, 2.6H, H-3β, H-5’α, H-




138.8, 138.3, 138.3, 138.2, 137.9, 137.9, 137.4, 137.2 (Cq), 129.2, 129.1, 128.5, 128.5, 128.5, 128.5, 128.4, 128.4, 
128.3, 128.3, 128.2, 128.2, 128.1, 128.0, 128.0, 127.9, 127.8, 127.7, 127.7, 127.6, 127.5 (CHarom), 105.1 (C-1β), 105.0 
(C-1α), 102.3 (C-1’β), 101.5 (CHPhα), 101.4 (CHPhβ), 98.4 (C-1’α), 83.9 (C-3β), 82.4 (C-4’α), 82.0 (C-4β), 81.9 (C-2α ), 81.6 
(C-4’β), 81.4 (C-2β), 79.3 (C-5α), 79.2 (C-3’β), 76.2 (C-3’α), 75.5, 75.4 (CH2 Bn), 75.2 (C-3α), 75.1, 75.0, 75.0, 74.8 (CH2 
Bn), 74.4 (C-4α), 74.3 (C-5β), 68.5 (C-6’α,β), 66.7 (C-2’β), 66.2 (C-5’β), 63.1 (C-5’α), 62.8 (C-2’α), 57.6 (OMeα,β), 53.0 
(CO2Meβ), 52.9 (CO2Meα); HRMS: [M+Na]+ calcd for C42H45N3O11Na 790.2946, found 790.2962. 
Methyl 6-O-(2,3-di-O-benzyl-4,6-O-benzylidene-α/β-D-glucopyranosyl)-2,3,4-tri-O-




2,3,4-tri-O-benzyl-α-D-glucopyranoside (21B). See Chapter 4, compound 3C for 
synthesis and analytical data. 
 
Methyl 6-O-(2,3-di-O-benzyl-4,6-O-benzylidene-α/β-D-glucopyranosyl)-2,3,4-tri-O-
benzoyl-α-D-glucopyranoside (22A). Donor A and acceptor 2253 were condensed using 
the general procedure for Tf2O/Ph2SO mediated glycosylations (E) yielding product 
22A (80 mg, 86 μmol, 86%, α:β = 3 : 1) as a colorless oil. Rf: 0.40 (4/1 pentane/EtOAc). 
Spectroscopic data were in accord with those previously reported for the α-anomer. 
59 IR (thin film): 648, 696, 708, 727, 906, 1026, 1053, 1068, 1088, 1261, 1277, 1452, 1726; 1H NMR (400 MHz, CDCl3) 
δ 8.02 – 7.91 (m, 4H, CHarom), 7.90 – 7.82 (m, 2H, CHarom), 7.56 – 7.43 (m, 4H, CHarom), 7.43 – 7.16 (m, 20H, CHarom), 
6.24 – 6.12 (m, 1H, H-3), 5.57 – 5.46 (m, 2H, CHPh, H-4), 5.33 – 5.19 (m, 2H, H-1, H-2), 4.94 – 4.64 (m, 5H, 2xCH2 Bn, 
H-1’), 4.41 – 4.30 (m, 1H, H-5), 4.18 (dd, 1H, J = 10.0, 4.8 Hz, H-6’), 4.11 – 3.96 (m, 2H, H-3’, H-5’), 3.91 – 3.82 (m, 1H, 
H-6), 3.78 – 3.52 (m, 5H, H-2’, H-4’, H-6, H-6’), 3.52 – 3.36 (m, 3H, CH3 OMe); 13C-APT NMR (CDCl3, 101 MHz, HSQC): 
δ 165.9, 165.9, 165.5 (C=O), 138.8, 138.4, 137.7 (Cq), 133.5, 133.4, 133.2, 130.0, 130.0, 129.8 (CHarom), 129.3, 129.2, 
129.0 (Cq), 128.5, 128.5, 128.5, 128.5, 128.4, 128.3, 128.3, 128.3, 128.1, 128.1, 128.0, 127.9, 127.6, 126.2 (CHarom), 
101.3 (CHPh), 98.3 (C-1’), 97.0 (C-1), 82.2 (C-4’), 79.4 (C-2’), 78.3 (C-3’), 75.2, 73.6 (CH2 Bn), 72.2 (C-2), 70.6 (C-3), 69.7 
(C-4), 69.0 (C-6’), 68.7 (C-5), 67.3 (C-6), 62.6 (C-5’), 55.8 (OMe); Diagnostic peaks β-anomer: 1H NMR (400 MHz, CDCl3) 
δ 5.01 (d, 1H, J = 10.7 Hz, H-), 4.59 (d, J = 7.6 Hz, 1H); 13C-APT NMR (CDCl3, 101 MHz): δ 165.9, 165.9, 165.5, 138.6 
(C=O), 138.4, 137.4, 133.6 (Cq), 133.5-127.6 (CHarom), 104.4 (C-1’), 101.2 (CHPh), 97.0 (C-1) 82.3, 81.4, 80.9, 75.4, 72.1, 
70.5, 70.0, 69.2, 69.0, 66.1, 55.7; HRMS: [M+Na]+ calcd for C55H52O14Na 959.3255, found 959.3292. 
Methyl 6-O-(2-azido-3-O-benzyl-4,6-O-benzylidene-2-deoxy-α/β-D-glucopyranosyl)-
2,3,4-tri-O-benzoyl-α-D-glucopyranoside (22B). Donor B and acceptor 2253 were 
condensed using the general procedure for Tf2O/Ph2SO mediated glycosylations (E) 
yielding product 22B (83 mg, 95 μmol, 95%, α:β = 1 : 1.5) as a colorless oil. Rf: 0.32 
and 0.50 (4/1 pentane/EtOAc); product was contaminated with 10% of the 6-6 
homocoupled acceptor. IR (thin film): 698, 706, 735, 999, 1026, 1069, 1090, 1175, 1250, 1261, 1450, 1724, 2110; 1H 
NMR (CDCl3, 400 MHz, HH-COSY, HSQC, HMBC): δ 8.01 – 7.93 (m, 10H, CHarom), 7.89 – 7.84 (m, 5H, CHarom), 7.54 – 
7.25 (m, 47.5H, CHarom), 6.22 – 6.14 (m, 2.5H, H-3α, H-3β), 5.64 – 5.53 (m, 5H, CHPhα,β, H-4α, H-4β), 5.31 – 5.23 (m, 5H, 
H-1α, H-1β, H-2α, H-2β), 4.97 (d, 1H, J = 11.1 Hz, CHH Bnα), 4.95 – 4.89 (m, 2H, CHH Bnβ, H-1’α), 4.87 – 4.76 (m, 2H, CHH 
Bnα, CHH Bnβ), 4.44 (d, 1.5H, J = 8.0 Hz, H-1’β), 4.34 – 4.26 (m, 4H, H-5α, H-5β, H-6’β), 4.20 – 4.11 (m, 2H, H-3’, H-6’), 
4.07 (dd, 1.5H, J = 11.2, 2.2 Hz, H-6), 3.99 – 3.89 (m, 2H, H-5’, H-6), 3.80 (dd, 1.5H, J = 11.3, 6.3 Hz, H-6), 3.77 – 3.64 
(m, 6H, H-4’α, H-4’β, H-6α, H-6’α, H-6’β), 3.57 (t, 1.5H, J = 9.3 Hz, H-3’β), 3.50 (s, 4.5H, CH3 OMeβ), 3.48 – 3.43 (m, 4.5H, 
CH3 OMeα, H-2’β), 3.41 – 3.33 (m, 2.5H, H-2’α, H-5’β); 13C-APT NMR (CDCl3, 101 MHz, HSQC, HMBC): δ 165.9, 165.9, 
165.9, 165.5, 165.5 (C=O), 137.9, 137.4, 137.2 (Cq), 133.6, 133.5, 133.5, 133.2, 130.0, 130.0, 129.9, 129.8 (CHarom), 
129.3, 129.2, 129.1, 129.1, 129.0, 128.9 (Cq/CHarom), 128.6, 128.5, 128.5, 128.4, 128.4, 128.3, 128.2, 128.0, 126.2, 
126.1 (CHarom), 102.9 (C-1’β), 101.4, 101.4 (CHPhα,β), 98.8 (C-1’α), 97.1, 97.0 (C-1α, C-1β), 82.8 (C-4’α), 81.5 (C-4’β), 79.0 
(C-3’β), 75.8 (C-3’α), 75.1 (CH2 Bn), 72.1 (C-2, C-2β), 70.5, 70.4 (C-3α, C-3β), 69.7 (C-4β), 69.5 (C-4α), 68.9 (C-5α), 68.8 (C-
6β), 68.6 (C-6’α, C-6’β), 68.5 (C-5α), 67.0 (C-6α), 66.4 (C-2’β), 66.3 (C-5’β), 63.0 (C-2’α), 62.9 (C-5’α), 55.8 (OMe); HRMS: 

















2,3-di-O-benzyl-6-O-(4-nitrobenzoyl)-α-D-glucopyranoside (23A). Donor A 
and acceptor 23 were condensed using the general procedure for 
Tf2O/Ph2SO mediated glycosylations (E) yielding product 23A (88 mg, 92 
μmol, 92%, α:β = 3 : 1) as a colorless oil. Rf: 0.36 (4/1 pentane/EtOAc); IR 
(thin film): 696, 719, 735, 997, 1028, 1047, 1076, 1088, 1273, 1348, 1454, 1525, 1726, 2866, 2910, 2926; Data for the 
α-anomer: 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC): δ 8.22 – 8.15 (m, 4H, pNO2Bz), 7.44 – 7.17 (m, 25H, CHarom), 
5.71 (d, 1H, J = 4.0 Hz, H-1’), 5.47 (s, 1H, CHPh), 5.00 (d, 1H, J = 11.5 Hz, CHH Bn), 4.94 – 4.88 (m, 1H, CHH Bn), 4.82 – 
4.61 (m, 5H, 2xCHH Bn, 2x CHH Bn, H-6), 4.61 – 4.52 (m, 4H, 2x CHH Bn, H-1, H-6), 4.15 – 4.07 (m, 2H, H-3’, H-5), 4.03 
(t, 1H, J = 9.4 Hz, H-3), 4.01 – 3.95 (m, 2H, H-4, H-6’), 3.81 – 3.73 (m, 1H, H-5’), 3.63 – 3.52 (m, 4H, H-2, H-2’, H-4’, H-
6’), 3.39 (s, 3H, CH3 OMe); 13C-APT NMR (CDCl3, 101 MHz, HSQC): δ 164.4 (C=O), 150.6, 138.8, 138.5, 137.9, 137.8, 
137.3, 135.2 (Cq), 130.9, 128.6, 128.4, 128.4, 128.3, 128.3, 128.2, 128.2, 128.1, 128.0, 127.8, 127.8, 127.7, 127.7, 
126.8, 126.1, 123.6 (CHarom), 101.2 (CHPh), 98.1 (C-1’), 97.7 (C-1), 82.3 (C-4’), 81.6 (C-3’), 80.4 (C-2), 78.8, 78.7 (C-2’, 
C-3), 75.3, 74.6, 74.3 (CH2 Bn), 73.5 (C-4), 73.4 (CH2 Bn), 68.8 (C-6’), 67.9 (C-5), 64.8 (C-6), 63.7 (C-5’), 55.5 (OMe); 
Diagnostic peaks for the β-anomer: 1H NMR (CDCl3, 400 MHz): δ 8.28 – 8.23 (m, 2H, pNO2Bz), 8.10 – 8.06 (m, 2H, 
pNO2Bz), 5.52 (s, 1H, CHPh), 3.91 (dd, 1H, J = 9.5, 8.3 Hz), 3.66 (t, 1H, J = 9.3 Hz), 3.39 (s, 3H, CH3 OMe), 3.27 (td, 1H, 
J = 9.8, 5.0 Hz, H-5’); 13C-APT NMR (CDCl3, 101 MHz): δ 164.1, 139.0, 138.4, 138.2, 138.1, 137.2, 135.2, 130.7, 129.0, 
128.5, 128.3, 128.2, 128.2, 128.1, 127.8, 127.7, 127.4, 126.0, 103.6 (C-1’), 101.2 (CHPh), 98.0 (C-1), 82.7 (C-2’), 81.7 
(C-4’), 81.4 (C-3’), 79.9 (C-3), 79.2 (C-2), 78.5 (C-4), 75.8, 75.1, 73.7 (CH2 Bn), 68.8 (C-6’), 68.6 (C-5), 66.2 (C-5’), 63.9 
(C-6), 55.5 (OMe); HRMS: [M+H]+ calcd for C55H56NO14 954.3701, found 954.3745. 
Methyl 4-O-(2-azido-3-O-benzyl-4,6-O-benzylidene-2-deoxy-α/β-D-
glucopyranosyl)-2,3-di-O-benzyl-6-O-(4-nitrobenzoyl)-α-D-glucopyranoside 
(23B). Donor A and acceptor 23 were condensed using the general 
procedure for Tf2O/Ph2SO mediated glycosylations (E) yielding product 
23B (49 mg, 55 μmol, 55%, α:β = 1 : 1) as a colorless oil. Rf: 0.33 and 0.33 
(4/1 pentane/EtOAc); IR (thin film): 698, 719, 739, 999, 1015, 1028, 1049, 1094, 1275, 1454, 1528, 1728, 2110, 2868, 
2922; 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC, HMBC): δ 8.34 – 8.25 (m, 2H, pNO2Bz), 8.24 – 8.15 (m, 8H, pNO2Bz), 
7.46 – 7.25 (m, 40H, CHarom), 5.68 (d, 1H, J = 4.2 Hz, H-1’α), 5.51 (s, 1H, CHPhα), 5.49 (s, 1H, CHPhβ), 5.13 (d, 1H, J = 
10.4 Hz, CHH Bn), 4.99 – 4.86 (m, 5H, 2xCHH Bn, CHH Bn, CH2 Bn), 4.81 (dd, 1H, J = 12.0, 2.1 Hz, H-6β), 4.81 – 4.73 (m, 
4H, 2xCHH Bn, 2xCHH Bn), 4.71 (dd, 1H, J = 12.1, 2.4 Hz, H-6α), 4.65 (dd, 1H, J = 12.0, 4.8 Hz, H-6β), 4.65 – 4.59 (m, 4H, 
2xCHH Bn, H-1α, H-1β), 4.53 (dd, 1H, J = 12.0, 4.2 Hz, H-6α), 4.45 (d, 1H, J = 8.1 Hz, H-1’β), 4.13 (dd, 1H, J = 9.4, 8.8 Hz, 
H-3α), 4.06 – 3.94 (m, 6H, H-3β, H-3’α, H-5α, H-5β, H-6’α, H-6’β), 3.90 – 3.78 (m, 3H, H-4α, H-4β, H-5’α), 3.71 – 3.53 (m, 
6H, H-2α, H-2β, H-3’β, H-4’α, H-4’β, H-6’α), 3.48 (t, 1H, J = 10.3 Hz, H-6’β), 3.43 (dd, 1H, J = 9.1, 8.3 Hz, H-2’β), 3.40 (s, 3H, 
CH3 OMe), 3.40 (s, 3H, CH3 OMe), 3.36 (dd, 1H, J = 10.1, 4.2 Hz, H-2’α), 3.15 (ddd, 1H, J = 10.0, 9.0, 5.0 Hz, H-5’β); 13C-
APT NMR (CDCl3, 101 MHz, HSQC, HMBC): δ 164.4, 164.3 (C=O), 150.7, 150.7 (Cq NO2), 139.0, 138.5, 138.0, 137.8, 
137.7, 137.6, 137.0, 137.0, 135.3, 135.1 (Cq), 130.9, 130.8, 129.2, 129.2, 128.7, 128.6, 128.6, 128.6, 128.5, 128.4, 
128.4, 128.4, 128.3, 128.2, 128.1, 128.1, 128.0, 127.8, 127.6, 127.1, 126.1, 126.0, 123.8, 123.7 (CHarom), 102.3 (C-1’), 
101.3, 101.3 (CHPh), 99.0 (C-1’), 98.0, 97.8 (C-1, C-1), 82.5 (C-4’), 81.6 (C-3), 81.4 (C-4’), 80.7 (C-2), 80.1 (C-3), 79.7, 
79.6 (C-2, C-3’), 78.5 (C-4), 76.1 (C-3’), 75.5, 75.3, 75.1 (CH2 Bn), 75.1 (C-4), 75.0, 73.6, 73.4 (CH2 Bn), 68.5 (C-6’), 68.4 
(C-6’), 68.3 (C-5), 67.8 (C-5), 66.8 (C-2’), 66.4 (C-5’), 64.7 (C-6), 64.1 (C-6), 63.7 (C-5’), 62.8 (C-2’), 55.6, 55.6 (OMe); 
HRMS: [M+H]+ calcd for C48H49N4O13 889.3296, found 889.3331. 
Methyl 4-O-(2,3-di-O-benzyl-4,6-O-benzylidene-α/β-D-glucopyranosyl)-2,3-di-
O-benzyl-6-O-(3-nitrobenzoyl)-α-D-glucopyranoside (24A). Donor A and 
acceptor 24 were condensed using the general procedure for Tf2O/Ph2SO 
mediated glycosylations (E) yielding product 24A (47 mg, 49 μmol, 49%, α:β 
= 3.3 : 1) as a colorless oil. Rf: 0.30 (4/1 pentane/EtOAc); IR (thin film): 696, 
719, 737, 1028, 1047, 1076, 1088, 1261, 1350, 1454, 1533, 1730, 2868, 2908, 2926; Data for the α-anomer: 1H NMR 
(CDCl3, 500 MHz, HH-COSY, HSQC, HMBC): δ 8.85 – 8.83 (m, 1H, CHarom NO2Bz), 8.37 (ddd, 1H, J = 8.2, 2.3, 1.1 Hz, 
CHarom NO2Bz), 8.33 (dt, 1H, J = 7.8, 1.3 Hz, CHarom NO2Bz), 7.57 (t, 1H, J = 8.0 Hz, CHarom NO2Bz), 7.45 – 7.17 (m, 25H, 
CHarom), 5.70 (d, 1H, J = 4.0 Hz, H-1’), 5.47 (s, 1H, CHPh), 5.00 (d, 1H, J = 11.5 Hz, CHH Bn), 4.90 (d, 1H, J = 11.2 Hz, CHH 
Bn), 4.79 – 4.72 (m, 4H, CHH Bn, 2xCHH Bn, H-6), 4.69 (d, 1H, J = 12.0 Hz, CHH Bn), 4.60 – 4.52 (m, 4H, 2xCHH Bn, H-
1, H-6), 4.16 – 4.09 (m, 2H, H-3, H-5), 4.07 – 4.01 (m, 2H, H-3’, H-6’), 3.97 (dd, 1H, J = 9.9, 8.7 Hz, H-4), 3.80 – 3.74 (m, 
1H, H-5’), 3.63 – 3.57 (m, 3H, H-2, H-4’, H-6’), 3.55 (dd, 1H, J = 9.4, 4.0 Hz, H-2’), 3.40 (s, 3H, CH3 OMe); 13C-APT NMR 

















135.4 (Cq Bz), 131.7, 129.7, 129.0, 128.6, 128.6, 128.4, 128.4, 128.3, 128.3, 128.3, 128.2, 128.1, 128.1, 127.9, 127.8, 
127.7, 127.7, 127.6, 127.4, 126.9, 126.1, 124.8 (CHarom), 101.3 (CHPh), 98.2 (C-1), 97.8 (C-1’), 82.3 (C-4’), 81.6 (C-3), 
80.5 (C-2), 78.8, 78.7 (C-2’, C-3’), 75.4, 74.6, 74.2 (CH2 Bn), 73.7 (C-4), 73.5 (CH2 Bn), 68.8 (C-6’), 68.0 (C-5), 64.8 (C-6), 
63.8 (C-5’), 55.5 (OMe); Diagnostic peaks for the β-anomer: 1H NMR (CDCl3, 500 MHz): δ 8.76 – 8.72 (m, 1H, CHarom 
NO2Bz), 8.41 (ddd, 2H, J = 8.2, 2.3, 1.1 Hz, CHarom NO2Bz), 8.24 (dt, 1H, J = 7.7, 1.3 Hz, CHarom NO2Bz), 7.62 (t, 1H, J = 
8.0 Hz, CHarom NO2Bz), 5.51 (s, 1H, CHPh), 4.48 (dd, 1H, J = 11.8, 5.6 Hz, H-6), 4.19 (dd, 1H, J = 10.5, 5.0 Hz, H-6’), 3.93 
– 3.87 (m, 1H, H-3), 3.65 (t, 1H, J = 9.3 Hz, H-4’), 3.41 (s, 3H, CH3 OMe), 3.30 (td, 1H, J = 9.7, 5.0 Hz, H-5’); 13C-APT NMR 
(CDCl3, 126 MHz): δ 163.9 (C=O), 139.1 (Cq NO2), 138.5, 138.2, 138.2, 135.2 (Cq) - 124.7 (CHarom), 103.7 (C-1’), 101.2 
(CHPh), 98.1 (C-1), 82.8 (C-2’), 81.8 (C-4’), 81.5 (C-3’), 80.0 (C-3), 79.3 (C-2), 78.6 (C-4), 75.8, 75.8, 75.2, 73.7 (CH2 Bn), 
68.8 (C-6’), 68.7 (C-5), 66.3 (C-5’), 63.9 (C-6), 55.5 (OMe); HRMS: [M+Na]+ calcd for C55H55NO14Na 976.3520, found 
976.3550. 
Methyl 4-O-(2,3-di-O-benzyl-4,6-O-benzylidene-α/β-D-glucopyranosyl)-2,3-di-O-
benzyl-6-O-(2-nitrobenzoyl)-α-D-glucopyranoside (25A). Donor A and acceptor 
25 were condensed using the general procedure for Tf2O/Ph2SO mediated 
glycosylations (E) yielding product 25A (79 mg, 83 μmol, 83%, α:β = 3.5 : 1) as a 
colorless oil. Rf: 0.20 (4/1 pentane/EtOAc); IR (thin film): 696, 733, 995, 1028, 
1045, 1074, 1088, 1254, 1290, 1352, 1454, 1533, 1736, 2868, 2907; Data for 
the α-anomer: 1H NMR (CDCl3, 500 MHz, HH-COSY, HSQC): δ 7.86 – 7.82 (m, 1H, CHarom), 7.78 – 7.75 (m, 1H, CHarom), 
7.62 – 7.54 (m, 2H, CHarom), 7.51 – 7.46 (m, 2H, CHarom), 7.41 – 7.16 (m, 23H, CHarom), 5.60 (d, 1H, J = 3.9 Hz, H-1’), 5.50 
(s, 1H, CHPh), 4.99 – 4.87 (m, 2H, 2xCHH Bn), 4.82 – 4.64 (m, 5H, 2xCHH Bn, 2xCHH Bn, H-6), 4.63 (d, 1H, J = 3.3 Hz, 
H-1), 4.61 – 4.50 (m, 3H, 2xCHH Bn, H-6), 4.11 – 4.05 (m, 2H, H-3’, H-6’), 4.05 – 3.98 (m, 2H, H-3, H-5), 3.87 (dd, 1H, J 
= 9.8, 8.6 Hz, H-4), 3.84 – 3.77 (m, 1H, H-5’), 3.64 – 3.57 (m, 3H, H-2, H-4’, H-6’), 3.52 (dd, 1H, J = 9.5, 3.9 Hz, H-2’), 
3.39 (s, 3H, CH3 OMe); 13C-APT NMR (CDCl3, 126 MHz, HSQC): δ 164.9 (C=O), 148.6 (Cq NO2), 139.1, 138.7, 138.1, 
137.9, 137.5 (Cq), 132.7, 132.0, 130.4, 129.0, 128.5, 128.5, 128.4, 128.3, 128.3, 128.2, 128.1, 128.1, 128.0, 127.9, 
127.8, 127.7, 127.2 (CHarom), 127.0 (Cq Bz), 126.9, 126.2, 126.1, 123.8 (CHarom), 101.4 (CHPh), 98.3 (C-1’), 97.7 (C-1), 
82.3 (C-4’), 81.2 (C-3’), 80.2 (C-2), 78.8, 78.7 (C-2’, C-3), 75.3 (CH2 Bn), 74.5 (C-4), 74.4, 73.9, 73.4 (CH2 Bn), 68.9 (C-
6’), 68.1 (C-5), 65.3 (C-6), 63.6 (C-5’), 55.5 (OMe); Diagnostic peaks for the β-anomer: 1H NMR (CDCl3, 500 MHz): δ 
5.51 (s, 1H, CHPh), 4.22 (dd, 1H, J = 9.8, 4.4 Hz, H-6’), 3.73 (dd, 1H, J = 10.0, 8.7 Hz, H-4), 3.37 (s, 3H, CH3 OMe); 13C-
APT NMR (CDCl3, 126 MHz): δ 164.8, 148.6, 139.3, 138.4, 138.4, 132.7 - 123.8 (CHarom), 103.2 (C-1’), 101.2 (CHPh), 
98.2 (C-1), 82.9 (C-2’), 81.8 (C-4’), 81.6 (C-3’), 79.9 (C-3), 79.1 (C-2), 77.8 (C-4), 75.8, 75.5, 75.2, 73.7 (CH2 Bn), 68.9 (C-
6’), 68.5 (C-5), 65.9 (C-5’), 64.1 (C-6), 55.6 (OMe); HRMS: [M+Na]+ calcd for C55H55NO14Na 976.3520, found 976.3566. 
Methyl 4-O-(2,3-di-O-benzyl-4,6-O-benzylidene-α/β-D-glucopyranosyl)-2,3-di-O-
benzyl-6-O-(2,6-dinitrobenzoyl)-α-D-glucopyranoside (26A). Donor A and 
acceptor 26 were condensed using the general procedure for Tf2O/Ph2SO 
mediated glycosylations (E) yielding product 26A (83 mg, 83 μmol, 83%, α:β = 
5.6 : 1) as a colorless oil. Rf: 0.12 (4/1 pentane/EtOAc); IR (thin film): 696, 735, 
918, 1028, 1045, 1074, 1088, 1267, 1344, 1454, 1541, 1749, 2870; Data for the 
α-anomer: 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC): δ 8.36 (d, 2H, J = 8.3 Hz, NO2Bzmeta), 7.69 (t, 1H, J = 8.3 Hz, 
NO2Bzpara), 7.40 – 7.17 (m, 25H, CHarom), 5.52 (d, 1H, J = 3.9 Hz, H-1), 5.46 (s, 1H, CHPh), 5.01 (dd, 1H, J = 11.8, 2.2 Hz, 
H-6), 4.95 – 4.74 (m, 4H, 2xCH2 Bn), 4.73 – 4.62 (m, 4H, 2xCHH Bn, H-1, H-6), 4.59 – 4.51 (m, 2H, 2xCHH Bn), 4.09 (dd, 
1H, J = 9.6, 8.5 Hz, H-3), 4.10 – 3.87 (m, 4H, H-3’, H-5, H-5’, H-6’), 3.82 (dd, 1H, J = 9.8, 8.5 Hz, H-4), 3.63 – 3.51 (m, 
4H, H-2, H-2’, H-4’, H-6’), 3.40 (s, 3H, CH3 OMe); 13C-APT NMR (CDCl3, 101 MHz, HSQC): δ 162.3 (C=O), 146.7 (Cq NO2), 
139.1, 138.6, 138.1, 137.9, 137.5 (Cq), 129.7, 128.5, 128.4, 128.3, 128.3, 128.3, 128.2, 128.1, 128.0, 127.8, 127.7, 
127.6, 127.0, 126.2 (CHarom), 125.5 (Cq Bz), 101.3 (CHPh), 98.5 (C-1’), 97.7 (C-1), 82.2 (C-4’), 81.0 (C-3), 80.0 (C-2), 78.8 
(C-2’), 78.6 (C-3’), 75.6 (C-4), 75.3, 74.6, 73.8, 73.4 (CH2 Bn), 68.9 (C-6’), 68.5 (C-5), 66.2 (C-6), 63.5 (C-5’), 55.6 (OMe); 
Diagnostic peaks for the β-anomer: 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC): δ 8.42 (d, 2H, J = 8.3 Hz, NO2Bzmeta), 
7.75 (t, 1H, J = 8.3 Hz, NO2Bzpara), 4.45 (dd, 1H, J = 12.1, 2.4 Hz, H-6), 4.19 (dd, 1H, J = 10.1, 4.7 Hz, H-6’), 3.79 – 3.72 
(m, 1H), 3.47 (dd, 1H, J = 8.8, 7.7 Hz, H-2’), 3.42 (dd, 2H, J = 9.5, 3.6 Hz, H-2), 3.38 (s, 3H, CH3 OMe); 13C-APT NMR 
(CDCl3, 101 MHz, HSQC): δ 162.2, 146.7, 139.1, 138.6, 138.5, 138.3, 137.5, 131.2, 129.8, 129.0, 128.9, 128.5, 128.4, 
128.3, 128.1, 127.9, 127.9, 127.7, 127.5, 127.2, 126.1, 125.5, 103.0 (C-1’), 101.1 (CHPh), 98.2 (C-1), 82.9, 81.8, 81.6, 
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Furanosides are key structural components in a variety of bacterial and plant 
oligosaccharides.1–3 In this framework, the glycosylation of furanosides has been studied 
to obtain specific target oligosaccharides with the required anomeric configuration. 
Furanosylation is more extensively investigated for the synthesis of modified nucleosides 
and oligonucleotides.4–6 Besides structural variants, in which the ring oxygen is replaced 
by sulfur, selenium, nitrogen, or carbon, furanosides with differently configured amino 
or fluoro substituents have been studied.7–9 Uronic acid furanosides occur in natural 
compounds and have attracted attention as biomimics. Modified (oligo)nucleotides are 
studied as potential therapeutics and as radio-tracer compounds (primarily 18F, but also 
11C, 13N) in Positron Emission Tomography (PET).10–13 Despite their biological relevance, 
the synthesis of the differently substituted furanosides and their glycosylating properties 
are scarcely investigated.5 The development of effective routes of synthesis for these 




saccharides.14 For instance, oligosaccharides containing furanosyl moieties can be 
relevant for the development of carbohydrate based vaccines.4,7,15 Furthermore, insight 
in the reactivity of differently substituted furanosides will be a valuable asset to 
understand the mechanisms of the glycosylation reaction of both furanosides and 
pyranosides. This chapter describes the synthesis of all four diastereoisomers of the D-
pentofuranosides as their 2-fluoro, 2-azido, and 5-uronic acid derivatives. The influence 
of these functional groups in glycosylation reactions is the subject of Chapter 8, where 
they are studied using experimental and computational means.  
Results and discussion 
The strategy to obtain the three modifications on all four diastereoisomers is shown in 
Scheme 1. The C-2-modified furanoside donors were obtained by inversion of the 2-
hydroxy group in otherwise protected methyl furanosides. The C-5-methyl esters were 
generated from their suitably protected 5-hydroxy methyl furanosides. Subsequent 
anomeric hydrolysis and installation of the anomeric leaving group (LG), will then give 
all twelve D-pentofuranoside donors, four configurations for each functional group. 
 
 
Scheme 1. Retrosynthesis of C-2- and C-5-modified furanosides. 
 
*Center of inversion. LG = leaving group. 
 
The syntheses of the protected 2-hydroxy pentofuranoses is outlined in Scheme 
2. Adapting literature procedures, the 2-hydroxy pentofuranoses could be obtained on 
large scale (10-150 mmol). Ribo-configured structure 3 was prepared by treatment of 
fully protected 2 with SnCl4, inducing both anomerization and regioselective benzyl 
cleavage.16 Similarly protected xylose derivative 6 was obtained from 1,2-isopropylidene-
xylofuranose 4 in high yield (97%) by benzylation and CSA mediated acetal exchange.  




The syntheses of arabino- and lyxo-derivatives 9 and 13 required more steps, as 
di-isopropylidenation of arabinose yields the pyranoside and regioselective removal of 
the C-2–O-benzyl, as reported for ribose derivative 3, is unknown for these epimers.17 
First, the primary alcohol of arabinose was protected with a bulky TBDPS group to force 
the carbohydrate in the furanose form. Subsequent isopropylidene protection gave 7. 
Conveniently, the epimeric lyxose compound could be easily obtained from 7 by an 
oxidation-reduction sequence.18 Dess-Martin oxidation proved superior over the Sarett 
(CrO3, pyridine in DCM)19 and Moffat (DMSO, Ac2O)20 oxidations both in yield and ease 
of purification.21 Reduction of ulose 10 with NaBH4 gave optically pure lyxo-configured 
11. Both 7 and 11 were silyl-deprotected and benzylated in a one-pot procedure using 
KOH and BnCl in THF.22 An alternative two-step reaction sequence of removing the 
TBDPS (with TBAF, AcOH in THF) and subsequent benzylation (NaH, BnBr in DMF) 
was less efficient. Finally, acetal exchange yielded both the arabino-configured 9 and 
lyxo-configured 13. 
 
Scheme 2. Synthesis of 2-hydroxy pentofuranosides 3, 6, 9, and 13. 
 
Reagents and conditions: (a) AcCl, MeOH; (b) BnBr, NaH, DMF, 2: 89% (two steps); (c) SnCl4, DCM, 92%; (d) 
i. H2SO4, acetone; ii. HCl, H2O, aceton, 90% (two steps); (e) CSA, MeOH, 6: 97% (two steps), 9: 91%, 13: 84%; 
(f) i. TBDPSCl, imidazole, DMF; ii. dimethoxypropane, CSA, DCM, 53% (two steps); (g) BnCl, KOH, THF, 8: 




Having synthesized all 2-hydroxy pentofuranosides (3, 6, 9, 13), the inversion 
procedures were investigated. Fluoride substitutions were considered first, since a range 
of fluorination reagents are commercially available. Table 1 summarizes the results of the 
direct substitution reactions on ribose derivative 3. Unfortunately, none of the reagents 

















1 0.5 DAST (1.8) -60 to 20 72 12 
2 2.0 DAST (4) -60 to 45 24 13 
3 0.5 Deoxo-Fluor® (1.2) 0 to 20 72 15 
4 0.5 PFBS-F (2.2), TBAT (0.8), DiPEA (2.5) 0 to 20 30 < 25 
5 0.5 XtalFluor-E® (1.5), 3HF∙Et3N (1.5) 0 to 20 30 - 
 
aConcentration for all reactions was 0.2 M in DCM. 
 
Therefore, the 2-hydroxy groups in the projected furanoses were converted into 
the corresponding triflates followed by substitution with fluoride or azide anions, 
respectively.23 Figure 1 provides an overview of the triflates, readily prepared from the 
alcohols, the targeted substitution products as well as the side products obtained in the 









Figure 1. Furanosyl C-2–O-triflates (14-17) and their substitution products by fluoride inversion (18-21), and 
azide inversion (22-25). Major side products isolated from the reaction mixture (26-31), red color indicates the 
deviations from the expected products. Formation of the structures in grey was not observed. 
Table 2 reports the outcome of all substitution reactions. Entries 1-3 show that 
ribo-configured triflate 14 is readily substituted with the fluoride (TBAF, or CsF) and 
azide anions (NaN3), respectively. The yield of the fluoride substitution on triflate 14 
with TBAF in THF (71%) was increased to 86% when CsF was used in a polar protic 
solvent (tert-amyl alcohol, entry 2).24 Azide 22 was obtained in 93% yield. Substitution 
of the arabinotriflate 15 (a mixture of anomers), with fluorine and azide nucleophiles 
gave 19 and 23, respectively in reasonable to good yields. As reported by the group of 
Woerpel,22 only the β-anomer of 15 reacted with TBAF (entry 4), and the triflate of the 
α-anomer could be recovered. 
Under conditions B (entry 5) both anomers of 15 reacted and despite the 
generation of side product 26, the yield was increased to 63%. Azide 23 was obtained in 
high yield, although a similar migration to side product 27 occurred during the azide 
substitution (entry 6).25 The possible reaction pathways for the formation of these side 
products are displayed in Figure 2. The anomeric methoxy substituent can substitute the 




with inversion at the anomeric center, explaining the stereochemistry of the anomeric 
azide side product found (27). Alternatively, an SN1 reaction on the oxocarbenium ion, 
formed upon opening of the oxiranium ion, happens in entry 4 with the solvent, 
explaining the mixture of anomers found in product 26.  
 
Table 2. Results of substitution reactions on triflates 14-17. 











1 14 A (TBAF) 18 71 - - 
2 14 B (CsF) 18 86 - - 
3 14 C (N3) 22 93 - - 
4 15 A 19, β only 42 15α, 17% - 
5 15 B 19 63 26g, 17% - 
6 15 C 23 86c 27c - 
7 16α Ad 20α 44 6, 17% 16α, 3% 
8 16α Be 20α - 28α, 57% 30α, 21% 
9 16α Cf 24α 67 29α, 12% 30α, 7% 
10 16β Ad 20β - 28β, 18% 31h 
11 16β B 20β - 28β, 47% 21β, 10% 
12 16β Cf 24β - 29β, 30% - 
13 17 A,B,C 21 / 25 - 31h - 
aReagents and conditions: (A) 0.2 M solution in THF, 2.5 eq. TBAF, 0°C to 20°C, overnight; (B) 0.35 M solution 
in tert-amyl alcohol, 4 eq. CsF, 90°C, overnight; (C) 0.2 M solution in DMF, 5 eq. NaN3, 80°C, 2 h. bSee 
experimental section for the general procedure of the triflate formation. cCombined yield of 23 and 27, as a 4:1 
mixture. d70°C, 5 h for entry 7, overnight for entry 10. e110°C overnight. fovernight. gα : β = 88 : 12. . hYield not 
determined. 
Both anomers of xyloside 6 were obtained, therefore both triflates 16α and 16β 
could be independently studied. Substitution of 16α, using CsF in tert-amyl alcohol at 
90°C, only gave the side products 5-fluorolyxoside 28α and the bicycle 30α (entry 8). 
The formation of these products can be explained by participation of the C-5–O-benzyl 
group followed by substitution from the least hindered sites (path A and B, Figure 2B), 
to yield 5-fluorolyxoside 28α and the bicycle 30α, respectively. No products arising from 
double inversion (path C) or elimination were detected. Fortunately, heating 16α in a 




THF solution with TBAF for 5 hours did give the desired fluoride inversion and product 
20α was isolated in 44% yield (entry 7). Interestingly, the only observed side products 
were unreacted and hydrolysed triflate and no products derived from C-5–O-benzyl 
participation were found. Subjection of 16α to conditions C led to effective azide 
substitution to give the desired product 24α (entry 9) together with small amounts of 
bicycle 30α and 5-azidolyxoside 29α originating from pathways A and B, respectively 
(Figure 2B).  
 
 
Figure 2. Mechanistic pathways underlying the formation of side products 26-31. 
 
Similar reactions with β-xylotriflate 16β did not lead to the required substitutions 
(entries 10-12, Table 2). Both conditions A and B gave 5-fluoroxyloside 28β, and 
condition A led to elimination product 31, while condition B gave 21β. The more 
nucleophilic and basic fluoride ion in condition A resulted in substitution on triflate 16α, 
but elimination to furan 31 for 16β. The formation of 2-fluoroxyloside 21β with net 
retention of configuration can be explained by a double inversion mechanism as shown 
in Figure 2C (path C). Since 21β is one of the target compounds and its formation from 
lyxotriflate 17 was ineffective, generation of 21β through this route proved advantageous. 
Azide substitution at the C-5-position (path A) resulted in the formation of the 5-
azidolyxoside side product 29α. 
All substitutions with lyxotriflate 17 to attain the target C-2-substituted 
xylofuranosides were ineffective and resulted in the elimination product 31. The fast 
elimination of triflate 17 into furan 31 can be explained by the steric hindrance that is 
experienced during nucleophilic attack and the favorable H-OTf alignment for 














































An alternative approach towards the missing C-2-substituted xylofuranosides 21 
and 25 was devised (Scheme 3). This synthetic route started with the preparation of glycal 
35. Among the various procedures to generate glycals,27–31 two methods, using relatively 
neutral conditions, were examined. Direct conversion of diol 33 by the Garegg 
olefination conditions (I2, Ph3P, imidazole) led to the glycal but it could only be isolated 
in low yield.32–34 A two-step procedure via thionocarbonate 34 proved more effective and 
this method was reproducible and scalable.35,36 This Corey-Winter olefination method 
cleanly converted 34 into glycal 35 when 1,3-dimethyl-2-phenyl-1,3,2-
diazaphospholidine was used as desulfurization agent.37 
 
Scheme 3. Synthetic route towards 2-azidoxylose 52 via azidophenylselenation of glycal 35. 
 
Reagents and conditions: (a) TFA, THF, H2O, 84%; (b) DMAP, DiPEA, thiophosgene, DCM, 78%; (c) 1,3-
dimethyl-2-phenyl-1,3,2-diazaphospholidine, toluene, 76%; (d) N-(phenylseleno)phthalimide, TMSN3, TBAF, 
DCM, 65%; (e) NIS, H2O, acetone, THF, 87%. 
 
The glycal 35 can be transformed to 2-fluoroxyloside 48 by electrophilic 
fluorination or to 2-azidoselenoxyloside 36 by azidophenylselenation respectively, see 
Table 3. Although the diastereoselectivity of the addition with SelectFluor in 4:1 
DMF/H2O was good (9:1, xylo:lyxo),38 the yield was low (48, 36%) and a 2-fluoro-1-O-
formyl (32) side product was isolated in 18%, resulting from reaction with DMF. 
Standard azidophenylselenation conditions (entry 2) delivered 36 as a 9:1 xylo:lyxo 
product mixture, which proved difficult to purify. The incompatibility of this reagent 
system with O-benzyl groups has been noted before39,40 and a switch to an alternative 
reagent proved beneficial. The N-(phenylseleno)phthalimide (N-PSP) mediated 
azidophenylselenation proceeded much cleaner and with equally good regio- and 
diastereoselectivity to give product 36 (entry 3).41–46 
 
 




Table 3. Conversion of glycal 35 to 2-fluoro- and 2-azidoxylosides 48 and 36. 
 
Entry Conditionsa Product, yieldc xylo:lyxoc 
1 SelectFluor, DMF, H2O 
48, 36% 
32, 18% 
9 : 1 
2 TMSN3, BAIB, PhSeSePh, DCM 36, 50% 9 : 1 
3 TMSN3, TBAF, N-PSP, DCM 36, 65% 9 : 1 
aReaction time was 20 h, stirred from 0°C to 20°C. bYield of the isolated xylo-configuration. cRatio obtained by 
crude 1H-NMR.  
 
With the critical functionalizations at C-2 completed, the attention was turned to 
modification of the C-5-position. The general synthetic route towards the uronic acid 
esters is presented in Scheme 4. The intermediates 37-40 are synthesized from the D-
aldopentose by a straightforward four-step procedure giving roughly the same yield for 
all the diastereoisomers (41%-50%). The subsequent oxidation reaction was carried out 
in a biphasic system of DCM and H2O with catalytic TEMPO as the oxidating agent and 
BAIB as co-oxidant. Yields of the oxidation were high but loss of product was observed 
in the subsequent methylation step to give 41-44. Shorter reaction times and aqueous 
work up, without concentration of the reaction mixture, were crucial to a higher isolated 
yield. Quenching with acetic acid instead of water or methanol also helped to increase 
the yield. 
 
Scheme 4. Synthesis of 5-uronic acid functionalized methyl glycosides 41-44. 
 
Reagents and conditions: (a) i. AcCl, MeOH; ii. TrtCl, Et3N, DMF; iii. BnBr, NaH, DMF; iv. pTsOH∙H2O, MeOH, 
37: 41%, 38: 43%, 39: 46%, 40: 50%, (all over four steps); (b) i. TEMPO, BAIB, DCM, H2O; ii. MeI, K2CO3, 



















With all methyl furanosides 18-24 and 41-44 available, the conversion of these 
furanosides into suitable glycosyl donors was undertaken. The first step comprises the 
hydrolysis of the methyl acetals to give lactols 45-56. Because of the electron-
withdrawing nature of the azido, fluoro, and uronic acid ester substituents in the 
furanosides, the anomeric acetals proved relatively stable and optimization of the acidic 
hydrolysis was required to prevent concomitant C-5–O-benzyl cleavage. The results of 
the optimization studies are summarized in Table 4. 
In an attempt to obtain the acetyl donor 57, methyl furanoside 22 was treated with 
H2SO4 in acetic anhydride, but this led to formation of diacetyl compound 61 instead 
(entry 1, see experimental section). Heating an 80% aq. AcOH solution of 22 overnight 
(entry 2) gave no conversion, and upon HCl addition decomposition occurred (entry 
3).47 Aqueous 70-90% TFA at room temperature (entries 5-7) gave 49 in low yield with 
significant concurrent decomposition.48 Fortunately, using 50% aqueous TFA at 75°C 
significantly improved the outcome (entry 10), and also the use of 80% aqueous formic 
acid at this temperature provided the target compound. The best results were obtained 
with formic acid at a temperature of 60°C (entries 10 and 11).24  
 
Table 4. Evaluation of acidic hydrolysis conditions. 
 
Entry Conc.a Conditions Temperature (°C) Time (h) Yield (%) 
1 0.3 M 1.5% H2SO4 in Ac2O 0 0.3 b 
2 0.1 M 80% aq. AcOH 115 24 - 
3 0.2 M 20% 5M HCl in AcOH 85 16 - 
4 0.3 M Ph3C-BF4 in DCM 20 70 - 
5 0.2 M 90% aq. TFA 20 40 17 
6 0.2 M 80% aq. TFA 20 300 23 
7 0.2 M 70% aq. TFA 20 300 50 
8 0.1 M 50% aq. TFA 75 24 50 
9 0.05 M 80 aq. formic acid 75 24 51 
10 0.1 M 50% aq. TFA 60 80 73 
11 0.05 M 80 aq. formic acid 60 80 76 
aConcentration. Scale is 0.4 mmol except entry 1 (1.0 mmol) and entries 10 and 11 (1.5 mmol). bYield of 1,5-
di-O-acetyl-2-azido-3-O-benzyl-2-deoxy-α/β-D-arabinofuranoside 61 was 85%. 
  




The hydrolysis of all other furanosides are listed in Table 5. The formic acid 
conditions proved effective for the 2-fluoro (entries 1-4), and 2-azido (entries 5-7) series, 
to give the corresponding lactols in good yield. The reactivity of the different substrates 
varied greatly, and changing the temperature and reaction time was needed to push the 
reactions to completion. The uronic acids (entries 8-11) were hydrolysed with 90% 
aqueous TFA to give the lactol products in good yield. 
 
Table 5. Hydrolysis reaction results for methyl glycosides 18-24, and 41-44. 
 







1 18 AraF 45 A 65 64 63 
2 19 RibF 46 A 60 18 78 
3 20 LyxF 47 A 65 6 75 
4 21 XylF 48 A 60 6 75 
5 22 AraN3 49 A 60 80 76 
6 23 RibN3 50 A 65 6 70a 
7 24 LyxN3 51 A 60 18 62 
8 41 AraA 53 B 0 to 20 8 60 
9 42 RibA 54 B 0 to 20 7.5 73 
10 43 LyxA 55 B 0 to 20 6 85 
11 44 XylA 56 B 0 to 20 4 90 
Reagents and conditions: (A) HCOOH/H2O (4/1 v/v, 0.05 M); (B) TFA/H2O (9/1 v/v, 0.2 M). aYield over two 
steps (including inversion), the combined yield of the 4:1 mixture of 23 and 27 was 89%. 
The acetyl donors were prepared by treatment of the lactol precursors with acetic 
anhydride in pyridine (Table 6). But as a pilot study revealed that TMSOTf catalyzed 
glycosylations with allyl-trimethylsilane and deuterated triethylsilane were not 
productive using the acetyl donors even at room temperature, it was decided to generate 
the trifluoro-N-phenylimidate donors (Table 7, 62-73), as these are more reactive and 
can be activated under catalytical conditions.49 
The majority of the imidates were synthesized using an acetone/H2O mixture and 





Table 6. Conversion of lactols to acetyl donors 57-60. 
 
Entry Substrate Configuration Product α : β Yield (%) 
1 49 AraN3 57 2.3 : 1 90 
2 53 AraA 58 5.7 : 1 90 
3 54 RibA 59 0 : 1 91 
4 56 XylA 60 1.2 : 1 98 
Reagents and conditions: Ac2O (1.25 eq.) in pyridine (0.25 M), 0°C to r.t. 
issues occurred, separating the target compounds from the hydrolyzed or unreacted 
2,2,2-trifluoro-N-phenylacetimidoyl chloride, an anhydrous DCM/DBU procedure was 
explored. These reactions were complete within minutes, successfully generating the 
target compounds, even though work up and purification led to some degradation.  
Table 7. Conversion of lactols 45-56 to imidate donors 62-73. 
 
Entry Substrate Configuration Product Conditions α : β Yield (%) 
1 45 AraF 62 A 5 : 1 85 (69 + 16) 
2 46 RibF 63 A 0 : 1 98 
3 47 LyxF 64 A 1 : 0 82 
4 48 XylF 65 A 1 : 2 91 
5 49 AraN3 66 B 1.6 : 1 71 (44 + 27) 
6 50 RibN3 67 A 1 : 8 77 (8 + 69) 
7 51 LyxN3 68 B 1 : 1.2 67 (30 + 37) 
8 52 XylN3 69 A 1 : 1 100 
9 53 AraA 70 A 1 : 1 97 
10 54 RibA 71 A 0 : 1 85 
11 55 LyxA 72 A 5 : 1 85 (70 + 15) 
12 56 XylA 73 A 0 : 1 81 
Reagents and conditions: (A) 2,2,2-trifluoro-N-phenylacetimidoyl chloride (0.95 eq.), Cs2CO3 (1.1 eq.) in 
acetone/H2O (9/1 v/v, 0.2 M), 0°C to r.t. (B) 2,2,2-trifluoro-N-phenylacetimidoyl chloride (0.95 eq.), DBU (1 





























This chapter presents the synthesis of C-2- (2-fluoro, 2-azido) and C-5- (5-methyl 
uronates) modified furanosides of all four diastereoisomers. While the synthesis of the 
C-5-modified furanosides was relatively straightforward, the inversion reactions of the 
C-2-alcohols to provide the azides and fluorides, proved challenging. Eventually all 
synthetic pitfalls were overcome, leading to the successful synthesis of all twelve 
pentofuranoside imidate donors. The stereoelectronic effects originating from the newly 
introduced functional groups on C-2 and C-5 in glycosylation reactions will be discussed 






General procedure for the formation of 2-O-trifluoromethanesulfonyl-furanosides (14-17). A 0.2 M solution of the 
alcohol (1 eq.) in DCM was cooled to 0°C followed by the addition of pyridine (2 eq.) and Tf2O (1.2 eq.). After stirring 
for 40 min the reaction mixture was poured into cold 1 M aq. HCl and extracted twice with DCM. The combined organic 
layers were washed with cold H2O, cold sat. aq. NaHCO3, and brine. The organic layer was dried (Na2SO4), filtered, and 
concentrated under reduced pressure. After coevaporated with toluene the crude triflated furanoside was dissolved 
in the solvent required for the next synthetic step. 
General procedure for the inversion of 2-O-trifluoromethanesulfonyl-furanosides (18-24). Conditions A: The triflate (1 
eq.) was dissolved in tert-amyl alcohol (0.35 M) and CsF (4 eq.) was added. The reaction mixture was heated overnight 
at 90°C, followed by aqueous work up. Conditions B: The triflate (1 eq.) was dissolved in THF (0.2 M) and TBAF (1 M in 
THF, 2.5 eq.) was added at 0°C. The reaction mixture was allowed to reach room temperature and stirred overnight, 
followed by aqueous work up. Conditions C: The triflate (1 eq.) was dissolved in DMF (0.2 M) and NaN3 (5 eq.) was 
added. The reaction mixture was heated for 2 h at 80°C, followed by aqueous work up. Work up conditons: the 
reaction mixture was diluted with H2O (volume×10) and extracted with Et2O three times. The combined organic layers 
were washed with H2O, sat .aq. NaHCO3, and brine. The organic layer was dried (MgSO4), filtered and concentrated 
in vacuo. Flash column chromatography (1/0 to 9/1 pentane/EtOAc) provided the target inverted furanosides as 
colourless oils. 
General procedure for the synthesis of primary furanoside alcohols (37-40). To a suspension of D-pentose in MeOH (0.2 
M) was added AcCl (0.3-0.9 eq) and the reaction was stirred until complete conversion to the methyl furanoside was 
observed (TLC). NaHCO3 (s) was added to the reaction mixture until neutral. The slurry was filtered and concentrated 
under reduced pressure, followed by coevaporated with toluene. The residue was dissolved in DMF (0.2 M) and Et3N 
(2.0 eq.), TrtCl (1.5 eq.), and DMAP (0.05 eq.) were successively added. After stirring for 1-2 days the mixture was 
diluted with H2O and extracted twice with DCM. The combined DCM fractions were washed with H2O and brine, then 
dried with MgSO4, filtered and concentrated in vacuo followed by coevaporation with toluene. The crude tritylated 
product was redissolved in DMF (0.2 M) and cooled to 0°C. NaH (60% dispersion in mineral oil, 2.5 eq.) and TBAI (0.05 
eq.) were added, followed by drop wise addition of BnBr (2.5 eq.). After stirring overnight at room temperature, the 
reaction was quenched by the addition of H2O and extracted three times with Et2O. The combined organic layers were 
washed with H2O and brine, dried (MgSO4), filtered over a short plug of silica gel, and concentrated under reduced 
pressure. The crude material was dissolved in MeOH/DCM (1/1, v/v, 0.2 M) and pTsOH⋅H2O (0.1 eq.) was added and 
the reaction stirred at room temperature overnight and then quenched with Et3N (0.15 eq.) The solvent was removed 
under reduced pressure and the residue was purified by flash column chromatography (19/1 to 6/4 pentane/EtOAc) 
to yield the primary furanoside alcohols as yellow oils.  
General procedure for the synthesis furanosyl methyl uronates by TEMPO/BAIB oxidation and methylation (41-44). The 
primary alcohol was dissolved in DCM/H2O (2/1, v/v, 0.17 M) and the mixture was cooled to 0°C. TEMPO (0.2 eq.) and 
BAIB (2.5 eq.) were added and the reaction mixture was stirred vigorously overnight. A 10 % aq. NaS2O3 solution was 
added and the mixture stirred for 15 min at room temperature. The mixture was diluted with 0.01 M aq. HCl and DCM 
and phase separated and the aqueous layer extracted three times with DCM. The combined DCM layers were washed 
with H2O and brine, dried (MgSO4), filtered and concentrated under reduced pressure.  The crude carboxylic acid was 
dissolved in DMF (0.2 M) and K2CO3 (3 eq.) and MeI (3 eq.) were added at 0°C. The reaction was stirred for 3 h and 
then quenched with AcOH (5 eq). The solution was diluted with H2O and extracted three times with Et2O. The 
combined organic layers were washed with sat. aq. NaHCO3 and brine, dried with MgSO4, filtered, and concentrated 
under reduced pressure. The residue was purified by flash column chromatography (19/1 to 7/3) to give the uronic 
acid methyl ester. 
General procedure for the hydrolysis of methyl furanosides (49-64). Conditions A: The methyl glycoside was mixed with 
80% aq. formic acid to a concentration of 0.05 M and stirred at 60-65°C for 6-64 h as mentioned for each experiment. 
After the reaction mixture was cooled to room temperature and transferred to a seperatory funnel, it was diluted 5× 
with H2O and extracted three times with DCM. The combined DCM layers were washed with sat. aq. NaHCO3 and 
brine, dried over MgSO4, filtered and concentrated in vacuo. The resulting residue was purified by flash column 
chromatography (pentane/EtOAc mixtures) to provide the target lactol as a mixture of anomers. Conditions B: The 
methyl glycoside was dissolved in 90% aq. TFA at 0°C and stirred for 4-8 h. The reaction was diluted with DCM and 
washed with H2O three times. The aqueous layers were extracted twice with DCM and the combined organic layers 




were washed with sat. aq. NaHCO3 and brine. The organic layer was dried (MgSO4), filtered and concentrated under 
reduced pressure. The residu was purified by flash column chromatography (19/1 to 6/4 pentane/EtOAc) to provide 
the target lactol as a mixture of anomers. 
General procedure for the synthesis of acetyl donors from lactols (65-69). The furanose lactol was dissolved in pyridine 
(0.25 M) and cooled to 0°C. Ac2O (1.3 eq.) was added and the reaction mixture was stirred overnight at room 
temperature. The solution was diluted with 0.1 M aq. HCl and extracted three times with Et2O. The combined organic 
layers were washed with 0.1 M HCl, H2O, sat. aq. NaHCO3, and brine. The organic layer was dried (MgSO4), filtered, 
and concentrated in vacuo. Purification of the residue by flash column chromatography (1/0 to 8/2 pentane/EtOAc) 
gave the acetylated compound as a light yellow oil. 
General procedure for the installation of the trifluoro-N-phenylacetimidoyl group (71-86). Conditions A: The furanose 
lactol was dissolved in acetone/H2O (0.2 M, 9/1 v,v) and cooled to 0°C. Cs2CO3 (1.1 eq.) and 2,2,2-trifluoro-N-
phenylacetimidoyl chloride (0.95 eq.) were added and the reaction mixture stirred until TLC-analysis showed complete 
conversion (1-4 days). The reaction mixture was reduced in volume under reduced pressure and H2O was added. The 
aqueous phase was extracted twice with DCM and the combined organic layers were dried with Na2SO4, filtered, and 
concentrated under reduced pressure. Flash column chromatography (0-15% Et2O/pentane) of the residue provided 
the target imidate donors. Conditions B: The furanose lactol was dissolved in DCM (0.25 M) and cooled to 0°C. 2,2,2-
Trifluoro-N-phenylacetimidoyl chloride (0.95 eq.) was added followed bu DBU (1 eq.). The reaction mixture was stirred 
for 1 h and then concentrated under reduced pressure. Flash column chromatography (1/0 to 85/15 pentane/Et2O) 
of the residue provided the target imidate donors. 
Methyl 2,3,5-tri-O-benzyl-α/β-D-ribofuranoside (2). D-Ribose (25 g, 167 mmol, 1 eq.) was 
dissolved in 600 mL MeOH and AcCl (4 mL, 56 mmol, 0.3 eq.) was added. The reaction mixture 
was stirred for 5 h and then quenched by the addition of solid NaHCO3 (30 g). The mixture was 
filtered and concentrated under reduced pressure. The crude product 1 was coevaporated with toluene and then 
dissolved in 800 mL DMF and cooled to 0°C. NaH (60% dispersion in mineral oil, 26.7 g, 668 mmol, 4 eq.) was added 
in four portion while BnBr (80 mL, 668 mmol, 4 eq.) was slowly added over the course of 1 h. After stirring overnight 
the reaction was quenched by the addition of 75 mL MeOH and the reaction mixture was concentrated under reduced 
pressure. The crude mixture was taken up in H2O and extracted twice with Et2O. The combined Et2O layers were 
washed with brine, dried with MgSO4, filtered and concentrated in vacuo. Purification by flash column 
chromatography (19/1 to 2/1 pentane/EtOAc) gave compound 2 as a colourless oil (65 g, 150 mmol, 89%). 
Spectroscopic data were in accord with those previously reported.50 Data for the α-anomer: 1H NMR (CDCl3, 400 MHz, 
HH-COSY, HSQC): δ 7.36 – 7.25 (m, 13H, CHarom), 7.23 – 7.19 (m, 2H, CHarom), 4.88 (d, 1H, J = 4.2 Hz, H-1), 4.68 (d, 1H, 
J = 12.8 Hz, CHH Bn), 4.64 (d, 1H, J = 12.3 Hz, CHH Bn), 4.61 – 4.56 (m, 2H, 2xCHH Bn), 4.49 (d, 1H, J = 12.1 Hz, CHH 
Bn), 4.42 (d, 1H, J = 12.1 Hz, CHH Bn), 4.25 (td, 1H, J = 4.1, 2.9 Hz, H-4), 3.82 (dd, 1H, J = 6.8, 3.0 Hz, H-3), 3.77 (dd, 1H, 
J = 6.8, 4.2 Hz, H-2), 3.46 (s, 3H, CH3 OMe), 3.41 (dd, 1H, J = 10.4, 4.1 Hz, H-5), 3.35 (dd, 1H, J = 10.4, 4.2 Hz, H-5); 13C-
APT NMR (CDCl3, 101 MHz, HSQC): δ 138.6, 138.0, 137.9 (Cq), 128.5, 128.5, 128.4, 128.4, 128.2, 127.9, 127.8, 127.8 
(CHarom), 102.6 (C-1), 82.3 (C-4), 77.9 (C-2), 75.1 (C-3), 73.6, 72.6, 72.5 (CH2 Bn), 70.3 (C-5), 55.7 (OMe); Data for the 
β-anomer: 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC): δ 7.40 – 7.25 (m, 15H, CHarom), 4.92 (d, 1H, J = 1.0 Hz, H-1), 
4.67 (d, 1H, J = 12.1 Hz, CHH Bn), 4.61 (d, 1H, J = 12.1 Hz, CHH Bn), 4.59 (d, 1H, J = 12.2 Hz, CHH Bn), 4.55 (d, 1H, J = 
12.0 Hz, CHH Bn), 4.54 (d, 1H, J = 12.2 Hz, CHH Bn), 4.45 (d, 1H, J = 11.9 Hz, CHH Bn), 4.34 (ddd, 1H, J = 7.1, 5.8, 3.7 
Hz, H-4), 4.01 (dd, 1H, J = 7.1, 4.7 Hz, H-3), 3.84 (dd, 1H, J = 4.6, 1.0 Hz, H-2), 3.61 (dd, 1H, J = 10.6, 3.7 Hz, H-5), 3.51 
(dd, 1H, J = 10.6, 5.8 Hz, H-5), 3.31 (s, 3H, CH3 OMe); 13C-APT NMR (CDCl3, 101 MHz, HSQC): δ 138.3, 137.8, 137.8 (Cq), 
128.4, 128.4, 128.3, 128.0, 127.9, 127.8, 127.8, 127.6, 127.5 (CHarom), 106.3 (C-1), 80.5 (C-4), 79.6 (C-2), 78.3 (C-3), 
73.2, 72.4, 72.3 (CH2 Bn), 71.3 (C-5), 55.1 (OMe). 
Methyl 3,5-di-O-benzyl-α-D-ribofuranoside (3). Compound 2 (4.35 g, 10 mmol, 1 eq.) was 
coevaporated with toluene twice and then was dissolved in 50 mL DCM at 0°C, followed by the 
addition of a 1 M SnCl4 solution in DCM (10 mL, 10 mmol, 1 eq.). The reaction mixture was 
stirred overnight at 4°C and then quenched by the addition of sat. aq. NaHCO3. The organic layer was washed with 
H2O and brine, then dried (MgSO4), filtered and concentrated in vacuo. The residue was purified by flash column 
chromatography (9/1 to 7/3 pentane/EtOAc) to yield the title compound as a colourless oil (3.19 g, 9.26 mmol, 93%). 
Spectroscopic data were in accord with those previously reported.17 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC): δ 
7.36 – 7.22 (m, 10H, CHarom), 4.88 (d, 1H, J = 4.6 Hz, H-1), 4.72 (d, 1H, J = 12.4 Hz, CHH Bn), 4.57 (d, 1H, J = 12.3 Hz, 




4.06 (m, 1H, H-2), 3.78 (dd, 1H, J = 7.1, 3.2 Hz, H-3), 3.47 (s, 3H, CH3 OMe), 3.43 (dd, 1H, J = 10.4, 4.1 Hz, H-5), 3.35 
(dd, 1H, J = 10.4, 4.3 Hz, H-5), 2.96 (bd, 1H, J = 10.1 Hz, 2-OH); 13C-APT NMR (CDCl3, 101 MHz, HSQC): δ 137.9, 137.9 
(Cq), 128.5, 128.5, 128.0, 127.9, 127.8, 127.7 (CHarom), 103.0 (C-1), 82.0 (C-4), 76.4 (C-3), 73.5, 73.0 (CH2 Bn), 71.9 (C-
2), 70.1 (C-5), 55.7 (OMe); HRMS: [M+Na]+ calcd for C20H24O5Na 367.15160, found 367.15139. 
Methyl 3,5-di-O-benzyl-α/β-D-xylofuranoside (6). 1,2-O-Isopropylidene-α-D-xylofuranoside 451 
(28.6 g, 150 mmol, 1 eq.) was dissolved in 750 mL DMF and cooled to 0°C. NaH (60% dispersion 
in mineral oil, 15 g, 375 mmol, 2.5 eq.) was added followed by the slow addition of BnBr (45 mL, 
375 mmol, 2.5 eq.). After 4 h the reaction was quenched by the addition of 50 mL MeOH and the reaction mixture 
was concentrated under reduced pressure. The crude mixture was taken up in H2O and extracted twice with Et2O. The 
combined Et2O layers were washed with brine and dried with MgSO4. After filtration and concentration, the crude 
product 5 was dissolved in 750 mL MeOH and CSA (3.5 g, 15 mmol, 0.1 eq.) was added and the reaction mixture was 
refluxed for 4 h. The reaction was quenched by addition of solid NaHCO3, which after stirring for 15 min, was removed 
by filtration followed by concentration on the reaction mixture in vacuo. The residue was redissolved in EtOAc and 
was washed with H2O and brine, dried (MgSO4), filtered, and concentrated under reduced pressure. Purification by 
flash column chromatography (9/1 to 1/1 pentane/EtOAc) yielded compound 6 as a light yellow oils in three fractions 
(1: α only, 21.8 g, 63.4 mmol, 2: α/β mixture, 7.6 g, 22.2 mmol, 3: β only, 20.8 g, 60.5 mmol) combined yield: 146.1 
mmol, 97%. Spectroscopic data were in accord with those previously reported.52 Data for the α-anomer: 1H NMR 
(CDCl3, 400 MHz, HH-COSY, HSQC): δ 7.37 – 7.24 (m, 10H, CHarom), 4.99 (d, 1H, J = 4.7 Hz, H-1), 4.73 (d, 1H, J = 12.0 Hz, 
CHH Bn), 4.63 (d, 1H, J = 12.1 Hz, CHH Bn), 4.55 (d, 1H, J = 12.0 Hz, CHH Bn), 4.53 (d, 1H, J = 12.1 Hz, CHH Bn), 4.39 
(td, 1H, J = 6.4, 4.2 Hz, H-4), 4.26 (dt, 1H, J = 7.5, 4.4 Hz, H-2), 4.00 (dd, 1H, J = 6.0, 4.1 Hz, H-3), 3.72 (dd, 1H, J = 10.5, 
4.2 Hz, H-5), 3.65 (dd, 1H, J = 10.5, 6.7 Hz, H-5), 3.49 (s, 3H, CH3 OMe), 2.71 (d, 1H, J = 7.6 Hz, 2-OH); 13C-APT NMR 
(CDCl3, 101 MHz, HSQC): δ 138.4, 138.1 (Cq), 128.5, 128.5, 127.9, 127.8, 127.7, 127.7 (CHarom), 101.9 (C-1), 83.7 (C-3), 
77.5 (C-4), 77.1 (C-2), 73.6, 72.0 (CH2 Bn), 69.2 (C-5), 55.9 (OMe); Data for the β-anomer: 1H NMR (CDCl3, 400 MHz, 
HH-COSY, HSQC): δ 7.37 – 7.25 (m, 10H, CHarom), 4.80 (d, 1H, J = 1.7 Hz, H-1), 4.66 – 4.58 (m, 2H, 2xCHH Bn), 4.55 (d, 
1H, J = 12.0 Hz, CHH Bn), 4.54 (d, 1H, J = 12.2 Hz, CHH Bn), 4.47 (ddd, 1H, J = 7.2, 6.1, 4.6 Hz, H-4), 4.21 (ddd, 1H, J = 
4.7, 2.9, 1.7 Hz, H-2), 3.95 (dd, 1H, J = 6.1, 2.9 Hz, H-3), 3.77 (dd, 1H, J = 10.3, 4.7 Hz, H-5), 3.70 (dd, 1H, J = 10.3, 7.3 
Hz, H-5), 3.40 (s, 3H, CH3 OMe), 1.95 (d, 1H, J = 4.8 Hz, 2-OH); 13C-APT NMR (CDCl3, 101 MHz, HSQC): δ 138.4, 137.9 
(Cq), 128.6, 128.5, 128.0, 127.9, 127.9, 127.7 (CHarom), 109.6 (C-1), 83.5 (C-3), 80.1 (C-4), 79.8 (C-2), 73.6, 72.5 (CH2 
Bn), 70.0 (C-5), 55.9 (OMe). 
1,2-O-Isopropylidene-5-O-(tert-butyldiphenylsilyl)-β-D-arabinofuranoside (7). D-Arabinose (30 
g, 200 mmol, 1 eq.) was dissolved in 1 L DMF and imidazole (27.2 g, 400 mmol, 2 eq.) and 
TBDPSCl (52 mL, 200 mmol, 1 eq.) were added sequentially. The reaction mixture was heated 
to 60°C for 3 h and then two thirds of the DMF was removed under reduced pressure. The remaining solution was 
mixed with H2O (1.5 L) and conc. HCl (15 mL) and the aqueous phase extracted four times with EtOAc. The organic 
layers were combined and washed with sat. aq. NaHCO3 and brine. The organic phase was dried with MgSO4, filtered 
and concentrated under reduced pressure. The crude product was coevaporated with toluene and then dissolved in 
DCM (1.1 L) and cooled to 0°C. CSA (2.5 g, 10.8 mmol, 0.05 eq.) was added followed by dropwise addition of 2,2-
dimethoxypropane (44 mL, 360 mmol, 1.8 eq.). After 4 h, the reaction was quenched with Et3N (2.8 mL) and 
concentrated under reduced pressure. Flash column chromatography (19/1 to 8/2 pentane/EtOAc) yielded compound 
7 as a colourless oil (43.7 g, 102 mmol, 51%). Spectroscopic data were in accord with those previously reported.53 1H 
NMR (CDCl3, 500 MHz, HH-COSY, HSQC): δ 7.73 – 7.61 (m, 4H, CHarom), 7.46 – 7.33 (m, 6H, CHarom), 5.88 (d, 1H, J = 4.0 
Hz, H-1), 4.54 (d, 1H, J = 4.0 Hz, H-2), 4.43 (t, 1H, J = 3.1 Hz, H-3), 4.05 (ddd, 1H, J = 7.9, 5.7, 2.6 Hz, H-4), 3.86 – 3.78 
(m, 2H, H-5), 2.00 (d, 1H, J = 4.3 Hz, 3-OH), 1.32 (s, 3H, CH3 Me), 1.28 (s, 3H, CH3 Me), 1.06 (s, 9H, CH3 tBu); 13C-APT 
NMR (CDCl3, 126 MHz, HSQC): δ 135.7, 135.7 (CHarom), 133.3, 133.2 (Cq Ph), 129.9, 129.9, 127.9, 127.9 (CHarom), 112.6 
(Cq), 105.7 (C-1), 87.5 (C-4), 87.1 (C-2), 76.5 (C-3), 63.8 (C-5), 27.0, 27.0 (tBu), 26.2 (Me), 19.3 (Cq tBu). 
Methyl 3,5-di-O-benzyl-1,2-O-isopropylidene-β-D-arabinofuranoside (8). Compound 7 (14.1 g, 
32.8 mmol, 1 eq.) and BnCl (22.6 mL, 197 mmol, 6 eq.) were dissolved in 140 mL THF. Freshly 
crushed KOH pellets (35 g, 623 mmol, 19 eq.) were added and the reaction mixture was stirred 
under a N2 atmosphere at reflux overnight. Once the mixture was cooled to room temperature, it was filtered through 
glass wool and concentrated in vacuo. Flash column chromatography (1/0 to 9/1 pentane/EtOAc) afforded the title 
compound as a yellow oil (9.0 g, 24.3 mmol, 74%). Spectroscopic data were in accord with those previously reported.22 
1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC): δ 7.34 – 7.26 (m, 10H, CHarom), 5.90 (d, 1H, J = 4.0 Hz, H-1), 4.64 (d, 1H, J 
= 4.1 Hz, H-2), 4.62 – 4.57 (m, 2H, CH2 Bn), 4.57 – 4.51 (m, 2H, CH2 Bn), 4.27 (td, 1H, J = 6.3, 3.0 Hz, H-4), 4.02 (d, 1H, 
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J = 2.7 Hz, H-3), 3.63 (d, 2H, J = 6.2 Hz, H-5), 1.44 (s, 3H, CH3 Me), 1.32 (s, 3H, CH3 Me); 13C-APT NMR (CDCl3, 101 MHz, 
HSQC): δ 138.1, 137.4 (Cq Bn), 128.6, 128.5, 128.0, 127.9, 127.8, 127.8 (CHarom), 112.8 (Cq), 105.8 (C-1), 85.3 (C-2), 
83.7 (C-4), 83.2 (C-3), 73.5, 71.8 (CH2 Bn), 70.1 (C-5), 27.2, 26.4 (Me). 
Methyl 3,5-di-O-benzyl-α/β-D-arabinofuranoside (9). Fully protected compound 8 (11 g, 30 mmol, 
1 eq.) and CSA (0.7 g, 3.0 mmol, 0.1 eq.) were dissolved in 150 mL MeOH and brought to reflux. 
After stirring for 5 h, the reaction mixture was cooled down and solid NaHCO3 was added. The 
reaction mixture was concentrated and then H2O was added. Extraction with EtOAc twice and those combined organic 
layers were washed with brine, then dried with MgSO4, filtered, and concentrated in vacuo. Purification by flash 
column chromatography (19/1 to 8/2 pentane/EtOAc) afforded the title compound (9.4 g, 27 mmol, 91%) as a 
colourless oil. Spectroscopic data were in accord with those previously reported.22 Data for the α-anomer: 1H NMR 
(CDCl3, 400 MHz, HH-COSY, HSQC): δ 7.37 – 7.21 (m, 10H, CHarom), 4.89 (s, 1H, H-1), 4.68 (d, 1H, J = 12.3 Hz, CHH Bn), 
4.61 (d, 1H, J = 11.9 Hz, CHH Bn), 4.51 (d, 1H, J = 12.4 Hz, CHH Bn), 4.46 (d, 1H, J = 11.9 Hz, CHH Bn),4.26 (s, 1H, H-4), 
4.12 (d, 1H, J = 10.9 Hz, H-2), 3.84 (s, 1H, H-3), 3.64 (dd, 1H, J = 10.4, 2.4 Hz, H-5), 3.43 (dd, 1H, J = 10.4, 2.5 Hz, H-5), 
3.40 (s, 3H, CH3 OMe), 3.34 (d, 1H, J = 10.8 Hz, OH); Data for the β-anomer: 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC): 
δ 7.39 – 7.22 (m, 10H, CHarom), 4.84 (d, 1H, J = 4.7 Hz, H-1), 4.74 (d, 1H, J = 11.9 Hz, CHH Bn), 4.59 (d, 1H, J = 11.9 Hz, 
CHH Bn), 4.57 (s, 2H, CH2 Bn), 4.31 – 4.21 (m, 1H, H-2), 4.19 – 4.09 (m, 1H, H-4), 3.84 (t, 1H, J = 5.8 Hz, H-3), 3.53 (d, 
2H, J = 5.6 Hz, H-5), 3.41 (s, 3H, CH3 OMe), 2.57 (d, 1H, J = 9.4 Hz, OH); Data for the both anomers: 13C-APT NMR (CDCl3, 
101 MHz, HSQC): δ 138.1, 138.0, 137.8, 137.1 (Cq), 128.6, 128.5, 128.4, 128.1, 128.0, 127.9, 127.9, 127.8, 127.8, 127.7, 
127.7 (CHarom), 110.5 (C-1α), 102.8 (C-1β), 85.0 (C-3α), 84.7 (C-3β), 83.5 (C-4α), 80.8 (C-4β), 78.1 (C-2α), 78.0 (C-2β), 73.8, 
73.4, 72.2 (CH2 Bn), 72.1 (C-5β), 71.9 (CH2 Bn), 69.8 (C-5α), 55.4, 55.3 (OMe). 
1,2-O-Isopropylidene 5-O-(tert-butyldiphenylsilyl)-β-D-arabinofuran-3-uloside (10). 
Compound 7 (9.95 g, 23.2 mmol, 1 eq.) was dissolved in 230 mL DCM and Dess-Martin 
periodinane (13.4 g, 31 mmol, 1.36 eq.) was added. After stirring 4 h, Na2S2O3 (20 g) was 
added and the reaction mixture was poured into sat. aq. NaHCO3. The mixture was extracted with DCM three times 
and the combined organic layers were washed with H2O and brine. The organic layer was dried with MgSO4, filtered 
and concentrated under reduced pressure. Flash column chromatography (1/0 to 8/2 pentane/EtOAc) afforded the 
title compound as a colourless oil (7.65 g, 17.9 mmol, 77%). Spectroscopic data were in accord with those previously 
reported.18 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC): δ 7.75 – 7.63 (m, 4H, CHarom), 7.45 – 7.33 (m, 6H, CHarom), 6.03 
(d, 1H, J = 4.3 Hz, H-1), 4.39 (d, 1H, J = 4.3 Hz, H-2), 4.29 (dd, 1H, J = 6.3, 4.2 Hz, H-4), 3.99 – 3.87 (m, 2H, H-5), 1.37 (s, 
3H, CH3 Me), 1.35 (s, 3H, CH3 Me), 1.05 (s, 9H, CH3 tBu); 13C-APT NMR (CDCl3, 101 MHz, HSQC): δ 207.3 (C=O), 135.9, 
135.7 (CHarom), 133.2, 132.9 (Cq Ph), 129.9, 127.9 (CHarom), 114.9 (Cq), 102.7 (C-1), 82.5 (C-4), 76.9 (C-2), 64.6 (C-5), 
27.6 (Me), 26.9 (tBu), 19.4 (Cq tBu); 
1,2-O-Isopropylidene-5-O-(tert-butyldiphenylsilyl)-β-D-lyxofuranoside (11). Ketone 9 (6.9 g, 
16.2 mmol, 1 eq.) was dissolved in DCM/MeOH (100 mL, 1/1) and cooled to 0C. NaBH4 (1.8 
g, 48 mmol, 3 eq.) was added in three equal portions and the reaction mixture was stirred 
for 30 min after each addition. After 1.5 h sat. aq. NH4Cl was added and the mixture was extracted three times with 
DCM. The combined organic layers were washed with sat. aq. NH4Cl, H2O, and brine. The organic layer was then dried 
(MgSO4), filtered, and concentrated under reduced pressure. Flash column chromatography (2% to 14% 
EtOAc/pentane) afforded the title compound as a yellow oil (5.2 g, 13.1 mmol, 75%). Spectroscopic data were in 
accord with those previously reported.54 1H NMR (CDCl3, HH-COSY, HSQC): δ 7.78 – 7.62 (m, 4H, CHarom), 7.48 – 7.31
(m, 6H, CHarom), 5.71 (d, 1H, J = 4.1 Hz, H-1), 4.60 (dd, 1H, J = 5.8, 4.1 Hz, H-2), 4.33 (q, 1H, J = 5.9 Hz, H-3), 4.20 – 4.11 
(m, 2H, H-4, H-5), 3.93 – 3.84 (m, 1H, H-5), 3.10 (d, 1H, J = 6.4 Hz, 3-OH), 1.42 (s, 3H, CH3 Me), 1.34 (s, 3H, CH3 Me), 
1.06 (s, 9H, CH3 tBu); 13C-APT NMR (CDCl3, 101 MHz, HSQC): δ 135.7, 135.7 (CHarom), 133.2, 133 (Cq Ph).1, 129.8, 127.8,
127.8 (CHarom), 114.1 (Cq), 105.0 (C-1), 81.4 (C-4), 79.9 (C-2), 71.0 (C-3), 63.3 (C-5), 26.9 (CH3 tBu), 26.8, 26.6 (Me),
19.2 (Cq tBu). 
Methyl 3,5-di-O-benzyl-1,2-O-isopropylidene-β-D-lyxofuranoside (12). Compound 11 (9.0 g, 21 
mmol, 1 eq.) and BnCl (14 mL, 123 mmol, 5.9 eq.) were dissolved in 90 mL THF. Freshly crushed 
KOH pellets (19.7 g, 351 mmol, 16.7 eq.) were added and the reaction mixture was stirred under 
a N2 atmosphere at reflux overnight. Once the mixture was cooled to room temperature, it was filtered through glass 
wool and concentrated in vacuo. Flash column chromatography (1/0 to 8/2 pentane/EtOAc) afforded the title 
compound as a colourless oil (7.9 g, 21 mmol, 100%). Spectroscopic data were in accord with those previously 
reported for the L-enantiomer.55 Rf: 0.16 (9/1 pentane/EtOAc). [α]  = +15° (c = 0.44, CHCl3). IR (thin film): 698, 737, 
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1026, 1097, 1152, 1209, 1255, 1454, 2868, 2946, 2986; 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC): δ 7.41 – 7.18 (m, 
10H, CHarom), 5.70 (d, 1H, J = 4.0 Hz, H-1), 4.67 (d, 1H, J = 12.1 Hz, CHH Bn), 4.63 – 4.57 (m, 3H, CH2 Bn, CHH Bn), 4.55 
(dd, 1H, J = 5.1, 4.0 Hz, H-2), 4.32 (dt, 1H, J = 7.2, 5.8 Hz, H-4), 4.05 (dd, 1H, J = 7.3, 5.1 Hz, H-3), 3.88 (d, 2H, J = 5.9 Hz, 
2xH-5), 1.48 (s, 3H, CH3 Me), 1.30 (s, 3H, CH3 Me); 13C-APT NMR (CDCl3, 101 MHz, HSQC): δ 138.4, 137.5 (Cq Bn), 128.5, 
128.3, 128.0, 127.9, 127.8, 127.5 (CHarom), 113.5 (Cq), 104.7 (C-1), 80.0 (C-4), 78.4 (C-2), 77.2 (C-3), 73.3, 72.6 (CH2 Bn), 
69.9 (C-5), 26.6, 26.1 (Me); HRMS: [M+NH4]+ calcd for C22H30NO5 388.21185, found 388.21226. 
Methyl 3,5-di-O-benzyl-α-D-lyxofuranoside (13). Fully protected compound 12 (7.8 g, 21 mmol, 
1 eq.) and CSA (0.46 g, 2.0 mmol, 0.1 eq.) were dissolved in 100 mL MeOH and brought to reflux. 
After stirring for 5 h, the reaction mixture was cooled down and solid NaHCO3 was added. The 
reaction mixture was concentrated and then H2O was added. Extraction with EtOAc twice and those combined organic 
layers were washed with brine, then dried with MgSO4, filtered, and concentrated in vacuo. Purification by flash 
column chromatography (19/1 to 8/2 pentane/EtOAc) afforded the title compound (6.1 g, 17.7 mmol, 84%) as a 
colourless oil and a single anomer. Spectroscopic data were in accord with those previously reported.56 1H NMR (CDCl3, 
400 MHz, HH-COSY, HSQC): δ 7.39 – 7.24 (m, 10H, CHarom), 4.86 (s, 1H, H-1), 4.72 (d, 1H, J = 11.4 Hz, CHH Bn), 4.64 (d, 
1H, J = 11.8 Hz, CHH Bn), 4.55 (d, 1H, J = 11.8 Hz, CHH Bn), 4.48 (d, 1H, J = 11.4 Hz, CHH Bn), 4.40 (dd, 1H, J = 8.0, 4.9 
Hz, H-3), 4.35 – 4.28 (m, 2H, H-4, 2-OH), 4.05 (dd, 1H, J = 10.2, 4.9 Hz, H-2), 3.67 (dd, 1H, J = 10.5, 3.3 Hz, H-5), 3.61 
(dd, 1H, J = 10.5, 2.3 Hz, H-5), 3.34 (s, 3H, CH3 OMe); 13C-APT NMR (CDCl3, 101 MHz, HSQC): δ 137.9, 137.3 (Cq), 128.6, 
128.5, 128.0, 128.0, 127.9 (CHarom), 108.6 (C-1), 77.8 (C-3), 77.5 (C-4), 74.0, 72.6 (CH2 Bn), 72.2 (C-2), 68.0 (C-5), 55.2 
(OMe). 
Methyl 3,5-di-O-benzyl-2-O-trifluoromethanesulfonate-α-D-ribofuranoside (14). The title 
compound was generated by the general procedure for triflate formation and used crude. 
Spectroscopic data were in accord with those previously reported.57 1H NMR (CDCl3, 400 MHz, 
HH-COSY, HSQC): δ 7.37 – 7.21 (m, 10H, CHarom), 5.09 (d, 1H, J = 4.3 Hz, H-1), 5.01 (dd, 1H, J = 6.5, 4.3 Hz, H-2), 4.75 
(d, 1H, J = 12.2 Hz, CHH Bn), 4.53 – 4.44 (m, 2H, CHH Bn, CHH Bn), 4.40 (d, 1H, J = 12.0 Hz, CHH Bn), 4.19 (dt, 1H, J = 
5.8, 3.1 Hz, H-4), 4.07 (dd, 1H, J = 6.5, 5.0 Hz, H-3), 3.53 (dd, 1H, J = 10.9, 2.9 Hzm H-5), 3.51 (s, 3H, CH3 OMe), 3.33 
(dd, 1H, J = 10.8, 3.3 Hz, H-5); 13C-APT NMR (CDCl3, 101 MHz, HSQC): δ 137.7, 137.1 (Cq), 128.7, 128.6, 128.4, 128.3, 
128.0, 127.9 (CHarom), 118.7 (d, J = 319.6 Hz), 101.1 (C-1), 81.4 (C-2), 81.1 (C-4), 74.6 (C-3), 73.7, 73.5 (CH2 Bn), 68.5 
(C-5), 56.4 (OMe); HRMS: [M+NH4]+ calcd for C21H27F3NO7S 494.14548, found 494.14526. 
Methyl 3,5-di-O-benzyl-2-O-trifluoromethanesulfonate-α/β-D-arabinofuranoside (15). The title 
compound was generated by the general procedure for triflate formation and used crude. Data 
for the α-anomer: 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC): δ 7.38 – 7.23 (m, 10H, CHarom), 
5.20 (s, 1H, H-2), 5.10 (s, 1H, H-1), 4.70 (d, 1H, J = 11.9 Hz, CHH Bn), 4.55 (d, 1H, J = 12.1 Hz, CHH Bn), 4.52 – 4.45 (m, 
2H, 2x CHH Bn), 4.22 – 4.18 (m, 1H, H-4), 4.13 (ddd, 1H, J = 5.9, 1.7, 0.9 Hz, H-3), 3.61 (dd, 1H, J = 10.9, 3.6 Hz, H-5), 
3.54 (dd, 1H, J = 10.9, 4.6 Hz, H-5), 3.42 (s, 3H, CH3 OMe); 13C-APT NMR (CDCl3, 101 MHz, HSQC): δ 137.8, 136.7 (Cq), 
128.7, 128.5, 128.3, 128.1, 127.9, 127.9 (CHarom), 118.5 (q, J = 319.8 Hz), 105.9 (C-1), 92.7 (C-2), 82.6 (C-3), 81.8 (C-4), 
73.7, 72.8 (CH2 Bn), 68.6 (C-5), 55.2 (OMe); Diagnostic peaks β-anomer: 1H NMR (CDCl3, 400 MHz): δ 5.11 – 5.07 (m, 
1H, H-1), 5.00 (d, 1H, J = 4.4 Hz, H-2), 4.62 (d, 1H, J = 11.8 Hz, CHH Bn), 4.57 (d, 1H, J = 11.8 Hz, CHH Bn), 4.55 – 4.48 
(m, 2H, CH2 Bn), 4.29 (dd, 1H, J = 6.5, 5.4 Hz, H-3), 4.17 – 4.12 (m, 1H, H-4), 3.57 – 3.53 (m, 1H, H-5), 3.47 (dd, 1H, J = 
9.9, 6.2 Hz, H-5), 3.39 (s, 3H, CH3 OMe); 13C-APT NMR (CDCl3, 101 MHz, HSQC): δ 100.4 (C-1), 88.3 (C-2), 80.9 (C-3), 
79.8 (C-4), 73.5, 72.6 (CH2 Bn), 71.4 (C-5), 55.5 (OMe). 
Methyl 3,5-di-O-benzyl-2-O-trifluoromethanesulfonate-α/β-D-xylofuranoside (16). The title 
compound was generated by the general procedure for triflate formation (anomers were 
treated separately) and used crude. Data for the α-anomer: 1H NMR (CDCl3, 400 MHz, HH-COSY, 
HSQC): δ 7.37 – 7.21 (m, 10H, CHarom), 5.18 (t, 1H, J = 5.1 Hz, H-2), 5.06 (d, 1H, J = 4.4 Hz, H-1), 4.66 (d, 1H, J = 11.7 Hz, 
CHH Bn), 4.57 (d, 1H, J = 12.0 Hz, CHH Bn), 4.55 – 4.50 (m, 2H, 2xCHH Bn), 4.44 (dd, 1H, J = 6.9, 5.8 Hz, H-3), 4.33 (dt, 
1H, J = 7.0, 4.6 Hz, H-4), 3.67 (dd, 1H, J = 10.5, 4.2 Hz, H-5), 3.59 (dd, 1H, J = 10.5, 5.1 Hz, H-5), 3.44 (s, 3H, CH3 OMe); 
13C-APT NMR (CDCl3, 101 MHz, HSQC): δ 137.9, 136.9 (Cq), 128.7, 128.5, 128.3, 127.9, 127.8, 127.8 (CHarom), 118.6 (q, 
J = 319.6 Hz), 99.6 (C-1), 87.9 (C-2), 79.3 (C-3), 75.7 (C-4), 73.7, 73.3 (CH2 Bn), 68.4 (C-5), 56.0 (OMe); Data for the β-
anomer: 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC): δ 7.42 – 7.23 (m, 10H, CHarom), 5.17 (s, 1H, H-2), 5.05 (s, 1H, H-
1), 4.71 (d, 1H, J = 12.1 Hz, CHH Bn), 4.59 (d, 1H, J = 12.0 Hz, CHH Bn), 4.54 (d, 1H, J = 12.0 Hz, CHH Bn), 4.53 (d, 1H, J 
= 12.1 Hz, CHH Bn), 4.48 (dt, 1H, J = 6.7, 5.5 Hz, H-4), 4.21 (dd, 1H, J = 5.9, 1.8 Hz, H-3), 3.74 (dd, 1H, J = 10.3, 5.1 Hz, 
H-5), 3.69 (dd, 1H, J = 10.3, 7.0 Hz, H-5), 3.42 (s, 3H, CH3 OMe); 13C-APT NMR (CDCl3, 101 MHz, HSQC): δ 138.0, 136.6,
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128.7, 128.5, 128.4, 128.1, 128.0, 127.9, 106.4, 91.2, 80.6, 80.4, 73.7, 72.8, 69.2, 56.1; HRMS: [M+NH4]+ calcd for 
C21H27F3NO7S 494.14548, found 494.14515. 
Methyl 3,5-di-O-benzyl-2-O-trifluoromethanesulfonate-α-D-lyxofuranoside (17). The title 
compound was generated by the general procedure for triflate formation and used crude. 1H 
NMR (CDCl3, 400 MHz, HH-COSY, HSQC): δ 7.43 – 7.13 (m, 10H, CHarom), 5.08 (s, 1H, H-1), 5.05 
(d, 1H, J = 4.3 Hz, H-2), 4.73 (d, 1H, J = 11.7 Hz, CHH Bn), 4.63 (d, 1H, J = 12.0 Hz, CHH Bn), 4.51 (d, 1H, J = 11.7 Hz, 
CHH Bn), 4.50 (d, 1H, J = 12.0 Hz, CHH Bn), 4.46 – 4.37 (m, 2H, H-3, H-4), 3.74 (dd, 1H, J = 10.5, 4.1 Hz, H-5), 3.64 (dd, 
1H, J = 10.5, 7.3 Hz, H-5), 3.38 (s, 3H, CH3 OMe); 13C-APT NMR (CDCl3, 101 MHz, HSQC): δ 138.0, 136.9 (Cq), 128.7, 
128.5, 128.3, 128.0, 128.0, 127.8 (CHarom), 118.6 (q, J = 319.6 Hz, CF3), 104.0 (C-1), 86.2 (C-2), 77.5 (C-4), 76.4 (C-3), 
73.9, 73.7 (CH2 Bn), 69.6 (C-5), 55.7 (OMe). 
Methyl 3,5-di-O-benzyl-2-deoxy-2-fluoro-α-D-arabinofuranoside (18). Employing conditions A of 
the general experimental for inversion of furanosyl triflates gave 18 in 86% yield (0.95 mmol) 
from triflate 14. Spectroscopic data were in accord with those previously reported.24 IR (thin 
film): 696, 737, 947, 988, 1039, 1055, 1098, 1193, 1364, 1454, 2862, 2922; 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC): 
δ 7.37 – 7.25 (m, 10H, CHarom), 5.06 (d, 1H, J = 12.0 Hz, H-1), 4.94 (dd, 1H, J = 51.3, 1.8 Hz, H-2), 4.67 (d, 1H, J = 12.0 
Hz, CHH Bn), 4.58 (d, 1H, J = 12.1 Hz, CHH Bn), 4.56 – 4.51 (m, 2H, 2xCHH Bn), 4.21 (ddd, 1H, J = 6.4, 5.2, 3.8 Hz, H-4), 
3.99 (dddd, 1H, J = 24.7, 6.4, 1.9, 1.0 Hz, H-3), 3.63 (dd, 1H, J = 10.8, 3.8 Hz, H-5), 3.58 (dd, 1H, J = 10.8, 5.1 Hz, H-5), 
3.40 (s, 3H, CH3 OMe); 13C-APT NMR (CDCl3, 126 MHz, HSQC): δ 138.0, 137.2 (Cq), 128.5, 128.4, 128.0, 127.7, 127.7 
(CHarom), 106.5 (d, J = 36.0 Hz, C-1), 99.6 (d, J = 181.3 Hz, C-2), 83.0 (d, J = 25.6 Hz, C-3), 81.3 (d, J = 4.0 Hz, C-4), 73.4, 
72.5 (CH2 Bn), 69.3 (C-5), 54.9 (OMe); 19F NMR (CDCl3, 471 MHz): δ -188.39 (ddd, J = 51.3, 24.6, 12.0 Hz); 13C HSQC-
HECADE NMR (CDCl3, 126 MHz): 2JC1-H2 = -0.7 Hz, 2JC2-H1 = -2.0 Hz; HRMS: [M+NH4]+ calcd for C20H27NFO4 364.19186, 
found 364.19196. 
Methyl 3,5-di-O-benzyl-2-deoxy-2-fluoro-α/β-D-ribofuranoside (19). Employing conditions A of 
the general experimental for inversion of furanosyl triflates gave 19 in 63% yield (3.2 mmol), as 
two anomers (Rf: 0.47, and Rf: 0.15, 9/1 pentane/EtOAc) and two anomers of 26. Spectroscopic 
data were in accord with those previously reported for the β-anomer.22 Data for the α-anomer: 1H NMR (CDCl3, 400 
MHz, HH-COSY, HSQC): δ 7.41 – 7.27 (m, 10H, CHarom), 5.09 (dd, 1H, J = 4.1, 3.5 Hz, H-1), 4.88 (ddd, 1H, J = 51.1, 6.1, 
4.2 Hz), 4.82 (d, 1H, J = 12.4 Hz, CHH Bn), 4.59 (d, 1H, J = 12.4 Hz, CHH Bn), 4.58 (d, 1H, J = 12.1 Hz, CHH Bn), 4.49 (d, 
1H, J = 12.1 Hz, CHH Bn), 4.30 (dt, 1H, J = 5.3, 3.4 Hz, H-4), 4.00 (ddd, 1H, J = 7.6, 6.0, 5.2 Hz, H-3), 3.63 (dd, 1H, J = 
10.9, 2.9 Hz, H-5), 3.56 (s, 3H, CH3 OMe), 3.49 (dd, 1H, J = 10.8, 3.7 Hz, H-5); 13C-APT NMR (CDCl3, 101 MHz, HSQC): δ 
137.9, 137.8 (Cq), 128.5, 128.5, 128.0, 128.0, 127.8, 127.7 (CHarom), 101.8 (d, J = 15.9 Hz, C-1), 88.2 (d, J = 202.7 Hz, C-
2), 80.9 (d, J = 2.1 Hz, C-4), 74.6 (d, J = 14.8 Hz, C-3), 73.6 (CH2 5-OBn), 72.9 (d, J = 2.2 Hz, CH2 3-OBn), 69.1 (C-5), 56.1 
(OMe); 19F NMR (CDCl3, 470 MHz): δ -216.73 (ddd, J = 51.2, 7.6, 3.3 Hz); 13C HSQC-HECADE NMR (CDCl3, 126 MHz): 
2JC1-H2: +2.4 Hz, 2JC2-H1: -+3.2 Hz; Data for the β-anomer: 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC): δ 7.35 – 7.26 (m, 
10H, CHarom), 5.00 (d, 1H, J = 10.6 Hz, H-1), 4.76 (dd, 1H, J = 53.2, 3.7 Hz, H-2), 4.66 (d, 1H, J = 11.7 Hz, CHH Bn), 4.59 
(d, 1H, J = 12.1 Hz, CHH Bn), 4.54 (d, 1H, J = 12.1 Hz, CHH Bn), 4.54 (d, 1H, J = 11.7 Hz, CHH Bn), 4.30 (ddd, 1H, J = 8.0, 
5.7, 3.4 Hz, H-4), 4.07 (ddd, 1H, J = 24.6, 7.7, 3.7 Hz, H-3), 3.64 (dd, 1H, J = 10.6, 3.4 Hz, H-5), 3.53 (dd, 1H, J = 10.6, 
5.7 Hz, H-5), 3.32 (s, 3H, CH3 OMe); 13C-APT NMR (CDCl3, 101 MHz, HSQC): δ 138.3, 137.4 (Cq), 128.6, 128.4, 128.1, 
128.0, 127.7 (CHarom), 105.7 (d, J = 29.3 Hz, C-1), 91.2 (d, J = 185.1 Hz, C-2), 80.1 (C-4), 77.8 (d, J = 15.6 Hz, C-3), 73.3, 
72.8 (CH2 Bn), 71.0 (C-5), 55.1 (OMe); 19F NMR (CDCl3, 471 MHz): δ -209.71 (ddd, J = 53.2, 24.6, 10.6 Hz); 13C HSQC-
HECADE NMR (CDCl3, 126 MHz): 2JC1-H2: +1.6 Hz, 2JC2-H1: -1.6 Hz; HRMS: [M+NH4]+ calcd for C20H24FNO4 364.19186, 
found 364.19205. 
Methyl 3,5-di-O-benzyl-2-deoxy-2-fluoro-α-D-lyxofuranoside (20). Employing conditions B of the 
general experimental for inversion of furanosyl triflates, with an additional 70°C reflux for 7 h, 
gave 20 in 44% yield (2.19 mmol) from triflate 16α. Conditions A yielded 57% 28 and 21% 30. IR 
(thin film): 698, 739, 1056, 1452, 2932; 1H NMR (CDCl3, 500 MHz, HH-COSY, HSQC): δ 7.40 – 7.24 (m, 10H, CHarom), 
5.08 (dd, 1H, J = 10.0, 1.0 Hz, H-1), 4.80 (ddd, 1H, J = 52.8, 4.1, 1.0 Hz, H-2), 4.68 (d, 1H, J = 11.9 Hz, CHH Bn), 4.65 (d, 
1H, J = 12.1 Hz, CHH Bn), 4.53 (d, 1H, J = 11.8 Hz, CHH Bn), 4.52 (d, 1H, J = 12.1 Hz, CHH Bn), 4.42 (ddd, 1H, J = 8.0, 7.1, 
3.8 Hz, H-4), 4.30 (ddd, 1H, J = 20.9, 7.1, 4.1 Hz, H-3), 3.77 (dd, 1H, J = 10.5, 3.8 Hz, H-5), 3.67 (ddd, 1H, J = 10.5, 8.0, 
1.4 Hz, H-5); 13C-APT NMR (CDCl3, 126 MHz, HSQC): δ 138.4, 137.5 (Cq), 128.6, 128.5, 128.1, 128.0, 127.8, 127.7 
(CHarom), 105.0 (d, J = 29.8 Hz, C-1), 92.4 (d, J = 187.9 Hz, C-2), 77.7 (C-4), 77.1 (d, J = 14.9 Hz, C-3), 73.6, 73.3 (CH2 Bn), 







HSQC-HECADE NMR (CDCl3, 126 MHz): 2JC2,H1 = -2.5 Hz; HRMS: [M+Na]+ calcd for C20H23FO4Na 369.14726, found 
369.14734. 
Methyl 3,5-di-O-benzyl-2-deoxy-2-fluoro-β-D-xylofuranoside (21). Employing conditions A of the 
general experimental for inversion of furanosyl triflates gave 21 in 10% yield (0.52 mmol) as the 
minor product from triflate 16β. IR (thin film): 698, 712, 978, 1068, 1107, 2929; 1H NMR (CDCl3, 
500 MHz, HH-COSY, HSQC): δ 7.37 – 7.26 (m, 10H, CHarom), 5.02 (d, 1H, J = 14.8 Hz, H-1), 4.93 (d, 1H, J = 50.6 Hz, H-2), 
4.68 (d, 1H, J = 12.2 Hz, CHH Bn), 4.60 (d, 1H, J = 12.0 Hz, CHH Bn), 4.55 (d, 1H, J = 12.0 Hz, CHH Bn), 4.54 (d, 1H, J = 
12.1 Hz, CHH Bn), 4.52 – 4.48 (m, 1H, H-4), 4.15 (ddd, 1H, J = 18.2, 6.1, 1.7 Hz, H-3), 3.76 (dd, 1H, J = 10.3, 4.9 Hz, H-
5), 3.70 (dd, 1H, J = 10.3, 7.3 Hz, H-5), 3.41 (s, 3H, CH3 OMe); 13C-APT NMR (CDCl3, 126 MHz, HSQC): δ 138.3, 137.4 
(Cq), 128.6, 128.5, 128.1, 127.9, 127.9, 127.8 (CHarom), 107.1 (d, J = 35.2 Hz, C-1), 98.4 (d, J = 181.0 Hz, C-2), 80.9 (d, J 
= 25.9 Hz, C-3), 80.7 (d, J = 1.9 Hz, C-4), 73.6, 72.7 (CH2 Bn), 69.7 (C-5), 55.8 (OMe); 19F NMR (CDCl3, 471 MHz): δ -
192.85 (ddd, J = 50.6, 18.1, 14.9 Hz); 13C HSQC-HECADE NMR (CDCl3, 126 MHz): 2JC1,H2 = -2.6 Hz, 2JC2,H1 = -0.2 Hz; HRMS: 
[M+NH4]+ calcd for C20H27FNO4 364.19186, found 364.19192. 
Methyl 2-azido-3,5-di-O-benzyl-2-deoxy-α-D-arabinofuranoside (22). Employing conditions C of 
the general experimental for inversion of furanosyl triflates gave 22 in 93% yield (5.37 mmol) 
from triflate 14. [α]  = +76.4° (c = 1.0, CHCl3). IR (thin film): 698, 714, 1026, 1070, 1097, 1107, 
1271, 1452, 2104, 2932; 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC): δ 7.35 – 7.23 (m, 10H, CHarom), 4.88 (d, 1H, J = 
1.5 Hz, H-1), 4.61 (d, 1H, J = 12.0 Hz, CHH Bn), 4.56 (d, 1H, J = 12.1 Hz, CHH Bn), 4.49 (d, 1H, J = 12.2 Hz, CHH Bn), 4.49 
(d, 1H, J = 12.0 Hz, CHH Bn), 4.23 – 4.15 (m, 1H, H-4), 3.92 – 3.85 (m, 2H, H-2, H-3), 3.60 (dd, 1H, J = 10.8, 3.6 Hz, H-
5), 3.54 (dd, 1H, J = 10.8, 4.8 Hz, H-5), 3.39 (s, 3H, CH3 OMe); 13C-APT NMR (CDCl3, 101 MHz, HSQC): δ 137.9, 137.2 
(Cq), 128.5, 128.4, 128.0, 128.0, 127.8, 127.7 (CHarom), 107.0 (C-1), 83.1 (C-3), 81.2 (C-4), 73.5, 72.6 (CH2 Bn), 70.8 (C-
2), 69.0 (C-5), 55.3 (OMe); 13C HSQC-HECADE NMR (CDCl3, 126 MHz): 2JC1,H2 = -2.1 Hz, 2JC2,H1 = -0.3 Hz; HRMS: [M+NH4]+ 
calcd for C20H27N4O4 387.20268, found 387.20271. 
Methyl 2-azido-3,5-di-O-benzyl-2-deoxy-α/β-D-ribofuranoside (23). Employing conditions C of 
the general experimental for inversion of furanosyl triflates gave 23 as an α:β = 1:2 mixture from 
triflate 15, and as a 4:1 mixture of 23 and 27, combined yield 86% (4.3 mmol). IR (thin film): 698, 
740, 1028, 1066, 1107, 1271, 1452, 2108, 2918; Data for the α-anomer (intermixed with 27, vide infra): 1H NMR (CDCl3, 
400 MHz, HH-COSY, HSQC): δ 7.35 – 7.20 (m, 10H, CHarom), 5.03 (d, 1H, J = 4.6 Hz, H-1), 4.76 (d, 1H, J = 12.5 Hz, CHH 
Bn), 4.58 (d, 1H, J = 12.5 Hz, CHH Bn), 4.47 (d, 1H, J = 12.1 Hz, CHH Bn), 4.40 (d, 1H, J = 12.1 Hz, CHH Bn), 4.30 – 4.22 
(m, 1H, H-4), 3.99 (dd, 1H, J = 7.2, 3.7 Hz, H-3), 3.49 (s, 3H, OMe), 3.45 (dd, 1H, J = 10.5, 3.7 Hz, H-5), 3.36 – 3.28 (m, 
2H, H-2, H-5); 13C-APT NMR (CDCl3, 101 MHz, HSQC): δ 137.8, 137.6 (Cq), 128.4, 128.4, 128.0, 128.0, 127.7 (CHarom), 
104.5 (C-1), 82.5 (C-4), 77.8 (C-3), 73.5, 72.9 (CH2 Bn), 69.5 (C-5), 61.0 (C-2), 55.7 (OMe); Data for the β-anomer: 1H 
NMR (CDCl3, 400 MHz, HH-COSY, HSQC): δ 7.38 – 7.23 (m, 10H, CHarom), 4.83 (s, 1H, H-1), 4.63 (d, 1H, J = 11.7 Hz, CHH 
Bn), 4.56 (d, 1H, J = 12.1 Hz, CHH Bn), 4.51 (d, 1H, J = 12.1 Hz, CHH Bn), 4.51 (d, 1H, J = 11.7 Hz, CHH Bn), 4.28 – 4.21 
(m, 2H, H-3, H-4), 3.80 (d, 1H, J = 3.8 Hz, H-2), 3.59 – 3.54 (m, 1H, H-5), 3.52 – 3.47 (m, 1H, H-5), 3.29 (s, 3H, CH3 OMe); 
13C-APT NMR (CDCl3, 101 MHz, HSQC): δ 138.1, 137.3 (Cq), 128.5, 128.4, 128.1, 127.9, 127.6 (CHarom), 106.6 (C-1), 80.7 
(C-4), 79.8 (C-3), 73.2, 73.0 (CH2 Bn), 71.2 (C-5), 64.6 (C-2), 55.0 (OMe); HRMS: [M-N2+H]+ calcd for C20H24NO4 
387.20268, found 387.20275. 
Methyl 2-azido-3,5-di-O-benzyl-2-deoxy-α-D-lyxofuranoside (24). Employing conditions C of the 
general experimental for inversion of furanosyl triflates, with additional 16 h stirring, gave 24 in 
67% yield (3.36 mmol) from triflate 16α, and side products 29α (12%) and 30 (7%). Spectroscopic 
data were in accord with those previously reported.58 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC): δ 7.34 – 7.27 (m, 
10H, CHarom), 4.95 (d, 1H, J = 2.1 Hz, H-1), 4.69 (d, 1H, J = 11.7 Hz, CHH Bn), 4.60 (d, 1H, J = 11.9 Hz, CHH Bn), 4.52 (d, 
1H, J = 11.7 Hz, CHH Bn), 4.49 (d, 1H, J = 12.0 Hz, CHH Bn), 4.38 – 4.31 (m, 2H, H-3, H-4), 3.79 – 3.66 (m, 3H, H-2, H-5, 
H-5), 3.36 (s, 3H, CH3 OMe); 13C-APT NMR (CDCl3, 101 MHz, HSQC): δ 138.1, 137.4 (Cq), 128.5, 128.4, 128.0, 127.9,
127.8, 127.7 (CHarom), 105.9 (C-1), 79.0 (C-3), 78.2 (C-4), 73.9, 73.6 (CH2 Bn), 69.2 (C-5), 65.9 (C-2), 55.6 (OMe); 13C 
HSQC-HECADE NMR (CDCl3, 126 MHz): 2JC1,H2 = -3.2 Hz, 2JC2,H1 = -0.1 Hz, 3JC1,H3 = +2.3 Hz, 3JC3,H1 = +2.4 Hz; HRMS:
[M+Na]+ calcd for C20H23N3O4 392.15808, found 392.15787. 
(2-Methyl-2-butyl) 3,5-di-O-benzyl-2-methyl-α/β-D-ribofuranoside (26). Formed as an 88:12 
α:β anomeric mixture. Data for the isolated α-anomer: [α]  = +86.3° (c = 0.35, CHCl3).IR 
(thin film): 698, 739, 1026, 1042, 1109, 1211, 1454, 2928, 2970; 1H NMR (CDCl3, 500 MHz, 
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Hz, CHH Bn), 4.55 – 4.49 (m, 2H, CHH Bn, CHH Bn), 4.42 (d, 1H, J = 12.1 Hz, CHH Bn), 4.22 (q, 1H, J = 3.9 Hz, H-4), 3.91 
(dd, 1H, J = 6.5, 4.5 Hz, H-3), 3.57 (dd, 1H, J = 6.5, 4.2 Hz, H-2), 3.50 – 3.44 (m, 4H, CH3 OMe, H-5), 3.36 (dd, 1H, J = 
10.6, 3.9 Hz, H-5), 1.60 (q, 2H, J = 7.5 Hz, CH2CH3 t-amyl), 1.26 (s, 3H, CH3 t-amyl), 1.24 (s, 3H, CH3 t-amyl), 0.93 (t, 3H, 
J = 7.5 Hz, CH2CH3 t-amyl); 13C-APT NMR (CDCl3, 126 MHz, HSQC): δ 138.5, 138.2 (Cq), 128.3, 128.2, 128.0, 127.6, 
127.5, 127.5 (CHarom), 95.9 (C-1), 80.6, 80.5 (C-2, C-4), 77.0 (Cq t-amylOH)75.7 (C-3), 73.3, 72.2 (CH2 Bn), 70.0 (C-5), 
58.8 (OMe), 34.5 (CH2 t-amyl), 26.1, 25.9 (CqCH3 t-amyl), 8.6 (CH2CH3 t-amyl); HRMS: [M+Na]+ calcd for C25H34O5Na 
437.22985, found 437.22953. 
1-Azido 3,5-di-O-benzyl-1-deoxy-2-methyl-β-D-ribofuranoside (27). Intermixed with 24. (vide 
supra). 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC): δ 7.34 – 7.20 (m, 10H, CHarom), 5.32 (d, 1H, J 
= 1.9 Hz, H-1), 4.60 – 4.56 (m, 2H, 2xCHH Bn), 4.53 (d, 1H, J = 11.9 Hz, CHH Bn), 4.51 (d, 1H, J =
12.2 Hz, CHH Bn), 4.29 – 4.22 (m, 1H, H-4), 4.08 (dd, 1H, J = 6.9, 4.6 Hz, H-3), 3.64 (dd, 1H, J = 10.8, 3.3 Hz, H-5), 3.52 
(dd, 1H, J = 10.9, 4.6 Hz, H-5), 3.50 – 3.47 (m, 1H, H-2), 3.40 (s, 3H, CH3 OMe); 13C-APT NMR (CDCl3, 101 MHz, HSQC): 
δ 138.1, 137.5 (Cq), 128.4, 128.4, 128.0, 127.9, 127.8, 127.6 (CHarom), 92.2 (C-1), 82.5 (C-2), 81.3 (C-4), 77.1 (C-3), 73.4, 
72.7 (CH2 Bn), 69.8 (C-5), 58.3 (OMe); After hydrolysis of the mixture of 24 an 27, 3,5-di-O-benzyl-2-O-methyl-α/β-D-
ribofuranose could be isolated as a α:β = 1:0.7 anomeric mixture. Spectroscopic data were in accord with those 
previously reported.59 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC): δ 7.39 – 7.22 (m, 17H), 5.32 (dd, 1H, J = 11.2, 4.1 
Hz, H-1α), 5.28 (d, 0.7H, J = 6.4 Hz, H-1β), 4.68 (d, 1H, J = 11.9 Hz, CHH Bnα), 4.63 (d, 0.7H, J = 12.0 Hz, CHH Bnβ), 4.61 
(d, 1H, J = 11.9 Hz, CHH Bnα), 4.59 – 4.42 (m, 4.1H, CH2 Bnα,β, CHH Bnβ), 4.35 (td, 1H, J = 4.2, 2.4 Hz, H-4α), 4.27 – 4.17 
(m, 1.4H, H-3β, H-4β), 4.12 (d, 1H, J = 11.2 Hz, 1-OHα), 4.01 (dd, 1H, J = 5.0, 2.4 Hz, H-3α), 3.78 (dd, 1H, J = 4.9, 4.3 Hz, 
H-2α), 3.67 – 3.59 (m, 2.1H, H-2β, H-5β, 1-OHβ), 3.52 – 3.43 (m, 7.8H, CH3 OMeα,β, H-5β, 2xH-5α); 13C-APT NMR (CDCl3, 
101 MHz, HSQC): δ 137.9, 137.8, 137.5, 137.4 (Cq), 128.6, 128.6, 128.5, 128.5, 128.1, 128.0, 128.0, 127.9, 127.8, 127.7 
(CHarom), 99.7 (C-1β), 96.1 (C-1α), 83.4 (C-2β), 81.0 (C-4α), 80.7 (C-3β), 80.2 (C-2β), 77.4 (C-3α), 77.2 (C-4β), 73.6, 73.5, 
72.8, 72.7 (CH2 Bn), 70.0 (C-5α), 69.6 (C-5β), 58.6, 58.4 (OMe); HRMS: [M+Na]+ calcd for C20H24O5Na 367.15160, found
367.15164. 
Methyl 2,5-di-O-benzyl-5-deoxy-5-fluoro-α/β-D-lyxofuranoside (28). Data for the α-anomer: m.p. 
62-64 °C. [α]  = +16.6° (c = 0.62, CHCl3); IR (thin film): 698, 737, 1009, 1026, 1069, 1107, 1150,
1454, 2922, 3032; 1H NMR (CDCl3, 500 MHz, HH-COSY, HH-NOESY, HSQC): δ 7.36 – 7.28 (m, 10H, 
CHarom), 5.00 (d, 1H, J = 1.6 Hz, H-1), 4.74 – 4.62 (m, 4H, 2xCHH Bn, H-5, H-5), 4.60 (d, 1H, J = 11.9 Hz, CHH Bn), 4.50 
(d, 1H, J = 11.8 Hz, CHH Bn), 4.44 (dtd, 1H, J = 15.6, 6.8, 4.4 Hz, H-4), 4.30 (dd, 1H, J = 6.6, 4.6 Hz, H-3), 3.88 (dt, 1H, J 
= 4.6, 1.6 Hz, H-2), 3.36 (s, 3H, CH3 OMe); 13C-APT NMR (CDCl3, 126 MHz, HSQC): δ 137.8, 137.7 (Cq), 128.5, 128.5, 
128.0, 127.9, 127.8, 127.8 (CHarom), 106.2 (C-1), 84.0 (d, J = 164.8 Hz, C-5), 81.1 (C-2), 77.8 (d, J = 7.1 Hz, C-3), 77.3 (d, 
J = 20.2 Hz, C-4), 73.2, 72.7 (CH2 Bn), 55.5 (OMe); 19F NMR (CDCl3, 471 MHz): δ -228.75 (td, J = 47.6, 15.7 Hz); 13C 
HSQC-HECADE NMR: 2JC1,H2 = -0.8 Hz, 2JC2,H1 = -0.8 Hz; HRMS: [M+NH4]+ calcd for C20H27NFO4 364.19186, found 
364.19199. Data for the β-anomer: [α]  = -100.5° (c = 0.95, CHCl3); IR (thin film): 698, 737, 1003, 1066, 1109, 1163, 
1348, 1454, 2910, 2924; 1H NMR (CDCl3, 500 MHz, HH-COSY, HH-NOESY, HSQC): δ 7.37 – 7.27 (m, 10H, CHarom), 4.84 
(dd, 1H, J = 4.5, 1.2 Hz, H-1), 4.82 (d, 1H, J = 12.5 Hz, CHH Bn), 4.70 – 4.64 (m, 2H, CHH Bn, H-5), 4.63 – 4.59 (m, 2H, 
2xCHH Bn), 4.59 – 4.52 (m, 1H, H-5), 4.28 (dddd, 1H, J = 14.4, 7.0, 6.0, 5.1 Hz, H-4), 4.11 (t, 1H, J = 6.0 Hz, H-3), 3.80 
(dd, 1H, J = 5.9, 4.5 Hz, H-2), 3.46 (s, 3H, CH3 OMe); 13C-APT NMR (CDCl3, 126 MHz, HSQC): δ 138.2, 137.7 (Cq), 128.6, 
128.5, 128.3, 128.1, 128.0, 127.9 (CHarom), 101.7 (C-1), 83.8 (d, J = 165.6 Hz, C-5), 79.1 (d, J = 0.9 Hz, C-2), 78.5 (d, J = 
21.4 Hz, C-4), 74.7 (d, J = 6.0 Hz, C-3), 73.9, 72.7 (CH2 Bn), 55.8 (OMe); 19F NMR (CDCl3, 471 MHz): δ -227.76 (td, J = 
47.5, 14.4 Hz); HRMS: [M+NH4]+ calcd for C20H27NFO4 364.19186, found 364.19178. 
Methyl 5-azido-2,5-di-O-benzyl-5-deoxy-α/β-D-lyxofuranoside (29). Data for the α-anomer: IR (thin 
film):695, 734, 923, 1047, 1101, 1145, 1270, 1454, 2095; 1H NMR (CDCl3, 400 MHz, HH-COSY, 
HSQC, HMBC): δ 7.38 – 7.24 (m, 10H, CHarom), 4.98 (d, 1H, J = 1.6 Hz, H-1), 4.71 – 4.63 (m, 2H, 
2xCHH Bn), 4.59 (d, 1H, J = 11.9 Hz, CHH Bn), 4.47 (d, 1H, J = 11.7 Hz, CHH Bn), 4.29 – 4.19 (m, 2H, H-3, H-4), 3.88 (dd, 
1H, J = 4.3, 1.7 Hz, H-2), 3.62 (dd, 1H, J = 12.8, 7.6 Hz, H-5), 3.45 (dd, 1H, J = 12.9, 3.8 Hz, H-5), 3.34 (s, 3H, CH3 OMe); 
13C-APT NMR (CDCl3, 101 MHz, HSQC, HMBC): δ 137.8 (Cq), 128.5, 128.0, 127.9, 127.9, 127.8 (CHarom), 106.1 (C-1), 
81.5 (C-2), 77.9, 77.8 (C-3, C-4), 73.2, 72.8 (CH2 Bn), 55.5 (OMe), 52.1 (C-5); 13C HSQC-HECADE NMR: 2JC1,H2 = -0.9 Hz, 
2JC2,H1 = -1.0 Hz, 2JC3,H2 = +0.7 Hz; HRMS: [M+NH4]+ calcd for C20H27N4O4 387.20268, found 387.20275. Data for the β-
anomer: [α]  = -58.5° (c = 0.48, CHCl3); IR (thin film): 698, 737, 999, 1053, 1105, 1157, 1454, 2096, 2874, 2914, 3030; 
1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC): δ 7.41 – 7.27 (m, 10H, CHarom), 4.89 – 4.83 (m, 2H, CHH Bn, H-1), 4.72 (d, 
1H, J = 12.2 Hz, CHH Bn), 4.62 (d, 1H, J = 12.2 Hz, CHH Bn), 4.58 (d, 1H, J = 12.3 Hz, CHH Bn), 4.13 (ddd, 1H, J = 8.7, 5.9, 
4.3 Hz, H-4), 4.05 (t, 1H, J = 5.9 Hz, H-3), 3.83 (dd, 1H, J = 5.8, 4.5 Hz, H-2), 3.66 (dd, 1H, J = 13.0, 8.7 Hz, H-5), 3.47 (s, 
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3H, CH3 OMe), 3.29 (dd, 1H, J = 13.0, 4.3 Hz, H-5); 13C-APT NMR (CDCl3, 101 MHz, HSQC): δ 138.1, 137.7 (Cq), 128.6, 
128.5, 128.3, 128.1, 128.0, 127.9 (CHarom), 102.0 (C-1), 79.3 (C-4), 79.0 (C-2), 75.0 (C-3), 73.8, 72.8 (CH2 Bn), 55.9 
(OMe), 52.8 (C-5); 13C HSQC-HECADE NMR (CDCl3, 126 MHz): 2JC1,H2 = +1.0 Hz, 2JC2,H1 = +2.5 Hz; HRMS: [M+NH4]+ calcd 
for C20H27N4O4 387.20268, found 387.20272. 
Methyl 2,5-anhydro-3-O-benzyl-α-D-lyxofuranoside (30). [α]  = +88.3° (c = 0.41, CHCl3); IR (thin 
film): 698, 741, 880, 989, 1028, 1051, 1107, 11998, 1454, 2882, 2940; 1H NMR (CDCl3, 400 MHz, 
HH-COSY, HSQC): δ 7.38 – 7.28 (m, 5H, CHarom), 4.74 (s, 1H, H-1), 4.66 (d, 1H, J = 11.7 Hz, CHH Bn), 
4.55 (d, 1H, J = 11.8 Hz, CHH Bn), 4.25 (d, 1H, J = 2.7 Hz, H-4), 4.23 (d, 1H, J = 2.6 Hz, H-3), 4.10 (s, 1H, H-2), 3.99 (d, 
1H, J = 7.8 Hz, H-5), 3.70 (d, 1H, J = 7.8 Hz, H-5), 3.36 (s, 3H, CH3 OMe); 13C-APT NMR (CDCl3, 101 MHz, HSQC): δ 137.7 
(Cq), 128.6, 128.1, 127.9 (CHarom), 106.2 (C-1), 78.6 (C-3), 76.7 (C-2), 75.0 (C-4), 72.5, 70.9 (CH2 Bn), 55.5 (OMe); HRMS: 
[M+NH4]+ calcd for C13H20NO4 254.13868, found 254.13878. 
3-benzyloxy-2-(benzyloxy)methyl-furan (31). Spectroscopic data were in accord with those previously 
reported.57 1H NMR (CDCl3, 400 MHz): δ 7.36 – 7.21 (m, 10H), 7.20 (d, 1H, J = 2.1 Hz), 6.25 (d, 1H, J = 
2.1 Hz), 4.95 (s, 2H), 4.47 (s, 2H), 4.46 (s, 2H). 
Formyl 3,5-di-O-benzyl-2-deoxy-2-fluoro-α/β-D-xylofuranoside (32). Data for the α-anomer: IR 
(thin film):698, 737, 1026, 1088, 1271, 1454, 1732, 2868, 2926; 1H NMR (CDCl3, 500 MHz, HH-
COSY, HSQC): δ 8.09 (d, 1H, J = 0.5 Hz, HC=O), 7.37 – 7.26 (m, 10H, CHarom), 6.45 (dd, 1H, J = 
4.2, 1.9 Hz, H-1), 5.23 (dt, 1H, J = 52.7, 4.7 Hz, H-2), 4.73 (d, 1H, J = 11.9 Hz, CHH Bn), 4.59 – 4.54 (m, 3H, CH2 Bn, CHH 
Bn), 4.53 – 4.50 (m, 1H, H-4), 4.39 (ddd, 1H, J = 15.9, 6.7, 5.0 Hz, H-3), 3.70 (ddd, 1H, J = 10.6, 4.1, 0.8 Hz, H-5), 3.64 
(dd, 1H, J = 10.6, 5.1 Hz, H-5); 13C-APT NMR (CDCl3, 101 MHz, HSQC): δ 159.5 (HC=O), 138.0, 137.2 (Cq), 128.7, 128.2, 
127.8 (CHarom), 93.7 (d, J = 199.3 Hz, C-1), 93.4 (d, J = 17.4 Hz, C-2), 79.4 (d, J = 22.4 Hz, C-3), 78.7 (d, J = 7.1 Hz, C-4), 
73.7, 72.7 (CHarom), 68.1 (C-5); 19F NMR (CDCl3, 471 MHz): -202.33 (dd, 0.3F J = 52.6, 15.9 Hz, F-2α); 13C HSQC-HECADE 
NMR: 2JC1,H2 = +2.8 Hz, 2JC2,H1 = +3.3 Hz; Data for the β-anomer: 1H NMR (CDCl3, 500 MHz, HH-COSY, HSQC): δ 8.03 (dd, 
1H, J = 2.2, 0.9 Hz, HC=O), 7.40 – 7.25 (m, 10H, CHarom), 6.33 (d, 1H, J = 13.3 Hz, H-1), 5.07 (dd, 1H, J = 49.5, 1.4 Hz, H-
2), 4.67 (d, 1H, J = 12.0 Hz, CHH Bn), 4.60 – 4.53 (m, 4H, CHH Bn, CH2 Bn, H-4), 4.22 (ddd, 1H, J = 14.9, 5.6, 1.3 Hz, H-
3), 3.80 (dd, 1H, J = 10.3, 5.4 Hz, H-5), 3.72 (dd, 1H, J = 10.3, 6.5 Hz, H-5); 13C-APT NMR (CDCl3, 101 MHz, HSQC): δ 
159.5 (HC=O), 138.0, 137.0 (Cq), 128.7, 128.5, 128.3, 127.9, 127.8 (CHarom), 98.8 (d, J = 37.3 Hz, C-1), 96.8 (d, J = 184.2 
Hz, C-2), 82.7 (C-4), 79.7 (d, J = 25.7 Hz, C-3), 73.6, 73.0 (CH2 Bn), 68.4 (C-5); 19F NMR (CDCl3, 471 MHz): δ -193.49 – -
193.70 (m, 1F, F-2β); 13C HSQC-HECADE NMR (CDCl3, 126 MHz): 2JC1,H2 = +0.3 Hz, 2JC2,H1 = -1.7 Hz; HRMS: [M+Na]+ calcd 
for C20H21FO5Na 383.1271, found 383.1276. 
3,5-di-O-benzyl-α/β-D-xylofuranose (33). Xyloside 6 (7.6 g, 22 mmol) was dissolved in 20 mL THF 
and 40 mL H2O and cooled to 0°C, followed by the slow addition of 100 mL TFA. After stirring 
overnight, the reaction mixture was partitioned between DCM and H2O, and the aqueous layer 
was extracted three times with DCM. The combined DCM layers were washed with sat. aq. NaHCO3 and brine, dried 
with MgSO4, filtered and concentrated in vacuo. Flash column chromatography (9/1 to 1/1 pentane/EtOAc) afforded 
the title compound (6.1 g, 18.5 mmol, 84%) as a waxy material of a α:β = 70:30 anomeric composition. Spectroscopic 
data were in accord with those previously reported.60 1H NMR (CDCl3, 500 MHz, HH-COSY, HSQC): δ 7.34 – 7.23 (m, 
10H, CHarom), 5.44 (t, 0.7H, J = 4.8 Hz, H-1α), 5.11 (d, 0.3H, J = 10.9 Hz, H-1β), 4.87 (d, 0.7H, J = 5.5 Hz, 1-OHα), 4.66 – 
4.53 (m, 2H, 2xCHH Bnα, 2xCHH Bnβ), 4.52 – 4.43 (m, 2.7H, 2xCHH Bnα, 2xCHH Bnβ, H-4α), 4.40 (q, 0.3H, J = 5.2 Hz, H-
4β), 4.19 (t, 0.3H, J = 2.9 Hz, H-2β), 4.13 – 4.08 (m, 1H, H-2α, 1-OHβ), 3.98 – 3.93 (m, 1H, H-3α, H-3β), 3.77 – 3.70 (m, 
0.6H, H-5β, H-5β), 3.66 – 3.64 (m, 1.4H, H-5α, H-5α), 3.30 (d, 0.7H, J = 5.8 Hz, 2-OHα), 3.14 (d, 0.3H, J = 4.3 Hz, 2-OHβ); 
13C-APT NMR (CDCl3, 126 MHz, HSQC): δ 137.9, 137.7, 137.4 (Cq), 128.6, 128.5, 128.5, 128.5, 128.1, 128.0, 128.0, 
127.9, 127.8, 127.8, 127.8, 127.6 (CHarom), 103.5 (C-1β), 96.1 (C-1α), 83.6 (C-3α), 82.9 (C-3β), 80.0 (C-4β), 79.2 (C-2β), 
77.5 (C-4α), 75.6 (C-2α), 73.7 (CH2 Bnα), 73.6 (CH2 Bnβ), 72.7 (CH2 Bnα), 72.0 (CH2 Bnβ), 69.2 (C-5), 69.1 (C-5α); HRMS: 
[M+Na]+ calcd for C19H22O5Na 353.13594, found 353.13594. 
1,2-O-thiocarbonate-3,5-di-O-benzyl-α/β-D-xylofuranose (34). Diol 33 (1.65 g, 5 mmol, 1 eq.) was 
dissolved in 25 mL DCM and cooled to 0°C. DiPEA (7 ml, 40 mmol, 8 eq.) and DMAP (122 mg, 1 
mmol, 0.2 eq.) were added, followed by the addition of thiophosgene (0.5 mL, 6.25 mmol, 1.25 
eq., dissolved in 25 mL DCM). After 15 min the reaction was complete as concluded from TLC analysis. The reaction 
mixture was diluted with DCM and washed with 1 M aq. HCl, sat. aq. NH4Cl, sat. aq. NaHCO3, and brine. The organic 
layer was dried with Na2SO4, filtered and concentrated in vacuo. Flash column chromatography (19/1 to 8/2 
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pentane/EtOAc) afforded the title compound (1.45 g, 3.9 mmol, 78%) as a light orange oil. Spectroscopic data were in 
accord with those previously reported.61,62 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC): δ 7.38 – 7.25 (m, 10H, CHarom), 
6.40 (d, 1H, J = 4.7 Hz, H-1), 5.08 (d, 1H, J = 4.7 Hz, H-2), 4.65 (d, 1H, J = 11.9 Hz, CHH Bn), 4.60 (d, 1H, J = 11.9 Hz, CHH 
Bn), 4.56 (d, 1H, J = 11.9 Hz, CHH Bn), 4.52 (d, 1H, J = 11.8 Hz, CHH Bn), 4.35 (td, 1H, J = 5.8, 3.5 Hz, H-4), 4.20 (d, 1H, 
J = 3.5 Hz, H-3), 3.78 (d, 2H, J = 5.8 Hz, H-5); 13C-APT NMR (CDCl3, 101 MHz, HSQC): δ 189.8 (C=S), 137.6, 136.3 (Cq), 
128.9, 128.7, 128.6, 128.1, 128.1, 127.9 (CHarom), 107.8 (C-1), 86.0 (C-2), 80.7 (C-4), 79.4 (C-3), 73.8, 73.0 (CH2 Bn), 
66.5 (C-5). 
3-benzyloxy-2-(benzyloxy)methyl-2,3-dihydrofuran (35). Thionocarbonate 34 (330 mg, 0.89 mmol, 1 
eq.) was dissolved in toluene (1.8 mL) and heated to 70°C. When the target temperature was reached 
1,3-dimethyl-2-phenyl-1,3,2-diazaphospholidine (0.18 mL, 0.98 mmol, 1.1 eq.) was added, and the 
reaction was continued to stir for 20 min. The reaction mixture was concentrated in vacuo and flash column 
chromatography (1/0 to 85/15 pentane/Et2O) afforded the title compound (191 mg, 0.68 mmol, 76%) as a colourless 
oil. Spectroscopic data were in accord with those previously reported.36 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC): 
δ 7.38 – 7.23 (m, 10H, CHarom), 6.61 (d, 1H, J = 2.8 Hz, H-1), 5.24 (t, 1H, J = 2.6 Hz, H-2), 4.64 (d, 1H, J = 12.0 Hz, CHH 
Bn), 4.61 (ddd, 2H, J = 7.1, 2.5, 0.7 Hz, H-3), 4.55 (d, 1H, J = 12.0 Hz, CHH Bn), 4.50 – 4.44 (m, 2H, CHH Bn, H-4), 4.42 
(d, 1H, J = 12.0 Hz, CHH Bn), 3.96 (dd, 1H, J = 10.6, 4.6 Hz, H-5), 3.85 (dd, 1H, J = 10.6, 7.7 Hz, H-5); 13C-APT NMR 
(CDCl3, 101 MHz, HSQC): δ 150.6 (C-1), 138.5, 138.1 (Cq), 128.4, 128.4, 127.8, 127.7, 127.6, 127.5 (CHarom), 101.4 (C-
2), 83.3 (C-4), 79.5 (C-3), 73.6, 70.7 (CH2 Bn), 67.8 (C-5). 
Phenyl 2-azido-3,5-di-O-benzyl-2-deoxy-1-seleno-α/β-D-xylofuranoside (36). Glycal 35 (314 mg, 
1.11 mmol, 1 eq.) was dissolved in DCM (5.5 mL) followed by the subsequent addition of TMSN3 
(295 µL, 2.22 mmol, 2 eq.), TBAF (1M solution in THF, 220 µL, 0.22 mmol, 0.2 eq.), and N-
(phenylseleno)phthalimide (671 mg, 2.22 mmol, 2 eq.). The reaction was stirred overnight, diluted with DCM and 
washed with sat. aq. NaHCO3 and brine. The organic layer was dried (MgSO4), filtered and concentrated under reduced 
pressure. The residu was purified by flash column chromatography (1/0 to 85/15 pentane/Et2O) to give the still impure 
title compound (360 mg, 0.72 mmol, <65%) and was used direct in the subsequent hydrolysis (vide infra, 52). The 
major product was confirmed as the trans-xylo isomer: 1H NMR (CDCl3, 400 MHz, HH-COSY, NOESY, HSQC): δ 7.66 – 
7.59 (m, 2H, CHarom), 7.36 – 7.27 (m, 13H, CHarom), 5.46 (d, 1H, J = 3.7 Hz, H-1), 4.66 (d, 1H, J = 11.8 Hz, CHH Bn), 4.62 
– 4.53 (m, 3H, CHH Bn, CH2 Bn), 4.34 (q, 1H, J = 5.4 Hz, H-4), 4.27 (t, 1H, J = 3.4 Hz, H-2), 4.01 (dd, 1H, J = 5.4, 3.2 Hz, 
H-3), 3.78 (dd, 1H, J = 10.2, 5.2 Hz, H-5), 3.73 (dd, 1H, J = 10.2, 6.0 Hz, H-5); 13C-APT NMR (CDCl3, 101 MHz, HSQC): δ 
138.1, 137.1 (Cq), 134.3 (CHarom), 130.0 (Cq), 129.2, 128.7, 128.6, 128.4, 128.1, 127.9, 127.9, 127.8, 127.8, 127.7 
(CHarom), 85.7 (C-1), 81.6 (C-3), 81.1 (C-4), 73.6, 72.7 (CH2 Bn), 70.1 (C-2), 68.6 (C-5); 13C HSQC-HECADE NMR: 2JC1,H2 =
-1.1 Hz, 2JC2,H1 = -3.1 Hz, 2JC2,H1 = -4.0 Hz. And minor products are identified as cis-xylo (13C HSQC-HECADE NMR (CDCl3, 
126 MHz): 2JC1,H2 = +0.9 Hz, 2JC2,H1 = +1.3 Hz), and trans-lyxo (13C HSQC-HECADE NMR (CDCl3, 126 MHz):2JC1,H2 = -0.7
Hz, 2JC2,H1 = -3.0 Hz).
Methyl 2,3-di-O-benzyl-α/β-D-arabinofuranoside (37). The title compound was prepared by the 
general procedure for the synthesis of primary furanoside alcohols from D-arabinose (200 mmol) 
in 41% as a yellow oil (28.2 g, 82 mmol). Spectroscopic data were in accord with those previously 
reported.63 Data for the α-anomer: 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC): δ 7.39 – 7.26 (m, 10H,  CHarom), 4.94 
(s, 1H, H-1), 4.69 – 4.41 (m, 4H, CH2Bn), 4.19 – 4.11 (m, 1H, H-3), 4.03 – 3.93 (m, 2H, H-2, H-4), 3.83 (ddd, 1H, J = 12.1, 
4.2, 2.8 Hz, H-5), 3.64 (ddd, 1H, J = 12.0, 7.9, 4.1 Hz, H-5), 3.38 (s, 3H, CH3 OMe); 13C-APT NMR (CDCl3, 101 MHz, HSQC): 
δ 137.8, 137.4 (Cq), 128.6, 128.6, 128.1, 128.1, 128.0, 128.0 (CHarom), 107.6 (C-1), 87.8 (C-2), 82.6 (C-4), 82.5 (C-3), 
72.5, 72.0 (CH2Bn), 62.4 (C-5), 55.1 (OMe); Data for the β-anomer: 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC): δ 7.42 
– 7.27 (m, 10H, CHarom), 4.73 – 4.56 (m, 5H, H-1, 2xCH2Bn), 4.27 (dd, 1H, J = 6.9, 6.1 Hz, H-3), 4.07 (m, 2H, J = 9.4, 6.4,
3.8 Hz, H-2, H-3), 3.69 (d, 1H, J = 11.8 Hz, H-5), 3.57 (dt, 1H, J = 11.6, 5.6 Hz, H-5), 3.40 (s, 3H, CH3 OMe); 13C-APT NMR 
(CDCl3, 101 MHz, HSQC): δ 138.0, 137.6 (Cq), 128.6, 128.6, 128.3, 128.2, 128.0, 127.9 (CHarom), 101.9 (C-1), 84.4 (C-2),
82.4 (C-4), 81.1 (C-3), 72.8, 72.7 (CH2 Bn), 64.1 (C-5), 55.9 (OMe); HRMS: [M+NH4]+ calcd for C20H28NO5 362.19620,
found 362.19611. 
Methyl 2,3-di-O-benzyl-α/β-D-ribofuranoside (38). The title compound was prepared by the 
general procedure for the synthesis of primary furanoside alcohols from D-ribose (100 mmol) in 
43% as a yellow oil (14.8 g, 43 mmol). Spectroscopic data were in accord with those previously 
reported.64 Data for the α-anomer: 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC): δ 7.40 – 7.27 (m, 10H, CHarom), 4.87 







(d, J = 12.7 Hz, CHH Bn), 4.17 (q, 1H, J = 3.5 Hz, H-3), 3.84 (dd, 1H, J = 6.9, 3.6 Hz, H-4), 3.73 (dd, 1H, J = 6.9, 4.3 Hz, H-
2), 3.66 (dd, 1H, J = 12.0, 3.2 Hz, H-5), 3.46 (s, 3H, CH3OMe), 3.44 – 3.37 (m, 1H, H-5); 13C-APT NMR (CDCl3, 101 MHz, 
HSQC): δ 138.3, 137.9 (Cq), 128.5, 128.5, 128.3, 128.1, 128. 0, 127.9 (CHarom), 102.8 (C-1), 83.2 (C-3), 78.3 (C-2), 74.8 
(C-4), 72.8, 72.7 (CH2Bn), 62.9 (C-5), 55.7 (OMe); Data for the β-anomer: 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC): 
δ 7.44 – 7.25 (m, 10H, CHarom), 4.89 (s, 1H, H-1), 4.65 (d, 1H, J = 12.0 Hz, CHH Bn), 4.61 (d, 1H, J = 12.0 Hz, CHH Bn), 
4.56 (d, 1H, J = 11.7 Hz, CHH Bn), 4.48 (d, 1H, J = 11.7 Hz, CHH Bn), 4.27 (dt, 1H, J = 6.8, 3.4 Hz, H-4), 4.11 (dd, 1H, J = 
7.0, 4.7 Hz, H-3), 3.86 (d, 1H, J = 4.7 Hz, H-2), 3.79 (dt, 1H, J = 12.0, 3.4 Hz, H-5), 3.56 (ddd, 1H, J = 12.1, 8.5, 3.8 Hz, H-
5), 3.35 (s, 3H, CH3 OMe), 2.06 (dd, 1H, J = 8.5, 4.1 Hz, OH); 13C-APT NMR (CDCl3, 101 MHz, HSQC): δ 137.8, 137.7 (Cq), 
128.5, 128.1, 128.0, 127.9 (CHarom), 106.9 (C-1), 82.4 (C-4), 80.2 (C-2), 77.3 (C-3), 72.7, 72.5 (CH2 Bn), 62.8 (C-5), 55.7 
(OMe); HRMS: [M+Na]+ calcd for C20H24O5Na 367.15160, found 367.15159.  
Methyl 2,3-di-O-benzyl-α-D-lyxofuranoside (39). The title compound was prepared by the general 
procedure for the synthesis of primary furanoside alcohols from D-lyxose (160 mmol) in 42% as 
a yellow oil (23.1 g, 67.2 mmol). Spectroscopic data were in accord with those previously 
reported.65 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC): δ 7.39 – 7.26 (m, 10H, CHarom), 5.00 (s, 1H, H-1), 4.72 (d, 1H, J 
= 11.8 Hz, CHH Bn), 4.64 (d, 1H, J = 11.8 Hz, CHH Bn), 4.59 (d, 1H, J = 11.9 Hz, CHH Bn), 4.46 (d, 1H, J = 11.8 Hz, CHH 
Bn), 4.36 (dd, 1H, J = 7.3, 4.9 Hz, H-3), 4.26 (dt, 1H, J = 7.5, 4.2 Hz, H-4), 3.88 (dd, 1H, J = 4.8, 0.8 Hz, H-2), 3.85 – 3.80 
(m, 2H, H-5), 3.34 (s, 3H, CH3 OMe), 2.68 (t, 1H, J = 6.1 Hz, OH); 13C-APT NMR (CDCl3, 101 MHz, HSQC): δ 137.7, 137.4 
(Cq), 128.6, 128.6, 128.1, 128.0, 128.0, 127.7 (CHarom), 105.5 (C-1), 80.0 (C-2), 78.4 (C-4), 78.3 (C-3), 73.0, 72.8 (CH2 
Bn), 62.0 (C-5), 55.3 (OMe); HRMS: [M+H]+ calcd for C20H25O5 345.16965, found 345.16967. 
Methyl 2,3-di-O-benzyl-α/β-D-xylofuranoside (40). The title compound was prepared by the 
general procedure for the synthesis of primary furanoside alcohols from D-xylose (200 mmol) in 
50% as a yellow oil (34.4 g, 100 mmol). Spectroscopic data were in accord with those previously 
reported.66 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC): δ 7.40 – 7.25 (m, 18H, CHarom), 4.90 (d, 1H, J = 1.9 Hz, H-1β), 
4.80 (d, 0.8H, J = 4.2 Hz, H-1α), 4.73 (d, 0.8H, J = 11.8 Hz, CHH Bnα), 4.67 – 4.47 (m, 6.4H, CHH Bnα, CH2 Bnα, 2xCH2 
Bnβ), 4.43 (dd, 0.8H, J = 7.8, 6.5 Hz, H-3α), 4.31 (dt, 1H, J = 6.8, 4.8 Hz, H-4β), 4.22 (dd, 0.8H, J = 7.7, 3.9 Hz, H-4α), 4.18 
(dd, 1H, J = 6.8, 3.8 Hz, H-3β), 4.10 (dd, 1H, J = 3.9, 1.9 Hz, H-2β), 4.05 (dd, 0.8H, J = 6.5, 4.2 Hz, H-2α), 3.83 – 3.70 (m, 
3.6H, 2xH-5α, 2xH-5β), 3.40 (s, 3H, CH3 OMeβ), 3.38 (s, 2.4H, CH3 OMeα), 2.58 (t, 1H, J = 6.6 Hz, 5-OHβ), 2.43 (dd, 0.8H, 
J = 8.7, 5.0 Hz, 5-OHα); 13C-APT NMR (CDCl3, 101 MHz, HSQC): δ 137.6, 137.5 (Cq), 128.6, 128.6, 128.6, 128.3, 128.1, 
128.1, 128.0, 127.9, 127.9, 127.8 (CHarom), 108.0 (C-1β), 100.2 (C-1α), 87.2 (C-2β), 84.6 (C-2α), 82.9 (C-3β), 82.3 (C-3α), 
80.6 (C-4β), 76.3 (C-4α), 72.8, 72.7, 72.5, 72.3 (CH2 Bn), 62.3, 62.3 (C-5α,β), 55.7 (OMeβ), 55.2 (OMeα); HRMS: [M+Na]+ 
calcd for C20H24O5Na 367.15160, found 367.15152. 
Methyl (methyl 2,3-di-O-benzyl-α/β-D-arabinofuranosyl uronate) (41). The title compound was 
generated from 37 (28.2 g, 78.8 mmol) by the general procedure for TEMPO/BAIB oxidation. 
Yield: 70% (20.6 g, 55.3 mmol) as a yellow oil. Rf: 0.75 (7/3 pentane/EtOAc). IR (thin film): 698, 
737, 1028, 1059, 1099, 1207, 1360, 1454, 1734, 1755, 2874, 2916, 2949, 3030. Data for the α-
anomer: 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC): δ 7.44 – 7.21 (m, 10H, CHarom), 5.09 (s, 1H, H-1), 4.63 (d, 1H, J = 
4.8 Hz, H-4), 4.67 – 4.54 (m, 2H, CH2 Bn), 4.47 (d, 1H, J = 12.0 Hz, CHH Bn), 4.41 (d, 1H, J = 12.0 Hz, CHH Bn), 4.15 (dd, 
1H, J = 4.8, 1.8 Hz, H-3), 3.96 (dd, 1H, J = 1.8, 0.8 Hz, H-2), 3.73 (s, 3H, CH3 CO2Me), 3.41 (s, 3H, CH3 OMe); 13C-APT 
NMR (CDCl3, 101 MHz, HSQC): δ 170.6 (C=O), 137.2, 137.2 (Cq), 128.4, 128.2, 128.0, 127.9, 127.9, 127.9 (CHarom), 108.0 
(C-1), 86.5 (C-2), 84.9 (C-3), 80.9 (C-4), 72.1, 71.7 (CH2 Bn), 55.5 (CH3 OMe), 52.4 (CH3 CO2Me); Data for the β-anomer: 
1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC): δ 7.37 – 7.22 (m, 10H, CHarom), 4.76 (d, 1H, J = 4.2 Hz, H-1), 4.73 (d, 1H, J 
= 11.8 Hz, CHH Bn), 4.67 (d, 1H, J = 11.8 Hz, CHH Bn), 4.64 – 4.58 (m, 2H, CH2 Bn), 4.53 (dd, 1H, J = 6.6, 4.9 Hz, H-3), 
4.42 (d, 1H, J = 4.9 Hz, H-4), 4.01 (dd, 1H, J = 6.6, 4.2 Hz, H-2), 3.73 (s, 3H, CH3 CO2Me), 3.42 (s, 3H, CH3 OMe); 13C-APT 
NMR (CDCl3, 101 MHz, HSQC): δ 171.5 (C=O), 137.7, 137.4 (Cq), 128.4, 128.4, 128.3, 128.1, 127.9, 127.7 (CHarom), 102.3 
(C-1), 83.8, 83.8 (C-2, C-3), 79.4 (C-4), 72.5, 72.5 (CH2 Bn), 55.5 (CH3 OMe), 52.2 (CH3 CO2Me); HRMS: [M+NH4]+ calcd 
for C21H28NO6 390.19111, found 390.19094. 
Methyl (methyl 2,3-di-O-benzyl-α/β-D-ribofuranosyl uronate) (42). The title compound was 
generated from 38 (13.3 g, 38.7 mmol) by the general procedure for TEMPO/BAIB oxidation. 
Yield: 87% (12.5 g, 33.7 mmol) as a yellow oil. Rf: 0.73 (7/3 pentane/EtOAc). Spectroscopic data 
were in accord with those previously reported.67 Data for the β-anomer: IR (thin film): 698, 739, 
957, 1026, 1063, 1111, 1136, 1205, 1358, 1454, 1738, 1753, 2930, 3030; 1H NMR (CDCl3, 500 MHz, HH-COSY, HH-
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Hz, CHH Bn), 4.57 (d, 1H, J = 12.0 Hz, CHH Bn), 4.35 (dd, 1H, J = 6.4, 4.7 Hz, H-3), 3.85 (d, 1H, J = 4.6 Hz, H-2), 3.74 (s, 
3H, CH3 CO2Me), 3.38 (s, 3H, CH3 OMe); 13C-APT NMR (CDCl3, 126 MHz, HSQC): δ 172.0 (C=O), 137.6, 137.5 (Cq), 128.5, 
128.4, 128.0, 127.9, 127.9 (CHarom), 107.1 (C-1), 80.6 (C-3), 79.8 (C-2), 79.6 (C-4), 72.8, 72.7 (CH2 Bn), 55.3 (CH3 OMe), 
52.3 (CH3 CO2Me); 13C HSQC-HECADE NMR (CDCl3, 126 MHz): 2JC1,H2: +0.3 Hz, 2JC2,H1: -0.6 Hz; HRMS: [M+NH4]+ calcd 
for C21H28NO6 390.19111, found 390.19105. 
Methyl (methyl 2,3-di-O-benzyl-α-D-lyxofuranosyl uronate) (43). The title compound was 
generated from 39 (9.91 g, 28.8 mmol) by the general procedure for TEMPO/BAIB oxidation. 
Yield: 89% (9.5 g, 25.5 mmol) as a white solid. Rf: 0.70 (7/3 pentane/EtOAc). m.p. 76-80 °C. [α]  
= +29.7° (c = 0.92, CHCl3); IR (thin film): 698, 739, 1028, 1065, 1145, 1211, 1454, 1734, 1767, 
2949; 1H NMR (CDCl3, 500 MHz, HH-COSY, HSQC): δ 7.38 – 7.23 (m, 10H, CHarom), 5.23 (d, 1H, J = 3.6 Hz, H-1), 4.76 (d, 
1H, J = 11.8 Hz, CHH Bn), 4.72 (d, 1H, J = 4.7 Hz, H-4), 4.69 (d, 1H, J = 12.0 Hz, CHH Bn), 4.63 (d, 1H, J = 12.0 Hz, CHH 
Bn), 4.59 (d, 1H, J = 11.8 Hz, CHH Bn), 4.35 (t, 1H, J = 4.7 Hz, H-3), 3.93 (dd, 1H, J = 4.6, 3.6 Hz, H-2), 3.72 (s, 3H, CH3 
CO2Me), 3.43 (s, 3H, CH3 OMe); 13C-APT NMR (CDCl3, 126 MHz, HSQC): δ 169.1 (C=O), 138.0, 137.8 (Cq), 128.5, 128.4, 
127.9, 127.9, 127.8, 127.8 (CHarom), 108.0 (C-1), 83.3 (C-2), 79.0 (C-3), 78.5 (C-4), 73.9, 72.8 (CH2 Bn), 56.5 (CH3 OMe), 
52.3 (CH3 CO2Me); 13C HSQC-HECADE NMR (CDCl3, 126 MHz): 2JC1,H2 = -2.8 Hz, 2JC2,H1 = -1.6 Hz; HRMS: [M+H]+ calcd for 
C21H25O6 373.16456, found 373.16471. 
Methyl (methyl 2,3-di-O-benzyl-α/β-D-xylofuranosyl uronate) (44). The title compound was 
generated from 40 (34.4 g, 100 mmol) by the general procedure for TEMPO/BAIB oxidation. 
Yield: 88% (30.8 g, 88.2 mmol) as a yellow oil. Rf: 0.65 (7/3 pentane/EtOAc). IR (thin film): 698, 
739, 1063, 1119, 1207, 1454, 1738, 1765, 2916, 2949, 3030. Data for the α-anomer: 1H NMR 
(CDCl3, 400 MHz, HH-COSY, HSQC): δ 7.39 – 7.21 (m, 10H, CHarom), 4.94 (d, 1H, J = 4.3 Hz, H-1), 4.79 (d, 1H, J = 7.4 Hz, 
H-4), 4.64 – 4.57 (m, 4H, 2xCH2 Bn), 4.47 (dd, 1H, J = 7.4, 6.2 Hz, H-3), 4.11 (dd, 1H, J = 6.2, 4.3 Hz, H-2), 3.73 (s, 3H, 
CH3 CO2Me), 3.40 (s, 3H, CH3 OMe); 13C-APT NMR (CDCl3, 101 MHz, HSQC): δ 169.7 (C=O), 137.6, 137.4 (Cq), 128.5,
128.4, 128.2, 128.1, 127.7, 127.5 (CHarom), 101.6 (C-1), 82.5 (C-2), 81.8 (C-3), 76.5 (C-4), 73.0, 72.9 (CH2 Bn), 55.7 
(OMe), 52.2 (CO2Me); Data for the β-anomer: 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC): δ 7.40 – 7.23 (m, 10H,
CHarom), 5.04 (s, 1H, H-1), 4.90 (d, 1H, J = 6.2 Hz, H-4), 4.61 – 4.56 (m, 1H, CHH Bn) 4.53 (d, 1H, J = 12.5 Hz, CHH Bn),
4.43 (d, 1H, J = 11.9 Hz, CHH Bn), 4.39 (d, 1H, J = 11.9 Hz, CHH Bn), 4.23 (dd, 1H, J = 6.2, 1.4 Hz, H-2), 3.98 – 3.97 (m, 
1H, H-2), 3.77 (s, 3H, CH3 CO2Me), 3.53 (s, 3H, CH3 OMe); 13C-APT NMR (CDCl3, 101 MHz, HSQC): δ 169.7 (C=O), 137.2,
137.2 (Cq), 128.5, 128.5, 128.1, 128.0, 127.7, 127.5 (CHarom), 108.8 (C-1), 85.1 (C-2), 81.2 (C-3), 81.1 (C-4), 72.7, 71.9 
(CH2 Bn), 56.0 (OMe), 52.1 (CO2Me); HRMS: [M+H]+ calcd for C21H25O6 373.16456, found 373.16448.
3,5-di-O-benzyl-2-deoxy-2-fluoro-α/β-D-arabinofuranose (45). The title compound was generated 
from 18 (470 mg, 1.36 mmol) by the general procedure for methyl furanoside hydrolysis, 
conditions A (65°C, 64 h). Yield: 63% α:β = 70:30 (0.85 mmol) as a colourless oil. Spectroscopic 
data were in accord with those previously reported.24 Data for the α-anomer: 1H NMR (CDCl3, 500 MHz, HH-COSY, 
HSQC): δ 7.37 – 7.23 (m, 10H, CHarom), 5.45 (dd, 1H, J = 10.7, 2.9 Hz, H-1), 4.93 (d, 1H, J = 50.2 Hz, H-2), 4.62 (d, 1H, J 
= 12.0 Hz, CHH Bn), 4.57 – 4.47 (m, 3H, CH2 Bn, CHH Bn), 4.43 (q, 1H, J = 5.2 Hz, H-4), 3.98 (dd, 1H, J = 21.0, 4.8 Hz, H-
3), 3.76 (d, 1H, J = 4.1 Hz, OH), 3.58 – 3.54 (m, 1H, H-5), 3.51 (dd, 1H, J = 10.3, 5.1 Hz, H-5); 13C-APT NMR (CDCl3, 126 
MHz, HSQC): δ 137.9, 137.0 (Cq), 128.6, 128.4, 128.1, 128.0, 127.8, 127.8 (CHarom), 100.4 (d, J = 34.5 Hz, C-2), 98.4 (d, 
J = 182.7 Hz, C-1), 82.6 (d, J = 25.6 Hz, C-3), 81.9 (d, J = 2.0 Hz, C-4), 73.5, 72.4 (CH2 Bn), 69.7 (C-5); 19F NMR (CDCl3, 
471 MHz): δ -189.12 (ddd, J = 50.7, 21.0, 10.8 Hz); 13C HSQC-HECADE NMR: 2JC1-H2 = +1.8 Hz, 2JC2-H1 = +3.9 Hz; Data for 
the β-anomer: 1H NMR (CDCl3, 500 MHz, HH-COSY, HSQC): δ 7.36 – 7.23 (m, 10H, CHarom), 5.32 – 5.24 (m, 1H, H-1), 
5.00 – 4.85 (m, 1H, H-2), 4.66 (d, 1H, J = 11.8 Hz, CHH Bn), 4.57 – 4.47 (m, 3H, CHH Bn, CH2 Bn), 4.28 (dt, 1H, J = 17.8, 
4.9 Hz, H-3), 4.22 (d, 1H, J = 9.5 Hz, OH), 4.09 (q, 1H, J = 3.8 Hz, H-4), 3.58 – 3.54 (m, 1H, H-5), 3.47 (dd, 1H, J = 10.3, 
3.8 Hz, H-5); 13C-APT NMR (CDCl3, 126 MHz, HSQC): δ 137.3, 137.1 (Cq), 128.6, 128.6, 128.1, 128.1, 128.0, 127.9 
(CHarom), 95.8 (d, J = 194.1 Hz, C-2), 95.4 (d, J = 18.8 Hz, C-1), 80.6 (d, J = 22.8 Hz, C-3), 80.1 (d, J = 8.2 Hz, C-4), 73.7, 
72.2 (CH2 Bn), 70.0 (C-5); 19F NMR (CDCl3, 471 MHz): δ -202.72 (dd, J = 52.7, 17.8 Hz); HRMS: [M+Na]+ calcd for 
C19H21FO4Na 355.13161, found 355.13160. 
3,5-di-O-benzyl-2-deoxy-2-fluoro-α/β-D-ribofuranose (46). The title compound was generated 
from 19 (205 mg, 0.59 mmol) by the general procedure for methyl furanoside hydrolysis, 
conditions A (60°C, 18 h). Yield: 78% α:β = 25:75 (0.46 mmol). Spectroscopic data were in accord 
with those previously reported.22 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC): δ 7.40 – 7.21 (m, 10H, CHarom), 5.35 (dd, 
0.75H, J = 8.5, 6.7 Hz, H-1β), 5.33 (dt, 0.25H, J = 11.7, 3.6 Hz, H-1α), 4.91 (dt, 0.25H, J = 51.8, 4.3 Hz, H-2α), 4.76 (dd, 
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0.75H, J = 53.3, 3.4 Hz, H-2β), 4.72 (d, 0.25H, J = 11.8 Hz, CHH Bnα), 4.66 (d, 0.75H, J = 11.7 Hz, CHH Bnβ), 4.60 – 4.42 
(m, 3H, CHH Bnα, CHH Bnβ, CH2 Bnα, CH2 Bnβ), 4.34 (qd, 0.25H, J = 3.4, 1.0 Hz, H-4α), 4.31 – 4.21 (m, 1.5H, H-3β, H-4β), 
4.09 – 4.01 (m, 0.5H, H-3α, 1-OHα), 3.89 (dd, 0.75H, J = 6.7, 0.9 Hz, 1-OHβ), 3.66 (dd, 0.75H, J = 10.4, 2.4 Hz, H-5β), 3.54 
(dd, 0.25H, J = 10.7, 3.3 Hz, H-5α), 3.51 – 3.45 (m, 1H, H-5α, H-5β); 13C-APT NMR (CDCl3, 101 MHz, HSQC): δ 137.8, 
137.3, 137.1 (Cq), 128.6, 128.6, 128.5, 128.2, 128.1, 128.1, 128.0, 127.9, 127.7 (CHarom), 99.8 (d, J = 29.2 Hz, C-1β), 95.9 
(d, J = 18.5 Hz, C-1α), 91.9 (d, J = 187.5 Hz, C-2β), 88.8 (d, J = 197.2 Hz, C-2α), 80.7 (d, J = 3.5 Hz, C-4α), 76.8 (C-4β), 76.8 
(d, J = 14.7 Hz, C-3α), 76.5 (d, J = 15.5 Hz, C-3β), 73.6 (CH2 Bnα), 73.6 (CH2 Bnβ), 73.2 (d, J = 2.2 Hz, CH2 Bnα), 72.8 (CH2 
Bnβ), 69.4 (C-5α), 69.1 (C-5β); 13C HSQC-HECADE NMR (CDCl3, 126 MHz): α-anomer: 2JC1-H2: +1.8 Hz, 2JC2-H1: -+2.0 Hz, β-
anomer: 2JC2-H1: -0.3 Hz; HRMS: [M+Na]+ calcd for C19H21FO4Na 355.13161, found 355.13147. 
3,5-di-O-benzyl-2-deoxy-2-fluoro-α/β-D-lyxofuranose (47). The title compound was generated 
from 20 (340 mg, 0.98 mmol) by the general procedure for methyl furanoside hydrolysis, 
conditions A (65°C, 6 h). Yield: 75% α:β = 1:1 (0.73 mmol). IR (thin film): 696, 735, 1027, 1045, 
1454, 2864, 2926, 3410; 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC): δ 7.42 – 7.29 (m, 20H, CHarom), 5.58 (dd, 1H, J = 
9.8, 2.6 Hz, H-1α), 5.28 (dd, 1H, J = 12.5, 4.5 Hz, H-1β), 4.94 (dt, 1H, J = 50.3, 4.4 Hz, H-2α), 4.87 (d, 1H, J = 11.3 Hz, CHH 
Bn), 4.87 (ddd, 1H, J = 52.6, 4.1, 1.0 Hz, H-2β), 4.73 (d, 1H, J = 11.9 Hz, CHH Bn), 4.68 – 4.61 (m, 3H, CHH Bn 2xCHH 
Bn), 4.60 – 4.53 (m, 4H, 3xCHH Bn, H-4α), 4.40 (ddd, 1H, J = 20.3, 7.1, 4.1 Hz, H-3α), 4.25 (td, 1H, J = 4.2, 1.8 Hz, H-3β), 
4.23 – 4.18 (m, 1H, H-4β), 4.17 (dd, 1H, J = 12.6, 1.0 Hz, 1-OHβ), 3.85 (dd, 1H, J = 9.7, 6.6 Hz, H-5β), 3.79 (dd, 1H, J = 
10.5, 3.6 Hz, H-5α), 3.76 – 3.67 (m, 2H, H-5α, H-5β), 3.43 (t, 1H, J = 2.9 Hz, 1-OHα); 13C-APT NMR (CDCl3, 101 MHz, 
HSQC): δ 138.1, 137.8, 137.4, 137.0 (Cq), 128.7, 128.6, 128.6, 128.5, 128.4, 128.1, 128.1, 128.0, 127.9, 127.8, 127.7 
(CHarom), 99.0 (d, J = 30.5 Hz, C-1α), 95.1 (d, J = 19.2 Hz, C-1β), 92.9 (d, J = 187.9 Hz, C-2α), 89.5 (d, J = 202.2 Hz, C-2β), 
77.7 (C-4α), 77.4 (d, J = 5.9 Hz, C-4β), 76.9 (d, J = 15.0 Hz, C-3α), 76.3 (d, J = 14.6 Hz, C-3β), 74.5 (d, J = 3.1 Hz, CH2 Bn), 
73.8, 73.6 (CH2 Bn), 73.2 (d, J = 1.3 Hz, CH2 Bn), 70.3 (d, J = 1.2 Hz, C-5α), 68.9 (C-5β); 19F NMR (CDCl3, 471 MHz): δ -
207.67 (ddd, J = 52.6, 20.1, 9.3 Hz, C2-Fα), -214.36 (d, J = 50.4 Hz, C2-Fβ); HRMS: [M+Na]+ calcd for C19H21FO4Na 
355.13161, found 355.13164.  
3,5-di-O-benzyl-2-deoxy-2-fluoro-α/β-D-xylofuranose (48). The title compound was generated 
from 21 (181 mg, 0.52 mmol) by the general procedure for methyl furanoside hydrolysis, 
conditions A (60°C, 6 h). Yield: 75% α:β = 30:70 (0.40 mmol) as a colourless oil. Spectroscopic 
data were in accord with those previously reported for the L-enantiomer.68 IR (thin film): 696, 735, 1026, 1047, 1454, 
2868, 2924, 3400; 1H NMR (CDCl3, 500 MHz, HH-COSY, HSQC): δ 7.37 – 7.24 (m, 10H), 5.48 (td, 0.3H, J = 8.3, 3.7 Hz, 
H-1α), 5.29 (dd, 0.7H, J = 13.9, 11.6 Hz, H-1β), 4.95 (ddd, 0.7H, J = 52.2, 3.2, 0.8 Hz, H-2β), 4.90 (dt, 0.3H, J = 52.1, 3.4 
Hz, H-2α), 4.68 (d, 0.7H, J = 11.7 Hz, CHH Bnβ), 4.65 (d, 0.3H, J = 11.9 Hz, CHH Bnα), 4.60 – 4.50 (m, 3H, CHH Bnα, CHH 
Bnβ, CH2 Bnα, CH2 Bnβ), 4.50 – 4.46 (m, 0.3H, H-4α), 4.39 (dt, 0.7H, J = 6.1, 4.2 Hz, H-4β), 4.27 (ddd, 0.3H, J = 13.2, 5.3, 
3.1 Hz, H-3α), 4.23 (dddd, 0.7H, J = 17.8, 6.1, 3.0, 0.7 Hz, H-3β), 4.14 (d, 0.7H, J = 11.6 Hz, 1-OHβ), 3.73 (ddd, 0.7H, J = 
10.1, 4.6, 1.2 Hz, H-5β), 3.71 – 3.67 (m, 1H, H-5α, H-5β), 3.64 (dd, 0.3H, J = 10.2, 5.9 Hz, H-5α), 3.57 (dd, 0.3H, J = 8.5, 
3.2 Hz, 1-OHα); 13C-APT NMR (CDCl3, 126 MHz, HSQC): δ 138.1, 137.4, 137.3, 137.0 (Cq), 128.7, 128.6, 128.6, 128.4,
128.2, 128.1, 128.0, 127.9, 127.8, 127.7 (CHarom), 101.0 (d, J = 34.4 Hz, C-1β), 99.1 (d, J = 185.0 Hz, C-2β), 95.6 (d, J = 
17.1 Hz, C-1α), 93.8 (d, J = 191.1 Hz, C-2α), 80.9 (d, J = 24.6 Hz, C-3β), 80.3 (d, J = 24.1 Hz, C-3α), 80.0 (d, J = 3.4 Hz, C-
4β), 77.2 (d, J = 4.1 Hz, C-4α), 73.9 (CH2 Bnβ), 73.6 (CH2 Bnα), 73.0 (CH2 Bnβ), 72.7 (CH2 Bnα), 68.4 (C-5α), 68.4 (C-5β); 
19F NMR (CDCl3, 471 MHz): δ -189.88 (ddd, 0.7F, J = 52.2, 17.7, 14.1 Hz, F-2β), -204.74 (dt, 0.3F, J = 52.2, 9.7 Hz, F-2α); 
13C HSQC-HECADE NMR (CDCl3, 126 MHz): α-anomer: 2JC1,H2 = +3.1 Hz, 2JC2,H1 = +5.6 Hz, β-anomer: 2JC2,H1 = -2.3 Hz; 
HRMS: [M+Na]+ calcd for C19H21FO4Na 355.1322, found 355.1326.
2-azido-3,5-di-O-benzyl-2-deoxy-α/β-D-arabinofuranose (49). The title compound was generated 
from 22 (554 mg, 1.50 mmol) by the general procedure for methyl furanoside hydrolysis, 
conditions A (60°C, 64 h). Yield: 76% α:β = 1:1 (1.1 mmol) as a colourless oil. IR (thin film): 696,
735, 1070, 1454, 2108, 3320; 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC): δ 7.45 – 7.10 (m, 20H), 5.33 (d, 1H, J = 7.0 
Hz, H-1α), 5.30 (dd, 1H, J = 9.1, 4.6 Hz, H-1β), 4.68 (d, 1H, J = 11.7 Hz, CHH Bn), 4.62 (d, 1H, J = 12.0 Hz, CHH Bn), 4.58 
– 4.54 (m, 4H, 2x CH2 Bn), 4.52 (d, 1H, J = 11.8 Hz, CHH Bn), 4.50 (d, 1H, J = 11.8 Hz, CHH Bn), 4.45 – 4.38 (m, 1H, H-
4α), 4.24 (dd, 1H, J = 7.0, 5.2 Hz, H-3β), 4.16 (dt, 1H, J = 5.2, 3.0 Hz, H-4β), 3.98 – 3.94 (m, 2H, H-2α, OHβ), 3.91 (ddd, 
1H, J = 4.3, 2.6, 0.6 Hz, H-3α), 3.80 (dd, 1H, J = 6.9, 4.5 Hz, H-2β), 3.59 (dd, 1H, J = 10.3, 3.2 Hz, H-5β), 3.60 – 3.50 (m,
2H, 2xH-5α), 3.41 (dd, 1H, J = 10.3, 3.0 Hz, H-5β), 3.30 (d, 1H, J = 6.9 Hz, OHα); 13C-APT NMR (CDCl3, 101 MHz, HSQC): 
δ 137.9, 137.4, 136.9, 136.8 (Cq), 128.8, 128.7, 128.7, 128.6, 128.4, 128.3, 128.3, 128.1, 128.1, 128.1, 127.9 (CHarom), 
101.0 (C-1α), 97.4 (C-1β), 82.9 (C-3α), 82.2 (C-4α), 81.8 (C-4β), 80.3 (C-3β), 73.9, 73.6, 72.7, 72.6 (CH2 Bn), 70.2 (C-2α), 
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69.9 (C-5β), 69.6 (C-5α), 68.7 (C-2β); 13C HSQC-HECADE NMR (CDCl3, 126 MHz): α-anomer: 2JC1-H2 = -2.2 Hz, 2JC2-H1 = -
0.1 Hz. β-anomer: 2JC1-H2 = -2.1 Hz, 2JC2-H1 = +2.2 Hz; HRMS: [M+Na]+ calcd for C19H26N3O4Na 378.14243, found 
378.14248. 
2-azido-3,5-di-O-benzyl-2-deoxy-α/β-D-ribofuranose (50). The title compound was generated 
from a 4:1 mixture of 23 and 27 by the general procedure for methyl furanoside hydrolysis, 
conditions A (65°C, 6 h). Combined yield: 89%, Yield of 42 was 70% over two steps (from 15), α:β 
= 33:67 (0.29 mmol) as a colourless oil. IR (thin film): 696, 741, 1094, 1454, 2105, 2866, 3330; 1H NMR (CDCl3, 400 
MHz, HH-COSY, HSQC): δ 7.37 – 7.22 (m, 15H, CHarom), 5.35 (bs, 0.5H, H-1α), 5.23 (s, 1H, H-1β), 4.68 – 4.58 (m, 2H, CH2 
Bnα, CHH Bnβ), 4.53 (d, 1H, J = 11.8 Hz, CHH Bnβ), 4.49 – 4.35 (m, 4.5H, 2xCHH Bnβ, CH2 Bnα, H-3β, H-4α), 4.21 (dt, 1H, 
J = 6.4, 3.1 Hz, H-4β), 4.13 (bs, 1H, 1-OHβ), 4.09 (dd, 0.5H, J = 5.4, 2.7 Hz, H-3α), 3.96 (bs, 0.5H, 1-OHα), 3.78 (d, 1H, J = 
5.1 Hz, H-2β), 3.66 (dd, 0.5H, J = 5.4, 4.4 Hz, H-2α), 3.62 (dd, 1H, J = 10.4, 2.9 Hz, H-5β), 3.49 – 3.40 (m, 1.5H, H-5β, 2xH-
5α); 13C-APT NMR (CDCl3, 101 MHz, HSQC): δ 137.6, 137.2, 137.0, 136.8 (Cq), 128.6, 128.6, 128.6, 128.5, 128.3, 128.2, 
128.1, 128.0, 128.0, 127.9, 127.7 (CHarom), 100.8 (C-1β), 97.6 (C-1α), 81.6 (C-4α), 80.9 (C-4β), 78.8 (C-3α), 78.4 (C-3β), 
73.6, 73.6, 73.1, 73.0 (CH2 Bn), 69.6 (C-5α), 69.3 (C-5β), 65.9 (C-2β), 62.1 (C-2α); HRMS: [M+NH4]+ calcd for C19H25N4O4 
373.18703, found 373.18699. 
2-azido-3,5-di-O-benzyl-2-deoxy-α/β-D-lyxofuranose (51). The title compound was generated 
from 24 (620 mg, 1.68 mmol) by the general procedure for methyl furanoside hydrolysis, 
conditions A (60°C, 18 h). Yield: 62% α:β = 60:40 (1.04 mmol) as a colourless oil. IR (thin film): 
696, 734, 1026, 1070, 1269, 1454, 2110, 2868, 2924, 3400; 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC): δ 7.37 – 7.28 
(m, 10H, CHarom), 5.45 (t, 0.6H, J = 2.7 Hz, H-1α), 5.28 (dd, 0.4H, J = 12.2, 4.6 Hz, H-1β), 4.80 (d, 0.4H, J = 11.0 Hz, CHH 
Bnβ), 4.72 (d, 0.6H, J = 11.7 Hz, CHH Bnα), 4.65 (d, 0.4H, J = 11.0 Hz, CHH Bnβ), 4.62 – 4.47 (m, 3.2H, CH2 Bnα, CH2 Bnβ, 
CHH Bnα, H-4α), 4.41 (t, 0.6H, J = 5.5 Hz, H-3α), 4.22 (t, 0.4H, J = 4.0 Hz, H-3β), 4.17 (ddd, 0.4H, J = 7.2, 5.5, 3.8 Hz, H-
4β), 3.84 – 3.76 (m, 1.4H, H-2α, H-5β, OHβ), 3.74 – 3.67 (m, 1.6H, H-5β, H-5α, H-5α), 3.63 (t, 0.4H, J = 4.4 Hz, H-2β), 3.06 
(d, 0.6H, J = 3.1 Hz, OHα); 13C-APT NMR (CDCl3, 101 MHz, HSQC): δ 128.7, 128.6, 128.6, 128.5, 128.5, 128.4, 128.2, 
128.1, 128.0, 128.0, 127.8 (CHarom), 99.8 (C-1α), 97.3 (C-1β), 79.6 (C-4α), 79.0 (C-3), 78.5, 78.4 (C-3β, C-4β), 75.0, 74.0, 
73.9, 73.7 (CH2 Bn), 69.4 (C-5α), 68.8 (C-5β), 66.6 (C-2α), 63.0 (C-2β); HRMS: [M+Na]+ calcd for C19H21N3O4Na 378.14243, 
found 378.14233. 
2-azido-3,5-di-O-benzyl-2-deoxy-α/β-D-xylofuranose (52). Selenoglycoside 36 (360 mg, 0.72 mmol,
1 eq.) was dissolved in THF/H2O/acetone (3/2/3 v/v/v, 8 mL) and cooled to 0°C, followed by
addition of NIS (180 mg, 0.8 mmol, 1.1 eq.). After 1 h the reaction mixture was quenched by 
addition of 10% Na2S2O3, diluted with H2O and extracted with DCM three times. The combined organic layer was 
washed with brine, dried (MgSO4), filtered and concentrated in vacuo. Purification by flash column chromatography 
(19/1 to 8/2 pentane/EtOAc) gave the title compound as a colourless oil (222 mg, 0.62 mmol, 87%). IR (thin film): 696, 
737, 1053, 1255, 1454, 2102, 2866, 2924, 3390; 1H NMR (CDCl3, 400 MHz, HH-COSY, NOESY, HSQC): δ 7.37 – 7.25 (m, 
20H, CHarom), 5.48 (dd, 1H, J = 5.4, 4.6 Hz, H-1α), 5.15 (dd, 1H, J = 11.4, 1.7 Hz, H-1β), 4.66 (d, 1H, J = 11.7 Hz, CHH Bn), 
4.65 (d, 1H, J = 11.8 Hz, CHH Bn), 4.61 (d, 1H, J = 11.7 Hz, CHH Bn), 4.59 – 4.54 (m, 4H, CHH Bn, 3xCHH Bn), 4.52 (d, 
1H, J = 12.0 Hz, CHH Bn), 4.47 (td, 1H, J = 6.1, 4.5 Hz, H-4α), 4.29 (dt, 1H, J = 5.6, 4.5 Hz, H-4β), 4.23 (dd, 1H, J = 5.9, 5.2 
Hz, H-3α), 4.15 (d, 1H, J = 11.4 Hz, 1-OHβ), 4.03 (dd, 1H, J = 5.6, 3.7 Hz, H-3β), 3.99 (dd, 1H, J = 4.1, 1.7 Hz, H-2β), 3.89 
– 3.85 (m, 1H, H-2α), 3.73 (dd, 1H, J = 10.1, 4.7 Hz, H-5β), 3.70 (dd, 1H, J = 10.1, 4.3 Hz, H-5β), 3.68 (dd, 1H, J = 10.3, 
4.6 Hz, H-5α), 3.61 (dd, 1H, J = 10.3, 6.2 Hz, H-5α), 3.61 (d, 1H, J = 5.6 Hz, 1-OHα); 13C-APT NMR (CDCl3, 101 MHz,
HSQC): δ 137.9, 137.3, 136.9 (Cq), 128.7, 128.6, 128.5, 128.4, 128.1, 128.1, 128.0, 128.0, 127.9, 127.9, 127.8 (CHarom), 
101.2 (C-1β), 96.2 (C-1α), 81.6 (C-3β), 80.8 (C-3α), 79.5 (C-4β), 77.1 (C-4α), 73.9, 73.6, 73.2, 73.0 (CH2 Bn), 70.5 (C-2β), 
68.8 (C-5α), 68.5 (C-5β), 66.9 (C-2α); 13C HSQC-HECADE NMR (CDCl3, 126 MHz): α-anomer: 2JC1,H2 = -0.5 Hz, 2JC2,H1 =
+3.9 Hz, β-anomer: 2JC1,H2 = -2.4 Hz, 2JC2,H1 = -0.2 Hz; As additional confirmation of the xylo-configuration: α -anomer: 
2JC2,H3 = -2.8 Hz, 2JC3,H2 = -5.0 Hz, β -anomer: 2JC2,H3 = -3.3 Hz, 2JC3,H2 = -4.6 Hz). HRMS: [M+Na]+ calcd for C19H21N3O4Na
378.14243, found 378.14235. 
Methyl (2,3-di-O-benzyl-α/β-D-arabinofuranosyl uronate) (53). The title compound was generated 
from 41 (11.9 g, 32 mmol) by the general procedure for methyl furanoside hydrolysis, conditions 
B (8 h). Yield: 60% α:β = 2:1 (6.87 g, 19.2 mmol) as a yellow oil. Rf: 0.38 (7/3 pentane/EtOAc). IR 
(thin film): 698, 739, 1028, 1076, 1090, 1207, 1454, 1740. Data for the α-anomer: 1H NMR (CDCl3, 
400 MHz, HH-COSY, HSQC): δ 7.40 – 7.22 (m, 10H, CHarom), 5.51 (d, 1H, J = 10.2 Hz, H-1), 4.86 (d, 1H, J = 1.7 Hz, H-4), 
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4.70 (d, 1H, J = 11.8 Hz, CHH Bn), 4.59 (d, 1H, J = 11.8 Hz, CHH Bn), 4.53 (d, 1H, J = 11.7 Hz, CHH Bn), 4.46 (d, 1H, J = 
11.7 Hz, CHH Bn), 4.38 – 4.34 (m, 1H, H-3), 3.94 (d, 1H, J = 0.9 Hz, H-2), 3.69 (s, 3H, CH3 CO2Me), 3.41 (d, 1H, J = 10.3 
Hz, OH); 13C-APT NMR (CDCl3, 101 MHz, HSQC): δ 170.5 (C=O), 137.1, 136.7 (Cq), 128.6, 128.5, 128.4, 128.0, 128.0, 
127.7 (CHarom), 102.1 (C-1), 84.6 (C-2), 84.1 (C-3), 81.1 (C-4), 72.3, 71.6 (CH2 Bn), 52.4 (CH3 CO2Me); Data for the β-
anomer: 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC): δ 7.40 – 7.22 (m, 10H, CHarom), 5.55 (dd, 1H, J = 10.0, 3.9 Hz, H-
1), 4.66 (d, 1H, J = 11.9 Hz, CHH Bn), 4.57 – 4.54 (m, 1H, CHH Bn), 4.53 (d, 1H, J = 2.2 Hz, H-4), 4.38 – 4.34 (m, 1H, H-
3), 3.91 (dd, 1H, J = 3.9, 2.7 Hz, H-2), 3.85 (d, 1H, J = 10.0 Hz, OH), 3.72 (s, 3H, CH3 CO2Me); 13C-APT NMR (CDCl3, 101 
MHz, HSQC): δ 171.8 (C=O), 137.2, 136.9 (Cq), 128.5, 128.2, 128.2, 128.0, 127.9, 127.8 (CHarom), 98.2 (C-1), 84.2 (C-3), 
81.5 (C-2), 79.7 (C-4), 72.7, 72.1 (CH2 Bn), 52.5 (CH3 CO2Me); HRMS: [M+NH4]+ calcd for C20H26NO6 376.17546, found 
376.17566. 
Methyl (2,3-di-O-benzyl-α/β-D-ribofuranosyl uronate) (54). The title compound was generated 
from 42 (8.33 g, 22.38 mmol) by the general procedure for methyl furanoside hydrolysis, 
conditions B (7.5 h). Yield: 73% α:β = 1.1:1 (5.87 g, 16.4) as a colourless oil. Rf: 0.54 (7/3 
pentane/EtOAc). IR (thin film): 698, 739, 1026, 1070, 1209, 1358, 1454, 1740, 2870, 2951, 3030, 
3441; Data for the α-anomer: 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC): δ 7.40 – 7.25 (m, 10H, CHarom ), 5.45 (dd, 
1H, J = 11.1, 4.3 Hz, H-1), 4.82 – 4.44 (m, 5H, 2xCH2Bn, H-4), 4.19 (d, 1H, J = 11.5 Hz, OH), 4.16 – 4.06 (m, 1H, H-3), 
3.89 (d, 1H, J = 4.5 Hz, H-2), 3.71 (d, 3H, J = 4.2 Hz, CH3 CO2Me); 13C-APT NMR (CDCl3, 101 MHz, HSQC): δ 170.6 (C=O), 
137.11, 136.74 (Cq), 128.5 – 127.9 (CHarom), 96.8 (C-1), 80.2 (C-2), 79.1 (C-4), 77.5 (C-3), 72.5, 72.4 (CH2Bn), 52.6 (CH3 
CO2Me); Data for the β-anomer: 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC): δ 7.40 – 7.25 (m, 10H, CHarom), 5.55 (s, 
1H, H-1), 5.07 – 4.88 (m, 1H, OH), 4.78, (d, J = 1.4 Hz, H-4), 4.82 – 4.44 (m, 4H, 2xCH2Bn), 4.38 (dd, 1H, J = 6.5, 4.5 Hz, 
H-3), 3.93 (t, 1H, J = 4.6 Hz, H-2), 3.71 (d, 3H, J = 4.2 Hz, CH3 CO2Me); 13C-APT NMR (CDCl3, 101 MHz, HSQC): δ 173.3 
(C=O), 137.6, 137.4 (Cq), 128.5 – 127.9 (CHarom), 101.1 (C-1), 80.4 (C-3), 80.2 (C-2), 79.7 (C-4), 73.0, 72.7 (CH2Bn), 52.6 
(CH3 CO2Me); HRMS: [M+Na]+ calcd for C20H22O6Na 381.13086, found 381.13084. 
Methyl (2,3-di-O-benzyl-β-D-lyxofuranosyl uronate) (55). The title compound was generated from 
43 (1.0 g, 2.7 mmol) by the general procedure for methyl furanoside hydrolysis, conditions B (6 
h). Yield: 85% β only (818 mg, 2.28 mmol) as a white solid. Rf: 0.35 (1/1 pentane/EtOAc). IR (thin 
film): 698, 739, 1026, 1065, 1141, 1211, 1360, 1437, 1454, 1738, 1763, 2874, 2951, 3466. 1H 
NMR (CDCl3, 400 MHz, HH-COSY, HSQC): δ 7.43 – 7.22 (m, 10H, CHarom), 5.40 (dd, 1H, J = 12.6, 4.3 Hz, H-1), 4.85 (d, 
1H, J = 11.2 Hz, CHH Bn), 4.80 (d, 1H, J = 11.6 Hz, CHH Bn), 4.63 – 4.59 (m, 3H, 2xCHH Bn, H-4), 4.37 (t, 1H, J = 4.4 Hz, 
H-3), 4.33 (d, 1H, J = 12.6 Hz, OH), 3.91 (t, 1H, J = 4.2 Hz, H-2), 3.73 (s, 3H, CH3 OMe); 13C-APT NMR (CDCl3, 101 MHz,
HSQC): δ 169.5 (C=O), 137.3, 137.2 (Cq), 128.7, 128.5, 128.2, 128.2, 128.1, 127.9 (CHarom), 97.0 (C-1), 78.8 (C-4), 78.5,
78.4 (C-2, C-3), 74.8, 72.2 (CH2 Bn), 52.4 (CH3 CO2Me); HRMS: [M+Na]+ calcd for C20H22O6Na 376.17546, found
376.17580. 
Methyl (2,3-di-O-benzyl-α/β-D-xylofuranosyl uronate) (56). The title compound was generated 
from 44 (17.7 g, 47.6 mmol) by the general procedure for methyl furanoside hydrolysis, 
conditions B (4 h). Yield: 90% α:β = 1:1.3 (15.3 mg, 42.7 mmol) as a light yellow oil. Rf: 0.2 (8/2 
pentane/EtOAc). IR (thin film): 698, 739, 1028, 1061, 1072, 1209, 1366, 1437, 1454, 1738, 1759, 
2951, 3030, 3430; 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC): δ 7.45 – 7.21 (m, 17.5H, CHarom), 5.65 (dd, 0.75H, J = 
10.1, 4.0 Hz, H-1α), 5.39 (d, 1H, J = 11.3 Hz, H-1β), 4.90 (d, 1H, J = 5.9 Hz, H-4β), 4.83 (d, 0.75H, J = 5.2 Hz, H-4α), 4.61 
– 4.49 (m, 7H, CH2 Bn), 4.28 (ddd, 1H, J = 5.9, 2.4, 0.8 Hz, H-3β), 4.25 (ddd, 1H, J = 5.2, 2.5, 0.4 Hz, H-3α), 4.00 (d, 1H, J
= 11.6 Hz, 1-OHβ), 4.00 (dt, 1H, J = 2.4, 0.8 Hz, H-2β), 3.94 (dd, 0.75H, J = 3.9, 2.6 Hz, H-2α), 3.84 (d, 0.75H, J = 10.1 Hz,
1-OHα), 3.77 (s, 3H, CH3 CO2Meβ), 3.74 (s, 2.25H, CH3 CO2Meα); 13C-APT NMR (CDCl3, 101 MHz, HSQC): δ 171.2, 169.7
(C=O), 137.1, 136.7 (Cq), 128.7, 128.6, 128.5, 128.5, 128.3, 128.1, 128.1, 127.9, 127.8 (CHarom), 102.8 (C-1β), 97.4 (C-
1α), 85.2 (C-2β), 82.1 (C-3β), 81.7 (C-3α), 80.8 (C-4β), 80.4 (C-2α), 77.9 (C-4α), 73.2, 73.0, 72.8, 72.1 (CH2 Bn), 52.5 
(CO2Meβ), 52.1 (CO2Meα); HRMS: [M+NH4]+ calcd for C20H26NO6 376.17546, found 376.17564.
Acetyl 2-azido-3,5-di-O-benzyl-2-deoxy-α/β-D-arabinofuranoside (57). The title compound was 
generated from 49 (107 mg, 0.3 mmol) by the general procedure for acetyl donor synthesis. 
Yield: 90% α:β = 2.3:1 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC): δ 7.41 – 7.22 (m, 10H, CHarom), 
6.24 (d, 0.3H, J = 4.6 Hz, H-1β), 6.11 (d, 0.7H, J = 1.0 Hz, H-1α), 4.71 – 4.47 (m, 4H, 4xCH2 Bnα,β), 4.33 (dt, 0.7H, J = 5.8, 
4.5 Hz, H-4α), 4.25 – 4.15 (m, 0.6H, H-3β, H-4β), 4.05 (dd, 0.7H, J = 3.1, 1.3 Hz, H-2α), 3.95 (ddd, 1H, J = 10.3, 6.8, 3.9 
Hz, H-2β, H-3α), 3.63 – 3.55 (m, 1.4H, H-5α), 3.53 (dd, 0.6H, J = 4.7, 1.9 Hz, H-5β); 13C-APT NMR (CDCl3, 101 MHz, HSQC): 
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127.6 (CHarom), 100.4 (C-1β), 95.2 (C-1α), 83.4 (C-4β), 83.0 (C-3β), 82.1 (C-4α), 80.4 (C-3α), 73.5, 73.3, 72.8, 72.6 (CH2 
Bn), 70.5 (C-2β), 70.3 (C-5α), 68.7 (C-5β), 66.4 (C-2α), 21.1, 21.0 (CH3 OAc); HRMS: [M+Na]+ calcd for C19H21N3O4Na 
378.1424, found 378.1425. 
Methyl (acetyl 2,3-di-O-benzyl-α/β-D-arabinofuranosyl uronate) (58). The title compound was 
generated from 53 (5.20 g, 14.5 mmol) by the general procedure for acetyl donor synthesis. 
Yield: 91% α:β = 6.7:1 (5.29 g, 13.2 mmol) as a light yellow oil. Rf: 0.80 (7/3 pentane/EtOAc). IR 
(thin film): 698, 1011, 1223, 1371, 1454, 1734, 1749, 2872, 2951, 3030. Data for the α-anomer:  
1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC): δ 7.39 – 7.26 (m, 8.5H, CHarom), 6.36 (s, 0.85H, H-1), 4.76 (d, 0.85H, J = 3.9 
Hz, H-4), 4.62 (d, 0.85H, J = 12.0 Hz, CHH Bn), 4.62 (d, 0.85H, J = 12.0 Hz, CHH Bn), 4.54 (d, 0.85H, J = 12.0 Hz, CHH Bn), 
4.49 (d, 0.85H, J = 12.1 Hz, CHH Bn), 4.25 (ddd, 0.85H, J = 3.9, 1.4, 0.7 Hz, H-3), 4.04 (dd, 0.85H, J = 1.4, 0.5 Hz, H-2), 
3.74 (s, 2.55H, CH3 CO2Me), 2.08 (s, 2.55H, CH3 OAc); 13C-APT NMR (CDCl3, 101 MHz, HSQC): δ 169.8, 169.7 (C=O), 
137.2, 137.0 (Cq), 128.5, 128.1, 127.9, 127.9 (CHarom), 100.7 (C-1), 85.3 (C-2), 85.0 (C-3), 82.8 (C-4), 72.2, 72.0 (CH2 Bn), 
52.6 (CH3 CO2Me), 21.2 (OAc); Data for the β-anomer: 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC): δ 7.37 – 7.26 (m, 
1.5H, CHarom), 6.24 (d, 0.15H, J = 4.3 Hz, H-1), 4.75 (d, 0.15H, J = 11.7 Hz, CHH Bn), 4.68 (d, 0.15, J = 11.8 Hz, CHH Bn), 
4.57 – 4.46 (m, 0.6H, CH2 Bn, H-3, H-4), 4.18 (dd, 0.15H, J = 6.4, 4.2 Hz, H-2), 3.76 (s, 0.45H, CH3 CO2Me), 2.07 (s, 
0.45H, CH3 OAc); 13C-APT NMR (CDCl3, 101 MHz, HSQC): δ 170.9, 170.0 (C=O), 137.5, 137.1 (Cq), 128.6, 128.5, 128.5, 
128.2, 128.0, 128.0 (CHarom), 94.5 (C-1), 83.4 (C-3), 83.2 (C-2), 80.4 (C-4), 73.1, 72.8 (CH2 Bn), 52.6 (CO2Me), 21.2 (OAc); 
HRMS: [M+NH4]+ calcd for C22H28NO7 418.18603, found 418.18598. 
Methyl (acetyl 2,3-di-O-benzyl-β-D-ribofuranosyl uronate) (59). The title compound was 
generated from 54 (5.9 g, 16.4 mmol) by the general procedure for acetyl donor synthesis. Yield: 
90% β only (5.9 g, 14.7 mmol) as a light yellow oil. Rf: 0.67 (7/3 pentane/EtOAc). IR (thin film): 
698, 738, 959, 1013, 1094, 1138, 1209, 1371, 1454, 1749, 2870, 2951; 1H NMR (CDCl3, 400 MHz, 
HH-COSY, HSQC): δ 7.40 – 7.30 (m, 10H, CHarom), 6.24 (s, 1H, H-1), 4.73 (d, 1H, J = 12.1 Hz, CHH Bn), 4.69 (d, 1H, J = 
6.7 Hz, H-4), 4.64 (d, 1H, J = 12.2 Hz, CHH Bn), 4.60 (d, J = 12.0 Hz, CHH Bn), 4.57 (d, 1H, J = 12.0 Hz, CHH Bn), 4.32 (dd, 
1H, J = 6.7, 4.7 Hz, H-3), 3.94 (d, 1H, J = 4.6 Hz, H-2), 3.76 (s, 3H, CH3 CO2Me), 2.05 (s, 3H, CH3 OAc); 13C-APT NMR 
(CDCl3, 101 MHz, HSQC): δ 171.3 (C=O CO2Me), 169.7 (C=O OAc), 137.3, 137.2 (Cq), 128.6, 128.6, 128.2, 128.1, 127.9 
(CHarom), 99.4 (C-1), 80.4 (C-4), 79.7 (C-3), 79.0 (C-2), 72.8, 72.6 (CH2 Bn), 52.7 (CH3 CO2Me), 21.3 (CH3 OAc); HRMS: 
[M+NH4]+ calcd for C22H28NO7 418.18603, found 418.18605. 
Methyl (acetyl 2,3-di-O-benzyl-α/β-D-xylofuranosyl uronate) (60). The title compound was 
generated from 56 (15.3 g, 42.7 mmol) by the general procedure for acetyl donor synthesis. 
Yield: 89% α:β = 1.3:1 (15.2 g, 38.1 mmol) as a light yellow oil. Rf: 0.60 and 0.73 (8/2 
pentane/EtOAc). IR (thin film): 698, 739, 1016, 1026, 1098, 1211, 1369, 1454, 1748, 2872, 2951, 
3030. 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC): δ 7.39 – 7.21 (m, 17.5H), 6.42 (d, 1H, J = 4.4 Hz, H-1α), 6.24 (s, 
0.75H, H-1β), 4.95 (d, 0.75H, J = 5.8 Hz, H-4β), 4.87 (d, 1H, J = 7.3 Hz, H-4α), 4.66 – 4.48 (m, 7H, 2xCH2 Bnα, 2x CH2 Bnβ), 
4.47 – 4.43 (m, 1H, H-3α), 4.30 (dd, 1H, J = 6.6, 4.4 Hz, H-2α), 4.27 (ddd, 0.75H, J = 5.8, 1.5, 0.6 Hz, H-3β), 4.08 (dt, 
0.75H, J = 1.4, 0.7 Hz, H-2β), 3.74 (s, 2.25H, CH3 CO2Meα), 3.73 (s, 3H, CH3 CO2Meβ), 2.09 (s, 2.25H, CH3 OAcα), 2.07 (s, 
3H, CH3 OAcβ); 13C-APT NMR (CDCl3, 101 MHz, HSQC): δ 170.3, 169.7, 169.2, 168.8 (C=O), 137.4, 137.2, 137.2, 137.0 
(Cq), 128.6, 128.6, 128.5, 128.5, 128.2, 128.2, 128.0, 128.0, 127.9, 127.8, 127.6, 127.5 (CHarom), 100.7 (C-1β), 94.4 (C-
1α), 83.9 (C-2β), 82.2 (C-4β), 81.8 (C-2α), 81.6 (C-3β), 81.0 (C-3α), 77.7 (C-4α), 73.6, 73.1, 72.6, 72.2 (CH2 Bn), 52.3 (C-
5α), 52.2 (C-5β), 21.3 (OAcβ), 21.2 (OAcα); HRMS: [M+NH4]+ calcd for C22H28NO7 418.18603, found 418.18599. 
1,5-Di-O-acetyl 2-azido-3-O-benzyl-2-deoxy-α/β-D-arabinofuranoside. (61).1H NMR (CDCl3, 400 
MHz, HH-COSY, HSQC, HMBC): δ 7.39 – 7.29 (m, 7.9H, CHarom), 6.29 (d, 0.58H, J = 4.5 Hz, H-1β), 
6.11 (d, 1H, J = 1.2 Hz, H-1α), 4.73 (d, 0.58H, J = 11.7 Hz, CHH Bnβ), 4.69 – 4.61 (m, 1.58H, CHH 
Bnα, CHH Bnβ), 4.57 (d, 1H, J = 11.8 Hz, CHH Bnα), 4.36 (td, 1H, J = 5.6, 3.4 Hz, H-4α), 4.26 (dd, 1H, J = 12.2, 3.5 Hz, H-
5α), 4.23 – 4.19 (m, 0.58H, H-4β), 4.17 – 4.04 (m, 3.74H, H-2α, H-3β, H-5α, H-5β, H-5β), 3.99 (dd, 0.58H, J = 7.8, 4.6 Hz, 
H-2β), 3.86 (dd, 1H, J = 6.2, 3.1 Hz, H-3α), 2.09 (s, 1.74H, CH3 OAcβ), 2.09 (s, 3H, CH3 OAcα), 2.05 (s, 1.74H, CH3 OAcβ), 
2.02 (s, 3H, CH3 OAcα); 13C-APT NMR (CDCl3, 101 MHz, HSQC, HMBC): δ 170.4, 170.3, 169.6, 169.1 (C=O, Ac), 136.8,
136.7 (Cq Bn), 128.6, 128.2, 128.2, 127.8, 127.8 (CHarom), 100.4 (C-1α), 95.2 (C-1β), 82.7 (C-3α), 81.8 (C-4α), 80.6 (C-4β), 
80.1 (C-3β), 72.9 (CH2 Bnβ), 72.7 (CH2 Bnα), 70.2 (C-2α), 66.3 (C-2β), 64.6 (C-5β), 62.8 (C-5α), 21.0, 21.0, 20.6, 20.6 (CH3 
OAc); 13C HSQC-HECADE NMR (CDCl3, 126 MHz): α-anomer: 2JC1,H2 = -3.5 Hz, 2JC2,H1 = -0.5 Hz, β-anomer: 2JC1,H2 = -0.6




arabinofuranoside (62). The title compound was generated from 45 by the general 
procedure for imidate donor synthesis, conditions A. Yield: 85% α:β = 5:1 as separate 
anomers (0.14 mmol and 0.60 mmol respectively) as colourless oils. Data for the α-anomer: [α]  = +67.7° (c = 1.39, 
CHCl3); IR (thin film): 696, 933, 1101, 1153, 1159, 1207, 1327, 1454, 1714, 2866, 3032; 1H NMR (CDCl3, T = 323 K, 500 
MHz, HH-COSY, HSQC): δ 7.35 – 7.24 (m, 12H, CHarom), 7.11 – 7.06 (m, 1H, NPh), 6.83 (d, 2H, J = 7.5 Hz, NPh), 6.37 (d, 
1H, J = 8.3 Hz, H-1), 5.17 (dd, 1H, J = 50.5, 1.6 Hz, H-2), 4.65 (d, 1H, J = 12.0 Hz, CHH Bn), 4.61 – 4.55 (m, 2H, CHH Bn, 
CHH Bn), 4.53 (d, 1H, J = 12.1 Hz, CHH Bn), 4.44 (q, 1H, J = 4.9 Hz, H-4), 4.16 (dddd, 1H, J = 23.1, 5.8, 1.8, 0.9 Hz, H-3), 
3.64 (d, 2H, J = 4.7 Hz, H-5, H-5); 13C-APT NMR (CDCl3, T = 323 K, 126 MHz, HSQC): δ 143.8 (Cq NPh), 138.1, 137.4 (Cq 
Bn), 128.9, 128.7, 128.6, 128.2, 127.9, 127.9, 124.6, 119.8 (CHarom), 116.2 (q, J = 286.8 Hz, CF3), 102.7 (d, J = 38.8 Hz, 
C-1), 98.9 (d, J = 184.9 Hz, C-2), 84.3 (d, J = 3.4 Hz, C-4), 82.9 (d, J = 25.7 Hz, C-3), 73.8, 72.8 (CH2 Bn), 69.2 (C-5); 19F 
NMR (CDCl3, T = 323 K, 471 MHz, HH-COSY, HSQC): δ -66.34 (bs, 3F, CF3), -188.59 (ddd, 1F, J = 50.5, 23.1, 11.0 Hz, F-
2); Data for the β-anomer: [α]  = -43.0° (c = 0.6, CHCl3); IR (thin film): 696, 1026, 1072, 1092, 1153, 1159, 1207, 1319,
1717, 2864; 1H NMR (CDCl3, T = 323 K, 500 MHz, HH-COSY, HSQC): δ 7.35 – 7.24 (m, 12H, CHarom), 7.10 – 7.05 (m, 1H,
NPh), 6.80 (dd, 2H, J = 8.4, 1.1 Hz, NPh), 6.46 (bs, 1H, H-1), 5.17 (ddd, 1H, J = 52.0, 5.8, 4.5 Hz, H-2), 4.69 (d, 1H, J = 
11.7 Hz, CHH Bn), 4.60 (d, 1H, J = 11.8 Hz, CHH Bn), 4.57 (d, 1H, J = 12.1 Hz, CHH Bn), 4.54 (d, 1H, J = 12.1 Hz, CHH Bn), 
4.32 (dt, 1H, J = 16.7, 5.9 Hz, H-3), 4.25 (q, 1H, J = 5.7 Hz, H-4), 3.63 (dd, 1H, J = 10.4, 5.6 Hz, H-5), 3.60 (dd, 1H, J =
10.5, 5.5 Hz, H-5); 13C-APT NMR (CDCl3, T = 323 K, 126 MHz, HSQC): δ 143.8 (Cq NPh), 138.1, 137.5 (Cq Bn), 128.9,
128.6, 128.6, 128.1, 127.9, 127.9, 127.9, 124.4, 119.7 (CHarom), 116.1 (q, J = 285.9 Hz, CF3), 96.9 (d, J = 18.1 Hz, C-1), 
95.1 (d, J = 201.9 Hz, C-2), 81.9 (d, J = 9.0 Hz, C-4), 81.2 (d, J = 21.4 Hz, C-3), 73.7, 72.7 (CH2 Bn), 70.9 (C-5); 19F NMR 
(CDCl3, T = 323 K, 471 MHz, HH-COSY, HSQC): δ -66.45 (bs, 3F, CF3), -203.20 (dd, 1F, J = 52.1, 16.7 Hz, F-2); HRMS: 
[M+H]+ calcd for C27H26F4NO4 504.17925, found 504.17933.
3,5-di-O-benzyl-2-deoxy-2-fluoro-1-O-(N-[phenyl]trifluoroacetimidoyl)-α/β-D-ribofuranoside 
(63). The title compound was generated from 46 by the general procedure for imidate 
donor synthesis, conditions A. Yield: 98% β only (0.45 mmol) as a white solid, includes ~10% 
acetamide. IR (thin film): 694, 1092, 1151, 1207, 1712, 2869; 1H NMR (CDCl3, T = 328 K, 400 MHz, HH-COSY, HSQC): δ 
7.36 – 7.21 (m, 12H, CHarom), 7.11 – 7.04 (m, 1H, NPh), 6.79 (d, 2H, J = 8.2 Hz, NPh), 6.36 (d, 1H, J = 9.1 Hz, H-1), 4.95 
(dd, 1H, J = 52.3, 3.5 Hz, H-2), 4.66 (d, 1H, J = 11.6 Hz, CHH Bn), 4.60 – 4.49 (m, 3H, CH2 Bn, CHH Bn), 4.38 (dt, 1H, J = 
7.6, 3.9 Hz, H-4), 4.24 (ddd, 1H, J = 23.6, 7.6, 3.6 Hz, H-3), 3.69 (dd, 1H, J = 11.1, 3.1 Hz, H-5), 3.58 (dd, 1H, J = 11.1, 
4.4 Hz, H-5); 13C-APT NMR (CDCl3, T = 328 K, 101 MHz, HSQC): δ 143.6 (Cq NPh), 138.2, 137.3 (Cq Bn), 129.4, 128.8, 
128.6, 128.5, 128.2, 128.0, 127.8, 127.7, 124.6, 119.6 (CHarom), 116.0 (q, J = 286.1 Hz, CF3), 101.2 (d, J = 32.4 Hz, C-1), 
91.0 (d, J = 188.6 Hz, C-2), 82.0 (C-4), 77.0 (d, J = 15.7 Hz, C-3), 73.5, 73.2 (CH2 Bn), 69.7 (C-5); 19F NMR (CDCl3, T =298 
K, 471 MHz): δ -65.81 (bs, 3F, CF3), -209.42 (ddd, 1F, J = 52.3, 23.9, 9.4 Hz); HRMS: [M+H]+ calcd for C27H26F4NO4 
504.17925, found 504.17889. 
3,5-di-O-benzyl-2-deoxy-2-fluoro-1-O-(N-[phenyl]trifluoroacetimidoyl)-α/β-D-lyxofuranoside 
(64). The title compound was generated from 47 by the general procedure for imidate 
donor synthesis, conditions A. Yield: 82% α only (0.54 mmol) as a colourless oil. [α]  = 
+50.2° (c = 1.30, CHCl3); IR (thin film): 694, 737, 931, 1086, 1097, 1150, 1207, 1321, 1715, 2872, 3032; 1H NMR (CDCl3, 
T = 323 K, 500 MHz, HH-COSY, HSQC): δ 7.36 – 7.22 (m, 12H, CHarom), 7.11 – 7.04 (m, 1H, NPh), 6.82 (d, 2H, J = 7.5 Hz, 
NPh), 6.41 (bs, 1H, H-1), 5.02 (dd, 1H, J = 51.7, 3.8 Hz, H-2), 4.69 (d, 1H, J = 11.6 Hz, CHH Bn), 4.60 – 4.53 (m, 3H, CHH
Bn, CHH Bn, H-4), 4.50 (d, 1H, J = 12.0 Hz, CHH Bn), 4.34 (ddd, 1H, J = 17.6, 6.4, 4.3 Hz, H-3), 3.83 (dd, 1H, J = 10.7, 4.5 
Hz, H-5), 3.68 (dd, 1H, J = 9.8, 7.3 Hz, H-5); 13C-APT NMR (CDCl3, 126 MHz, HSQC): δ 143.6 (Cq NPh), 142.9 (q, J = 36.4 
Hz, F3CC=N), 138.3, 137.4 (Cq Bn), 128.9, 128.6, 128.5, 128.2, 127.9, 127.7, 124.6, 119.7 (CHarom), 116.2 (q, J = 285.9 
Hz, CF3), 101.3 (d, J = 33.4 Hz, C-1), 92.6 (d, J = 192.3 Hz, C-2), 80.2 (C-4), 76.6 (d, J = 15.0 Hz, C-3), 73.7, 73.7 (CH2 Bn), 
69.5 (C-5); 19F NMR (CDCl3, T = 323 K, 471 MHz): δ -66.49 (bs, 3F, CF3), -207.43 (ddd, 1F J = 51.8, 17.6, 9.5 Hz, C2-F); 
HRMS: [2M+NH4]+ calcd for C54H54F8N3O8 1024.37777, found 1024.37849.
3,5-di-O-benzyl-2-deoxy-2-fluoro-1-O-(N-[phenyl]trifluoroacetimidoyl)-α/β-D-xylofuranoside 
(65). The title compound was generated from 48 by the general procedure for imidate donor 
synthesis, conditions A. Yield: 91% α:β = 37:63 (0.36 mmol) as a colourless oil. IR (thin film): 
694, 1086, 1153, 1207, 1323, 1715; 1H NMR (CDCl3, T = 323 K, 500 MHz, HH-COSY, HSQC): δ 7.35 – 7.22 (m, 12H, 
CHarom), 7.11 – 7.04 (m, 1H, NPh), 6.84 – 6.78 (m, 2H, NPh), 6.46 (bs, 0.37H, H-1α), 6.34 (d, 0.63H, J = 12.5 Hz, H-1β), 
5.23 (dt, 0.37H, J = 51.9, 4.0 Hz, H-2α), 5.18 (dd, 0.63H, J = 49.8, 1.6 Hz, H-2β), 4.71 (d, 0.37H, J = 11.8 Hz, CHH Bnα), 
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(ddd, 0.63H, J = 16.2, 5.8, 1.6 Hz, H-3β), 3.85 (dd, 0.63H, J = 10.5, 5.4 Hz, H-5β), 3.75 (dd, 0.63H, J = 10.4, 6.6 Hz, H-5β), 
3.72 (dd, 0.37H, J = 10.7, 4.5 Hz, H-5α), 3.65 (dd, 0.37H, J = 10.6, 5.0 Hz, H-5α); 13C-APT NMR (CDCl3, T = 323K, 126 
MHz, HSQC): δ 143.9, 143.8 (Cq NPh), 138.4, 138.2, 137.4, 137.4 (Cq Bn), 128.9, 128.9, 128.7, 128.5, 128.5, 128.2, 
128.1, 127.8, 127.8, 127.8, 127.6, 124.5, 124.4, 119.7 (CHarom), 116.1 (q, J = 286.3 Hz, CF3), 102.1 (d, J = 37.5 Hz, H-1β), 
97.0 (d, J = 16.8 Hz, H-1α), 97.0 (d, J = 184.5 Hz, H-2β), 94.1 (d, J = 200.0 Hz, H-2α), 83.1 (C-4β), 80.5 (d, J = 25.6 Hz, C-
3β), 79.9 (d, J = 22.9 Hz, C-3α), 79.0 (d, J = 6.8 Hz, C-4α), 73.8 (CH2 Bnα), 73.7, 73.2 (CH2 Bnβ), 72.9 (CH2 Bnα), 68.9 (C-
5β), 68.2 (C-5α); 19F NMR (CDCl3, T = 323 K, 471 MHz): δ -66.32 (s, 3F, CF3), -193.57 (dt, 0.63F, J = 49.8, 14.1 Hz, F-2β), 
-202.33 (dd, 0.37F, J = 52.1, 15.6 Hz, F-2α); HRMS: [2M+NH4]+ calcd for C54H54F8N3O8 1024.37777, found 1024.37842.
2-azido-3,5-di-O-benzyl-2-deoxy-1-O-(N-[phenyl]trifluoroacetimidoyl)-α/β-D-
arabinofuranoside (66). The title compound was generated from 49 by the general 
procedure for imidate donor synthesis, conditions B. Yield: 71% α:β = 1.6:1 as separate 
anomers (0.31 mmol and 0.19 mmol respectively) as colourless oils. Data for the α-anomer: [α]  = +5.4° (c = 0.50, 
CHCl3); IR (thin film): 696, 929, 1103, 1161, 1207, 1329, 1456, 1700, 1717, 2106, 2866, 3032; 1H NMR (CDCl3, T = 323 
K, 500 MHz, HH-COSY, HSQC): δ 7.38 – 7.22 (m, 12H, CHarom), 7.08 (t, 1H, J = 7.5 Hz, NPh), 6.82 (d, 2H, J = 7.7 Hz, NPh), 
6.18 (bs, 1H, H-1), 4.63 – 4.56 (m, 2H, CH2 Bn), 4.56 (d, 1H, J = 12.1 Hz, CHH Bn), 4.51 (d, 1H, J = 12.1 Hz, CHH Bn), 4.42 
(q, 1H, J = 4.6 Hz, H-4), 4.17 (d, 1H, J = 2.2 Hz, H-2), 4.00 (dd, 1H, J = 6.0, 3.1 Hz, H-3), 3.64 (dd, 1H, J = 11.0, 4.2 Hz, H-
5), 3.61 (dd, 1H, J = 11.0, 4.8 Hz, H-5); 13C-APT NMR (CDCl3, T = 323 K, 126 MHz, HSQC): δ 143.7 (Cq NPh), 138.0, 137.4 
(Cq Bn), 128.9, 128.7, 128.5, 128.2, 127.9, 127.9, 127.9, 124.6, 119.8 (CHarom), 116.1 (q, J = 286.7 Hz, CF3), 104.0 (C-1), 
84.2 (C-4), 83.4 (C-3), 73.7, 73.0 (CH2 Bn), 70.8 (C-5), 68.9 (C-2); HRMS: [2M+NH4]+ calcd for C54H54F6N9O8 1070.39941, 
found 1070.40019. Data for the β-anomer: [α]  = -56.1° (c = 1.30, CHCl3); IR (thin film): 696, 1024, 1094, 1144, 1161, 
1207, 1317, 1713, 2110, 2864; 1H NMR (CDCl3, T = 323 K, 500 MHz, HH-COSY, HSQC): δ 7.36 – 7.22 (m, 12H, CHarom), 
7.12 – 7.03 (m, 1H, NPh), 6.81 (d, 2H, J = 7.5 Hz, NPh), 6.43 (bs, 1H, H-1), 4.67 (d, 1H, J = 11.7 Hz, CHH Bn), 4.63 (d, 1H, 
J = 11.7 Hz, CHH Bn), 4.59 – 4.52 (m, 2H, CH2 Bn), 4.26 (q, 1H, J = 5.6 Hz, H-4), 4.21 (dd, 1H, J = 7.5, 6.0 Hz, H-3), 4.04 
(dd, 1H, J = 7.5, 4.5 Hz, H-2), 3.63 – 3.53 (m, 2H, H-5); 13C-APT NMR (CDCl3, T = 323 K, 126 MHz, HSQC): δ 143.8 (Cq 
NPh), 138.0, 137.5 (Cq Bn), 128.9, 128.7, 128.6, 128.2, 128.0, 127.9, 127.9, 124.5, 119.6 (CHarom), 116.1 (d, J = 286.6 
Hz, CF3), 98.6 (C-1), 82.9 (C-4), 81.5 (C-3), 73.7, 73.1 (CH2 Bn), 70.9 (C-5), 67.4 (C-2); HRMS: [M+NH4]+ calcd for 
C27H29F3N5O4 544.21662, found 544.21623. 
2-azido-3,5-di-O-benzyl-2-deoxy-1-O-(N-[phenyl]trifluoroacetimidoyl)-α/β-D-ribofuranoside 
(67). The title compound was generated from 50 by the general procedure for imidate 
donor synthesis, conditions A. Yield: 77% α:β = 1:8 as separate anomers (0.085 mmol and
0.69 mmol respectively) as a white soild. Data for the α-anomer: [α]  = +52.4° (c = 0.46, CHCl3); IR (thin film): 696, 
1101, 1144, 1161, 1207, 1319, 1713, 2114, 2864; 1H NMR (CDCl3, 500 MHz, HH-COSY, HSQC): δ 7.36 – 7.25 (m, 10H, 
CHarom), 7.25 – 7.21 (m, 2H, CHarom), 7.11 – 7.05 (m, 1H, NPh), 6.87 (d, 2H, J = 7.7 Hz, NPh), 6.45 (bs, 1H, H-1), 4.74 (d, 
1H, J = 12.2 Hz, CHH Bn), 4.61 (d, 1H, J = 12.2 Hz, CHH Bn), 4.49 (d, 1H, J = 12.0 Hz, CHH Bn), 4.45 – 4.40 (m, 2H, CHH 
Bn, H-4), 4.18 (dd, 1H, J = 6.6, 3.1 Hz, H-3), 3.63 – 3.58 (m, 1H, H-2), 3.51 (dd, 1H, J = 10.8, 3.7 Hz, H-5), 3.45 (dd, 1H, 
J = 10.7, 3.3 Hz, H-5); 13C-APT NMR (CDCl3, 126 MHz, HSQC): δ 144.0 (Cq NPh), 137.8, 137.7 (Cq Bn), 128.9, 128.6, 
128.6, 128.0, 127.8, 124.5, 119.9 (CHarom), 99.9 (C-1), 84.8 (C-4), 78.3 (C-3), 73.9, 73.1 (CH2 Bn), 69.6 (C-5), 61.4 (C-2); 
HRMS: [M+Na]+ calcd for C27H25F3N4O4Na 549.17201, found 549.17174. Data for the β-anomer: [α]  = -1.6° (c = 0.70, 
CHCl3); IR (thin film): 696, 1090, 1144, 1159, 1207, 1331, 1715, 2108, 2862; 1H NMR (CDCl3, 500 MHz, HH-COSY, 
HSQC): δ 7.35 – 7.24 (m, 12H, CHarom), 7.08 (t, 1H, J = 7.4 Hz, NPh), 6.80 (d, 2H, J = 7.7 Hz, NPh), 6.18 (bs, 1H, H-1), 
4.64 (d, 1H, J = 11.6 Hz, CHH Bn), 4.58 (d, 1H, J = 11.6 Hz, CHH Bn), 4.56 (d, 1H, J = 12.2 Hz, CHH Bn), 4.53 (d, 1H, J = 
12.1 Hz, CHH Bn), 4.39 (dd, 1H, J = 7.0, 5.0 Hz, H-3), 4.33 (dt, 1H, J = 7.0, 4.3 Hz, H-4), 4.03 (d, 1H, J = 5.0 Hz, H-2), 3.64 
(dd, 1H, J = 10.9, 4.0 Hz, H-5), 3.57 (dd, 1H, J = 10.9, 4.7 Hz, H-5); 13C-APT NMR (CDCl3, 126 MHz, HSQC): δ 143.7 (Cq 
NPh), 138.1, 137.2 (Cq Bn), 128.9, 128.7, 128.5, 128.3, 128.1, 127.8, 127.8, 124.6, 119.7 (CHarom), 116.06 (q, J = 286.0 
Hz, CF3), 102.5 (C-1), 82.6 (C-4), 79.0 (C-3), 73.6, 73.6 (CH2 Bn), 70.0 (C-5), 64.8 (C-2); HRMS: [2M+NH4]+ calcd for 
C54H54F6N9O8 1070.39941, found 1070.40023. 
2-azido-3,5-di-O-benzyl-2-deoxy-1-O-(N-[phenyl]trifluoroacetimidoyl)-α/β-D-lyxofuranoside 
(68). The title compound was generated from 51 by the general procedure for imidate 
donor synthesis, conditions B. Yield: 67% α:β = 1:1.2 (0.30 mmol and 0.37 mmol
respectively) as colourless oils. Data for the α-anomer: [α]  = -57.5° (c = 0.69, CHCl3); IR (thin film): 696, 1045, 1098, 
1144, 1207, 1323, 1714, 2112, 2866, 2926; 1H NMR (CDCl3, T = 323 K, 500 MHz, HH-COSY, HSQC): δ 7.37 – 7.22 (m, 
12H, CHarom), 7.11 – 7.03 (m, 1H, NPh), 6.82 (d, 2H, J = 7.5 Hz, NPh), 6.27 (bs, 1H, H-1), 4.71 (d, 1H, J = 11.5 Hz, CHH 
Bn), 4.59 (d, 1H, J = 11.6 Hz, CHH Bn), 4.56 (d, 1H, J = 12.0 Hz, CHH Bn), 4.53 – 4.47 (m, 2H, CHH Bn, H-4), 4.41 (t, 1H, 
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J = 5.5 Hz, H-3), 4.02 (dd, 1H, J = 5.1, 1.9 Hz, H-1), 3.81 (dd, 1H, J = 10.4, 5.4 Hz, H-5), 3.71 (dd, 1H, J = 10.4, 6.5 Hz, H-
5); 13C-APT NMR (CDCl3, T = 323 K, 126 MHz, HSQC): δ 143.7 (Cq NPh), 138.2, 137.2 (Cq Bn), 128.9, 128.7, 128.5, 128.2, 
127.9, 127.9, 127.8, 124.6, 119.7 (CHarom), 116.2 (q, J = 286.9 Hz, CF3), 102.3 (C-1), 80.7 (C-4), 78.6 (C-3), 74.4, 73.7 
(CH2 Bn), 68.7 (C-5), 66.2 (C-2); HRMS: [M+NH4]+ calcd for C27H29F3N5O4 544.21662, found 544.21667. Data for the β-
anomer: [α]  = +24.9° (c = 0.68, CHCl3); IR (thin film): 696, 1094, 1144, 1153, 1207, 1319, 1717, 2110, 2926; 1H NMR 
(CDCl3, T = 323 K, 500 MHz, HH-COSY, HSQC): δ 7.37 – 7.21 (m, 12H, CHarom), 7.10 – 7.02 (m, 1H, NPh), 6.84 (d, 2H, J = 
7.5 Hz, NPh), 6.41 (bs, 1H, H-1), 4.83 (d, 1H, J = 11.7 Hz, CHH Bn), 4.66 (d, 1H, J = 11.7 Hz, CHH Bn), 4.51 (d, 1H, J = 
11.8 Hz, CHH Bn), 4.46 (d, 1H, J = 11.8 Hz, CHH Bn), 4.36 (q, 1H, J = 6.3 Hz, H-4), 4.26 (t, 1H, J = 5.4 Hz, H-3), 3.82 (dd, 
1H, J = 9.9, 6.7 Hz, H-5), 3.70 (dd, 1H, J = 9.9, 6.2 Hz, H-5), 3.51 (t, 1H, J = 4.9 Hz, H-2); 13C-APT NMR (CDCl3, T = 323 K, 
126 MHz, HSQC): δ 143.9 (Cq NPh), 138.1, 137.6 (Cq Bn), 128.8, 128.5, 128.5, 127.9, 127.8, 127.5, 124.4, 119.7 (CHarom), 
116.2 (q, J = 286.3 Hz, CF3), 98.5 (C-1), 82.2 (C-4), 77.7 (C-3), 74.7, 73.8 (CH2 Bn), 69.0 (C-5), 62.2 (C-2); HRMS: 
[2M+NH4]+ calcd for C54H54F6N9O8 1070.39941, found 1070.39931. 
2-azido-3,5-di-O-benzyl-2-deoxy-1-O-(N-[phenyl]trifluoroacetimidoyl)-α/β-D-xylofuranoside 
(69). The title compound was generated from 52 by the general procedure for imidate 
donor synthesis, conditions A. Yield: 100% α:β = 1:1 (0.33 mmol) as a colourless oil. IR (thin 
film): 696, 1044, 1099, 1143, 1207, 1321, 1712, 2114; 1H NMR (CDCl3, T = 323 K, 500 MHz, HH-COSY, HSQC): δ 7.36 – 
7.23 (m, 24H, CHarom), 7.10 – 7.06 (m, 2H, NPh), 6.84 (d, 2H, J = 7.7 Hz, NPh), 6.80 (d, 2H, J = 7.6 Hz, NPh), 6.43 (bs, 
1H, H-1α), 6.15 (bs, 1H, H-1β), 4.69 (d, 1H, J = 11.7 Hz, CHH Bn), 4.64 – 4.57 (m, 4H, CH2 Bn, CHH Bn, CHH Bn), 4.56 – 
4.50 (m, 4H, CH2 Bn, CHH Bn, H-4β), 4.50 – 4.45 (m, 1H, H-4α), 4.32 (t, 1H, J = 6.7 Hz, H-3α), 4.22 (bs, 1H, H-2β), 4.17 – 
4.11 (m, 1H, H-2α), 4.08 (dd, 1H, J = 5.8, 2.8 Hz, H-3β), 3.85 (dd, 1H, J = 10.5, 5.3 Hz, H-5β), 3.76 (dd, 1H, J = 10.5, 6.5 
Hz, H-5β), 3.71 (dd, 1H, J = 10.7, 4.4 Hz, H-5α), 3.61 (dd, 1H, J = 10.7, 4.9 Hz, H-5α); 13C-APT NMR (CDCl3, T = 323 K, 126 
MHz, HSQC): δ 143.8, 143.8 (Cq NPh), 138.3, 138.2, 137.4, 137.4 (Cq Bn), 128.9, 128.9, 128.7, 128.5, 128.5, 128.3, 
128.3, 127.9, 127.9, 127.8, 127.8, 127.8, 127.8, 124.5, 119.8, 119.7 (CHarom), 103.2 (C-1β), 98.4 (C-1α), 82.7 (C-4β), 81.6 
(C-3β), 79.1 (C-3α), 73.8 (C-4α), 73.8, 73.6, 73.3 (CH2 Bn), 69.1 (C-2β), 69.0 (C-5β), 68.5 (C-5α), 66.7 (C-2α); HRMS: only 
mass of hydrolysis found [M+Na]+ calcd for C19H21N3O4Na 378.1430, found 378.1433. 
Methyl (2,3-di-O-benzyl-1-O-(N-[phenyl]trifluoroacetimidoyl)-α/β-D-arabinofuranosyl 
uronate) (70). The title compound was generated from 53 (466 mg, 1.3 mmol) by the 
general procedure for imidate donor synthesis, conditions A. Yield: 97%, α:β = 1:1.2 (670 
mg, 1.27 mmol) as a white solid. Rf: 0.51 (8/2 pentane/Et2O). IR (thin film): 696, 1074, 1105, 
1318, 1712, 1769; 1H NMR (CDCl3, T = 323 K, 500 MHz, HH-COSY, HSQC): δ 7.35 – 7.20 (m, 24H, CHarom), 7.10 – 7.02 
(m, 2H, NPh), 6.79 (d, 2H, J = 7.7 Hz, NPh), 6.77 – 6.74 (m, 2H, NPh), 6.41 (bs, 1H, H-1β), 6.29 (bs, 1H, H-1α), 4.82 (d, 
1H, J = 3.8 Hz, H-4β), 4.76 (d, 1H, J = 11.8 Hz, CHH Bn), 4.72 – 4.61 (m, 4H, CH2 Bn, CHH Bn, CHH Bn), 4.60 – 4.53 (m, 
4H, CH2 Bn, H-3α, H-4α), 4.50 (d, 1H, J = 12.0 Hz, CHH Bn), 4.29 (d, 1H, J = 3.1 Hz, H-3β), 4.24 – 4.18 (m, 2H, H-2α, H-
2β), 3.74 (s, 3H, CH3 CO2Me), 3.73 (s, 3H, CH3 CO2Me); 13C-APT NMR (CDCl3, T = 323 K, 126 MHz, HSQC): δ 170.7, 169.6 
(C=O), 144.0, 143.8, 137.8, 137.5, 137.4, 137.1 (Cq), 128.8, 128.7, 128.6, 128.6, 128.5, 128.5, 128.2, 128.1, 128.0, 
128.0, 128.0, 127.9, 127.9, 127.8, 124.5, 124.2, 119.8, 119.6 (CHarom), 116.1 (q, J = 286.7 Hz, CF3), 116.1 (q, J = 286.5 
Hz, CF3), 104.0 (C-1α), 97.3 (C-1β), 85.2, 85.2 (C-2β, C-3α), 84.0 (C-2α), 83.7 (C-3β), 83.3 (C-4α), 80.9 (C-4β), 73.4, 73.0, 
72.4, 72.2 (CH2 Bn), 52.5 (OMe); 19F NMR (CDCl3, 471 MHz): δ -66.18; HRMS: [M+Na]+ calcd for C28H26F3NO6Na 
552.16044, found 552.16010. 
Methyl (2,3-di-O-benzyl-1-O-(N-[phenyl]trifluoroacetimidoyl)-β-D-ribofuranosyl uronate) 
(71). The title compound was generated from 54 (1.0 g, 2.8 mmol) by the general procedure 
for imidate donor synthesis, conditions A. Yield: 85% β only (1.26 g, 2.38 mmol) as a white 
solid. Rf: 0.54 (7/3 pentane/Et2O). [α]  = +18.6° (c = 0.90, CHCl3); IR (thin film): 696, 1090, 
1146, 1206, 1456, 1717, 1740; 1H NMR (CDCl3, 500 MHz, HH-COSY, HSQC): δ 7.35 – 7.25 (m, 12H, CHarom), 7.08 (t, 1H, 
J = 7.5 Hz, NPh), 6.81 (d, 2H, J = 7.5 Hz, NPh), 6.29 (bs, 1H, H-1), 4.72 (d, 1H, J = 6.4 Hz, H-4), 4.68 – 4.63 (m, 3H, CH2 
Bn, CHH Bn), 4.62 (d, 1H, J = 11.8 Hz, CHH Bn), 4.43 (dd, 1H, J = 6.3, 4.7 Hz, H-3), 4.09 (d, 1H, J = 4.5 Hz, H-2), 3.76 (s, 
3H, CH3 OMe); 13C-APT NMR (CDCl3, 126 MHz, HSQC): δ 170.9 (C=O), 143.9 (Cq NPh), 137.5, 137.4 (Cq Bn), 128.9, 128.7, 
128.6, 128.2, 128.2, 128.1, 128.1, 124.5, 119.7 (CHarom), 116.11 (q, J = 285.8 Hz, CF3), 102.6 (C-1), 81.2 (C-4), 80.3 (C-
3), 79.7 (C-2), 73.3, 73.0 (CH2 Bn), 52.5 (CH3 CO2Me); 19F NMR (CDCl3, 471 MHz): δ -66.62; HRMS: [M+H]+ calcd for 
C28H27F3NO6 530.17850, found 530.17802. 
Synthesis of C-2- and C-5-modified furanosides 
189 
Methyl (2,3-di-O-benzyl-1-O-(N-[phenyl]trifluoroacetimidoyl)-α/β-D-lyxofuranosyl uronate) 
(72). The title compound was generated from 55 (1.05 g, 2.90 mmol) by the general 
procedure for imidate donor synthesis, conditions A. Yield: 85% as two separate anomers 
(487 mg, 0.92 mmol α and 105 mg, 0.20 mmol β respectively) as colourless oils. Rf: 0.24 
and 0.69 (8/2 pentane/Et2O). Data for the α-anomer: [α]  = -5.5° (c = 1.23, CHCl3); IR (thin film): 696, 1026, 1101, 
1159, 1207, 1327, 1707, 1734, 1770; 1H NMR (CDCl3, T = 323 K, 500 MHz, HH-COSY, HSQC): δ 7.33 – 7.22 (m, 12H, 
CHarom), 7.10 – 7.02 (m, 1H, NPh), 6.80 (d, 2H, J = 7.5 Hz, NPh), 6.49 (bs, 1H, H-1), 4.81 (d, 1H, J = 5.3 Hz, H-4), 4.71 (d, 
1H, J = 11.7 Hz, CHH Bn), 4.66 (s, 2H, CH2 Bn), 4.61 (d, 1H, J = 11.7 Hz, CHH Bn), 4.43 (t, 1H, J = 5.1 Hz, H-3), 4.20 (dd, 
1H, J = 4.6, 2.7 Hz, H-2), 3.68 (s, 3H, CH3 CO2Me); 13C-APT NMR (CDCl3, T = 323 K, 126 MHz, HSQC): δ 167.9 (C=O), 
143.7 (Cq NPh), 143.1 (q, J = 36.2 Hz, CF3-C=N), 137.7, 137.3 (Cq Bn), 128.8, 128.5, 128.4, 128.1, 127.9, 127.8, 124.5, 
119.7, (CHarom), 116.1 (q, J = 285.8 Hz, CF3), 103.5 (C-1), 82.0 (C-2), 79.7 (C-4), 78.4 (C-3), 73.9, 73.0 (CH2 Bn), 52.1 (CH3 
CO2Me); HRMS: [M+NH4]+ calcd for C28H30F3N2O6 547.20505, found 547.20459. Data for the β-anomer: [α]  = -66.4° 
(c = 0.70, CHCl3); IR (thin film): 696, 1074, 1086, 1144, 1327, 1715, 1769; 1H NMR (CDCl3, T = 323 K, 500 MHz, HH-
COSY, HSQC): δ 7.35 – 7.25 (m, 10H, CHarom), 7.25 – 7.19 (m, 3H, NPh), 7.09 – 6.99 (m, 1H, NPh), 6.79 (d, 2H, J = 7.7 
Hz, NPh), 6.40 (bs, 1H, H-1), 4.89 (d, 1H, J = 11.7 Hz, CHH Bn), 4.74 (d, 1H, J = 5.5 Hz, H-4), 4.69 (d, 1H, J = 12.1 Hz, CHH 
Bn), 4.66 (d, 1H, J = 12.0 Hz, CHH Bn), 4.62 (d, 1H, J = 11.7 Hz, CHH Bn), 4.39 (t, 1H, J = 5.3 Hz, H-3), 3.98 (t, 1H, J = 4.6 
Hz, H-2), 3.64 (s, 3H, CH3 CO2Me); 13C-APT NMR (CDCl3, T = 323 K, 126 MHz, HSQC): δ 168.3 (C=O), 144.4 (Cq NPh), 
138.4, 137.4 (Cq Bn), 128.7, 128.7, 128.2, 128.2, 127.7, 127.4, 127.3, 124.0, 119.8 (CHarom), 116.3 (q, J = 286.8 Hz, CF3), 
96.4 (C-1), 81.1 (C-4), 79.9 (C-2), 76.4 (C-3), 74.2, 73.3 (CH2 Bn), 52.0 (CH3 CO2Me); HRMS: [M+H]+ calcd for 
C28H27F3NO6 530.17850, found 530.17835. 
Methyl (2,3-di-O-benzyl-1-O-(N-[phenyl]trifluoroacetimidoyl)-β-D-xylofuranosyl uronate) 
(73). The title compound was generated from 56 (1.20 g, 3.0 mmol) by the general 
procedure for imidate donor synthesis, conditions A. Yield: 81% β only (561 mg, 1.06 mmol) 
as a colourless oil. Rf: 0.28 (8/2 pentane/Et2O). [α]  = +10.2° (c = 0.55, CHCl3); IR (thin film): 
696, 1105, 1159, 1207, 1325, 1717, 1732, 1771; 1H NMR (CDCl3, T = 323 K, 500 MHz, HH-COSY, HSQC): δ 7.34 – 7.22 
(m, 12H, CHarom), 7.15 – 7.02 (m, 1H, NPh), 6.82 (d, 1H, J = 7.5 Hz, NPh), 6.32 (bs, 1H, H-1), 5.00 (d, 1H, J = 6.0 Hz, H-
4), 4.57 (d, 1H, J = 12.0 Hz, CHH Bn), 4.55 – 4.50 (m, 3H, CH2 Bn, CHH Bn), 4.32 (dd, 1H, J = 6.0, 1.2 Hz, H-3), 4.23 (s, 
1H, H-2), 3.72 (s, 3H, CH3 CO2Me); 13C-APT NMR (CDCl3, T = 323 K, 126 MHz, HSQC): δ 168.6 (C=O), 144.1 (Cq NPh), 
137.5, 137.1 (Cq Bn), 128.8, 128.7, 128.5, 128.3, 128.0, 127.9, 127.6, 124.2, 119.8 (CHarom), 116.1 (q, J = 286.8 Hz, CF3), 
103.3 (C-1), 84.0 (C-2), 82.9 (C-4), 82.0 (C-3), 73.1, 72.5 (CH2 Bn), 52.0 (CH3 CO2 Me); HRMS: [M+Na]+ calcd for 
C28H26F3NO6Na 552.16044, found 552.15999. 
Methyl (2,3-di-O-benzyl-D-ribosyl uronate) diphenyl mercaptal (74). Compound 59 (200 mg, 
0.5 mmol) was dissolved in 2 mL DCM and cooled to 0°C. Thiophenol (90 μL, 0.88 mmol, 1.75 
eq.) and BF3⋅OEt2 (105 μL, 0.85 mmol, 1.7 eq.) were added and the reaction stirred for 4 h. 
The reaction was quenched by the addition of sat. aq. NaHCO3 and the mixture was extracted with DCM three times. 
The combined organic layers were washed with H2O and brine, then dried (MgSO4), filtered and concentrated in vacuo. 
Purfication by flash column chromatography (1/0 to 8/2 pentane/EtOAc) gave the dithioacetal as a colourless oil (156, 
0.28 mmol, 56%). IR (thin film): 696, 737, 1026, 1101, 1217, 1230, 1267, 1439, 1454, 1481, 1581, 1734, 2873, 2922, 
2949, 3030, 3059, 3466; 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC): δ 7.50 – 7.11 (m, 20H, CHarom), 5.19 (d, 1H, J = 
10.5 Hz, CHH Bn), 5.05 (s, 1H, H-1), 4.76 (d, 1H, J = 11.3 Hz, CHH Bn), 4.56 (d, 1H, J = 10.5 Hz, CHH Bn), 4.53 (bs, 1H, 
H-4), 4.48 (d, 1H, J = 11.3 Hz, CHH Bn), 4.39 – 4.30 (m, 2H, H-2, H-3), 3.42 (s, 3H, CH3 CO2Me), 3.02 (bs, 1H, OH); 13C-
APT NMR (CDCl3, 101 MHz, HSQC): δ 172.8 (C=O), 137.9, 137.5, 136.0, 135.1 (Cq), 131.3, 130.7, 129.2, 129.1, 128.5,
128.4, 128.3, 127.9, 127.8, 127.3, 127.0 (CHarom), 81.4, 78.8 (C-2, C-3), 74.8, 73.4 (CH2 Bn), 69.8 (C-4), 60.4 (C-1), 52.6 
(CH3 CO2Me); HRMS: [M+Na]+ calcd for C32H32O5S2Na 583.158.34, found 583.15803. 
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Stereoselectivity of C-2- and C-5-modified 





Of the many structurally different carbohydrates, furanosides, the five-membered ring 
carbohydrates, are common components of plant- and bacterial oligosaccharides, and 
form the basis of DNA/RNA as nucleotides.1–7 Glycosylation reactions with furanosides 
proceed with much the same chemistry as six-membered ring pyranosides. The 
glycosylation mechanism therefore proceeds through a pathway having SN1-like and SN2-
like character. Furanosides are typically more reactive than pyranosides because they 
have one electron-withdrawing oxygen substituent less, and they are conformationally 
more flexible and can easier accommodate the double bond character upon 
oxocarbenium ion formation in the ring. In this chapter the stereoselectivity of SN1-type 
glycosylations are investigated for furanosides, bearing different ring substituents. The 
stereoelectronic effects brought about by fluorine, azide, or the benzyloxy groups on C-
2 and a methyl uronate or benzyloxymethyl group at C-5 are probed, as these can have 




reaction. The stereochemical outcome of experimental glycosylations of the differently 
functionalized furanosides is interpreted using computational analysis of the stability of 
the reactive intermediates in the dissociative mechanism, the furanosyl oxocarbenium 
ion. 
 
   
Figure 1. (A) Pseudo-rotational circle showing twenty distinct furanoside structures, with phase-angle P and 
puckering amplitude τm.8 Green circles indicate the two major conformations of oxocarbenium ions. (B) Two 
resonance structures of a cyclic furanosyl oxocarbenium ion. (C) The two principal conformations of the two-
conformer model (E3-3E) shown for every carbohydrate configuration, example taken as their tri-O-benzyl 
protected form. Colors indicate relative preferential orientations for H-2 and O-3 (see Chapter 1), green is 
relatively stabilizing whereas red is relatively destabilizing. 
Furanosides readily attain different conformations, and all the different possible 
geometric shapes a five-membered ring can adopt can be described by a pseudo-
rotational circle (Figure 1A).9,10 The phase angle (P) defines the conformation of the ring, 
and the puckering amplitude (τm) describes the amount of distortion from the median 
plane the outlying atoms have.8,11 In the middle of this circle, all five ring atoms are in the 
same plane, and all the substituents suffer from eclipsing interactions. Each furanoside, 
neutral or charged, has its own preferential conformation or suite of conformations, 
depending on the nature of the ring substituents and their orientation. 
The conformations adopted by the reactive intermediates in SN1-type 
substitutions, the oxocarbenium ions, are limited to a smaller region of the pseudo-
rotational circle.12 The oxocarbenium ion has two extreme resonance structures (Figure 








































































Stereoselectivity of C-2- and C-5-modified furanosides: a computational and experimental study 
ring atoms in the same plane. The remaining ring-atom, C-3, will be out of the 
oxocarbenium ion plane, to minimize eclipsing interactions of its substituents. 
Therefore, the two most likely structures of an oxocarbenium ion will be the E3 and 3E 
conformations, or conformations closely related to those. The orientational preferences 
of each substituent in these two conformations has been investigated by the group of 
Woerpel (see also Chapter 1), the results of which are graphically displayed in Figure 
1C.13–17 The substituent on C-2 is preferentially placed in a sterically less demanding 
pseudo-equatorial orientation, simultaneously allowing the pseudo-axially orientated  
C–H bond to be aligned for hyperconjugative stabilization (σ→p/π*) of the anomeric 
carbocation. The substituent on C-3, on the other hand, is preferentially placed in a 
pseudo-axial orientation, as this brings the electron density of the electronegative oxygen 
atom closer to the oxocarbenium ion than it would in a pseudo-equatorial setting. This 
makes the effect of the C-3–O-3 bond less electron-withdrawing and allows for through-
space electrostatic stabilization by the lone electron pairs on oxygen. 
The stereoselectivity in glycosylations with furanosides that follow an SN1 
mechanism can be traced to the stereoselectivity inferred by the oxocarbenium ion. 
Woerpel and co-workers have established a model to account for the selectivity based on 
the E3 and 3E oxocarbenium ion conformations (Figure 2).17–20 In this model, coined the 
two-conformer model, attack on the inside of the oxocarbenium ion is preferred over 
attack on the outside of the oxocarbenium ion. The basis of this rationale is the 
developing eclipsing interactions that occur in the transition state of the glycosylation 
reaction. When nucleophilic attack occurs on the outside of the oxocarbenium ion, the 
incoming nucleophile experiences eclipsing interactions with the pseudo-axially 
orientated substituent at C-2. The pseudo-equatorially orientated substituents at C-1 and 
C-2 also experience increased eclipsing interactions in the transition state upon 
rehybridization when a nucleophile attacks from the outside. 
The stability of the oxocarbenium ion, dictated by its substituents, and the 
preference for inside attack leading to a more favorable transition state, leads to a model 
that can predict stereoselectivity based on oxocarbenium ion stability. The reasoning of 
this model is valid by the Hammond postulate: the geometry of the product-forming 
transition state is assumed to resemble the structure of the oxocarbenium ion 
intermediate, and the stereoselective preference of the ground-state oxocarbenium ion 







Figure 2. (left, middle) The two-conformer model, visualizing preferential nucleophilic attack from the inside 
face. Important rotations are denoted by dashed arrows. (right) Ground-state approximation to oxocarbenium 
ion stereoselectivity. ΔG≈ΔΔG‡, energy levels are arbitrarily chosen for illustrative purposes. Reaction 
coordinate only visualized for the two inside attack pathways. 
energy difference of two oxocarbenium ions (ΔG) is assumed to be similar to their 
transition state energy difference (ΔΔG‡), thereby resulting in similar reaction rates of 
both inside attack pathways, and a product ratio mirroring the oxocarbenium ion ratio. 
It can be difficult to predict which of the E3-3E envelopes is the more stable 
conformation on the basis of individual substituent effects, especially when there are 
conflicting orientational interests between the substituents. Furthermore, a change in 
protecting- or functional groups on the furanoside ring may have an unforeseen 
stereoelectronic influence, leading to less obvious geometries.21,22 To assess the 
conformational behavior of furanosyl oxocarbenium ions, a method was devised based 
on Density Functional Theory (DFT), with which the relative stabilities of each 
conformation in the complete pseudo-rotational circle can be calculated, generating 
Conformational Energy Landscape (CEL) maps.23 This method has been previously used 
by van Rijssel et al. to calculate the relative energies of furanosyl oxocarbenium ions of 
all four pentose furanosyl configurations (arabino-, ribo-, lyxo-, and xylo-configured, 49, 
53, 57, and 61, Figure 3), bearing three O-methyl groups.24,25 The results obtained by this 
method were in excellent agreement with experimental glycosylations (using the per-
benzylated substrates, see also Table 1), and prompted further application of the DFT 
method to study relevant structural modifications. This chapter describes in detail the 
effects of the 2-fluoro, 2-azido, and 5-methyl uronate groups on the stability of the 
oxocarbenium ion conformations. The stereochemical outcome of experimental 
glycosylations is related to the structures of the intermediate oxocarbenium ions as 
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Results and discussion 
Glycosylations 
Sixteen furanosides, comprising all four configurations of the D-pentofuranoses, with a 
2-fluoro, 2-azido, or a 5-uronic acid ester substituent are studied, while the previously 
investigated fully benzylated donors are used for comparison.24 The synthesis of all used 
furanosyl donors is described in Chapter 7. 
The glycosyl donors of the C-2- and C-5-modified furanosides feature a trifluoro-
N-phenylimidate anomeric leaving group (9-20, Table 1), since the corresponding acetyl 
donors proved inactive due to the presence of more electron-withdrawing substituents. 
Besides, allylations were preferred here over reactions with triethylsilane-d (TES-D) 
because the structure of the products could be determined with more ease, generally less 
side products were formed, the products could be easier separated from the 
contaminants, and the yields of the reactions were generally higher.26 For the reactions 
of the C-2-azido donors TES-D was used because allyltrimethylsilane (allyl-TMS) did not 
lead to product formation even at higher temperatures (+5°C) and further increase of 
temperature led to degradation of the donor. 
First the effect of these changes was probed by the condensation of tri-O-benzyl 
trifluoro-N-phenylimidate donors 5-8, with allyl-TMS), showing nearly identical 
selectivities as those obtained previously by van Rijssel et al. with the four perbenzylated 
furanosyl acetates 1-4 with TES-D as the acceptor (see entries 1-4 vs entries 5-8, Table 
1).24 The high 1,2-cis-selectivity of all tri-O-benzyl furanosides (1-8, entries 1-8, Table 1) 
is apparent (α for ribo- and xylo-configured, β for arabino- and lyxo-configured 
substrates). The ribo- and lyxo-configured donors give solely the 1,2-cis-glycosylated 
products (21, 23, 25, 27). The xylo-configured donors show poorer selectivity and a 85:15 
α:β product ratio is obtained when both xylosyl donors are condensed with allyl-TMS 
(28) or TES-D (24). Arabinoside 1 is highly β-selective with TES-D (21) and forms a 
small amount of the other anomer when glycosylated as imidate 5 with allyl-TMS (25).  
This 1,2-cis-selectivity largely remains in the series of C-2- and C-5-modified 
furanosides: all configurations except xylose are highly 1,2-cis-selective for all 
modifications tested. Rather strikingly, it thus appears that the nature of the substituents 
on furanosyl donors, have relatively little effect on the stereochemical outcome of the 
glycosylation reactions, when following a SN1-like pathway. The 2-fluoroxyloside 36 is 

















Product α : β 
Yield 
(%) 
1 1 β-Rib 2 eq. TES-D -78 70 21 >98 : 2 50 
2 2 α/β-Ara (2/1) 2 eq. TES-D -78 165 22 <2 : 98 62 
3 3 α-Lyx 2 eq. TES-D -78 165 23 <2 : 98 100 
4 4 α/β-Xyl (1/3) 2 eq. TES-D -78 165 24 85 : 15 40 
5 5 β-Rib 2 eq. allyl-TMS -78 24 25 >98 : 2 e  
6 6 α-Ara 2 eq. allyl-TMS -78 24 26 10 : 90 e 
7 7 α-Lyx 2 eq. allyl-TMS -78 24 27 <2 : 98 e  
8 8 α/β-Xyl (1/6) 2 eq. allyl-TMS -78 24 28 85 : 15 e  
9 9 β-RibA 4 eq. allyl-TMS -20 100 29 >98 : 2 79 
10 10 α/β-AraA (1/1) 4 eq. allyl-TMS -20 100 30 5 : 95 76 
11 11 α-LyxAc 4 eq. allyl-TMS -20 100 31 <2 : 98 76 
12 12 β-XylA 4 eq. allyl-TMS -20 100 32 45 : 55 57d 
13 13 β-RibF 4 eq. allyl-TMS -20 100 33 >98 : 2 76 
14 14 α-AraFc 4 eq. allyl-TMS -20 100 34 <2 : 98 79 
15 15 α-LyxF 4 eq. allyl-TMS -20 100 35 <2 : 98 90 
16 16 α/β-XylF (3/5) 4 eq. allyl-TMS -20 100 36 70 : 30 62 
17 17 β-RibN3c 4 eq. TES-D +5 100 37 >98 : 2 68 
18 18 α-AraN3c 4 eq. TES-D +5 100 38 <2 : 98 57 
19 19 β-LyxN3c 4 eq. TES-D +5 100 39 <2 : 98 59 
20 20 α/β-XylN3 (1/1) 4 eq. TES-D +5 100 40 85 : 15 68d 
Anomeric configuration established by HSQC-HECADE and NOESY NMR.27–29 aDetailed experimental 
conditions are provided in the experimental section. bImidates were assigned by 1H NMR at +50°C in CDCl3, 
but rotational dynamics still interfered with definite anomeric determination and the imidates are tentatively 
assigned based on 13C chemical shift; imidate anomeric mixtures served as a reference. cThese imidates were 
formed as an anomeric mixture and isolated as separate anomers, indicated is the anomer used in the reaction. 




Stereoselectivity of C-2- and C-5-modified furanosides: a computational and experimental study 
anomers (product 40), identical to the reaction of the corresponding tri-O-benzyl donor. 
The uronic acid xyloside donor 12 is the least selective (entry 12, Table 1), giving roughly 
equal amounts of both the α- and the β-product (32). The reactions of the xylosides also 
provided significant quantities of different side products. Beside 45, the product 
originating from an intramolecular electrophilic aromatic substitution, the yet 
unreported trifluoro-N-phenylacetamide linked glycosides (41-44) were formed (Figure 
4). The furanosides with other configurations only showed minor amounts of these side 
products.  
 
Figure 4. Side products 41-45 identified as side products, percentages obtained from the crude 1H NMR.  
 
Computations 
With the experimental glycosylation stereoselectivity data available, the computational 
studies of the intermediate oxocarbenium ions were undertaken next. The oxocarbenium 
ions which are used in DFT calculations are displayed in Figure 3 and they are all 
protected with O-methyl ethers to limit rotational degrees of freedom and reduce 
computational cost. 
The DFT calculations were executed by screening all the conformations on the 
pseudo-rotational circle, akin to the method described by van Rijssel et al. An initial 
geometry-optimized structure was taken as the base conformation and by changing the 
dihedral angles of the ring atoms, a set of 81 conformations was generated, with a 
maximum ring puckering of 40° (See Experimental section). While these dihedral angles 
were constrained, the other internal coordinates were allowed to change in the 
subsequent energy optimization calculations, performed by the Gaussian 03 software 
package,30 at a computational level of B3LYP/6-311G**. Three separate sets of 81 
















































totaling 243 data points. For the uronic acids, two sets of 81 conformations, for the 
eclipsed and bisected structures, were assessed providing 162 data points. The energy 
obtained from the DFT calculations was corrected for solvation in DCM by a polarized 
continuum model (PCM). Additionaly, a Gibbs free energy correction was applied at the 
temperature of the glycosylation reactions.31 The energy of all conformers was then 
visualized as a polar contour plot on the pseudo-rotational circle, with isoenergetic values 
as the contour lines, resulting in the Conformational Energy Landscape (CEL) maps (vide 
infra). Separate CEL maps are generated for the C-4–C-5 bond rotamers (gg, gt, tg, or 
eclipsed and bisected). 
 
Figure 3. Oxocarbenium ions evaluated computationally in this chapter. 
The modifications at C-2 and C-5 have been be examined for each configuration and 
Tables 2-5 report the CEL maps for each configuration, the contributions of each C-4–
C-5 rotamer, the relative energy of the most favorable conformations, as well as the 
experimental stereoselectivities.  
The results of the computational study of the ribo-configured furanosyl 
oxocarbenium ions 49-52 are provided in Table 2. The overall shape of the energy 
landscape is comparable for all four ions in the combined rotamer CEL maps, with the 
energy minima centered on the E3 conformation, which places all the individual 
substituents in their most favorable orientation. The three individual rotamers provide 
similar maps for the different C-2 modifications, with gg being clearly the most favorable 
rotamer, as this species benefits from a stabilizing interaction of the O-5 lone pairs and 
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Table 2. CEL maps of ribo-configured oxocarbenium ions 49-52. 
Ribose 
    
Combined 
rotamers 
   
 
   





E3 : 0.0 
4T3 : 1.1 
4E : 1.1 
3E : 1.9 
E3 : 0.0 
4T3 : 0.5 
4E : 1.5 
3E : 5.2 
4T3 : 0.0 
E3 : 0.1 
4E : 1.4 
3E : 2.8 
E3 : 0.0 
4T3 : 0.3 
3E : 2.5 
     
Experimental 
(α : β) 
>98 : 2 >98 : 2 >98 : 2 >98 : 2 



























rotamers, being the eclipsed and bisected ones. Apparently both can benefit from a 
charge-stabilizing interaction by the lone pairs of the oxygen atoms of the uronic acid 
ester. The CEL maps of both are similar, with the stabilization originating from the C=O 
being somewhat more favorable than the stabilization of the OMe group. The most 
appreciable structural difference that can be derived from the CEL maps of the four 
ribosyl oxocarbenium ions, is the stronger tendency of the fluorine atom to occupy a 
pseudo-equatorial orientation. The 3E conformer of 50 is 5.2 kcal∙mol-1 higher in energy 
than the lowest energy E3 conformer, whereas this difference is only 1.9 kcal∙mol-1 for 49 
and around 2.5 kcal∙mol-1 for 51 and 52. The introduction of an electron-withdrawing 
substituent on C-2 or C-5 also led to the decrease of the relative energy of the twist 4T3 
structures, closely related to the E3 conformation. Using the lowest energy E3 conformers, 
or closely related 4T3 structures, as product forming intermediates the formation of the 
1,2-cis-products can be accounted for using the inside attack model. Thus the 
stereoelectronic effects of the C-2–OBn, C-2–F and C-2–N3 on the stability and reactivity 
of the intermediate oxocarbenium ions appear to be very similar.  
The CEL maps for arabino-configured furanosyl oxocarbenium ions 53-56 
(depicted in Tabel 3) also have a very similar overall shape, with the energy minima at 
the 3E conformations. The substituents for arabino-configured furanosyl oxocarbenium 
ions cannot simultaneously take up a most stabilizing orientation and the contribution 
of the C-2–H hyperconjugation seems to be most dominating, resulting in the 3E as the 
lowest energy structure. The three C-4–C-5 rotamers show the expected order of 
stability: gg > gt > tg. There are small structural differences apparent caused by the 
stereoelectronic effects of the fluoro, and azido groups respectively. The 3E conformation 
is clearly the most stable structure, but a second minimum appears on the other side of 
the CEL map at a minimally puckered E3 conformation. The largest difference is seen for 
the C-2–N3 gg-rotamer, where a second minimum-energy conformer can be found for 
structures adopting a 4T3/4E conformation with minimal puckering, and one without any 
puckering (Figure 5). The uronic acid oxocarbenium ion 56 preferentially takes up a 3E 
structure, with the related 3T4 conformation being relatively close in energy (0.9  
kcal∙mol-1).  
The stereoselectivity of the condensation reactions of the arabinofuranosyl 
donors, which are all highly 1,2-cis-selective, may be explained using the 3E/3T4 structures 
as product forming intermediates. This would indicate that attack on the more flat  
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Table 3. CEL maps of arabino-configured oxocarbenium ions 53-56. 
Arabinose 
    
Combined 
rotamers 
    
 
    
 
   
  
   
Energies 
(kcal∙mol-1) 
3E : 0.0 
flat-E3 : 1.2 
E3 : 2.2 
3E : 0.0 
flat-4E : 0.6 
flat-4T3: 1.1 
flat-E3 : 1.2 
3E : 0.0 
flat-4E : 0.3 
flat: 0.4 
flat-E3 : 0.9 
3E : 0.0 
3T4: 0.9 
E3 : 1.2 
           
Experimental 
(α : β) 
<2 : 98 <2 : 98 <2 : 98 5 : 95 









































Figure 5. Ball-stick model of the flat conformation of 2-azidoarabinosyl oxocarbenium ion 55, viewed through 
the C-2–C-3 bond and C-1–C-2 bond respectively. 
 
 
All lyxo-configured oxocarbenium ions 57-60 (Table 4) show a single energy 
minimum on the 3E side of the CEL map. The difference in energy between this structure 
and the other conformers appears to be even larger than the energy differences observed 
for the ribosyl oxocarbenium ions. This can be understood by realizing that the ‘inverted’ 
envelope, the E3, not only loses the stabilizing interactions of the C-2 and C-3 
substituents, but also experiences severe 1,3-diaxial interactions between the C-2 and  
C-4 groups, especially for the electronically most favorable gg-rotamer. In the most stable 
3E conformer, the steric interaction between the C-5–OMe and the C-3–OMe (a 1,3-
diaxial like interaction) increases the relative energy of the gg-rotamer, and the gt-
rotamer is the most favorable rotamer providing the energy minimum in the overall CEL 
map. Also in the lyxo-case, the effect of the different substituents is minimal, although 
structures occupying a 3T4 conformation are relatively favorable for all three 
modifications (being 1.2-2.1 kcal∙mol-1 higher in energy than the neighboring E3 
envelopes). Again the lowest energy oxocarbenium ions account for the observed 
experimental all-cis stereoselectivity, following the inside attack model.  
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Finally, the xylo-configured oxocarbenium ions 61-64 (Table 5) were assessed. 
Again, the CEL maps of the differently functionalized xylosides appear to be rather 
similar. Two minima are apparent on either side of the CEL maps. These minima 
originate from C-4–C-5 rotamers, with the gg- and gt-rotamers leading to low energy E3-
like and 3E-like structures respectively. The energy minima located on the south side of 
the CEL maps are relatively ‘broad’ and not only encompass the E3 conformations but 
also, as noted earlier by van Rijssel et al., the 4T3 structures, and perhaps more striking, 
the 4E envelope conformation. This latter conformer is in fact the lowest energy species 
for 2-fluoroxyloside 62 and xylosyl uronate 64. This conformation is unable to use the 
stabilizing effect of the O-3 lone electron pairs, or the hyperconjugation of the C–H bond 
on C-2 to its full extent (Figure 6). Instead, the driving stabilization now appears to be 
the interaction of the C-5–O-benzyl with the anomeric center. In the 4E conformation, 
the steric interactions between C-5 and the substituents at C-3 and the C-2–H are 
reduced when compared to the sterically unfavorable situation in the E3 conformer.  
When the relative energy of the different configurations is compared, it becomes 
clear that the xylose oxocarbenium ions are higher in energy than their configurational 
counterparts. This may, in part, account for the higher amount of side products formed 
in the reactions of the xylosyl donors.32 The established broad energy minima may be at 
the basis for the poor stereoselectivity observed in the condensations of the xylosyl 




Figure 6. Ball-stick model of the 4E conformation of 2-fluoroxylosyl oxocarbenium ion 62, viewed through 
the C-2–C-3 bond and C-1–C-2 bond respectively.  
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A set of twelve functionalized furanosides has been glycosylated under conditions 
favoring an SN1-type substitution reaction with allyltrimethylsilane or triethylsilane-d to 
investigate the stereoselectivity of these reactions. The experimental results have been 
complemented by computational studies, generating Conformational Energy Landscape 
(CEL) maps for the intermediate oxocarbenium ions. Striking similarities have been 
observed for the CEL maps of the oxocarbenium ions featuring different C-2 and C-5 
substituents and –as a result– very similar stereoselectivities are obtained in the 
glycosylations of the different donors. Nonetheless, the CEL map method also revealed 
conformers different from the 3E-E3 pair as relatively stable conformers and structural 
deviations to 4E, 4T3, 3T4 and flat conformations have been revealed in some cases for the 
2-fluoro, 2-azido, and 5-methyl uronate substituted species. The changes in the 
population of the different conformational states of the reactive intermediate only had a 
minor effect on the outcome of the glycosylations, which where across the board highly 
1,2-cis-selective, except for the xylo-configured furanosides which consistently provided 
anomeric mixtures. The appearance of more low-energy conformations for the xylo-
configured oxocarbenium ions could account for the erosion of stereoselectivity. CEL 
maps with a localized single energy minimum corresponded to reactions that are 
completely stereoselective. Overall, the study described here has shown that the nature 
of the substituent, C-2–OBn vs –F or –N3 and C-4–CH2OBn vs –CO2Me, does not 
significantly affect the structure of the intermediate ions and the course of the SN1-type 
reactions studied here. This stands in sharp contrast to the effect that these substituents 
have in glycosylations of pyranosyl donors (See for example chapter 4 and 6). The effect 
of the different substituents in this case can probably best be reconciled with a change in 
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Experimental section 
General procedure for furanoside imidate glycosylations. The imidate donor (0.1 mmol, 1 eq.) was coevaporated twice 
with dry toluene and then dissolved in dry DCM (1 mL). Activated 3 Å molecular sieves and the acceptor (2 or 4 eq.) 
were added and the solution was stirred for 30 min at room temperature under an inert atmosphere (N2 or Ar). The 
reaction mixture was cooled to the indicated temperature and a freshly prepared stock solution (0.2 M in DCM) of 
TMSOTf or TfOH was introduced via syringe (50 µL, 0.01 mmol, 0.1 eq.). The reaction mixture was stirred for 1-4 days 
at the indicated temperature, and was then quenched by the addition of sat. aq. NaHCO3. The mixture was diluted 
with H2O and twice extracted with DCM. The combined organic layers were dried with MgSO4, filtered, and 
concentrated in vacuo. The residue was purified by flash column chromatography (1/0 to 80/20 pentane/Et2O) to 
provide the glycosylated furanoside. 
General procedure for quantum mechanical calculations. Analogous to the work of van Rijssel,24 all calculations were 
performed with DFT calculations with the B3LYP hybrid functional. The starting conformer for the Conformational 
Energy Landscapes (CEL) was obtained by a conformer distribution search in the Spartan 10 program in the gas phase, 
with a 6-31G(d) basis set. All resulting geometries were further optimized at the 6-311G(d,p) level in the Gaussian 03 
program, with a polarized continuum model (PCM) to correct for solvation in dichloromethane, and further corrected 
for their zero-point energy (ZPE). The geometry with the lowest, ZPE corrected solvated energy, was selected and 
used as the starting geometry for the CEL. Two dihedral angles of the five-membered ring were constrained: C4-O4-
C1-C2 and C1-C2-C3-C4 by scanning with 10° per step, over 9 steps (-40° to 40°), totaling 81 conformations spanning 
the entire pseudo rotational sphere with a maximum puckering amplitude (τm) of 40°. All other internal coordinates 
were unconstrained. Three separate staggered rotamers (gg, gt, tg) of the O4-C4-C5-O5 dihedral angle (-65°, 65°, 
175°) were considered and their CEL maps were calculated separately by pre-rotating the C4-C5 bond (not 
constrained), bringing the total conformations for each configuration to 243 geometries. The final denoted free Gibbs 
energy was calculated using Equation (1) in which ∆Egas is the gas-phase energy (electronic energy), ∆GTgas (T = 298.15 
K and pressure = 1 atm.) is the sum of corrections from the electronic energy to free Gibbs energy in the harmonic 
oscillator approximation also including zero-point-vibrational energy, and ∆GTsolv is their corresponding free solvation 
Gibbs energy.  
                                                    ΔGin solutionT = ΔEgas+ ΔGgasT + ΔGsolv                                                          (1) 
= ΔGgasT + ΔGsolv 
 
All found minima were checked for negative frequencies. The CEL was visualized as a polar contour plot by the Origin 
pro 9 software, with the energy plotted as 0.5 kcal⋅mol-1 colored intervals, the phase angle P as the azimuth angle and 
the puckering amplitude (τm) as the radius, with a smoothing factor of 0.001. The computed stereoselectivity was 
based on the 3E - E3 two conformer (inside-attack) model, as the ratio of conformers obtained from the Boltzmann 
distribution over these two conformers, at the temperature of the experiment. 
2,3,5-tri-O-benzyl-1-O-(N-[phenyl]trifluoroacetimidoyl)-α-D-arabinofuranoside (6). The 
arabinofuranose lactol24 (421 mg, 1 mmol) was dissolved in acetone (6 mL) and H2O (0.1 
mL) and cooled to 0°C. Cs2CO3 (358 mg, 1,1 mmol, 1.1 eq.) and 2,2,2-trifluoro-N-
phenylacetimidoyl chloride (317 μL, 2 mmol, 2 eq.) were added and the reaction mixture stirred overnight. Very little 
conversion was observed (TLC-analysis), therefore DBU (0.12 mL) was added and the conversion was complete 
immediately. The reaction mixture was reduced in volume under reduced pressure and H2O was added. The aqueous 
phase was extracted twice with DCM and the combined organic layers were dried with Na2SO4, filtered, and 
concentrated under reduced pressure. Flash column chromatography (0-15% Et2O/pentane, with 0.5% Et3N) of the 
residue provided the target imidate donor. Yield = 425 mg, 0.72 mmol, 72% as a waxy solid. Rf: 0.81 (85/15 
pentane/Et2O). 1H NMR (CDCl3, T = 323 K, 400 MHz, HH-COSY, HSQC): δ 7.32 – 7.22 (m, 17H, CHarom), 7.09 – 7.01 (m, 
1H, NPh), 6.80 (d, 2H, J = 8.0 Hz, NPh), 6.27 (bs, 1H, H-1), 4.60 – 4.47 (m, 6H, 3xCH2 Bn), 4.45 (q, 1H, J = 5.1 Hz, H-4), 
4.23 (d, 1H, J = 1.8 Hz, H-2), 4.03 (dd, 1H, J = 5.5, 2.0 Hz, H-3), 3.63 (d, 2H, J = 5.1 Hz, H-5, H-5); 13C-APT NMR (CDCl3, 
T = 323 K, 101 MHz, HSQC): δ 144.0 (Cq NPh), 138.1, 137.9, 137.4 (Cq Bn), 128.8, 128.5, 128.5, 128.4, 127.9, 127.9, 
127.8, 127.7, 124.3, 119.8 (CHarom), 104.0 (C-1), 87.0 (C-2), 84.1 (C-4), 83.8 (C-3), 73.5, 72.3 (CH2 Bn), 69.7 (C-5); HRMS: 




2,3,5-tri-O-benzyl-1-O-(N-[phenyl]trifluoroacetimidoyl)-β-D-ribofuranoside (5). The 
ribofuranose lactol24 (421 mg, 1 mmol) was dissolved in acetone (6 mL) and H2O (0.1 mL) 
and cooled to 0°C. Cs2CO3 (489 mg, 1,5 mmol, 1.5 eq.) and 2,2,2-trifluoro-N-
phenylacetimidoyl chloride (238 μL, 1.5 mmol, 1.5 eq.) were added and the reaction mixture stirred for 2 days. The 
reaction mixture was reduced in volume under reduced pressure and H2O was added. The aqueous phase was 
extracted twice with DCM and the combined organic layers were dried with Na2SO4, filtered, and concentrated under 
reduced pressure. Flash column chromatography (0-15% Et2O/pentane, with 0.5% Et3N) of the residue provided the 
target imidate donor. Yield = 327 mg, 0.55 mmol, 55% as a colourless oil. Rf: 0.15 (95/5 pentane/Et2O). Spectroscopic 
data were in accord with those previously reported.33 1H NMR (CDCl3, T = 295 K, 400 MHz, HH-COSY, HSQC): δ 7.34 – 
7.26 (m, 17H, CHarom), 7.14 – 7.06 (m, 1H, NPh), 6.80 (d, 2H, J = 7.5 Hz, NPh), 6.33 (bs, 1H, H-1), 4.75 – 4.50 (m, 5H, 
2xCH2 Bn, CHH Bn), 4.49 – 4.43 (m, 2H, CHH Bn, H-4), 4.16 (dd, 1H, J = 7.3, 4.7 Hz, H-3), 4.07 (d, 1H, J = 4.0 Hz, H-2), 
3.71 (dd, 1H, J = 11.0, 3.1 Hz, H-5), 3.59 (dd, 1H, J = 11.0, 4.9 Hz, H-5); 13C-APT NMR (CDCl3, T = 295 K, 101 MHz, HSQC): 
δ 143.8 (Cq NPh), 138.2, 137.5, 137.4 (Cq Bn), 128.8, 128.5, 128.5, 128.4, 128.2, 128.1, 128.0, 127.9, 127.6, 124.3, 
119.7 (CHarom), 102.5 (C-1), 82.2 (C-4), 78.5 (C-2), 77.3 (C-3), 73.3, 72.7, 72.3 (CH2 Bn), 70.0 (C-5). 
2,3,5-tri-O-benzyl-1-O-(N-[phenyl]trifluoroacetimidoyl)-α-D-lyxofuranoside (7). The 
lyxofuranose lactol24 (660 mg, 1,58 mmol) was dissolved in acetone (8 mL) and H2O (0.5 mL) 
and cooled to 0°C. Cs2CO3 (619 mg, 1,9 mmol, 1.2 eq.) and 2,2,2-trifluoro-N-
phenylacetimidoyl chloride (500 μL, 3.17 mmol, 2 eq.) were added and the reaction mixture stirred overnight. Very 
little conversion was observed (TLC-analysis), therefore DBU (0.2 mL) was added and the conversion was complete 
immediately. The reaction mixture was reduced in volume under reduced pressure and coevaporated with dioxane 
and toluene. The residue was dissolved in DCM and filtered over Celite, the filtrate was concentrated under reduced 
pressure. Flash column chromatography (0-15% Et2O/pentane, with 0.5% Et3N) of the residue provided the target 
imidate donor. Yield = 930 mg, 1.57 mmol, 100% as a white solid.  Rf: 0.8 (85/15 pentane/Et2O). 1H NMR (CDCl3, T = 
323 K, 400 MHz, HH-COSY, HSQC): δ 7.34 – 7.20 (m, 17H, CHarom), 7.09 – 7.01 (m, 1H, NPh), 6.78 (d, 2H, J = 8.0 Hz, 
NPh), 6.31 (bs, 1H, H-1), 4.68 – 4.44 (m, 7H, 3xCH2 Bn, H-4), 4.25 (t, 1H, J = 5.1 Hz, H-3), 4.13 (d, 1H, J = 4.2 Hz, H-2), 
3.83 (dd, 1H, J = 10.5, 4.7 Hz, H-5), 3.76 (dd, 1H, J = 10.4, 7.3 Hz, H-5); 13C-APT NMR (CDCl3, T = 323 K, 101 MHz, HSQC): 
δ 143.9 (Cq NPh), 138.2, 137.9, 137.5 (Cq Bn), 129.3, 128.8, 128.5, 128.4, 128.4, 128.0, 127.9, 127.8, 127.7, 124.4, 
119.7 (CHarom), 103.0 (C-1), 81.7 (C-2), 80.5 (C-4), 77.4 (C-3), 73.5, 73.5, 72.9 (CH2 Bn), 69.5 (C-5). 
2,3,5-tri-O-benzyl-1-O-(N-[phenyl]trifluoroacetimidoyl)-α/β-D-xylofuranoside (8). The 
xylofuranose lactol24 (421 mg, 1 mmol) was dissolved in acetone (10 mL) and cooled to 0°C. 
2,2,2-Trifluoro-N-phenylacetimidoyl chloride (190 μL, 1.2 mmol, 1.2 eq.) and DBU (165 μL, 
1.1 mmol, 1.1 eq.) were added and the reaction mixture stirred for 1 h. The reaction mixture was reduced in volume 
under reduced pressure and H2O was added. The aqueous phase was extracted twice with DCM and the combined 
organic layers were dried with Na2SO4, filtered, and concentrated under reduced pressure. Flash column 
chromatography (0-15% Et2O/pentane, with 0.5% Et3N) of the residue provided the target imidate donor. Yield = 427 
mg, 0.72 mmol, 72% as a waxy solid. Rf: 0.38 and 0.47 (9/1 pentane/Et2O). Data for the β-anomer: 1H NMR (CDCl3, T 
= 295 K, 400 MHz, HH-COSY, HSQC): δ 7.34 – 7.18 (m, 17H, CHarom), 7.05 (t, 1H, J = 7.4 Hz, NPh), 6.77 (d, 2H, J = 7.6 
Hz, NPh), 6.30 (bs, 1H, H-1), 4.65 (q, 1H, J = 5.6 Hz, H-4), 4.60 – 4.42 (m, 6H, 3xCH2 Bn), 4.24 (s, 1H, H-2), 4.10 (d, 1H, 
J = 5.4 Hz, H-3), 3.86 (dd, 1H, J = 10.4, 5.1 Hz, H-5), 3.80 (dd, 1H, J = 10.2, 7.2 Hz, H-5); 13C-APT NMR (CDCl3, T = 295 K, 
101 MHz, HSQC): δ 143.9 (Cq NPh), 138.2, 137.7, 137.2 (Cq Bn), 129.1, 128.7, 128.5, 128.4, 128.3, 128.0, 127.8, 127.7, 
127.6, 127.5, 124.2, 119.6 (CHarom), 103.5 (C-1), 84.5 (C-2), 83.0 (C-4), 81.1 (C-3), 73.4, 72.4, 72.1 (CH2 Bn), 69.1 (C-5). 
 Allyl 2,3,5-tri-O-benzyl-1-deoxy-α-D-ribofuranoside (25). Donor 5 and allyltrimethylsilane (2 
eq.) were condensed using the general procedure for furanosyl imidate glycosylations at -78°C 
for 24 h with TMSOTf as the promotor. Rf: 0.27 (19/1 pentane/EtOAc). Spectroscopic data 
were in accord with those previously reported.34 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC): δ 7.40 – 7.23 (m, 15H, 
CHarom), 5.79 (ddt, 1H, J = 17.1, 10.2, 6.9 Hz, CH allyl), 5.10 (dq, 1H, J = 17.2, 1.5 Hz, CHH allyl), 5.04 (ddt, 1H, J = 10.2, 
2.1, 1.1 Hz, CHH allyl), 4.81 (d, 1H, J = 11.7 Hz, CHH Bn), 4.64 – 4.45 (m, 5H, CHH Bn, 2xCH2 Bn), 4.21 (dt, 1H, J = 7.1, 
3.5 Hz, H-4), 4.10 (dd, 1H, J = 7.1, 4.3 Hz, H-3), 4.05 (td, 1H, J = 7.0, 3.9 Hz, H-1), 3.98 (t, 1H, J = 4.1 Hz, H-2), 3.63 (dd, 
1H, J = 10.7, 3.3 Hz, H-5), 3.52 (dd, 1H, J = 10.7, 3.8 Hz, H-5), 2.51 (t, 2H, J = 7.0 Hz, CH2 allylic); 13C-APT NMR (CDCl3, 
101 MHz, HSQC): δ 138.6, 138.4, 138.1 (Cq Bn), 135.1 (CH allyl), 128.5, 128.4, 128.4, 127.9, 127.8, 127.8, 127.7, 127.7 
(CHarom), 117.0 (CH2 allyl), 80.2 (C-1), 80.1 (C-3), 79.6 (C-4), 77.7 (C-2), 73.5, 73.4, 72.8 (CH2 Bn), 70.2 (C-5), 34.4 (CH2 
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 Allyl 2,3,5-tri-O-benzyl-1-deoxy-α/β-D-arabinofuranoside (26). Donor 6 and allyltrimethylsilane 
(2 eq.) were condensed using the general procedure for furanosyl imidate glycosylations at -
78°C for 24 h with TMSOTf as the promotor. (α:β = 10:90). Spectroscopic data were in accord 
with those previously reported.35 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC): δ 7.36 – 7.23 (m, 15H, CHarom), 5.80 (ddt, 
1H, J = 17.1, 10.2, 7.0 Hz, CH allyl), 5.15 – 5.00 (m, 2H, CH2 allyl), 4.61 – 4.47 (m, 5H, 2x CH2 Bn, CHH Bn), 4.36 (d, 1H, 
J = 11.9 Hz, CHH Bn), 4.08 (td, 1H, J = 6.7, 2.8 Hz, H-4), 4.03 (td, 1H, J = 7.0, 3.5 Hz, H-1), 3.92 (d, 1H, J = 2.7 Hz, H-3), 
3.81 (d, 1H, J = 3.5 Hz, H-2), 3.63 (dd, 1H, J = 9.8, 5.8 Hz, H-5), 3.51 (dd, 1H, J = 9.8, 6.9 Hz, H-5), 2.52 – 2.47 (m, 2H, 
CH2 allylic); 13C-APT NMR (CDCl3, 101 MHz, HSQC): δ 138.3, 138.0, 137.9 (Cq Bn), 135.0 (CH allyl), 128.6, 128.5, 128.4, 
127.9, 127.8, 127.8, 127.8, 127.7 (CHarom), 117.1 (CH2 allyl), 83.8 (C-3), 82.9 (C-2), 82.8 (C-4), 81.1 (C-1), 73.4, 71.5, 
71.4 (CH2 Bn), 70.7 (C-5), 33.3 (CH2 allylic). 
 Allyl 2,3,5-tri-O-benzyl-1-deoxy-β-D-lyxofuranoside (27). Donor 7 and allyltrimethylsilane (2 
eq.) were condensed using the general procedure for furanosyl imidate glycosylations at -78°C 
for 24 h with TMSOTf as the promotor. Rf: 0.47 (9/1 pentane/EtOAc). 1H NMR (CDCl3, 400 MHz, 
HH-COSY, HSQC): δ 7.36 – 7.24 (m, 15H, CHarom), 5.82 (ddt, 1H, J = 17.1, 10.2, 7.0 Hz, CH allyl), 5.07 (dq, 1H, J = 17.1, 
1.5 Hz, CHH allyl), 5.02 (ddt, 1H, J = 10.2, 2.2, 1.2 Hz, CHH allyl), 4.76 (d, 1H, J = 11.8 Hz, CHH Bn), 4.68 (d, 1H, J = 11.9 
Hz, CHH Bn), 4.61 (d, 1H, J = 11.9 Hz, CHH Bn), 4.59 (d, 1H, J = 12.1 Hz, CHH Bn), 4.54 (d, 1H, J = 11.8 Hz, CHH Bn), 4.52 
(d, 1H, J = 12.1 Hz, CHH Bn), 4.24 – 4.19 (m, 1H, H-4), 4.17 (dd, 1H, J = 6.1, 3.9 Hz, H-3), 4.01 – 3.94 (m, 2H, H-1, H-2), 
3.83 (dd, 1H, J = 10.1, 4.8 Hz, H-5), 3.72 (dd, 1H, J = 10.1, 6.6 Hz, H-5), 2.53 – 2.46 (m, 2H, CH2 allylic);  13C-APT NMR 
(CDCl3, 101 MHz, HSQC): δ 138.6, 138.5, 138.4 (Cq Bn), 135.6 (CH allyl), 128.5, 128.4, 128.4, 127.9, 127.7, 127.7, 127.6, 
127.5 (CHarom), 116.7 (CH2 allyl), 79.6 (C-3), 79.1 (C-1), 78.9 (C-2), 78.0 (C-4), 73.4, 73.3, 73.3 (CH2 Bn), 70.5 (C-5), 35.4 
(CH allylic); 13C HSQC-HECADE NMR (CDCl3, 101 MHz): 2JC1,H2 = +1.0 Hz, 2JC2,H1 = +1.5 Hz, 3JH2,C-allyl = +1.6 Hz; HRMS: 
[M+H]+ calcd for C29H33O4 445.23709, found 445.23704. 
Allyl 2,3,5-tri-O-benzyl-1-deoxy-α/β-D-xylofuranoside (28). Donor 8 and allyltrimethylsilane (2 
eq.) were condensed using the general procedure for furanosyl imidate glycosylations at -78°C 
for 24 h with TMSOTf as the promotor. Rf: 0.38 (92/8 pentane/Et2O). Spectroscopic data were 
in accord with those previously reported for the β-anomer.36 Data for the α-anomer: 1H NMR (CDCl3, 400 MHz, HH-
COSY, HSQC): δ 7.40 – 7.22 (m, 15H, CHarom), 5.78 (ddt, 1H, J = 17.1, 10.2, 6.9 Hz, CH allyl), 5.10 (dq, 1H, J = 17.2, 1.6 
Hz, CHH allyl), 5.02 (ddd, 1H, J = 10.2, 2.2, 1.1 Hz, CHH allyl), 4.64 – 4.35 (m, 6H, 3xCH2 Bn), 4.37 (td, 1H, J = 6.3, 4.1 
Hz, H-4), 4.16 (td, 1H, J = 7.1, 3.7 Hz, H-1), 4.03 (dd, 1H, J = 4.1, 1.1 Hz, H-3), 3.83 (dd, 1H, J = 3.7, 1.1 Hz, H-2), 3.72 
(dd, 1H, J = 9.6, 6.4 Hz, H-5), 3.67 (dd, 1H, J = 9.6, 6.3 Hz, H-5); 13C-APT NMR (CDCl3, 101 MHz, HSQC): δ 138.4, 138.1, 
138.0 (Cq Bn), 135.2 (CH allyl), 128.6, 128.5, 128.4, 127.9, 127.9, 127.8, 127.7 (CHarom), 116.9 (CH2 allyl), 81.8 (C-2), 
81.4 (C-3), 80.1 (C-1), 78.8 (C-4), 73.5, 72.4, 72.1 (CH2 Bn), 68.5 (C-5), 33.7 (CH2 allylic); 13C HSQC-HECADE NMR (CDCl3, 
101 MHz): 2JC1,H2 = +4.2 Hz, 2JC2,H1 = +2.2 Hz, 3JCallyl,H2 = +0.5 Hz; Diagnostic peaks for the β-anomer: 1H NMR (CDCl3, 
400 MHz, HH-COSY, HSQC): δ 4.24 – 4.18 (m, 1H, H-4), 3.96 (dd, 1H, J = 3.9, 1.0 Hz, H-3), 3.92 (ddd, 1H, J = 7.1, 6.4, 
3.5 Hz, H-1), 3.81 – 3.70 (m, 3H, H-2, H-5, H-5); 13C-APT NMR (CDCl3, 101 MHz, HSQC): δ 134.6 (CH allyl), 117.3 (CH2 
allyl), 85.9 (C-2), 83.4 (C-1), 83.0 (C-3), 80.1 (C-4), 73.6, 71.7, 71.7 (CH2 Bn), 68.5 (C-5), 38.5 (CH2 allylic); 13C HSQC-
HECADE NMR (CDCl3, 101 MHz): 2JC2,H1 = -4.0 Hz, 3JCallyl,H2 = +4.5 Hz; HRMS: [M+H]+ calcd for C29H33O4 445.23709, found 
445.23734. 
Methyl (1-allyl-2,3-di-O-benzyl-1-deoxy-α-D-ribofuranosyl uronate) (29). Donor 9 and 
allyltrimethylsilane (4 eq.) were condensed using the general procedure for furanosyl imidate 
glycosylations at -20°C for 100 h with TfOH as the promotor. Yield = 30.5 mg, 79 μmol, 79% as 
a white solid. Rf: 0.57 (4/1 pentane/EtOAc).  [α]  = +28.3° (c = 0.60, CHCl3); IR (thin film): 698, 
737, 916, 1026, 1099, 1144, 1206, 1275, 1356, 1454, 1748, 2868, 2922, 3030; 1H NMR (CDCl3, 500 MHz, HH-COSY, 
HSQC): δ 7.38 – 7.27 (m, 10H, CHarom), 5.77 (ddt, 1H, J = 17.1, 10.2, 6.9 Hz, CH allyl), 5.11 (dq, 1H, J = 17.2, 1.6 Hz, CHH 
allyl), 5.04 (ddt, 1H, J = 10.2, 2.0, 1.1 Hz, CHH allyl), 4.82 (d, 1H, J = 11.6 Hz, CHH Bn), 4.67 (d, 1H, J = 12.0 Hz, CHH Bn), 
4.63 (d, 1H, J = 12.0 Hz, CHH Bn), 4.59 (d, 1H, J = 6.0 Hz, H-4), 4.56 (d, 1H, J = 11.6 Hz, CHH Bn), 4.22 (dd, 1H, J = 6.0, 
4.5 Hz, H-3), 4.17 (td, 1H, J = 7.0, 4.1 Hz, H-1), 3.99 (t, 1H, J = 4.3 Hz, H-2), 3.73 (s, 3H, CH3 CO2Me), 2.56 – 2.48 (m, 2H, 
CH2 allylic); 13C-APT NMR (CDCl3, 126 MHz, HSQC): δ 172.7 (C=O), 138.2, 137.6 (Cq), 134.6 (CH allyl), 128.6, 128.5, 
128.1, 128.0, 127.9 (CHarom), 117.3 (CH2 allyl), 82.7 (C-3), 81.1 (C-1), 79.3 (C-4), 77.8 (C-2), 73.6, 72.8 (CH2 Bn), 52.4 
(CH3 CO2Me), 34.0 (CH2 allylic); 13C HSQC-HECADE NMR (CDCl3, 126 MHz): 2JC2,H1: +1.5 Hz, 3JCallyl,H2: +0.7 Hz; HRMS: 




Methyl (1-allyl-2,3-di-O-benzyl-1-deoxy-β-D-arabinofuranosyl uronate) (30). Donor 10 and 
allyltrimethylsilane (4 eq.) were condensed using the general procedure for furanosyl imidate 
glycosylations at -20°C for 100 h with TfOH as the promotor. Yield = 29 mg, 76 μmol, 76% as a 
white solid (α:β = 5:95). Rf: 0.64 (4/1 pentane/EtOAc). [α]  = +32.4° (c = 0.38, CHCl3); IR (thin 
film): 698, 737, 916, 1028, 1101, 1207, 1279, 1454, 1726, 1761, 2920; 1H NMR (CDCl3, 500 MHz, HH-COSY, HSQC): δ 
7.44 – 7.18 (m, 10H, CHarom), 5.79 (ddt, 1H, J = 17.1, 10.2, 7.0 Hz, CH allyl), 5.14 (dq, 1H, J = 17.1, 1.5 Hz, CHH allyl), 
5.08 – 5.02 (m, 1H, CHH allyl), 4.66 (d, 1H, J = 11.9 Hz, CHH Bn), 4.56 (d, 1H, J = 11.9 Hz, CHH Bn), 4.51 (d, 1H, J = 1.7 
Hz, H-4), 4.49 (d, 1H, J = 11.8 Hz, CHH Bn), 4.39 – 4.34 (m, 2H, CHH Bn, H-3), 4.21 (td, 1H, J = 7.2, 3.5 Hz, H-1), 3.81 
(dd, 1H, J = 3.5, 0.8 Hz, H-2), 3.68 (s, 3H, CH3 CO2Me), 2.64 – 2.50 (m, 2H, CH2 allylic); 13C-APT NMR (CDCl3, 126 MHz, 
HSQC): δ 171.4 (C=O) 137.7, 137.5 (Cq), 134.7 (CH allyl), 128.6, 128.5, 128.1, 127.9, 127.9, 127.8 (CHarom), 117.3 (CH2 
allyl), 85.2 (C-3), 82.4 (C-1), 81.6 (C-4), 81.3 (C-2), 71.9, 71.8 (CH2 Bn), 52.3 (CO2Me), 33.3 (CH2 allylic); 13C HSQC-
HECADE NMR (CDCl3, 126 MHz): 2JC1,H2 = +2.5 Hz, 2JC2,H1 = +2.5 Hz, 3JCallyl,H2 = +0.3 Hz; HRMS: [M+Na]+ calcd for 
C23H26O5Na 405.16725, found 405.16656.  
Methyl (1-allyl-2,3-di-O-benzyl-1-deoxy-β-D-lyxofuranosyl uronate) (31). Donor 11 and 
allyltrimethylsilane (4 eq.) were condensed using the general procedure for furanosyl imidate 
glycosylations at -20°C for 100 h with TfOH as the promotor. Yield = 29 mg, 76 μmol, 76% as a 
white solid. Rf: 0.32 (4/1 pentane/EtOAc). [α]  = +3.6° (c = 0.58, CHCl3); IR (thin film): 698, 
737, 1028, 1072, 1084, 1099, 1152, 1207, 1356, 1437, 1454, 1732, 1763, 2870, 2920, 2949. 1H NMR (CDCl3, 500 MHz, 
HH-COSY, HSQC): δ 7.39 – 7.21 (m, 10H, CHarom), 5.92 (ddt, 1H, J = 17.2, 10.2, 7.0 Hz, CH allyl), 5.15 (dq, 1H, J = 17.2, 
1.4 Hz, CHH allyl), 5.09 – 5.04 (m, 1H, CHH allyl), 4.76 – 4.67 (m, 3H, CH2 Bn, CHH Bn), 4.62 (d, 1H, J = 6.0 Hz, H-4), 4.56 
(d, 1H, J = 11.8 Hz, CHH Bn), 4.34 (dd, 1H, J = 6.0, 4.4 Hz, H-3), 4.13 (dt, 1H, J = 8.8, 5.4 Hz, H-1), 4.04 (dd, 1H, J = 6.0, 
4.4 Hz, H-2), 3.66 (s, 3H, CH3 CO2Me), 2.75 – 2.64 (m, 1H, CHH allylic), 2.58 – 2.48 (m, 1H, CHH allylic); 13C-APT NMR 
(CDCl3, 126 MHz, HSQC): δ 170.3 (C=O), 138.2, 138.2 (Cq), 135.8 (CH allyl), 128.5, 128.4, 127.8, 127.7, 127.6 (CHarom), 
116.8 (CH2 allyl), 80.5 (C-1), 80.1 (C-3), 79.2 (C-2), 78.3 (C-4), 73.9, 73.2 (CH2 Bn), 51.9 (CO2Me), 35.0 (CH2 allylic); 13C 
HSQC-HECADE NMR (CDCl3, 126 MHz): 2JC2,H1 = -0.25 Hz, 3JCallyl,H2 = +2.9 Hz; HRMS: [M+NH4]+ calcd for C23H30NO5 
400.21185, found 400.21167. 
Methyl (1-allyl-2,3-di-O-benzyl-1-deoxy-α/β-D-xylofuranosyl uronate) (32). Donor 12 and 
allyltrimethylsilane (4 eq.) were condensed using the general procedure for furanosyl imidate 
glycosylations at -20°C for 100 h with TfOH as the promotor. Four fractions were isolated: 
amide 44 (1 mg, Rf: 0.66), mixed fraction (22 mg, product 32, α:β = 35:65 as 68 wt%, and amide 
44 as 32 wt%), title product 45 (7 mg, α:β = 69:33), cyclized product 61 (2 mg, Rf: 0.38 ) Calculated total title product 
yield = 22 mg, 57 μmol, 57%, (α:β = 45:55). Rf: 0.61 and 0.57 (4/1 pentane/EtOAc). Reported as a 1:1 mixture. IR (thin 
film): 698, 737, 1028, 1078, 1094, 1206, 1290, 1454, 1732, 1765, 2862, 2949. 1H NMR (CDCl3, 500 MHz, HH-COSY, 
HSQC): δ 7.38 – 7.24 (m, 20H, CHarom), 5.88 – 5.72 (m, 2H, CH allyl), 5.16 – 5.03 (m, 4H, CH2 allyl), 4.82 (d, 1H, J = 5.1 
Hz, H-4α), 4.69 (d, 1H, J = 4.8 Hz, H-4β), 4.54 – 4.38 (m, 8H, 4xCH2 Bn), 4.36 (ddd, 1H, J = 7.9, 6.5, 3.3 Hz, H-1α), 4.27 
(dd, 1H, J = 5.1, 1.0 Hz, H-3α), 4.24 (dd, 1H, J = 4.8, 1.7 Hz, H-3β), 4.01 (td, 1H, J = 6.9, 3.3 Hz, H-1β), 3.82 (d, 1H, J = 3.5 
Hz, H-2α), 3.82 (d, 1H, J = 3.4 Hz, H-2β), 3.76 (s, 3H, CH3 CO2Meβ), 3.73 (s, 3H, CH3 CO2Meα), 2.64 – 2.41 (m, 4H, CH2 
allylic); 13C-APT NMR (CDCl3, 126 MHz, HSQC): δ 170.6 (C=Oα), 169.6 (C=Oβ), 137.7 (Cqα), 137.7 (Cqβ), 137.6 (Cqβ), 137.5 
(Cqα), 134.5 (CH allylα), 134.4 (CH allylβ), 128.6, 128.6, 128.6, 128.6, 128.1, 128.1, 128.1, 127.9, 127.9, 127.9 (CHarom), 
117.6 (CH2 allylicβ), 117.3 (CH2 allylicα), 84.7 (C-2β), 84.0 (C-1β), 83.9 (C-3β), 82.9 (C-3α), 81.6 (C-1α), 81.4 (C-2α), 80.4 
(C-4β), 80.0 (C-4α), 73.0, 72.5, 72.3, 72.0 (CH2 Bn), 52.1 (CO2Meβ), 52.0 (CO2Meα), 38.1 (CH2 allylicβ), 33.1 (CH2 allylicα); 
13C HSQC-HECADE NMR (CDCl3, 126 MHz): α-anomer: 2JC1,H2 = +1.5 Hz, 2JC2,H1 = +2.4 Hz, 3JCallyl,H2 = +0.2 Hz, β-anomer: 
2JC1,H2 = -1.5 Hz, 2JC2,H1 = -4.5 Hz, 3JCallyl,H2 = +2.9 Hz; HRMS: [M+NH4]+ calcd for C23H30NO5 400.21185, found 400.21153. 
Allyl 3,5-di-O-benzyl-1,2-dideoxy-2-fluoro-α-D-ribofuranoside (33). Donor 13 and 
allyltrimethylsilane (4 eq.) were condensed using the general procedure for furanosyl imidate 
glycosylations at -20°C for 100 h with TfOH as the promotor. Yield = 27 mg, 76 μmol, 76% as a 
white solid. Rf: 0.52 (8/2 pentane/Et2O). Spectroscopic data were in accord with those previously reported.13 1H NMR 
(CDCl3, 500 MHz, HH-COSY, HSQC): δ 7.40 – 7.19 (m, 10H, CHarom), 5.80 (ddtd, 1H, J = 17.3, 10.2, 7.0, 0.8 Hz, CH allyl), 
5.20 – 5.14 (m, 1H, CHH allyl), 5.09 (ddt, 1H, J = 10.2, 2.1, 1.1 Hz, CHH allyl), 4.89 (dt, 1H, J = 55.2, 2.9 Hz, H-2), 4.69 
(d, 1H, J = 11.7 Hz, CHH Bn), 4.59 (d, 1H, J = 12.1 Hz, CHH Bn), 4.52 (d, 1H, J = 11.7 Hz, CHH Bn), 4.49 (d, 1H, J = 12.1 
Hz, CHH Bn), 4.21 – 4.16 (m, 1H, H-4), 4.11 (ddd, 1H, J = 8.6, 3.5, 0.5 Hz, H-3), 4.05 (dtd, 1H, J = 29.3, 7.4, 2.4 Hz, H-1), 
3.71 (dd, 1H, J = 10.8, 2.4 Hz, H-5), 3.56 (dd, 1H, J = 10.9, 3.4 Hz, H-5), 2.49 (ddt, 2H, J = 7.0, 5.6, 1.4 Hz, CH2 allylic); 
13C-APT NMR (CDCl3, 126 MHz, HSQC): δ 138.3, 137.6 (Cq), 133.6 (CH allyl), 128.6, 128.5, 128.1, 128.0, 127.8, 127.7 
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(CHarom), 118.0 (CH allyl), 90.1 (d, J = 191.0 Hz, C-2), 80.0 (d, J = 18.3 Hz, C-1), 79.2 (C-4), 78.6 (d, J = 16.5 Hz, C-3), 73.6, 
72.5 (CH2 Bn), 69.6 (C-5), 33.7 (d, J = 9.3 Hz, CH allylic); 19F NMR (CDCl3, 471 MHz): δ -215.30 (ddd, J = 53.7, 29.4, 23.5 
Hz, F-2); 13C HSQC-HECADE NMR (CDCl3, 126 MHz): 2JC2,H1 = +4.9 Hz, 3JCallyl,H2 = +0.2 Hz; HRMS: [M+NH4]+ calcd for 
C22H29FNO3 374.21260, found 374.21252. 
Allyl 3,5-di-O-benzyl-1,2-dideoxy-2-fluoro-β-D-arabinofuranoside (34). Donor 14 and 
allyltrimethylsilane (4 eq.) were condensed using the general procedure for furanosyl imidate 
glycosylations at -20°C for 100 h with TfOH as the promotor. Yield = 28 mg, 79 μmol, 79% as a 
colourless oil. Rf: 0.80 (9/1 pentane/EtOAc). [α]  = -29.7° (c = 0.93, CHCl3); IR (thin film):700, 712, 1026, 1070, 1096, 
1269, 1452, 2924; 1H NMR (CDCl3, 500 MHz, HH-COSY, HH-NOESY, HSQC): δ 7.36 – 7.25 (m, 10H, CHarom), 5.84 (ddtd, 
1H, J = 17.2, 10.2, 7.1, 0.7 Hz, CH allyl), 5.17 (dq, 1H, J = 17.1, 1.5 Hz, CHH allyl), 5.10 (ddt, 1H, J = 10.2, 2.0, 1.1 Hz, 
CHH allyl), 4.88 (dd, 1H, J = 52.0, 2.8 Hz, H-2), 4.66 – 4.53 (m, 4H, 2xCH2 Bn), 4.04 – 3.98 (m, 2.5H, H-1, H-3, H-4), 3.95 
(td, 0.5H, J = 7.2, 2.8 Hz, H-3), 3.65 – 3.59 (m, 1H, H-5), 3.56 – 3.51 (m, 1H, H-5), 2.55 – 2.42 (m, 2H, CH2 allylic);13C-
APT NMR (CDCl3, 126 MHz, HSQC): δ 138.2, 137.4 (Cq), 133.8 (CH allyl), 128.6, 128.5, 128.1, 127.9, 127.9, 127.8 
(CHarom), 117.8 (CH2 allyl), 95.89 (d, J = 186.6 Hz, C-2), 84.71 (d, J = 27.3 Hz, C-3), 82.5 (C-4), 80.70 (d, J = 20.9 Hz, C-1), 
73.6, 72.2 (CH2 Bn), 70.2 (C-5), 32.63 (d, J = 8.1 Hz, CH2 allylic); 19F NMR (CDCl3, 471 MHz): δ -198.80 (ddd, J = 50.6, 
29.6, 20.2 Hz); 13C HSQC-HECADE NMR (CDCl3, 126 MHz): 2JC1,H2 = +4.2 Hz, 2JC2,H1 = +5.6 Hz, 3JCallyl,H2 = 0.1 Hz; HRMS: 
[M+NH4]+ calcd for C22H29FNO3 374.21260, found 374.21280. 
Allyl 3,5-di-O-benzyl-1,2-dideoxy-2-fluoro-β-D-lyxofuranoside (35). Donor 15 and 
allyltrimethylsilane (4 eq.) were condensed using the general procedure for furanosyl imidate 
glycosylations at -20°C for 100 h with TfOH as the promotor. Yield = 32 mg, 90 μmol, 90% as a 
white solid. Rf: 0.28 (9/1 pentane/EtOAc). [α]  = -10.5° (c = 1.07, CHCl3); IR (thin film): 696, 711, 737, 1026, 1070, 
1271, 1452, 2870, 2922; 1H NMR (CDCl3, 500 MHz, HH-COSY, HSQC): δ 7.42 – 7.21 (m, 10H, CHarom), 5.82 (ddt, 1H, J = 
17.2, 10.2, 7.0 Hz, CH allyl), 5.17 (dd, 1H, J = 17.1, 1.5 Hz, CHH allyl), 5.12 – 5.06 (m, 1H, CHH allyl), 4.89 (ddd, 1H, J = 
54.6, 4.0, 2.9 Hz, H-2), 4.69 (d, 1H, J = 11.9 Hz, CHH Bn), 4.62 (d, 1H, J = 12.2 Hz, CHH Bn), 4.58 – 4.51 (m, 2H, 2xCHH 
Bn), 4.28 (td, 1H, J = 7.7, 3.6 Hz, H-4), 4.19 (ddd, 1H, J = 22.8, 7.8, 4.0 Hz, H-3), 3.84 (dtd, 1H, J = 27.3, 7.2, 2.8 Hz, H-
1), 3.80 (dd, 1H, J = 10.6, 3.7 Hz, H-5), 3.65 (ddd, 1H, J = 10.6, 7.7, 1.7 Hz, H-5), 2.51 (t, 2H, J = 7.1 Hz, CH2 allylic); 13C-
APT NMR (CDCl3, 126 MHz, HSQC): δ 138.6, 137.5 (Cq), 133.7 (CH allyl), 128.6, 128.4, 128.1, 127.9, 127.8, 127.6 
(CHarom), 117.9 (CH2 allyl), 90.2 (d, J = 193.1 Hz, C-2), 79.3 (d, J = 18.8 Hz, C-1), 78.6 (d, J = 15.7 Hz, C-3), 78.2 (C-4), 
73.5, 72.8 (CH2 Bn), 70.6 (d, J = 2.7 Hz, C-5), 33.9 (d, J = 8.1 Hz, CH2 allylic); 19F NMR (CDCl3, 471 MHz): δ -213.57 (ddd, 
J = 54.5, 27.2, 22.9 Hz); 13C HSQC-HECADE NMR (CDCl3, 126 MHz): 2JC1,H2 = +1.2 Hz, 2JC2,H1 = +5.2 Hz, 3JCallyl,H2 = +0.4 Hz; 
HRMS: [M+NH4]+ calcd for C22H29FNO3 374.21260, found 374.21295. 
Allyl 3,5-di-O-benzyl-1,2-dideoxy-2-fluoro-α/β-D-xylofuranoside (36). Donor 16 and 
allyltrimethylsilane (4 eq.) were condensed using the general procedure for furanosyl imidate 
glycosylations at -20°C for 100 h with TfOH as the promotor. Yield = 22 mg, 62 μmol, 62% as a 
colourless oil (α:β = 70:30), and 12 mg (24%) of the anomeric amide (42). Rf: 0.53 and 0.40 (9/1 pentane/Et2O). IR 
(thin film): 696, 735, 1028, 1076, 1088, 1454, 2868, 2922; 1H NMR (CDCl3, 500 MHz, HH-COSY, HSQC): δ 7.37 – 7.25 
(m, 10H, CHarom), 5.88 – 5.77 (m, 1H, CH allyl), 5.19 – 5.07 (m, 2H, CH2 allyl), 4.91 (ddd, 0.7H, J = 51.4, 2.8, 1.3 Hz, H-
2α), 4.79 (ddd, 0.3H, J = 52.6, 2.9, 1.4 Hz, H-2β), 4.65 (d, 0.3H, J = 11.9 Hz, CHH Bnβ), 4.65 – 4.58 (m, 1.7H, 2xCHH Bnα, 
CHH Bnβ), 4.56 (d, 0.7H, J = 11.9 Hz, CHH Bnα), 4.53 – 4.49 (m, 1.3H, 2xCHH Bnβ, CHH Bnα), 4.42 – 4.36 (m, 0.7H, H-
4α), 4.26 – 4.12 (m, 1.7H, H-1α, H-3α, H-4β), 4.08 (ddd, 0.3H, J = 8.9, 4.3, 1.3 Hz, H-3β), 4.02 (dddd, 0.3H, J = 13.9, 7.3, 
6.5, 2.8 Hz, H-1β), 3.76 (dd, 0.3H, J = 10.0, 5.3 Hz, H-5β), 3.73 – 3.69 (m, 1H, H-5α, H-5β), 3.67 (dd, 0.7H, J = 9.8, 6.4 Hz, 
H-5α), 2.54 – 2.36 (m, 2H, CH2 allylic); 13C-APT NMR (CDCl3, 126 MHz, HSQC): δ 138.3, 138.2, 137.6 (Cq), 134.0 (CH
allylα), 133.8 (CHallylβ), 128.6, 128.6, 128.5, 128.1, 128.0, 127.9, 127.9, 127.8, 127.7, 127.7, 127.7 (CHarom), 117.8 (CH2 
allylβ), 117.7 (CH2 allylα), 97.7 (d, J = 182.9 Hz, C-2β), 94.4 (d, J = 187.9 Hz, C-2α), 82.4 (d, J = 35.5 Hz, C-3β), 82.4 (d, J = 
13.9 Hz, C-1β), 81.8 (d, J = 25.8 Hz, C-3α), 79.8 (d, J = 1.6 Hz, C-4β), 79.6 (d, J = 19.0 Hz, C-1α), 78.9 (C-4α), 73.6 (CH2 
Bnβ), 73.6, 72.9 (CH2 Bnα), 72.1 (CH2 Bnβ), 68.3 (C-5β), 68.2 (C-5α), 37.4 (d, J = 7.6 Hz, CH2 allylicβ), 33.1 (d, J = 10.3 Hz, 
CH2 allylicα); 19F NMR (CDCl3, 471 MHz): δ -183.53 (dddd, 0.3F, J = 52.6, 28.0, 13.2, 1.8 Hz), -201.43 (dddd, 0.7F, J =
51.4, 31.9, 9.9, 2.5 Hz); 13C HSQC-HECADE NMR (CDCl3, 126 MHz): α-anomer: 2JC1,H2 = +5.0 Hz, 2JC2,H1 = +4.5 Hz, 3JCallyl,H2 
= +0.3 Hz, β-anomer: 2JC1,H2 = +1.3 Hz, 2JC2,H1 = -5.4 Hz, 3JCallyl,H2 = +2.8 Hz; HRMS: [M+Na]+ calcd for C22H25FO3Na 




1-[2H]-1,4-anhydro-2-azido-3,5-di-O-benzyl-2-deoxy-α-D-ribitol (37). Donor 17 and triethylsilane-d 
(4 eq.) were condensed using the general procedure for furanosyl imidate glycosylations at 0-5°C 
for 100 h with TfOH as the promotor. Yield = 23 mg, 68 μmol, 68% as a colourless oil. Inseparable 
mixture of 37 and amide 46 (in a 95:5 ratio). Rf: 0.26 (9/1 pentane/EtOAc). [α]  = +88° (c = 0.77, CHCl3) IR (thin film): 
698, 738, 1028, 1089, 1269, 1454, 2104, 2864; 1H NMR (CDCl3, 500 MHz, HH-COSY, HH-NOESY, HSQC): δ 7.38 – 7.26 
(m, 10H, CHarom), 4.69 (d, 1H, J = 11.8 Hz, CHH Bn), 4.57 – 4.52 (m, 2H, CHH Bn, CHH Bn), 4.48 (d, 1H, J = 12.0 Hz, CHH 
Bn), 4.14 (dd, 1H, J = 6.1, 5.5 Hz, H-3), 4.09 – 4.02 (m, 2H, H-1, H-4), 3.89 (t, 1H, J = 5.4 Hz, H-2), 3.61 (dd, 1H, J = 10.7, 
3.3 Hz, H-5), 3.50 (dd, 1H, J = 10.7, 4.0 Hz, H-5); 13C-APT NMR (CDCl3, 126 MHz, HSQC): δ 138.1, 137.4 (Cq), 128.6, 
128.5, 128.2, 128.1, 127.8, 127.8 (CHarom), 80.9 (C-4), 79.9 (C-3), 73.6, 73.0 (CH2 Bn), 70.2 (t, J =22.8 Hz, C-1), 69.8 (C-
5), 60.8 (C-2); 2H NMR (CHCl3, 77 MHz): δ 3.90; 13C HSQC-HECADE NMR (CDCl3, 126 MHz): 2JC1-H2: +1.5 Hz, 2JC2-H1: +1.3 
Hz; HRMS: [M+Na]+ calcd for C19H20DN3O3Na 363.1543, found 363.1546. 
1-[2H]-1,4-anhydro-2-azido-3,5-di-O-benzyl-2-deoxy-β-D-arabitol (38). Donor 18 and triethylsilane-
d (4 eq.) were condensed using the general procedure for furanosyl imidate glycosylations at 0-
5°C for 100 h with TfOH as the promotor. Yield = 19.5 mg, 57 μmol, 57% as a colourless oil. Rf: 0.38 
(9/1 pentane/EtOAc). Spectroscopic data were in accord with those previously reported for the non-deuterated 
compound.37 [α]  = -14.6° (c = 0.98, CHCl3); IR 1H NMR (CDCl3, 500 MHz, HH-COSY, HSQC): δ 7.37 – 7.26 (m, 10H, 
CHarom), 4.59 (d, 1H, J = 11.8 Hz, CHH Bn), 4.56 (s, 2H, CH2 Bn), 4.54 (d, 1H, J = 11.8 Hz, CHH Bn), 4.02 (td, 1H, J = 5.3, 
4.3 Hz, H-4), 4.00 (bs, 1H, H-1), 3.98 (dd, 1H, J = 5.0, 1.9 Hz, H-2), 3.92 (dd, 1H, J = 4.3, 1.9 Hz, H-3), 3.59 (dd, 1H, J = 
10.3, 5.5 Hz, H-5), 3.57 (dd, 1H, J = 10.3, 5.2 Hz, H-5); 13C-APT NMR (CDCl3, 126 MHz, HSQC): δ 138.1, 137.4 (Cq), 128.7, 
128.5, 128.2, 128.0, 127.9, 127.8 (CHarom), 85.0 (C-3), 83.4 (C-4), 73.6, 72.4 (CH2 Bn), 70.7 (t, J = 23.0 Hz, C-1), 70.5, 
70.0 (C-5), 65.9 (C-2); 2H NMR (CHCl3, 77 MHz): δ 4.02; 13C HSQC-HECADE NMR (CDCl3, 126 MHz): 2JC1-H2: +1.1 Hz, 2JC2-
H1: +2.3 Hz; HRMS: [M+NH4]+ calcd for C19H24DN4O3 358.19839, found 358.19858. 
1-[2H]-1,4-anhydro-2-azido-3,5-di-O-benzyl-2-deoxy-β-D-lyxitol (39). Donor 19 and triethylsilane-d 
(4 eq.) were condensed using the general procedure for furanosyl imidate glycosylations at 0-5°C 
for 100 h with TfOH as the promotor. Yield = 20 mg, 59 μmol, 59% as a colourless oil. Rf: 0.13 (9/1 
pentane/EtOAc). [α]  = -37° (c = 1.0, CHCl3); IR (thin film): 698, 738, 1984, 1269, 1452, 2104, 2868, 2922, 3032; 1H 
NMR (CDCl3, 500 MHz, HH-COSY, HSQC): δ 7.36 – 7.26 (m, 10H, CHarom), 4.77 (d, 1H, J = 11.6 Hz, CHH Bn), 4.61 – 4.56 
(m, 2H, CHH Bn, CHH Bn), 4.50 (d, 1H, J = 11.9 Hz, CHH Bn), 4.20 (t, 1H, J = 5.2 Hz, H-3), 4.15 (dt, 1H, J = 6.9, 5.2 Hz, H-
4), 3.92 (d, 1H, J = 6.4 Hz, H-1), 3.86 (dd, 1H, J = 6.3, 5.1 Hz, H-2), 3.73 (dd, 1H, J = 10.1, 5.0 Hz, H-5), 3.68 (dd, 1H, J = 
10.1, 7.0 Hz, H-5); 13C-APT NMR (CDCl3, 126 MHz, HSQC): δ 138.2, 137.5 (Cq), 128.6, 128.5, 128.1, 128.0, 127.9, 127.8 
(CHarom), 79.6, 79.6 (C-3, C-4), 74.0, 73.7 (CH2 Bn), 69.0 (C-5), 68.7 (t, J = 22.8 Hz, C-1), 61.3 (C-2); 2H NMR (CHCl3, 77 
MHz): δ 3.95; 13C HSQC-HECADE NMR: 2JC2,H1 = +0.2 Hz; HRMS: [M+Na]+ calcd for C19H20DN3O3Na 363.1543, found 
363.1551. 
1-[2H]-1,4-anhydro-2-azido-3,5-di-O-benzyl-2-deoxy-α/β-D-xylitol (40). Donor 20 and triethylsilane-
d (4 eq.) were condensed using the general procedure for furanosyl imidate glycosylations at 0-
5°C for 100 h with TfOH as the promotor. Yield = 23 mg, 68 μmol, 68% as a colourless oil (α:β = 
85:15). Inseparable mixture of 40 and amide 43 (in a 73:27 ratio) Rf: 0.30 (85/15 pentane/Et2O). IR (thin film): 696, 
735, 1061, 1088, 1207, 1454, 1494, 1690, 2106, 2916; 1H NMR (CDCl3, 500 MHz, HH-COSY, HSQC): δ 7.38 – 7.24 (m, 
10H, CHarom), 4.65 – 4.58 (m, 2H, 2xCHH Bn), 4.54 (d, 1H, J = 11.9 Hz, CHH Bn), 4.52 (d, 1H, J = 11.9 Hz, CHH Bn), 4.21 
– 4.15 (m, 1.85H, H-1α, H-4), 4.04 (dd, 1H, J = 5.5, 1.9 Hz, H-2), 3.99 (dd, 1H, J = 4.4, 1.9 Hz, H-3), 3.74 – 3.70 (m, 1.15H, 
H-1β, H-5), 3.68 (dd, 1H, J = 10.0, 6.4 Hz, H-5); 13C-APT NMR (CDCl3, 126 MHz, HSQC): δ 138.2, 137.4 (Cq), 128.7, 128.5, 
128.2, 127.9, 127.8, 127.8 (CHarom), 82.9 (C-3), 79.7 (C-4), 73.7, 72.6 (CH2 Bn), 70.0 (t, J = 22.7 Hz C-1β), 70.0 (t, J = 
22.7, C-1α) 68.4 (C-5), 65.0 (C-2); 2H NMR (CHCl3, 77 MHz): δ 4.19 (s, 0.15H), 3.75 (s, 0.85H);13C HSQC-HECADE NMR 
(CDCl3, 126 MHz): α-anomer: 2JC2,H1 = +0.7 Hz; β-anomer: 2JC2,H1 = -4.3 Hz; HRMS: [M+Na]+ calcd for C19H20DN3O3Na 
363.1543, found 363.1549.  
3,5-di-O-benzyl-1,2-dideoxy-2-fluoro-1-N-[phenyl]trifluoroacetyl-α/β-D-xylofuranoside (42). 
IR (thin film): 698, 737, 1070, 1153, 1188, 1207, 1454, 1495, 1595, 1690, 2862, 2922; 1H 
NMR (CDCl3, 500 MHz, HH-COSY, HSQC): δ 7.43 – 7.19 (m, 15H, CHarom), 6.31 (dd, 1H, J = 
11.0, 5.1 Hz, H-1), 5.45 (ddd, 1H, J = 52.9, 5.0, 3.8 Hz, H-2), 4.65 (d, 1H, J = 11.9 Hz, CHH 
Bn), 4.47 (d, 1H, J = 11.9 Hz, CHH Bn), 4.40 (s, 2H, CH2 Bn), 3.91 (dt, 1H, J = 14.3, 4.1 Hz, H-3), 3.77 (qd, 1H, J = 4.7, 1.7 
Hz, H-4), 3.56 (ddd, 1H, J = 10.5, 4.4, 0.7 Hz, H-5), 3.49 (dd, 1H, J = 10.6, 4.8 Hz, H-5); 13C-APT NMR (CDCl3, 101 MHz, 
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194.8 Hz, C-2), 87.2 (d, J = 17.4 Hz, C-1), 80.1 (d, J = 23.2 Hz, C-3), 79.1 (d, J = 3.5 Hz, C-4), 73.4, 72.6 (CH2 Bn), 68.0 (C-
5); 19F NMR (CDCl3, 471 MHz): δ -68.17 (s, 3F, CF3), -196.37 (dt, 1F, J = 53.1, 12.7 Hz, F-2). 
2-azido-3,5-di-O-benzyl-1,2-dideoxy-1-N-[phenyl]trifluoroacetyl-α/β-D-xylofuranoside (43). 
Intermixed with 40. The anomeric amide was formed in an α:β = 93:7 ratio. Data for the α-
anomer: 1H NMR (CDCl3, 500 MHz, HH-COSY, HSQC): δ 7.17 (dd, 2H, J = 6.6, 2.6 Hz, NPh), 
6.33 (d, 1H, J = 6.6 Hz, H-1), 4.59 (t, 1H, J = 6.6 Hz, H-2), 4.50 (d, 1H, J = 11.7 Hz, CHH Bn), 
4.46 – 4.40 (m, 3H, CH2 Bn, CHH Bn), 3.66 (t, 1H, J = 4.3 Hz, H-4), 3.59 (t, 1H, J = 6.8 Hz, H-3), 3.49 (dd, 1H, J = 10.7, 4.0 
Hz, H-5), 3.41 (dd, 1H, J = 10.7, 4.5 Hz, H-5); 13C-APT NMR (CDCl3, 126 MHz, HSQC): δ 157.0 (q, J = 36.4 Hz, F3C-C=O), 
138.0, 137.0 (Cq), 132.0, 130.7, 129.6, 129.5, 128.7, 128.3, 128.1, 127.8, 127.8, 127.7, 126.5, 120.6 (CHarom), 116.0 (q, 
J = 288.7 Hz, CF3), 86.9 (C-1), 80.9 (C-3), 78.6 (C-4), 73.5, 73.3 (CH2 Bn), 68.6 (C-5), 67.1 (C-2); 19F NMR (CDCl3, 471 
MHz): δ -68.04 (s, CF3,α), -68.18 (s, CF3,β); 13C HSQC-HECADE NMR (CDCl3, 126 MHz): α-anomer: 2JC1,H2 = -0.2 Hz, 2JC2,H1 
= +1.1 Hz; Diagnostic peaks for the β-anomer: 1H NMR (CDCl3, 500 MHz, HH-COSY, HSQC): 5.98 (d, 0.07H, J = 6.2 Hz, 
H-1), 4.28 (td, 0.07H, J = 6.3, 4.6 Hz, H-4); 13C HSQC-HECADE NMR: 2JC1,H2 = -4.0 Hz, 2JC2,H1 = -2.1 Hz. 
Methyl (2,3-di-O-benzyl-1-deoxy-1-N-[phenyl]trifluoroacetyl-α/β-D-xylofuranosyl uronate) 
(44). 1H NMR (CDCl3, 500 MHz, HH-COSY, HH-NOESY, HSQC, HMBC): δ 7.41 – 7.28 (m, 18H, 
CHarom), 7.15 (dd, 2H, J = 7.3, 2.0 Hz, CHarom), 6.59 (d, 1H, J = 6.1 Hz, H-1), 4.70 (d, 1H, J = 
11.2 Hz, CHH Bn), 4.58 (d, 1H, J = 11.2 Hz, CHH Bn), 4.51 (t, 1H, J = 6.1 Hz, H-2), 4.44 (d, 1H, 
J = 11.7 Hz, CHH Bn), 4.38 (d, 1H, J = 11.9 Hz, CHH Bn), 4.15 (d, 1H, J = 6.5 Hz, H-4), 3.77 – 3.72 (m, 1H, H-3), 3.67 (s, 
3H, CH3 CO2Me); 13C-APT NMR (CDCl3, 126 MHz, HSQC, HMBC): δ 169.5 (C=O), 137.3, 137.1 (Cq), 129.6, 128.7, 128.6, 
128.5, 128.3, 128.2, 128.1, 127.9 (CHarom), 87.6 (C-1), 81.9 (C-2), 81.1 (C-3), 78.2 (C-4), 74.3, 72.9 (CH2 Bn), 52.3 
(CO2Me); 19F NMR (CDCl3, 471 MHz): δ -68.09; 13C HSQC-HECADE NMR (CDCl3, 126 MHz): 2JC1,H2 = +1.5 Hz. 
Methyl (2S,3R,3aS,9bR)-3-(benzyloxy)-3,3a,5,9b-tetrahydro-2H-furo[3,2-c]isochromene-2-
carboxylate (45). 1H NMR (CDCl3, 500 MHz, HH-COSY, HH-NOESY, HSQC): δ 7.61 – 7.57 (m, 1H, 
CHarom), 7.37 – 7.28 (m, 7H, CHarom), 7.08 – 7.04 (m, 1H, CHarom), 5.16 (d, 1H, J = 2.8 Hz, H-1), 
4.92 (d, 1H, J = 4.9 Hz, H-4), 4.78 (d, 1H, J = 14.6 Hz, CHH Bn (C-2)), 4.72 (d, 1H, J = 11.9 Hz, CHH 
Bn (C-3)), 4.65 (d, 1H, J = 14.8 Hz, CHH Bn (C-2)), 4.64 (d, 1H, J = 12.0 Hz, CHH Bn (C-3)), 4.44 (d, 1H, J = 5.1 Hz, H-3), 4.26 
(d, 1H, J = 3.0 Hz, H-2), 3.76 (s, 3H, CH3 CO2Me); 13C-APT NMR (CDCl3, 126 MHz, HSQC): δ 170.2 (C=O), 134.4, 130.9, 
130.3 (Cq), 128.7, 128.6, 128.1, 127.7, 127.7, 124.2 (CHarom), 85.2 (C-3), 80.4 (C-4), 79.5 (C-2), 74.9 (C-1), 73.2 (CH2 
Bn(C-3)), 67.2 (CH2 Bn(C-2)), 52.1 (CO2Me). 
3,5-di-O-benzyl-1,2-dideoxy-2-fluoro-1-N-[phenyl]trifluoroacetyl-α-D-ribofuranoside (46). 
Intermixed with 37. Diagnostic peaks: 1H NMR (CDCl3, 500 MHz): δ 6.04 (d, 1H, J = 5.1 Hz, H-
1), 4.61 (t, 1H, J = 5.5 Hz, H-2), 4.44 (d, 1H, J = 11.6 Hz, CHH Bn), 4.41 (d, 1H, J = 12.0 Hz, CHH 
Bn), 4.30 (d, 1H, J = 12.0 Hz, CHH Bn), 3.44 (dd, 1H, J = 11.3, 2.5 Hz, H-5), 3.32 (dd, 1H, J = 
11.3, 3.5 Hz, H-5); 13C-APT NMR (CDCl3, 126 MHz, HSQC): δ 88.1 (C-1), 80.3 (C-4), 77.0 (C-3), 73.4, 73.3 (CH2 Bn), 68.0 
(C-5), 62.9 (C-2). 
Methyl (2S,3S,3aR,9bS)-3-(benzyloxy)-3,3a,5,9b-tetrahydro-2H-furo[3,2-c]isochromene-2-
carboxylate (47). Intermixed with 30. 1H NMR (CDCl3, 500 MHz, HH-COSY, HSQC): δ 7.52 (dd, 
1H, J = 5.5, 3.6 Hz, CHarom), 7.44 – 7.25 (m, 7H, CHarom), 7.07 (dd, 1H, J = 5.4, 3.8 Hz, CHarom), 
4.93 (d, 1H, J = 2.9 Hz, H-1), 4.79 (d, 1H, J = 12.1 Hz, CHH 3-OBn), 4.79 (d, 1H, J = 14.7 Hz, CHH 
2-OBn), 4.72 (d, 1H, J = 12.1 Hz, CHH 3-OBn), 4.66 (d, 1H, J = 14.7 Hz, CHH 2-OBn), 4.64 (d, 1H, J = 2.8 Hz, H-4), 4.46 
(dd, 1H, J = 2.7, 0.7 Hz, H-3), 4.21 (d, 1H, J = 3.0 Hz, H-2), 3.71 (s, 3H, CH3 CO2Me); 13C-APT NMR (CDCl3, 126 MHz, 
HSQC): δ 170.6 (C=O), 137.4, 134.7, 130.7 (Cq), 129.8, 128.7, 128.1, 128.0, 128.0, 127.5, 124.2 (CHarom), 87.8 (C-3), 
82.2 (C-4), 79.8 (C-2), 75.3 (C-1), 72.4, 67.0 (CH2 Bn), 52.4 (CO2Me); 13C HSQC-HECADE NMR (CDCl3, 126 MHz): 2JC1,H2 
= +6.0 Hz, 2JC2,H1 = +2.4 Hz. 
Methyl (2,3-di-O-benzyl-1-deoxy-1-N-[phenyl]trifluoroacetyl-α-D-ribofuranosyl uronate) (48). 
1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC): δ 7.43 – 7.16 (m, 14H, CHarom), 7.09 – 7.00 (m, 
1H, NPh), 6.44 (d, 1H, J = 5.8 Hz, H-1), 4.75 (d, 1H, J = 11.1 Hz, CHH Bn), 4.65 (d, 1H, J = 11.0 
Hz, CHH Bn), 4.48 – 4.39 (m, 2H, CHH Bn, H-2), 4.35 (d, 1H, J = 12.0 Hz, CHH Bn), 4.02 – 3.99 
(m, 2H, H-3, H-4), 3.67 (s, 3H, CH3 CO2Me); 13C-APT NMR (CDCl3, 101 MHz, HSQC): δ 170.5 (C=O), 137.4, 137.0, 133.5 
(Cq), 132.1, 131.8, 129.1, 128.6, 128.5, 128.3, 128.2, 128.2, 128.1 (CHarom), 88.5 (C-1), 79.9, 79.0 (C-3, C-4), 77.2 (C-2), 
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Chapter 9 
Summary and future prospects 
Summary 
The demand for biologically relevant oligosaccharides and glycoconstructs is ever 
increasing. Chemical synthesis can provide pure and well-defined carbohydrates, which 
are generally difficult to obtain from nature. One of the challenges in synthetic 
carbohydrate chemistry is the efficient construction of 1,2-cis-glycosidic linkages. The 
synthesis of this type of glycosidic bond often requires time-consuming, trial-and-error 
based optimization experiments. It would be highly beneficial if more insight into the 
mechanism of the glycosylation reaction in general, and the formation of 1,2-cis-bonds 
in particular, could be obtained. In this thesis, systematic studies on the reactivity of both 
reaction partners, the glycosyl donor and the glycosyl acceptor, and the influence thereof 
on the selectivity of a glycosylation reaction, are conducted. With these studies more 
insight into the glycosylation mechanism is obtained and it provides a direction how to 
improve the stereoselectivity in the formation of 1,2-cis-glycosidic linkages. 
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The general glycosylation reaction mechanism and the reactivity of carbohydrate 
building blocks in glycosylation reactions is described in Chapter 1 and Chapter 2. The 
first chapter describes the reactivity from the perspective of the glycosyl donor, the 
electrophilic species. In the second chapter the focus is laid on the nucleophilic reaction 
partner, the acceptor. The reactivity of both species depends on the protecting groups 
they carry. Although much insight has been gained how the protecting groups on the 
donor glycoside impact the reactivity of this coupling partner, the reactivity of acceptor 
glycosides as a function of the protecting and functional group pattern is rather ill-
documented. It also remains unclear how the changing reactivity impacts the change in 
mechanisms from an SN2- to SN1-like substitution reaction, which can have far reaching 
consequences for the stereoselectivity of a glycosylations reaction. Chapter 2 provides an 
overview of recent and older examples that show how small changes in the structure and 
reactivity of the acceptor can lead to large changes in yield, selectivity, and reaction rates. 
Figure 1. Donors 1-4 and model acceptors 5-8 used in Chapters 3 and 4. 
Chapter 3 describes how the reactivity of the acceptor affects the glycosylation 
reaction mechanism. A set of model acceptors (5-8, Figure 1) of gradually changing 
reactivity is used to unveil the influence of the reactivity of the acceptor on the 
stereochemical outcome of the glycosylation reaction. The model acceptors are based on 
ethanol with a varying amount of fluorine substituents (up to three fluorine atoms). The 
presence of more electron-withdrawing fluorine atoms makes the acceptor less reactive. 
The glycosylation method chosen was based on the preactivation of thioglycoside 
donors, to ensure the formation of an anomeric triflate intermediate and prevent 
alternative reaction pathways associated with in situ glycosylation protocols. Ethanol 5, 
the most reactive model acceptor, gave high β-selectivity in glycosylations with three 
donors tested: benzylidene glucose 3, benzylidene mannose 1 and mannuronic acid 
methyl ester 2. The significantly less reactive trifluoroethanol 8 gave high α-selectivity 
for the benzylidene glucose donor, in contrast to the other two donors, that provided 
mostly the β-products. The mono- and difluoroethanols 6 and 7 gave mixtures of 
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anomeric products with the glucose donor, with more α-product for the less reactive 
difluoroethanol. These results indicated that the glycosylations of benzylidene glucose 
donor 3 are very susceptible to changes in acceptor reactivity, while the outcome of the 
glycosylations of the benzylidene mannose and mannuronic acid proved to be less 
sensitive to changes in acceptor nucleophilicity. Subsequently, carbohydrate acceptors 
were tested and it was found that the reactivity of these larger acceptors also proved 
decisive for the glycosylation outcome. Primary and secondary equatorial hydroxyls gave 
relatively high β-selectivity, while secondary axial hydroxyls gave α-selectivity for the 
benzylidene glucose donor. Benzylidene mannose and mannuronic acid donors were 
consistently β-selective for the carbohydrate acceptors. With these results the correlation 
between reactivity of the acceptor and a change in the glycosylation mechanism was 
established. Stronger nucleophiles participate in a more SN2-like mechanism, providing 
the β-product, while weaker nucleophiles react with more SN1-substitution character. 
For benzylidene glucose the SN1 intermediate is an oxocarbenium ion in the 4H3/4E 
conformation, preferably attacked from the α-face, whereas the benzylidene mannose 
and mannuronic acid preferentially take up a B2,5 and 3H4 conformation respectively, 
which are attacked on the β-face. 
The donor scope was extended in Chapter 4 to study the effect of the azide as an 
amine masking group on benzylidene glucosamine donors, and to compare the results 
of glycosylations with these donors with the benzylidene glucose donor from Chapter 3. 
The azide is an electron-withdrawing group and destabilizes the formation of positive 
charge on the anomeric center more than an O-benzyl group does. As a consequence, the 
glycosylations with benzylidene glucosazide donors (such as 4, Figure 1) proceed with 
more SN2-character when compared to reactions with benzylidene glucose, and the 2-
azido group is therefore β-directing. Further structural modifications on the donor were 
also investigated. Changing the C-3 position of the donor from an O-benzyl to an O-
benzoyl group made the donor slightly more β-selective, as a result of the electron-
withdrawing effect of the benzoyl group. Changing the benzylidene ring for a silylidene 
ring made the donor less β-selective, and in combination with a poorly nucleophilic 
acceptor, high α-selectivity can be achieved. 
Instead of the benzylidene or silylidene ring, which span over positions C-4 and 
C-6, a tethering group spanning C-3 and C-4, the butanediacetal (BDA) group, is studied 
as a protecting group of glucosazide donors in Chapter 5. Glycosylations with the set of
fluorinated model acceptors showed that the glucosazide donor bearing the BDA group
Chapter 9 
220 
glycosylates significantly more β-selective than its benzylidene counterpart. Likely, the 
conformational restriction inferred by the cyclic BDA group, prevents the formation of 
charge on the anomeric center, making SN1-pathways less favorable. Consequently, 
reactions with this donor proceed with a high degree of SN2 substitution. 
The reactivity of glycosyl acceptors was studied in more detail in Chapter 6. With 
a large selection of C-4–OH glucose acceptors bearing O-benzyl and O-benzoyl groups 
in all possible patterns, the influence of acceptor reactivity on the glycosylation 
stereoselectivity was studied. The benzylidene protected glucose and glucosazide donors 
from Chapters 3 and 4 served as donors to map the acceptor structure-reactivity-
stereoselectivity relationships. The outcome of glycosylations of these two donors is very 
sensitive to changes in acceptor reactivity and complement each other, with the 
benzylidene glucosazide donor providing more β-product (resulting from more SN2 
character in the condensation reactions) than the benzylidene glucose donor. From this 
study it became evident that the reactivity of carbohydrate acceptors can also be changed 
by the manipulation of protecting groups. The strategic placement of a single benzoyl 
group is sufficient to turn the glycosylation with the benzylidene glycose donor 
completely α-selective. With a second benzoyl group, also the glucosazide donor 
becomes completely α-selective, providing a method to construct 1,2-cis-glucosamine 
linkages. Also, the effect of electron-withdrawing substituents on the aromatic ring of the 
benzoates were studied. These substituents had a minor influence, and only the presence 
of two nitro groups, at both ortho-positions, gave the required drop in reactivity and 
increase in α-selectivity. 
Chapter 7 and Chapter 8 focus on five-membered ring sugars, the furanoses, and 
their selectivity in glycosylations. In the first chapter different functionalities are installed 
on the furanoses. The C-2 position is modified with an azido or a fluoro group and the 
C-5 position is oxidized to the methyl ester. The chosen strategy to install the azide and
fluoride via inversion of a triflate leaving group, was not without problems. The inversion 
of 2-O-triflylriboside smoothly gave the 2-fluoro- and 2-azidoarabinosides. The success
of the nucleophilic substitution on arabinose to give the ribosides, depended on the
anomeric configuration, with partial migration of the anomeric O-methyl group to the
C-2 position in the α-anomer. The inversion of 2-O-triflylxylosides to give the
corresponding lyxose products only proceeded with the α-anomer. Side products during 
this reaction originated from intramolecular participation of the C-5-O-benzyl group.
Inverting 2-O-triflyllyxoside was unsuccessful and only the aromatic furan was formed.
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The 2-fluoro- and 2-azidoxylosides therefore had to be made via an alternative route, for 
which the electrophilic addition to a glycal was chosen. Further modifications to generate 
a set of twelve imidate donors went uneventful. These donors were glycosylated with 
model acceptors in Chapter 8.  
The selectivity of furanosides in glycosylation reactions, under SN1-conditions, 
was investigated in Chapter 8. The oxocarbenium ions that serve as reactive 
intermediates in these glycosylations are responsible for the observed stereoselectivity. 
First, the stereoselectivities were experimentally determined with nucleophilic model 
acceptors allyltrimethylsilane and triethylsilane-d. Almost all glycosylations proceeded 
with exclusive 1,2-cis-selectivity, except for xylo-configured donors which gave anomeric 
mixtures. Next, the relative energies of all possible conformations of the oxocarbenium 
ions were assessed using Density Functional Theory (DFT). The collective set of data 
points for each configuration and C-2/C-5 modification was then plotted as a 
Conformational Energy Landscape (CEL) map. From the computational data it became 
evident that when a single conformation was strongly preferred, the experimental 
glycosylations proceeded with excellent stereoselectivity. In the arabino-configuration 
multiple low in energy conformations were found, of which several were nearly flat. The 
influence of these conformers on the stereochemical outcome of the glycosylations 
proved to be limited and also for the studied C-2/C-5 arabinofuranosides high 1,2-cis-
selectivity was found. The CEL maps of the xylo-configured oxocarbenium ions also 
displayed multiple low in energy conformations. Besides the 3E and E3 conformations, 
which are the most common furanosyl oxocarbenium ion conformations, the 4E 
envelope was found as one of the major contributors to the conformer population. The 
multitude of available conformations led to anomeric mixtures in the glycosylation 
reactions. The computational method is able to effectively show the differences in 
conformer population distribution when groups exhibiting different stereoelectronic 
effects are introduced, like the azido, fluoro, and uronic acid ester groups. With the 
relative stabilities of each conformation of an oxocarbenium ion available, it can be 
determined whether a glycosylation reaction under SN1-conditions proceeds with 
exclusive stereoselectivity. Erosion of stereoselectivity may occur when the 




The main goal of this thesis was to shed more light on the glycosylation reaction 
mechanism. The influence the acceptor has on the glycosylation mechanism is profound, 
but is difficult to quantify. Several techniques referred to in the previous chapters can be 
extended to the model systems used in Chapters 3-5 as well as applied to the carbohydrate 
acceptors of Chapter 6. A few approaches to obtain both qualitative and quantitative 
information on the glycosylation mechanism and/or acceptor reactivity will be discussed 
below. The two extreme situations of the glycosylation mechanism, the SN1 or SN2 
substitution reactions, can be discerned by experimental kinetics and transition state 
models as studied by computational methods.  
Kinetic Isotope Effects 
The rate-determining step for a typical SN1 mechanism is dissociation of the leaving 
group and generation of an (oxo)carbenium ion. This is followed by addition of the 
nucleophile in the product-forming step. In a SN2 reaction, the rate-determining step is 
also the product-forming step. Dissecting the mechanism of glycosylation into its SN1 
and SN2 extremes can be effectively done by studying Kinetic Isotope Effects (KIEs).1,2 
Primary KIEs are measured by integrating NMR signals of the electrophilic anomeric 
carbon atom, either with isotopically enriched substances or using the naturally 
abundant 13C/12C isotopes. The vibrational energy levels of the bonds to the heavier 13C 
isotope (8% mass increase compared to 12C) are lower than those to the 12C atom, 
resulting in a slightly higher bond dissociation energy for the former. This has an 
immediate effect on the SN2 reaction transition state, creating an energy difference 
between the pathways having a 13C or 12C anomeric center carbon (rate constants k12>k13). 
The rate of SN1 reactions is much less effected by the difference between 13C and 12C 
atoms and the ratio of reaction rates (k12/k13) is close to unity. Secondary deuterium KIEs 
(SDKIEs) are measured of an atom at which the reaction does not take place, but which 
is in (close) proximity to the reacting center. The deuterium atom in isotopically labelled 
carbohydrates can be directly attached to the anomeric center (α-SDKIE), or positioned 
further away (β-SDKIE, γ-SDKIE). The ratio of reaction rates is again indicative of the 
reaction mechanism, but it is reversed as compared to primary-KIEs. The SN1 SDKIE is 
often observed to be high (>1.20), while that of the SN2 pathway is around unity.  
KIEs have been studied in the context of glycosylations by the groups of Crich, 
Tantillo, and Bennet, among others, a selection of the results are summarized in 
Summary and future prospects 
223 
Table 1.3–12 Primary KIEs obtained with the strongly nucleophilic acceptor isopropanol 
12 are indicative of an SN2 mechanism for the formation of both anomeric products from 
benzylidene glucose donor 10, and the β-product from benzylidene mannose donor 9 
(entries 1 and 2). The α-product of benzylidene mannose gave a value indicating an SN1 
mechanism of formation, consistent with the postulates given in Chapter 3 that an 
oxocarbenium ion in the 4H3 conformation is at play here. Secondary KIEs measured for 
a weaker carbohydrate acceptor (13, entry 3) gave values corresponding to an SN2 
reaction with significant oxocarbenium ion character (an “exploded SN2-reaction) for the 
formation of both anomers of benzylidene mannose 11.  
Table 1. Kinetic isotope effects measured for glycosylation reactions.  





















β: 1.12±0.01 SN2/SN1 
aH* indicates partial deuterium labelling. bValues for the anomers are indicated. cSN2 is described in each case 
to be a loosened-SN2 transition state.  
It would be worthwhile to determine KIEs of a range of donor-acceptor pairs, in 
which the reactivity of both partners is gradually changed. For example, the two donors 
used in Chapter 6 (3 and 4, Figure 2) can be used in conjunction with the set of 
fluorinated model acceptors (5-8, Figure 2) in a broad KIE study. The set of model 
acceptors is expected to show a steady decline of primary KIEs or steady increase of 
secondary KIEs due to the increased oxocarbenium ion contribution in the transition 
states for these reactions.  




Another approach to derive kinetic data for glycosylation reactions is based on the 
competition reactions using the cation-clock methodology. The reaction rate in an SN2 
reaction is dependent on the concentration of the electrophile and the nucleophile, while 
the rate of the SN1 reaction is independent of the nucleophile. Changing the 
concentration of a nucleophile and establishing the reaction rate, is therefore a practical 
means to determine whether a reaction proceed through an SN1 or SN2 path. Since 
glycosylation reactions are very fast, when using a preactivation setup (see also the next 
section), and rates of conversion are difficult to measure on a practical time-scale, Crich 
and co-workers have developed a cation-clock competition set-up in which an internal 
and external nucleophile compete for the electrophilic species.13–15 The internal 
nucleophile is a weak nucleophile and will only react with the more electrophilic 
oxocarbenium ion via an SN1 mechanism, giving a cyclized product at a fixed rate (clock). 
In the presence of a competing nucleophile, the oxocarbenium ion or the covalent triflate 
may be captured. A strong external nucleophile will outcompete the internal nucleophile 
(following the SN2-path), while weaker nucleophiles will have more competition from 
internal cyclization. Crich and co-workers used the strong nucleophile isopropanol 12 
and allyltrimethylsilane 14 (Figure 3) as acceptors in combination with benzylidene 
mannose donor 15 and benzylidene glucose donor 16 and found that 
Figure 3. Cation-clock substitution products from external and internal nucleophiles. 
the β-manno-anomer 19 is formed with a much higher concentration dependence than 
internal cyclization product 23, consistent with an SN2 scenario. It was also shown that 
formation of the α-anomer 17 was not concentration dependent. In contrast, the gluco-
β-anomer 20 is formed with the same concentration dependence as α-anomer 18, and 
both react with significant SN2 character. The reactions of C-nucleophile 14, followed SN1 
kinetics (pseudo-first order in these experiments). 
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As the research in this thesis has shown that secondary carbohydrate alcohols are 
significantly weaker nucleophlies than iso-propanol it would be of interest to perform 
this type of cation clock experiments with the set of partially fluorinated ethanols. 
Systematic variation in the reactivity of the donors (by slightly changing the protecting 
group pattern as described in Chapters 3 and 4) will be of interest, to pinpoint when the 
mechanism most radically changes. 
Preactivation-based competition experiments 
Decreasing the reactivity of an acceptor has consequences for the stereoselectivity of the 
glycosylation reaction by a change in the mechanism, as the results from Chapters 3-6 
confirm. How the reactivity of the acceptor changes by its structural modifications can 
be effectively studied by competition of two acceptors for a limiting amount of donor, as 
was demonstrated in Chapter 2 by the work of the group of Crich and the group of 
Rúveda. The set of fluorinated model acceptors and the array of carbohydrate acceptors 
from Chapter 6 would serve as excellent substrates for acceptor competition experiments 
(Figure 4). Donors varying in reactivity, for example one favoring SN2 and the other 
favoring SN1 reactions would further help to establish the reactivities of acceptors under 
different circumstances. To keep the mechanistic picture of the competition experiments 
close to the actual glycosylations reported throughout this thesis, a preactivation setup 
would be the preferred method for competitive glycosylations. Preliminary results 
indicate that the preactivation setup may be too reactive for efficient competition 
between two nucleophiles either from the set of model acceptors or carbohydrate 
acceptors. Further studies in the field of preactivation glycosylations are necessary to 
develop this method of competitive glycosylations. 





Computational evaluation of the reactivity of the acceptor 
In Chapter 2 the work of Stortz was described quantifying the reactivity of glycosyl 
acceptors.16 They calculated the energy of formation of cationic species originating from 
the reaction of glycosyl alcohols with a methyl cation (Figure 5). The difference in energy 
of formation (ΔΔE) explained the relative reactivities of two acceptors 30 and 31 (30/31, 
5:1). It would be of interest to probe this method to a wider range of glycosyl acceptors 
and to find out how the ΔΔE found for various acceptors correlates with experimentally 
obtained stereoselectivities or relative reactivity values. The set of model acceptors 
introduced in Chapter 3 may serve to benchmark the system and a range of acceptors 
like those from Chapter 6 can then be studied following the computational approach of 
Stortz and co-workers. 
 
Figure 5. Methylated acceptors 30 and 31, and methylated model acceptors 32-35. 
 
Assessing steric and conformational effects in acceptor reactivity 
The set of model acceptors introduced in Chapter 3 (5-8, vide supra) was used to 
determine how electronic effects in the acceptor affected the stereoselectivity in 
glycosylation reactions. It is clear that in a glycosylation reaction, that unites two bulky 
coupling partners, sterics also play a major role. Therefore, it would be of interest to 
develop a system to systematically gauge the effect of different steric environments on  
 
Table 4. Glycosylations with model acceptors 36-38. 
 
Entry Donor Acceptor Yield Ratio Product 
1 3 36 65 1 : 2.5 39 
2 3 37 52 1.5 : 1 40 
3 3 38 71 1 : 5.1 41 
4 4 36 96 1 : 17 42 

































E = -107.6 kcal·mol-1 E = -99.7 kcal·mol-1
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the stereochemical outcome of a glycosylation reaction. A systematic series of acceptors 
could be formed by ethanol, iso-propanol, and tert-butanol. More substituted systems in 
which the orientation of the alcohol and neighboring groups can be modulated should 
be considered next. Initial experiments in this direction are displayed in Table 4. 
Conformationally locked cyclohexanols 36 and 37 were glycosylated with donors 3 and 
4 to assess the difference in reactivity between an axial and equatorial alcohol. 
Interestingly, both stereoisomers were less β-selective than cyclohexanol 38 (entries 3 
and 5), indicating that flexibility of the acceptor can have an important effect on the 
glycosylation reaction, as was previously also noted by Zhang et al.17 
In Chapter 6 the stereoselectivity of condensation reactions of several C-4–OH 
gluco-configured carbohydrate acceptors with donor 3 and 4 was determined. It is of 
interest to expand the set of acceptors to carbohydrates having a different configuration 
and vary the protecting group pattern. This will further prove the generality of the 
approach and may lead to an acceptor reactivity chart that will serve as a reference for 
Table 5. Additional glycosylations with donors 3 and 4 and carbohydrate acceptors 44-48. 
Acceptor 
49 
12 : 1 
(72 %) 
50 
3 : 1 
(86 %) 
51 
6 : 1 
(85 %) 
52 
1 : 1.3 
(88 %) 
53 
10 : 1 
(87 %) 
54 
1 : 1.3 
(73 %) 
55 
1.4 : 1 
(71 %) 
56 
1 : 1.6 
(80 %) 
57 






















many future glycosylation reactions. For example, galactoside acceptors 44-46 have been 
used and glycosylations of these acceptors with donors 3 and 4 show that all three of 
them are moderately α-selective (Table 5). Further decreasing their reactivity by placing 
benzoyl groups on the acceptors should further increase their α-selectivity. Other 
relevant systems to investigate, include manno-configured acceptors, acceptors of the L-
configuration such as fucose and rhamnose, but also disaccharides or thioglycosides.  
Changing the substituents of the benzoyl groups may increase their electron-
withdrawing capacity offering another way to fine-tune acceptor reactivity (Table 5). A 
series of mono-nitrated ortho-, meta-, and para- nitrobenzoyl groups was successfully 
glycosylated and a small increase in α-selectivity was observed from para- to ortho-
nitrobenzoyl (from α/β = 3 : 1 to α/β =  3.5 : 1). Placing two nitro groups enhanced the 
α-selectivity further (5.6:1) as shown in Chapter 6. Surprisingly, installing a third nitro 
group (48) had an adverse effect, decreasing the selectivity to α/β = 2.1 : 1. The 
pentafluorobenzoate in acceptor 47 was even less selective providing product 55 in an 
α/β = 1.4 : 1 anomeric mixture.19  
 
Experimental and computational evaluation of 5-deoxy furanosyl oxocarbenium ions 
In Chapter 7 and 8 furanoses bearing different substituents on the C-2- and C-5-position 
were synthesized and studied under SN1-glycosylation conditions to probe the effect of 
these substituents on the stereoselectivity of the reactions. The intermediate 
oxocarbenium ions were studied by the CEL map method. Initial studies into the effect 
of a 5-deoxy functionality have also been undertaken to investigate the effect of this 
modification on the stereoselectivity of the glycosylation reactions. To this end furanosyl 
donors 59-62 were synthesized and glycosylated with allyl trimethyl silane (Figure 6).  
 
  
Figure 6. Imidate donors 59-62, acetyl donor 63 and glycosylation products 65-69 of 5-deoxy furanosides. 
Inset: top view of the protruding C–H bonds on the acceptor. 
 




The results of these glycosylations and the CEL maps of the 5-deoxyfuranosyl 
oxocarbenium ions are shown in Table 6. For the 5-deoxyribose and 5-deoxylyxose 
oxocarbenium ions 71 and 72 the C-2 and C-3 substituents can take up a most stabilizing 
orientation in the E3 and 3E conformation, respectively. The ribo- and lyxo-configured 5-
deoxyfuranoside imidate donors 60 and 61 provide exclusively the 1,2-cis-product in 
glycosylations with allyl-TMS (66, 67, Figure 6), in line with all other modifications on 
these two configurations. The arabino- and xylo-configured 5-deoxyfuranosides give  
 
Table 6: CEL maps of ribo-configured oxocarbenium ions 70-73. 
 Arabinose Ribose Lyxose Xylose 
 
    
R = CH2OBn 
R = CH3 
   
Energies 
(kcal∙mol-1) 
3E : 0.0 
3T4 : 0.5 
E3 : 1.0 
E3 : 0.0 
4T3 : 0.85 
3E : 1.5 
3E : 0.0 
3T4 : 1.7 
E3 : 4.5 
3E : 0.0 
E3 : 0.4 
     
Experimental 
(α : β) 65; 40 : 60
a 66; >98 : 2a 67; <2 : 98a 
68; 60 : 40a 
69; 40 : 60b 
Yield (%) 86 89 56 60 and 77 
aAllyl-TMS was the acceptor. bTES-D was the acceptor, acetyl donor 63, see experimental section. Reagents and 
conditions: donor (0.1 mmol), acceptor (0.4 mmol), TfOH (0.01 mmol), DCM (1 mL), 3Å M.S., -75°C  
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anomeric mixtures. This is not surprising considering the conflicting interest of the C-2 
and C-3 substituents in both the arabino- and xylo-configurations. However, the CEL 
maps predict a different stereochemical outcome. There is no clear explanation for this 
discrepancy. It may be that the use of an acetyl donor and TES-D as a nucleophile 
provides a different outcome. Indeed, the use of these conditions slightly changed the 
anomeric ratio in the case of the 5-deoxyxylose donor (63). 
Furanoside O-glycosylations 
Chapter 7 and 8 have reported on glycosylation reactions of differently substituted 
furanosyl donors with allyl-TMS and TES-D as nucleophiles. In line with previous 
studies by van Rijssel et al. the stereoselectivity in these condensations could be 
adequately accounted for using the CEL maps of the intermediate oxocarbenium ions.20 
Thus, these glycosylations very likely proceed with an SN1-like mechanism. To 
investigate how O-nucleophiles react with the set of furanosyl donors the imidate donors 
of all perbenzylated pentofuranoses and their thiophenyl equivalents (77-84) have been 
glycosylated with acceptors 5, 8, and 76. Table 7 lists the outcome of these experiments 
and compares them to the reaction with allyl-TMS 75. It is clear that there is a relatively 
poor correlation between the outcome of the reactions of the O- versus the C-
nucleophiles. Even the results of the condensations of the weak O-nucleophile, 
trifluoroethanol, deviate form those using TES-D and allyl-TMS. It is difficult to distill a 
trend from the results in Table 7, and no clear single mechanistic explanation is available 
to account for the observed selectivities. It is likely that the more nucleophilic acceptors 
5 and 76 react in glycosylations with more SN2-character. Therefore the nature, stability 
and reactivity of the intermediate anomeric triflates should be investigated by Low-
Temperature NMR.21 It may also be that the inside attack model, devised by Woerpel and 
co-workers, does not hold for glycosylations of O-nucleophiles and furanosyl 
oxocarbenium ions. Computational models of the triflates, and the transition states of 
the SN1 and SN2 reactions should help to build a better understanding of O-glycosylation 
of furanosides. 




Table 7. Glycosylations of furanosides with model acceptors. 
     
Donor α : β (yield) α : β (yield) α : β (yield) α : β (yield) 
 
85 
>98 : 2 
- 
86 
68 : 32 
(85%) 
87 
64 : 36 
(52%) 
88 




>98 : 2 
(31%) 
86 
65 : 35 
(86%) 
87 
67 : 33 
- 
88 




5 : 95 
- 
90 
13 : 87 
(80%) 
91 
44 : 56 
(78%) 
92 




10 : 90 
(25%) 
90 
14 : 86 
(85%) 
91 





<2 : 98 
(54%) 
94 
48 : 52 
(98%) 
95 
73 : 26 
(72%) 
96 








25 : 75 
- 
96 




80 : 20 
(68%) 
98 
84 : 16 
(85%) 
99 





85 : 15 
(35%) 
98 
71 : 29 
(74%) 
99 











glucopyranoside (39). Donor 3 and acceptor 36 were condensed using the 
general procedure for Tf2O/Ph2SO mediated glycosylations as described in 
Chapter 3 yielding product 39 (38 mg, 65 μmol, 65%, α:β = 1 : 2.5) as a white solid. Rf: 0.28 (toluene). IR (thin film): 
696, 732, 997, 1028, 1074, 1365, 2862, 2940; 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC): δ 7.53 – 7.46 (m, 2.6H, 
CHarom), 7.41 – 7.24 (m, 16.9H, CHarom), 5.55 (s, 1.3H, CHPhα,β), 4.96 – 4.66 (m, 5.5H, 2xCH2 Bnα,β, H-1α), 4.62 (d, 1H, J 
= 7.7 Hz, H-1β), 4.33 (dd, 1H, J = 10.5, 5.0 Hz, H-6β), 4.26 (dd, 0.3H, J = 10.2, 4.9 Hz, H-6β), 4.06 (t, 0.3H, J = 9.3 Hz, H-
3α), 3.95 (td, 0.3H, J = 10.0, 4.8 Hz, H-5α), 3.79 (t, 1H, J = 10.3 Hz, H-6β), 3.76 – 3.52 (m, 3.9H, H-2α, H-3β, H-4α, H-4β, 
H-6α, CH Cyβ), 3.49 – 3.35 (m, 2.3H, H-2β, H-5β, CH Cyα), 2.20 – 0.95 (m, 11.7H, CH2 Cy), 0.85 (s, 11.7H, tBu); 13C-APT 
NMR (CDCl3, 101 MHz, HSQC): δ 139.0, 138.6, 138.5, 138.4, 137.5, 137.4 (Cq), 131.6, 130.3, 129.3, 128.9, 128.9, 128.4,
128.4, 128.3, 128.3, 128.2, 128.2, 128.1, 128.0, 128.0, 127.8, 127.7, 127.6, 127.5, 126.0, 126.0, 124.4 (CHarom), 102.5 
(C-1β), 101.2 (CHPh), 101.1 (C-1α), 96.1, 82.4, 82.2, 81.5, 81.1, 79.4, 79.3, 78.7, 76.8, 75.4, 75.1, 73.4, 69.1, 68.9, 66.0,
62.4, 47.2, 47.2, 34.2, 33.8, 32.7, 32.3, 31.9, 27.7, 25.9, 25.7, 25.6, 25.6; HRMS: [M+H]+ calcd for C37H47O6 587.33672,
found 587.33666. 
Cis-4-tert-butylcyclohexyl 2,3-di-O-benzyl-4,6-O-benzylidene-α/β-D-glucopyranoside 
(40). Donor 3 and acceptor 37 were condensed using the general procedure for 
Tf2O/Ph2SO mediated glycosylations as described in Chapter 3 yielding product 40 
(31 mg, 52 μmol, 52%, α:β = 1.5 : 1) as a white solid.  Rf: 0.25 and 0.22 (toluene). IR 
(thin film): 660, 733, 999, 1028, 1072, 1084, 1365, 2864, 2938; 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC): δ 7.62 – 
7.18 (m, 25.5H, CHarom), 5.56 (s, 1H, CHPhα), 5.55 (s, 0.7H, CHPhβ), 5.02 – 4.66 (m, 7.8H, 2xCH2 Bn, H-1α), 4.58 (d, 0.7H, 
J = 7.7 Hz, H-1β), 4.32 (dd, 0.7H, J = 10.4, 5.0 Hz, H-6β), 4.25 (dd, 1H, J = 10.2, 4.8 Hz, H-6α), 4.09 (t, 1H, J = 9.2 Hz, H-
3α), 4.02 (t, 0.7H, J = 2.6 Hz, CH Cyβ), 3.94 (td, 1H, J = 10.0, 5.0 Hz, H-5α), 3.85 – 3.66 (m, 4.4H, H-3β, H-4β, H-6α, H-6β, 
CH Cyα), 3.62 (t, 1H, J = 9.4 Hz, H-4α), 3.57 (dd, 1H, J = 9.3, 3.7 Hz, H-2α), 3.48 (t, 0.7H, J = 8.0 Hz, H-2β), 3.39 (td, 0.7H, 
J = 9.5, 4.9 Hz, H-5β), 2.09 – 1.88 (m, 3.4H, CH2 Cy), 1.61 – 1.24 (m, 10.2H, CH2 Cy), 1.05 – 0.94 (m, 1.7H, CH Cy), 0.83 
(s, 9H, tBu), 0.81 (s, 6.3H, tBu); 13C-APT NMR (CDCl3, 101 MHz, HSQC): δ 139.0, 138.7, 138.6, 137.6, 137.5, 129.0, 129.0, 
128.4, 128.4, 128.3, 128.1, 128.1, 127.9, 127.7, 127.7, 127.7, 127.6, 126.1, 102.1 (C-1β), 101.3, 101.2 (CHPh), 96.1 (C-
1α), 82.6 (C-4α), 82.1 (C-2α), 81.7, 81.2 (C-3β, C-4β), 79.8 (C-2α), 78.5 (C-3α), 75.3, 75.2, 75.2, 73.2 (CH2 Bn), 73.1 (CH 
Cy), 71.8 (CH Cyα), 69.4 (C-6α), 69.0 (C-6β), 66.2 (C-5α), 62.8 (C-5β), 48.0, 48.0, 32.7, 32.7, 32.6, 32.4, 29.8, 27.7, 27.6, 
21.9, 21.8, 21.7, 21.5; HRMS: [M+H]+ calcd for C37H47O6 587.33672, found 587.33660. 
Methyl 2,3-di-O-benzyl-6-O-(2,3,4,5,6-pentafluorobenzoyl)-α-ᴅ-glucopyranoside (47). Methyl 
2,3-di-O-benzyl-α-D-glucopyranoside22 (374 mg, 1.0 mmol, 1 eq.) was converted to the title 
compound 47 following general procedure C of Chapter 6 (pentafluorobenzoyl chloride; 145 
μL, 1.05 mmol, 1.05 eq.). Yield: 550 mg, 0.97 mmol, 97%. [α]  = +22.7° (c = 0.6, CHCl3); IR 
(thin film): 698, 739, 1007, 1057, 1229, 1325, 1497, 1524, 1653, 1740, 2916, 3500; 1H NMR 
(CDCl3, 500 MHz, HH-COSY, HSQC): δ 7.40 – 7.30 (m, 10H, CHarom), 5.03 (d, 1H, J = 11.5 Hz, 
CHH Bn), 4.78 (d, 1H, J = 12.1 Hz, CHH Bn), 4.71 (d, 1H, J = 11.5 Hz, CHH Bn), 4.66 (d, 1H, J = 12.1 Hz, CHH Bn), 4.62 (d, 
1H, J = 3.5 Hz, H-1), 4.62 (dd, 1H, J = 11.9, 2.2 Hz, H-6), 4.54 (dd, 1H, J = 11.9, 5.4 Hz, H-6), 3.86 (ddd, 1H, J = 10.0, 5.4, 
2.2 Hz, H-5), 3.80 (t, 1H, J = 9.2 Hz, H-3), 3.52 (dd, 1H, J = 9.6, 3.5 Hz, H-2), 3.51 – 3.45 (m, 1H, H-4), 3.39 (s, 3H, CH3 
OMe), 2.33 (d, 1H, J = 2.7 Hz, 4-OH); 13C-APT NMR (CDCl3, 126 MHz, HSQC): δ 159.0 (C=O), 146.7, 144.5, 142.4, 
(CFortho/para), 138.8, 138.7 (CFmeta), 138.0 (Cq), 136.9, 136.8 (CFmeta), 128.8, 128.7, 128.2, 128.2 (CHarom), 108.0 (Cq-ipso), 
98.3 (C-1), 81.2 (C-3), 79.8 (C-2), 75.6, 73.3 (CH2 Bn), 70.0 (C-4), 68.9 (C-5), 65.6 (C-6), 55.5 (OMe); 19F NMR (CDCl3, 
471 MHz): δ -137.87 (dp, 2F, J = 16.5, 5.4 Hz, ortho-F5Bz), -148.29 (tt, 1F, J = 20.9, 4.8 Hz, para-F5Bz), -160.46 (tt, 2F, J 
= 21.0, 5.9 Hz, meta-F5Bz); HRMS: [M+Na]+ calcd for C28H25F5O7Na 591.1418, found 591.1431. 
2,4,6-Trinitrobenzoyl chloride (S1). Toluene (2.1 mL, 20 mmol) was dissolved in 17 mL H2SO4 and 
cooled to 0°C. To this mixture a solution of HNO3 (99%, 4.2 mL) in 15 mL H2SO4 was slowly added 
(15 min, temperature remains below 40°C). When addition was complete, the reaction mixture 
was slowly heated to 95°C and kept at that temperature for 3 h. The solution was cooled and 
poured over ice. The precipitate was collected, washed with cold H2O, air-dried, and crystallized 
from boiling EtOH (50 mL) to form large needles of 2,4,6-trinitrotoluene (TNT) (3.8 g, 16.8 mmol, 84%). 1H NMR (DMSO, 
400 MHz): δ 9.03 (s, 2H), 2.57 (s, 3H). The TNT (2.27 g, 10 mmol) was dissolved in H2SO4 (18 mL) and K2Cr2O7 (3.18 g, 
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10.8 mmol) was added in small portions, mainting a temperature below 35°C (ice-bath). After stirring overnight at 
room temperature, the reaction mixture was poured on ice and the precipitate collected, washed with cold H2O, dried 
and crystallized from boiling H2O to yield 2,4,5-trinitrobenzoic acid (TNBA) as yellow crystals (1,1 g, 4.3 mmol, 43%). 
1H NMR (MeOD, 400 MHz): δ 9.23 (s, 2H); 13C-APT NMR (MeOD, 101 MHz): δ 164.1, 149.3, 148.6, 131.6, 125.6. The 
TNBA (390 mg, 1.5 mmol) was suspended in DCE (300 μL) and DMF (15 μL), thionyl chloride was slowly added (375 
μL) and the mixture heated to 80°C for 2 h. The reaction mixture was cooled to 0°C and the precipitate was collected 
by filtration and washed with cold DCE to yield the 2,4,6-trinitrobenzoyl chloride as a yellow solid (250 mg, 0.9 mmol, 
60%). Spectroscopic data were in accord with those previously reported.23 1H NMR (DMSO, 400 MHz): δ 9.14 (s, 2H); 
13C-APT NMR (DMSO, 101 MHz): δ 162.4, 147.6, 146.7, 129.7, 125.0. 
Methyl 2,3-di-O-benzyl-6-O-(2,4,6-trinitrobenzoyl)-α-ᴅ-glucopyranoside (48). Methyl 2,3-
di-O-benzyl-α-D-glucopyranoside22 (374 mg, 1.0 mmol, 1 eq.) was converted to the title
compound 48 following general procedure C of Chapter 6 (2,4,6-trinitrobenzoyl chloride 
S1; 250 mg , 0.9 mmol, 0.9 eq. and 90 μL pyridine, 1.2 eq.). Yield: 137 mg, 0.22 mmol, 22%. [α]  = +29.7° (c = 0.67, CHCl3); IR (thin film): 700, 735, 1059, 1261, 1279, 1342, 1454,
1545, 1553, 1609, 1751, 2922, 3600; 1H NMR (CDCl3, 500 MHz, HH-COSY, HSQC): δ 9.23
(s, 2H, CHarom NO2Bz), 7.37 – 7.26 (m, 10H, CHarom Bn), 4.99 (d, 1H, J = 11.4 Hz, CHH Bn), 4.78 – 4.72 (m, 2H, CHH Bn, 
H-6), 4.72 – 4.66 (m, 2H, CHH Bn, H-6), 4.66 – 4.62 (m, 2H, CHH Bn, H-1), 3.89 (ddd, 1H, J = 10.1, 4.9, 2.2 Hz, H-5), 3.80
(t, 1H, J = 9.2 Hz, H-3), 3.50 – 3.44 (m, 2H, H-2, H-4), 3.36 (s, 3H, CH3 OMe), 2.42 (d, 1H, J = 2.9 Hz, 4-OH); 13C-APT NMR 
(CDCl3, 126 MHz, HSQC): δ 160.7 (C=O), 147.9, 147.3 (Cq NO2), 138.7, 138.0 (Cq Bn), 129.9 (Cq Bz), 128.7, 128.6, 128.2,
128.1, 128.1, 124.6 (CHarom), 98.4 (C-1), 81.2 (C-3), 79.6 (C-2), 75.6, 73.2 (CH2 Bn), 69.8 (C-4), 68.9 (C-5), 67.0 (C-6),
55.6 (OMe); HRMS: [M+Na]+ calcd for C28H27N3O13Na 636.1442, found 636.1451.
Methyl 4-O-(2,3-di-O-benzyl-4,6-O-benzylidene-α-D-glucopyranosyl)-2,3,6-tri-O-
benzyl-α-D-galactopyranoside (49). Donor 3 and acceptor 44 were condensed using 
the general procedure for Tf2O/Ph2SO mediated glycosylations as described in 
Chapter 3 yielding product 49 (60 mg, 72 μmol, 72%, α:β = 12 : 1) as a colorless oil. 
Rf: 0.50 (4/1 pentane/EtOAc). Spectroscopic data were in accord with those 
previously reported.24 ); IR (thin film): 694, 733, 995, 1026, 1049, 1076, 1086, 1364, 1452, 1498, 2864, 2926; 1H NMR 
(CDCl3, 400 MHz, HH-COSY, HSQC, HMBC): δ 7.53 – 7.49 (m, 2H, CHarom), 7.45 – 7.15 (m, 28H, CHarom), 5.52 (s, 1H, 
CHPh), 4.97 – 4.93 (m, 2H, CHH Bn, H-1’), 4.89 (d, 1H, J = 12.3 Hz, CHH Bn), 4.87 (d, 1H, J = 11.9 Hz, CHH Bn), 4.81 – 
4.74 (m, 4H, CH2 Bn, 2xCHH Bn), 4.70 (d, 1H, J = 11.9 Hz, CHH Bn), 4.65 (d, 1H, J = 3.5 Hz, H-1), 4.29 (td, 1H, J = 10.0, 
4.9 Hz, H-5’), 4.26 (d, 1H, J = 11.9 Hz, CHH Bn), 4.22 (d, 1H, J = 11.9 Hz, CHH Bn), 4.06 (d, 1H, J = 2.3 Hz, H-4), 4.02 (t, 
1H, J = 9.3 Hz, H-3’), 3.97 – 3.78 (m, 5H, H-2, H-3, H-5, H-6, H-6’), 3.60 (dd, 1H, J = 9.7, 9.3 Hz, H-4’), 3.56 (dd, 1H, J = 
9.5, 3.6 Hz, H-2’), 3.52 – 3.46 (m, 2H, H-6, H-6’), 3.36 (s, 3H, CH3 OMe); 13C-APT NMR (CDCl3, 101 MHz, HSQC, HMBC): 
δ 138.9, 138.6, 138.4, 138.3, 138.3, 137.8 (Cq), 128.8, 128.6, 128.5, 128.5, 128.5, 128.4, 128.3, 128.3, 128.3, 128.2, 
128.1, 128.0, 127.9, 127.8, 127.8, 127.7, 127.7, 127.6, 127.5, 126.1 (CHarom), 101.2 (CHPh), 100.6 (C-1’), 99.1 (C-1), 
82.9 (C-4’), 79.7 (C-2’), 79.2 (C-3’), 77.8 (C-3), 77.3 (C-4), 75.2, 74.4 (CH2 Bn), 74.4 (C-2), 73.6, 73.0, 73.0 (CH2 Bn), 69.4 
(C-5), 69.1 (C-6’), 68.1 (C-6), 63.1 (C-5’), 55.5 (OMe); HRMS: [M+Na]+ calcd for C55H58O11Na 917.3877, found 917.3903. 
Methyl 4-O-(2-azido-3-O-benzyl-4,6-O-benzylidene-2-deoxy-α/β-D-glucopyranosyl)-
2,3,6-tri-O-benzyl-α-D-galactopyranoside (50). Donor 4 and acceptor 44 were 
condensed using the general procedure for Tf2O/Ph2SO mediated glycosylations as 
described in Chapter 3 yielding product 50 (70 mg, 86 μmol, 86%, α:β = 3 : 1) as a 
colorless oil. Rf: 0.60 (4/1 pentane/EtOAc); IR (thin film): 696, 737,997, 1034, 1055, 
1092, 1369, 1454, 1497, 2106, 2866, 2928, 3030; Data for the α-anomer: 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC): 
δ 7.54 – 7.15 (m, 25H, CHarom), 5.52 (s, 1H, CHPh), 4.95 (d, 1H, J = 10.7 Hz, CHH Bn), 4.84 – 4.78 (m, 5H, 2xCH2 Bn, H-
1’), 4.74 (d, 1H, J = 10.7 Hz, CHH Bn), 4.68 (d, 1H, J = 3.3 Hz, H-1), 4.57 (d, 1H, J = 11.8 Hz, CHH Bn), 4.49 (d, 1H, J = 
11.8 Hz, CHH Bn), 4.32 (td, 1H, J = 10.0, 4.9 Hz, H-5’), 4.13 (d, 1H, J = 2.3 Hz, H-4), 3.97 – 3.84 (m, 5H, H-2, H-3, H-3’, 
H-5, H-6), 3.77 (dd, 1H, J = 10.1, 4.9 Hz, H-6’), 3.64 (t, J = 9.5 Hz, 1H, H-4’), 3.55 – 3.46 (m, 2H, H-6, H-6’), 3.36 (s, 3H, 
CH3 OMe), 3.33 (dd, 1H, J = 10.0, 3.8 Hz, H-2’); 13C-APT NMR (CDCl3, 101 MHz, HSQC): δ 138.5, 138.2, 138.1, 137.7,
137.6 (Cq), 128.6, 128.6, 128.6, 128.5, 128.3, 128.2, 127.6, 126.1 (CHarom), 101.2 (CHPh), 99.0 (C-1’), 98.9 (C-1), 83.0 
(C-4’), 77.3 (C-2), 77.0 (C-3’), 75.7 (C-4), 75.2 (CH2 Bn), 74.7 (C-3), 73.6, 73.4, 73.2 (CH2 Bn), 68.8, 68.8 (C-5, C-6’), 67.1
(C-6), 63.8 (C-2’), 62.9 (C-5’), 55.5 (OMe); Diagnostic peaks β-anomer: 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC): δ 
4.95 (d, 1H, J = 12.0 Hz, CHH Bn), 4.90 (d, 1H, J = 11.4 Hz, CHH Bn), 4.62 (d, 1H, J = 3.7 Hz, H-1), 4.55 (d, 1H, J = 11.9 













J = 9.8, 5.0 Hz, H-5’); 13C-APT NMR (CDCl3, 101 MHz, HSQC): δ 139.0, 138.6, 138.3, 138.0, 137.2 (Cq), 102.1 (C-1’), 101.4 
(CHPh), 98.9 (C-1), 81.6, 79.0, 78.4, 76.4, 75.0, 73.9, 73.8, 73.4, 69.6, 69.0, 68.6, 66.5 (C-2’), 66.0 (C-5’), 55.5 (OMe); 
HRMS: [M+Na]+ calcd for C48H51N3O10Na 852.3472, found 852.3488. 
Methyl 3-O-(2,3-di-O-benzyl-4,6-O-benzylidene-α/β-D-glucopyranosyl)-2,4,6-tri-O-
benzyl-α-D-galactopyranoside (51). Donor 3 and acceptor 45 were condensed using 
the general procedure for Tf2O/Ph2SO mediated glycosylations as described in 
Chapter 3 yielding product 51 (76 mg, 85 μmol, 85%, α:β = 6 : 1) as a colorless oil. 
Rf: 0.25 and 0.51 (4/1 pentane/EtOAc); IR (thin film): 696, 735, 1028, 1049, 1074, 1088, 1350, 1368, 154, 2864, 2914; 
Data for the α-anomer: 1H NMR (CDCl3, 500 MHz, HH-COSY, HSQC): δ 7.48 – 7.45 (m, 2H, CHarom), 7.40 – 7.14 (m, 28H, 
CHarom), 5.54 (s, 1H, CHPh), 5.06 (d, 1H, J = 3.6 Hz, H-1’), 5.00 (d, 1H, J = 11.3 Hz, CHH Bn), 4.91 (d, 1H, J = 11.5 Hz, CHH 
Bn), 4.84 (d, 1H, J = 11.4 Hz, CHH Bn), 4.80 – 4.75 (m, 2H, CHH Bn, CHH Bn), 4.68 (d, 1H, J = 11.5 Hz, CHH Bn), 4.62 (d, 
1H, J = 3.5 Hz, H-1), 4.56 (d, 1H, J = 11.9 Hz, CHH Bn), 4.47 (d, 1H, J = 11.8 Hz, CHH Bn), 4.37 (d, 1H, J = 11.8 Hz, CHH 
Bn), 4.36 (d, 1H, J = 11.4 Hz, CHH Bn), 4.23 (td, 1H, J = 10.0, 4.9 Hz, H-5’), 4.16 (dd, 1H, J = 10.1, 4.9 Hz, H-6’), 4.10 (t, 
1H, J = 9.3 Hz, H-3’), 4.04 (dd, 1H, J = 10.2, 2.8 Hz, H-3), 3.96 (dd, 1H, J = 10.2, 3.6 Hz, H-2), 3.91 (dd, 1H, J = 2.8, 1.1 
Hz, H-4), 3.83 (t, 1H, J = 6.9 Hz, H-6), 3.64 (t, 1H, J = 9.5 Hz, H-4’), 3.63 (t, 1H, J = 10.2 Hz, H-6’), 3.62 (dd, 1H, J = 9.4, 
3.5 Hz, H-2’), 3.48 – 3.46 (m, 2H, H-5, H-6), 3.31 (s, 3H, CH3 OMe); 13C-APT NMR (CDCl3, 126 MHz, HSQC): δ 139.1, 
138.7, 138.3, 138.1, 138.1, 137.8 (Cq), 128.5, 128.5, 128.5, 128.4, 128.2, 128.2, 128.2, 128.2, 128.1, 127.9, 127.9, 
127.8, 127.7, 127.4, 126.3 (CHarom), 101.3 (CHPh), 98.5 (C-1’), 98.5 (C-1), 82.7 (C-4’), 79.8 (C-2’), 78.7 (C-3’), 78.2 (C-
3), 75.8 (C-2), 75.5 (C-4), 75.1, 75.0, 74.6, 73.6, 73.4 (CH2 Bn), 69.3 (C-5), 69.2 (C-6), 69.0 (C-6’), 63.1 (C-5’), 55.3 (OMe); 
Diagnostic peaks β-anomer: 1H NMR (CDCl3, 500 MHz, HH-COSY, HSQC): δ 7.52 – 7.48 (m, 2H, CHarom), 7.42 – 7.16 (m, 
28H, CHarom), 5.57 (s, 1H, CHPh), 5.04 (d, 1H, J = 7.7 Hz, H-1’), 5.00 (d, 1H, J = 11.5 Hz, CHH Bn), 4.98 (d, 1H, J = 11.4 
Hz, CHH Bn), 4.94 (d, 1H, J = 11.3 Hz, CHH Bn), 4.84 (d, 1H, J = 11.5 Hz, CHH Bn), 4.82 (d, 1H, J = 11.3 Hz, CHH Bn), 4.65 
(d, 1H, J = 11.5 Hz, CHH Bn), 4.63 (d, 1H, J = 11.8 Hz, CHH Bn), 4.55 (d, 1H, J = 3.7 Hz, H-1), 4.48 (d, 1H, J = 11.6 Hz, 
CHH Bn), 4.40 (d, 1H, J = 11.6 Hz, CHH Bn), 4.32 (dd, 1H, J = 10.5, 5.1 Hz, H-6’), 4.32 (d, 1H, J = 11.8 Hz, CHH Bn), 4.24 
(dd, 1H, J = 10.1, 3.1 Hz, H-3), 3.99 (dd, 1H, J = 10.1, 3.7 Hz, H-2), 3.97 – 3.93 (m, 2H, H-4, H-6), 3.79 – 3.74 (m, 2H, H-
3’, H-6’), 3.69 (t, 1H, J = 9.3 Hz, H-4), 3.54 – 3.52 (m, 2H, H-5, H-6), 3.46 (dd, 1H, J = 8.7, 7.8 Hz, H-2’), 3.40 (td, 1H, J = 
9.9, 5.1 Hz, H-5’), 3.31 (s, 3H, CH3 OMe); 13C-APT NMR (CDCl3, 126 MHz, HSQC): δ 103.9 (C-1’), 101.2 (CHPh), 98.5 (C-
1), 82.9 (C-2’), 81.9 (C-4’), 81.1(C-3’), 77.9, 75.3, 75.3, 75.2, 73.7, 73.6, 69.1, 69.1, 68.9, 65.8 (C-5’), 55.4 (OMe);  HRMS: 
[M+Na]+ calcd for C55H58O11Na 917.3877, found 917.3885. 
Methyl 3-O-(2-azido-3-O-benzyl-4,6-O-benzylidene-2-deoxy-α/β-D-glucopyranosyl)-
2,4,6-tri-O-benzyl-α-D-galactopyranoside (52). Donor 4 and acceptor 45 were 
condensed using the general procedure for Tf2O/Ph2SO mediated glycosylations as 
described in Chapter 3 yielding product 52 (73 mg, 88 μmol, 88%, α:β = 1 : 1.3) as a 
colorless oil. Rf: 0.43 and 0.66 (4/1 pentane/EtOAc); IR (thin film): 696, 735, 995, 1028, 1047, 1092, 1350, 1369, 1454, 
2108, 2866, 2910; 1H NMR (CDCl3, 500 MHz, HH-COSY, HSQC): δ 7.48 – 7.21 (m, 57.5H, CHarom), 5.57 (s, 1.3H, CHPhβ), 
5.55 (s, 1H, CHPhα), 5.13 (d, 1H, J = 3.6 Hz, H-1’α), 5.01 (d, 1H, J = 11.2 Hz, CHH Bnα), 4.94 – 4.84 (m, 6.2H, 4xCHH Bn, 
H-1’β), 4.80 (d, 1.3H, J = 11.2 Hz, CHH Bnβ), 4.76 (d, 1H, J = 11.9 Hz, CHH Bnα), 4.75 (d, 1H, J = 11.0 Hz, CHH Bnα), 4.65 
(d, 1H, J = 3.6 Hz, H-1α), 4.60 – 4.53 (m, 5.9H, 4xCHH Bn, H-1β), 4.48 (d, 1H, J = 11.7 Hz, CHH Bnα), 4.48 (d, 1.3H, J = 
11.8 Hz, CHH Bnβ), 4.40 (d, 1H, J = 11.7 Hz, CHH Bnα), 4.40 (d, 1.3H, J = 11.7 Hz, CHH Bnβ), 4.31 (dd, 1.3H, J = 10.4, 5.1 
Hz, H-6’β), 4.27 – 4.22 (m, 2H, H-5’α, H-6’α), 4.19 (dd, 1.3H, J = 10.1, 3.2 Hz, H-3β), 4.12 (dd, 1H, J = 10.3, 2.9 Hz, H-3α), 
4.10 – 4.04 (m, 2.3H, H-2β, H-3’α), 4.02 – 3.97 (m, 2H, H-2α, H-4α), 3.95 – 3.87 (m, 3.6H, H-4β, H-5α, H-5β), 3.78 – 3.64 
(m, 4.6H, H-4’α, H-4’β, H-6’α, H-6’β), 3.56 – 3.49 (m, 6.9H, H-2’α, H-3’β, H-6α, H-6α, H-6β, H-6β), 3.42 (dd, 1.3H, J = 9.5, 
8.0 Hz, H-2’β), 3.36 (td, 1.3H, J = 9.9, 5.1 Hz, H-5’β), 3.33 (s, 3H, CH3 OMeα), 3.31 (s, 3.9H, CH3 OMeβ); 13C-APT NMR 
(CDCl3, 126 MHz, HSQC): δ 138.7, 138.7, 138.3, 138.2, 138.1, 138.0, 137.9, 137.8, 137.6, 137.2 (Cq), 129.1, 129.0, 
128.6, 128.5, 128.5, 128.5, 128.5, 128.4, 128.4, 128.4, 128.4, 128.3, 128.2, 128.1, 128.1, 128.0, 128.0, 127.9, 127.9, 
127.9, 127.9, 127.8, 127.7, 126.3, 126.1 (CHarom), 102.9 (C-1’β), 101.5 (CHPhα), 101.4 (CHPhβ), 98.5 (C-1α), 98.3 (C-1β), 
96.1 (C-1’α), 83.0 (C-4’α), 81.8 (C-4’β), 79.1 (C-3’β), 77.4, 77.3 (C-2β, C-4β), 76.8 (C-3β), 76.2 (C-3’α), 75.8 (C-3α), 75.3 (C-
2α), 75.2, 75.1, 75.0, 75.0 (CH2 Bn), 74.1 (C-4α), 73.7, 73.6, 73.6, 73.6 (CH2 Bn), 69.1, 69.0 (C-5α, C-5β), 69.0, 68.9, 68.8, 
68.7 (C-6α, C-6β, C-6’α, C-6’β), 66.9 (C-2’β), 66.0 (C-5’β), 63.6 (C-2’α), 62.9 (C-5’α), 55.4, 55.4 (OMe); HRMS: [M+Na]+ 
calcd for C48H51N3O10Na 852.3472, found 852.3482. 
  





benzyl-α-D-galactopyranoside (53). Donor 3 and acceptor 46 were condensed 
using the general procedure for Tf2O/Ph2SO mediated glycosylations as described 
in Chapter 3 yielding product 53 (78 mg, 87 μmol, 87%, α:β = 10 : 1) as a colorless 
oil. Rf: 0.60 (4/1 pentane/EtOAc); IR (thin film): 696, 734, 1028, 1053, 1076, 1085, 1366, 1454, 2864, 2914; Data for 
the α-anomer: 1H NMR (CDCl3, 500 MHz, HH-COSY, HSQC): δ 7.44 – 7.12 (m, 30H, CHarom), 5.51 (s, 1H, CHPh), 4.92 – 
4.86 (m, 4H, 2xCHH Bn, H-1, H-1’), 4.86 – 4.80 (m, 3H, 2xCHH Bn, CHH Bn), 4.71 (d, 1H, J = 12.3 Hz, CHH Bn), 4.67 (d, 
1H, J = 11.5 Hz, CHH Bn), 4.52 (d, 1H, J = 11.3 Hz, CHH Bn), 4.51 (d, 1H, J = 11.8 Hz, CHH Bn), 4.43 (d, 1H, J = 11.7 Hz, 
CHH Bn), 4.33 (dd, 1H, J = 10.3, 3.5 Hz, H-2), 4.25 (td, 1H, J = 10.0, 5.0 Hz, H-5’), 4.15 (dd, 1H, J = 10.1, 5.0 Hz, H-6’), 
4.13 (t, 1H, J = 9.2 Hz, H-3’), 4.02 (dd, 1H, J = 10.3, 2.8 Hz, H-3), 3.95 (dd, 1H, J = 2.9, 1.2 Hz, H-4), 3.94 – 3.91 (m, 1H, 
H-6), 3.62 (t, 1H, J = 10.2 Hz, H-6’), 3.61 – 3.53 (m, 4H, H-2’, H-4’, H-5, H-6), 3.42 (s, 3H); 13C-APT NMR (CDCl3, 126 
MHz, HSQC): δ 138.9, 138.7, 138.6, 138.2, 138.0, 137.8 (Cq), 128.8, 128.5, 128.5, 128.4, 128.4, 128.3, 128.3, 128.1, 
128.1, 128.1, 127.9, 127.9, 127.9, 127.9, 127.7, 127.6, 127.6, 126.3 (CHarom), 101.3 (CHPh), 97.0 (C-1), 95.5 (C-1’), 82.3 
(C-4’), 78.9 (C-2’), 78.6 (C-3’), 77.6 (C-3), 75.2 (CH2 Bn), 75.1 (C-4), 75.0, 73.7, 73.4, 73.4 (CH2 Bn), 72.0 (C-2), 69.5 (C-
5), 69.2 (C-6), 69.0 (C-6’), 62.4 (C-5’), 55.2 (OMe); Diagnostic peaks β-anomer: 1H NMR (CDCl3, 500 MHz, HH-COSY, 
HSQC): δ 5.54 (s, 1H, CHPh), 5.00 (d, 1H, J = 11.2 Hz, CHH Bn), 3.76 (t, 1H, J = 10.3 Hz), 3.77 – 3.66 (m, 2H), 3.41 (s, 3H, 
CH3 OMe); 13C-APT NMR (CDCl3, 126 MHz, HSQC): δ 105.0 (C-1’), 101.2 (CHPh), 100.0 (C-1), 82.1, 81.4, 81.0, 78.4, 
75.1, 75.0, 73.6, 73.0, 69.3, 69.1, 68.8, 66.0, 62.4, 55.2; HRMS: [M+Na]+ calcd for C55H58O11Na 917.3877, found 
917.3874. 
Methyl 2-O-(2-azido-3-O-benzyl-4,6-O-benzylidene-2-deoxy-α/β-D-
glucopyranosyl)-3,4,6-tri-O-benzyl-α-D-galactopyranoside (54). Donor 4 and 
acceptor 46 were condensed using the general procedure for Tf2O/Ph2SO 
mediated glycosylations as described in Chapter 3 yielding product 54 (60 mg, 73 
μmol, 73%, α:β = 1 : 1.3) as a colorless oil. Rf: 0.74 (4/1 pentane/EtOAc); IR (thin film): 696, 735, 997, 1028, 1051, 1090, 
1356, 1368, 1454, 2108, 2866, 2912; 1H NMR (CDCl3, 500 MHz, HH-COSY, HSQC): δ 7.49 – 7.22 (m, 57.5H, CHarom), 
5.55 (s, 1.3H, CHPhβ), 5.54 (s, 1H, CHPhα), 4.98 (d, 1H, J = 3.7 Hz, H-1’α), 4.94 – 4.86 (m, 6.9H, 5xCHH Bn, H-1α), 4.85 
(d, 1.3H, J = 3.7 Hz, H-1β), 4.79 (d, 1.3H, J = 11.3 Hz, CHH Bn), 4.75 (d, 1H, J = 11.0 Hz, CHH Bn), 4.74 (d, 1H, J = 11.6 
Hz, CHH Bn), 4.69 (d, 1.3H, J = 11.5 Hz, CHH Bn), 4.65 (d, 1H, J = 11.5 Hz, CHH Bn), 4.58 (d, 1H, J = 8.0 Hz, H-1’β), 4.54 
– 4.50 (m, 3.3H, CHH Bn, 2xCHH Bn), 4.47 (d, 1.3H, J = 11.8 Hz, CHH Bn), 4.43 (d, 1H, J = 11.8 Hz, CHH Bn), 4.39 (d, 
1.3H, J = 11.8 Hz, CHH Bn), 4.31 – 4.23 (m, 3.3H, H-2α, H-5’, H-6’β), 4.17 (dd, 1H, J = 10.2, 5.0 Hz, H-6’α), 4.16 (dd, 1.3H, 
J = 9.7, 3.7 Hz, H-2β), 4.08 (dd, 1H, J = 9.8, 9.2 Hz, H-3’α), 3.97 – 3.89 (m, 6.9H, H-3α, H-3β, H-4α, H-4β, H-5α, H-5β), 3.74 
(t, 1.3H, J = 10.3 Hz, H-6’β), 3.73 – 3.65 (m, 3.3H, H-4’α, H-4’β, H-6’α), 3.62 – 3.55 (m, 3.9H, H-2’β, H-3’β, H-6β), 3.52 (dd, 
2H, J = 6.4, 3.2 Hz, H-6α), 3.43 (s, 3H, CH3 OMeα), 3.43 (dd, 1H, J = 9.9, 3.7 Hz, H-2’α), 3.39 (s, 3.9H, CH3 OMeβ), 3.36 
(td, 1.3H, J = 10.0, 5.0 Hz, H-5’β); 13C-APT NMR (CDCl3, 126 MHz, HSQC): δ 138.7, 138.6, 138.6, 138.1, 138.1, 138.0, 
137.9, 137.9, 137.6, 137.2 (Cq), 129.1, 129.0, 128.6, 128.5, 128.5, 128.5, 128.5, 128.4, 128.4, 128.4, 128.4, 128.3, 
128.3, 128.2, 128.0, 127.9, 127.9, 127.8, 127.8, 127.8, 127.8, 127.7, 126.3, 126.1 (CHarom), 103.6 (C-1’β), 101.5, 101.4 
(CHPh), 100.0 (C-1β), 97.1 (C-1α), 95.6 (C-1’α), 82.9 (C-4’α), 81.6 (C-4’β), 79.6 (C-3’β), 78.1, 77.9, 77.5 (C-2β, C-3α, C-3β), 
76.2 (C-3’α), 75.2, 74.9 (C-4α, C-4β), 75.1, 75.1, 75.0, 75.0 (CH2 Bn), 73.7, 73.6, 73.3, 73.3 (CH2 Bn), 72.5 (C-2α), 69.4, 
69.2 (C-5α, C-5β), 69.1, 69.0 (C-6α, C-6β), 68.9 (C-6’α), 68.6 (C-6’β), 66.1 (C-5’β), 65.9 (C-2’β), 63.0 (C-2’α), 62.7 (C-5’α); 
HRMS: [M+Na]+ calcd for C48H51N3O10Na 852.3472, found 852.3488. 
Methyl 4-O-(2,3-di-O-benzyl-4,6-O-benzylidene-α/β-D-glucopyranosyl)-2,3-
di-O-benzyl-6-O-(2,3,4,5,6-pentafluorobenzoyl)-α-D-glucopyranoside (55). 
Donor 3 and acceptor 47 were condensed using the general procedure for 
Tf2O/Ph2SO mediated glycosylations as described in Chapter 3 yielding 
product 55 (71 mg, 71 μmol, 71%, α:β = 1.4 : 1) as a colorless oil. Rf: 0.82 (4/1 
pentane/EtOAc); IR (thin film): 696, 735, 1007, 1028, 1047, 1076, 1088, 1227, 
1325, 1454, 1496, 1524, 1740, 2870, 2926; Data reported as a 1 : 0.7 mixture of anomers: 1H NMR (CDCl3, 500 MHz, 
HH-COSY, HSQC, HMBC): δ 7.51 – 7.18 (m, 42.5H), 5.56 (d, 1H, J = 3.9 Hz, H-1’α), 5.52 (s, 0.7H, CHPhβ), 5.49 (s, 1H, 
CHPhα), 4.97 (d, 1H, J = 11.5 Hz, CHH Bnα), 4.95 – 4.90 (m, 3.1H, CHH Bnα, 3xCHH Bnβ), 4.83 (d, 0.7H, J = 10.7 Hz, CHH 
Bnβ), 4.81 – 4.74 (m, 5.1H, 2xCHH Bnα, 2xCHH Bnβ, CHH Bnβ, H-6α), 4.73 – 4.67 (m, 2H, 2xCHH Bnα), 4.63 (dd, 0.7H, J = 
12.0, 2.0 Hz, H-6β), 4.62 (d, 0.7H, J = 12.1 Hz, CHH Bnβ), 4.59 – 4.51 (m, 5.4H, 2xCHH Bnα, H-1α, H-1β, H-1’β, H-6α), 4.49 
(dd, 0.7H, J = 12.0, 4.2 Hz, H-6β), 4.20 (dd, 0.7H, J = 10.5, 5.0 Hz, H-6’β), 4.12 (dd, 1H, J = 10.3, 4.7 Hz, H-6’α), 4.08 (dd, 









































3’β, H-4β, H-5’α), 3.70 (ddd, 0.7H, J = 9.8, 4.1, 1.9 Hz, H-5β), 3.67 – 3.58 (m, 2.7H, H-4’α, H-4’β, H-6’α), 3.56 – 3.50 (m, 
2.7H, H-2α, H-2’α, H-6’β), 3.48 – 3.44 (m, 1.4H, H-2β, H-2’β), 3.39 (s, 3H, CH3 OMeα), 3.38 (s, 2.1H, CH3 OMeβ), 3.29 (td, 
0.7H, J = 9.9, 5.0 Hz, H-5’β); 13C-APT NMR (CDCl3, 126 MHz, HSQC, HMBC): δ 158.7, 158.5 (C=O), 146.8, 144.8 (CF-ortho), 
144.5, 142.4 (CF-para), 139.1, 139.0 (Cq), 138.8 (CF-meta), 138.6, 138.5, 138.3, 138.1, 137.9, 137.4, 137.3 (Cq), 136.8 (CF-
meta), 129.1, 129.0, 128.6, 128.6, 128.5, 128.4, 128.4, 128.4, 128.4, 128.3, 128.3, 128.1, 128.1, 128.0, 128.0, 127.8, 
127.8, 127.7, 127.7, 127.6, 127.3, 126.9, 126.1, 126.0 (CHarom), 107.8 (Cq-ipso), 103.4 (C-1’β), 101.3 (CHPhα), 101.2 
(CHPhβ), 98.4 (C-1’α), 98.3 (C-1β), 97.9 (C-1α), 82.8 (C-2’β), 82.3 (C-4’α), 81.8 (C-4’β), 81.6 (C-3’β), 81.2 (C-3α), 80.3 (C-
2α), 79.9 (C-3β), 79.2 (C-2β), 78.8 (C-2’α), 78.6 (C-3’α), 78.1 (C-4β), 75.9, 75.7, 75.3, 75.2, 74.7 (CH2 Bn), 74.6 (C-4α), 74.1, 
73.8, 73.5 (CH2 Bn), 69.0 (C-6’α), 68.8 (C-6’β), 68.4 (C-5β), 67.9 (C-5α), 66.2 (C-5’β), 65.4 (C-6α), 64.5 (C-6β), 63.7 (C-5’α), 
55.6 (OMeβ), 55.5 (OMeα); 19F NMR (CDCl3, 471 MHz): δ -137.33 (dp, 2F, J = 16.6, 5.4 Hz, orthoF5Bzα), -137.83 (dp, 1.4F, 
J = 16.5, 5.4 Hz, orthoF5Bzβ), -147.86 – -148.26 (m, 1.7F, paraF5Bzα,β), -160.23 (tt, 1.4F, J = 21.1, 5.8 Hz, metaF5Bzβ), -160.41 
(tt, 2F, J = 21.1, 5.8 Hz, metaF5Bzα); HRMS: [M+Na]+ calcd for C55H51F5O12Na 1021.3198, found 1021.3237. 
Methyl 4-O-(2-azido-3-O-benzyl-4,6-O-benzylidene-2-deoxy-α/β-D-
glucopyranosyl)-2,3-di-O-benzyl-6-O-(2,3,4,5,6-pentafluorobenzoyl)-α-D-
glucopyranoside (56). Donor 4 and acceptor 47 were condensed using the 
general procedure for Tf2O/Ph2SO mediated glycosylations as described in 
Chapter 3 yielding product 56 (75 mg, 80 μmol, 80%, α:β = 1 : 1.7) as a 
colorless oil. Rf: 0.69 and 0.82 (4/1 pentane/EtOAc); IR (thin film): 696, 735, 
997, 1003, 1028, 1047, 1092, 1227, 1325, 1454, 1498, 1524, 1653, 1740, 2110, 2872, 2914; 1H NMR (CDCl3, 500 MHz, 
HH-COSY, HSQC): δ 7.46 – 7.42 (m, 5.4H, CHarom), 7.40 – 7.25 (m, 48.6H, CHarom), 5.58 (d, 1H, J = 4.1 Hz, H-1’α), 5.53 (s, 
1H, CHPhα), 5.49 (s, 1.7H, CHPhβ), 5.12 (d, 1H, J = 10.6 Hz, CHH Bnα), 4.97 (d, 1H, J = 10.9 Hz, CHH Bnα), 4.94 – 4.88 (m, 
6.1H, 3xCHH Bnβ, CHH Bnα), 4.84 (dd, 1.7H, J = 12.1, 2.1 Hz, H-6β), 4.79 – 4.73 (m, 5.4H, 2xCHH Bnα, 2xCHH Bnβ), 4.68 
(dd, 1H, J = 11.9, 2.4 Hzα), 4.65 (dd, 1.7H, J = 12.2, 4.0 Hz, H-6β), 4.63 – 4.57 (m, 5.4H, CHH Bnα, CHH Bnβ, H-1α, H-1β), 
4.50 (dd, 1H, J = 11.9, 4.4 Hz, H-6α), 4.41 (d, 1.7H, J = 8.1 Hz, H-1’), 4.16 (dd, 1H, J = 10.3, 4.9 Hz, H-6’α), 4.10 (dd, 1H, 
J = 9.4, 8.8 Hz, H-3α), 4.05 – 4.00 (m, 2.7H, H-3’α, H-6’β), 3.99 – 3.90 (m, 4.4H, H-3β, H-5α, H-5β), 3.84 – 3.76 (m, 3.7H, 
H-4α, H-4β, H-5’α), 3.70 – 3.60 (m, 5.4H, H-3’β, H-4α, H-4’β, H-6’α), 3.54 (dd, 1H, J = 9.6, 3.5 Hz, H-2α), 3.49 (dd, 1.7H, J 
= 9.6, 3.6 Hz, H-2β), 3.47 (t, 1.7H, J = 10.3 Hz, H-6’β), 3.43 (dd, 1.7H, J = 9.2, 8.2 Hz, H-2’β), 3.40 (s, 5.1H, CH3 OMeβ), 
3.39 (s, 3H, CH3 OMeα), 3.35 (dd, 1H, J = 10.1, 4.1 Hz, H-2’α), 3.20 (ddd, 1.7H, J = 9.9, 9.0, 5.0 Hz, H-5’β); 13C-APT NMR 
(CDCl3, 126 MHz, HSQC): δ 158.8, 158.7 (m, C=O), 146.7, 144.7, 144.4, 142.5 (m, CFarom), 139.2 (Cq), 138.8 (m, CFarom), 
138.7, 138.1, 137.8, 137.8, 137.7, 137.1 (Cq), 136.8 (m, CFarom), 129.2, 129.1, 128.7, 128.6, 128.5, 128.5, 128.4, 128.4, 
128.3, 128.3, 128.3, 128.2, 128.2, 128.0, 128.0, 127.6, 127.6, 127.6, 127.3, 126.1, 126.0 (CHarom), 107.8 (m, Cq(ipso-F5Bz)), 
102.2 (C-1’β), 101.3, 101.3 (CHPh), 99.1 (C-1’α), 98.2 (C-1β), 97.8 (C-1α), 82.6 (C-4α), 81.7 (C-4’β), 81.2 (C-3α), 80.6 (C-
2α), 79.9 (C-3β), 79.8 (C-3’β), 79.4 (C-2β), 78.3 (C-4β), 76.2 (C-3’α), 75.6 (C-4α), 75.5, 75.2, 75.1, 75.0, 73.7, 73.4 (CH2 Bn), 
68.6 (C-6’α), 68.5 (C-6’β), 68.1, 67.7 (C-5α, C-5β), 66.8 (C-2’β), 66.3 (C-5’β), 65.4 (C-6α), 64.8 (C-6β), 63.7 (C-5’α), 62.9 (C-
2’α), 55.7 (OMeα), 55.6 (OMeβ); 19F NMR (CDCl3, 471 MHz): δ -137.42 (dp, J = 16.7, 5.5 Hz), -137.96 (dp, J = 16.5, 5.5 
Hz), -147.83 – -148.02 (m), -160.08 (tt, J = 21.1, 5.8 Hz), -160.31 (tt, J = 21.1, 5.9 Hz);  HRMS: [M+Na]+ calcd for 
C48H44F5N3O11Na 956.2794, found 956.2816. 
Methyl 4-O-(2,3-di-O-benzyl-4,6-O-benzylidene-α/β-D-glucopyranosyl)-2,3-
di-O-benzyl-6-O-(2,4,6-trinitrobenzoyl)-α-D-glucopyranoside (57). Donor 3 
and acceptor 48 were condensed using the general procedure for 
Tf2O/Ph2SO mediated glycosylations as described in Chapter 3 yielding 
product 57 (78 mg, 75 μmol, 75%, α:β = 2.1 : 1) as a colorless oil. Rf: 0.43 
(4/1 pentane/EtOAc); IR (thin film): 698, 735, 1028, 1047, 1074, 1088, 
1269, 1342, 1454, 1545, 1557, 1755, 2872, 2928; Data for the α-anomer: 1H NMR (CDCl3, 500 MHz, HH-COSY, HSQC, 
HMBC): δ 8.97 (s, 2H, CHarom NO2Bz), 7.38 – 7.14 (m, 25H, CHarom), 5.53 (d, 1H, J = 3.9 Hz, H-1’), 5.38 (s, 1H, CHPh), 
5.06 (dd, 1H, J = 11.7, 2.2 Hz, H-6), 4.97 – 4.86 (m, 3H, 2xCHH Bn, H-6), 4.80 – 4.64 (m, 6H, 2xCHH Bn, 2xCHH Bn, H-1, 
H-6), 4.57 (d, 1H, J = 12.0 Hz, CHH Bn), 4.54 (d, 1H, J = 12.0 Hz, CHH Bn), 4.11 – 4.04 (m, 2H, H-3, H-5), 4.01 (t, 1H, J = 
9.3 Hz, H-3’), 3.87 – 3.83 (m, 2H, H-5’, H-6’), 3.80 (dd, 1H, J = 9.8, 8.6 Hz, H-4), 3.57 – 3.49 (m, 4H, H-2, H-2’, H-4’, H-
6’), 3.41 (s, 3H, CH3 OMe); 13C-APT NMR (CDCl3, 126 MHz, HSQC, HMBC): δ 160.6 (C=O), 147.8, 147.1 (Cq NO2), 138.9, 
138.6, 138.1, 137.9, 137.3, 129.6 (Cq), 129.0, 128.6, 128.5, 128.4, 128.3, 128.3, 128.3, 128.1, 128.1, 128.1, 128.1, 
127.8, 127.8, 127.7, 127.3, 127.0, 126.1, 125.9, 124.5 (CHarom), 101.0 (CHPh), 98.0 (C-1’), 97.8 (C-1), 82.1 (C-4’), 81.1 
(C-3), 80.3 (C-2), 78.9 (C-2’), 78.5 (C-3’), 75.3, 74.6 (CH2 Bn), 74.3 (C-4), 73.9, 73.4 (CH2 Bn), 68.9 (C-6’), 68.3 (C-5), 66.9 
(C-6), 63.3 (C-5’), 55.7 (OMe); Diagnostic peaks for the β-anomer: 1H NMR (CDCl3, 500 MHz, HH-COSY, HSQC): δ 9.13 




















(t, 1H, J = 9.3 Hz, H-4’), 3.45 (dd, 1H, J = 8.8, 7.7 Hz, H-2’), 3.42 (dd, 1H, J = 10.0, 4.0 Hz, H-2), 3.39 (s, 3H, CH3 OMe); 
13C-APT NMR (CDCl3, 126 MHz, HSQC): δ 160.5 (C=O), 147.8, 147.2 (Cq NO2), 139.1, 138.5, 138.3, 137.4, 129.7 (Cq), 
129.0 - 124.6 (CHarom), 103.0 (C-1’), 101.2 (CHPh), 98.2 (C-1), 83.1 (C-2’), 81.9 (C-4’), 81.5 (C-3’), 79.8 (C-3), 78.9 (C-2), 
77.9 (C-4), 75.8 , 75.7, 73.5 (CH2 Bn), 68.8 (C-6’), 68.2 (C-5), 66.6 (C-5’), 66.0 (C-6), 55.7 (OMe); HRMS: [M+Na]+ calcd 
for C55H53N3O18Na 1066.3222, found 1066.3257. 
Preparation of 5-deoxy furanosyl imidates. 
 
Reagents and conditions: (a) i. TsCl, pyridine, DCM; ii. LiAlH4, Et2O, S5: 75%, S6: 80%; (b) i. AcCl, MeOH; ii. Ph3P, I2, imidazole, 
THF, iii. Pd(OH)2/C, H2, DiPEA; iv. BnBr, NaH, DMF, S3: 40%, S4: 52%; (c) HCOOH/H2O (4/1 v/v, 0.05 M), 50°C, S7: 86%, S8: 72%, 
S9: 92%, S10: 92%; (d) 2,2,2-trifluoro-N-phenylacetimidoyl chloride (0.95 eq.), DBU (1 eq.) in DCM (0.25 M), 0°C, 77: 48%, 79: 
56%, 81: 44%, 83: 66%. 
Methyl 2,3-di-O-benzyl-5-deoxy-α/β-D-ribofuranoside (S3). To a 0°C solution of D-ribose (3 g, 20 
mmol) in MeOH (70 mL) was added AcCl (0.6 mL, 9 mmol, 0.45 eq.) and the reaction was stirred 
overnight at room temperature. The reaction was quenched by the addition of solid K2CO3 (5 g), 
stirred for 10 min, then filtered and concentrated under reduced pressure. The crude methyl glycoside was dissolved 
in THF (80 mL) and Ph3P (7.9 g, 30 mmol, 1.5 eq.) and imidazole (2.7 g, 40 mmol, 2 eq.) were added and the reaction 
mixture brought to reflux. To the boiling reaction mixture was slowly added a solution of I2 (7.6 g, 30 mmol, 1.5 eq.) 
in THF (30 mL). After 3 h the reaction was cooled to room temperature, MeOH (10 mL) was added and the reaction 
mixture was concentrated under reduced pressure. The residue was filtered over silica gel (5% MeOH in DCM) and 
the filtrate was concentrated under reduced pressure. The crude iodide was dissolved in MeOH (60 mL) and DiPEA (5 
mL, 29 mmol). Pd(OH)2 (20% on C, 0.85 g) was added and the reaction flask was purged with N2. The flask was 
subsequently purged with H2 for 5 min and then kept under a H2 atmosphere (balloon) for 3 h. The reaction mixture 
was purged with N2, filtered over Celite and evaporated. The residue was dissolved in 5% MeOH in DCM and filtered 
over silica gel, the filtrate concentrated under reduced pressure and coevaporated once with toluene. The crude 
material was dissolved in DMF (50 mL), cooled to 0°C, and treated with BnBr (4.2 mL, 35 mmol) and NaH (60% 
dispersion in mineral oil, 1.2 g, 30 mmol) and stirred overnight. The reaction mixture was quenched by the addition 
of H2O, and then extracted three times with Et2O. The combined organic layers were washed with 0.1 M aq. HCl, H2O, 
and brine. The organic layer was dried (MgSO4), filtered, and concentrated under reduced pressure. The residue was 
purified by flash column chromatography 0% to 10% EtOAc in pentane) to give the title compound as a colourless oil 
(1.93 g, 5.9 mmol, 30%, β anomer. The α anomer (10%) was impure and discarded). Data for the β-anomer: Rf: 0.50 
(9/1 pentane/EtOAc). [α]  = +35.9° (c = 0.66, CHCl3); IR (thin film): 698, 737, 935, 1028, 1038, 1111, 1454, 2911, 2926, 
2972; 1H NMR (CDCl3, 400 MHz, HH-COSY, HH-NOESY, HSQC): δ 7.40 – 7.25 (m, 10H, CHarom), 4.87 (s, 1H, H-1), 4.68 
(d, 1H, J = 12.0 Hz, CHH Bn), 4.60 (d, 1H, J = 12.0 Hz, CHH Bn), 4.58 (d, 1H, J = 11.9 Hz, CHH Bn), 4.45 (d, 1H, J = 11.9 
Hz, CHH Bn), 4.24 (dq, 1H, J = 7.3, 6.3 Hz, H-4), 3.84 (dd, 1H, J = 4.6, 1.0 Hz, H-2), 3.74 (dd, 1H, J = 7.3, 4.6 Hz, H-3), 
3.33 (s, 3H, CH3 OMe), 1.30 (d, 3H, J = 6.3 Hz, H-5); 13C-APT NMR (CDCl3, 101 MHz, HSQC): δ 138.0, 137.9 (Cq), 128.5, 
128.5, 128.1, 127.9, 127.9 (CHarom), 106.3 (C-1), 83.2 (C-3), 80.0 (C-2), 77.3 (C-4), 72.5, 72.4 (CH2 Bn), 55.0 (CH3 OMe), 
20.6 (C-5); HRMS: [M+Na]+ calcd for C20H24O4Na 351.1572, found 351.1582. 
Methyl 2,3-di-O-benzyl-5-deoxy-α/β-D-arabinofuranoside (S4). To a 0°C solution of D-arabinose (3 g, 
20 mmol) in MeOH (70 mL) was added AcCl (0.8 mL, 12 mmol, 0.6 eq.) and the reaction was stirred 
overnight at room temperature. The reaction was quenched by the addition of solid K2CO3 (5 g), 
stirred for 10 min, then filtered and concentrated under reduced pressure. The crude methyl glycoside was dissolved 
in THF (80 mL) and Ph3P (7.9 g, 30 mmol, 1.5 eq.) and imidazole (2.7 g, 40 mmol, 2 eq.) were added and the reaction 
mixture brought to reflux. To the boiling reaction mixture was slowly added a solution of I2 (7.6 g, 30 mmol, 1.5 eq.) 
in THF (30 mL). After 2 h the reaction was cooled to room temperature, MeOH (10 mL) was added and the reaction 
mixture was concentrated under reduced pressure. The residue was filtered over silica gel (5% MeOH in DCM) and 
the filtrate was concentrated under reduced pressure to give nearly pure methyl 5-iodo arabinoside (4.12 g, 15 mmol, 













































(20% on C, 0.4 g) was added and the reaction flask was purged with N2. The flask was subsequently purged with H2 for 
5 min and then kept under a H2 atmosphere (balloon) for 3 h. The reaction mixture was purged with N2, filtered over 
Celite and evaporated. The residue was dissolved in 5% MeOH in DCM and filtered over silica gel, the filtrate 
concentrated under reduced pressure and coevaporated once with toluene to give 4.15 mmol (83%) of reduced 
compound. The crude material (4 mmol) was dissolved in DMF (20 mL), cooled to 0°C, and treated with BnBr (1.43 
mL, 12 mmol, 3 eq.) and NaH (60% dispersion in mineral oil, 480 mg, 12 mmol, 3 eq.) and stirred overnight. The 
reaction mixture was quenched by the addition of H2O, and then extracted three times with Et2O. The combined 
organic layers were washed with sat. aq. NH4Cl, H2O, and brine. The organic layer was dried (MgSO4), filtered, and 
concentrated under reduced pressure. The residue was purified by flash column chromatography (2% to 12% EtOAc 
in pentane) to give the title compound as a colourless oil (1.1 g, 3.5 mmol, 84%) in 52% over four steps, α:β = 2:1 
anomeric mixture. IR (thin film): 698, 748, 1049, 1109, 1452, 2926; Data for the α-anomer: 1H NMR (CDCl3, 400 MHz, 
HH-COSY, HSQC): δ 7.47 – 7.18 (m, 10H, CHarom), 4.87 (s, 1H, H-1), 4.59 (d, 1H, J = 12.0 Hz, CHH Bn), 4.57 (d, 1H, J = 
11.8 Hz, CHH Bn), 4.54 – 4.46 (m, 2H, 2xCHH Bn), 4.09 (p, 1H, J = 6.3 Hz, H-4), 3.97 (dd, 1H, J = 3.5, 1.0 Hz, H-2), 3.59 
(dd, 1H, J = 7.1, 3.5 Hz, H-3), 3.37 (s, 3H, CH3 OMe), 1.32 (d, 3H, J = 6.3 Hz, H-5); 13C-APT NMR (CDCl3, 101 MHz, HSQC): 
δ 138.0, 137.7 (Cq), 128.6, 128.5, 128.1, 128.0, 127.9, 127.9 (CHarom), 107.1 (C-1), 89.1 (C-2), 88.8 (C-3), 76.8 (C-4), 
72.4, 72.2 (CH2 Bn), 54.9 (OMe), 18.8 (C-5); Data for the β-anomer: 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC): δ 7.43 
– 7.24 (m, 10H, CHarom), 4.74 – 4.67 (m, 2H, CHH Bn, H-1), 4.66 – 4.57 (m, 3H, CH2 Bn, CHH Bn), 4.06 – 3.95 (m, 3H, H-
2, H-3, H-4), 3.37 (s, 3H, CH3 OMe), 1.33 (d, 3H, J = 6.2 Hz, H-5); 13C-APT NMR (CDCl3, 101 MHz, HSQC): δ 138.3, 137.8 
(Cq), 128.5, 128.3, 128.0, 127.9, 127.8 (CHarom), 101.5 (C-1), 87.1 (C-3/4), 84.5 (C-2), 77.6 (C-3/4), 72.6, 72.6 (CH2 Bn), 
54.9 (OMe), 22.3 (C-5); HRMS: [M+NH4]+ calcd for C20H28NO4 346.20128, found 346.20131. 
Methyl 2,3-di-O-benzyl-5-deoxy-α-D-lyxofuranoside (S5). To a solution of methyl 2,3-di-O-benzyl-α-
D-lyxofuranoside25  (1.03 g, 3.0 mmol, 1 eq.) and pyridine (1.4 mL, 18 mmol, 6 eq.) in DCM (15 mL) 
was added TsCl (2.3 g, 12 mmol, 4 eq.) and the reaction mixture was stirred for two days. The 
reaction mixture was poured into 1 M aq. HCl and extracted twice with Et2O. The combined organic 
layers were washed with H2O, sat. aq. NaHCO3, and brine, then dried with MgSO4, filtered and concentrated under 
reduced pressure. After coevaporation with dry toluene, the crude tosylate was dissolved in Et2O (30 mL) and LiAlH4 
(4 M in Et2O, 2.5 mL, 10 mmol, 5 eq.) was slowly added. The solution was refluxed for 3 h and then cooled to 0°C and 
quenched with EtOAc and H2O. The reaction mixture was poured in 0.1 M HCl and extracted twice with Et2O. The 
combined organic layers were washed with H2O, sat. aq. NaHCO3, and brine, then dried (MgSO4), filtered and 
concentrated under reduced pressure. Purification by flash column chromatography (1/0 to 85/15 pentane/EtOAc) 
gave the title compound as a colourless oil, which crystalized on standing. Yield: 740 mg, 2.25 mmol, 75%. m.p. 34-
36 °C. [α]  = +16.0° (c = 1.0, CHCl3); IR (neat): 692, 729, 955, 1015, 1028, 1051, 1098, 1132, 1159, 1366, 1450, 2899, 
1933, 2976; 1H NMR (CDCl3, 500 MHz, HH-COSY, HH-NOESY, HSQC): δ 7.38 – 7.23 (m, 10H, CHarom), 5.00 (d, 1H, J = 2.8 
Hz, H-1), 4.73 (d, 1H, J = 12.0 Hz, CHH Bn), 4.66 (d, 1H, J = 12.1 Hz, CHH Bn), 4.62 – 4.53 (m, 2H, 2xCHH Bn), 4.23 (qd, 
1H, J = 6.4, 4.6 Hz, H-4), 3.96 (t, 1H, J = 4.6 Hz, H-3), 3.92 (dd, 1H, J = 4.7, 2.8 Hz, H-2), 3.36 (s, 3H, CH3 OMe), 1.32 (d, 
3H, J = 6.5 Hz, H-5); 13C-APT NMR (CDCl3, 126 MHz, HSQC): δ 138.4, 138.1 (Cq), 128.4, 128.3, 127.8, 127.7, 127.6 
(CHarom), 106.7 (C-1), 84.0 (C-2), 78.9 (C-3), 75.7 (C-4), 73.2, 72.6 (CH2 Bn), 55.5 (OMe), 15.7 (C-5); 13C HSQC-HECADE 
NMR (CDCl3, 126 MHz): 2JC1,H2 = -2.5 Hz, 2JC2,H1 = -1.2 Hz; HRMS: [M+Na]+ calcd for C20H24O4Na 351.1572, found 
351.1580. 
Methyl 2,3-di-O-benzyl-5-deoxy-α/β-D-xylofuranoside (S6). To a solution of methyl 2,3-di-O-benzyl-
α-D-xylofuranoside26 (2.2 g, 6.39 mmol, 1 eq.) in pyridine (15 mL) was added TsCl (2.4 g, 12.8 mmol, 
2 eq.) and the reaction mixture was stirred overnight. The reaction mixture was poured into 1 M aq. 
HCl and extracted twice with Et2O. The combined organic layers were washed with 1 M HCl, H2O, sat. aq. NaHCO3, and 
brine, then dried with MgSO4, filtered and concentrated under reduced pressure. After coevaporation with dry 
toluene, the crude tosylate was dissolved in Et2O (60 mL) and LiAlH4 (4 M in Et2O, 5 mL, 20 mmol, 3.1 eq.) was slowly 
added. The solution was refluxed for 8 h and then cooled to 0°C and quenched with EtOAc and H2O. The reaction 
mixture was poured in 0.1 M HCl and extracted twice with Et2O. The combined organic layers were washed with H2O, 
sat. aq. NaHCO3, and brine, then dried (MgSO4), filtered and concentrated under reduced pressure. Purification by 
flash column chromatography (1/0 to 85/15 pentane/EtOAc) gave the title compound as a colourless oil. Yield: 1.68 g, 
5.1 mmol, 80% as an α:β = 1:1.2 anomeric mixture. Rf: 0.55 and 0.38 (9/1 pentane/EtOAc). IR (neat): 696, 735, 1026, 
1063, 1107, 1454, 2870, 2909, 2930; 1H NMR (CDCl3, 500 MHz, HH-COSY, HSQC): δ 7.39 – 7.26 (m, 22H, CHarom), 4.86 
(d, 1.2H, J = 1.9 Hz, H-1β), 4.77 (d, 1H, J = 4.3 Hz, H-1α), 4.65 (d, 1H, J = 12.0 Hz, CHH Bnα), 4.62 – 4.48 (m, 7.8H, CHH 
Bnα, CH2 Bnα, 2xCH2 Bnβ), 4.40 – 4.31 (m, 2.2H, H-4α, H-4β), 4.15 (dd, 1H, J = 6.7, 5.4 Hz, H-3α), 4.02 (dd, 1.2H, J = 3.2, 
1.9 Hz, H-2β), 3.98 (dd, 1H, J = 5.4, 4.3 Hz, H-2α), 3.91 (dd, 1.2H, J = 5.8, 3.2 Hz, H-3β), 3.40 (s, 3.6H, CH3 OMeβ), 3.39 
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(s, 3H, CH3 OMeα), 1.32 (d, 3.6H, J = 6.6 Hz, H-5β), 1.25 (d, 3H, J = 6.6 Hz, H-5α); 13C-APT NMR (CDCl3, 126 MHz, HSQC): 
δ 138.3, 138.1, 137.8, 137.7 (Cq), 128.4, 128.4, 128.4, 128.1, 127.9, 127.8, 127.8, 127.7, 127.7, 127.6, 127.5 (CHarom), 
108.1 (C-1β), 100.3 (C-1α), 87.4 (C-2β), 84.4 (C-2α), 82.5 (C-3β), 82.3 (C-3α), 76.9 (C-4β), 73.4 (C-4α), 72.6, 72.2, 72.0, 
71.9 (CH2 Bn), 55.5 (OMeβ), 55.0 (OMeα), 16.2 (C-5β), 15.6 (C-5α); HRMS: [M+Na]+ calcd for C20H24O4Na 351.1572, 
found 351.1585. 
2,3-di-O-benzyl-5-deoxy-α/β-D-ribofuranose (S7). The title compound was generated from S3 (1.1 g, 
3.35 mmol) by the general procedure for methyl furanoside hydrolysis, conditions A (50°C, 2 h) as 
described in Chapter 7. Yield: 86% α:β = 1:2.5 (909 mg, 2.9 mmol) as a colourless oil. Rf: 0.16 (8/2 
pentane/EtOAc). Spectroscopic data were in accord with those previously reported.27 1H NMR (CDCl3, 400 MHz, HH-
COSY, HSQC): δ 7.42 – 7.26 (m, 15.5H, CHarom), 5.34 (d, 0.55H, J = 2.9 Hz, H-1β), 5.30 (dd, 1H, J = 11.2, 4.2 Hz, H-1α), 
4.74 – 4.67 (m, 3.1H, 2x CHH Bnα, 2x CHH Bnβ), 4.65 – 4.58 (m, 2.55H, CHH Bnβ, 2xCHH Bnα), 4.46 (d, 0.55H, J = 11.9 
Hz, CHH Bnβ), 4.33 (qd, 1H, J = 6.5, 3.4 Hz, H-4α), 4.26 (d, 1H, J = 11.3 Hz, 1-OHα), 4.29 – 4.17 (m, 0.55H, H-4β), 3.93 (t, 
1H, J = 4.5 Hz, H-2α), 3.85 (dd, 0.55H, J = 4.6, 0.9 Hz, H-2β), 3.79 (dd, 0.55H, J = 7.4, 4.6 Hz, H-3β), 3.62 (dd, 1H, J = 4.9, 
3.4 Hz, H-3α), 3.16 (d, 0.55H, J = 3.4 Hz, 1-OHβ), 1.33 (d, 1.65H, J = 6.3 Hz, H-5β), 1.17 (d, 3H, J = 6.6 Hz, H-5α); 13C-APT 
NMR (CDCl3, 101 MHz, HSQC): δ 137.9, 137.9, 137.6, 137.4 (Cq), 128.6, 128.6, 128.5, 128.5, 128.2, 128.1, 128.0, 127.9 
(CHarom), 100.1 (C-1β), 95.9 (C-1α), 82.8 (C-3β), 81.8 (C-3α), 80.4 (C-2β), 77.3, 77.3, 77.2 (C-2α, C-4α, C-4β), 72.9, 72.8, 
72.6, 72.3 (CH2 Bn), 20.6 (C-5β), 19.8 (C-5α); HRMS: [M+Na]+ calcd for C19H22O4Na 337.1410, found 337.1425. 
2,3-di-O-benzyl-5-deoxy-α/β-D-arabinofuranose (S8). The title compound was generated from S4 (600 
mg, 1.87 mmol) by the general procedure for methyl furanoside hydrolysis, conditions A (50°C, 2 h) 
as described in Chapter 7. Yield: 72% α:β = 1:2.5 (413 mg, 1.31 mmol) as a colourless oil. Rf: 0.54 (7/3 
pentane/EtOAc). IR (neat): 694, 733, 995, 1055, 1207, 1454, 1497, 2872, 2905, 2928, 2972, 3030, 3395; 1H NMR 
(CDCl3, 400 MHz, HH-COSY, HSQC): δ 7.39 – 7.26 (m, 14H, CHarom), 5.38 (d, 1H, J = 6.8 Hz, H-1α), 5.31 (dd, 0.4H, J = 8.6, 
4.3 Hz, H-1β), 4.67 – 4.49 (m, 5.6H, 2xCH2 Bnα, 2xCH2 Bnβ), 4.35 (qd, 1H, J = 6.4, 4.8 Hz, H-4α), 3.98 (dd, 1H, J = 2.5, 0.9 
Hz, H-2α), 4.00 – 3.89 (m, 0.8H, H-2β, H-4β), 3.78 (d, 0.4H, J = 8.6 Hz, 1-OHβ), 3.75 (dd, 0.4H, J = 5.1, 4.3 Hz, H-3β), 3.66 
(ddd, 1H, J = 4.7, 2.5, 0.7 Hz, H-3α), 3.37 (d, 1H, J = 6.8 Hz, 1-OHα), 1.35 (d, 1.2H, J = 6.4 Hz, H-5β), 1.31 (d, 3H, J = 6.5 
Hz, H-5α); 13C-APT NMR (CDCl3, 101 MHz, HSQC): δ 137.8, 137.6, 137.5, 137.1 (Cq), 128.7, 128.6, 128.6, 128.3, 128.2, 
128.1, 128.0, 128.0, 127.9, 127.9, 127.8 (CHarom), 100.9 (C-1α), 96.0 (C-1β), 87.6 (C-2α), 87.4 (C-3α), 86.7 (C-3β), 83.2 
(C-2β), 78.6 (C-4α), 76.5 (C-4β), 72.7, 72.3, 72.3, 72.0 (CH2 Bn), 20.9 (C-5β), 19.4 (C-5α); HRMS: [M+Na]+ calcd for 
C19H22O4Na 337.1410, found 337.1426. 
2,3-di-O-benzyl-5-deoxy-α/β-D-lyxofuranose (S9). The title compound was generated from S5 (370 mg, 
1.13 mmol) by the general procedure for methyl furanoside hydrolysis, conditions A (50°C, 1.5 h) as 
described in Chapter 7. Yield: 92% α:β = 1:4 (327 mg, 1.04 mmol) as a colourless oil. Rf: 0.35 (7/3 
pentane/EtOAc). IR (thin film): 698, 735, 1058, 1159, 1454, 2926, 3408; 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC): δ 
7.43 – 7.27 (m, 12.5H), 5.49 (t, 0.25H, J = 3.1 Hz, H-1α), 5.24 (dd, 1H, J = 12.2, 3.9 Hz, H-1β), 4.89 (d, 1H, J = 11.6 Hz, 
CHH Bnβ), 4.81 – 4.73 (m, 1.25H, CHH Bnα, CHH Bnβ), 4.70 (d, 0.25H, J = 12.1 Hz, CHH Bnα), 4.67 – 4.57 (m, 2.5H, 
2xCHH Bnα, 2xCHH Bnβ), 4.37 (qd, 0.25H, J = 6.5, 4.7 Hz, H-4α), 4.25 (d, 1H, J = 12.2 Hz, 1-OHβ), 4.09 – 4.01 (m, 1.25H, 
H-3α, H-4β), 3.96 – 3.89 (m, 2.25H, H-2α, H-2β, H-3β), 3.04 (d, 0.25H, J = 3.5 Hz, 1-OHα), 1.35 (d, 3H, J = 6.5 Hz, H-5β), 
1.31 (d, 1H, J = 6.5 Hz, H-5α); 13C-APT NMR (CDCl3, 101 MHz, HSQC): δ 138.4, 138.1, 137.9, 137.7 (Cq), 128.6, 128.5,
128.5, 128.4, 128.0, 128.0, 127.9, 127.8, 127.8 (CHarom), 100.2 (C-1α), 95.6 (C-1β), 84.7 (C-2α), 79.9 (C-3β), 78.8 (C-3α), 
78.5 (C-2β), 76.0 (C-4α), 75.6 (C-4β), 74.2, 73.3, 72.6, 72.0 (CH2 Bn), 16.6 (C-5β), 15.9 (C-5α); HRMS: [M+Na]+ calcd for
C19H22O4Na 337.1410, found 337.1428. 
2,3-di-O-benzyl-5-deoxy-α/β-D-xylofuranose (S10). The title compound was generated from S6 (887 
mg, 2.7 mmol) by the general procedure for methyl furanoside hydrolysis, conditions A (50°C, 2 h) as 
described in Chapter 7. Yield: 92% α:β = 1.1:1 (778 mg, 2.47 mmol) as a colourless oil. Rf: 0.37 (8/2 
pentane/EtOAc). IR (neat): 694, 733, 1026, 1057, 1207, 1454, 1497, 2870, 2932, 3030, 3400; 1H NMR (CDCl3, 500 MHz, 
HH-COSY, HSQC): δ 7.39 – 7.26 (m, 19H, CHarom), 5.44 (dd, 0.9H, J = 9.0, 4.4 Hz, H-1α), 5.23 (d, 1H, J = 11.0 Hz, H-1β), 
4.64 – 4.50 (m, 5.7H, CH2 Bnα, CH2 Bnβ, CHH Bnα, CHH Bnβ), 4.48 (d, 1H, J = 11.9 Hz, CHH Bnβ), 4.44 (d, 0.9H, J = 12.2 
Hz, CHH Bnα), 4.39 – 4.30 (m, 1.9H, H-4α, H-4β), 3.98 (d, 1H, J = 1.2 Hz, H-2β), 3.95 (dd, 0.9H, J = 4.4, 2.1 Hz, H-2α), 3.91 
(d, 0.9H, J = 9.0 Hz, 1-OHα), 3.81 (dd, 0.9H, J = 4.2, 2.1 Hz, H-3α), 3.77 (ddd, 1H, J = 3.9, 1.3, 0.7 Hz, H-3β), 3.35 (d, 1H, 
J = 11.0 Hz, 1-OHβ), 1.37 (d, 3H, J = 6.6 Hz, H-5β), 1.26 (d, 2.7H, J = 6.5 Hz, H-5α); 13C-APT NMR (CDCl3, 126 MHz, HSQC): 




(CHarom), 101.1 (C-1β), 95.7 (C-1α), 85.3 (C-2β), 82.5 (C-3α), 82.3 (C-2α), 81.5 (C-3β), 78.0 (C-4β), 74.7 (C-4α), 73.3, 72.5, 
72.1, 72.0 (CH2 Bn), 15.5 (C-5β), 14.6 (C-5α); HRMS: [M+Na]+ calcd for C19H22O4Na 337.1410, found 337.1429. 
2,3-di-O-benzyl-5-deoxy-1-O-(N-[phenyl]trifluoroacetimidoyl)-α-D-arabinofuranoside (59). The 
title compound was generated from 61 (330 mg, 1.05 mmol) by the general procedure for 
imidate donor synthesis, conditions B as described in Chapter 7. Yield: 56% α only (286 mg, 0.59 
mmol) as a colourless oil. Rf: 0.55 (9/1 pentane/Et2O). [α]  = -1.1° (c = 0.75, CHCl3); IR (thin film): 696, 905, 1103, 
1120, 1161, 1207, 1330, 1454, 1707, 2932; 1H NMR (CDCl3, T = 323 K, 500 MHz, HH-COSY, HSQC): δ 7.36 – 7.24 (m, 
12H, CHarom), 7.11 – 7.02 (m, 1H, NPh), 6.81 (d, 2H, J = 7.7 Hz, NPh), 6.19 (bs, 1H, H-1), 4.65 – 4.50 (m, 4H, 2xCH2 Bn), 
4.32 (p, 1H, J = 6.2 Hz, H-4), 4.21 (d, 1H, J = 2.7 Hz, H-2), 3.69 (dd, 1H, J = 6.3, 2.8 Hz, H-3), 1.35 (d, 3H, J = 6.3 Hz, H-
5); 13C-APT NMR (CDCl3, T = 323 K, 126 MHz, HSQC): δ 144.2 (Cq NPh), 138.0, 137.5 (Cq Bn), 128.8, 128.8, 128.6, 128.6, 
128.2, 128.1, 128.0, 127.8, 124.4, 119.9 (CHarom), 116.3 (q, J = 286.3 Hz, CF3), 104.0 (C-1), 88.9 (C-3), 88.0 (C-2), 80.1 
(C-4), 72.6, 72.6 (CH2 Bn), 18.9 (C-5); HRMS: only mass of hydrolysis found [M+Na]+ calcd for C19H22O4Na 337.1416, 
found 337.1416.  
2,3-di-O-benzyl-5-deoxy-1-O-(N-[phenyl]trifluoroacetimidoyl)-β-D-ribofuranoside (60). The title 
compound was generated from 62 (355 mg, 1.13 mmol) by the general procedure for imidate 
donor synthesis, conditions B as described in Chapter 7. Yield: 48% β only (264 mg, 0.54 mmol) 
as a colourless oil. Rf: 0.75 (8/2 pentane/Et2O). [α]  = +82.8° (c = 1.09, CHCl3); IR (thin film): 696, 1092, 1151, 1207, 
1454, 1712, 2872, 2930; 1H NMR (CDCl3, 500 MHz, HH-COSY, HSQC): δ 7.35 – 7.24 (m, 12H, CHarom), 7.08 (t, 1H, J = 7.5 
Hz, NPh), 6.81 (d, 2H, J = 7.7 Hz, NPh), 6.19 (bs, 1H, H-1), 4.68 (d, 1H, J = 11.9 Hz, CHH Bn), 4.60 (d, 1H, J = 12.1 Hz, 
CHH Bn), 4.56 (d, 1H, J = 11.7 Hz, CHH Bn), 4.48 (d, 1H, J = 11.7 Hz, CHH Bn), 4.36 (p, 1H, J = 6.4 Hz, H-4), 4.05 (d, 1H, 
J = 4.3 Hz, H-2), 3.79 (dd, 1H, J = 7.6, 4.5 Hz, H-3), 1.35 (d, 3H, J = 6.3 Hz, H-5); 13C-APT NMR (CDCl3, 126 MHz, HSQC): 
δ 144.1 (Cq NPh), 143.55 (q, J = 37.1 Hz, CF3-C=NPh), 137.8, 137.7, 137.7, 128.9, 128.6, 128.2, 128.1, 128.1, 127.9, 
124.4, 119.8 (CHarom), 116.17 (q, J = 285.7 Hz, CF3), 102.9 (C-1), 82.9 (C-3), 79.4 (C-2), 79.2 (C-4), 72.9, 72.5 (CH2 Bn), 
20.1 (C-5); HRMS: only mass of hydrolysis found [M+Na]+ calcd for C19H22O4Na 337.1416, found 337.1420.  
2,3-di-O-benzyl-5-deoxy-1-O-(N-[phenyl]trifluoroacetimidoyl)-α-D-lyxofuranoside (61). The title 
compound was generated from 63 (195 mg, 0.62 mmol) by the general procedure for imidate 
donor synthesis, conditions B as described in Chapter 7. Yield: 44% α:β = 1:4 (132 mg, 0.27 
mmol) as a colourless oil. IR (thin film): 696, 1091, 1207, 1454, 1716, 2868; Data for the α-anomer: 1H NMR (CDCl3, T 
= 328 K, 500 MHz, HH-COSY, HSQC): δ 7.34 – 7.24 (m, 12H, CHarom), 7.09 – 7.05 (m, 1H, NPh), 6.82 (dd, 2H, J = 8.4, 1.0 
Hz, NPh), 6.26 (bs, 1H, H-1), 4.69 (d, 1H, J = 11.8 Hz, CHH Bn), 4.68 – 4.60 (m, 2H, CH2 Bn), 4.55 (d, 1H, J = 11.8 Hz, 
CHH Bn), 4.39 (p, 1H, J = 6.3 Hz, H-4), 4.15 (dd, 1H, J = 4.7, 1.9 Hz, H-2), 4.08 (t, 1H, J = 5.1 Hz, H-3), 1.34 (d, 3H, J = 6.5 
Hz, H-5); 13C-APT NMR (CDCl3, T = 328 K, 126 MHz, HSQC): δ 144.2 (Cq NPh), 143.8 (q, J = 35.4 Hz, C=NPh), 138.3, 137.8 
(Cq Bn), 128.8, 128.6, 128.5, 128.0, 127.9, 127.9, 127.8, 124.4, 119.9 (CHarom), 116.38 (q, J = 286.0 Hz, CF3) 103.5 (C-
1), 82.8 (C-2), 78.3 (C-3), 78.1 (C-4), 73.4, 73.0 (CH2 Bn), 15.8 (C-5); Diagnostic peaks β-anomer: 1H NMR (CDCl3, T = 
328 K, 500 MHz, HH-COSY, HSQC): δ 7.40 – 7.18 (m, 12H, CHarom), 7.04 – 6.99 (m, 1H, NPh), 6.75 (d, 2H, J = 7.9 Hz, 
NPh), 6.35 (bs, 1H, H-1), 4.90 (d, 1H, J = 12.0 Hz, CHH Bn), 4.74 – 4.60 (m, 3H, CHH Bn, CH2 Bn), 4.23 (qd, 1H, J = 6.5, 
4.7 Hz, H-4), 4.05 – 4.01 (m, 1H, H-2), 3.95 (t, 1H, J = 4.9 Hz, H-3), 1.37 (d, 3H, J = 6.6 Hz, H-5); 13C-APT NMR (CDCl3, T 
= 328 K, 126 MHz, HSQC): δ 144.6 (Cq NPh), 139.0, 137.9 (Cq Bn), 128.7, 128.6, 128.3, 128.0, 127.6, 127.5, 127.4, 
124.0, 120.0 (CHarom), 97.2 (C-1), 81.0 (C-2), 78.8 (C-4), 76.4 (C-3), 73.5, 73.3 (CH2 Bn), 16.1 (C-5); HRMS: only mass of 
hydrolysis found [M+Na]+ calcd for C19H22O4Na 337.1416, found 337.1422. 
2,3-di-O-benzyl-5-deoxy-1-O-(N-[phenyl]trifluoroacetimidoyl)-α/β-D-xylofuranoside (62). The 
title compound was generated from 64 (285 mg, 0.91 mmol) by the general procedure for 
imidate donor synthesis, conditions B as described in Chapter 7. Yield: 66% α:β = 1:3 (290 mg, 
0.59 mmol) as a colourless oil. Rf: 0.41 (9/1 pentane/Et2O). IR (thin film): 696, 1085, 1154, 1207, 1454, 1708, 2864; 1H 
NMR (CDCl3, 500 MHz, HH-COSY, HSQC): δ 7.35 – 7.21 (m, 16H, CHarom), 7.09 – 7.02 (m, 1.33H, NPh), 6.82 – 6.77 (m, 
1H, NPh), 6.74 (d, 0.33H, J = 7.5 Hz, NPh), 6.32 (bs, 0.33H, H-1α), 6.18 (bs, 1H, H-1β), 4.67 – 4.47 (m, 6.67H, 2xCH2 Bnα, 
2xCH2 Bnβ, H-4α, H-4β), 4.27 (d, 1H, J = 2.3 Hz, H-2β), 4.18 – 4.14 (m, 0.67H, H-2α, H-3α), 3.97 (dd, 1H, J = 5.7, 2.6 Hz, 
H-3β), 1.37 (d, 3H, J = 6.7 Hz, H-5β), 1.27 (d, 1H, J = 6.6 Hz, H-5α); 13C-APT NMR (CDCl3, 126 MHz, HSQC): δ 144.3, 144.2 
(Cq NPh), 138.2, 138.1, 137.8, 137.6 (Cq Bn), 129.5, 128.8, 128.6, 128.5, 128.1, 128.1, 128.0, 127.9, 127.8, 127.6, 127.6, 
126.5, 124.2, 120.7, 119.8 (CHarom), 116.23 (q, J = 286.4 Hz, CF3), 103.8 (C-1β), 97.8 (C-1α), 86.1 (C-2β), 84.3 (C-2α), 82.6 
(C-3β), 81.7 (C-3α), 80.1 (C-4β), 76.4 (C-4α), 73.4, 72.6, 72.5, 72.4 (CH2 Bn), 15.8 (C-5β), 15.4 (C-5α); HRMS: only mass 
of hydrolysis found [M+Na]+ calcd for C19H22O4Na 337.1416, found 337.1417.  




Acetyl 2,3-di-O-benzyl-5-deoxy-α/β-D-xylofuranoside (63). The title compound was generated from 
S10 (220 mg, 0.7 mmol) by the general procedure for acetyl donor synthesis as described in Chapter 
7. Yield: 95% α:β = 1:2.5 (236 mg, 0.66 mmol) as a colourless oil. IR (thin film): 604, 696, 735, 1007, 
1090, 1231, 1373, 1454, 1741, 2934, 3030; 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC): δ 7.39 – 7.23 (m, 14H, CHarom), 
6.28 (d, 0.4H, J = 4.1 Hz, H-1α), 6.12 (s, 1H, H-1β), 4.64 (d, 1H, J = 12.0 Hz, CHH Bnβ), 4.62 – 4.42 (m, 6H, CHH Bnβ, CH2 
Bnβ, 2xCH2 Bnα, H-4α, H-4β), 4.15 – 4.08 (m, 1.8H, H-2α, H-2β, H-3α), 3.89 (dd, 1H, J = 5.2, 2.3 Hz, H-3β), 2.06 (s, 1.2H, 
CH3 OAcα), 2.04 (s, 3H, CH3 OAcβ), 1.34 (d, 3H, J = 6.6 Hz, H-5β), 1.27 (d, 1.2H, J = 6.5 Hz, H-5α); 13C-APT NMR (CDCl3, 
101 MHz, HSQC): δ 170.3, 170.2 (C=O), 138.0, 137.8, 137.4, 137.4 (Cq), 128.5, 128.4, 128.0, 128.0, 128.0, 127.8, 127.7, 
127.5, 127.5 (CHarom), 100.5 (C-1β), 94.2 (C-1α), 85.8 (C-2β), 83.6 (C-2α), 81.9 (C-3β), 81.5 (C-3α), 79.1 (C-4β), 75.7 (C-
4α), 73.2, 72.2, 72.1, 71.8 (CH2 Bn), 21.4 (CH3 OAcβ), 21.2 (CH3 OAcα), 15.5 (C-5β), 15.4 (C-5α); HRMS: [M+Na]+ calcd 
for C21H24O5Na 379.1521, found 379.1525. 
Allyl 2,3-di-O-benzyl-1,5-dideoxy-α/β-D-arabinofuranoside (65). Donor 59 and allyltrimethylsilane (4 
eq.) were condensed using the general procedure for furanosyl imidate glycosylations at -78°C for 
90 h with TfOH as the promotor. Yield = 28 mg, 83 μmol, 83% as a colourless oil (α:β = 40:60). Rf: 
0.55 (85/15 pentane/EtOAc). IR (thin film): 698, 737, 1028, 1069, 1098, 1454, 2866, 2900, 2974; 1H NMR (CDCl3, 400 
MHz, HH-COSY, HH-NOESY, HSQC): δ 7.39 – 7.27 (m, 10H, CHarom), 5.89 – 5.77 (m, 1H, CH allyl), 5.17 – 5.03 (m, 2H, 
CH2 allyl), 4.59 (d, 0.6H, J = 12.0 Hz, CHH Bnβ), 4.56 – 4.44 (m, 3.4H, CHH Bnβ, CH2 Bnβ, 2xCH2 Bnα), 4.14 (qd, 0.4H, J = 
6.5, 4.4 Hz, H-4α), 4.08 (td, 0.4H, J = 6.7, 4.1 Hz, H-1α), 3.96 (td, 0.6H, J = 7.0, 3.7 Hz, H-1β), 3.92 (qd, 0.6H, J = 6.5, 3.8 
Hz, H-4β), 3.84 (dd, 0.4H, J = 4.0, 2.8 Hz, H-2α), 3.82 (dd, 0.6H, J = 3.7, 0.9 Hz, H-2β), 3.75 (dd, 0.4H, J = 4.3, 2.8 Hz, H-
3α), 3.65 (dd, 0.6H, J = 3.8, 1.0 Hz, H-3β), 2.51 (tq, 1.2H, J = 6.9, 1.3 Hz, CH2 allylicβ), 2.44 – 2.34 (m, 0.4H, CH2 allylicα), 
1.34 (d, 1.8H, J = 6.5 Hz, H-5β), 1.31 (d, 1.2H, J = 6.5 Hz, H-5α); 13C-APT NMR (CDCl3, 101 MHz, HSQC): δ 138.2, 138.1, 
138.0, 138.0 (Cq), 135.1 (CH allylβ), 134.5 (CH allylα), 128.6, 128.6, 128.6, 128.5, 128.0, 127.9, 127.9, 127.8, 127.8, 
127.7 (CHarom), 117.6 (CH2 allylα), 117.0 (CH2 allylβ), 89.7 (C-3α), 88.7 (C-3β), 87.6 (C-2α), 83.6 (C-2β), 81.4 (C-1α), 80.9 
(C-1β), 79.9 (C-4β), 78.1 (C-4α), 72.1, 72.0, 71.8, 71.6 (CH2 Bn), 38.0 (CH2 allylicα), 33.5 (CH2 allylicβ), 20.1 (C-5β), 19.5 
(C-5α); 13C HSQC-HECADE NMR (CDCl3, 126 MHz): α-anomer: 2JC1,H2 = -0.7 Hz, 2JC2,H1 = -4.2 Hz, 3JCallyl,H2 = +3.7 Hz, β-
anomer: 2JC1,H2 = +2.2 Hz, 2JC2,H1 = +3.4 Hz, 3JCallyl,H2 = +0.3 Hz; HRMS: [M+Na]+ calcd for C22H26O3Na 361.1780, found 
361.1780.  
Allyl 2,3-di-O-benzyl-1,5-dideoxy-α-D-ribofuranoside (66). Donor 60 and allyltrimethylsilane (4 eq.) 
were condensed using the general procedure for furanosyl imidate glycosylations at -78°C for 90 h 
with TfOH as the promotor. Yield = 30 mg, 89 μmol, 89% as a colourless oil. Rf: 0.61 (85/15 
pentane/EtOAc). [α]  = +50.9° (c = 1.0, CHCl3); IR (thin film): 696, 737, 914, 1026, 1094, 1273, 1454, 2926, 2970, 
3032; 1H NMR (CDCl3, 400 MHz, HH-COSY, HH-NOESY, HSQC): δ 7.42 – 7.25 (m, 10H, CHarom), 5.80 (ddt, 1H, J = 17.1, 
10.2, 6.9 Hz, CH allyl), 5.10 (dq, 1H, J = 17.2, 1.6 Hz, CHH allyl), 5.04 (ddt, 1H, J = 10.2, 2.1, 1.1 Hz, CHH allyl), 4.81 (d, 
1H, J = 11.7 Hz, CHH Bn), 4.67 (d, 1H, J = 12.0 Hz, CHH Bn), 4.59 (d, 1H, J = 11.7 Hz, CHH Bn), 4.54 (d, 1H, J = 12.0 Hz, 
CHH Bn), 4.17 (dq, 1H, J = 7.5, 6.2 Hz, H-4), 4.05 (td, 1H, J = 7.0, 4.0 Hz, H-1), 3.97 (t, 1H, J = 4.1 Hz, H-2), 3.61 (dd, 1H, 
J = 7.5, 4.2 Hz, H-3), 2.54 – 2.41 (m, 2H, CH2 allylic), 1.24 (d, 3H, J = 6.2 Hz, H-5); 13C-APT NMR (CDCl3, 101 MHz, HSQC): 
δ 138.6, 138.1 (Cq), 135.2 (CH allyl), 128.6, 128.4, 127.9, 127.8, 127.8, 127.7 (CHarom), 117.0 (CH2 allyl), 85.7 (C-3), 79.4 
(C-1), 77.8 (C-2), 75.5 (C-4), 73.5, 72.8 (CH2 Bn), 34.6 (CH2 allylic), 19.6 (C-5); 13C HSQC-HECADE NMR (CDCl3, 126 MHz): 
α-anomer: 2JC1,H2 = +0.9 Hz, 2JC2,H1 = +1.6 Hz, 3JCallyl,H2 = +1.5 Hz; HRMS: [M+Na]+ calcd for C22H26O3Na 361.1780, found 
361.1779. 
Allyl 2,3-di-O-benzyl-1,5-dideoxy-β-D-lyxofuranoside (67). Donor 61 and allyltrimethylsilane (4 eq.) 
were condensed using the general procedure for furanosyl imidate glycosylations at -78°C for 90 h 
with TfOH as the promotor. Yield = 19 mg, 56 μmol, 56% as a colourless oil. Rf: 0.25 (85/15 
pentane/EtOAc). [α]  = -7.1° (c = 0.63, CHCl3); IR (thin film): 696, 735, 912, 1028, 1065, 1086, 1159, 1454, 2866, 2926, 
3030, 3064; 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC): δ 7.39 – 7.26 (m, 10H, CHarom), 5.84 (ddt, 1H, J = 17.2, 10.2, 
6.9 Hz, CH allyl), 5.10 (ddt, 1H, J = 17.2, 2.1, 1.5 Hz, CHH allyl), 5.03 (ddt, 1H, J = 10.2, 2.2, 1.2 Hz, CHH allyl), 4.79 (d, 
1H, J = 11.8 Hz, CHH Bn), 4.70 (d, 1H, J = 12.1 Hz, CHH Bn), 4.61 (d, 1H, J = 12.1 Hz, CHH Bn), 4.57 (d, 1H, J = 11.8 Hz, 
CHH Bn), 4.16 – 4.08 (m, 1H, H-4), 4.04 – 3.98 (m, 2H, H-2, H-3), 3.94 – 3.88 (m, 1H, H-1), 2.53 – 2.46 (m, 2H, CH2 
allylic), 1.33 (d, 3H, J = 6.4 Hz, H-5); 13C-APT NMR (CDCl3, 101 MHz, HSQC): δ 138.7, 138.6 (Cq), 135.7 (CH allyl), 128.5, 
128.4, 127.7, 127.6, 127.6, 127.5 (CHarom), 116.7 (CH2 allyl), 80.4 (C-3), 79.4 (C-2), 78.8 (C-1), 75.1 (C-4), 73.4, 73.1 
(CH2 Bn), 35.4 (CH2 allylic), 16.9 (C-5); 13C HSQC-HECADE NMR (CDCl3, 126 MHz): 2JC1,H2 = +1.5 Hz, 2JC2,H1 = +1.5 Hz, 










Allyl 2,3-di-O-benzyl-1,5-dideoxy-α/β-D-xylofuranoside (68). Donor 62 and allyltrimethylsilane (4 
eq.) were condensed using the general procedure for furanosyl imidate glycosylations at -78°C for 
90 h with TfOH as the promotor. Isolated yield = 28 mg, calculated product yield = 20 mg, 60 μmol, 
60% (α:β = 60:40), intermixed with amide 74 (16%). Rf: 0.58 (80/20 pentane/EtOAc). IR (thin film): 696, 734, 914, 1028, 
1067, 1086, 1205, 1454, 2866, 2930, 3032; 1H NMR (CDCl3, 500 MHz, HH-COSY, HSQC): δ 7.39 – 7.19 (m, 17H, CHarom), 
5.87 – 5.76 (m, 1.7H, CH allyl), 5.14 – 5.02 (m, 3.4H, CH2 allyl), 4.59 – 4.52 (m, 2.7H, 3xCHH Bn), 4.50 – 4.44 (m, 4.4H, 
3xCHH Bn, CH2 Bn), 4.29 (qd, 1H, J = 6.5, 4.0 Hz, H-4α), 4.17 (td, 1H, J = 7.1, 4.0 Hz, H-1α), 4.08 (qd, 0.7H, J = 6.4, 3.7 
Hz, H-4β), 3.88 (dd, 1H, J = 4.0, 1.4 Hz, H-2α), 3.83 (td, 0.7H, J = 6.7, 3.9 Hz, H-1β), 3.80 (dd, 1H, J = 4.0, 1.4 Hz, H-3α), 
3.77 – 3.73 (m, 1.4H, H-2β, H-3β), 2.49 – 2.34 (m, 3.4H, CH2 allylic), 1.33 (d, 2.1H, J = 6.4 Hz, H-5β), 1.26 (d, 3H, J = 6.5 
Hz, H-5α); 13C-APT NMR (CDCl3, 126 MHz, HSQC): δ 138.3, 138.3, 138.1, 138.0 (Cq), 135.4 (CH allylα), 134.7 (CH allylβ), 
129.2, 128.6, 128.6, 128.5, 128.4, 128.2, 127.9, 127.9, 127.9, 127.8, 127.8, 127.8, 127.7, 127.7, 127.6 (CHarom), 117.3 
(CH2 allylβ), 116.8 (CH2 allylα), 86.9 (C-2β), 84.2 (C-3β), 82.9 (C-1β), 82.8 (C-3α), 82.5 (C-2α), 79.4 (C-1α), 77.1 (C-4β), 75.8 
(C-4α), 72.3, 72.2 (CH2 Bnα), 71.8, 71.6 (CH2 Bnβ), 38.6 (CH2 allylicβ), 33.9 (CH2 allylicα), 14.8 (C-5α), 14.3 (C-5β); 13C 
HSQC-HECADE NMR (CDCl3, 126 MHz): α-anomer: 2JC1,H2 = +2.0 Hz, 2JC2,H1 = +2.0 Hz, 3JCallyl,H2 = +0.4 Hz; β-anomer:2JC2,H1 
= -4.4 Hz, 3JCallyl,H2 = +3.7 Hz; HRMS: [M+Na]+ calcd for C22H26O3Na 361.1780, found 361.1779. 
1-[2H]-1,4-anhydro-2,3-di-O-benzyl-5-deoxy-α/β-D-xylitol (69). Donor 60 and triethylsilane-d (4 eq.) 
were condensed using the procedure published by van Rijssel et al.20 -78°C for 90 h with TMSOTf (1.3 
eq.) as the promotor. Yield = 23 mg, 77 μmol, 77% as a colourless oil (α:β = 40:60). Rf: 0.42 (9/1 
pentane/EtOAc). IR (thin film): 709, 1026, 1096, 1109, 1267, 1452, 2933; 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC): 
δ 7.38 – 7.27 (m, 10H, CHarom), 4.61 (d, 1H, J = 12.2 Hz, CHH Bn), 4.50 (d, 1H, J = 12.2 Hz, CHH Bn), 4.49 (s, 2H, CH2 Bn), 
4.14 (t, 0.6H, J = 5.5 Hz, H-1β), 4.15 – 4.06 (m, 2H, H-2, H-4), 3.80 (dd, 1H, J = 3.8, 1.2 Hz, H-3), 3.71 (dt, 0.4H, J = 2.7, 
1.3 Hz, H-1α), 1.30 (d, 3H, J = 6.4 Hz, H-5); 13C-APT NMR (CDCl3, 101 MHz, HSQC): δ 138.2, 137.9 (Cq), 128.6, 128.6, 
128.0, 127.9, 127.7 (CHarom), 83.3 (C-3), 82.9 (C-2), 76.8 (C-4), 71.9, 71.7 (CH2 Bn), 71.1 (t, J = 22.4 Hz, C-1), 71.1 (t, J = 
22.4 Hz, C-1), 14.1 (C-5); 2H NMR (CHCl3, 77 MHz): δ 4.18 (s, 0.4D, D-1α), 3.74 (s, 0.6D, D-1β); 13C HSQC-HECADE NMR 
(CDCl3, 126 MHz): α-anomer: 2JC2,H1 = +1.2 Hz; β-anomer:2JC2,H1 = -4.5 Hz.  
2,3-di-O-benzyl-1,5-dideoxy-1-N-[phenyl]trifluoroacetyl-α/β-D-xylofuranoside (74). Intermixed 
with 68. The anomeric amide was formed in an α:β = 96:4 ratio. Data for the α-anomer: 1H NMR 
(CDCl3, 500 MHz, HH-COSY, HSQC): δ 7.40 – 7.20 (m, 15H, CHarom), 6.31 (d, 1H, J = 5.6 Hz, H-1), 
4.69 (d, 1H, J = 11.1 Hz, CHH Bn), 4.54 (d, 1H, J = 11.2 Hz, CHH Bn), 4.50 – 4.46 (m, 1H, CHH Bn), 
4.42 (dd, 1H, J = 5.7, 3.3 Hz, H-4), 4.34 (d, 1H, J = 12.1 Hz, CHH Bn), 3.52 – 3.47 (m, 2H, H-2, H-3), 1.03 (d, 3H, J = 6.1 
Hz, H-5); 13C-APT NMR (CDCl3, 126 MHz, HSQC): δ 156.5 (C=O), 137.8, 137.4 (Cq Bn), 134.6 (Cq Ph), 132.1 - 127.6 
(CHarom), 116.1 (q, J = 289 Hz, CF3, 87.8 (C-1), 83.1 (C-2), 81.6 (C-3), 76.6 (C-4), 74.1, 72.0 (CH2 Bn), 15.1 (C-5); 19F NMR 
(CDCl3, 471 MHz): δ -68.08 ; 13C HSQC-HECADE NMR (CDCl3, 126 MHz): 2JC1,H2 = +1.2 Hz, 2JC2,H1 = +2.0 Hz; 
Phenyl 2,3,5-tri-O-benzyl-1-thio-α/β-D-ribofuranoside (77). A solution of 1,2,3,5-tetra-O-acetyl-
α/β-D-ribofuranose20 (1.59 g, 3.43 mmol, 1 eq.), thiophenol (0,40 mL, 3.77 mmol, 1.1 eq.) and 
BF3⋅OEt2 (0.51 mL, 4.12 mmol, 1.2 eq.) at 0°C was stirred for 2 h. The reaction was quenched 
with sat. aq. NaHCO3 and the mixture was extracted with EtOAc and washed with brine. The organic layer was dried 
(MgSO4), filtered and concentrated in vacuo. Flash column chromatography of the residue (1/0 to 19/1 
pentane/EtOAc) afforded the title compound as a colourless oil (Yield = 1.237 g, 2.41 mmol, 70%, α:β = 1:2.7). 
Spectroscopic data was previously reported28 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC): δ 7.81 – 7.36 (m, 55.5H, 
CHarom), 5.97 (d, 1H, J = 5.3 Hz, H-1α), 5.73 (d, 2.7H, J = 3.7 Hz, H-1β), 4.99 (d, 1H, J = 11.7 Hz, CHH Bnα), 4.92 (d, 1H, J 
= 12.1 Hz, CHH Bnα), 4.84 (d, 1H, J = 11.7 Hz, CHH Bnα), 4.80 (d, 2.7H, J = 11.9 Hz, CHH Bnβ), 4.75 – 4.63 (m, 16.5H, 
2xCHH Bnβ, 3xCHH Bnβ, CHH Bnα, CHH Bnα, H-4α), 4.61 (d, 1H, J = 12.1 Hz, CHH Bnα), 4.58 – 4.54 (m, 2.7H, H-4β), 4.38 
(t, 1H, J = 5.5 Hz, H-2α), 4.20 (t, 1H, J = 5.4 Hz, H-3α), 4.18 – 4.14 (m, 5.4H, H-2β, H-3β), 3.80 (dd, 1H, J = 10.9, 3.3 Hz, 
H-5α), 3.74 (d, 5.4H, J = 4.5 Hz, H-5β, H-5β), 3.71 (dd, 1H, J = 10.8, 3.5 Hz, H-5α); 13C-APT NMR (CDCl3, 101 MHz, HSQC): 
δ 137.9, 137.9, 137.8, 137.5, 137.4, 137.2, 136.4, 133.3 (Cq), 131.9, 130.4, 128.6, 128.5, 128.1, 128.1, 128.0, 127.8, 
127.7, 127.6, 127.5, 127.5, 127.4, 127.3, 127.3, 127.3, 127.3, 127.2, 126.2 (CHarom), 90.4 (C-1α), 88.4 (C-1β), 81.7 (C-
4β), 80.6 (C-4α), 80.2 (C-2β), 78.3 (C-2α), 77.2 (C-3β), 76.9 (C-3α), 73.0, 72.9, 72.9, 72.2, 71.8 (CH2 Bn), 70.0 (C-5β), 69.0 
(C-5α); 13C-HSQC-HECADE NMR (101 MHz, CDCl3): α-anomer: 2JC1,H2 = +2.0 Hz; β-anomer: 2JC2,H1 = -2.9 Hz; HRMS: 
[M+Na]+ calcd for C32H32O4SNa 535.19135, found 535.19064.  
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Phenyl 2,3,5-tri-O-benzyl-1-thio-α/β-D-arabinofuranoside (79). A solution of 1,2,3,5-tetra-O-
acetyl-α/β-D-arabinofuranose20 (889 mg, 1.92 mmol, 1 eq.), thiophenol (0.22 mL, 2.11 mmol, 
1.1 eq.) and BF3⋅OEt2 (0.30 mL, 2.31 mmol, 1.2 eq.) at 0°C was stirred for 2 h. The reaction was 
quenched with sat. aq. NaHCO3 and the mixture was extracted with EtOAc and washed with brine. The organic layer 
was dried (MgSO4), filtered and concentrated in vacuo. Flash column chromatography of the residue (1/0 to 19/1 
pentane/EtOAc) afforded the title compound as a colourless oil (Yield = 291 mg, 0.57 mmol, 30%, α:β = 4:1). 
Spectroscopic data for the β-anomer was reported previously.29 Data for the α-anomer: IR (thin film): 693, 734, 1026, 
1068, 1270, 1361, 1453, 1722, 2864; 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC): δ 7.54 – 7.46 (m, 2H, CHarom), 7.38 
– 7.18 (m, 18H, CHarom), 5.62 (d, 1H, J = 2.8 Hz, H-1), 4.66 – 4.45 (m, 6H, 3xCH2 Bn), 4.40 (dt, 1H, J = 6.7, 4.4 Hz, H-4), 
4.13 (t, 1H, J = 3.1 Hz, H-2), 4.05 (dd, 1H, J = 6.7, 3.3 Hz, H-3), 3.68 (dd, 1H, J = 10.9, 3.9 Hz, H-5), 3.63 (dd, 1H, J = 10.9, 
4.8 Hz, H-5); 13C-APT NMR (CDCl3, 101 MHz, HSQC): δ 138.1, 137.7, 137.3, 134.9 (Cq), 131.2, 128.9, 128.5, 128.4, 128.4, 
128.0, 128.0, 127.8, 127.8, 127.7, 127.6, 127.1 (CHarom), 90.3 (C-1), 88.5 (C-2), 83.4 (C-3), 80.5 (C-4), 73.3, 72.3, 72.1 
(CH2 Bn), 69.0 (C-5); 13C-HSQC-HECADE NMR (101 MHz, CDCl3): α-anomer: 2JC1,H2 = +0.6 Hz, 2JC2,H1 = -4.0 Hz;  HRMS: 
[M+Na]+ calcd for C32H32O4SNa 535.19135, found 535.19024. 
Phenyl 2,3,5-tri-O-benzyl-1-thio-α/β-D-lyxofuranoside (81). A solution of 1,2,3,5-tetra-O-acetyl-
α/β-D-lyxofuranose20 (1.86 g, 4.02 mmol, 1 eq.), thiophenol (0.50 mL, 4.43 mmol, 1.1 eq.) and 
BF3⋅OEt2 (0.60 mL, 4.83 mmol, 1.2 eq.) at 0°C was stirred for 2 h. The reaction was quenched 
with sat. aq. NaHCO3 and the mixture was extracted with EtOAc and washed with brine. The organic layer was dried 
(MgSO4), filtered and concentrated in vacuo. Flash column chromatography of the residue (1/0 to 19/1 
pentane/EtOAc) afforded the title compound as a colourless oil (Yield = 1.11 g, 2.17 mmol, 54%, α:β = 97:3). Data for 
the α-anomer: IR (thin film): 693, 733, 1025, 1072, 1453, 2859; 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC): δ 7.49 – 
7.43 (m, 2H, CHarom), 7.31 – 7.16 (m, 17H, CHarom), 5.54 (d, 1H, J = 6.0 Hz, H-1), 4.70 (d, 1H, J = 11.7 Hz, CHH Bn), 4.60 
(d, 1H, J = 12.0 Hz, CHH Bn), 4.55 (d, 1H, J = 12.0 Hz, CHH Bn), 4.53 (d, 1H, J = 11.7 Hz, CHH Bn), 4.51 (d, 1H, J = 11.9 
Hz, CHH Bn), 4.44 (d, 1H, J = 11.9 Hz, CHH Bn), 4.27 (td, 1H, J = 6.2, 3.8 Hz, H-4), 3.99 (t, 1H, J = 4.1 Hz, H-3), 3.94 (dd, 
1H, J = 5.9, 4.4 Hz, H-2), 3.80 (dd, 1H, J = 9.9, 6.3 Hz, H-5), 3.70 (dd, 1H, J = 9.9, 6.2 Hz, H-5); 13C-APT NMR (CDCl3, 101 
MHz, HSQC): δ 138.0, 138.0, 137.4, 134.0 (Cq), 131.7, 128.8, 128.4, 128.3, 128.2, 127.8, 127.8, 127.8, 127.7, 127.6, 
127.6, 127.2 (CHarom), 88.4 (C-1), 83.2 (C-2), 79.0 (C-4), 76.8 (C-3), 73.5, 73.3, 72.6 (CH2 Bn), 68.2 (C-5); 13C-HSQC-
HECADE NMR (101 MHz, CDCl3): 2JC1,H2 = -2.2 Hz, 2JC2,H1 = -4.5 Hz; HRMS: [M+Na]+ calcd for C32H32O4SNa 535.19135, 
found 535.19018. 
Phenyl 2,3,5-tri-O-benzyl-1-thio-α/β-D-xylofuranoside (81). A solution of 1,2,3,5-tetra-O-acetyl-
α/β-D-xylofuranose20 (3.55 g, 7.68 mmol, 1 eq.), thiophenol (0.90 mL, 8.45 mmol, 1.1 eq.) and 
BF3⋅OEt2 (1.15 mL, 9.22 mmol, 1.2 eq.) at 0°C was stirred for 2 h. The reaction was quenched 
with sat. aq. NaHCO3 and the mixture was extracted with EtOAc and washed with brine. The organic layer was dried 
(MgSO4), filtered and concentrated in vacuo. Flash column chromatography of the residue (1/0 to 19/1 
pentane/EtOAc) afforded the title compound as a colourless oil (Yield = 2.07 g, 4.04 mmol, 53%, α:β = 1:0.8). 
Spectroscopic data for the α-anomer was reported previously.29 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC): δ 7.55 – 
7.47 (m, 4H, CHarom), 7.40 – 7.14 (m, 32H, CHarom), 5.80 (d, 1H, J = 5.0 Hz, H-1α), 5.37 (d, 0.8H, J = 2.9 Hz, H-1β), 4.69 – 
4.37 (m, 12.6H, 3xCH2 Bnα,β, H-4α), 4.21 (dd, 1H, J = 5.0, 2.3 Hz, H-2α), 4.15 – 4.11 (m, 0.8H, H-2β), 4.09 (dd, 1H, J = 
4.5, 2.3 Hz, H-3α), 4.03 (dd, 0.8H, J = 4.7, 1.8 Hz, H-3β), 3.87 – 3.76 (m, 2.6H, H-5α, H-5β,β), 3.71 (dd, 1H, J = 10.1, 5.8 
Hz, H-5α); 13C-APT NMR (CDCl3, 101 MHz, HSQC): δ 138.1, 137.7, 137.6, 137.3, 135.6, 135.3 (Cq), 130.9, 128.8, 128.7, 
128.4, 128.3, 128.2, 127.9, 127.8, 127.7, 127.6, 127.6, 127.6, 127.5, 126.9, 126.5 (CHarom), 90.0 (C-1α), 89.9 (C-1β), 
86.6 (C-2β), 83.7 (C-2α), 81.6 (C-3α), 81.5 (C-3β), 81.2 (C-4β), 78.1 (C-4α), 73.3, 73.2, 72.8, 72.1, 71.8, 71.7 (CH2 Bn), 
68.6 (C-5β), 67.7 (C-5α); 13C-HSQC-HECADE NMR (101 MHz, CDCl3): α-anomer: 2JC1,H2 = +2.5 Hz, 2JC2,H1 = +0.7 Hz; β-
anomer: 2JC1,H2 = 0 Hz, 2JC2,H1 = -4.5 Hz; HRMS: [M+Na]+ calcd for C32H32O4SNa 535.19135, found 535.19046. 
2,2,2-Trifluoroethyl 2,3,5-tri-O-benzyl-α/β-D-ribofuranoside (86). Donor 77 and acceptor 8 
were condensed using the general procedure for Tf2O/Ph2SO mediated glycosylations as 
described in Chapter 3 (2h at -60°C) yielding product 86 (42.7 mg, 85 μmol, 85%, α:β = 68 : 
32) as a colorless oil. IR (thin film): 697, 735, 1028, 1046, 1114, 1153, 1279, 1454, 2861, 2930; Data for the α-anomer: 
1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC): δ 7.39 – 7.26 (m, 13H, CHarom), 7.20 (dd, 2H, J = 7.7, 1.8 Hz, CHarom), 5.13 
(t, 1H, J = 2.1 Hz, H-1), 4.72 (d, 1H, J = 12.5 Hz, CHH Bn), 4.68 (d, 1H, J = 12.1 Hz, CHH Bn), 4.62 (d, 1H, J = 12.1 Hz, CHH 
Bn), 4.53 (d, 1H, J = 12.5 Hz, CHH Bn), 4.48 (d, 1H, J = 12.2 Hz, CHH Bn), 4.41 (d, 1H, J = 12.1 Hz, CHH Bn), 4.28 – 4.22 




(dd, 1H, J = 10.6, 4.1 Hz, H-5); 13C-APT NMR (CDCl3, 101 MHz, HSQC): δ 138.3, 137.9, 137.8 (Cq), 128.5, 128.4, 128.2, 
128.0, 127.9, 127.8, 127.8, (CHarom), 124.3 (d, J = 279.5 Hz), 101.5 (C-1), 82.6 (C-4), 77.9 (C-3), 75.3 (C-2), 73.6, 72.8, 
72.6 (CH2 Bn), 69.9 (C-5), 64.2 (q, J = 34.4 Hz, CH2-CF3); 13C-HSQC-HECADE NMR (101 MHz, CDCl3): 2JC1,H2 = +3.5 Hz, 
2JC2,H1 = +4.4 Hz; Data for the β-anomer:: 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC): δ 7.36 – 7.24 (m, 15H, CHarom), 
5.06 (s, 1H, H-1), 4.69 – 4.42 (m, 6H, 3xCH2 Bn), 4.36 (ddd, 1H, J = 7.4, 5.5, 3.3 Hz, H-4), 4.08 (dd, 1H, J = 7.4, 4.6 Hz, 
H-3), 3.95 (d, 1H, J = 4.6 Hz, H-2), 3.90 – 3.70 (m, 1H, CH2 TFE), 3.63 (dd, 1H, J = 10.6, 3.3 Hz, H-5), 3.46 (dd, 1H, J = 
10.6, 5.5 Hz, H-5); 13C-APT NMR (CDCl3, 101 MHz, HSQC): δ 138.1, 137.6 (Cq), 128.6, 128.5, 128.1, 128.1, 128.0, 128.0, 
128.0, 127.9, 127.8 (CHarom), 124.0 (q, J = 278.3 Hz, CF3), 105.1 (C-1), 81.2 (C-4), 79.5 (C-2), 78.0 (C-3), 73.3, 72.7, 72.7 
(CH2 Bn), 70.6 (C-5), 63.9 (q, J = 34.5 Hz, CH2-CF3); 13C-HSQC-HECADE NMR (101 MHz, CDCl3): 2JC2,H1 = -1.0 Hz; HRMS: 
[M+Na]+ calcd for C28H29F3O5Na 525.18593, found 525.18488. 
Cyclohexyl 2,3,5-tri-O-benzyl-α/β-D-ribofuranoside (87). Donor 77 and acceptor 76 were 
condensed using the general procedure for Tf2O/Ph2SO mediated glycosylations as 
described in Chapter 3 (2h at -60°C) yielding product 87 (26.2 mg, 52 μmol, 52%, α:β = 64 : 
36) as a colorless oil. 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC): δ 7.42 – 7.19 (m, 22.5H, CHarom), 5.19 – 5.15 (m, 
1.5H, H-1α,β), 4.74 – 4.41 (m, 9H, 3xCH2 Bnα,β), 4.32 (td, 0.5H, J = 6.3, 4.1 Hz, H-4β), 4.24 (q, 1H, J = 4.1 Hz, H-4α), 4.00 
(dd, 0.5H, J = 6.8, 4.8 Hz, H-3β), 3.86 – 3.80 (m, 1.5H, H-2β, H-3α), 3.76 (dd, 1H, J = 6.9, 4.2 Hz, H-2α), 3.65 – 3.49 (m, 
2.5H, H-5β,β, CH Cyα,β), 3.46 (dd, 1H, J = 10.6, 3.7 Hz, H-5α), 3.37 (dd, 1H, J = 10.6, 4.2 Hz, H-5α), 2.01 – 1.11 (m, 15H, 
CH2 Cyα,β); 13C-APT NMR (CDCl3, 101 MHz, HSQC): δ 138.7, 138.4, 138.3, 138.2, 138.1 (Cq), 128.5, 128.4, 128.4, 128.4, 
128.3, 128.1, 128.1, 128.1, 127.9, 127.9, 127.8, 127.8, 127.7, 127.6 (CHarom), 103.3 (C-1β), 99.7 (C-1α), 81.0 (C-4α), 80.3 
(C-2β, C-4β), 78.9 (C-3β), 77.4 (C-2α), 76.3 (CH Cyα), 75.6 (C-3α), 75.3 (CH Cyβ), 73.5, 73.3, 72.4, 72.3 (CH2 Bn), 71.9 (C-
5β), 70.1 (C-5α), 33.9, 33.7, 32.1, 31.6, 25.8, 25.8, 24.7, 24.6, 24.3, 24.1 (CH2 Cy); 13C-HSQC-HECADE NMR (101 MHz, 
CDCl3): α-anomer::  2JC1,H2 = +1.2 Hz; β-anomer:: 2JC1,H2 = -0.5 Hz; HRMS: [M+Na]+ calcd for C32H38O5Na 525.26115, 
found 525.26028. 
Ethyl 2,3,5-tri-O-benzyl-α/β-D-ribofuranoside (88). Donor 77 and acceptor 5 were condensed 
using the general procedure for Tf2O/Ph2SO mediated glycosylations as described in Chapter 
3 (2h at -60°C) yielding product 88 (32.4 mg, 72 μmol, 72%, α:β = 81 : 19) as a colorless oil. IR 
(thin film): 694, 739, 1044, 1090, 1444, 2879, 2930, 3065; 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC): δ 7.38 – 7.26 
(m, 18H, CHarom), 5.02 (d, 1.2H, J = 4.2 Hz, H-1α,β), 4.73 – 4.40 (m, 7.2H, 3xCH2 Bnα,β), 4.37 – 4.30 (m, 0.2H, H-4β), 4.25 
(q, 1H, J = 3.9 Hz, H-4α), 4.04 (dd, 0.2H, J = 7.0, 4.7 Hz, H-3β), 3.88 – 3.80 (m, 2.2H, H-2β, H-3α, CHH Etα), 3.79 – 3.69 
(m, 1.2H, H-2α, CHH Etβ), 3.65 – 3.57 (m, 1.2H, H-5β, CHH Etα), 3.52 (dd, 0.2H, J = 10.6, 5.9 Hz, H-5β), 3.47 – 3.38 (m, 
1.2H, H-5α, CHH Etβ), 3.35 (dd, 1H, J = 10.5, 4.2 Hz, H-5α), 1.28 (t, 3H, J = 7.1 Hz, CH3 Etα), 1.11 (t, 0.6H, J = 7.1 Hz, CH3 
Etβ); 13C-APT NMR (CDCl3, 101 MHz, HSQC): δ 138.4, 138.0, 138.0 (Cq), 131.2, 129.4, 128.5, 128.4, 128.4, 128.4, 128.3, 
128.3, 128.1, 128.0, 127.9, 127.8, 127.8, 127.7, 127.7, 127.6, 124.9 (CHarom)105.1 (C-1β), 101.1 (C-1α), 81.6 (C-4α), 
80.4 (C-4β), 79.9 (C-2β), 78.7 (C-3β), 77.6 (C-2α), 75.3 (C-3α), 73.5, 73.2, 72.5, 72.5, 72.4, 72.3 (CH2 Bn), 71.6 (C-5β), 70.1 
(C-5α), 63.8 (CH2 Etα), 63.3 (CH2 Etβ), 15.4 (CH3 Etα), 15.1 (CH3 Etβ); 13C-HSQC-HECADE NMR (101 MHz, CDCl3): α-
anomer: 2JC1,H2 = +1.4 Hz, 2JC2,H1 = +2.2 Hz HRMS: [M+Na]+ calcd for C28H32O5Na 471.21420, found 471.21324. 
2,2,2-Trifluoroethyl 2,3,5-tri-O-benzyl-α/β-D-arabinofuranoside (90). Donor 79 and acceptor 
8 were condensed using the general procedure for Tf2O/Ph2SO mediated glycosylations as 
described in Chapter 3 (2h at -60°C) yielding product 90 (40 mg, 80 μmol, 80%, α:β = 13 : 
87) as a colorless oil. IR (thin film): 697, 736, 1072, 1116, 1161, 1279, 1454, 2879, 2930; 1H NMR (CDCl3, 400 MHz, HH-
COSY, HSQC): δ 7.43 – 7.31 (m, 18H, CHarom), 5.19 (s, 0.2H, H-1α), 5.01 (d, 1H, J = 3.8 Hz, H-1β), 4.77 – 4.49 (m, 7.2H, 
CH2 Bnα,β), 4.29 – 4.25 (m, 0.2H, H-4α), 4.21 – 4.13 (m, 3.2H, H-2α, H-2β, H-3β, H-4β), 3.99 (dd, 0.2H, J = 6.9, 3.2 Hz, H-
3α), 3.89 – 3.79 (m, 2.4H, CH2 TFEα,β), 3.69 (dd, 0.2H, J = 10.8, 3.5 Hz, H-5α), 3.63 (dd, 0.2H, J = 10.8, 5.4 Hz, H-5α), 3.59 
– 3.50 (m, 2H, H-5β, H-5β); 13C-APT NMR (CDCl3, 101 MHz, HSQC): δ 138.1, 137.9, 137.7, 137.5 (Cq), 128.9, 128.6, 
128.5, 128.5, 128.4, 128.2, 128.1, 128.0, 127.9, 127.9, 127.9, 127.8 (CHarom), 124.1 (q, J = 278.8 Hz, CF3), 106.4 (C-1α), 
100.6 (C-1β), 87.9 (C-2α), 84.3 (C-2β), 83.4 (C-3α), 82.4 (C-3β), 81.3 (C-4α), 80.8 (C-4β), 73.5, 73.4, 72.7, 72.6, 72.3, 72.3 
(CH2 Bn), 71.8 (C-5β), 69.5 (C-5α), 64.0 (q, J = 34.6 Hz, CH2-CF3 α), 63.8 (q, J = 34.4 Hz, CH2-CF3 β); 13C-HSQC-HECADE 
NMR (101 MHz, CDCl3): α-anomer: 2JC1,H2 = -2.1 Hz, 2JC2,H1 = -1.8 Hz; β-anomer: 2JC1,H2 = +2.1 Hz, 2JC2,H1 = +1.8 Hz; HRMS: 
[M+Na]+ calcd for C28H29F3O5Na 525.18593, found 525.18480. 
Cyclohexyl 2,3,5-tri-O-benzyl-α/β-D-arabinofuranoside (91). Donor 79 and acceptor 76 were 
condensed using the general procedure for Tf2O/Ph2SO mediated glycosylations as 




described in Chapter 3 (2h at -60°C) yielding product 91 (39mg, 78 μmol, 78%, α:β = 44 : 56) as a colorless oil. 1H NMR 
(CDCl3, 400 MHz, HH-COSY, HSQC): δ 7.46 – 7.20 (m, 27H, CHarom), 5.27 (d, 0.8H, J = 1.2 Hz, H-1α), 5.15 (d, 1H, J = 4.3 
Hz, H-1β), 4.76 – 4.50 (m, 10.8H, 3xCH2 Bnα,β), 4.26 (ddd, 0.8H, J = 7.3, 5.2, 3.4 Hz, H-4α), 4.17 – 4.08 (m, 3.8H, H-2β, 
H-3β, H-4β), 4.07 (dd, 0.8H, J = 3.6, 1.6 Hz, H-2α), 3.97 (dd, 0.8H, J = 7.2, 3.6 Hz, H-3α), 3.72 – 3.55 (m, 5.4H, H-5α,β, H-
5α,β, CH Cyα,β), 2.00 – 1.12 (m, 18H, CH2 Cyα,β); 13C-APT NMR (CDCl3, 101 MHz, HSQC): δ 138.4, 138.3, 138.2, 138.1, 
137.9, 137.8 (Cq), 128.5, 128.5, 128.4, 128.4, 128.2, 128.0, 128.0, 127.9, 127.9, 127.9, 127.8, 127.8, 127.7, 127.7 
(CHarom), 104.1 (C-1α), 98.8 (C-1β), 88.9 (C-2α), 84.1, 83.8 (C-2β, C-3β), 83.6 (C-3α), 80.1, 80.1 (C-4α,β), 76.0, 75.0 (CH 
Cyα,β), 73.5 (CH2 Bn), 73.4 (C-5β), 73.1, 72.4, 72.3, 72.2, 72.0 (CH2 Bn), 69.8 (C-5α), 33.8, 33.8, 31.9, 31.8, 29.8, 25.8, 
25.7, 24.6, 24.4, 24.4, 24.2 (CH2 Cyα,β); 13C-HSQC-HECADE NMR (101 MHz, CDCl3): α-anomer: 2JC1,H2 = -2.2 Hz, 2JC2,H1 = 
-1.5 Hz; β-anomer: 2JC1,H2 = +1.2 Hz, 2JC2,H1 = +4.0 Hz; HRMS: [M+Na]+ calcd for C32H38O5Na 525.26115, found 525.25999. 
Ethyl 2,3,5-tri-O-benzyl-α/β-D-arabinofuranoside (92). Donor 79 and acceptor 5 were 
condensed using the general procedure for Tf2O/Ph2SO mediated glycosylations as described 
in Chapter 3 (2h at -60°C) yielding product 92 (22.7 mg, 51 μmol, 51%, α:β = 30 : 70) as a 
colorless oil. IR (thin film): 696, 735, 1099, 1453, 2862, 2902; 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC): δ 7.37 – 7.22 
(m, 15H, CHarom), 5.06 (d, 0.7H, J = 1.3 Hz, H-1α), 4.85 (d, 0.3H, J = 4.2 Hz, H-1β), 4.69 – 4.45 (m, 6H, 3xCH2 Bnα,β), 4.21 
(ddd, 0.7H, J = 6.9, 5.3, 3.6 Hz, H-4α), 4.14 – 4.03 (m, 0.9H, H-2β, H-3β, H-4β), 4.02 (dd, 0.7H, J = 3.3, 1.4 Hz, H-2α), 3.91 
(dd, 0.7H, J = 6.9, 3.2 Hz, H-3α), 3.79 (dq, 0.7H, J = 9.8, 7.1 Hz, CHH Etα), 3.74 – 3.35 (m, 3.3H, H-5β,β, H-5α,α, CHH Etα, 
CH2 Etβ), 1.22 (t, 2.1H, J = 7.1 Hz, CH3 Etα), 1.17 (t, 0.9H, J = 7.1 Hz, CH3 Etβ); 13C-APT NMR (CDCl3, 101 MHz, HSQC): δ 
138.3, 138.2, 138.2, 138.0, 137.9, 137.8 (Cq), 128.5, 128.5, 128.5, 128.5, 128.3, 128.0, 127.9, 127.9, 127.8, 127.8, 
127.8, 127.7, 127.7 (CHarom), 106.0 (C-1α), 100.4 (C-1β), 88.6 (C-2α), 84.3 (C-2β), 83.6 (C-3α,β), 80.6 (C-4α), 80.3 (C-4β), 
73.5, 73.4, 72.8, 72.6, 72.4, 72.2, 72.1, 69.9 (CH2 Bn, C-5α,β), 63.3 (CH2 Etβ), 63.2 (CH2 Etα), 15.3 (CH3 Etα), 15.2 (CH3 
Etβ); 13C-HSQC-HECADE NMR (101 MHz, CDCl3): α-anomer: 2JC1,H2 = -2.0 Hz, 2JC2,H1 = -1.1 Hz; β-anomer: 2JC1,H2 = +0.3 
Hz, 2JC2,H1 = +1.8 Hz; HRMS: [M+Na]+ calcd for C28H32O5Na 471.21420, found 471.21298. 
2,2,2-Trifluoroethyl 2,3,5-tri-O-benzyl-α/β-D-lyxofuranoside (94). Donor 81 and acceptor 8 
were condensed using the general procedure for Tf2O/Ph2SO mediated glycosylations as 
described in Chapter 3 (2h at -60°C) yielding product 94 (49 mg, 98 μmol, 98%, α:β = 48 : 
52) as a colorless oil. Data for the α-anomer: 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC): δ 7.35 – 7.25 (m, 15H, CHarom), 
5.19 (d, 1H, J = 2.1 Hz, H-1), 4.68 (d, 1H, J = 11.8 Hz, CHH Bn), 4.66 (d, 1H, J = 12.1 Hz, CHH Bn), 4.61 (d, 1H, J = 12.0 
Hz, CHH Bn), 4.60 (d, 1H, J = 12.1 Hz, CHH Bn), 4.52 (d, 1H, J = 11.8 Hz, CHH Bn), 4.50 (d, 1H, J = 12.0 Hz, CHH Bn), 4.37 
(q, 1H, J = 5.7 Hz, H-4), 4.21 (t, 1H, J = 5.1 Hz, H-3), 4.06 – 3.94 (m, 2H, H-2, CHH-CF3), 3.84 (dq, 1H, J = 12.4, 8.6 Hz, 
CHH-CF3), 3.78 – 3.74 (m, 2H, H-5); 13C-APT NMR (CDCl3, 101 MHz, HSQC): δ 138.2, 138.0, 137.7 (Cq), 128.6, 128.5, 
128.0, 128.0, 127.9, 127.9, 127.8 (CHarom), 124.0 (q, J = 278.3 Hz, CF3), 105.7 (C-1), 82.3 (C-2), 79.1 (C-4), 77.9 (C-3), 
73.6, 73.5, 72.8 (CH2 Bn), 69.6 (C-5), 64.7 (q, J = 34.6 Hz, CH2-CF3); 13C-HSQC-HECADE NMR (101 MHz, CDCl3): 2JC1,H2 = 
-1.9 Hz, 2JC2,H1 = -1.1 Hz; Data for the β-anomer: 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC): δ 7.39 – 7.22 (m, 15H, 
CHarom), 5.12 (d, 1H, J = 4.6 Hz, H-1), 4.86 (d, 1H, J = 12.2 Hz, CHH Bn), 4.71 (d, 1H, J = 12.0 Hz, CHH Bn), 4.58 (d, 2H, J 
= 12.0 Hz, 2xCHH Bn), 4.54 (d, 1H, J = 12.0 Hz, CHH Bn), 4.51 (d, 1H, J = 12.0 Hz, CHH Bn), 4.19 (dt, 1H, J = 7.2, 5.1 Hz, 
H-4), 4.07 (t, 1H, J = 5.3 Hz, H-3), 4.00 (dd, 1H, J = 9.0, 1.2 Hz, CHH-CF3), 3.96 (dd, 1H, J = 8.9, 0.9 Hz, CHH-CF3), 3.89 (t, 
1H, J = 5.2 Hz, H-2), 3.74 (dd, 1H, J = 10.2, 5.1 Hz, H-5), 3.68 (dd, 1H, J = 10.1, 7.2 Hz, H-5); 13C-APT NMR (CDCl3, 101 
MHz, HSQC): δ 138.5, 138.1, 137.7 (Cq), 128.6, 128.5, 128.3, 128.0, 128.0, 127.9, 127.8, 127.8, 127.6 (CHarom), 124.3 
(q, J = 279.1 Hz, CF3), 100.1 (C-1), 79.7 (C-2), 79.5 (C-4), 75.1 (C-3), 73.6, 73.6, 72.6 (CH2 Bn), 69.7 (C-5), 64.0 (q, J = 
34.4 Hz, CH2-CF3); 13C-HSQC-HECADE NMR (101 MHz, CDCl3): 2JC1,H2 = +2.0 Hz, 2JC2,H1 = +2.3 Hz; HRMS: [M+Na]+ calcd 
for C28H29F3O5Na 525.18593, found 525.18468. 
Cyclohexyl 2,3,5-tri-O-benzyl-α/β-D-lyxofuranoside (95). Donor 81 and acceptor 76 were 
condensed using the general procedure for Tf2O/Ph2SO mediated glycosylations as 
described in Chapter 3 (2h at -60°C) yielding product 95 (36 mg, 72 μmol, 72%, α:β = 73 : 
26) as a colorless oil. Data for the α-anomer: 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC): δ 7.36 – 7.23 (m, 15H, CHarom), 
5.27 (d, 1H, J = 2.7 Hz, H-1), 4.69 (d, 1H, J = 12.0 Hz, CHH Bn), 4.65 – 4.59 (m, 3H, 2xCHH Bn, CHH Bn), 4.54 (d, 1H, J = 
11.9 Hz, CHH Bn), 4.50 (d, 1H, J = 12.0 Hz, CHH Bn), 4.36 (dt, 1H, J = 6.9, 5.2 Hz, H-4), 4.20 (t, 1H, J = 4.9 Hz, H-3), 3.90 
(dd, 1H, J = 4.6, 2.7 Hz, H-2), 3.78 (dd, 1H, J = 10.1, 5.1 Hz, H-5), 3.72 (dd, 1H, J = 10.1, 7.0 Hz, H-5), 3.58 (tt, 1H, J = 
9.2, 4.1 Hz, CH Cy), 1.92 – 1.84 (m, 2H, CH2 Cy), 1.69 (d, 2H, J = 5.8 Hz, CH2 Cy), 1.55 – 1.47 (m, 1H, CH2 Cy), 1.34 – 1.15 
(m, 5H, CH2 Cy); 13C-APT NMR (CDCl3, 101 MHz, HSQC): δ 138.4, 138.4, 138.2 (Cq), 128.5, 128.4, 128.4, 128.0, 127.8, 




Bn), 69.8 (C-5), 33.8, 31.9, 25.8, 24.4, 24.2 (CH2 Cy); 13C-HSQC-HECADE NMR (101 MHz, CDCl3): 2JC1,H2 = -2.2 Hz, 2JC2,H1 
= -1.5 Hz; Data for the β-anomer: 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC): δ 7.38 – 7.26 (m, 15H, CHarom), 5.14 (d, 
1H, J = 4.6 Hz, H-1), 4.85 (d, 1H, J = 12.4 Hz, CHH Bn), 4.74 (d, 1H, J = 12.2 Hz, CHH Bn), 4.58 (d, 1H, J = 12.4 Hz, CHH 
Bn), 4.57 (d, 1H, J = 12.2 Hz, CHH Bn), 4.56 (d, 1H, J = 11.9 Hz, CHH Bn), 4.51 (d, 1H, J = 11.9 Hz, CHH Bn), 4.19 (dt, 1H, 
J = 6.9, 5.3 Hz, H-4), 4.06 (t, 1H, J = 5.7 Hz, H-3), 3.82 – 3.71 (m, 3H, H-2, H-5, H-5), 3.62 (ddd, 1H, J = 13.6, 9.6, 3.8 Hz, 
CH Cy), 1.91 (d, 2H, J = 10.0 Hz, CH2 Cy), 1.81 – 1.71 (m, 2H, CH2 Cy), 1.57 – 1.48 (m, 1H, CH Cy), 1.40 – 1.18 (m, 5H, 
CH2 Cy); 13C-APT NMR (CDCl3, 101 MHz, HSQC): δ 139.0, 138.5, 138.3 (Cq), 128.5, 128.4, 128.2, 128.0, 127.9, 127.8, 
127.7, 127.6, 127.4 (CHarom), 98.6 (C-1), 79.0 (C-2), 78.9 (C-4), 76.1 (CH Cy), 75.8 (C-3), 73.6, 73.3, 72.3 (CH2 Bn), 70.8 
(C-5), 33.8, 32.0, 25.9, 24.6, 24.4 (CH2 Cy); 13C-HSQC-HECADE NMR (101 MHz, CDCl3): 2JC1,H2 = +1.8 Hz, 2JC2,H1 = +2.2 
Hz; HRMS: [M+Na]+ calcd for C32H38O5Na 525.26115, found 525.26001. 
Ethyl 2,3,5-tri-O-benzyl-α/β-D-lyxofuranoside (96). Donor 81 and acceptor 5 were condensed 
using the general procedure for Tf2O/Ph2SO mediated glycosylations as described in Chapter 
3 (2h at -60°C) yielding product 96 (34 mg, 76 μmol, 76%, α:β = 78 : 22) as a colorless oil. 1H 
NMR (CDCl3, 400 MHz, HH-COSY, HSQC): δ 7.36 – 7.25 (m, 19.5H), 5.13 (d, 1H, J = 2.6 Hz, H-1α), 4.97 (d, 0.3H, J = 4.6 
Hz, H-1β), 4.83 (d, 0.3H, J = 12.5 Hz, CHH Bnβ), 4.70 – 4.48 (m, 7.5H, 3xCH2 Bnα, 2xCH2 Bnβ, CHH Bnβ), 4.36 (dt, 1H, J = 
7.0, 5.2 Hz, H-4α), 4.20 (t, 1H, J = 5.0 Hz, H-3α), 4.18 (dt, 0.3H, J = 6.8, 5.5 Hz, H-4β), 4.05 (t, 0.3H, J = 5.6 Hz, H-3β), 3.91 
(dd, 1H, J = 4.6, 2.6 Hz, H-2α), 3.82 – 3.68 (m, 4.2H, H-2β, H-5α,α, H-5β,β, CHH Etα,β), 3.60 (dq, 0.3H, J = 10.1, 7.0 Hz, CHH 
Etβ), 3.47 (dq, 1H, J = 9.7, 7.0 Hz, CHH Etα), 1.24 (t, 0.9H, J = 7.1 Hz, CH3 Etβ), 1.18 (t, 3H, J = 7.1 Hz, CH3 Etα); 13C-APT 
NMR (CDCl3, 101 MHz, HSQC): δ 138.7, 138.4, 138.3, 138.1 (Cq), 128.5, 128.5, 128.4, 128.4, 128.3, 128.0, 128.0, 127.9, 
127.9, 127.8, 127.8, 127.8, 127.7, 127.5 (CHarom), 105.2 (C-1α), 99.9 (C-1β), 82.8 (C-2α), 79.1 (C-2β), 79.1 (C-4β), 78.2 
(C4α), 78.1 (C-3α), 75.2 (C-3β), 73.5, 73.4, 72.6, 72.4 (CH2 Bn), 70.5 (C-5β), 69.8 (C-5α), 63.9 (CH2 Etα), 63.8 (CH2 Etβ), 
15.4 (CH2 Etβ), 15.3 (CH2 Etα); 13C-HSQC-HECADE NMR (101 MHz, CDCl3): α-anomer: 2JC1,H2 = -2.2 Hz, 2JC2,H1 = -1.7 Hz; 
β-anomer: 2JC1,H2 = +0.8 Hz, 2JC2,H1 = +2.0 Hz; HRMS: [M+Na]+ calcd for C28H32O5Na 471.21420, found 471.21299. 
2,2,2-Trifluoroethyl 2,3,5-tri-O-benzyl-α/β-D-xylofuranoside (98). Donor 83 and acceptor 8 
were condensed using the general procedure for Tf2O/Ph2SO mediated glycosylations as 
described in Chapter 3 (2h at -60°C) yielding product 98 (42.7 mg, 85 μmol, 85%, α:β = 84 : 
16) as a colorless oil. 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC): δ 7.44 – 7.27 (m, 18H, CHarom), 5.17 (s, 0.2H, H-1β), 
5.11 (d, 1H, J = 4.2 Hz, H-1α), 4.72 – 4.44 (m, 8.4H, 3xCH2 Bnα,β ,H-4α,β), 4.38 (dd, 1H, J = 7.2, 6.0 Hz, H-3α), 4.16 – 3.85 
(m, 2.2H, H-2α,β, H-3β), 3.82 – 3.71 (m, 1.4H, H-5α,β,β), 3.65 (dd, 1H, J = 10.7, 6.8 Hz, H-5α); 13C-APT NMR (CDCl3, 101 
MHz, HSQC): δ 138.2, 138.1, 137.7, 137.5, 137.3 (Cq), 129.8, 128.6, 128.6, 128.5, 128.5, 128.4, 128.2, 128.0, 127.9, 
127.9, 127.8, 127.8, 127.7, 127.7, (CHarom), 124.1 (q, J = 278.8 Hz, CF3), 106.9 (C-1β), 99.8 (C-1α), 86.5 (C-2β), 84.0 (C-
2α), 81.8 (C-3β), 81.3 (C-3α), 81.0 (C-4β), 76.8 (C-4α), 73.6, 73.5, 72.8, 72.7, 72.3 (CH2 Bn), 69.6 (C-5β), 69.3 (C-5α), 64.4 
(q, J = 34.5 Hz, CH2CF3 β), 64.2 (q, J = 34.5 Hz CH2CF3 α); 13C-HSQC-HECADE NMR (101 MHz, CDCl3): α-anomer: 2JC1,H2 = 
+2.0 Hz, 2JC2,H1 = +2.1 Hz; β-anomer: 2JC1,H2 = -1.7 Hz, 2JC2,H1 = -1.2 Hz; HRMS: [M+Na]+ calcd for C28H29F3O5Na 525.18593, 
found 525.18492. 
Cyclohexyl 2,3,5-tri-O-benzyl-α/β-D-xylofuranoside (99). Donor 83 and acceptor 76 were 
condensed using the general procedure for Tf2O/Ph2SO mediated glycosylations as 
described in Chapter 3 (2h at -60°C) yielding product 99 (39.7 mg, 79 μmol, 79%, α:β = 62 : 
38) as a colorless oil. 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC): δ 7.40 – 7.22 (m, 24H, CHarom), 5.17 – 5.14 (m, 2H, 
H-1α,β), 4.69 – 4.35 (m, 11.2H, 3xCH2 Bnα,β, H-4α,β), 4.33 (dd, 0.6H, J = 7.1, 5.9 Hz, H-3α), 4.08 (dd, 1H, J = 6.2, 3.5 Hz, 
H-3β), 4.03 – 3.95 (m, 1.6H, H-2α,β), 3.78 (dd, 1H, J = 10.3, 4.7 Hz, H-5β), 3.78 – 3.67 (m, 1.6H, H-5α,β), 3.68 – 3.54 (m, 
2.2H, H-5α, CH Cyα,β), 1.95 – 1.86 (m, 3.2H, CH2 Cyα,β), 1.80 – 1.66 (m, 3.2H, CH2 Cyα,β), 1.52 (d, 1.6H, J = 5.9 Hz, CH2 
Cyα,β), 1.45 – 1.15 (m, 8H, CH2 Cyα,β); 13C-APT NMR (CDCl3, 101 MHz, HSQC): δ 138.5, 138.4, 138.1, 137.9, 137.9 (Cq), 
128.5, 128.5, 128.4, 128.2, 128.0, 127.9, 127.9, 127.7, 127.7, 127.6, 127.6, 127.6 (CHarom), 105.0 (C-1β), 97.8 (C-1α), 
87.6 (C-2β), 84.2 (C-2α), 82.2 (C-3β), 82.0 (C-3α), 79.4 (C-4β), 75.9, 75.8, 75.7 (C-4α, CHCy α,β), 73.6, 73.5, 72.6, 72.3, 72.0 
(CH2 Bn), 70.1 (C-5β), 69.6 (C-5α), 33.9, 33.6, 32.1, 31.8, 25.8, 25.8, 24.6, 24.5, 24.3, 24.2 (CH2 Cyα,β); 13C-HSQC-HECADE 
NMR (101 MHz, CDCl3): α-anomer: 2JC1,H2 = +1.4 Hz, 2JC2,H1 = +2.0 Hz; β-anomer: 2JC1,H2 = -2.5 Hz, 2JC2,H1 = -1.5 Hz; HRMS: 
[M+Na]+ calcd for C32H38O5Na 525.26115, found 525.26005.  
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Samenvatting in het Nederlands 
Reactiviteit en selectiviteit in glycosyleringsreacties 
Koolhydraten, sachariden en suikers zijn benamingen voor in de natuur voorkomende 
moleculen die wat structuur betreft enorm divers zijn. Bijvoorbeeld niet alleen de 
polymeren zetmeel en glycogeen zijn koolhydraten, maar ook kleinere structuren zoals 
de oligosachariden die kenmerkend zijn voor de menselijke bloedgroepen. Sachariden 
spelen een belangrijke rol bij een groot aantal essentiële biologische processen in alle 
vormen van leven en zijn daardoor van belang voor bestaande en nog te ontwikkelen 
medicijnen. Koolhydraten die van belang zijn voor het ophelderen en beïnvloeden van 
biologische processen kunnen echter vaak in onvoldoende mate in zuivere toestand uit 
de natuur worden geïsoleerd. De chemische synthese van deze specifieke 
koolhydraatverbindingen is daarom van groot belang. Koolhydraten bestaan uit lineaire 
of vertakte ketens van verschillende monosacchariden zoals glucose en mannose. Een 
van de grootste uitdagingen bij het synthetiseren van koolhydraten is het aanbrengen van 
de juiste binding tussen de monosachariden onderling of tussen een monosaccharide en 
een groeiende koolhydraatketen. Deze glycosidische binding dient op één specifieke 
wijze te worden aangebracht. Deze selectiviteit betreft niet alleen de positie van de 
naburige suiker waaraan de suiker in kwestie vastgemaakt wordt (de zogenoemde 
regiochemie) maar ook de richting van de nieuw te vormen glycosidische binding (de 
zogenoemde stereochemie), die 1,2-trans of 1,2-cis kan zijn. De positie van de 
glycosidische binding en de introductie van 1,2-trans-bindingen kunnen veelal met 
beschermgroepen worden gestuurd. Voor het verkrijgen van 1,2-cis-glycosidische 
bindingen is geen degelijke algemene oplossing en de invoering verloopt vaak met vallen 
en opstaan. Een dergelijke procedure gaat gepaard met tijdrovende optimalisaties. Meer 
inzicht in hoe 1,2-cis-glycosidische bindingen tot stand komen is dus wenselijk. Dit 
proefschrift beschrijft systematische studies naar de invloed van de reactiviteit van de 
reactiepartners op de stereoselectiviteit van een chemische glycosylering. Deze 
reactiepartners zijn de elektrofiele donor en de nucleofiele acceptor, die met elkaar 
reageren onder invloed van een activator. Met behulp van deze studies is er meer inzicht 
verkregen in het mechanisme van de glycosyleringsreactie en hoe deze te beïnvloeden is 
om 1,2-cis-selectieve koppelingen te geven. 
De bestaande kennis over de reactiviteit van donoren en acceptoren alsmede de 
invloed daarvan op de selectiviteit van glycosyleringen wordt in Hoofdstukken 1 en 2 
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beschreven. Het eerste hoofdstuk behandelt de bestaande inzichten in het mechanisme 
van de glycosyleringsreactie en de invloed van de reactiviteit van de donor, het elektrofiel, 
in deze reactie. In het tweede hoofdstuk ligt de nadruk op het nucleofiel, de acceptor. De 
reactiviteit van zowel de donor als de acceptor kan worden beïnvloed door de wijze 
waarop de niet reagerende functies in de bouwstenen zijn beschermd met 
beschermgroepen. In het algemeen verminderen sterk elektronenzuigende 
acylbeschermgroepen de reactiviteit meer dan relatief minder sterk elektronenzuigende 
alkylbeschermgroepen. Waar de reactiviteit van glycosyldonoren goed onderzocht is en 
het algemeen geaccepteerd is dat verschillen in donorreactiviteit een verschuiving van 
een SN2-type naar een SN1-type mechanisme tot gevolg kan hebben, is de reactiviteit van 
glycosylacceptoren nauwelijks systematisch onderzocht en is de invloed hiervan op het 
reactiemechanisme niet in kaart gebracht. Hoofdstuk 2 geeft een overzicht met 
voorbeelden uit het recente en minder recente verleden die aantonen dat kleine 
veranderingen in de reactiviteit van de acceptor kunnen leiden tot grote verschuivingen 
in opbrengst, selectiviteit en reactiesnelheden van glycosyleringsreacties. 
Hoofdstuk 3 beschrijft het eerste systematische onderzoek naar hoe de reactiviteit 
van een acceptor het mechanisme van glycosyleringsreacties beïnvloedt. Daartoe is een 
set modelacceptoren van verschillende nucleofiliciteit gebruikt. De modelacceptoren zijn 
gebaseerd op ethanol en bevatten een verschillend aantal fluoratomen (0 tot 3). Hoe meer 
fluoratomen het molecuul bevat, hoe minder nucleofiel het is. Dit komt door de 
elektronenzuigende werking van de fluoratomen. Het reactieve ethanol bleek hoge β-
selectiviteit te geven in glycosyleringen met benzylideen beschermde glucose- en 
mannosedonoren en met een mannuronzuurdonor. Het veel minder reactieve 
trifluorethanol gaf juist hoge α-selectiviteit met de benzylideenglucosedonor en liet 
slechts een kleine afname in β-selectiviteit zien voor de benzylideenmannose- en 
mannuronzuurdonoren. Mono- en difluorethanol gaven mengsels van beide anomere 
producten in glycosyleringen met de glucosedonor, waarbij meer α-product voor het 
minder reactieve difluorethanol werd gevormd. Deze resultaten tonen aan dat de 
koppelingen van de benzylideenglucosedonor gevoelig zijn voor veranderingen in 
acceptorreactiviteit, terwijl de koppelingen van benzylideenmannose- en 
mannuronzuurdonoren dat niet zijn. Vervolgens werden relevante suikeracceptoren 
getest. Suikeracceptoren met primaire of equatoriale secundaire hydroxylgroepen waren 
voornamelijk β-selectief; axiale secundaire hydroxylgroepen werden juist α-selectief 
voor de glucosedonor. Wederom bleven de mannose- en mannuronzuurdonoren β-
 
251 
selectief. Hiermee kan het verband worden gelegd tussen de reactiviteit van de acceptor 
en de verschuiving van het reactiemechanisme: substituties met sterke nucleofielen 
hebben meer een SN2-karakter en substituties met zwakke nucleofielen meer een SN1-
karakter. Voor glucose geven deze twee mechanismen twee verschillende producten. Een 
SN2-reactie met het anomere triflaat als vetrekkende groep geeft het β-product, terwijl 
een SN1-reactie via het oxocarbeniumion in de 4H3/4E-conformatie het α-product geeft. 
De reden dat benzylideenmannose- en mannuronzuurdonoren juist erg β-selectief 
bleven kan worden verklaard met de β-selectieve conformeren van de 
oxocarbeniumionen in de SN1-reacties. Zowel de B2,5-conformatie die de 
benzylideenmannosedonor kan aannemen als de 3H4-conformatie die 
mannuronzuurdonoren prefereren, zijn β-selectief.  
In Hoofdstuk 4 wordt de invloed van een azide-functionaliteit als 
aminebeschermgroep in een glucosaminedonor behandeld door de glycosyleringen van 
benzylideenglucosazide te vergelijken met benzylideenglucose uit hoofdstuk 3. De 2-
azido-substituent is een elektronenzuigende groep en destabiliseert de vorming van 
lading op het anomere centrum meer dan een 2-O-benzylgroep, waardoor het SN1-SN2-
evenwicht van de glycosyleringen meer aan de SN2-kant komt te liggen. Dit heeft als 
gevolg dat koppelingen van glucosazidedonoren met hogere β-selectiviteit verlopen. 
Omdat het α-product, met de 1,2-cis-configuratie, juist vaak gewenst is, werden ook de 
andere beschermgroepen op deze donor geëvalueerd. Het vervangen van de O-
benzylgroep op de C-3-positie door een meer zuigende O-benzoylgroep had een gering 
effect en de donor werd, zoals verwacht, nog β-selectiever. De benzylideenring vervangen 
door een silylideenring maakte de donor juist reactiever en minder β-selectief. In 
combinatie met een zwak nucleofiel kan daarmee hoge α-selectiviteit worden verkregen. 
Waar de silylideen- en benzylideenbeschermgroepen een ring spannen tussen de 
C-4- en C-6-posities in monosacchariden, wordt in Hoofdstuk 5 de invloed van een 
cyclische bisacetaalgroep, die de alcoholen op C-3 en C-4 beschermd, besproken. 
Gebruik van de door butaandion-di-acetaal (BDA) beschermde glucosazidedonor geeft 
β-selectieve koppelingen. De BDA-ring vermindert de conformationele vrijheid van de 
donor en hindert als zodanig de vorming van het oxocarbeniumion, wat vervolgens leidt 
tot veel SN2-karakter en hoge β-selectiviteit in de koppelingen.  
De rol van de nucleofiliciteit van de acceptor wordt in detail behandeld in 
Hoofdstuk 6. Een uitgebreide reeks van suikeracceptoren met alle mogelijke 
beschermgroeppatronen van benzyl- en benzoylgroepen op een glucoseacceptor werd 
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geëvalueerd. De door benzylideen beschermde glucose- en glucosazidedonoren uit 
hoofdstukken 3 en 4 werden als modeldonoren gekozen om de reactiviteit-
selectiviteitsrelatie van de acceptoren in kaart te brengen. De koppelingen van beide 
donoren zijn zeer gevoelig voor veranderingen van acceptorreactiviteit en zijn 
complementair aan elkaar, waarbij de glucosazidedonor steevast meer β-product geeft. 
Uit deze studie kwam naar voren dat verandering van reactiviteit van acceptoren, door 
variatie van beschermgroepen op de C-3- en C-4-posities, een grote invloed kan hebben 
op de stereoselectiviteit in glycosyleringen. Een enkele strategisch geplaatste 
benzoylgroep op de acceptor was voldoende om volledige α-selectiviteit te geven met de 
glucosedonor en hoge α-selectiviteit met de overeenkomstige glucosazidedonor. Door 
introductie van een tweede benzoylgroep in de acceptor kon ook de koppeling van deze 
laatste donor met volledige α-selectiviteit worden bewerkstelligd. Gesubstitueerde 
benzoylbeschermgroepen op de C-6-positie van de acceptor bleken echter minder effect 
te hebben en alleen twee nitrogroepen op beide ortho-posities gaf een afname in 
reactiviteit en een toename in α-selectiviteit. 
Hoofdstuk 7 en 8 hebben vijfringsuikers, ook wel furanoses genoemd, als 
onderwerp. Het eerste hoofdstuk beschrijft de synthese van een set van furanoses met 
verschillende substituenten op de C-2- of C-5-positie. Op C-2 werd een fluor of een azide 
geïnstalleerd en C-5 werd geoxideerd tot een uronzuur (methylester). Oxidatie van de  
C-5-alcoholen in alle furanoses verliep zonder problemen maar het installeren van de 
substituenten op de C-2-positie bleek niet triviaal. De gekozen strategie omvatte in eerste 
instantie de inversie van de C-2-positie door gebruik te maken van een triflaat als O-
vertrekkende groep en fluoride- of azide-anionen als nucleofielen. Voor de vier 
verschillende configuraties van de furanoses (arabinose, ribose, lyxose en xylose) verliep 
de inversie met verschillende uitkomsten. Het inverteren van ribose gaf geen problemen 
en de 2-fluoro- en 2-azidoarabinoses waren gemakkelijk te verkrijgen. Zowel het 
arabinosetriflaat inverteren om zo de riboseconfiguratie te verkrijgen, als de 
transformatie van een xylose- naar een lyxose-geconfigureerde bouwsteen, gaf 
bijproducten door participatie van de beschermgroepen. Voor arabinose was de β-
anomeer probleemloos om te zetten naar 2-fluoro- en 2-azidoribose, maar de α-anomeer 
gaf een ongewenste en verrassende migratie van de anomere O-methylgroep naar de  
C-2-positie. In het geval van xylose gaf alleen de α-anomeer het gewenste lyxoseproduct 
en beide anomeren gaven significante hoeveelheden bijproducten als gevolg van 
participatie van de C-5–O-benzylgroep. Het inverteren van lyxose naar xylose bleek 
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onmogelijk en alleen furan werd gevormd. Om de gewenste 2-fluoro- en 2-azidoxyloses 
te kunnen maken werd gebruik gemaakt van een andere strategie: met behulp van een 
glycaal werden de azido- en fluorogroepen geïnstalleerd. Tenslotte werden er van de vier 
furanoseconfiguraties imidaatdonoren gesynthetiseerd, met in elk van de configuraties 
een variatie in de drie verschillende C-2- of C-5-modificaties. De glycosylerende 
eigenschappen van deze twaalf donoren met modelacceptoren wordt in Hoofdstuk 8 
besproken. 
Hoofdstuk 8 beschrijft een onderzoek naar de selectiviteit van furanosedonoren 
als de reacties worden uitgevoerd onder SN1-condities, waarbij verondersteld wordt dat 
oxocarbeniumion-intermediairen verantwoordelijk zijn voor de selectiviteit. Allereerst 
werden de imidaatdonoren uit Hoofdstuk 7 geglycosyleerd met de modelacceptoren 
allyltrimethylsilaan of triethylsilaan-d. De koppelingen van de arabinose-, ribose- en 
lyxosedonoren verliepen met uitstekende 1,2-cis-selectiviteit, terwijl xylosedonoren 
anomere mengsels gaven. Vervolgens werd met behulp van kwantummechanische 
berekeningen de energie van alle mogelijke conformaties van de oxocarbeniumionen 
berekend en bepaald welke conformeren het meest stabiel waren. Daaruit kwam naar 
voren dat oxocarbeniumionen die een enkele conformatie sterk prefereerden ook zeer 
selectief waren in de experimentele glycosyleringen. In het geval van het arabinosyl-
oxocarbeniumion werden meerdere conformaties laag in energie gevonden. Deze 
conformaties waren nagenoeg plat. Echter, dit had geen invloed op de experimentele 
glycosyleringen, welke volledig 1,2-cis-selectief bleken. Voor de verschillende xylosyl-
oxocarbeniumionen werden ook meerdere conformaties gevonden die vergelijkbaar laag 
in energie waren. Naast de gebruikelijke conformaties uit het bestaande SN1-model voor 
furanoseglycosyleringen, waarbij de E3- en 3E-conformaties de hoofdrol spelen, werd nu 
ook de 4E-conformatie aangetroffen. Doordat er meerdere gunstige conformaties waren, 
gaven de glycosyleringsreacties anomere mengsels. Uit de studie kan geconcludeerd 
worden dat de gebruikte kwantummechanische methode in staat is verschuivingen in de 
populatieverdeling van de verschillende conformaties in kaart te brengen. Deze 
verschuivingen worden veroorzaakt door de stereo-elektronische effecten van 
functionele groepen zoals een azide, fluoride, of uronzuur. Met de berekende 
energieverdeling van de conformaties van een oxocarbeniumion kan vrij nauwkeurig 
worden voorspeld of een glycosyleringsreactie onder SN1-condities selectief verloopt of 
dat erosie van selectiviteit verwacht kan worden. 
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Appendix: General experimental procedures 
All chemicals were of commercial grade and used as received unless stated otherwise. 
Dichloromethane (DCM) was stored over activated 4 Å molecular sieves for at least 24 h 
before use. Trifluoromethanesulfonic anhydride (Tf2O) was distilled over P2O5 and stored at 
-20°C under a nitrogen atmosphere. Triethylamine (Et3N) was distilled over CaH2 and stored 
over KOH pellets. Overnight temperature control was achieved by a FT902 Immersion Cooler 
(Julabo). Flash column chromatography was performed on silica gel 60 Å (0.04 – 0.063 mm, 
Screening Devices B.V.). Size-exclusion chromatography was performed on Sephadex (LH-
20, GE Healthcare Life Sciences) by isocratic elution with DCM/MeOH (1/1, v/v). Thin-layer 
chromatography (TLC) analysis was conducted on TLC silica gel 60 plates (Kieselgel 60 F254, 
Merck) with UV detection by (254 nm) and by spraying with 20% sulfuric acid in ethanol or 
by spraying with a solution of (NH4)6Mo7O24·H2O (25 g/L) and (NH4)4Ce(SO4)4·2H2O (10 g/L) 
in 10% aq. sulfuric acid followed by charring at ±250 °C. TLC-MS analysis was performed on 
a Camag TLC-MS Interface combined with an API165 (SCIEX) mass spectrometer (eluted 
with tert-butylmethylether/EtOAc/MeOH, 5/4/1, v/v/v + 0.1% formic acid, flow rate 0.12 
mL/min). LC-MS analysis was conducted on a Finnigan LCQ Advantage Max mass 
spectrometer with a Finnigan Surveyor HPLC system eluted with a gradient solvent (8 min, 
1 mL/min, 10%-90% CH3CN in H2O + 1% TFA, total sample run 12 min). High-resolution 
mass spectrometry (HRMS) was performed on a Thermo Finnigan LTQ Orbitrap mass 
spectrometer equipped with an electrospray ion source in positive-ion mode (source voltage 
3.5 kV, sheath gas flow 10, capillary temperature 275 °C) with resolution R = 60.000 at m/z 
400 (mass range of 150-4000) and dioctylphtalate (m/z=391.28428) as lock mass, or on a 
Waters Synapt G2-Si (TOF) equipped with an electrospray ion source in positive mode 
(source voltage 3.5 kV) and LeuEnk (m/z = 556.2771). as internal lock mass. 1H, 2H and 13C 
NMR spectra were recorded on a Bruker AV-400 NMR, a Bruker DMX-400 NMR instrument 
(400, 61 and 101 MHz respectively), a Bruker AV-500 NMR instrument (500, 77, 126 MHz 
respectively), and 19F spectra were recorded on a Bruker AV-500 NMR (470 MHz). Chemical 
shifts (δ) are given in ppm relative to tetramethylsilane as internal standard or the residual 
signal of the deuterated solvent. Coupling constants (J) are given in Hz. All given 13C-APT 
spectra are proton decoupled. NMR peak assignments were made using COSY and HSQC. If 
necessary additional NOESY, TOCSY, HMBC, (HMBC-)GATED, and HSQC-HECADE 
experiments were used to further elucidate the structure. The anomeric product ratios were 
based on careful analysis of the crude reaction mixture and the purified reaction product by 
integration of representative 1H NMR signals. IR spectra were recorded on a Shimadzu FTIR-
8300 IR spectrometer and are reported in cm-1. Specific rotations were measured on a Propol 
automatic polarimeter or an Anton-Paar MCP-100 modular circular polarimeter at 589 nm 
unless otherwise stated. 
